<SEC-DOCUMENT>0001179929-20-000139.txt : 20201029
<SEC-HEADER>0001179929-20-000139.hdr.sgml : 20201029
<ACCEPTANCE-DATETIME>20201029093208
ACCESSION NUMBER:		0001179929-20-000139
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201029
DATE AS OF CHANGE:		20201029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		201270777

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>moh-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1,d:5a44908a328044dfb2ef6755dcd9b05e--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:moh="http://www.molinahealthcare.com/20200930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moh-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF8zLTEtMS0xLTA_c6f9def2-59b4-4056-8152-17e7e852f0f5">0001179929</ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF80LTEtMS0xLTA_d16db0bf-a0ee-45c8-a404-153888cd9ed3">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF81LTEtMS0xLTA_19023719-c46c-4aff-be84-99e5fabde668">2020</ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF82LTEtMS0xLTA_12efe96a-4206-4294-9b51-541450964955">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF83LTEtMS0xLTA_58da4ecd-0d7c-4691-84b7-0885532b166c">false</ix:nonNumeric><ix:nonNumeric contextRef="ie7e315d8927941868fea6f62af5f9ae4_D20200101-20200930" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAxOA_433cf4cd-b6db-4c94-b366-da8b885a7b9b">P3Y</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIwNQ_b867bab6-89db-4d51-870f-e673f35a08fa">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_36c7aba9-b228-4098-809b-4b0742eb5288">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_6f9e707f-eddf-4292-bc86-3bc4e82d34e9">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_897dcfc8-9208-498d-a87d-164137209947">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_e217e431-349f-4209-9c6c-c5fa100385e7">0</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTE2L2ZyYWc6NDE4MzA4MzM2MDY4NDFiNjg2MTU4OWYxZTVhZjM4ZDUvdGV4dHJlZ2lvbjo0MTgzMDgzMzYwNjg0MWI2ODYxNTg5ZjFlNWFmMzhkNV8xMzc0Mzg5NTM0NzIwNg_46376686-0cdf-492b-b931-076d93d0ff3f">0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moh-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3f8089a429f642bbacfc310486fd7f75_I20201023"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d66342f0554395ae8b108843d586cb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ifccb71ed99474db29c92a1c32422fdb8_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4249323997a74c5394dec06850d9f0ff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9d47f2dd374531b3635ad709e30b61_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bc664f05b14a159d4a8313d75faeee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84d8cff947c4de9b53a8f49e428deeb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49f2fd8b17184789ae8cfea2f06254dd_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic740cdd3e1084065ac35011ddfb13474_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9475aa9426a4b6f8e55461a9f80ca69_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief76444e7aed463c9fd6220ebe36686c_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id344fdf6e2c44551837ef61def1551e5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic13075558c9348ac82d3505a66e25fd8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d34ec6b04954e97a9776fc5aedb9282_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f3031a4db94a98813421cfe891840e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ecabd9c5a444209a8aff852fbc4b21c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97892307215d43df8f22c0fbb18dcb61_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0058815da1e149d0ad521442a393bdb0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d0f3207cc784b74b39646cac08d8410_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5169226800d4ed096165ba76faed776_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5003122e804b988dea74c354c83d41_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i509d18c4ec7246019d82673921cdfeb0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i857bc8d2434e40239068a4279a5cd1f0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ee588c43d0c4cb79042f4cb63afaa3e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5afc4b5afff4b129fe93aba117db965_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab11086ddd47417bb18ccbb3186696ce_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c897de179cf4b5485a5907b73918b51_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c3a00daa4bd49bb8c6a462ee00a7935_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e25cb2bdbeb4161b0c79bc643ab2e01_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf672f433e474e1390b199db5bd6d157_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2e39a6516be42729bf559f4b31b0042_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic225d023312e446db67441be17efc548_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b143b9b73dc4003a812274a03246027_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc23cfa3d184d399207901dadbc36b8_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfd68fed97114006a3e5e802d1c89c42_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i907d5beeecf040dd9ceadd4dd8ece877_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i772d4e400b1f469faf8028c4422dbcb3_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide746b337aa049e7b40293ed6f01a425_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7722c16ae6c94fc29e287a669c377710_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e79de45409e408d8a51666f4d41bb77_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b51ea44331043d0bc2c91aad3925ba5_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ec3a4bd50d040a2aded930121774fb7_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib17d434488324479a0237837e1d52044_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81fbd2b196d1417d8d35142ae0959b35_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1742427719e433ba0aeb9e8493e3bb8_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf4919d73e0b4df7a87e1da456ef828e_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b37edd89d46497ab1c4734ff26bcd16_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8def59bebfc44b69808ea12af90bd829_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie988e47ff15147608fa252205cc655bd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e2fcc6a71f44a2d81e67581370faa03_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1867d439641b408886f363900a45fc2e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd328f3fb2a48b38a19eaf541451af9_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85567348a9a24e39aafcb86cb42628ce_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i032e64312b634c9192f40d8aad600f2b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i795403e420354184bcfbf7b34e4879dd_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfb9c978b5184509bd25b72a644093ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i446692be62344c64a03638faefd95842_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>moh:segment</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>moh:state</xbrli:measure></xbrli:unit><xbrli:context id="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>moh:member</xbrli:measure></xbrli:unit><xbrli:context id="ie7e315d8927941868fea6f62af5f9ae4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b9468a421a64284ad5b14f3032873c3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i391a70c55331438f93619826459906eb_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd699a73b5be49539d4149d71a08fadd_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b8da8ee91eb4ef58dbbb2775da3afce_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6e8716ea12c44aaaacb9d6db8985ade_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6a3fd1845154357ac826603e0ae69b7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0147887cf13f4458be0b3970d80acbc0_D20200618-20200618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">moh:MaineCommunityHealthOptionsv.UnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-18</xbrli:startDate><xbrli:endDate>2020-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1e4e51fc373341cb966c120414402a2c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf82ebc1b18c49939d196d8bf9931c3e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if72eeeb9a99b4477ab11023ecac0d4ae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c9cc48effd74e3db60699619b9bc2e7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71a512cf78114e5cbc32223760854d4b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2833620245ff437a9d61acd7e7dbfa4d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33f1b142cbf04ffc961177d0573c2b33_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id396aa5e78ce44cca988d14d35592f10_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1cccaa6b1874d0b97e1e7d43c952948_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6158f7ac8714b678e788253d6cc7e0e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dcf40f147894f828c6c0e0d48d7b212_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9a2b45e286440acaf152463d403a03c_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="business_combination"><xbrli:measure>moh:business_combination</xbrli:measure></xbrli:unit><xbrli:context id="id749608c745740b08f21cdaad564831d_D20200701-20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:YourCareHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87dd32a9ad2d4055800c9652ac634681_I20200701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:YourCareHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4beec814285e499c89a31cc2a5afc464_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i433cfe399a704a47bba65a8c3a8b4e14_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70c7a62c77174856b9b975dfcec870fa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8354adbb632c45a49e8c71116d0bd934_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5b787b7098243d881eb301f892af3a4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb06886bec8d4d3a8d4d744db0da88ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:TradeNameMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6d40c8167db46f2a37e7382c7546b67_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:TradeNameMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0f13a84316c4f71b4b314485e38873d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if845f286887c45ceb4f63de315dc91f9_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i421938697dd9476f9e8ed3a9387bbc72_I20200901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i044a1952a952424d842a4e7856f32813_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputMeasurementPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16ad5df3e0954d1db28ec31f056ff595_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputExpectedAssetVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79740d5150ff4f4db489bbeb8788d206_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e6dcbb92a8c4409987fd92c2d6dd158_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058f38bcf796477da567b0db7952dc1e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e90c966b6be4707a4a4282651786edc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6748d59d26dd4b4e9a668279c29380d7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfdb1a74a3b545d0aee5dd04c31c43db_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5933b867152b47d29c8a2374b54fa5a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if75cd98fb83f46158ac380589d92af6e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7ec79780ff9483fafe419776c6fff72_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9ab90b62c74c95810d0a07c314ddd4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie806826c7c874d3cbee4baa4d5c22d75_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f05ad2ae9724998ae461d78e2462361_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie647fc62813f495f8d1417451ba88a73_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57fc15dc5d8d48bea4aaa778a0932e03_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a101af7d174776bc9ad4386eed46b9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcf557a6480b4644969946f54ab51f8e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2741d275f3f4c36bced0a05c8aefec9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie22b9a72648d4042884d35282e080c18_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bef829bfb5741c39a8a5d311beab675_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a868439a3ab4ddba3f5532d5ceda157_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ca2500088d432999b9943027a2975b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6ad5bafcd3a45f386f7d9e4c0f9f4a0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0f2cbbc505437587d85744ac0979eb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79dc47d8b0274fb7814a8ba0de483d90_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6363a2d3e25d4dd98cfe015a124dada4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caaaa444e8946e8a72451037d62eb94_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3048d9541ec340368f67b9914fdd4373_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9c2e228625445018b01f1a9744f8c80_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a0edf748fe453aa44bb4508f73e5f4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d9bab2071e4d2bbff6fa531b293a7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if241099a610c4f3785fd872f815a3259_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8832b45f6ca43d392a187f977e3dbf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i690ef92af3884583b912258ff28d709f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i668462f9d37f4932b5b594b4f0fcb1e9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59cc966e3845472abbcb53a46a0573e8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcef928989144ada890aa6c205760cfe_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i234c36ce5254435e9cd31cb07a130065_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73f8fb252fba435384882b7d0bd11132_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id693148d77924496941bc5d2a267a6d8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc37b2026d5149db9253f8ee18a2d9b2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c9899abdda479e99525c731ad8ded7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i522376b3702049e087e884d659c89675_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iece312dcb67946698766f966c89eafa2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id50eed5aa516417bbac56da2beaea590_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68b250a3de064792b082df53482bf14c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c760dd71e144ec18a78b0cb8844490b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia96df6f9f64a43558623ace7f058a832_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcc73a3dc4644046892c7265608f9887_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa4f9337eb184ec2bdfe4334c287f7b5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0202efdf49a94c0fa927080c97980d08_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb61a08e25544eebb8b370e51386f60b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6efdc95e7240149d457a1f9ae63e55_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ec964ecd3644f5a8e9d165b2153cfe2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2526f7970b8c4c11bfd963e67d99f188_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e4e03da2559470b9e01c0f4e7f534db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic12f63d329ee4926b7f91daa16eca22b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ae382dc57714c32a69f64a22d44f4c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3796bb08765846f69522f7b72d8e436a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ad60777eaf94a25b4eb9085704435f9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i721461de0d57453f954cd5a2ea7e6120_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf4f5c72cbac46beb3ae4a136d11034d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11b1b5fd2c3d451da9d56d574c319476_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3586192295fd40e39cdd133fd5eda38f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3035128b95994c0192502f66cc8725c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9eafdb5b66a49c39b778405016244ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d552ba27235403b8fea92d279192c84_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28a5c4abcb034316be3389b51a439633_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f50b9933fcc48f99b974e53b1d2003b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0209dd5a4ba48f1b5ae0d8164855055_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cc3a3bcad764ec5b23c25c4598cbcf6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icfe4a0d7268840d4a04e16db85cbe422_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957912dee94240ee9072f0022698ffe5_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if265cab40d764aa8a6f7a638b651c059_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58388cfb135745d5a3d2212619472938_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0145a0902d4f00a6773060e4727efb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ded383a09c049409bb8aa4e1578f251_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7126a354069c4673ae6ccf8c5fe6c977_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95b0e5cb5ad441cbe5353c0775eada6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if151f099c6024c06a2e13a64537444dc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2aeeae1e1894e5ba53a5d2f756ecd8d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf1097073c7c4951a8a0493f53a52d9f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i920b911bb1d54c89b67a30da5c6a439a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45acf5d8b86b488a9df5b605c415166a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d429d24c23a4067aa9eefd0f1237fb1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a584d33b6bd4620a88cdb8f036b2df2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607fd186209b46f88148885246fba93d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd06b3418b6d4f8889dd763f2cfe3ecb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2d1a36636ff4190a026b7df75b9f3d5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff0aba0320264b41967f2e901f1c1b66_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i338d7f40d6294accbb73f4a509d10ae4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf2d1b248d0349fc8ac32939e896036e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide774a0690994809ae6d22cf1b4a5ec5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f28d6910080420eadec07f4dd9557ee_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb5372aaf360432383af74ac21bc50e1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9afc1ea189844c5eb735f3f4d963e7ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92d5297b47514ec9a062d743f1f8ebfa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ccea875e1a344df9d2d0328fcf08ab5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4004e550b88493b9d96d33568d57593_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic451188dc3fe4b559f5d53786e36984b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9cd3c1e16c54817acea356e158e1192_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="security"><xbrli:measure>moh:Security</xbrli:measure></xbrli:unit><xbrli:context id="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6353bdf90f6442659a69205e4bac7e7b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie3bb5a95ca0d417782d4613370c18f6c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ec3ae376fbe4ad4a14e9b7642cf575e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91235a939abc46cc8cfe1379d6385693_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57960c7b966c4efba497e4524f1b3ddc_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0fd66717c68402a9c361f8c9ddd1136_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30bd18227ccc47deafa6692e187cac66_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d5fccb82c934bd1a15e322807ce290d_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27fd4a76e49d4598ab2278e6e645278d_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6273b5316944e4a596a67c24741345_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">moh:SwinglineSubFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i145a7ab1554b4757b2e887181fd98cc8_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">moh:LetterOfCreditSubFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea4eec6ff70b47cb9fc4f0eee52a397e_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:IncrementalTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:IncrementalTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e5997156224aac9afd99b367288856_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0212554bfd054535bec808876e3e5018_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id69307e89f364334ae9a43b18c71f4fe_I20200602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b80a28bab8c433a9545d7749e346c8a_D20200602-20200602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-02</xbrli:startDate><xbrli:endDate>2020-06-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2c093122fce40f5b352eff79a18d1c2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2538a5ed9cd54fd5ada2143661d2e391_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550d7fb1a5cf4341ba55c9010cbc88be_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4024fea4fe14739828013441b0f2c9a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0123ff206dc2499598383ffd43d68eb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffdf9fbfeb9745b5b757815afe72494f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fe4a961d1eb4aa8b35c53d34bea3f7c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb569255aff4cb1a507ded6878088ab_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fa4dac681a24334be8e8b77ddebd9c6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1eb474cbb156487da5ef2d111573f379_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id606f46ed6204025ae6c824bbc5386c5_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideda1271d72d4f0f8c9490daadf92cba_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6768058042744166a9675351d4ec6518_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09b03eb47e834f2ea94525c02f9c659c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib455ca5f2b5947a895ea50f53562ffd9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51b83677a3114d00b5fb75fa5b867b67_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1601849c348540f59d2211b5d20125f8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f1814b002a47d38a368f6700e92992_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.270%"><tr><td style="width:1.0%"></td><td style="width:10.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.266%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.718%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM5_f86f02a1-3a6a-4393-9def-f116ca176d4e">10-Q</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:15pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:96.982%"><tr><td style="width:1.0%"></td><td style="width:10.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.196%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.753%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MDdmMGI2ZDAxZGRmNDY4NDliZGE3MTgxMzk4YjNlNmMvdGFibGVyYW5nZTowN2YwYjZkMDFkZGY0Njg0OWJkYTcxODEzOThiM2U2Y18wLTAtMS0xLTA_33a83564-72f7-456c-8911-9b96b6bcd738">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18xNDA_5471bae4-3173-4e3c-a656-a0d798db6685">September 30, 2020</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6YTY2Y2FkYjQ2YzFkNDVjMWE4YzdjOTUwN2NlZTFmOTUvdGFibGVyYW5nZTphNjZjYWRiNDZjMWQ0NWMxYThjN2M5NTA3Y2VlMWY5NV8wLTAtMS0xLTA_910cd5ef-8e39-4547-9ba9-ee862ba321c9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTMy_e3115353-f9c9-4608-b054-6135ce8a3ed6">001-31719</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="moh-20200930_g1.jpg" alt="moh-20200930_g1.jpg" style="height:76px;width:220px;"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTMz_3f31babd-d07a-4fdd-a518-c84d44f26560">MOLINA HEALTHCARE, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8wLTAtMS0xLTA_27b7b602-9490-48ee-b3f2-b7af75a4c2e9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8wLTMtMS0xLTA_87b0f515-d717-46cc-b9f2-43b8b48903ec">13-4204626</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8zLTAtMS0xLTA_1c2659ae-ba9d-4aa9-a4a5-e45c44cb93b2">200 Oceangate, Suite 100</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTAtMS0xLTA_3e0a408e-a8e6-4a68-89a9-3664f764ca12">Long Beach,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTEtMS0xLTA_07170472-ff9d-43d3-a2ef-071319194a68">California</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTMtMS0xLTA_ffda9a94-e325-4c7b-87d6-017ee2fa548e">90802</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQy_5bf3333a-7ae5-48be-a41a-6ce1da3b2f49">562</ix:nonNumeric>) <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM0_495c599b-21b8-4983-ae26-1f5151171dc5">435-3666</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.132%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:75.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:33.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.489%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTAtMS0xLTA_e617eabf-3896-4fe2-860e-f32f5ce8c38a">Common Stock, $0.001 Par Value</ix:nonNumeric> </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTEtMS0xLTA_46995e0f-0c97-4675-a33b-dfe164006073">MOH</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTItMS0xLTA_b43dad89-f739-45de-9518-cea9d4090a76">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM1_6bfb9400-f31b-42fe-8ff7-702f11f33fd4">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM2_65003c4f-c1de-4f10-b4a7-a7806ac5ae39">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM3_c1a44f8f-e90f-40ee-adf0-4049b733afc2" continuedAt="i76b7429bc31d4fc5a4b4f0a298aa7161">L</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="i76b7429bc31d4fc5a4b4f0a298aa7161">arge Accelerated Filer</ix:continuation> &#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-Accelerated Filer  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQw_c39e97f6-350e-4fc3-8af6-60e9296cf44b">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM4_33701d84-0c3d-457f-bef7-ccb4c1375123">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">   &#9744;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;   Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQx_384ca72a-6f3e-44ca-95ec-6c648052f227">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.001 par value, outstanding as of October&#160;23, 2020, was approximately <ix:nonFraction unitRef="shares" contextRef="i3f8089a429f642bbacfc310486fd7f75_I20201023" decimals="0" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yNzQ4Nzc5MDcxNjA3_4e7562f4-be74-4dc2-abb6-cce70de2aa12">59,300,000</ix:nonFraction>.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC. FORM 10-Q</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 </span></div><div><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:73.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.399%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ITEM NUMBER</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_10">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_73">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_73">24</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_115">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_118">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART II</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_121">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_121">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_124">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_124">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_127">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_127">44</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Information</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_130">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_130">45</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_133">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_133">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_13"></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share amounts)<br/>(Unaudited) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS0xLTEtMS0w_8cdb70b7-117a-40c2-8d4d-ee01fcb3bc77">4,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS0zLTEtMS0w_e0bb33ec-8f65-4515-96d9-2d3c8e7936a9">4,084</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS01LTEtMS0w_33f02825-16a7-41e6-a0b6-f9c3d5f9771c">13,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsEarnedNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS03LTEtMS0w_741a8b5e-940a-4004-8745-c1e6ab5956be">12,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi0xLTEtMS0w_837db78b-77e8-4b1b-8d37-55d124427df6">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi0zLTEtMS0w_f75894e2-24f1-42de-be5c-6cfb0d94e69b">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi01LTEtMS0w_dcb649b8-3335-4843-a169-788e67f16d25">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi03LTEtMS0w_bd051657-ab48-432d-ba3b-41b950f11d48">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees reimbursed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy0xLTEtMS0w_36763518-b711-4dc7-ae74-00a5df9f90d1">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy0zLTEtMS0w_4c66d939-b8fb-4cdd-b06a-5c94c4caf12f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy01LTEtMS0w_8e151dad-a7b1-4f9e-9e02-423bee7993bb">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy03LTEtMS0w_056c9b0f-ded2-430b-8094-b6a51205fb35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC0xLTEtMS0w_bac5718d-a043-4976-8f23-f2f63005a456">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC0zLTEtMS0w_c1b1cbb9-18be-4181-bc71-23ca093e3b9a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC01LTEtMS0w_411954f2-11d6-4628-a348-1253ac746966">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC03LTEtMS0w_7adff3e6-4ebd-447f-b0e7-03515cb37c15">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS0xLTEtMS0w_7adcf18d-572d-406c-bbe2-d1f4249c22da">5,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS0zLTEtMS0w_5d4c28f8-de78-4463-9a5d-7fcadfb1e704">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS01LTEtMS0w_7f66fa77-0df6-45e3-8697-b0289fb0f3c2">14,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS03LTEtMS0w_0dbae95a-a9b5-41f7-881f-82d6699fcd5b">12,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtMS0xLTEtMA_19376960-4ebb-4a8e-aa04-bb0b8db53c0a">4,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtMy0xLTEtMA_0ff8fccf-54d1-4aed-a264-04c39d7515cd">3,523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtNS0xLTEtMA_4bf7459b-2ca3-4d6b-9a73-254c7593cab8">11,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtNy0xLTEtMA_8df70ff1-aa93-46bf-88bb-e2ed0bed3dc0">10,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItMS0xLTEtMA_10a4ac5e-44b0-4c88-aba8-d012dbeff732">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItMy0xLTEtMA_ba1a95b3-f731-465f-8bd6-d78cf1ed97d5">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItNS0xLTEtMA_a0b6bca2-b005-4906-b1ac-0f0b4ad9e466">1,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItNy0xLTEtMA_bc66bf44-7376-4567-a71e-94f9db6b3bb1">953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtMS0xLTEtMA_9de58684-46d2-473a-a844-8a815e9de1be">170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtMy0xLTEtMA_7fabb6b4-3750-4f46-a384-b9f43ea26842">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtNS0xLTEtMA_f70e1790-bbfc-4060-b211-77f36a089e0f">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtNy0xLTEtMA_4641532e-079e-4dda-b069-51447fc1c1dc">367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtMS0xLTEtMA_81c78450-954d-417f-a032-d6b17b2cf4af">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtMy0xLTEtMA_2d1273e5-f098-4d2f-9f6c-66a8cdf24293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtNS0xLTEtMA_ade345eb-d7cd-4722-8afd-119bdc87be8a">209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtNy0xLTEtMA_12a9427a-c572-4c26-a7f4-59f0d380b52a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtMS0xLTEtMA_bee13d33-41e6-487e-b5f5-8056cfa527c5">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtMy0xLTEtMA_90f90d83-5d02-427e-9d20-800fbe96c4af">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtNS0xLTEtMA_c477147d-5925-4376-b51b-79a142af5925">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtNy0xLTEtMA_dabb09f4-9312-48a3-91df-1ca7eb86a427">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtMS0xLTEtMA_ba2e3bc4-4a30-4795-8162-a2d9812702fc">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtMy0xLTEtMA_8b765ef7-665f-4825-8e22-e7dff5dfcf6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtNS0xLTEtMA_e1de166a-ee5f-4356-8103-b9a27bcb5453">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtNy0xLTEtMA_ca3824c6-df65-4c12-bc0a-fdbbff73f912">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctMS0xLTEtMA_ddd912bb-0f60-4763-85c4-d67c17fbd10d">4,732</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctMy0xLTEtMA_cdae399b-4ffb-445d-bcbe-8b6a732306eb">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctNS0xLTEtMA_dccfe74a-cd13-4fa9-8517-6c2a0e4d9b69">13,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctNy0xLTEtMA_4ac778e7-78a6-41ce-9b00-280efaa83063">11,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtMS0xLTEtMA_65994dd7-4e8a-40a1-a5b7-2d727a5e003d">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtMy0xLTEtMA_9605590e-8b2b-4761-a444-2753385a61c4">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtNS0xLTEtMA_1a2612c6-2b53-4bf7-a351-1039d3afa868">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtNy0xLTEtMA_5da0d947-3be1-4227-a81d-c1dcf2a08e26">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtMS0xLTEtMA_24ac8e79-e0b2-49a5-8774-09e6d1bf4555">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtMy0xLTEtMA_8bfe7852-f996-4360-a4e1-63dd1b871bc3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtNS0xLTEtMA_9243f93d-74e9-4e39-a667-18e077442ce6">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtNy0xLTEtMA_b35179ac-8ba1-417c-85f0-99bbc1176780">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtMS0xLTEtMA_585a9894-6fab-4e97-9c01-0b15491c4c5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtMy0xLTEtMA_ce1f58e8-1787-4a15-bff1-7ec26539804a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtNS0xLTEtMA_0755bc40-8386-4530-8425-26533228aff7">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtNy0xLTEtMA_d2727c57-3e88-4edf-baf1-e206a0a11d3c">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItMS0xLTEtMA_176f4a97-9dea-4992-8052-c001fcea1491">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItMy0xLTEtMA_bb91fc51-1fbd-45ba-9844-0fb1e3e7701a">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItNS0xLTEtMA_ae11dba0-0d52-4912-ab2b-6d22ae2df4c8">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItNy0xLTEtMA_2c922025-037c-4030-8cfb-afae7b7f066b">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtMS0xLTEtMA_d1aa7e6c-eca0-41aa-a936-7a19f2d161d4">262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtMy0xLTEtMA_dc843b4d-afcb-4f0d-a7b9-6deba5e53684">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtNS0xLTEtMA_bf161825-e2e3-4071-a1e1-2f98133e5d4f">910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtNy0xLTEtMA_a509d06c-604c-43ec-955d-70e76ea47c0f">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtMS0xLTEtMA_7e55eed8-8c60-4739-8a88-9452ab310982">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtMy0xLTEtMA_93e05cc4-e7ce-4218-b6c3-c18478519052">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtNS0xLTEtMA_3fa4def2-9957-417a-a2d0-40e82f6a123d">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtNy0xLTEtMA_f54a9ded-e300-4eda-b85a-a092f442ce2c">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d66342f0554395ae8b108843d586cb_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtMS0xLTEtMA_9cad71aa-9b2d-410c-972d-b0217785efa9">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtMy0xLTEtMA_085dd245-b702-4804-9c60-8db84d170fce">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtNS0xLTEtMA_bd300e1c-8ebe-4e9c-a586-01d27b34ef13">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtNy0xLTEtMA_f215bb9c-8ae5-4cda-bd5e-fbc673eeacb1">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctMS0xLTEtMA_91e1e96e-4301-4d53-b1e6-3ab5c2a6b13d">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctMy0xLTEtMA_18fb0887-7239-46af-b7ad-0594acfff017">2.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctNS0xLTEtMA_6c3385d8-22dd-4c85-95dd-749909976b4e">10.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctNy0xLTEtMA_af437401-1948-46c7-87d4-b220b0bb61d1">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtMS0xLTEtMA_d8ecfcbd-a929-4710-9252-1a9bdd072968">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtMy0xLTEtMA_52aa9f1b-31ff-4ab3-8647-a8a30abcd5d6">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtNS0xLTEtMA_a240d5cc-08ea-4d1b-ac83-de115693a2f3">10.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtNy0xLTEtMA_11d71459-30a7-4f8c-96be-626db681df87">8.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC0xLTEtMS0w_8f669590-1dd9-40bf-a2b5-ed5d6787f24f">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC0zLTEtMS0w_e98cdfc0-c710-4eaf-9a7b-0c9f535261b1">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC01LTEtMS0w_b1853129-6bbe-4867-aa51-d4aaacd80ff6">639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC03LTEtMS0w_00031fb3-62f6-461e-ad57-356c8f31b538">569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi0xLTEtMS0w_37c6852f-fd06-416c-a4ca-d7d82f168634">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi0zLTEtMS0w_868844c9-8f56-482a-9d85-37b174209a6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi01LTEtMS0w_66e0f18e-d481-42d4-8e15-7209bd86c870">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi03LTEtMS0w_75145f76-af68-4c4c-a6ed-88d764b1db40">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy0xLTEtMS0w_13debc00-4414-4499-890a-b400ba1262a3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy0zLTEtMS0w_27b2782c-9a87-4f6c-be86-e76b4a33249d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy01LTEtMS0w_94c30633-ff56-43a8-b865-7474bd311d78">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy03LTEtMS0w_8d42d66c-2271-440e-9250-f54724efee15">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC0xLTEtMS0w_f0231f38-a923-4468-95f7-f4b71025ab7c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC0zLTEtMS0w_5bb80fee-1706-4501-9b67-9ca15eee8573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC01LTEtMS0w_03dcff2a-2eaa-4ff2-8ac1-2de1032c1966">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC03LTEtMS0w_9d915d5a-3111-4014-9436-f8a28102747f">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS0xLTEtMS0w_a1512577-6818-4740-9c3d-6afb6b123418">190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS0zLTEtMS0w_851936bb-968d-4029-b3f0-8783dba0b95d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS01LTEtMS0w_bc655fe7-ffbc-4145-9f80-165da6d7c0b1">672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS03LTEtMS0w_005c7262-6357-4a12-8d48-7c98604c8186">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 3</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions,<br/>except per-share amounts)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNi0xLTEtMS0w_bb32e3ee-44b5-42f4-a013-eef4b6489266">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNi0zLTEtMS0w_eaf5e8a7-dbb6-4132-b0e8-149c9ccc9ac9">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNy0xLTEtMS0w_1054930e-cde8-4dee-82a1-8adc0f2aa767">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNy0zLTEtMS0w_6d6adf40-aff3-4c9f-aa39-a94e87cc57e6">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOC0xLTEtMS0w_bf133e3f-b877-4d54-8e21-233f5789cb3b">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOC0zLTEtMS0w_8af6ac66-9b37-4e0b-a50f-51bc9c717ab3">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOS0xLTEtMS0w_a1fd37cb-05c5-46be-8156-59e0899ab9ae">213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOS0zLTEtMS0w_0e06929e-faae-4c3e-82ea-f0492c1c88eb">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTAtMS0xLTEtMA_e9d9a600-4a89-4c06-80cc-45a7e40a21e5">6,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTAtMy0xLTEtMA_02d52de9-16a1-418d-a0e5-391ea9b80213">5,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTEtMS0xLTEtMA_e03a7332-0d3c-4e6b-a2f0-4f2a48c7338f">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTEtMy0xLTEtMA_451b4fd0-dca8-46e8-a5ae-e28428859a29">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTItMS0xLTEtMA_8193b118-4483-4cc6-95e8-dc2fc3ea219b">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTItMy0xLTEtMA_20fab758-042d-4394-aca5-e528d097ed46">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTMtMS0xLTEtMA_e9dcf01b-c1a5-446a-b48d-156927f869c4">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTMtMy0xLTEtMA_bcfd59e6-bb91-40d3-a4a8-db067e07fa18">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTQtMS0xLTEtMA_38a6cc30-80c7-4435-aa73-c4593d54fecb">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTQtMy0xLTEtMA_79c257a7-43c8-4674-a687-6d361ca6ce84">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTUtMS0xLTEtMA_3e8f5cef-c4f6-496e-97d0-78710004f908">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTUtMy0xLTEtMA_4e661475-ab2b-4210-b0c7-a76d0d302ddf">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTYtMS0xLTEtMA_70d3f96a-cf29-4b30-b3eb-59bf333fa319">7,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTYtMy0xLTEtMA_c746cc13-9212-4dfe-976a-554aeaa69802">6,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjAtMS0xLTEtMA_96bb2760-3aeb-4233-821e-908cdf40a3a1">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjAtMy0xLTEtMA_412087fc-da36-43e5-87f1-debaf268e387">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjEtMS0xLTEtMA_49366502-1511-4deb-9fee-e7797bf7d973">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjEtMy0xLTEtMA_43b14014-c2fb-473a-8c7f-0a40cb8bfed9">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjItMS0xLTEtMA_77093f8e-df39-45af-b0cb-18e17c11619f">566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjItMy0xLTEtMA_75be610a-cb1e-471f-84b4-1ea91f3c1a8e">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjMtMS0xLTEtMA_7722f575-4feb-4f0e-8f79-659ba1699cb9">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjMtMy0xLTEtMA_b15d9d66-fa73-44d8-add2-5c7fe8c4e96d">249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjQtMS0xLTEtMA_83d9b2fe-23de-4f05-a140-ed38838ef66f">3,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjQtMy0xLTEtMA_8c717ff0-1c8e-4beb-92a1-dfc7387e8dd7">3,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjUtMS0xLTEtMA_7afc2f5b-4262-4025-8478-5c77a42c6460">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjUtMy0xLTEtMA_18b0a595-4a20-49cc-908f-58d75ea5e771">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjYtMS0xLTEtMA_93b6b771-2527-47ad-9855-8f10939376b6">226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjYtMy0xLTEtMA_5e12f16e-47b6-4aeb-a157-238d0ce95bdf">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjctMS0xLTEtMA_238a934d-5cad-4c61-a54a-7f03ae1b694d">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjctMy0xLTEtMA_ad5d6cd9-4c29-4890-badc-60acbeb6564f">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjgtMS0xLTEtMA_e7f0fe82-d289-49d7-9a2d-0a7d12c4ebe6">5,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjgtMy0xLTEtMA_57b935fd-cdef-4c74-885c-16002add9360">4,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzE5_d5c265df-3cc8-47b6-8901-47255cba1221"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzE5_dc877d60-ddf6-4a26-8f2a-18583ac3737c">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzMz_60b33212-4342-491b-adb6-2627a08d1bd8"><ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzMz_eab024fa-f5bc-42c1-8cb9-705e315e5830">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzY4_ba4302d1-94e9-4032-8087-557c367b93dd">59</ix:nonFraction> million shares at September&#160;30, 2020, and <ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4Xzg5_5ae5ae99-96d9-47e7-815b-d0c9c4bc7cdc">62</ix:nonFraction> million shares at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMS0xLTEtMA_0443cf66-1eda-4618-ac7a-b710c28b8434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:CommonStockValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMy0xLTEtMA_00001f6b-58da-40c0-a1bc-a38e4056de45">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzIy_97f5b429-6f2b-42d1-8c17-41e6c860237c"><ix:nonFraction unitRef="usdPerShare" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzIy_c1ea64e1-e3d9-4422-b58e-b2dbc9ad772c">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzM2_0dbdb35c-c024-44aa-b772-db841adf0f9b"><ix:nonFraction unitRef="shares" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzM2_511d4a10-30ef-486d-992d-a4b60d933785">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_0c587742-209e-47f9-89eb-431ac045c732"><ix:nonFraction unitRef="shares" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_1c8ffd73-79d3-4b24-ae5e-33509230487d"><ix:nonFraction unitRef="shares" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_21cd6ca3-64e2-4c7a-87fc-401a3080d8bb"><ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_b9a9196d-71b5-401e-a9cd-173af6313ef6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMS0xLTEtMA_9dfd96cf-26b4-4280-a45a-9d4cab8029b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMy0xLTEtMA_7690d9b8-d4f2-4317-b50b-e4c03af30a0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzItMS0xLTEtMA_35443e21-982a-49e4-a57b-a2717b7e0396">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzItMy0xLTEtMA_7ffe920b-9465-4e44-ac6d-ed825e34b5f3">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzMtMS0xLTEtMA_9e34d778-43f1-4ca7-b676-446a11e837ad">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzMtMy0xLTEtMA_b81c2052-ac37-48b6-940d-22bc04fd5c80">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzQtMS0xLTEtMA_89d090f6-22be-4826-83f1-bbaf4ee39b1b">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzQtMy0xLTEtMA_d209ba10-d61d-413e-833f-9712207516fe">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzUtMS0xLTEtMA_b14f3f25-434c-473d-9b38-1232d9804769">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzUtMy0xLTEtMA_14802871-7e45-4f2b-a8bd-1c761dd33a22">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzYtMS0xLTEtMA_eba49ab5-6ccb-48b1-b8c6-ec6cf1832939">7,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzYtMy0xLTEtMA_14144a2c-3ca0-42a4-8467-687a24f96083">6,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 4</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss) </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0xLTEtMS0w_169db7ff-9160-47cc-8f0b-dbbe538f6bcd">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0zLTEtMS0w_d543b3ba-63a7-4575-8755-2f347396e423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9d47f2dd374531b3635ad709e30b61_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS01LTEtMS0w_68233338-5a2b-4327-87c6-0e6ad55b255a">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bc664f05b14a159d4a8313d75faeee_I20191231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS03LTEtMS0w_667259f8-e02e-4353-9f92-ccdec300c701">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if84d8cff947c4de9b53a8f49e428deeb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS05LTEtMS0w_46643207-e288-4a5a-b471-5612e495c040">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0xMS0xLTEtMA_6c6fa333-a9bc-4176-b18b-a3f9d09520f8">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNi05LTEtMS0w_7f897128-721f-4d85-b0c1-338884bd22dc">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNi0xMS0xLTEtMA_3a98f37b-981f-42be-9499-462c37cf7536">178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy0xLTEtMS0w_6c58972d-9862-42d3-bf79-9dcd0c552f10">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy01LTEtMS0w_7edf75e4-5890-4fbb-9fbf-70e66637cd4f">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy05LTEtMS0w_d98f7da1-c27e-4b84-bd4d-9b6b0e385fdf">437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy0xMS0xLTEtMA_1e97c72d-51ab-41c7-8ea2-1445329f45aa">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOC01LTEtMS0w_ae4ea174-57ac-4a74-b8a7-bed05744f13a">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOC0xMS0xLTEtMA_3f66ee2a-3be0-47d1-9465-cd09f6a786c2">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49f2fd8b17184789ae8cfea2f06254dd_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOS03LTEtMS0w_70e1dedb-4209-4105-b165-74886ad9a313">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOS0xMS0xLTEtMA_e99f7fef-8196-43f5-a3ca-1001a7bbab86">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTAtNS0xLTEtMA_02adf040-8fe0-4572-b248-a75f3bd7bfa2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTAtMTEtMS0xLTA_2b001464-1009-4a33-ac76-7ec81c8722d1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic740cdd3e1084065ac35011ddfb13474_I20200331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMS0xLTEtMA_2f31519d-8927-4544-9af7-d459d9d712b5">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic740cdd3e1084065ac35011ddfb13474_I20200331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMy0xLTEtMA_43e41927-95ca-4a47-9489-93c6b086a11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9475aa9426a4b6f8e55461a9f80ca69_I20200331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtNS0xLTEtMA_9c2e77ae-d5f5-467f-9698-7f61d66f385e">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief76444e7aed463c9fd6220ebe36686c_I20200331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtNy0xLTEtMA_4f2e6a29-bc0b-4c05-9c12-cc0ab237d616">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id344fdf6e2c44551837ef61def1551e5_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtOS0xLTEtMA_ae640a19-3035-4d81-b230-7bd85b57e53e">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic13075558c9348ac82d3505a66e25fd8_I20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMTEtMS0xLTA_6fd58e21-7990-49f8-bad3-715dd38c60c0">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d34ec6b04954e97a9776fc5aedb9282_D20200401-20200630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTItOS0xLTEtMA_8b2fedf3-4574-4101-99b4-e18d5fa4d161">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTItMTEtMS0xLTA_afe67e64-48ac-4319-8645-828f93a300d9">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f3031a4db94a98813421cfe891840e_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTMtNy0xLTEtMA_c4305f7e-cd6d-49da-8ae2-0f2b8dac0308">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTMtMTEtMS0xLTA_c3236b49-2dfb-46e1-b9d8-5e41e2f4949b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecabd9c5a444209a8aff852fbc4b21c_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTQtNS0xLTEtMA_4410f915-b0fd-47af-95b9-e692edf2a0f4">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTQtMTEtMS0xLTA_983aca7b-a8b5-4be7-a0fb-ce2c28e58afd">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97892307215d43df8f22c0fbb18dcb61_I20200630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMS0xLTEtMA_4feb3703-62af-4461-8267-649c6ec74b63">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97892307215d43df8f22c0fbb18dcb61_I20200630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMy0xLTEtMA_2196821c-be43-40bf-8d0b-ff6728d79f76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0058815da1e149d0ad521442a393bdb0_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtNS0xLTEtMA_0177d926-5a01-4807-bf9a-9bf86cddf896">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0f3207cc784b74b39646cac08d8410_I20200630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtNy0xLTEtMA_02be6992-5421-4b19-9d64-4f26acfae435">32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5169226800d4ed096165ba76faed776_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtOS0xLTEtMA_b4830db9-f136-4551-81eb-e65c1bcf2fd4">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5003122e804b988dea74c354c83d41_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMTEtMS0xLTA_8fda3ed1-5b9d-4ce4-977f-e1165eb6f2d3">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d66342f0554395ae8b108843d586cb_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTYtOS0xLTEtNzU_9cad71aa-9b2d-410c-972d-b0217785efa9">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTYtMTEtMS0xLTI2Ng_4a1e8eb8-5e8e-4e9c-9917-257c5343c3f4">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTctNy0xLTEtODE_f0231f38-a923-4468-95f7-f4b71025ab7c">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTctMTEtMS0xLTI3Mw_c4e29c36-e03b-4537-8bbc-b5b17b0f4815">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i509d18c4ec7246019d82673921cdfeb0_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTgtNS0xLTEtMjgz_dc3d282c-89d0-46fe-a324-4acf26ab70c9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTgtMTEtMS0xLTI3OQ_36378d99-ac54-4dfe-b07d-26b7763a467e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMS0xLTEtODA1_ea7c53ab-0fbe-4baf-a084-82b0da893f3f">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMy0xLTEtODA2_a75f9a16-444c-4b1a-94af-0fb9a5831b75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i857bc8d2434e40239068a4279a5cd1f0_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktNS0xLTEtODA4_7c5dd012-3fe7-4021-a990-ea09f8491706">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee588c43d0c4cb79042f4cb63afaa3e_I20200930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktNy0xLTEtODEw_c808aac0-7f8f-4f64-ad6b-97e270275eb6">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5afc4b5afff4b129fe93aba117db965_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktOS0xLTEtODEz_4e4bc459-297f-41c9-9f05-271fffba7e9e">1,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMTEtMS0xLTgxNA_be2e44d3-daa4-4d29-bf41-7b0de47e23af">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:34.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.890%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab11086ddd47417bb18ccbb3186696ce_I20181231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0xLTEtMS0w_2d5a6bce-a79b-441a-b124-9ab1d10dd811">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab11086ddd47417bb18ccbb3186696ce_I20181231" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0zLTEtMS0w_a42e8abe-9fe9-4813-b219-e03e76b690d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c897de179cf4b5485a5907b73918b51_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS01LTEtMS0w_1373454c-ae2a-4d0c-8a38-f891f01d2655">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9c3a00daa4bd49bb8c6a462ee00a7935_I20181231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS03LTEtMS0w_01d0b346-55d8-433e-8886-b9c529995739">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e25cb2bdbeb4161b0c79bc643ab2e01_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS05LTEtMS0w_8234f798-45f6-43f6-9ecc-600f97ce7f08">1,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0xMS0xLTEtMA_8c04208c-f64a-4abf-93e2-63697cb79ffb">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2e39a6516be42729bf559f4b31b0042_D20190101-20190331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNi05LTEtMS0w_677b1816-a261-4aa0-9d2a-ea3171243703">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNi0xMS0xLTEtMA_f8872c0c-8195-45c6-a794-95a01b36ee40">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adoption of new accounting standard</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b143b9b73dc4003a812274a03246027_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNy05LTEtMS0w_611889e0-d5a4-43fc-b6ba-4328dac3a890">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc23cfa3d184d399207901dadbc36b8_I20181231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNy0xMS0xLTEtMA_c95fd7bd-6a60-4949-92b9-fcbbf4d31a80">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partial termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOC01LTEtMS0w_9e9a543d-1df8-4262-a81a-fdbafdc916f4">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOC0xMS0xLTEtMA_0927d5d3-b394-443c-b1ea-73072bad0b2f">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfd68fed97114006a3e5e802d1c89c42_D20190101-20190331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOS03LTEtMS0w_a73a84ed-ac9e-41ab-b6e2-5694727b775a">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOS0xMS0xLTEtMA_cda91a7a-d9ee-4370-bae4-6681ecd815ab">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i907d5beeecf040dd9ceadd4dd8ece877_D20190101-20190331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtMS0xLTEtMA_64e2ee6d-b3cc-4c69-b353-75c5a5e66cc8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtNS0xLTEtMA_28a5dd2c-6105-432e-b010-6e493bd57e5e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtMTEtMS0xLTA_6f58fbad-b276-4221-a62e-b65f9d4507b9">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i772d4e400b1f469faf8028c4422dbcb3_I20190331" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMS0xLTEtMA_0d873964-ac83-4539-b04d-c39ea9127546">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i772d4e400b1f469faf8028c4422dbcb3_I20190331" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMy0xLTEtMA_e2416c1d-7c60-447c-8b30-6a9da3ac0619">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide746b337aa049e7b40293ed6f01a425_I20190331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtNS0xLTEtMA_c201c0ce-67a1-4f4d-8cf8-d5f1343e3e4e">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7722c16ae6c94fc29e287a669c377710_I20190331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtNy0xLTEtMA_ac65d333-7d27-46b5-a76a-b15abc11914e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e79de45409e408d8a51666f4d41bb77_I20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtOS0xLTEtMA_1c2da2e9-7365-46d9-a5fc-917c3791d9aa">1,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b51ea44331043d0bc2c91aad3925ba5_I20190331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMTEtMS0xLTA_8a813144-87af-4da9-b018-af49dad5455f">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ec3a4bd50d040a2aded930121774fb7_D20190401-20190630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTItOS0xLTEtMA_c45734f7-f5ee-403a-bf81-034661090535">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTItMTEtMS0xLTA_91e81f06-6488-492d-a40c-5fed7fdce644">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partial termination of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTMtNS0xLTEtMA_b80b0f01-3636-4849-8445-68bd28576962">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTMtMTEtMS0xLTA_7d2a1076-4b41-426b-b679-cc4bb1856b50">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib17d434488324479a0237837e1d52044_D20190401-20190630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTQtNy0xLTEtMA_847751d5-30ed-4fb4-b6ff-b2d4a3347b8a">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTQtMTEtMS0xLTA_54ed18ca-856e-4d03-b753-f90690890669">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTUtNS0xLTEtMA_a3d74bb0-762b-4bb8-9ed7-356e298042c6">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTUtMTEtMS0xLTA_e7facc23-9c79-4df7-b888-1d80c38bac24">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81fbd2b196d1417d8d35142ae0959b35_I20190630" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMS0xLTEtMA_ddf45be6-5e53-48dd-81dc-5478a51ad445">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81fbd2b196d1417d8d35142ae0959b35_I20190630" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMy0xLTEtMA_b6190576-e196-42c1-8d3e-26df49f6ace1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1742427719e433ba0aeb9e8493e3bb8_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtNS0xLTEtMA_7f44017c-067c-40ba-ba18-b3a63d9a48de">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf4919d73e0b4df7a87e1da456ef828e_I20190630" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtNy0xLTEtMA_3b6f7e10-795e-4a93-bd95-c8915b3f7476">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b37edd89d46497ab1c4734ff26bcd16_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtOS0xLTEtMA_c63f0b3d-8c31-456c-b080-cebed000bd80">1,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8def59bebfc44b69808ea12af90bd829_I20190630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMTEtMS0xLTA_d59f9721-3926-4cc8-8e01-8a7c9f29fbd1">1,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie988e47ff15147608fa252205cc655bd_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTctOS0xLTEtODE3_7a5ef181-b62d-479b-8095-29803c44310d">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTctMTEtMS0xLTgxOQ_959a89a9-bed8-4cdb-8249-fe95433ec075">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partial termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTgtNS0xLTEtODIy_8370ab09-17be-4f12-8df4-1f4cf13fe675">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTgtMTEtMS0xLTgyMQ_f02d4294-7f4c-4e1a-b5d4-d4d24afe58c3">90</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTktNS0xLTEtODI1_04cc691f-1692-4300-8730-eae64060af3c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTktMTEtMS0xLTgyNw_2f9efabd-9292-422f-9e53-6e8541954469">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e2fcc6a71f44a2d81e67581370faa03_I20190930" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMS0xLTEtODM4_9ad6b412-a85f-4652-9f33-b1d7464e9791">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2fcc6a71f44a2d81e67581370faa03_I20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMy0xLTEtODM2_60938893-46f3-4909-8b81-d42727d61c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1867d439641b408886f363900a45fc2e_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtNS0xLTEtODQw_d2ead299-d91d-4120-be35-408f0f770cfe">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd328f3fb2a48b38a19eaf541451af9_I20190930" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtNy0xLTEtODM0_342d85d9-06bd-48b3-ba1a-9e6a8e76c501">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85567348a9a24e39aafcb86cb42628ce_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtOS0xLTEtODMy_e3672fc2-86de-4850-a542-b233812eee89">1,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMTEtMS0xLTgyOQ_8926ce27-ff43-4df7-914b-ff66a029a7df">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 5</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNS0xLTEtMS0w_8a668315-05cc-4738-b5f2-443f4797e602">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNS0zLTEtMS0w_25610389-0569-403e-a5c3-b00d0d0dd613">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNy0xLTEtMS0w_7644c966-69e5-4f9e-afcd-720966fcd183">64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNy0zLTEtMS0w_500844b4-3ae9-47a6-b6b6-1da6a8ad4b39">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOC0xLTEtMS0w_4da44f08-2d8b-4aa2-bd8b-a879e4ca829a">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOC0zLTEtMS0w_48c52421-7517-4488-a42d-790c6f7d8710">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOS0xLTEtMS0w_9142da1c-cf08-4948-a9c3-a7df6c2ee7e8">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOS0zLTEtMS0w_746f6d8d-ae88-456f-bffa-c090ea8ca99c">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss (gain) on debt repayment </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTEtMS0xLTEtMA_48873374-199c-4b2f-85b3-54c230707794">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTEtMy0xLTEtMA_8d9606c7-b94f-4d78-a63f-ee2333d4a5ac">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTQtMS0xLTEtMA_14b06685-7993-4769-900d-9774574a679d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTQtMy0xLTEtMA_a5ca25d7-6b7d-4f40-95dc-258bfe6e202c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTYtMS0xLTEtMA_42b29abd-21e2-4b60-83e7-35b9e113ac26">369</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTYtMy0xLTEtMA_05bc5c57-e3f1-4db2-8da4-5cee9e087b2a">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTctMS0xLTEtMA_83637689-e191-4302-94c5-9c4f1899138d">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTctMy0xLTEtMA_45ca4d49-951e-472e-a67e-df8ee2ab70a1">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTgtMS0xLTEtMA_fac6f4f9-de9e-4440-95bc-40b7ff75d0bf">431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTgtMy0xLTEtMA_1a9a932d-9a76-4227-963b-9c8733c9098b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTktMS0xLTEtMA_cd992b35-5304-4ea8-8807-eee556fade15">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTktMy0xLTEtMA_68269258-992b-4712-a780-c2cf517c0c23">355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjAtMS0xLTEtMA_761f9191-773a-40c5-9837-1ce7694d05b9">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjAtMy0xLTEtMA_2c907e21-776c-4b21-9c70-00204c60266f">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjEtMS0xLTEtMA_b50927e4-b353-4e47-be68-9354c4df21cf">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjEtMy0xLTEtMA_9a191cc1-bd34-44b9-9d3d-6a783a37d469">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjItMS0xLTEtMA_5e12e717-7a27-4fd5-98c4-1a91be3d838e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjItMy0xLTEtMA_9b309ec8-b747-4122-b149-870ea8bb3c2c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjMtMS0xLTEtMA_21ee678f-7376-4e33-93b6-7020777f616e">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjMtMy0xLTEtMA_9519ab58-85a3-4b4f-b63a-0738f8f00b89">398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjUtMS0xLTEtMA_982561fa-5781-4693-a8fe-5e872c2098ab">670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjUtMy0xLTEtMA_41da54a8-52f7-41b8-8f2f-f865184c4f7c">1,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjYtMS0xLTEtMA_0673aafc-c1d4-4b93-8984-213c79d8b131">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjYtMy0xLTEtMA_4f597f65-cc2c-4137-8284-b54f2a3ecc20">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMS0xLTEtNzkx_6530fbc1-2d75-4937-b9fc-e5865e6d8d76">62</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMy0xLTEtNzkx_c157287f-0c66-4896-a159-41ce956b95d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMS0xLTEtMA_84ee3479-8d89-4171-b8a3-249949d13c81">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMy0xLTEtMA_0ac06817-ed3a-4dd6-b25b-6f12cf5b3bab">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjgtMS0xLTEtMA_9eb322e1-3fc4-498a-966a-d4b0520cbd96">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjgtMy0xLTEtMA_41daf00e-e403-48d8-bcba-d299bcab6e8b">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjktMS0xLTEtMA_cec5fcda-8334-4043-8584-cec620fd935e">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjktMy0xLTEtMA_0d670c24-fefd-44cd-a6e7-3075210827f4">80</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from senior notes offering, net of issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzEtMS0xLTEtMA_c7efca1b-9b6d-4821-8b75-ef44124a989e">789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzEtMy0xLTEtMA_dab31b3c-8a9d-453c-9b5b-61edc1a3e054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzItMS0xLTEtMA_7b21545c-09a9-435c-9ab2-c8f4e4a7cd84">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzItMy0xLTEtMA_b9d45f5f-7754-499f-b287-9b87cea0439c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzMtMS0xLTEtMA_1e8bfd09-89c4-489a-911a-024ea10eed3c">453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzMtMy0xLTEtMA_7fb2708c-caf4-4ff2-8607-154eb2720ff9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzQtMS0xLTEtMA_4fb14572-5749-4a63-acc4-986f0a13cda8">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzQtMy0xLTEtMA_91c9789f-8aeb-44c2-b842-4853b3a83629">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzUtMS0xLTEtMA_4223f80e-84b3-432b-847b-a1a322721cfd">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzUtMy0xLTEtMA_bda37bfa-e253-4756-8816-186c94526899">514</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial settlement of conversion option </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzYtMS0xLTEtMA_edd12318-50f8-4e16-aa9d-3cec63cc7da5">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzYtMy0xLTEtMA_41bc608c-0e2c-4e24-a3a5-fbb0a286ba2f">578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for partial settlement of call option</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzctMS0xLTEtMA_234afb9d-a6da-484c-b200-711c03eea040">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzctMy0xLTEtMA_b8444246-c50d-4d0a-a260-60ef42296b99">578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal amount of convertible senior notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzgtMS0xLTEtMA_64154494-cbb5-42ec-8ae3-5268e5697549">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzgtMy0xLTEtMA_2b9cc095-f446-4f13-bab8-4c9c9939cd1d">240</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzktMS0xLTEtMA_93c262b4-682e-48bf-ac4e-2c23b6be91a2">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzktMy0xLTEtMA_2b766f69-6e8e-43e6-86f9-09a3de206fa0">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDAtMS0xLTEtMA_bd5ab820-a86a-4c07-beee-047831b71a1c">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDAtMy0xLTEtMA_51630e57-18e4-444b-a96c-a055c473a317">510</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDEtMS0xLTEtMA_ddf1dfd1-bf4d-4510-95af-f79d741e0152">758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDEtMy0xLTEtMA_c16a18f2-9e51-4cbd-b04b-eebb7f189ec8">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDItMS0xLTEtMA_9e901491-7d72-4a2c-a1cd-f0f9224f7a21">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDItMy0xLTEtMA_2566f88a-e60c-462d-93e8-e2a68702a5a4">2,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDMtMS0xLTEtMA_8fc2f907-90aa-4f89-af66-7a49f52ce4f0">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDMtMy0xLTEtMA_2afd326c-8a5a-4813-a5f6-0019daa0b448">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">(continued)</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)<br/>(Unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedule of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock used for share-based compensation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:StockIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfNy0xLTEtMS0w_131ab9ec-d164-4552-9c76-4f36419dd972">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:StockIssued1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfNy0zLTEtMS0w_c171bb27-ccfa-41b9-be01-0034b8cc5aad">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Details of business combinations: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMS0xLTEtODQ4_b0e693ed-7351-4c64-9717-726db5d1ca7e">106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:FairValueOfAssetsAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMy0xLTEtODQ5_8af3745f-aab0-4ede-a8a7-ae788624d568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of contingent consideration liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMS0xLTEtODUy_38644bb6-9698-4441-a3e0-5bf074070ccc">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMy0xLTEtODUz_c4ee26aa-52f7-4b4a-a52c-cf2fd493bcf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:LiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMS0xLTEtODU1_37f8733c-9926-4c51-8bc9-1c62b2bf8a05">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMy0xLTEtODU3_b63ced24-17a0-46be-bc99-4670375177d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTMtMS0xLTEtODU5_f6e63668-6a6b-451b-82b3-74f11e4208ce">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTMtMy0xLTEtODYx_ae145d24-d984-4b59-b6ae-40ddb7b6b5cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Details of change in fair value of derivatives, net:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Loss) gain on call option</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i032e64312b634c9192f40d8aad600f2b_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMS0xLTEtMA_9cb54d79-b17c-4964-9844-45f2d4a6dae3">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i795403e420354184bcfbf7b34e4879dd_D20190101-20190930" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMy0xLTEtMA_32c78a0e-e06a-4edc-838e-899c0c875804">124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) on conversion option</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfb9c978b5184509bd25b72a644093ea_D20200101-20200930" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMS0xLTEtMA_b375ce09-5d13-4387-9c6e-a263fe0c91f7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i446692be62344c64a03638faefd95842_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMy0xLTEtMA_759ba360-c7c1-4a82-97e0-f0816635d69d">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of derivatives, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMS0xLTEtMA_e5cabf1f-6a38-456a-bede-df7db0b07c1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMy0xLTEtMA_b93f8a17-d635-48db-8c0b-93e37269fd0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_31"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">SEPTEMBER&#160;30, 2020 </span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_34"></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">1. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ5MQ_1b452f25-da79-4c22-8a54-01aac5931b71" continuedAt="ie87095b47d9c42358436df43fbe7ea33" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="ie87095b47d9c42358436df43fbe7ea33" continuedAt="i350249c598654e0cbc8f0b4aa74bae90"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have <ix:nonFraction unitRef="segment" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMjI4_19d32be4-18c1-4af1-bd74-d2c81d9ee769">two</ix:nonFraction> reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Health Plans segment consisted of health plans operating in <ix:nonFraction unitRef="state" contextRef="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930" decimals="INF" name="us-gaap:NumberOfStatesInWhichEntityOperates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNDc2_8180130d-953e-44f0-a340-a434be0f2a69">15</ix:nonFraction> states and the Commonwealth of Puerto Rico, and served approximately <ix:nonFraction unitRef="member" contextRef="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930" decimals="-5" format="ixt:numdotdecimal" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNTcz_9e34ac7e-2af9-4bf7-8960-60b2f23c80d5">4.0</ix:nonFraction> million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. The health plans are generally operated by our respective wholly owned subsidiaries in those states and licensed as health maintenance organizations (&#8220;HMO&#8221;). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAxOA_433cf4cd-b6db-4c94-b366-da8b885a7b9b">three</span>&#160;to&#160;<ix:nonNumeric contextRef="i4b9468a421a64284ad5b14f3032873c3_D20200101-20200930" format="ixt-sec:durwordsen" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAyNA_91e39ff4-f0d9-4c32-b3cb-25665b649721">five years</ix:nonNumeric>, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments - Health Plans Segment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc. The net purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="i391a70c55331438f93619826459906eb_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTA5OTUxMTY0MTQ3Nw_532f2334-c463-4a00-8edb-1aba3ac79bdf">380</ix:nonFraction>&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close as early as the second quarter of 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we completed the acquisition of certain assets of YourCare Health Plan, Inc. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we completed the acquisition of certain assets of Passport Health Plan, Inc. See Note 4, &#8220;Business Combinations,&#8221; for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, our Kentucky health plan had been selected as an awardee pursuant to the statewide Medicaid managed care RFP issued by the Kentucky Cabinet for Health and Family Services, Department for Medicaid Services. On October 23, 2020, pursuant to a protest filing appeal with regard to the RFP awards, a court ordered the addition of a sixth health plan to the Kentucky Medicaid program for 2021. That ruling did not rescind the Medicaid contract award to our Kentucky health plan for 2021, nor did it have any impact on the earlier novation of the Passport Medicaid contract to us. The new Medicaid contract is currently expected to begin on January 1, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Magellan Complete Care (&#8220;MCC&#8221;). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into a definitive agreement to acquire the MCC line of business of Magellan Health, Inc. The purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="idd699a73b5be49539d4149d71a08fadd_D20200401-20200430" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTA5OTUxMTY0MTUwMg_2c27da22-3310-437c-a70d-caaa1abb4fdf">820</ix:nonFraction>&#160;million, net of certain tax benefits, which we intend to fund with cash on hand. The transaction is subject to federal and state regulatory approvals, and other customary closing conditions, and is expected to close around the end of 2020. In connection with this transaction, Magellan Health, Inc. has agreed to provide certain transition services following the closing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Texas Health and Human Services Commission (&#8220;HHSC&#8221;) notified our Texas health plan that HHSC had upheld our protest and had canceled all previously awarded contracts associated with the re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurement awards announced in October 2019 for the ABD program (known in Texas as &#8220;STAR+PLUS&#8221;). In addition, HHSC canceled the pending re-procurement associated with the TANF and CHIP programs (known in Texas as &#8220;STAR/CHIP&#8221;). HHSC further indicated that it was deliberating next steps with respect to both re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurements. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i350249c598654e0cbc8f0b4aa74bae90" continuedAt="ic5968233524b4c35ab9c05cfc522df1c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will exit Puerto Rico&#8217;s Medicaid program when our current contract expires on October 31, 2020. We are working closely with the regulatory authorities and the provider community to ensure that our members in Puerto Rico have reliable continuity of care. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illinois</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2020, we terminated our agreement to acquire all of the capital stock of NextLevel Health Partners, Inc. due to the seller&#8217;s stated unwillingness to close pursuant to the terms of the acquisition agreement. </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ2OA_c1198164-64e8-450e-b063-2d06b2b914ad" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results for the entire year ending December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2019, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ4Ng_f3b3adaa-e0ef-49ac-840d-444aeb447e88" continuedAt="i8f7ea14c1f8842aabe527a8c8b4a3fd2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable of our Health Plans segment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic5968233524b4c35ab9c05cfc522df1c" continuedAt="ided1ab0c65cc4b6cbe1169fa44a6385a"><ix:continuation id="i8f7ea14c1f8842aabe527a8c8b4a3fd2" continuedAt="ia0eabf5d8eec44dbba284ec1cacfb945">&#8226;</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:continuation id="ided1ab0c65cc4b6cbe1169fa44a6385a"><ix:continuation id="ia0eabf5d8eec44dbba284ec1cacfb945">The determination of unrecognized tax benefits.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">2. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxODc_cd1ff90e-9c7c-4403-ab46-76a1931a23cd" continuedAt="i7585f4b16d784519851ca03740cf4d8c" escape="true">Significant Accounting Policies</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i7585f4b16d784519851ca03740cf4d8c" continuedAt="iddb1ea8b655a4ad6bf7b28d750fb8f82"> </ix:continuation></span></div><ix:continuation id="iddb1ea8b655a4ad6bf7b28d750fb8f82" continuedAt="i22dde495b7dd47258934ec9471418e5f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMjA_5bb931ca-e53d-45b6-9c4d-1a0cd3b3f3e7" continuedAt="ic96cc96a7ce6459a9f8843c06109ef75" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic96cc96a7ce6459a9f8843c06109ef75">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNzY_2f1748a2-d7e2-4498-b006-4b6fba7255eb" continuedAt="i3c42ef817a424d349b76cdad5e9ca3af" escape="true"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxOTU_0bccd8eb-b41c-45cf-99fb-130db27fe591" continuedAt="i2d03d86c1c24413497e3cfb206ae5e57" escape="true">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.</ix:nonNumeric></ix:nonNumeric></ix:continuation><ix:continuation id="i3c42ef817a424d349b76cdad5e9ca3af" continuedAt="i60a5bc1962f546e88d05a29309a2c7f3"><ix:continuation id="i2d03d86c1c24413497e3cfb206ae5e57" continuedAt="i34ed38726e384413b3078ae65e65c557"> </ix:continuation></ix:continuation></span></div><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i60a5bc1962f546e88d05a29309a2c7f3"><ix:continuation id="i34ed38726e384413b3078ae65e65c557"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNC0xLTEtMS0w_bb32e3ee-44b5-42f4-a013-eef4b6489266">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNC0zLTEtMS0w_fddbf0ab-be3d-4b10-884e-56bc0027b86e">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNS0xLTEtMS0w_eeb8a577-0898-42bc-ab29-a41966d46f75">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNS0zLTEtMS0w_f319ed37-ea82-490d-ae44-3290c659a6d3">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNi0xLTEtMS0w_8fc2f907-90aa-4f89-af66-7a49f52ce4f0">3,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNi0zLTEtMS0w_2afd326c-8a5a-4813-a5f6-0019daa0b448">2,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i22dde495b7dd47258934ec9471418e5f" continuedAt="i949669344e7347af8bfa58ef86e05b10"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM3NDM4OTUzNjkzODI_1ec4af3b-a91c-45de-870b-f42bea181b52" continuedAt="i74f4ce1013784477bff8f200e087968d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income (loss), net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses, and unrealized losses arising from credit-related factors with respect to AFS and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all our investments have final maturities of less than <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:duryear" name="moh:InvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTY0Mg_320ef10a-2146-4bd5-9c70-04c6454ad76a">10</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:duryear" name="moh:InvestmentsAverageMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTY1OQ_97cde43d-0e71-4240-8f63-eba4d55f0c89">10</ix:nonNumeric> years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221;</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable relating to our AFS and HTM securities is presented within &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets, and amounted to $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjQ1MA_0453853f-924f-492f-84cf-a53b2d9de4ab">9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjQ1Nw_1f30aa12-6c38-4b33-bfc5-337915257c75">12</ix:nonFraction> million at September 30, 2020, and December 31, 2019, respectively. <ix:continuation id="i74f4ce1013784477bff8f200e087968d">We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of interest income. No accrued interest was written off during the nine months ended September 30, 2020.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM3NDM4OTUzNjkzODM_ca3f0e87-8221-4481-9e68-9e81ce0c3cca" continuedAt="i525111143b79411db81cecf55f0d61da" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Premiums Receivable </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our Health Plans segment contracts related to our Medicaid, Medicare and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are recognized as &#8220;Amounts due government agencies&#8221; in the accompanying consolidated balance sheets, and included the following categories by program:</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:center"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ReservesReportedToOtherAgenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMjE_5141ef21-0420-4ca8-98f0-59eca36ae2ed" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.283%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNC0xLTEtMS0w_72082654-efbe-47d7-bc14-ce3d478b025f">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNC0zLTEtMS0w_58d79e5e-2c0a-41a9-b18f-925df4801ff3">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNS0xLTEtMS0w_3b749b87-6d0f-4dc8-82f7-edb71cbca9aa">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNS0zLTEtMS0w_9d563176-31c9-49e2-98f0-2cd432ca745d">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNy0xLTEtMS0w_dfb8e52b-c019-4705-b172-8c1ddb01d85c">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNy0zLTEtMS0w_37b27f71-4d5a-48d4-93dd-4c7668824e2c">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOC0xLTEtMS0w_557bc3f9-097b-4512-9d7f-d58bb741b41d">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOC0zLTEtMS0w_9c119dd5-e3cc-4d5d-938c-fc343528b119">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOS0xLTEtMS0w_049ffa98-aa5a-43fa-afd8-c4a5fcc987ac">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOS0zLTEtMS0w_073d3409-3e10-43e5-8a72-46d9744687b1">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTEtMS0xLTEtMA_77397080-8b95-4201-af36-e1287f15643e">265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTEtMy0xLTEtMA_4db7f196-92ca-416d-a1c5-4b8133d440be">368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTItMS0xLTEtMA_ad8ac93b-1320-48ab-8773-e46c46027130">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTItMy0xLTEtMA_878b35b3-3d8a-43c6-976e-fb3bd24bd437">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTQtMS0xLTEtMA_7dec078c-0cee-47e2-bbad-8c9d681a085c">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTQtMy0xLTEtMA_ccd7af5c-b2d0-4b3d-8adf-7878c23ddc0a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTUtMS0xLTEtMA_81f82b1a-2ec3-4020-b676-be902fbd974c">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTUtMy0xLTEtMA_b6b4a520-5765-4208-af1b-a7c3e826bce9">664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i949669344e7347af8bfa58ef86e05b10" continuedAt="i06eca80efc39482fb4d8f086d85b1096"><ix:continuation id="i525111143b79411db81cecf55f0d61da" continuedAt="icb32a316907841168cf54439454762fc"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i0b8da8ee91eb4ef58dbbb2775da3afce_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDg4MA_49e66510-b6c0-4d65-bddd-a135327aa7c7">75</ix:nonFraction>&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $<ix:nonFraction unitRef="usd" contextRef="if6e8716ea12c44aaaacb9d6db8985ade_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDkwOA_28fe8791-31c9-4349-9a3b-c30f688e1739">88</ix:nonFraction>&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $<ix:nonFraction unitRef="usd" contextRef="ie6a3fd1845154357ac826603e0ae69b7_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDg5NA_68ef9cc9-53d7-4bd4-821d-5419f1bf0e05">163</ix:nonFraction>&#160;million recognized in the nine months ended September 30, 2020. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a minimum annual medical loss ratio (&#8220;Minimum MLR&#8221;) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor Settlement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the United States Supreme Court held that &#167;1342 of the Affordable Care Act obligated the federal government to pay participating insurers the full Marketplace risk corridor amounts calculated by that statute, and that impacted insurers may sue the federal government in the U.S. Court of Federal Claims to recover damages for breach of that obligation. In June 2020, the Claims Court granted us judgment in the amount of $<ix:nonFraction unitRef="usd" contextRef="i0147887cf13f4458be0b3970d80acbc0_D20200618-20200618" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesAwardedValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfODA3NQ_32054a92-e106-44b0-8a9d-2730d37303b2">128.1</ix:nonFraction>&#160;million for our 2014, 2015, and 2016 Marketplace risk corridor claims, which we received in October 2020. Since we accounted for the judgment as a gain contingency at September 30, 2020, it will be recognized in our fourth quarter 2020 financial results. The judgment does not create additional Minimum MLR rebates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="icb32a316907841168cf54439454762fc" continuedAt="ia23a887107d24577a9ed42e1fc8ede57">Risk Adjustment.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia23a887107d24577a9ed42e1fc8ede57" continuedAt="ice012b1cd9a84b1e8749617939153d0c"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</ix:continuation> As of September&#160;30, 2020, Marketplace risk adjustment payables amounted </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i06eca80efc39482fb4d8f086d85b1096" continuedAt="i3b718022aa2049c19ee6a9c9409653de"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTExOA_8cbff3d6-fec6-4382-b977-e94f59143cca">265</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE1Nw_001b08e4-237f-4dd1-92d3-734281bc0629">59</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE4Mg_7335860e-121c-481d-8e80-7437288c6f12">206</ix:nonFraction> million. This net payable consisted of $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE5NQ_835d3e8d-acf8-4d2a-94ce-994aba411a77">230</ix:nonFraction>&#160;million in payables relating to 2020, and $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTIxOA_18e8917e-5de0-4857-8ca3-a27df08ba578">24</ix:nonFraction> million in receivables relating primarily to 2019. As of December&#160;31, 2019, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTMwNw_ba4b147c-ced5-4a72-bbb1-9edc3550a1be">368</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTM0Ng_885a09f6-ace8-4b87-b84e-d40a99099d75">63</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTM3MQ_5d863b44-5c60-42c8-be9b-d328eda9114b">305</ix:nonFraction> million, which related primarily to 2019 and prior periods. </span></div><ix:continuation id="ice012b1cd9a84b1e8749617939153d0c" continuedAt="iaa94f3e1ec7e4be2ab96274efe5c4af8"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="iaa94f3e1ec7e4be2ab96274efe5c4af8" continuedAt="i99eb8322a26c458c9642815e07a0f4ca"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At many of our health plans, revenue ranging from approximately <ix:nonFraction unitRef="number" contextRef="i1e4e51fc373341cb966c120414402a2c_D20200101-20200930" decimals="2" sign="-" name="moh:PercentageOfAdditionalIncrementalRevenueEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTkxOA_8b7f9b51-848f-4e5e-a8fd-1666e7d874e8">1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="idf82ebc1b18c49939d196d8bf9931c3e_D20200101-20200930" decimals="2" sign="-" name="moh:PercentageOfAdditionalIncrementalRevenueEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTkyNA_4e084d92-c72c-4508-9f48-b90f5583f59c">4</ix:nonFraction>% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, &#8220;Organization and Basis of Presentation&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i99eb8322a26c458c9642815e07a0f4ca">,&#8221; recognition of quality incentive premium revenue is subject to the use of estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTQ_bbe083f8-0eae-42f9-97e5-a8585ea04ee8" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maximum available quality incentive premium - current period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:MaximumAvailableQualityIncentivePremiumCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC0xLTEtMS0w_009db8d7-be02-4e88-accf-6384ed6bab87">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:MaximumAvailableQualityIncentivePremiumCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC0zLTEtMS0w_5ad75196-1fab-4d49-996f-0c41dcde838c">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:MaximumAvailableQualityIncentivePremiumCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC01LTEtMS0w_d43887c4-b233-4b69-8f3e-5a3eabb0602b">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:MaximumAvailableQualityIncentivePremiumCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC03LTEtMS0w_7e866ab6-2701-438f-b5e2-12c72c0237ee">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized in current period:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned current period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy0xLTEtMS0w_c5927c94-6bd8-44e4-9fd8-61de494fe743">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy0zLTEtMS0w_d4924a52-d54a-441e-a1f9-6632d24db3cb">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy01LTEtMS0w_d1e8b630-68c9-41b6-abf6-7c3d7e871995">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy03LTEtMS0w_c1de9f10-41b3-4267-9a69-3db79b625b9e">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC0xLTEtMS0w_4e416721-fa4c-469a-aecb-282ffaa0c385">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC0zLTEtMS0w_9eb8d2a9-900e-456d-8728-6ac2b19b52ee">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC01LTEtMS0w_b7047fd1-2d5d-4cc5-a498-cbf4cac31f6b">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC03LTEtMS0w_7097f723-ea5d-4c60-af74-faf040b100b9">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="moh:QualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS0xLTEtMS0w_0127212f-710c-4970-9f4c-0d575a8bae43">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="moh:QualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS0zLTEtMS0w_a4831de5-acbb-45d3-b679-cd086000f095">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:QualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS01LTEtMS0w_7935b84e-d57f-445a-9afe-ed9454c3c826">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:QualityIncentivePremiumRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS03LTEtMS0w_85ff3eae-d04b-4b27-9c04-8b044586a991">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized as a percentage of total premium revenue </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="3" name="moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtMS0xLTEtMA_bafbe86d-7bf3-4d81-9c76-b6931922a109">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="3" name="moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtMy0xLTEtMA_e85550ff-b825-4074-b0a5-10e593230478">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="3" name="moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtNS0xLTEtMA_0e9ea1de-9064-4f51-a1a2-2e455c82aa14">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="3" name="moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtNy0xLTEtMA_e51008d2-4955-4453-b513-2bf1edb40501">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNjA_20850db4-dd36-44bc-ad92-f1cc0e11f626" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMzA_e90f4f78-f5bb-49d6-bf9c-c774c4be88cc" escape="true"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if72eeeb9a99b4477ab11023ecac0d4ae_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfMy0xLTEtMS0w_679d5bf2-c2cf-4081-af98-b87ee7ccfe0b">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c9cc48effd74e3db60699619b9bc2e7_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfMy0zLTEtMS0w_ff87db9f-7c18-4804-89a4-fdb397c06e98">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71a512cf78114e5cbc32223760854d4b_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNC0xLTEtMS0w_e79d4707-bc4f-4751-b34e-baec87d1a0bf">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2833620245ff437a9d61acd7e7dbfa4d_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNC0zLTEtMS0w_ac13ad63-8cb1-467b-8aab-05d64247e2b5">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33f1b142cbf04ffc961177d0573c2b33_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNS0xLTEtMS0w_8c295187-01e8-429f-9239-01365321391e">180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id396aa5e78ce44cca988d14d35592f10_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNS0zLTEtMS0w_0cebd5c0-86f7-4ed8-a141-b6fded3e1ba1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1cccaa6b1874d0b97e1e7d43c952948_I20200930" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNi0xLTEtMS0w_b1e7467f-7925-4424-9390-706acacffe1d">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6158f7ac8714b678e788253d6cc7e0e_I20191231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNi0zLTEtMS0w_7fca9206-5b1e-4ef1-a2be-254253cd0bfb">195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNy0xLTEtMS0w_88984336-d1e3-4c0f-a468-25e60e04ae5b">1,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNy0zLTEtMS0w_9e4ba18a-da8d-4de2-beec-9f87e7292c61">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ReinsuranceAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNjQ_32399f19-7dbd-43eb-8ed8-3a761babd8b8" continuedAt="i862c141676aa449f997ce021fde81825" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. Until the second quarter of 2020, we limited our risk of catastrophic losses solely by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;). Beginning in the second quarter of 2020, we now retain certain of these risks through our wholly-owned, captive insurance subsidiary (the &#8220;captive&#8221;). We continue to reduce our exposure to significant catastrophic losses by insuring levels of coverage, with the third-party reinsurer, for losses in excess of what we retain with the captive. Because we remain liable to our policyholders in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. We report reinsurance premiums as </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i3b718022aa2049c19ee6a9c9409653de" continuedAt="ic5699393f81f4a89a5accafc39ddeeec"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i862c141676aa449f997ce021fde81825">a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Intercompany transactions with our captive are eliminated in consolidation.</ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves on Loss Contracts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the profitability of our medical care policies to identify groups of contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. In the third quarter of 2020, we recognized a premium deficiency reserve of $<ix:nonFraction unitRef="usd" contextRef="i2dcf40f147894f828c6c0e0d48d7b212_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTA0NDUzNjA0ODYwNDE_7fda1dae-d9fc-4c2c-8c79-47113b71d628">10</ix:nonFraction>&#160;million for our Medicaid contract in Puerto Rico. As described in Note 1, &#8220;Organization and Basis of Presentation,&#8221; we will exit Puerto Rico&#8217;s Medicaid program when our current contract expires on October 31, 2020. No premium deficiency reserve was recorded as of December 31, 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTc_05b39a82-a3cc-4f0a-9169-5457e7416305" continuedAt="iaafd4a213e7e456fb47f26a31394405b" escape="true">Concentrations of Credit Risk</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaafd4a213e7e456fb47f26a31394405b">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:duryear" name="moh:InvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTI1MTY_fcfa0a56-12f0-4899-a40b-aca7ee76f38b">10</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:duryear" name="moh:InvestmentsMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTI1MzM_fcfa0a56-12f0-4899-a40b-aca7ee76f38b">10</ix:nonNumeric> years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurer Fee</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ACA, the federal government imposes an annual fee, or excise tax, on health insurers for each calendar year (the &#8220;HIF&#8221;). Public Law No. 115-120 provided for a HIF moratorium in 2019; therefore, there was no HIF incurred or reimbursed in that year. The HIF was reinstated in 2020, but the Further Consolidated Appropriations Act, 2020, repealed the HIF effective for years after 2020. The HIF is allocated to health insurers based on each health insurer's share of net premiums for all U.S. health insurers in the year preceding the assessment. Our HIF liability for 2020 is $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:HealthCareInsuranceFeeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM1NDY_a878f554-98a1-45c0-ac87-d5e3985d7d06">277</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="if9a2b45e286440acaf152463d403a03c_I20200101" decimals="-6" format="ixt:numdotdecimal" name="moh:HealthCareInsuranceFeeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM1NjA_969547e3-6e66-4d5c-83e3-62b294590862">271</ix:nonFraction>&#160;million was accrued as of January 1, 2020 and an additional $<ix:nonFraction unitRef="usd" contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630" decimals="-6" format="ixt:numdotdecimal" name="moh:IncreaseDecreaseInHealthInsuranceFeeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM2MTY_1efc0fec-ff02-4dd6-94fe-027508a02758">6</ix:nonFraction>&#160;million was accrued in the second quarter, with a corresponding deferred expense asset amortized to expense through December 31, 2020, on a straight-line basis. We settled the 2020 HIF liability in September 2020. The HIF is not deductible for income tax purposes. Due to the reinstatement of the HIF in 2020, our effective tax rate is higher in 2020 compared with 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We have obtained a contractual commitment or are receiving payments from all states in which we operate Medicaid programs to reimburse us for the HIF, and such HIF revenue is being recognized ratably throughout the year. </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTU_d7294ed2-097e-49ab-ac1d-30f1e2ca6177" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, nondeductible expenses such as the HIF, certain compensation, and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMzY_862fee82-b21b-41c3-bb31-2fcf5fbbaa56" continuedAt="i67561e17e7f7416583ede2022584ef02" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was subsequently modified by several ASUs issued in 2018 and 2019. We adopted Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we recognized the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020, which was immaterial. </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="ic5699393f81f4a89a5accafc39ddeeec"><ix:continuation id="i67561e17e7f7416583ede2022584ef02"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by a change in the reference rate from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued, if certain conditions are met. ASU 2020-04 is effective immediately and expires after December 31, 2022. We are evaluating the effect of reference rate reform and this guidance on our contracts and other transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_46"></div><div><span><br/></span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">3. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RleHRyZWdpb246MmFiZmMwMDE1MmZlNGIwNjk1ZjIwZTIxNWY4Y2UwMWFfNDE4_3a42bf51-d6d9-429c-8acf-725bb9f2ac89" continuedAt="i5afe2a2882f245a1aa850df9723556da" escape="true">Net Income per Share </ix:nonNumeric></span></div><ix:continuation id="i5afe2a2882f245a1aa850df9723556da"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RleHRyZWdpb246MmFiZmMwMDE1MmZlNGIwNjk1ZjIwZTIxNWY4Y2UwMWFfNDI2_3a5c9bf0-7412-4b7a-b567-64d4886939e6" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS0xLTEtMS0w_fcad0154-3eb8-4518-83d1-e8e470f6a06a">185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS0zLTEtMS0w_412e764f-8e70-4863-92d1-1ef47e482432">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS01LTEtMS0w_b1853129-6bbe-4867-aa51-d4aaacd80ff6">639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS03LTEtMS0w_00031fb3-62f6-461e-ad57-356c8f31b538">569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife5003122e804b988dea74c354c83d41_I20200630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy0xLTEtMS0w_2aa22d6b-a0cd-48d6-8291-ac69e695a488">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8def59bebfc44b69808ea12af90bd829_I20190630" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy0zLTEtMS0w_782385f6-a73f-4f11-b1e9-f3e8a7a7b6b7">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy01LTEtMS0w_2a36149a-b093-4f36-abd2-7a81f4a89afb">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231" decimals="-5" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy03LTEtMS0w_29813d87-2475-47d3-8836-a4756f8b3c95">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS0xLTEtMS0w_a83357f1-010f-4d4c-8f78-c3e16195188a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS0zLTEtMS0w_eb362188-9889-4293-87a7-2890e58cb7e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS01LTEtMS0w_64926d70-17b4-4bf1-9461-2423c2fce4a7">2.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS03LTEtMS0w_3de77080-0985-464b-aae0-b7096b936cc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMS0xLTEtMTA3OQ_921323c3-24cb-4699-aec7-95b6ecfbc570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" format="ixt:zerodash" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMy0xLTEtMTA3OQ_7210e80f-04c3-4153-96ca-53a0ebf57579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNS0xLTEtMTA3OQ_60bc29ec-75d8-4d51-ab68-b8bb0029ee49">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNy0xLTEtMTA3OQ_886b5e5e-3481-4aa8-b908-fafda4fc2f96">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMS0xLTEtMA_a4384528-076c-4b8e-a7e6-bb52e175e3ae">58.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMy0xLTEtMA_83412398-6d5c-451f-af64-08f74c105be0">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNS0xLTEtMA_6e6fbb91-a035-4720-aea9-bd8b6a388606">59.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNy0xLTEtMA_5b6ecef5-9815-447a-910f-8edc3653b9ca">62.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItMS0xLTEtMA_cfebecfd-5e9a-47c6-a66d-d6dee35e1329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItMy0xLTEtMA_11bfba31-ed64-425f-b445-e8fd12545d0f">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" format="ixt:zerodash" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItNS0xLTEtMA_2c1ce694-04e3-4634-af7d-d523f6d80cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItNy0xLTEtMA_b8cd18bf-253e-4d03-8575-7344058b4936">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtMS0xLTEtMA_f051b07a-95e7-42c2-ad6e-e7e89e090eb4">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtMy0xLTEtMA_42e44925-789b-437b-b802-cdc46873e3e8">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtNS0xLTEtMA_c2fea5b7-766a-40d3-a97c-8db4d85d1b59">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtNy0xLTEtMA_e27e2419-89f5-49bf-8d7f-3c6cf9ba865f">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtMS0xLTEtMA_0adfe496-a48e-4702-b303-08bc2514cec3">59.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtMy0xLTEtMA_895b7286-cb38-4145-ab4e-40748b2e4dee">63.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtNS0xLTEtMA_f9beded8-f05e-4f23-9322-5a918206e333">60.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtNy0xLTEtMA_83fb3976-2880-4cec-a8af-7704c7cc21c4">64.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtMS0xLTEtMA_91e1e96e-4301-4d53-b1e6-3ab5c2a6b13d">3.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtMy0xLTEtMA_18fb0887-7239-46af-b7ad-0594acfff017">2.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtNS0xLTEtMA_6c3385d8-22dd-4c85-95dd-749909976b4e">10.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtNy0xLTEtMA_af437401-1948-46c7-87d4-b220b0bb61d1">9.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctMS0xLTEtMA_d8ecfcbd-a929-4710-9252-1a9bdd072968">3.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctMy0xLTEtMA_52aa9f1b-31ff-4ab3-8647-a8a30abcd5d6">2.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctNS0xLTEtMA_a240d5cc-08ea-4d1b-ac83-de115693a2f3">10.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctNy0xLTEtMA_11d71459-30a7-4f8c-96be-626db681df87">8.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 9, &#8220;Stockholders' Equity.&#8221; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 14</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_1100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">4. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV81NDk3NTU4MTQ1NTA3_e612911e-8781-48e4-9c3c-cc3e9ee5faf2" continuedAt="i05797a054cca4bdeadf2a7b43c412213" escape="true">Business Combinations</ix:nonNumeric></span></div><ix:continuation id="i05797a054cca4bdeadf2a7b43c412213"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, we closed on <ix:nonFraction unitRef="business_combination" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="moh:BusinessCombinationNumberOfBusinessCombinations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV85ODk1NjA0NjY1OTgy_be672752-ca0d-4f1e-b7a9-bb60db5bff91">two</ix:nonFraction> business combinations in the Health Plans segment, consistent with our strategy to grow in our existing markets and expand into new markets. For both transactions, we applied the acquisition method of accounting, where the total purchase price was allocated, or preliminarily allocated, to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition dates. We expect to complete the final determination of the purchase price allocations as soon as practicable, but no later than one year following the closing date in accordance with Accounting Standards Codification Topic 805, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The table below illustrates the intangible assets acquired, by major class, for the <ix:nonFraction unitRef="business_combination" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="moh:BusinessCombinationNumberOfBusinessCombinations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMzc0Mzg5NTM2MzE4OA_a90d2f7c-5558-4b33-bf1d-7d27802d703a">two</ix:nonFraction> acquisitions. Acquisition-related costs were insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, we closed on the acquisition of certain assets of YourCare Health Plan, Inc., a Medicaid health plan, for a cash purchase price of $<ix:nonFraction unitRef="usd" contextRef="id749608c745740b08f21cdaad564831d_D20200701-20200701" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjI0_c9460686-a09d-4fca-ae5b-b927ebddbbbd">42</ix:nonFraction>&#160;million. In connection with this transaction, we added approximately <ix:nonFraction unitRef="member" contextRef="i87dd32a9ad2d4055800c9652ac634681_I20200701" decimals="-3" format="ixt:numdotdecimal" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjM3_8accfd48-c265-4fbf-a87c-e821ca9a9db7">47,000</ix:nonFraction> Medicaid members in New York. We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i87dd32a9ad2d4055800c9652ac634681_I20200701" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMzc0Mzg5NTM1NjMzNg_9e240bab-1925-4c5d-baec-f461b8f1cf8c">31</ix:nonFraction>&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from expected synergies to be achieved, including the use of our existing infrastructure to support the added membership. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we closed on the acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan. Effective on that same date, the Kentucky Medicaid agency approved the novation of Passport&#8217;s Medicaid contract to Molina Healthcare of Kentucky, Inc. As a result, we added approximately <ix:nonFraction unitRef="member" contextRef="i4beec814285e499c89a31cc2a5afc464_I20200901" decimals="-3" format="ixt:numdotdecimal" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xNjQ5MjY3NDU1NzU5_b7c5b6a1-b268-4acf-906b-62690422b978">325,000</ix:nonFraction> Medicaid members in Kentucky. As of September 30, 2020, the purchase price allocation was preliminary due to the proximity of the acquisition date to September 30, 2020, and the time and level of effort required to develop fair value measurements for the assets acquired and liabilities assumed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated total purchase price of $<ix:nonFraction unitRef="usd" contextRef="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMTk5MDIzMjY5OTI2_b5b1c7db-7a92-4827-9e15-23adbfa21b81">60</ix:nonFraction>&#160;million includes our initial cash payment of $<ix:nonFraction unitRef="usd" contextRef="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjUw_23c57e85-1e91-4e17-b98c-4c230f2ee322">20</ix:nonFraction> million in September 2020, plus estimated contingent consideration which consists primarily of an amount due to the seller for members we enroll in the open enrollment period for the 2021 plan year, over a minimum threshold, which resulted in an initial contingent consideration liability of $<ix:nonFraction unitRef="usd" contextRef="i433cfe399a704a47bba65a8c3a8b4e14_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMTk5MDIzMjY5OTM0_a4c51c9d-9660-4446-8064-b06e669faa24">40</ix:nonFraction>&#160;million. We expect to settle this liability in the first quarter of 2021. Contingent consideration liabilities are remeasured to fair value at each quarter until the contingencies are resolved with fair value adjustments, if any, recorded to operations. See further information in Note 5, &#8220;Fair Value Measurements.&#8221; We recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="i433cfe399a704a47bba65a8c3a8b4e14_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMDM0MDk2NTEyODE3OQ_af243e71-ed60-4923-a8fa-1c740256419f">27</ix:nonFraction>&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from the assembled workforce, and the future growth associated with the member contract rights that are incremental to the contract rights identified.</span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV81NDk3NTU4MTQ1NTIw_7535e482-a22a-4dee-bfe6-8a4073e7bba0" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the intangible assets identified in the transactions described above. The weighted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average amortization period for the identified intangible assets, in the aggregate, is <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjQzNzg2_ccc27431-ca4a-411f-9985-300c67f438f4">10.7</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible asset by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70c7a62c77174856b9b975dfcec870fa_I20200930" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTEtMS0xLTI2Mzc_94fd8be2-19d9-4114-ba1b-90070865a6ab">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8354adbb632c45a49e8c71116d0bd934_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTMtMS0xLTYxNTE_252f8931-3d04-48db-a6a5-e7921532e4f3">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie5b787b7098243d881eb301f892af3a4_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTMtMS0xLTI2Mzc_75cb98bd-89b3-4b91-b0a1-07f105c0b54a">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb06886bec8d4d3a8d4d744db0da88ee_I20200930" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTEtMS0xLTQ5NTI_94c44849-fba0-423b-8570-8ed205ddaf8e">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6d40c8167db46f2a37e7382c7546b67_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTMtMS0xLTQ5NTI_e7971d49-0b59-4abf-bc94-055845925e94">16</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0f13a84316c4f71b4b314485e38873d_I20200930" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTEtMS0xLTI2Mzc_df75e707-f84f-4213-9104-65099e951076">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if845f286887c45ceb4f63de315dc91f9_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTMtMS0xLTI2Mzc_5c214de4-331d-4bd2-ab6b-6353e90cbbc6">10</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV82LTEtMS0xLTIwMTk_45ec589b-69ba-4090-a6af-39205e58a992">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_49"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">5. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQyNQ_9fbec62e-ee3a-47b3-a15f-7d08d81922b2" continuedAt="i20cd71bfe2ea41efafc58a63cfbbb416" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i20cd71bfe2ea41efafc58a63cfbbb416" continuedAt="ie614257d498d4766b8632ed1e26b6c1d"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions that we use to a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2019 Annual Report on Form 10-K, Note 4, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $<ix:nonFraction unitRef="usd" contextRef="i421938697dd9476f9e8ed3a9387bbc72_I20200901" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTA5OTUxMTYzMTA5Nw_bb42fb65-066b-4a79-866f-7922032d49cd">40</ix:nonFraction> million, in connection with the Kentucky acquisition described in Note 4, &#8220;Business Combinations.&#8221; Such liabilities are reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets. The fair value of the contingent consideration was estimated using a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="ie614257d498d4766b8632ed1e26b6c1d" continuedAt="i23a44f243d7a4bc69401cf3c7f8749b7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simulation-based option pricing model through the end of the measurement period of approximately <ix:nonFraction unitRef="number" contextRef="i044a1952a952424d842a4e7856f32813_I20200930" decimals="0" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYxNg_2ef5ba68-8797-4c57-8762-e399f14901ae">5</ix:nonFraction> months, and included certain non-observable inputs. The key assumptions included a U.S. Treasury based risk-free rate of return, expected asset volatility of <ix:nonFraction unitRef="number" contextRef="i16ad5df3e0954d1db28ec31f056ff595_I20200930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYwNQ_3341eb7e-3068-4c19-b61a-b8a4fbec6401">35</ix:nonFraction>%, expected revenue volatility of <ix:nonFraction unitRef="number" contextRef="i79740d5150ff4f4db489bbeb8788d206_I20200930" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYxMA_300e4030-c52c-420a-b29f-cef26c9311e8">9</ix:nonFraction>%, forecasted membership enrollment, and other estimated revenue, asset and payment correlations and discount rates. The model produced an estimated range of undiscounted amounts Molina could pay under the contingent consideration arrangement of $<ix:nonFraction unitRef="usd" contextRef="i4e6dcbb92a8c4409987fd92c2d6dd158_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTY0OTI2NzQ1MjI1OQ_ee72cb93-87d0-47c2-acde-e18fd5da8b89">25</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i058f38bcf796477da567b0db7952dc1e_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTY0OTI2NzQ1MjI3Mg_7eee120f-3646-4d50-8c2d-6b04e8a8067b">75</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQ0Mw_233f1f0e-7425-4d2a-bdf2-842e761e2dc6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.209%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC0xLTEtMS0w_baeea074-19c8-4d52-b3da-405bc9a48021">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6748d59d26dd4b4e9a668279c29380d7_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC0zLTEtMS0w_9e2e60eb-b0b9-4886-8c31-c4efed76715e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfdb1a74a3b545d0aee5dd04c31c43db_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC01LTEtMS0w_417b4c40-623c-4071-a4b2-59fe6ec755bb">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5933b867152b47d29c8a2374b54fa5a6_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC03LTEtMS0w_580e873f-1727-4bf0-aeb6-b8b57a23f496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS0xLTEtMS0w_e4d25192-d881-4089-af20-e92be7f3fae6">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7ec79780ff9483fafe419776c6fff72_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS0zLTEtMS0w_5a058346-6c3d-4f33-a221-13f55c33a6be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e9ab90b62c74c95810d0a07c314ddd4_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS01LTEtMS0w_1a7553c4-ef2e-4414-b473-c00b9877a398">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie806826c7c874d3cbee4baa4d5c22d75_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS03LTEtMS0w_985b4de7-b99d-4c17-a301-4b949e639a87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi0xLTEtMS0w_1084a760-9959-4d88-a01f-d94fb1667543">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie647fc62813f495f8d1417451ba88a73_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi0zLTEtMS0w_e9782069-2ced-4d7f-b325-59518350b01c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57fc15dc5d8d48bea4aaa778a0932e03_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi01LTEtMS0w_4f043452-bc47-4ef0-9c48-0d5cdfdaf500">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0a101af7d174776bc9ad4386eed46b9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi03LTEtMS0w_822541a5-187a-4df5-8196-8ae0c3f5b437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy0xLTEtMS0w_3f1e282a-99b6-432f-ac07-f2eba1c9f9be">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2741d275f3f4c36bced0a05c8aefec9_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy0zLTEtMS0w_7ce21307-f9d8-4f29-aa4d-ea4e9b579ce4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie22b9a72648d4042884d35282e080c18_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy01LTEtMS0w_2bff5847-ec8f-4259-bd96-134745c1b5fe">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bef829bfb5741c39a8a5d311beab675_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy03LTEtMS0w_2c522cba-1ff1-45cf-b153-ea3c38d538f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC0xLTEtMS0w_6800d2a5-15f8-4c29-88e8-ad751883c62d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a868439a3ab4ddba3f5532d5ceda157_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC0zLTEtMS0w_bfb3b818-1b83-4873-b540-c8b97cfb4675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ca2500088d432999b9943027a2975b_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC01LTEtMS0w_3333eff9-cdc3-4b64-a366-20ed4371a91e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6ad5bafcd3a45f386f7d9e4c0f9f4a0_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC03LTEtMS0w_94eaa9c4-c037-4416-b264-11b148201e83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS0xLTEtMS0w_b0f9bd9a-a208-4c34-9c0c-93f6274f4c7b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79dc47d8b0274fb7814a8ba0de483d90_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS0zLTEtMS0w_c77508a0-4853-498d-999c-aadd68b2e597">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6363a2d3e25d4dd98cfe015a124dada4_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS01LTEtMS0w_10a57105-e9b6-4b11-ba23-b120dcfba96e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7caaaa444e8946e8a72451037d62eb94_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS03LTEtMS0w_b6118822-265b-43d5-89ca-5bc69020092d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItMS0xLTEtMA_ebd9eb3f-908b-4909-97da-efc66694773b">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItMy0xLTEtMA_e478bc8b-48fa-4f49-99d6-a6a82256b25d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItNS0xLTEtMA_1a3db20e-6e82-46b2-9ee1-3e0185d03843">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItNy0xLTEtMA_aa4458d9-7586-442a-a35c-ab1262f87ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtMS0xLTEtMTM1NQ_05e9afa4-5f4e-4db6-a972-90f2d30e5499">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtMy0xLTEtMTM1Nw_33674685-37df-421a-99bd-14aecf64409c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtNS0xLTEtMTM2Mg_803c89e8-7ab1-461d-a508-13473b370f8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtNy0xLTEtMTM2MA_694e3d83-d3a5-43a4-81a9-8869724c8125">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtMS0xLTEtMTMzNg_80ffd9d3-57ff-46f9-98fc-102dd5574f33">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtMy0xLTEtMTMzNw_e8fdd9bc-7627-457c-99ca-5c5111f18ab2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtNS0xLTEtMTM0MA_ae6fb122-3862-4523-a8c8-6caf96086018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtNy0xLTEtMTM0MQ_ae42af0b-799d-423e-a748-3ed5c512de9d">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC0xLTEtMS0w_032e84e3-528a-4c96-bbd9-aa4dd3ec00d0">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a0edf748fe453aa44bb4508f73e5f4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC0zLTEtMS0w_b4ee8885-cbe1-42fb-b521-edd8a597a995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d9bab2071e4d2bbff6fa531b293a7b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC01LTEtMS0w_b39259b6-c5cb-4a3e-9c65-7825658d544e">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if241099a610c4f3785fd872f815a3259_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC03LTEtMS0w_914e6837-7d90-4868-a6d9-47b36e2798c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS0xLTEtMS0w_97a92cf8-aa52-42b9-a4d4-eff1f4005254">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8832b45f6ca43d392a187f977e3dbf4_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS0zLTEtMS0w_2a4f7e3c-0e79-4315-a3b9-f5614fa8326a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i690ef92af3884583b912258ff28d709f_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS01LTEtMS0w_aacfd77f-490b-43eb-a70e-d5c718076abf">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i668462f9d37f4932b5b594b4f0fcb1e9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS03LTEtMS0w_c6607c26-2ab4-4005-91e3-bda3d61c6eaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi0xLTEtMS0w_f2d07007-29e8-4b9f-85ad-c073ec1ad744">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcef928989144ada890aa6c205760cfe_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi0zLTEtMS0w_9cdcd374-b53a-43f9-a279-91bcca2086ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i234c36ce5254435e9cd31cb07a130065_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi01LTEtMS0w_b68b5418-63f5-44c9-955d-3e49375116dd">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f8fb252fba435384882b7d0bd11132_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi03LTEtMS0w_998635f2-0598-4825-9b18-d49ef90c9343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy0xLTEtMS0w_d2803aba-f9b4-4509-bd68-4cc7160e427f">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id693148d77924496941bc5d2a267a6d8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy0zLTEtMS0w_c264d17b-e53e-473b-8f93-ccca913d3a5b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc37b2026d5149db9253f8ee18a2d9b2_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy01LTEtMS0w_11d1aace-e573-44c0-851e-794f66e5ffbf">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c9899abdda479e99525c731ad8ded7_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy03LTEtMS0w_d93bdfec-ffc4-4698-9917-16fa7d3b54e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522376b3702049e087e884d659c89675_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC0xLTEtMS0w_f8215fb4-575e-48e4-9a1b-2f4e3df54cd2">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iece312dcb67946698766f966c89eafa2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC0zLTEtMS0w_3531bc6c-0b89-4e9c-b0d6-4f98f6d503ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id50eed5aa516417bbac56da2beaea590_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC01LTEtMS0w_09b9d4d5-6eec-443e-9743-6bdeeb23e75e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68b250a3de064792b082df53482bf14c_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC03LTEtMS0w_7ac805ac-c4ba-4233-a76b-1ad8565e77f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS0xLTEtMS0w_b25a14bb-eabc-4035-95ba-06aca7850cc0">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia96df6f9f64a43558623ace7f058a832_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS0zLTEtMS0w_5a5091bd-4065-4356-872c-75eb4e14648a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc73a3dc4644046892c7265608f9887_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS01LTEtMS0w_17a7dd96-bb79-491d-8b4e-9a2ed328308a">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa4f9337eb184ec2bdfe4334c287f7b5_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS03LTEtMS0w_b8782039-49f0-406c-8fa9-acc97952a855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtMS0xLTEtMA_1b72bce8-d08d-4120-9d43-d93c830ad47d">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb61a08e25544eebb8b370e51386f60b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtMy0xLTEtMA_2c63b5d9-f8de-4d46-9d68-cb5cf72f094b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d6efdc95e7240149d457a1f9ae63e55_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtNS0xLTEtMA_249973d0-51c5-489b-91f2-67273d8cde4d">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ec964ecd3644f5a8e9d165b2153cfe2_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtNy0xLTEtMA_255bba13-d374-4bb6-8be5-963722541209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtMS0xLTEtMA_83f44fed-c6a2-402c-9f6a-a016158e6626">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2526f7970b8c4c11bfd963e67d99f188_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtMy0xLTEtMA_c2a13b76-9c46-410e-bea3-3d0f6b66c363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e4e03da2559470b9e01c0f4e7f534db_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtNS0xLTEtMA_65869e34-efe5-4c3d-80ad-ed4bcdaeccb3">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic12f63d329ee4926b7f91daa16eca22b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtNy0xLTEtMA_1e2b5a62-4d6f-4df6-a28a-7ec92c194eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItMS0xLTEtMA_475d59ec-dbbc-4e9b-b659-b39f22023c03">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItMy0xLTEtMA_cc78a935-ae14-41b1-a287-b3acfb1994ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItNS0xLTEtMA_195e6bfa-f0bb-4421-9e91-ddf2aa54bbc9">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItNy0xLTEtMA_b2349657-7f05-4277-a82a-c86fa049e88c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option derivative asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ad60777eaf94a25b4eb9085704435f9_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtMS0xLTEtMA_7f5cd9f3-4785-49af-be06-5c007b95426e">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i721461de0d57453f954cd5a2ea7e6120_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtMy0xLTEtMA_d1554624-0c31-495a-abc3-18d872cff720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf4f5c72cbac46beb3ae4a136d11034d_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtNS0xLTEtMA_a3ac1fd2-b5b0-49b9-a237-9df4a09ab034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11b1b5fd2c3d451da9d56d574c319476_I20191231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtNy0xLTEtMA_0d914e44-d830-4bff-8fa4-339c0e8a0b3c">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtMS0xLTEtMA_d60866b9-972d-4b19-8c08-2e7bf1a7b8e0">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtMy0xLTEtMA_d1cd2f48-c067-4ac4-b6cb-c1041da2cdc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtNS0xLTEtMA_b8d98585-6a69-4c09-b33e-10108c644eac">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtNy0xLTEtMA_0feac716-b7fe-4fd6-ac7f-388382ee469b">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3586192295fd40e39cdd133fd5eda38f_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtMS0xLTEtMA_5818e081-e22a-4676-bafb-49eb5b310384">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3035128b95994c0192502f66cc8725c3_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtMy0xLTEtMA_2993dcc2-2764-4d3d-81ba-f9d1bbcaffd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9eafdb5b66a49c39b778405016244ea_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtNS0xLTEtMA_9fa1b723-892e-4f97-98cb-3f22c379873c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d552ba27235403b8fea92d279192c84_I20191231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtNy0xLTEtMA_eb172798-8c1d-4e31-ae97-89eaed5167f0">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctMS0xLTEtMA_d9b72057-66df-407a-8e71-c2d0eeefa4e7">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctMy0xLTEtMA_63027d59-2974-4cc5-8ad8-3e25d15b66c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctNS0xLTEtMA_a2b5ca6b-2e41-4d09-8bb1-47cb4f09992c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctNy0xLTEtMA_2216713a-4db2-48a5-bf2d-dccead337df4">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the nine months ended September 30, 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i23a44f243d7a4bc69401cf3c7f8749b7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQyOA_2320d949-166f-41e5-8513-54effa7194ad" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the accompanying consolidated balance sheets:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets: Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28a5c4abcb034316be3389b51a439633_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNC0zLTEtMS0w_cacf9824-dc6b-48b2-881e-7d4a40e74a9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f50b9933fcc48f99b974e53b1d2003b_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNC01LTEtMS0w_8b01f637-6c97-4894-92e5-e09622e64d4e">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities: Accounts payable, accrued liabilities and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0209dd5a4ba48f1b5ae0d8164855055_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNi0zLTEtMS0w_ace862ff-1b85-4517-84f0-07cd4d8d3909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cc3a3bcad764ec5b23c25c4598cbcf6_I20191231" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNi01LTEtMS0w_dc9198f2-a2a6-4ec9-ac6c-33c077a4914f">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our derivative financial instruments, see Note 11, &#8220;Debt,&#8221; and Note 12, &#8220;Derivatives,&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we received $<ix:nonFraction unitRef="usd" contextRef="icfe4a0d7268840d4a04e16db85cbe422_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTgwOA_8aa0e75d-00a5-4727-bd9f-b59bf3b53329">27</ix:nonFraction> million for the settlement of the call option derivative asset, and we paid $<ix:nonFraction unitRef="usd" contextRef="i957912dee94240ee9072f0022698ffe5_D20200101-20200131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg3OQ_9da7f8ae-ebf5-4f0f-95bd-b59ac94fc349">39</ix:nonFraction> million to settle the outstanding $<ix:nonFraction unitRef="usd" contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg4NQ_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4">12</ix:nonFraction> million principal amount of the <ix:nonFraction unitRef="number" contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg5MA_04a18703-99ee-45b3-9a21-09a2eff622ac">1.125</ix:nonFraction>% Convertible Notes, and settle the related conversion option. For more information, refer to Notes 8, &#8220;Debt,&#8221; and 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTM3NDM4OTUzNTA1NjE_69cc7b09-6f2e-4190-8cde-36a267304f8d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0wLTEtMS0wL3RleHRyZWdpb246YWViOWY2YTNiNzBhNDJjZjk4ODUwMGM1Mjc2OTQ1MjVfNA_c747b537-b0de-448c-8595-8a4c52e1c47c">4.375</ix:nonFraction>% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58388cfb135745d5a3d2212619472938_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0xLTEtMS0w_0d15ad2f-e10d-4141-a3d0-83a311639b3c">789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0145a0902d4f00a6773060e4727efb_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0zLTEtMS0w_d8f1052a-da7c-44c0-848d-ad60dd2e3c1d">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ded383a09c049409bb8aa4e1578f251_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC01LTEtMS0w_4a34fa32-0995-4182-8c65-19141b016dbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7126a354069c4673ae6ccf8c5fe6c977_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC03LTEtMS0w_2f617ec9-10e3-4bd0-9513-522935ba451a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if95b0e5cb5ad441cbe5353c0775eada6_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0wLTEtMS0wL3RleHRyZWdpb246NDUxYjkxZWUzNmYzNDk1ZWI5ZTkyNzQ5ODY3Y2YyOTlfNA_0c727ed5-099f-4dd7-a977-10d3562c6a99">5.375</ix:nonFraction>% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if151f099c6024c06a2e13a64537444dc_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0xLTEtMS0w_7e0e5ea3-89ab-4a65-8d7e-a01045a61875">697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2aeeae1e1894e5ba53a5d2f756ecd8d_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0zLTEtMS0w_4ae5a519-0e85-4020-9d98-8396fb08cee6">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf1097073c7c4951a8a0493f53a52d9f_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS01LTEtMS0w_674427c9-07fa-4f2e-bd64-41b251c43904">696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i920b911bb1d54c89b67a30da5c6a439a_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS03LTEtMS0w_3634e980-b80b-4620-a279-d39bf863c2dd">745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45acf5d8b86b488a9df5b605c415166a_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0wLTEtMS0wL3RleHRyZWdpb246YzQxZTk5Zjg3M2U1NGYzMzgwOWExZmZhMzZhY2UxODNfNA_471ac8cb-0794-42e7-833b-8b0aa6ca9727">4.875</ix:nonFraction>% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d429d24c23a4067aa9eefd0f1237fb1_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0xLTEtMS0w_3f7448b4-d88f-4327-98c2-2d20afa560f8">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a584d33b6bd4620a88cdb8f036b2df2_I20200930" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0zLTEtMS0w_683bc919-3d0f-449b-abaf-84b876c36f8f">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i607fd186209b46f88148885246fba93d_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi01LTEtMS0w_67d63fbc-67e1-4ff4-90e6-6f5b4e54e1c0">327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd06b3418b6d4f8889dd763f2cfe3ecb_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi03LTEtMS0w_373aad98-7501-4de6-854c-97cd5504eb1f">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2d1a36636ff4190a026b7df75b9f3d5_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy0xLTEtMS0w_a24500f5-3497-41dd-a5a5-f7c8e90e4873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff0aba0320264b41967f2e901f1c1b66_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy0zLTEtMS0w_c8359ac8-9968-498d-99ac-0bdf08d2ec51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i338d7f40d6294accbb73f4a509d10ae4_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy01LTEtMS0w_e3a10abb-defd-4211-ac32-2a8d52b74663">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf2d1b248d0349fc8ac32939e896036e_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy03LTEtMS0w_a7e704c2-5472-41b8-95e0-39a9a140691e">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide774a0690994809ae6d22cf1b4a5ec5_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0wLTEtMS0wL3RleHRyZWdpb246MzEwN2UwNjU3ZmY5NGZmNmI1OWJmZWQ2Yjg0MWU2NTBfNA_eacf1e00-2415-46df-a0d9-e4dd6bcaf79e">1.125</ix:nonFraction>% Convertible Notes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f28d6910080420eadec07f4dd9557ee_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0xLTEtMS0w_7d6886fc-05dc-4387-a99d-55cca8b6e3fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5372aaf360432383af74ac21bc50e1_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0zLTEtMS0w_f5ad836d-6846-49ed-994f-2a9cf8af5b8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9afc1ea189844c5eb735f3f4d963e7ba_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC01LTEtMS0w_cd2b7e99-4463-439c-93d9-a001ac372802">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d5297b47514ec9a062d743f1f8ebfa_I20191231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC03LTEtMS0w_32697718-2cce-4fc5-84b1-c47dc6d01d4e">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ccea875e1a344df9d2d0328fcf08ab5_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS0xLTEtMS0w_56e7e64d-673a-491b-a4c1-65dd5653574c">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4004e550b88493b9d96d33568d57593_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS0zLTEtMS0w_60f3dd6f-b729-456e-9d68-53aa55db4bbe">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic451188dc3fe4b559f5d53786e36984b_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS01LTEtMS0w_5ebddce4-81ef-4c51-ab43-c50858feac48">1,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9cd3c1e16c54817acea356e158e1192_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS03LTEtMS0w_fedf4c8a-435b-4895-9a6d-83261bf94164">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For more information on financing activities, refer to Note 8, &#8220;Debt.&#8221;</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">6. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg4NA_a5fb335a-ed0b-4cc5-92f8-1f96e8e7e61b" continuedAt="i6b570ed840b74e7f9b6452618cb6aed8" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="i6b570ed840b74e7f9b6452618cb6aed8" continuedAt="if0237d1700514e178df5e522dff06ac0"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all our investments classified as current assets to be available-for-sale. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg4OA_17aa09d1-89e0-4231-b8b5-ec12025fb7e4" continuedAt="i7844d3a9dcf6448d885aa3aa45f58125" escape="true">The following tables summarize our investments as of the dates indicated:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i7844d3a9dcf6448d885aa3aa45f58125" continuedAt="i65897ab2308e4baaaf735233cdaac162"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS0xLTEtMS0w_352c599f-2e1c-4a2b-b978-da8cdf2f0719">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS0zLTEtMS0w_259fe14e-93df-421f-a770-9026be0142ba">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS01LTEtMS0w_77f6cb46-c334-423e-ac89-06ff9a239a85">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS03LTEtMS0w_d0e8460a-bd3c-45cc-ac56-2d376d099e94">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi0xLTEtMS0w_a037af47-afd9-4345-8069-3ff26c930c61">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi0zLTEtMS0w_7642d7ee-f504-405d-baf4-7765918bc7da">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi01LTEtMS0w_5d4fc1a6-2f74-4adb-9234-d5c273dc2ffa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi03LTEtMS0w_bf9c4f07-9a36-4aa5-a0e1-c6b20458a3d3">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy0xLTEtMS0w_9c825256-fd6d-4998-8efc-6dd48017003c">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy0zLTEtMS0w_5554c384-5c01-45b6-8167-e58a38f67f71">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy01LTEtMS0w_dafc4f4d-8915-4894-9154-927298bfaa92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy03LTEtMS0w_80081971-9c34-4c34-a7da-491b65491ebc">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC0xLTEtMS0w_b563dacd-db99-471a-a35b-0c33cd33723f">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC0zLTEtMS0w_0b27ab08-848a-4bdb-87cf-4d817a17a61b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC01LTEtMS0w_61dd44a9-519a-4532-9db4-2484bd9b507e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC03LTEtMS0w_b74952d3-90ac-4f3c-bb5e-d9bfa65067b2">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS0xLTEtMS0w_2b5d967e-39be-49f6-91ff-187d04c9bfce">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS0zLTEtMS0w_28cae912-de02-41f0-a970-84c1cead368d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS01LTEtMS0w_72be7a45-c8ae-4aad-813e-41c20a6c4566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS03LTEtMS0w_6226a618-7e7f-475d-abd7-1884a2be8e7f">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtMS0xLTEtMA_694d9017-0726-4af2-8774-a5946adad16a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtMy0xLTEtMA_febfa04a-e33e-47ae-aa27-8fa5ca275587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtNS0xLTEtMA_69b1457f-037b-4cf2-9d26-a744fc696587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtNy0xLTEtMA_18a77e0e-ba85-4af4-a264-7b33608af292">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtMS0xLTEtMA_328d4c56-b4e4-4775-93a0-e5e59d8a87c4">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtMy0xLTEtMA_cb467455-76ca-4c55-bea6-42bf5ab4e2a3">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtNS0xLTEtMA_b639150c-1d46-4f08-abd0-76d56493094d">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtNy0xLTEtMA_19f0e381-fe73-496d-9c2d-ba6fa6a50856">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="if0237d1700514e178df5e522dff06ac0" continuedAt="i6b84ed00612e4d10b40f415d9c892b8e"><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i65897ab2308e4baaaf735233cdaac162"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS0xLTEtMS0w_7ce41c96-e195-4fc2-a43c-5e277acfde4f">1,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS0zLTEtMS0w_657abf31-029a-416c-b8e0-b55c0805209e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS01LTEtMS0w_bce75dc7-a1eb-4bec-8a6c-25b3f1cbc9ab">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS03LTEtMS0w_0d3825ff-dd1b-4d00-be4e-424478168e26">1,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi0xLTEtMS0w_84416a17-722a-4278-9bd9-ebca456ea5a8">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi0zLTEtMS0w_888629b2-db27-4ce2-9a39-6bdbde0056ed">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi01LTEtMS0w_e7933a6b-b5d2-4f12-bcbb-db5c39a30594">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi03LTEtMS0w_7773f571-b11a-433b-a1fe-434943fc234e">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy0xLTEtMS0w_8b176ad9-dfa3-499e-a8c3-d417f3921ae6">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy0zLTEtMS0w_8b56b4ff-4fb9-4bbb-9181-2bb4b45c5aa6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy01LTEtMS0w_9f51022f-b25c-4ac1-b4d7-8e0599f5c7e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy03LTEtMS0w_96470513-af11-449d-86e6-9488e4ede52a">78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC0xLTEtMS0w_5ab51ef8-dbb0-4c2c-9212-b5757b251a1c">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC0zLTEtMS0w_3fefd858-c455-4bcf-b484-311467ebe9c7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC01LTEtMS0w_2ca1cb0e-8b93-499c-ac1e-70a01755532c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC03LTEtMS0w_d1bf556a-abc0-49ae-a41c-47f2afe48598">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522376b3702049e087e884d659c89675_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS0xLTEtMS0w_7faa11ee-d141-43eb-9048-dda90c60f024">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522376b3702049e087e884d659c89675_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS0zLTEtMS0w_49a2ada5-7d5e-4232-8a3f-e9c2c479704a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522376b3702049e087e884d659c89675_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS01LTEtMS0w_f4b3bc4d-26a0-4f92-a662-47d773934c1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i522376b3702049e087e884d659c89675_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS03LTEtMS0w_30f64671-6919-4603-8be1-8ab433a93e35">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtMS0xLTEtMA_920f8bb0-abd7-41d7-bfd0-43190426b38b">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtMy0xLTEtMA_e3d25d12-bf42-417d-a30b-49a60bc8c8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtNS0xLTEtMA_32c3449f-15b2-48ff-9c6b-719fb6c4791f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtNy0xLTEtMA_c625e28e-97d7-4efe-a92d-b276f2f7dfab">86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtMS0xLTEtMA_54fe31fb-fbef-4591-99ab-aa36575fa9dc">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtMy0xLTEtMA_b54c1c78-9eb3-4af0-8322-2287ddeb05da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtNS0xLTEtMA_77e37215-9335-4bee-a64a-415c3bf4c052">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtNy0xLTEtMA_805d21e4-ab91-4e64-b56f-ea942f7cbf58">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItMS0xLTEtMA_59d6b472-979c-413c-963d-68b246da01be">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItMy0xLTEtMA_d399c53f-9bbc-4382-b926-15b7b815265f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231" decimals="-6" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItNS0xLTEtMA_f7eb4589-d0f7-4188-a97e-f38d4c7680ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItNy0xLTEtMA_8d8e9fe6-df1d-4ada-b0c9-ad5fc3741aae">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtMS0xLTEtMA_cf4fdd93-1da3-449c-a4a3-719b2f3da766">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtMy0xLTEtMA_c55f8049-30b5-430f-9601-cb13ea08ebc4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtNS0xLTEtMA_f7bd2659-3427-4d57-ace1-b93d6701061c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtNy0xLTEtMA_af977459-5de6-4ca7-ac1a-de2e3398eda1">1,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg5NQ_f4c2758e-17ce-477d-a6ef-2c6947a08d46" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of September&#160;30, 2020 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfMy0xLTEtMS0w_de46e8c9-1414-4d0b-87e5-950e31b0f63a">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfMy0zLTEtMS0w_48418e19-0e54-4248-b736-f969addc31c7">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNC0xLTEtMS0w_b253b96d-b1e0-4c53-95d3-6afad30f7424">943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNC0zLTEtMS0w_a202c5ad-12ee-40b4-a966-683f2e927d5d">975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNS0xLTEtMS0w_98dab157-e26a-42c5-96cc-b77b2d3dbced">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNS0zLTEtMS0w_89700813-e232-4ee5-926a-bc82ef2b72b8">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNi0xLTEtMS0w_d9c53d54-656d-4264-91c4-873f5ce735fb">425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNi0zLTEtMS0w_32169eec-df25-4e6e-975d-d996aa2d6a64">434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNy0xLTEtMS0w_e94bfe68-0d56-4e92-a7d9-2ae05c84be01">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNy0zLTEtMS0w_69b99780-e12f-4617-b514-1fc2f3e210fb">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three months ended September 30, 2020, and amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfNTIw_6c69e755-a129-45f2-93a3-d730fd58f28c">6</ix:nonFraction> million for the nine months ended September 30, 2020. Gross realized investment gains amounted to $<ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMTA5OTUxMTYzMDkzMQ_bc25626e-f940-43ca-9d3f-43ae625a5809"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMTA5OTUxMTYzMDkzMQ_dbc4b057-b367-4d9d-8769-428861fc7a86">11</ix:nonFraction></ix:nonFraction>&#160;million for the three and nine months ended September 30, 2019. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2020, and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at September&#160;30, 2020, and December&#160;31, 2019, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&#160;</span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg5Ng_ab1adedb-e34f-4bcd-803e-3ceebcfb575b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0xLTEtMS0w_054783cd-b24d-42ad-86d3-d5fba22a4849">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0zLTEtMS0w_3d4aecf5-c7ba-46ad-af39-654240c5e364">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC01LTEtMS0w_ff90dca4-9829-4ca2-98af-edf82038b39c">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC03LTEtMS0w_485ecd92-dab4-47a0-8e9a-6d7f43ad33eb">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC05LTEtMS0w_1cc5a5d0-830a-47d5-8b7d-d7224ee507af">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0xMS0xLTEtMA_daaa0432-76c1-41ed-a834-de591a341bee">167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0xLTEtMS0w_fc948932-4663-41c0-8a46-385b2d84daef">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0zLTEtMS0w_67339be9-9139-4b74-abcf-9576e306e1fa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS01LTEtMS0w_f9b58b2e-f940-409a-baf4-8b177bab4da4">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS03LTEtMS0w_0e8a6193-813d-4614-bada-7c32dfa9acbd">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS05LTEtMS0w_19dc5906-4c7a-4cf7-a94f-fc361950ddfa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0xMS0xLTEtMA_64ad6cd1-8703-46c1-b050-ec4548250de2">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0xLTEtMS0w_12071966-9537-45c3-9221-e5e111f6a965">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0zLTEtMS0w_66e09fa6-a14f-4f0e-a782-55cd2c212215">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS01LTEtMS0w_1c1e29a5-2f98-4bb4-83a7-a182db9fc9d2">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS03LTEtMS0w_0a8e68b2-fea5-4ff4-b8b8-c58423b330dd">365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS05LTEtMS0w_5975f1a4-7359-4593-a922-e69fd409ee3c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="security" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0xMS0xLTEtMA_f4cc5306-229d-4555-ba0c-fc74f51a86dc">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our available-for-sale investments were in a continuous loss position for 12 months or more as of September&#160;30, 2020, or December&#160;31, 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b84ed00612e4d10b40f415d9c892b8e" continuedAt="i336a1b42721b495a8b4a0956f3d025df">of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </ix:continuation></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i336a1b42721b495a8b4a0956f3d025df">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjc1OQ_51bde8be-cd08-4a72-934a-85655361fbbf">93</ix:nonFraction> million at September&#160;30, 2020, of which $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjc3OA_ecb30356-6ff6-46bf-9aff-44be8402d1da">91</ix:nonFraction>&#160;million will mature in one year or less, and $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjgxOA_d795c084-df07-4ebc-9091-67f9f82509d3">2</ix:nonFraction>&#160;million will mature in after one through five years.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_55"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">7. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="moh:MedicalClaimsAndBenefitsPayableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkxOA_7140d991-85e0-460f-b43e-00b4b4880d54" continuedAt="iaa8e20e12a0141d2aa8a9ace0eb5d810" escape="true">Medical Claims and Benefits Payable</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="iaa8e20e12a0141d2aa8a9ace0eb5d810" continuedAt="i73b0763571a84750be95e330d254f75f"> </ix:continuation></span></div><ix:continuation id="i73b0763571a84750be95e330d254f75f" continuedAt="i389d898eeaad4603bcdd925b6f2f713e"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkyMA_ffbedd22-e69c-4e62-a601-dca12952b5fc" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfMy0xLTEtMS0w_3b120643-e002-4a6e-a2b1-bfc8b9383479">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfMy0zLTEtMS0w_88801cda-45c5-4510-bb2b-7ace2208d102">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNC0xLTEtMS0w_255911bf-056a-4b43-9f77-c6e5dc4a39e6">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNC0zLTEtMS0w_2019ac2b-6add-4372-a2eb-5091b3e39773">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNS0xLTEtMS0w_b0caa7a8-5eeb-4aeb-af9f-295c1436d803">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNS0zLTEtMS0w_b3d0e416-b6e1-4095-9fc9-fa0d8c6a1e16">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNi0xLTEtMS0w_2363e804-8c07-4920-b6de-60d1d4681fae">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNi0zLTEtMS0w_259e9e30-ea80-48c1-abcb-6a1fe32cc79c">267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNy0xLTEtMS0w_747b6ae2-6ef1-4234-ba40-baba50436157">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNy0zLTEtMS0w_412ff660-7796-4768-bd00-2352fe7b46f2">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalClaimsAndBenefitsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfNDQ1_048c939e-e8cd-4c63-9d7c-7eb38271ef7a">168</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:MedicalClaimsAndBenefitsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfNDUy_15c7cf89-6e2f-4555-9fbf-dd51a5d74b58">132</ix:nonFraction> million as of September&#160;30, 2020, and December&#160;31, 2019, respectively. </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkyMw_56b48202-b160-40de-a2c4-0de6ce2d432e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNC0xLTEtMS0w_515a5da9-893c-429b-9542-9da12ddac920">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNC0zLTEtMS0w_02cd81ca-ea74-456d-a821-74ea240014d1">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNi0xLTEtMS0w_8282575f-4aab-44b6-9be7-3c368cab675f">11,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNi0zLTEtMS0w_0add1bbc-f2c9-4f39-b29c-4856074d0a3f">10,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNy0xLTEtMS0w_f73a4418-62a5-4406-bdf7-a59ea7ba4df6">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNy0zLTEtMS0w_fb25c2b0-f380-4f9a-ad91-4120dcd31973">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOC0xLTEtMS0w_6650e1b5-629a-4989-8290-32ff1935b330">11,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOC0zLTEtMS0w_6f587bfb-1729-47c1-8f1b-a89d051968e4">10,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOS0xLTEtMS0w_5d869c65-7966-4f91-bb5e-93e7395273fa">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOS0zLTEtMS0w_fa896077-5494-4961-87bf-da78ce7e1c86">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTEtMS0xLTEtMA_b3f377a2-192d-4853-b34f-d1ebceebc080">9,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTEtMy0xLTEtMA_2641e272-c5a0-420d-8f7f-ac33618e5f4e">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTItMS0xLTEtMA_ce1786a4-ff4a-452b-abfd-e2054c54d17a">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTItMy0xLTEtMA_74090dd2-e0c8-4135-affa-e61a4f40f2c7">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTMtMS0xLTEtMA_2c8ee551-cf1a-4860-b4f4-c1284a2bc964">11,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTMtMy0xLTEtMA_66670e2b-2c09-40e2-ab25-832e0bf6338e">10,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTQtMS0xLTEtMA_315677e4-41c8-41ce-98e9-2d77443bdf36">2,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTQtMy0xLTEtMA_4c4bdd64-a1dc-4880-8f63-fb4cdd57d2f5">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2019, and 2018 developed favorably by approximately $<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTExMw_f73a4418-62a5-4406-bdf7-a59ea7ba4df6">66</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTEyMA_fb25c2b0-f380-4f9a-ad91-4120dcd31973">253</ix:nonFraction> million as of September&#160;30, 2020, and 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2020, medical care costs related to the prior year reflect the release of additional reserves for moderately adverse conditions included in our prior year estimates, partially offset by higher than expected costs for settling certain claims with certain providers. The differences between our original estimates for such claims in 2019, and the ultimate costs in 2020, were not discernible until additional information was provided to us in 2020 and the effect became clearer over time as claim payments were processed. The release of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i389d898eeaad4603bcdd925b6f2f713e">additional reserves for moderately adverse conditions included in our prior year estimates was substantially offset by the replenishment of the reserve recorded in medical care costs related to the current year.</ix:continuation></span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_58"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">8. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDI4MA_cc0f7a84-9d8b-49fa-923c-a3bc81ce7076" continuedAt="i5095ec007a2d4e3fa9a7f94c64090f33" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i5095ec007a2d4e3fa9a7f94c64090f33" continuedAt="i9d9f7a1ace594484abd3b062df9f93e4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDI4Ng_3e97f4fd-a9f5-4e9a-8b86-90372984d443" continuedAt="i5437a47278484eb4b76b310c9c730737" escape="true">The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:</ix:nonNumeric></span></div><ix:continuation id="i5437a47278484eb4b76b310c9c730737"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current portion of long-term debt: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930" decimals="-6" format="ixt:zerodash" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNC0xLTEtMS0w_7031cbed-cfac-4879-bdae-69caaa160e56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6353bdf90f6442659a69205e4bac7e7b_I20191231" decimals="-6" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNC0zLTEtMS0w_2567b300-b78d-4cba-abb1-c4397aedb02a">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ide774a0690994809ae6d22cf1b4a5ec5_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0wLTEtMS0wL3RleHRyZWdpb246NzVlYjQ1NTRiOWQ2NDVmN2FiZDRhMWZiZDQ4MGZlMGNfNQ_eacf1e00-2415-46df-a0d9-e4dd6bcaf79e">1.125</ix:nonFraction>% Convertible Notes, net of unamortized discount</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930" decimals="-6" format="ixt:zerodash" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0xLTEtMS0w_8c5ec021-b980-410e-9e3f-da734ea3634a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231" decimals="-6" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0zLTEtMS0w_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:zerodash" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNi0xLTEtMS0w_8177af22-48e4-4760-8f64-57f4f5db3f64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNi0zLTEtMS0w_35bb5202-9b15-432f-a195-6bf0a890d49a">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current portion of long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0wLTEtMS0wL3RleHRyZWdpb246Nzk2Zjk2NzFlMzg5NDdmMzhiNDVjNDQyNjRmNzA5ZmFfNA_c747b537-b0de-448c-8595-8a4c52e1c47c">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ec3ae376fbe4ad4a14e9b7642cf575e_I20200930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0xLTEtMS0w_bddaac18-b492-499b-9ac0-a04a0b748a41">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91235a939abc46cc8cfe1379d6385693_I20191231" decimals="-6" format="ixt:zerodash" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0zLTEtMS0w_6940d01b-a286-44bd-a064-93a911834458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if95b0e5cb5ad441cbe5353c0775eada6_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0wLTEtMS0wL3RleHRyZWdpb246OTEwMjM0NDIyM2VjNDE5YWIzODJjYmYyN2FhZDUzMTVfNA_0c727ed5-099f-4dd7-a977-10d3562c6a99">5.375</ix:nonFraction>% Notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0xLTEtMS0w_b7613901-d821-4c44-9e32-f6468ccaef8e">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0fd66717c68402a9c361f8c9ddd1136_I20191231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0zLTEtMS0w_7a437c33-0ecc-4954-9ca3-40af5ddca677">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45acf5d8b86b488a9df5b605c415166a_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjJkOTgzNjRkMzU2MzQ3N2VhYWJkNmZhMzExOWE5YWM0XzQ_471ac8cb-0794-42e7-833b-8b0aa6ca9727">4.875</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMS0xLTEtMA_1545d7b3-685f-4833-9e25-1c13babd745e">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30bd18227ccc47deafa6692e187cac66_I20191231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMy0xLTEtMA_bea1dd2a-942e-4f0a-b9d2-c65268ed98c0">330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930" decimals="-6" format="ixt:zerodash" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTEtMS0xLTEtMA_1ef8c03a-dcfb-4fb9-88ce-67984f980328">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6353bdf90f6442659a69205e4bac7e7b_I20191231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTEtMy0xLTEtMA_ebbe2152-5e86-45c5-ac7f-576f05f6e449">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTItMS0xLTEtMA_514d63d8-d996-46a7-be40-2e2da8b62e3d">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTItMy0xLTEtMA_17169c13-0be3-4da9-989a-3d6be22f2806">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTMtMS0xLTEtMA_0230ad62-4079-4e82-af02-f74121dd26cf">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTMtMy0xLTEtMA_34c64f6e-7f64-49f2-81af-8d60f848665e">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Reported in &#8220;Accounts payable, accrued liabilities and other.&#8221;</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a credit agreement (the &#8220;Credit Agreement&#8221;) that replaced our prior credit agreement. The terms of the Credit Agreement are substantially similar to the terms of the prior agreement. Among various provisions, significant changes incorporated to the Credit Agreement included:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of the revolving credit facility (the &#8220;Credit Facility&#8221;) from $<ix:nonFraction unitRef="usd" contextRef="i3d5fccb82c934bd1a15e322807ce290d_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzE0_08172bc8-735b-4165-9e94-3773c874bcec">500</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i27fd4a76e49d4598ab2278e6e645278d_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzIw_d52d4054-d8ed-4e84-87ec-7d73848c2baf">1.0</ix:nonFraction> billion;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A $<ix:nonFraction unitRef="usd" contextRef="i2c6273b5316944e4a596a67c24741345_I20200531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzI2_697ca9fa-da65-437f-a6b9-36427885308e">15</ix:nonFraction>&#160;million swingline sub-facility and a $<ix:nonFraction unitRef="usd" contextRef="i145a7ab1554b4757b2e887181fd98cc8_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzU4_abb80125-70c3-4ece-be6d-7316211ef517">100</ix:nonFraction>&#160;million letter of credit sub-facility;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of incremental term loans available to finance certain acquisitions from $<ix:nonFraction unitRef="usd" contextRef="iea4eec6ff70b47cb9fc4f0eee52a397e_I20200531" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfODc3_1c87cded-a534-4f82-a212-11835439df64">150</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfODgz_a3334ebc-2b8a-4347-9130-5df65c8a3508">500</ix:nonFraction>&#160;million, plus an unlimited amount as long as our consolidated net leverage ratio is not greater than <ix:nonFraction unitRef="number" contextRef="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630" decimals="INF" name="moh:ConsolidatedNetLeverage" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfOTc5_a00149f6-2853-4ea6-9abf-6aec6321fab4">3</ix:nonFraction>:1;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability to engage in acquisitions where the consummation of such acquisitions is not conditioned on the availability of, or on obtaining, third-party financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of the term loan facility under the prior credit agreement, which was repaid as described below; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LIBOR succession provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement has a term of <ix:nonNumeric contextRef="ie5e5997156224aac9afd99b367288856_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMTMyNw_e2cce557-83d1-4622-b1a5-71f42f58ab54">five years</ix:nonNumeric>, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2020, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September&#160;30, 2020, <ix:nonFraction unitRef="usd" contextRef="i0212554bfd054535bec808876e3e5018_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMTk2MA_d760e043-ccae-424c-9fec-1482bfe05c43">no</ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2020, we recognized losses on debt repayment of $<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA0MA_60fbe4d2-b373-4384-8ffa-7b5f910da67b">5</ix:nonFraction> million in connection with repayment of our term loan facility and other financing transactions. In the third quarter and nine months ended September 30, 2019, we recognized a loss on debt repayment of $<ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA2Nw_ce1f58e8-1787-4a15-bff1-7ec26539804a">2</ix:nonFraction> million and a gain on debt repayment of $<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA3MQ_d2727c57-3e88-4edf-baf1-e206a0a11d3c">15</ix:nonFraction> million, respectively, in connection with convertible senior notes repayment transactions. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i9d9f7a1ace594484abd3b062df9f93e4" continuedAt="ic841739930904a118a7544240b95d7f8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High-Yield Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjcwMg_ccd9970d-1c3e-45ce-b202-84fa4509f388">4.375</ix:nonFraction>% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2020, we completed the private offering of $<ix:nonFraction unitRef="usd" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjc3NQ_39aa4def-ee62-4c54-983b-42c92f2ca30d">800</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjgyNw_ccd9970d-1c3e-45ce-b202-84fa4509f388">4.375</ix:nonFraction>% Notes&#8221;) due June 15, 2028, unless earlier redeemed. The <ix:nonFraction unitRef="number" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjg4Ng_1d80a134-5cc6-4764-a984-82b45d0bf141">4.375</ix:nonFraction>% Notes contain optional early redemption provisions, with redemption prices in excess of par. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzAwNQ_ccd9970d-1c3e-45ce-b202-84fa4509f388">4.375</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15 of each year, commencing December&#160;15, 2020. A portion of the net proceeds from the <ix:nonFraction unitRef="number" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzE0Nw_ccd9970d-1c3e-45ce-b202-84fa4509f388">4.375</ix:nonFraction>% Notes offering was used to repay $<ix:nonFraction unitRef="usd" contextRef="i1b80a28bab8c433a9545d7749e346c8a_D20200602-20200602" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzE4Mw_f807c93d-2123-42a5-9f6f-c72d39b3ff7d">600</ix:nonFraction>&#160;million principal amount outstanding under the term loan facility of our prior credit agreement, and the balance is intended to be used for general corporate purposes. Deferred issuance costs amounted to $<ix:nonFraction unitRef="usd" contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM0Nw_d671aa96-17d4-451d-b8dd-3cf3a55016ca">11</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM1MQ_465328e4-5b9a-4059-b40f-9043d2387266">5.375</ix:nonFraction>% Notes due 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM3Nw_a16428a5-d6a4-461e-afaa-d44e075e9deb">700</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzQyOQ_465328e4-5b9a-4059-b40f-9043d2387266">5.375</ix:nonFraction>% Notes&#8221;) outstanding as of September&#160;30, 2020, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzU0Mw_465328e4-5b9a-4059-b40f-9043d2387266">5.375</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzYyMA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da">4.875</ix:nonFraction>% Notes due 2025. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $<ix:nonFraction unitRef="usd" contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzY0Ng_76e48bbc-c653-4d0d-be7f-d5da18c34823">330</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzY5OA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da">4.875</ix:nonFraction>% Notes&#8221;) outstanding as of September&#160;30, 2020, which are due June 15, 2025, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzgwOA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da">4.875</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzg4Ng_b9bcbbf9-4ff7-4ddb-8c45-9a8df1c77eeb">1.125</ix:nonFraction>% Cash Convertible Senior Notes due 2020  </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic841739930904a118a7544240b95d7f8">For a description of the <ix:nonFraction unitRef="number" contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzk1NQ_890043d2-0167-45e9-b0fb-6ce97f0a8259">1.125</ix:nonFraction>% cash convertible senior notes due January 15, 2020 (the &#8220;<ix:nonFraction unitRef="number" contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDAxNQ_7acb01dd-65ee-4838-9b05-88c59d6d3d73">1.125</ix:nonFraction>% Convertible Notes&#8221;), see Note 11, &#8220;Debt,&#8221; in our 2019 Annual Report on Form 10-K. In January 2020, we paid $<ix:nonFraction unitRef="usd" contextRef="i957912dee94240ee9072f0022698ffe5_D20200101-20200131" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDEyNQ_9da7f8ae-ebf5-4f0f-95bd-b59ac94fc349">39</ix:nonFraction> million to settle the outstanding $<ix:nonFraction unitRef="usd" contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231" decimals="-6" format="ixt:numdotdecimal" name="moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDE1NA_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4">12</ix:nonFraction> million principal amount of the <ix:nonFraction unitRef="number" contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDE4MQ_04a18703-99ee-45b3-9a21-09a2eff622ac">1.125</ix:nonFraction>% Convertible Notes, and settle the related conversion option.</ix:continuation> </span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_61"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">9. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjMxOA_9001c2ca-81a7-4b99-a81b-56d3038c5f9c" continuedAt="i75a5999ee21249ed8b627bd8b8829ebe" escape="true">Stockholders' Equity </ix:nonNumeric></span></div><ix:continuation id="i75a5999ee21249ed8b627bd8b8829ebe" continuedAt="i73e820a811b04e3889cbb728e4190d58"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjE5OTAyMzI1ODU4Mw_0b5032ce-57d5-4290-8d8e-302a2aa9cd36">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This program will be funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase will be determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. No shares were purchased under this program through October&#160;29, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTE2_e98241c1-5aea-412d-89ee-24ff9b94e6ed">500</ix:nonFraction> million, in the aggregate, of our common stock. This program was funded with existing cash on hand and was completed in March 2020. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMzI5_6cd9daed-dc00-4edf-9e1b-cd2acb76ea22">3.4</ix:nonFraction> million shares of our common stock for $<ix:nonFraction unitRef="usd" contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMzYz_4c838b8a-9c14-4669-9d39-76359ec80067">446</ix:nonFraction> million in the first quarter of 2020 (average cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNDEy_602d7fd0-f8b4-4bfd-b7f8-a81459447efa">132.45</ix:nonFraction> per share). In the first quarter of 2020, we also paid $<ix:nonFraction unitRef="usd" contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNDcw_687f0bdc-2558-4422-9209-20d05b831126">7</ix:nonFraction> million to settle shares purchased in late December 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930" decimals="INF" name="moh:ClassOfWarrantOrRightStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNTIz_73ace182-2ee8-4bc5-9a21-cf93031573d5">1.125</ix:nonFraction>% Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the <ix:nonFraction unitRef="number" contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930" decimals="INF" name="moh:ClassOfWarrantOrRightStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNTYw_083c737d-7ce1-4a15-b42e-45ab316d1abf">1.125</ix:nonFraction>% Warrants, refer to our 2019 Annual Report on Form 10-K, Note 12, &#8220;Derivatives,&#8221; and Note 14, &#8220;Stockholders&#8217; Equity.&#8221; Approximately <ix:nonFraction unitRef="shares" contextRef="i2538a5ed9cd54fd5ada2143661d2e391_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNjk0_b320e907-20d1-444a-9892-3345addd8081">310,000</ix:nonFraction> of the <ix:nonFraction unitRef="number" contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930" decimals="INF" name="moh:ClassOfWarrantOrRightStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNzA0_55a66ba7-4fbf-4272-8a1f-f862db0c96b6">1.125</ix:nonFraction>% Warrants were outstanding at December 31, 2019. In the first quarter of 2020, we entered into privately negotiated termination agreements under which we paid $<ix:nonFraction unitRef="usd" contextRef="i550d7fb1a5cf4341ba55c9010cbc88be_D20200101-20200331" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfODY1_db266e50-4711-4ae7-b489-8f76d55f0de4">30</ix:nonFraction> million to the counterparties for the termination of the remaining <ix:nonFraction unitRef="number" contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930" decimals="INF" name="moh:ClassOfWarrantOrRightStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfOTI3_f8a7c1fd-41e6-4436-9253-5546e9cc7e47">1.125</ix:nonFraction>% Warrants outstanding, which resulted in a reduction of additional paid-in-capital for the same amount. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our employee stock plans, approximately <ix:nonFraction unitRef="shares" contextRef="ic4024fea4fe14739828013441b0f2c9a_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTExOA_226aaa2b-d59c-4161-8815-88c3e6461913">192,000</ix:nonFraction> shares of common stock vested or were purchased, net of shares used to settle employees&#8217; income tax obligations, during the nine months ended September 30, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is recorded to &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income. Total share-based compensation expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTQzMw_8bf8ad18-f4c0-4f69-b09d-fdd8dd486529">15</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTQ0MA_d0d63899-28f3-4875-a413-3ac4e3c9ca91">10</ix:nonFraction> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="i73e820a811b04e3889cbb728e4190d58"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, respectively, in the third quarter of 2020 and 2019. Total share-based compensation expense amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTUyNw_c1533faa-7e4b-4bf4-a811-0f850b901aa7">43</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTUzNA_301169d3-7747-413a-a808-379dd2566565">29</ix:nonFraction> million, respectively, in the nine months ended September 30, 2020 and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTYwNQ_d4340e9f-3cab-4974-8101-f4ace1652386">76</ix:nonFraction> million of total unrecognized compensation expense related to unvested restricted stock awards (&#8220;RSAs&#8221;), and performance stock units (&#8220;PSUs&#8221;), which we expect to recognize over remaining weighted-average periods of <ix:nonNumeric contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTgxNQ_a2de122e-de29-496d-9dfd-de5d1afd1df0">2.4</ix:nonNumeric> years and <ix:nonNumeric contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTgyMg_6db1b6f4-2b72-4b2d-a959-5cedbbcfa2fd">1.5</ix:nonNumeric> years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of <ix:nonFraction unitRef="number" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="3" name="moh:UnrecognizedCompensationForfeitedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTkxNg_4f977ec3-bfbe-43a2-ab3d-85eb31690bac">11.5</ix:nonFraction>% for non-executive employees as of September&#160;30, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, unrecognized stock option expense was insignificant. <ix:nonFraction unitRef="shares" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjEwOQ_52daa097-21dc-49ae-8ebc-3997b3cd9fbe">No</ix:nonFraction> stock options were granted or exercised in the nine months ended September 30, 2020. </span></div><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjMyNw_27558e42-b22e-42a1-aefa-13e13bbd5a1d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for RSAs and PSUs is summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:40.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0123ff206dc2499598383ffd43d68eb2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS0xLTEtMS0w_842b06c2-06c8-4011-9099-a03bfc8b42c4">447,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0123ff206dc2499598383ffd43d68eb2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS0zLTEtMS0w_61eeb79c-3cee-445d-8ddb-cab0c3e1b975">102.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS01LTEtMS0w_97630785-d714-4494-a3b7-a6a8d8824cd2">324,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS03LTEtMS0w_500aff70-e8fa-4293-a971-dccc08124352">101.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi0xLTEtMS0w_ae53301a-08f2-4ca5-babc-db163b9b7140">334,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi0zLTEtMS0w_ef36b0b8-dfdc-47fa-afc1-35bfe50bd618">125.99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi01LTEtMS0w_d5e31ba1-fca0-4f1c-bd9d-ff3932af042d">187,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi03LTEtMS0w_06c93e3b-2718-41ad-a40c-baa6daee4417">123.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy0xLTEtMS0w_86016cc7-27d2-49dc-a152-3138387b1d55">166,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy0zLTEtMS0w_d9b5af12-241e-4add-9ea3-8d57fa8469ab">96.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy01LTEtMS0w_ae6a66ab-8c12-4676-853c-a3f7d0e4297c">7,368</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy03LTEtMS0w_e8af9535-11c7-4d3f-8ac8-1651dcb37b5c">68.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC0xLTEtMS0w_54de6309-d980-4b29-9475-1956c468f166">26,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC0zLTEtMS0w_b32c351f-9384-455c-a0fd-37c035856640">114.48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC01LTEtMS0w_2a557ce8-b35b-4ff4-b169-522bfed849ac">29,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC03LTEtMS0w_7420182b-5f30-4861-a667-025d0d90d2a1">98.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS0xLTEtMS0w_8aa88ed9-8360-4bb2-b69c-7086c007bd52">589,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS0zLTEtMS0w_bc6d3386-05c6-4251-9228-dce78278a947">116.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffdf9fbfeb9745b5b757815afe72494f_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS01LTEtMS0w_16be8206-3786-44a3-8e6f-b70754bd65e5">474,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffdf9fbfeb9745b5b757815afe72494f_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS03LTEtMS0w_add4343b-5d5b-432f-81a6-f25a9b4f72c8">110.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair values of RSAs and PSUs granted and vested are presented in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNS0xLTEtMS0w_a682e38b-7e3f-4150-a306-9391b4ee1ea0">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNS0zLTEtMS0w_d284b493-4bf9-43a6-89e0-2d918f28c443">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNi0xLTEtMS0w_35e12861-bde1-49a9-bf89-bfe6a83f3a2a">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNi0zLTEtMS0w_e2a16b4b-17b8-480a-ae9d-f8e8a040028f">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNy0xLTEtMS0w_b8294038-b7ad-46bb-81ef-1c2954120b3d">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNy0zLTEtMS0w_342d826f-67ad-4a3e-8fa0-b0bc554fd900">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfOS0xLTEtMS0w_e8dbf883-0f58-432e-a758-7d581b7abfc3">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfOS0zLTEtMS0w_d27c165d-30ef-4cf7-b7b6-750347eb84ba">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTAtMS0xLTEtMA_56392fab-c813-4b25-a931-b61c338c596c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTAtMy0xLTEtMA_257261b5-cb36-498c-af78-f81df62ea361">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTEtMS0xLTEtMA_1d3db5ee-aad1-4010-8f49-ebc509e2c8f2">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTEtMy0xLTEtMA_db801a87-e204-459c-a596-056b475c3c50">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_64"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">10. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTM0MQ_09dc35d0-bb81-45aa-9b2c-82e739a1a797" continuedAt="ie5eda5060411453e883823cb8344fca7" escape="true">Segments </ix:nonNumeric></span></div><ix:continuation id="ie5eda5060411453e883823cb8344fca7" continuedAt="ib4b97e714a2d47dea3f35dc73f0af404"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have <ix:nonFraction unitRef="segment" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTU_708f643f-924b-48f7-88ee-9763716e97f4">two</ix:nonFraction> reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. Margin for our Health Plans segment is referred to as &#8220;Medical Margin.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTMzMw_24a021d8-3e0c-42ee-8b79-d8ec0055694d" continuedAt="i7830469b8fb144a6aedcf9636c0b6f15" escape="true">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><ix:continuation id="ib4b97e714a2d47dea3f35dc73f0af404"><ix:continuation id="i7830469b8fb144a6aedcf9636c0b6f15"><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe4a961d1eb4aa8b35c53d34bea3f7c_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS0xLTEtMS0w_b478eeea-d0e4-48e5-8f71-6779870ef6cb">5,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb569255aff4cb1a507ded6878088ab_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS0zLTEtMS0w_9ddeb060-d055-4558-bb8d-8235035b2806">4,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fa4dac681a24334be8e8b77ddebd9c6_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS01LTEtMS0w_f5f0e113-5191-402f-8cef-fb504d9af342">14,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1eb474cbb156487da5ef2d111573f379_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS03LTEtMS0w_3f2c4b14-d6af-49de-9850-cbdcb7ba4fe7">12,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id606f46ed6204025ae6c824bbc5386c5_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi0xLTEtMS0w_cb6277fd-920e-434c-ac64-6af91c9bed47">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ideda1271d72d4f0f8c9490daadf92cba_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi0zLTEtMS0w_188cf359-1d83-4674-97da-6da7208a29d3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6768058042744166a9675351d4ec6518_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi01LTEtMS0w_aa409d4c-5866-419b-9134-6d95aaf7cfde">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09b03eb47e834f2ea94525c02f9c659c_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi03LTEtMS0w_3838d98e-4815-4274-ac44-72022924f7f9">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy0xLTEtMS0w_11caff84-7d15-4f84-b98c-46f81eaa3c4f">5,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy0zLTEtMS0w_c913185f-b3f0-4f77-b677-adb41bbc7abe">4,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy01LTEtMS0w_a3bc39b8-21f5-48f4-98a1-a89899813cda">14,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy03LTEtMS0w_fb75d497-3626-441a-80b3-7fd42abb25cc">12,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin to consolidated income before income taxes: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib455ca5f2b5947a895ea50f53562ffd9_D20200701-20200930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS0xLTEtMS0w_d1ef46f0-5a81-48fc-b91b-766a4a1e5a86">670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51b83677a3114d00b5fb75fa5b867b67_D20190701-20190930" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS0zLTEtMS0w_f63d6afb-7cee-4655-9a0a-0aeb887487e5">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1601849c348540f59d2211b5d20125f8_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS01LTEtMS0w_98bfe614-8dfc-4f02-a514-d3258e010925">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f1814b002a47d38a368f6700e92992_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS03LTEtMS0w_b980bb0b-80f2-4cb7-85dc-7b65ad446f3d">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC0xLTEtMS0w_f5c93aae-c220-4017-aee0-65a1f64228f3">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC0zLTEtMS0w_fc9b0ed0-f209-44ea-9f2a-ae9db71ebc61">159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC01LTEtMS0w_ec71ec29-5db0-4a34-a2c1-3e9448841b07">744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC03LTEtMS0w_e3b46d04-2396-4749-89dc-ac9dfeb2038d">470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtMS0xLTEtMA_cb73bf30-f475-4d69-9b68-5df1a31e954d">634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930" decimals="-6" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtMy0xLTEtMA_7fd500b5-6f6c-4248-85b5-45e0691fe852">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtNS0xLTEtMA_25634bca-ab93-4f13-9c45-3bd49d064107">1,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtNy0xLTEtMA_eafa4bbd-08a4-429e-9c4a-ae2d75ed5b28">1,393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtMS0xLTEtMA_0eaa0e07-31ed-4069-85bb-dfcadcf02b2d">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtMy0xLTEtMA_c072d300-c669-487c-b1e5-f524f2ae7f72">257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtNS0xLTEtMA_d9fc9cca-a1da-4b74-bf65-9cd5e08e2eed">987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtNy0xLTEtMA_b2ffdefd-d94a-4fe1-bbb7-fa2624b484ec">802</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItMS0xLTEtMA_dac13334-ec73-431d-b84c-16251fb54c86">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItMy0xLTEtMA_971c999f-c8df-4a5d-8c07-cb5259d56967">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItNS0xLTEtMA_f8d74149-6dbe-4eeb-b270-37ebb25b14ce">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItNy0xLTEtMA_84f9771b-d230-45af-bf05-d498771b1e1e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtMS0xLTEtMA_079c7c70-06c1-4847-8ced-08701957e3ef">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtMy0xLTEtMA_73737a76-40fb-4827-b3b2-a9ac82bdb6a0">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtNS0xLTEtMA_1bea3983-90c1-4c3d-ba92-2b172f7a510f">910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtNy0xLTEtMA_84714c93-baa0-4839-9e1b-0ef4e915a428">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, and investment income and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other costs.</span></div></ix:continuation></ix:continuation><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">11. <ix:nonNumeric contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82Ny9mcmFnOmNiZDBiNjI3MzEzMDQzOTk4ZmNkN2JjZDFmZTFkZTg4L3RleHRyZWdpb246Y2JkMGI2MjczMTMwNDM5OThmY2Q3YmNkMWZlMWRlODhfMTI2Ng_b15d645c-5785-46b2-b861-0656b9606062" continuedAt="i24df25d4ba4d4169a62f16814ce758bb" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i24df25d4ba4d4169a62f16814ce758bb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Penalties associated with violations of these laws and regulations include significant fines, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business we are involved in legal actions, some of which seek monetary damages which are not covered by insurance. We have accrued liabilities for certain matters for which we deem the loss to be both probable and reasonably estimable, but the outcome of legal actions is inherently uncertain and our estimates of such losses could be understated, and could also subsequently change as a result of further developments of these matters. For certain pending matters, accruals have not been established because we believe we are not liable or because such matters have not progressed sufficiently through discovery or factual development to enable us to reasonably estimate a range of possible loss. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 23</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (&#8220;MD&amp;A&#8221;)</span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section&#160;27A of the Securities Act of 1933, or Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, or Securities Exchange Act. Many of the forward-looking statements are located under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as &#8220;guidance,&#8221; &#8220;future,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;growth,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; and similar terms. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the sections titled &#8220;Risk Factors&#8221; in this Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2019, and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, and June 30, 2020, including without limitation the following:  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic on our operations and financial results;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the numerous political, judicial, and market-based uncertainties associated with the Affordable Care Act (the &#8220;ACA&#8221;) or &#8220;Obamacare,&#8221; including the ultimate outcome of the Texas et al. v. U.S. et al. matter now pending before the U.S. Supreme Court;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">significant budget pressures on state governments from diminished tax revenues and their efforts to curtail current rates, to implement expected rate increases, or to maintain existing benefit packages or membership eligibility thresholds or criteria; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the market dynamics surrounding the ACA Marketplaces, including but not limited to uncertainties associated with the elasticity of demand for our products based on our pricing, risk adjustment estimates and results, the potential for disproportionate enrollment of higher acuity members, and the discontinuation of premium tax credits;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the uncertainties associated with the November 2020 Presidential and Congressional election;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to consummate, integrate, and realize benefits from acquisitions, including the announced acquisitions of Magellan Complete Care and of Affinity;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the protest and appeal proceedings in Kentucky with regard to the Medicaid contract award to our Kentucky health plan; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">effective management of our medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with the flu or coronavirus;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the full reimbursement of the ACA health insurer fee, or HIF; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to retain existing or awarded government contracts, and the success of any bid submissions in response to requests for proposal, including our contracts in Ohio, California, Texas, and Kentucky; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">cyber-attacks, ransomware attacks, or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected health information;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success and renewal of our duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the accurate estimation of incurred but not reported or paid medical costs across our health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">efforts by states to recoup previously paid and recognized premium amounts; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">complications, member confusion, eligibility re-determinations, or enrollment backlogs related to the renewal of Medicaid coverage, as well as the chilling effect of the new so-called public charge rule;   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">government audits, reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, monitoring program, or premium recovery that may result therefrom;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">our expected exit from Puerto Rico, including the successful transfer of our members to alternative health plans, the effective run-out of claims, and the return of our capital;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes with respect to our provider contracts and the loss of providers; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">approval by state regulators of dividends and distributions by our health plan subsidiaries;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">high dollar claims related to catastrophic illness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the favorable resolution of litigation, arbitration, or administrative proceedings, including litigation involving the ACA to which we are not a direct party;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the relatively small number of states in which we operate health plans, including the greater scale and revenues of our California, Ohio, Texas, and Washington health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the failure to comply with the financial or other covenants in the Credit Agreement or the indentures governing our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the sufficiency of funds on hand to pay the amounts due upon maturity of our outstanding notes;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a state in which we operate to renew its federal Medicaid waiver;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">changes generally affecting the managed care industry; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">increases in government surcharges, taxes, and assessments;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.85pt">the unexpected loss of the leadership of one or more of our senior executives; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increasing competition and consolidation in the Medicaid industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms &#8220;Molina Healthcare, Inc.&#8221; &#8220;Molina Healthcare,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Readers should refer to the section entitled &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q, in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020, and June 30, 2020, and in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management&#8217;s Discussion and Analysis appearing in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 25</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). Through our locally operated health plans in 15 states and the Commonwealth of Puerto Rico, we served approximately 4.0 million members as of September&#160;30, 2020. The health plans are generally operated by our respective wholly owned subsidiaries in those states and licensed as health maintenance organizations (&#8220;HMO&#8221;). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">THIRD QUARTER 2020 HIGHLIGHTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported net income per diluted share of $3.10 for the third quarter of 2020, with net income of $185 million, which consisted of the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">Premium revenue of $4.8 billion, which increased 16.8% compared with the third quarter of 2019;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated medical care ratio (&#8220;MCR&#8221;) of 85.9%, which decreased 40 basis points compared with 86.3% in the third quarter of 2019;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expense (&#8220;G&amp;A&#8221;) ratio of 7.3%, which decreased 30 basis points compared with 7.6% in the third quarter of 2019; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After-tax margin of 3.7%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID Impacts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlike the second quarter of 2020, in which the combined COVID-related impacts temporarily increased our earnings, in the third quarter of 2020 the combination of COVID-related impacts netted to a negligible to slightly positive impact on earnings and included:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A modest net decrease in medical costs due primarily to COVID-related utilization curtailment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premium refunds to a number of our state Medicaid customers in response to the COVID-related utilization curtailment, which we experienced in both the second and third quarters of 2020;  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase in our G&amp;A spending on activities related to COVID; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A meaningful increase to our Medicaid membership.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we work through this unprecedented period of the COVID pandemic, we remain focused on executing on the underlying fundamentals of our business to continue to produce solid results, regardless of the short-term COVID-related impacts on our reported financial metrics and results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth Initiatives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We made another major stride in the third quarter of 2020 related to the activation of our growth strategy. In September 2020, we signed a definitive agreement to purchase the net assets of Affinity Health Plan in New York for approximately $380 million, which we currently expect to close as early as the second quarter of 2021. We believe this purchase is another milestone in a growth-oriented 2020. Our growth initiatives continue to be anchored by our capital allocation priorities: first, organic growth of our core businesses; second, inorganic growth through accretive acquisitions; and third, programmatically returning excess capital to shareholders.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FINANCIAL SUMMARY</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,768&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees reimbursed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Statistics:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending total membership</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,033,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,346,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,033,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,346,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MCR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">G&amp;A ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After-tax margin </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;MCR represents medical care costs as a percentage of premium revenue; premium tax ratio represents premium tax expenses as a percentage of premium revenue plus premium tax revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;G&amp;A ratio represents general and administrative expenses as a percentage of total revenue. After-tax margin represents net income as a percentage of total revenue. </span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONSOLIDATED RESULTS</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">NET INCOME AND OPERATING INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the third quarter of 2020 amounted to $185 million, or $3.10 per diluted share, compared with $175 million, or $2.75 per diluted share, in the third quarter of 2019. Operating income of $289 million in the third quarter of 2020, was higher compared with $257 million in the third quarter of 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income in the nine months ended September 30, 2020, amounted to $639 million, or $10.65 per diluted share, compared with $569 million, or $8.80 per diluted share, in the nine months ended September 30, 2019. Operating income of $987 million in the nine months ended September 30, 2020, was higher compared with $802 million in the nine months ended September 30, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The improvement in operating income for both periods was mainly due to higher premium revenues and a reduction in the MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share in the third quarter and nine months ended September 30, 2020, was favorably impacted by the reduction in common shares outstanding as a result of our share repurchase program that began in late 2019 and concluded in the first quarter of 2020. See further discussion in &#8220;Liquidity and Financial Condition,&#8221; below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">PREMIUM REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue increased $684 million in the third quarter of 2020, when compared with the third quarter of 2019, and increased $1,359 million in the nine months ended September 30, 2020, when compared with the nine months ended September 30, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both periods, the higher premium revenue reflected the increase in membership, primarily in Medicaid, and included the impact from the YourCare and Passport acquisitions. In the third quarter of 2020, we added 325,000 members from our acquisition of the Kentucky Passport business on September 1, 2020, and 47,000 members from our acquisition of the New York YourCare business on July 1, 2020. The increase in premium revenues from these acquisitions was slightly offset by the decline in membership, in the third quarter of 2020, associated with our announced exit of operations in Puerto Rico. The increase in premium revenue was net of COVID-related premium refunds that were enacted in several states. </span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MEDICAL CARE RATIO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR in the third quarter of 2020 decreased to 85.9%, compared to 86.3% in the third quarter of 2019, reflecting improved operating performance in Medicaid and Medicare, partially offset by underperformance in the Marketplace program. Additionally, the net effect of all of the COVID-related impacts, such as the reduced demand for medical services and the premium refunds, profit corridors and related actions, had a slightly favorable impact on our overall financial results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR in the nine months ended September 30, 2020, decreased to 84.9%, compared to 85.7% in the nine months ended September 30, 2019. Reserve development for the first nine months of 2020 was not material. The comparable period in the prior year was positively impacted by 100 basis points of favorable reserve development, primarily in the Medicaid program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">PREMIUM TAX REVENUE AND EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was 3.4% in the third quarter of 2020, compared with 2.8% the third quarter of 2019; and 3.4% compared with 2.9% for the nine months ended September 30, 2020 and 2019, respectively. The current year ratio increase was mainly due to the state of Illinois&#8217; implementation of a managed care organization provider assessment in the third quarter of 2019. </span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INVESTMENT INCOME AND OTHER REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income and other revenue decreased to $14 million in the third quarter of 2020, compared with $40 million in the third quarter of 2019, and decreased to $61 million in the nine months ended September 30, 2020, compared with $103 million in the nine months ended September 30, 2019. The year-over-year decrease was consistent with our expectation and was due to the low interest rate environment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">G&amp;A EXPENSES</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G&amp;A expense ratio decreased to 7.3% in the third quarter of 2020, from 7.6% in the third quarter of 2019, and decreased to 7.3% in the nine months ended September 30, 2020, compared with 7.6% in the nine months ended September 30, 2019. In both periods, the ratio improved due to increased revenues, partially offset by increased costs associated with the COVID-19 pandemic. The third quarter and nine months ended September 30, 2020, reflected approximately $7 million and $38 million, respectively, of net incremental expenses associated with a variety of new COVID-related operational protocols, technology implementations, and benefits for our employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">HEALTH INSURER FEES (&#8220;HIF&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020 and the nine months ended September 30, 2020, HIF expense amounted to $70 million and $209 million, respectively, and HIF reimbursements amounted to $69 million and $206 million, respectively. Public Law No. 115-120 provided for a HIF moratorium in 2019; therefore, there was no HIF incurred or reimbursed in that year. The HIF was reinstated in 2020, but the Further Consolidated Appropriations Act, 2020, repealed the HIF effective for years after 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INTEREST EXPENSE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased to $27 million in the third quarter of 2020, compared with $22 million in the third quarter of 2019, and increased to $72 million in the nine months ended September 30, 2020, compared with $67 million in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the nine months ended September 30, 2019. Additional interest expense relating to the 4.375% Notes issued in June 2020 was partially offset by the decrease in interest expense resulting from the settlement of the convertible senior notes in January 2020. As further described below in &#8220;Liquidity,&#8221; a portion of the net proceeds from the 4.375% Notes offering was used to repay $600&#160;million principal amount outstanding under the term loan facility of our prior credit agreement. See further discussion in Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OTHER EXPENSE (INCOME), NET</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2020, we recognized losses on debt repayment of $5 million in connection with repayment of our term loan facility and other financing transactions. In the third quarter and nine months ended September 30, 2019, we recognized a loss on debt repayment of $2 million, and a gain on debt repayment of $15 million, respectively, in connection with convertible senior notes repayment transactions. </span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">INCOME TAXES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense amounted to $77 million in the third quarter of 2020, or 29.5% of pretax income, compared with income tax expense of $58 million, or 24.7% of pretax income in the third quarter of 2019. Income tax expense amounted to $271 million in the nine months ended September 30, 2020, or 29.8% of pretax income, compared with income tax expense of $181 million, or 24.1% of pretax income in the nine months ended September 30, 2019. The effective tax rate has been higher in 2020 due to higher nondeductible expenses in 2020, primarily related to the nondeductible HIF. As discussed above, the HIF was not applicable in 2019 and has been repealed for years after 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_85"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">REPORTABLE SEGMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">HOW WE ASSESS PERFORMANCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Health Plans segment are premium revenue, margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margin for our Health Plans segment is referred to as &#8220;Medical Margin.&#8221; Medical Margin amounted to $670 million in the third quarter of 2020, and $561 million in the third quarter of 2019. Medical Margin amounted to $2,032 million in the nine months ended September 30, 2020, and $1,725 million in the nine months ended September 30, 2019. Management&#8217;s discussion and analysis of the changes in the individual components of Medical Margin follows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements, Note 10, &#8220;Segments,&#8221; for more information on our reportable segments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">HEALTH PLANS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Health Plans segment consisted of health plans operating in 15 states and the Commonwealth of Puerto Rico, and served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">TRENDS AND UNCERTAINTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, its ultimate impact to our business, results of operations, financial condition and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our Health Plans segment follow. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Federal Economic Stabilization Programs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the pandemic, various stabilization programs were enacted beginning in March 2020, which may impact our business directly or indirectly, including the following:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1 - Coronavirus Preparedness and Response Supplemental Appropriations Act. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enacted on March 6, 2020, this legislation provided $8.3 billion in COVID-19 response funding for developing a vaccine and preventing further spread of the virus.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2 </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Families First Coronavirus Response Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Enacted on March 18, 2020, this legislation provided $100 billion in worker assistance, temporarily increased each qualifying state and territory&#8217;s federal medical assistance percentage (&#8220;FMAP&#8221;) by 6.2% beginning January 1, 2020, and waived cost sharing for COVID-19 testing. The federal government guarantees matching funds to states for qualifying Medicaid expenditures based on each state&#8217;s FMAP. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective October 23, 2020, the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) announced that it has extended the COVID public health emergency for another 90 days. The renewal extends the emergency period until late January 2021. As a result, the enhanced FMAP rate will be extended through the end of the first quarter of 2021. The accompanying requirement that bans the loss of coverage from state eligibility redeterminations would be extended through the end of January 2021. Redetermination is the process through which Medicaid enrollees demonstrate whether they continue to meet the requirements for participation in the Medicaid program, in particular maximum household income. This is likely a positive indicator for continued membership gains, and to provide more support for an actuarially sound rate environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3 - Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Enacted on March 27, 2020, the CARES Act provided an estimated $2 trillion to fight the COVID-19 pandemic and stimulate the U.S. economy. This assistance included loans and support to major industries, including airlines and small businesses, direct payments to individuals and families, and $175 billion in relief funds to hospitals and other healthcare providers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3b - Paycheck Protection Program and Health Care Enhancement Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Enacted on April 24, 2020, this legislation provided $310 billion for the depleted Paycheck Protection Program, and additional funding for hospitals and testing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 4 stimulus package is currently under consideration by Congress.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the uncertainty as to the duration and breadth of the COVID-19 pandemic, we are unable to reasonably estimate the ultimate impact of the economic stabilization programs to our business, financial condition, and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Health Plan Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pandemic has impacted our business, and we currently expect it to further impact our business in the areas described below. As noted above, in the third quarter of 2020 the combination of COVID-related impacts netted to a negligible to slightly positive impact on earnings.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medical Care Costs and Demand for Healthcare Services.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Beginning in early 2020 the pandemic, along with the related quarantine and social distancing measures, initially reduced demand for certain routine and non-critical medical services, while at the same time increased demand for other medical services, such as COVID-19 testing and emergency services. Early in the second quarter of 2020, we experienced significantly lower utilization in a variety of cost categories, representing approximately two-thirds of our total medical cost spend, with utilization levels increasing slowly as the quarter progressed. We experienced several significant COVID-related impacts on medical care costs in the third quarter of 2020 as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At the beginning of the third quarter of 2020, utilization was still moderately curtailed, but rebounded to more normal levels during the quarter. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We attracted approximately 300,000 new Medicaid members since March 31, 2020, and we believe that the acuity of that population is lower than our average. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Direct costs to care for COVID patients totaled $35 million in the third quarter of 2020, as a resurgence of COVID infections and episodes has occurred in places such as Texas and California, and also disproportionately impacted certain of our Marketplace members. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, the net effect of these three factors reduced medical care costs and increased pretax earnings by a range of approximately $95 million to $105 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid Premium Actions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our position on rate adequacy has been consistent:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not intend, nor do we want, to keep state Medicaid money that was supposed to be spent on medical benefits but was not due to utilization curtailment caused by COVID;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In many of our Medicaid states, there are already mechanisms in place to protect against a surplus margin, as there are Minimum MLRs in seven of our states and profit caps in two others; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Once the COVID-19 pandemic abates, we believe that the traditional process of establishing prospective actuarially sound rates based on a credible medical cost baseline and cost trend off that baseline will resume. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Member Enrollment</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We added 625,000 Medicaid members as of September 30, 2020, compared with our Medicaid membership as of March 31, 2020, when we first began to report on the impacts of the pandemic. Included in this total are 325,000 members added from our acquisition of the Kentucky Passport business on September 1, 2020. The 47,000  member increase from our acquisition of the New York YourCare business on July 1, 2020, was offset by the decline in membership, in the third quarter of 2020, associated with our announced exit of operations in Puerto Rico. The remaining 300,000 increase in membership was mainly due to the suspension of redeterminations, as we believe that unemployment-related enrollment has not yet materially accessed managed Medicaid.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It remains unclear how high the COVID-related membership peak will be, how quickly it will fall as the economy recovers, and where it will ultimately settle. However it does now appear that since unemployment nationally is now just under 8%, the initial industry estimates of unemployment-related Medicaid membership increases were somewhat overstated. On a related note, the declaration of the extension of the public health emergency period into next year will also likely have an impact. Therefore, we are currently unable to predict the timing or amount of the expected increases in enrollment. Increased membership would increase our premium revenue, but would also likely result in a significant increase in medical care claims and related costs. We believe that we have the scalability necessary to both serve new members, and ably partner with our state customers for increases in membership.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital and Financial Resources</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to &#8220;Liquidity and Financial Condition&#8221; below for a discussion of our capital and financial resources.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Affordable Care Act</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, in a case brought by the state of Texas and nineteen other states, a federal judge in Texas held that the ACA&#8217;s individual mandate is unconstitutional. He further held that since the individual mandate is inseverable from the entire body of the ACA, the entire ACA is unconstitutional. The effect of his ruling was stayed pending the appeal of the ruling to the Fifth Circuit Court of Appeals. In December 2019, a three-judge panel of the Fifth Circuit Court of Appeal, in a two to one decision, affirmed the District Court&#8217;s ruling that the individual mandate </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is unconstitutional, but remanded the case back to the District Court for additional analysis and findings regarding severability and the consideration of additional arguments. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Supreme Court has accepted the appeal of the Fifth Circuit Court&#8217;s decision. Oral arguments before the Supreme Court are scheduled to take place on November 10, 2020, and a decision is expected in the first half of 2021. The ACA remains in effect pending the issuance of the Supreme Court&#8217;s opinion. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, we served a significant number of members enrolled in programs created by the ACA, including approximately 730,000 Medicaid Expansion members and 325,000 Marketplace members. In the nine months ended September 30, 2020, premium revenue associated with these members amounted to $3,644 million, and contributed Medical Margin of $681&#160;million. A decision by the Supreme Court that the entirety of the ACA is unconstitutional could have a material adverse effect on our business, financial condition, cash flows, or results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Recent Developments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close as early as the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, we closed on the acquisition of certain assets of YourCare Health Plan, Inc., a Medicaid health plan, for a cash purchase price of $42&#160;million. In connection with this transaction, we added approximately 47,000 Medicaid members in New York. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we closed on the acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan. Effective on that same date, the Kentucky Medicaid agency approved the novation of Passport&#8217;s Medicaid contract to Molina Healthcare of Kentucky, Inc. As a result, we added approximately 325,000 Medicaid members in Kentucky.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, our Kentucky health plan had been selected as an awardee pursuant to the statewide Medicaid managed care RFP issued by the Kentucky Cabinet for Health and Family Services, Department for Medicaid Services. On October 23, 2020, pursuant to a protest filing appeal with regard to the RFP awards, a court ordered the addition of a sixth health plan to the Kentucky Medicaid program for 2021. That ruling did not rescind the Medicaid contract award to our Kentucky health plan for 2021, nor did it have any impact on the earlier novation of the Passport Medicaid contract to us. The new Medicaid contract is currently expected to begin on January 1, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Magellan Complete Care. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into a definitive agreement to acquire the MCC line of business of Magellan Health, Inc. The purchase price for the transaction is approximately $820&#160;million, net of certain tax benefits, which we intend to fund with cash on hand.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCC is a managed care organization serving members in six states, including Medicaid members in Arizona and statewide in Virginia, and Integrated Acute Care members in Florida. Through its Senior Whole Health branded plans, MCC provides fully integrated plans for Medicaid and Medicare dual beneficiaries in Massachusetts, as well as Managed Long-Term Care in New York. MCC also provides consultative services to participants who self-direct their care through Wisconsin&#8217;s long-term services and supports (&#8220;LTSS&#8221;) program. As of December 31, 2019, MCC served approximately 155,000 members in managed care plans and provided services to 25,000 LTSS program participants in Wisconsin, with full year 2019 revenues over $2.7 billion. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction is subject to federal and state regulatory approvals, and other customary closing conditions, and is expected to close around the end of 2020. In connection with this transaction, Magellan Health, Inc. has agreed to provide certain transition services following the closing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketplace Risk Corridor Ruling</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In April 2020, the United States Supreme Court held that &#167;1342 of the Affordable Care Act obligated the federal government to pay participating insurers the full Marketplace risk corridor amounts calculated by that statute, and that impacted insurers may sue the federal government in the U.S. Court of Federal Claims to recover damages for breach of that obligation. In June 2020, the Claims Court granted us judgment in the amount of $128.1 million for our 2014, 2015, and 2016 Marketplace risk corridor claims, which we received in October 2020. Since we accounted for the judgment as a gain contingency at September 30, 2020, it will be recognized in our fourth quarter 2020 financial results. The judgment does not create additional Minimum MLR rebates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illinois</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2020, we terminated our agreement to acquire all of the capital stock of NextLevel Health Partners, Inc. due to the seller&#8217;s stated unwillingness to close pursuant to the terms of the acquisition agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will exit Puerto Rico&#8217;s Medicaid program when our current contract expires on October 31, 2020. We are working closely with the regulatory authorities and the provider community to ensure that our members in Puerto Rico have reliable continuity of care. As discussed in the Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies,&#8221; we recognized a $10 million premium deficiency reserve at September 30, 2020, in connection with the exit from this business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on Status of Significant Medicaid Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our managed care contracts with the California Department of Health Care Services (&#8220;DHCS&#8221;) cover six regions in central and southern California (including the Los Angeles region covered under a separate subcontract with Health Net, LLC). These contracts are effective through December 31, 2020, which we expect to be renewed annually until the effectiveness of new forms of contract following RFP awards. DHCS has publicly indicated it expects to release the final Medicaid RFP in 2021, for implementation in January 2024. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Ohio. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our managed care contract with the Ohio Department of Medicaid (&#8220;ODM&#8221;) is effective through July 1, 2021. In September 2020, the ODM released the RFP for the Ohio Medicaid program with a due date of November 20, 2020. The program will be regionally based on the current three regions (Central/Southeast, Northeast and West); plans may bid on one or all regions, and be awarded one or all regions. The contracts will be awarded on </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">January 25, 2021, with a go-live date of January 5, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On March 25, 2020, the Texas Health and Human Services Commission (&#8220;HHSC&#8221;), notified our Texas health plan that HHSC had upheld our protest and had canceled all previously awarded contracts associated with the re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurement awards announced in October 2019 for the ABD program (known in Texas as &#8220;STAR+PLUS&#8221;). In addition, HHSC canceled the pending re-procurement associated with the TANF and CHIP programs (known in Texas as &#8220;STAR/CHIP&#8221;). HHSC further indicated that it was deliberating next steps with respect to both re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurements. We do not expect the HHSC to re-issue the RFPs in the near future. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Update on Status of MMP Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MMP contracts in California, Illinois and Ohio are effective through December 31, 2022. Updates to our current Michigan, South Carolina and Texas MMP contracts are described below. The Michigan, South Carolina and Texas MMP contracts represented aggregate revenues of approximately $586 million in nine months ended September 30, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Michigan</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A one-year contract extension has been executed, through December 31, 2021. The state has submitted a formal letter of intent to extend the contract for five years through 2026; the five-year contract extension is under development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">South Carolina</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A three-year contract extension has been executed, effective through December 31, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A three-year contract extension amendment, through December 31, 2023, is under review and pending full execution.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional Health Plans segment trends, uncertainties and other developments, refer to our 2019 Annual Report on Form 10-K, &#8220;Item 1. Business&#8212;Our Business,&#8221; and &#8220;&#8212;Legislative and Political Environment.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">MEMBERSHIP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our Health Plans segment membership as of the dates indicated:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending Membership by Government Program:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,595,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,956,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,955,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,033,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,331,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,346,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ending Membership by Health Plan:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">565,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">580,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">132,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kentucky </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">391,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">341,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">947,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">818,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">510,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">456,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,033,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,331,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,346,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________________</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">On September 1, 2020, we closed on the acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan. Effective on that same date, the Kentucky Medicaid agency approved the novation of Passport&#8217;s Medicaid contract to Molina Healthcare of Kentucky, Inc. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">&#8220;Other&#8221; includes the Idaho, Mississippi, New Mexico, New York, Puerto Rico, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results. </span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables in the section below summarize premium revenue, Medical Margin, and MCR by state health plan and by government program for the periods indicated (dollars in millions):</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HEALTH PLANS</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">567&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kentucky </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Carolina </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,768&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.117%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Illinois</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kentucky </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,914&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Carolina </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,011&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">&#8220;Other&#8221; includes the Idaho, Mississippi, New Mexico, New York, Puerto Rico, Utah and Wisconsin health plans, which are not individually significant to our consolidated operating results.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As discussed in &#8220;Trends and Uncertainties&#8221; above, the combination of all the COVID-19 pandemic-related impacts netted to a negligible to slightly positive impact on our overall financial results for the third quarter of 2020. Some of these items increased earnings, such as lower than expected medical costs from the curtailment of utilization that benefited all our state health plans, and a meaningful increase in Medicaid membership, while others served to decrease earnings, such as the temporary, retroactive Medicaid premium refunds and related actions enacted by certain states.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comments relating to the performance of our health plans in California, Ohio, Texas and Washington, which represent our largest health plans from a premium revenue standpoint, follow:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter and nine months ended September 30, 2020, Medical Margin declined as the lower medical costs from the curtailment of utilization were more than offset by Medicaid premium actions and underperformance in the Marketplace.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter and nine months ended September 30, 2020, Medical Margin was higher when compared with the same periods in 2019 due to higher premiums and improved operating performance in Medicaid. Premium revenues were higher year-over-year, mainly due to increased membership, program changes and rate increases in Medicaid established before COVID-19. In the third quarter of 2020, the combined impacts from COVID-19 were negligible; however, the health plan experienced a modest benefit for the nine months ended September 30, 2020, as lower medical costs from the curtailment of utilization slightly exceeded the impact of retroactive Medicaid premium refunds and related actions.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter of 2020, Medical Margin improved compared with the third quarter of 2019, due to a decrease in the MCR in Medicaid, partially offset by underperformance in Marketplace. For the nine months ended September 30, 2020, performance declined year-over-year, with a lower Medical Margin compared with the same period in 2019. The decline resulted mainly from underperformance in Marketplace, due primarily to lower premiums and higher acuity mix for the new members we now serve, partially offset by lower MCRs in Medicaid and Medicare.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Washington. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the third quarter and nine months ended September 30, 2020, Medical Margin was higher when compared with the same periods in 2019, mainly driven by improved results in Medicaid. Medicaid premium revenues increased in both the third quarter and nine months ended September 30, 2020, due to membership growth in Medicaid. In addition, results in the nine months ended September 30, 2020, benefited modestly from lower medical costs due to the curtailment of utilization driven by COVID-19, which was partially offset by COVID-related provider payments mandated by the state in the second quarter of 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PROGRAMS</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">632&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,768&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,084&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.128%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium&#160;Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,415&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,427&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,896&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">272&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">388&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,085&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid premium revenue increased $586 million in the third quarter of 2020 when compared with the third quarter of 2019, and increased $1,176 million&#160;in the nine months ended September 30, 2020, when compared with the nine months ended September 30, 2019. The increase in both periods was mainly due to membership growth and premium increases in several states, partially offset by premium refunds and related actions stemming from COVID-19. The increase in membership includes the impact of the Passport members in Kentucky that we assumed on September 1, and the YourCare membership in New York that we assumed on July 1, as well as the impact from suspension of redeterminations due to COVID-19. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above in &#8220;Health Plans&#8212;Trends and Uncertainties,&#8221; we recognized approximately $88&#160;million and $163&#160;million, respectively, in the third quarter and nine months ended September 2020, for the impact of premium refunds and related actions enacted in several states in response to the lower utilization of medical services resulting from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical Margin in our Medicaid program increased $131 million, or 35%, in the third quarter of 2020 when compared with the third quarter of 2019, and increased $339 million, or 31% in the nine months ended September 30, 2020, when compared with the nine months ended September 30, 2019. The increase in both periods was driven by increased premium revenues and margin associated with the membership growth discussed above, and from a reduction in the MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid MCR decreased to 86.4% in the third quarter of 2020, from 88.1% in the third quarter of 2019, or 170 basis points, and decreased to 86.3% in the nine months ended September 30, 2020, from 88.2% in the nine months ended September 30, 2019, or 190 basis points. The improvements were generally present across all our programs. The year-over-year decrease in the third quarter of 2020 was due to increases in the premium revenue per member per month (&#8220;PMPM&#8221;) and improved operating performance, including enhanced medical cost initiatives. The combined impacts from COVID-19 were negligible to slightly positive in the third quarter of 2020. At the beginning of the third quarter of 2020, utilization was still moderately curtailed but reverted more to normal levels by the end of the quarter. For the nine months ended September 30, 2020, the MCR benefited from lower medical costs due to the curtailment of utilization from COVID-19, which modestly exceeded the impact of the retroactive Medicaid premium refunds and related actions enacted in several states.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, we recognized a $10 million premium deficiency reserve (&#8220;PDR&#8221;) associated with the Puerto Rico Medicaid business. As previously announced, we will exit this business when our current contract expires on October 31, 2020. The PDR represents the estimated remaining claims and administrative costs that exceed the estimated remaining premiums associated with the contract.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MCR for TANF and CHIP was relatively flat in the third quarter of 2020, when compared with the third quarter of 2019, while the MCR for the ABD program decreased 180 basis points, and the MCR for Medicaid Expansion decreased by 440 basis points. The MCR for TANF and CHIP reflected the impact of the Puerto Rico PDR </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussed above. Excluding the PDR, the MCR in all our Medicaid programs improved year-over-year, mainly from increases in the premium revenue PMPM rates and improved operating performance.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2020, the MCR decreased 40 basis points for TANF and CHIP, decreased 190 basis points for ABD, and decreased 440 basis points for Medicaid Expansion, when compared with the same period in 2020. The year-over-year improvement in the nine months ended September 30, 2020, was due to the increase in premium revenue PMPM, operating improvements, and the COVID-19 related net impacts. These improvements were partially offset by unfavorable year-over-year changes in prior year reserve development.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare premium revenue increased $73 million in the third quarter of 2020 and $214 million in the nine months ended September 30, 2020, primarily due to increases in premium revenue PMPM and member months. PMPMs improved due to increased revenue resulting from risk scores that are more commensurate with the acuity of our population and increases in quality incentive premium revenues.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Medical Margin for Medicare increased $11 million, or 14%, in the third quarter of 2020, and increased $84 million, or 34%, in the nine months ended September 30, 2020, when compared with the same periods, respectively, in 2019. The year-over-year improvement in both periods was mainly attributed to the increased revenues described above, and to a lesser extent, lower utilization of medical services stemming from COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare MCR was unchanged at 85.6% in the third quarter of 2020. The 280 basis point year-over-year decrease in the MCR in the nine months ended September 30, 2020, was due to the same factors impacting the year-over-year changes in Medical Margin as discussed above.    </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace premium revenue increased $25 million in the third quarter of 2020, but decreased $31 million in the nine months ended September 30, 2020, mainly due to lower pricing in an effort to be more competitive, and lower risk scores that were not commensurate with the risk of the population. The decrease in the nine months period also resulted from the impact of more health plans being subject to minimum medical loss ratio rebates when compared with the prior year, and the benefit from favorable retrospective adjustments to risk adjustment premiums was higher in the prior year. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Marketplace Medical Margin decreased $33 million in the third quarter of 2020, and $116 million in the nine months ended September 30, 2020, when compared with the same periods, respectively, in 2019. In both periods, the Medical Margin decrease was primarily due to the decline in premium revenues discussed above, and a higher than expected member acuity mix. Our risk scores continue to lag the acuity of our membership, and the rebound in utilization for Marketplace has been much more pronounced than our Medicaid and Medicare programs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The COVID-19 related utilization impact was unfavorable to the Marketplace business and contributed to the year-over-year decline.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace MCR increased in the third quarter and the nine months ended September 30, 2020, attributable to same factors impacting the year-over-year changes in Medical Margin discussed above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">OTHER</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other segment includes certain corporate amounts not allocated to the Health Plans segment. Such amounts are immaterial to our consolidated results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_97"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">LIQUIDITY AND FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. Our Health Plans segment regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our liquidity. In the nine months ended September 30, 2020, we did not experience noticeable delays of, or changes in, the timing and level of premium receipts as a result of the COVID-19 pandemic, but there can be no assurances that we will not experience such delays in the future. See further discussion below regarding various states&#8217; premium actions in &#8220;Future Sources and Uses of Liquidity&#8212;Future Uses.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of the assets held by our regulated health plan subsidiaries is in the form of cash, cash equivalents, and investments. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. In the third quarter and nine months ended September 30, 2020, the parent received $120 million and $355&#160;million, respectively, in dividends from the regulated health plan subsidiaries. See further discussion of dividends below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The parent company may also contribute capital to the regulated health plan subsidiaries to satisfy minimum statutory net worth requirements, including funding for newer health plans with growing enrollment. In the third quarter and nine months ended September 30, 2020, the parent contributed capital of $10 million and $62&#160;million, respectively, to the regulated health plan subsidiaries. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments at the parent company amounted to $1,286 million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $997 million as of September&#160;30, 2020, and December&#160;31, 2019, respectively. The increase as of September 30, 2020, was mainly due to net proceeds of $789 million for the 4.375% Notes issued in June 2020, $380 million drawn on the term loan facility in the first quarter of 2020, and $355&#160;million of dividends received from our regulated health plan subsidiaries year to date. The increase was partially offset by the $600 million repayment of the term loan facility, purchases of our common stock amounting to $453 million, $62&#160;million contributed to our health plan subsidiaries (including $42 million for the YourCare acquisition), $63 million for purchases of property, equipment and capitalized software, $42 million net cash paid for the aggregate convertible notes-related transactions, and $20 million for the initial cash payment for the Passport acquisition. As described in Note 2,&#8221; Significant Accounting Policies,&#8221; we received $128.1 million for the Marketplace risk corridor settlement in October 2020.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio remains strong and is rated AA. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 38</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">950&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month&#8217;s premium payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations for the nine months ended September 30, 2020 was $591 million, compared with $398 million in the nine months ended September 30, 2019. The $193 million increase in cash flow was due to stronger operating results in the nine months ended September 30, 2020, and the net impact of timing differences in government receivables and payables. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $98 million in the nine months ended September 30, 2020, compared with $80 million used in investing activities in the nine months ended September 30, 2019, an increase in cash flow of $178 million. The year over year increase was primarily due to decreased purchases of investments in the nine months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $69 million in the nine months ended September 30, 2020, compared with $510 million used in financing activities in the nine months ended September 30, 2019, an increase in cash flow of $579 million. In the nine months ended September 30, 2020, cash inflows included $789 million from the issuance of the 4.375% Notes and $380 million borrowed under the term loan facility. Cash outflows included the $600 million repayment of the term loan facility, common stock purchases of $453 million, which included $7 million to settle shares purchased in late December 2019, and net cash paid for the aggregate convertible senior notes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8209;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related transactions amounting to $42 million. In the nine months ended September 30, 2019, net cash paid for the aggregate convertible senior notes-related transactions amounted to $754 million, partially offset by proceeds of $220 million borrowed under the term loan facility.</span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_103"></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash resources, borrowing capacity available under the Credit Agreement as discussed further below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources,&#8221; and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, at September&#160;30, 2020, our working capital was $3,397 million, compared with $2,698 million at December&#160;31, 2019. At September&#160;30, 2020, our cash and investments amounted to $5,058 million, compared with $4,477 million at December&#160;31, 2019. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital and Dividend Restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our regulated HMO subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our HMO subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus (net assets) requirement for these subsidiaries was estimated to be approximately $1,300 million at September&#160;30, 2020, compared with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,110 million at December&#160;31, 2019. Our HMO subsidiaries were in compliance with these minimum capital requirements as of both dates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable regulatory requirements, the amount of dividends that may be paid by our HMO subsidiaries without prior approval by regulatory authorities as of September&#160;30, 2020, is approximately $187 million in the aggregate. Our HMO subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash and investments balances as of September&#160;30, 2020, management believes that its regulated health plan subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our high-yield senior notes is rated &#8220;BB-&#8221; by Standard &amp; Poor&#8217;s, and &#8220;Ba3&#8221; by Moody&#8217;s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our borrowing costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Covenants</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement. As of September&#160;30, 2020, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the indentures governing the high-yield notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_106"></div><div style="margin-bottom:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FUTURE SOURCES AND USES OF LIQUIDITY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Health Plans segment regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We added 625,000 Medicaid members as of September 30, 2020, compared with our Medicaid membership as of March 31, 2020, when we first began to report on the impacts of the pandemic. Included in this total are 325,000 members added from our acquisition of the Kentucky Passport business on September 1, 2020. The 47,000 member increase from our acquisition of the New York YourCare business on July 1, 2020, was offset by the decline in membership, in the third quarter of 2020, associated with our announced exit of operations in Puerto Rico. The remaining 300,000 increase in membership was mainly due to the suspension of redeterminations, as we believe that unemployment-related enrollment has not yet materially accessed managed Medicaid. It remains unclear how high the COVID-related membership peak will be, how quickly it will fall as the economy recovers, and where it will ultimately settle. However it does now appear that since unemployment nationally is now just under 8%, the initial industry estimates of unemployment-related Medicaid membership increases were somewhat overstated. On a related note, the declaration of the extension of the public health emergency period into next year will also likely have an impact. Therefore, we are currently unable to predict the timing or amount of the expected increases in enrollment. Increased membership would increase our premium revenue, but would also likely result in a significant increase in medical care claims and related costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends from Subsidiaries.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which would reduce the liquidity of the parent company.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Borrowing Capacity. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had available borrowing capacity of $1&#160;billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500&#160;million, plus an unlimited amount of such term loans as long as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we maintain a minimum consolidated net leverage ratio. See further discussion in the Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Uses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program will be funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase will be determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. No shares were purchased under this program through October&#160;29, 2020.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;We have a disciplined and steady approach to growth. Organic growth, which includes leveraging our existing health plan portfolio and winning new territories, is our highest priority. In addition to organic growth, we will consider targeted acquisitions that are a strategic fit that we believe will leverage operational synergies, and lead to incremental earnings accretion. For further information on our acquisitions, refer to the Notes to Consolidated Financial Statements, Note 4, &#8220;Business Combinations.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close as early as the second quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we completed the acquisition of certain assets of Passport Health Plan, Inc. The estimated total purchase price of $60&#160;million includes our initial cash payment of $20 million in September 2020, plus estimated contingent consideration which consists primarily of an amount due to the seller for members we enroll in the open enrollment period for the 2021 plan year, over a minimum threshold, which resulted in an estimated contingent consideration liability of $40&#160;million. We expect to settle this liability in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into a definitive agreement to acquire the MCC line of business of Magellan Health, Inc. The purchase price for the transaction is approximately $820&#160;million, net of certain tax benefits, which we intend to fund with cash on hand. The transaction is subject to federal and state regulatory approvals, and other customary closing conditions, and is expected to close around the end of 2020. In connection with this transaction, Magellan Health, Inc. has agreed to provide certain transition services following the closing.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Outcome of ACA Litigation</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described above in &#8220;Health Plans Segment&#8212;Trends and Uncertainties,&#8221; the U.S. Supreme Court has accepted the appeal of the Fifth Circuit Court&#8217;s decision regarding the constitutionality and severability of the individual mandate. The ACA remains in effect pending the issuance of the Supreme Court&#8217;s opinion.  A decision by the Supreme Court that the entirety of the ACA is unconstitutional could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Beginning in early 2020 the pandemic, along with the related quarantine and social distancing measures, initially reduced demand for certain routine and non-critical medical services, while at the same time increased demand for other medical services, such as COVID-19 testing and emergency services. At the beginning of the third quarter of 2020, utilization was still moderately curtailed, but rebounded to more normal levels during the quarter. Increased demand for medical services, which we are presently unable to predict the timing or magnitude, could result in a significant increase in medical care costs and related provider claims payments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, as described above in &#8220;Health Plans Segment&#8212;Trends and Uncertainties,&#8221; we have been subject to Medicaid premium actions as a result of the pandemic. Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020.  </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Capital Requirements and Dividend Restrictions.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Molina Healthcare Charitable Foundation. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we announced our commitment of $150 million to fund The Molina Healthcare Charitable Foundation (the &#8220;Foundation&#8221;), an independent not-for-profit charitable foundation. We intend to make a sizable contribution to the Foundation in the fourth quarter of 2020.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_109"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of future obligations under our various contractual obligations and commitments as of December&#160;31, 2019, was disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2019. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the financing transactions described in Notes to Consolidated Financial Statements, Note 8, &#8220;Debt,&#8221;  there were no significant changes to our contractual obligations and commitments outside the ordinary course of business during the nine months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_112"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medical claims and benefits payable</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Refer to Notes to Consolidated Financial Statements, Note 7, &#8220;Medical Claims and Benefits Payable,&#8221; for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, there have been no significant changes during the nine months ended September 30, 2020, to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may adjust or limit revenue or profit</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Goodwill and intangible assets, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There have been no significant changes, during the nine months ended September 30, 2020, to our disclosure reported in &#8220;Critical Accounting Estimates&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_115"></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at September&#160;30, 2020, the fair value of our fixed income investments would decrease by approximately $42 million.&#160;Declines in interest rates over time will reduce our investment income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 8, &#8220;Debt.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_118"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our management, with the participation of our chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), are effective to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> There has been no change in our internal control over financial reporting during the fiscal quarter ended September&#160;30, 2020, that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_121"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 11, &#8220;Commitments and Contingencies.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain risks may have a material adverse effect on our business, financial condition, cash flows, results of operations, or stock price, and you should carefully consider them before making an investment decision with respect to our securities. In addition to the other information set forth in this report, you should carefully consider the risk factors set forth below and those discussed under the caption &#8220;Risk Factors,&#8221; in our Annual Report on Form 10&#8209;K for the year ended December 31, 2019, and in our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2020 and June 30, 2020. The risk factors below, together with those described in the reports listed above, are not the only risks that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, results of operations, or stock price. In addition to the risks relating to the COVID-19 pandemic in the reports listed above, the effects of the COVID-19 pandemic may also have the effect of significantly heightening many of the other risks associated with our business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The May 2020 contract award to our Kentucky Medicaid plan is the subject of a legal challenge.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 23, 2020, pursuant to the appeal of a protest denial with regard to the May 2020 Kentucky RFP awards, a court ordered the addition of a sixth health plan to the Kentucky Medicaid program for 2021. That ruling did not rescind the Medicaid contract award to our Kentucky health plan for 2021, nor did it impact the earlier novation of the Passport Medicaid contract to us. On October 27, 2020, a different health plan filed an appeal with regard to the court&#8217;s October 23</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> order. The outcome of litigation and appellate proceedings is inherently unpredictable. In the event the contract award to our Kentucky health plan or the novation of the Passport Medicaid contract is challenged or overturned, the business and revenues of our Kentucky health plan may be materially affected.    </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 43</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of common stock made by us, or on our behalf during the quarter ended September&#160;30, 2020, including shares withheld by us to satisfy our employees&#8217; income tax obligations, are set forth below: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:44.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchased&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average&#160;Price&#160;Paid per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of&#160;Shares<br/>Purchased as Part of<br/>Publicly&#160;<br/>Announced&#160;<br/>Plans or <br/>Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dollar&#160;Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">of Shares that May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 1 - July 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179.12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1 - August 31</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 1 - September 30</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">During the three months ended September 30, 2020, we withheld 821 shares of common stock, to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan. For further information refer to Note 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">In September 2020, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMjcvZnJhZzpmOTBjYThmYjBlNGU0NjlmODQ5Y2RmNTBiNzgxZjA3ZC90ZXh0cmVnaW9uOmY5MGNhOGZiMGU0ZTQ2OWY4NDljZGY1MGI3ODFmMDdkXzIxOTkwMjMyNTcxMDY_0b5032ce-57d5-4290-8d8e-302a2aa9cd36">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This program will be funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase will be determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. No shares were purchased under this program through October&#160;29, 2020.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 44</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.184%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Method of Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="exhibit21affinity-apa.htm">2.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Asset Purchase Agreement, dated as of September 28, 2020, by and between Molina Healthcare, Inc. and Affinity Health Plan, Inc.*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh3q20ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 302 Certification of Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh3q20ex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Section 302 Certification of Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh3q20ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="moh3q20ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith. </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.005%"><tr><td style="width:0.1%"></td><td style="width:2.754%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain portions of this agreement have been omitted in accordance with Item 601(b)(10) of Regulation S-K. A copy of any omitted portion will be furnished to the Securities and Exchange Commission upon request. </span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 45</span></div></div></div><div id="i5a44908a328044dfb2ef6755dcd9b05e_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i5a44908a328044dfb2ef6755dcd9b05e_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.068%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MOLINA HEALTHCARE, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ JOSEPH M. ZUBRETSKY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 3.37pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dated: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 29, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/ THOMAS L. TRAN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Thomas L. Tran</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. September 30, 2020 Form 10-Q | 46</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exhibit21affinity-apa.htm
<DESCRIPTION>EX-2.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3c1195df7064453a9df5c32368f6ff05_1"></div><div style="min-height:72pt;width:100%;"><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXECUTION COPY</font></div></div><div><font><br></font></div><div style="text-align:right;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:7pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ASSET PURCHASE AGREEMENT</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">by and between</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AFFINITY HEALTH PLAN, INC.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MOLINA HEALTHCARE, INC.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Dated as of</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">September 28, 2020</font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="text-align:center;margin-bottom:12pt;"><font><br></font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:98.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-bottom:7pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#ffffff;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%;">43927.00005</font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Page</font></div></div><div style="padding-left:0.9pt;padding-right:36pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.291%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:74.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.868%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE I DEFINITIONS</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE II PURCHASE AND SALE</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase and Sale of Assets</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Excluded Assets</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assumed Liabilities</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Excluded Liabilities</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase Price</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.07</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Determination of Net Asset Value Purchase Price Adjustment</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 2.08</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third Party Consents</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE III CLOSING</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 3.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Closing</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 3.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Closing Deliverables</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE IV REPRESENTATIONS AND WARRANTIES OF AFFINITY</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Organization and Qualification</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Authority</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Conflicts&#59; Consents</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Statements</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Absence of Certain Changes, Events and Conditions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Material Contracts</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.07</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provider Contracts</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.08</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title to and Sufficiency of Purchased Assets&#59; Leased Real Property</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.09</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Intellectual Property&#59; Claims</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.10</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal Proceedings&#59; Orders</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.11</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Compliance With Laws</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.12</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">HIPAA and Privacy</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">37</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.13</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employment and Benefits Matters</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.14</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Taxes</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">41</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.15</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Brokers</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.16</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Health Care Matters</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.17</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Related Party Transactions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.18</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Environmental Matters</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- i -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Page</font></div></div><div style="padding-left:0.9pt;padding-right:36pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.291%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:74.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.868%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.19</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Insurance Coverage</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 4.20</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provider Network</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE V REPRESENTATIONS AND WARRANTIES OF BUYER</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Organization</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Authority</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Conflicts&#59; Consents</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Brokers</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Legal Proceedings</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">46</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 5.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financial Capability</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE VI COVENANTS</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conduct of Business Prior to the Closing</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">47</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Access to Information</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Solicitation of Other Bids</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notice of Certain Events</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Employees</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">52</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Confidentiality</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.07</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-competition&#59; Non-solicitation</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.08</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governmental Approvals and Consents</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">56</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.09</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">New Material Contracts</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.10</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Closing Conditions</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.11</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Public Announcements</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.12</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Reconciliation</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.13</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Transition Planning</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.14</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Further Assurances</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.15</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Post-Closing Access to Information</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.16</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-disparagement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.17</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Post-Closing Buyer Covenants</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">61</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.18</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Transfer Taxes</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.19</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Minimum Network Requirements</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.20</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Sale or Dissolution&#59; Post-Closing Cooperation</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 6.21</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Insurance Coverage</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE VII CONDITIONS TO CLOSING</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- ii -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Page</font></div></div><div style="padding-left:0.9pt;padding-right:36pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.291%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:74.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.868%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 7.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conditions to Obligations of All Parties</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">63</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 7.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conditions to Obligations of Buyer</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 7.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conditions to Obligations of Affinity</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE VIII INDEMNIFICATION</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Survival</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indemnification by Affinity</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">67</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indemnification by Buyer</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certain Limitations</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Indemnification Procedures</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payments</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">72</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.07</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tax Treatment of Indemnification Payments</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.08</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exclusive Remedy</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 8.09</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Materiality</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE IX TERMINATION</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 9.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Termination</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 9.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of Termination</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74</font></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ARTICLE X MISCELLANEOUS</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.01</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expenses</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.02</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Notices</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.03</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interpretation</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.04</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Headings</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.05</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Severability</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.06</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Entire Agreement</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">76</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.07</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Disclosure Schedules</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.08</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Successors and Assigns</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.09</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Third-Party Beneficiaries</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.10</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amendment and Modification&#59; Waiver</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.11</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Governing Law&#59; Submission to Jurisdiction&#59; Waiver of Jury Trial</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">78</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.12</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Specific Performance</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.13</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Recourse Against Non-Recourse Parties</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.14</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Acknowledgements&#59; Disclaimers</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">80</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.15</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prevailing Party</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81</font></td></tr></table></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- iii -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-right:5.75pt;text-align:center;"><font><br></font></div><div style="padding-left:0.05pt;padding-right:5.75pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Table of Contents</font></div><div style="padding-left:5.75pt;padding-right:5.75pt;text-align:right;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Page</font></div></div><div style="padding-left:0.9pt;padding-right:36pt;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:18.291%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:74.541%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:3.868%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.16</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Release</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">81</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.17</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Counterparts</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Section 10.18</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">No Strict Construction</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">82</font></td></tr></table></div><div style="text-indent:-0.9pt;padding-left:126pt;padding-right:36pt;margin-bottom:6pt;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- iv -</font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">EXHIBITS&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT A&#160;&#160;&#160;&#160;FORM OF ESCROW AGREEMENT</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT B&#160;&#160;&#160;&#160;FORM OF BILL OF SALE</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT C&#160;&#160;&#160;&#160;FORM OF ASSIGNMENT AND ASSUMPTION AGREEMENT</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT D&#160;&#160;&#160;&#160;FORM OF IP ASSIGNMENT AGREEMENT</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT E&#160;&#160;&#160;&#160;REQUIRED THIRD PARTY CONSENTS</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT F &#160;&#160;&#160;&#160;APPLICABLE ACCOUNTING PRINCIPLES AND SAMPLE CALCULATION</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">EXHIBIT G&#160;&#160;&#160;&#160;FORM OF FQHC NON-COMPETE AGREEMENT</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">v</font></div><div><font><br></font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ASSET PURCHASE AGREEMENT</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This Asset Purchase Agreement (this &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), dated as of September 28, 2020, is entered into by and between AFFINITY HEALTH PLAN, INC., a New York not-for-profit corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and MOLINA HEALTHCARE, INC., a Delaware corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Affinity and Buyer are sometimes referred to herein individually as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and collectively as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RECITALS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, Affinity is a prepaid health services plan pursuant to Section 4403-a of the New York Public Health Law and provides health care coverage under the New York State Medicaid Managed Care, Health and Recovery Plan, Child Health Plus, and Essential Plan programs (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, subject to the terms and conditions set forth in this Agreement, Affinity desires to sell to Buyer, and Buyer desires to purchase from Affinity, substantially all of the assets owned or leased by Affinity that are used or held for use in the operation of the Business&#59; and </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, pursuant to the terms and conditions hereof, the Parties desire to work cooperatively to obtain the requisite approvals, licenses, certificates, authorizations and permits to effect the sale, transfer, conveyance, assignment and delivery by Affinity to Buyer of the aforesaid assets so that all of Affinity&#8217;s members enrolled under the Payor Contracts (as defined herein) relating to the Business (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Enrollees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) at the time of transfer would be enrolled in a health plan operated by Buyer providing or arranging for health services to such Enrollees (except to the extent such Enrollees elect not to be so enrolled).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE I.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DEFINITIONS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">The following terms have the definitions set forth below or otherwise ascribed thereto in the Section of this Agreement identified below&#58;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition Proposal</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Action</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any claim, action, suit, corrective action plan, cause of action, lawsuit, arbitration, audit, written notice of violation, administrative proceeding, litigation, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity, before or by any Governmental Authority.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Adverse Claim Consequences</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">AEP Schedule</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.06(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affiliate</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of a Person means any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such Person. The term &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">control</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; (including the terms &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">controlled by</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">under common control with</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. For the avoidance of any doubt, the Parties acknowledge and agree that the FQHC Members shall not be deemed to be Affiliates of Affinity for purposes of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Employee Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, solely to the extent set forth and itemized on the AEP Schedule, each of the following&#58; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;any payments or other amounts due to employees of Affinity by reason of this Agreement or the consummation of the transactions contemplated by this Agreement, including any retention, stay or change in control payments&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;amounts payable to any Person (including additional contribution credits as a result of this Agreement or the transactions contemplated by this Agreement and Tax gross-up payments or amounts for which there is an acceleration of vesting) under any nonqualified deferred compensation plan of Affinity&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;all accrued but unpaid salaries, wages, commissions, severance (solely with respect to any employees of Affinity terminated by Affinity on or prior to the Closing Date), vacation or sick pay, personal leave, incentive compensation or other compensation or payroll items earned by, or accrued in respect of, any current employee of Affinity for any period through and including the Closing Date&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;with respect to the payments described in each of the foregoing clauses (i)-(iii), all employer related payroll Tax Liabilities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Employee Plan</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means each &#8220;employee benefit plan&#8221; within the meaning of Section 3(3) of ERISA (whether or not subject to ERISA) and each other employment, consulting, deferred compensation, incentive, change in control, retention, severance, vacation, paid time off, health, medical, fringe-benefit and other compensatory agreement, plan, policy, practice, program or arrangement which is or has been adopted, entered into, maintained, sponsored, contributed to, or required to be contributed to by Affinity with or for the benefit of any current or former employee, officer, or director of Affinity or the Business (or with or for the benefit of their respective spouses or dependents) or with respect to which Affinity otherwise has any Liabilities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Fundamental Representations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Organization and Qualification), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Authority) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Brokers).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 2 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Representative</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.17(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Transaction Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the aggregate amount of all fees, commissions, costs and expenses of Affinity incurred or to be incurred or reimbursed in connection with, or related to, the transactions contemplated by this Agreement, to the extent not paid in full at or prior to the Closing, including all legal, accounting, financial advisory, broker, consulting and all other fees and expenses of third parties, including service providers&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Affinity Transaction Expenses shall exclude any item included in the definition of Affinity Employee Payables.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Antitrust Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means applicable federal, state, local or foreign antitrust, competition, premerger notification or trade regulation Laws, including the Sherman Antitrust Act of 1890, the Clayton Act of 1914, the HSR Act and the Federal Trade Commission Act of 1914.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Applicable Accounting Principles</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">means the following&#58; (a) the accounting principles, judgments, methodologies, practices, classifications, estimation techniques and assumptions, including as to the establishment of premiums receivable accruals, reserves and determination of contingencies, set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit F</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, (b) to the extent not addressed in (a), the accounting principles, judgments, methodologies, practices and classifications used in the preparation of the Audited Financial Statements for the year ended December 31, 2019, and (c) to the extent not addressed in (a) or (b), SAP. For the avoidance of doubt (a) takes precedence over (b) and (c), and (b) takes precedence over (c). </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assigned Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(vii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assignment and Assumption Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an assignment and assumption agreement in substantially the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit C</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, duly executed by Buyer and Affinity, effecting the assignment to and assumption by Buyer of the Purchased Assets and the Assumed Liabilities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assumed Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Audited Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Balance Sheet</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Balance Sheet Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Basket Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 3 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Bill of Sale</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a bill of sale in substantially the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit B</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, duly executed by Affinity, transferring the personal property included in the Purchased Assets to Buyer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Books and Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(xii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the Recitals.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business Day</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any day except Saturday, Sunday or any other day on which commercial banks located in the State of New York are authorized or required by Law to be closed for business.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Licensed Intellectual Property and the Purchased Intellectual Property.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business IT Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business Software</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Software used in or material to the Business, including but not limited to Software embodied in products of the Business, other than commercially available &#8220;off the shelf&#8221; Software that has not been modified or customized for use by Affinity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the disclosure schedules delivered by Buyer to Affinity concurrently with the execution and delivery of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer Fundamental Representations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the representations and warranties of Buyer set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Organization), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Authority) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.04</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Brokers).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cap</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cash</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, as of any date of determination, cash, cash equivalents, marketable securities, security entitlements, and short-term investments of Affinity, checks and funds received by Affinity, less the amount of checks written by Affinity but not yet cleared, in each case calculated as of such date in accordance with SAP applied on a consistent basis with the Audited Financial Statements.  For the avoidance of doubt, &#8220;Cash&#8221; shall not include the Statutory Escrow Account, Retained Cash and Investments and any petty cash, and shall include all balances held in the operating accounts.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cash Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cause</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean (a) poor performance or any misconduct identified as a ground for termination in Buyer&#8217;s human resources policies, code of business conduct, or other written policies, practices or procedures, (b) commission of any criminal, fraudulent, or dishonest act in </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 4 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">connection with the individual&#8217;s employment, or (c) conviction of any felony or crime of moral turpitude.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Change in Health Care Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any adoption, implementation, promulgation, repeal, modification, amendment, reinterpretation, or change of any applicable New York state Law relating to Medicaid or otherwise relating to the health care, health insurance or managed care industry.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Claim Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 3.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Affinity Employee Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.06(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Cash</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Cash as of the Measurement Time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 3.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Date Indebtedness</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Indebtedness incurred by Affinity and outstanding as of immediately prior to the Closing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement Disputed Items</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement Objection Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.07(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">CMS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Centers for Medicare and Medicaid Services.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.04(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Code</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Internal Revenue Code of 1986, as amended.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Contract</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any agreement, contract, lease, deed, mortgage, license, instrument, promissory note, evidence of Indebtedness, security agreement, commitment, undertaking, indenture or joint venture, whether written or oral.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Court</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any court, arbitrator or tribunal of the United States, any domestic state, or any foreign country, and any political subdivision thereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Direct Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the disclosure schedules delivered by Affinity to Buyer concurrently with the execution and delivery of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Update</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.04(a)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 5 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">DOH</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the New York State Department of Health.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Dollars</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">$</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the lawful currency of the United States.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">DSRIP EIP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the New York State Delivery System Reform Incentive Payment program&#8217;s Equity Infrastructure Program.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">DSRIP EIP Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any payable by Affinity (or for which Affinity may have any liability) in connection with DSRIP EIP represented by the line item &#8220;Payable for NYSDOH Equity Program&#8221; on the Balance Sheet.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">DSRIP EIP Receivables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all proceeds due and payable to Affinity in connection with DSRIP EIP represented by the line item &#8220;Restricted Funds, NYSDOH DSRIP Equity Program&#8221; on the Balance Sheet.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Effective Time</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 3.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Emblem Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all proceeds due and payable to Affinity pursuant to or otherwise arising from Affinity&#8217;s rights under that certain Asset Purchase Agreement by and between Affinity and Greater Health Plan of New York dated as of October 27, 2018. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Encumbrance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any encumbrance, charge, claim, pledge, equitable interest, lien (statutory or other), option, security interest, mortgage, hypothecation, easement, encroachment, right of way, right of first refusal, restriction, levy or charge of any kind, including any restriction on use, voting, transfer, receipt of income or exercise of any other attribute of ownership.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Enrollees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the Recitals.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Environmental Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any applicable Law relating to the regulation or protection of the environment, natural resources, or human health or safety, including Laws relating to the manufacture, processing, distribution, sale, use, treatment, storage, disposal, transport, handling, remediation, cleanup, Release or threatened Release of or exposure to pollutants, contaminants, chemicals or other hazardous, harmful or deleterious materials or substances, including the Comprehensive Environmental Response, Compensation and Liability Act, 42 U.S.C. &#167;&#167; 9601 et seq.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">ERISA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Employee Retirement Income Security Act of 1974, as amended.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Escrow Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Citibank, National Association.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Escrow Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an Escrow Agreement, in substantially the form of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit&#160;A</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> attached hereto, to be entered into among Buyer, Affinity and the Escrow Agent.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Escrow Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Thirty-Seven Million Five Hundred Thousand Dollars ($37,500,000), as it may be increased or decreased from time to time as provided herein.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 6 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Escrow Fund</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.06(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Estimated Closing Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.07(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Estimated Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.02(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.04</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Matter</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any one or more of the following&#58; (i)&#160;any change in the United States or foreign economies or securities or financial markets&#59; (ii)&#160;any change that generally affects the Medicaid managed care industry (other than as a result of any Change in Health Care Law)&#59; (iii) any changes or proposed changes in applicable Laws or accounting rules (other than any Change in Health Care Law)&#59; (iv) taking of any action that is required by the terms of this Agreement or the consummation of the transactions contemplated by this Agreement&#59; (v)&#160;any failure, in and of itself, by Affinity to meet internal forecasts or projections (it being understood and agreed that the underlying facts and circumstances that cause such failure that are not otherwise excluded from the definition of a Material Adverse Effect may be taken into account in determining whether there has been a Material Adverse Effect)&#59; and (vi)&#160;any outbreak of hostilities, acts of war, sabotage or terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism or military actions existing or underway as of the date hereof&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that any event, occurrence, fact, condition, change or effect referred to in clauses (i), (ii), (iii), and (vi) shall be taken into account for purposes of determining whether a Material Adverse Effect has occurred solely to the extent that such occurrence, fact, condition, change or effect has a disproportionate adverse effect on Affinity or the Business, in each case, taken as a whole, relative to the adverse effect such events or changes have on other companies that participate in the geographic markets and industries in which Affinity operates.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Person, all reasonable and documented out-of-pocket fees and expenses (including all fees and expenses of counsel, accountants, financial advisors and investment bankers of such Person and its Affiliates, but excluding any Transfer Taxes), incurred by such Person or on its behalf in connection with or related to the authorization, preparation, negotiation, execution and performance of this Agreement and any transactions related thereto, any litigation with respect thereto, or in connection with other regulatory approvals, and all other matters related to transactions contemplated hereby. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Federal Health Care Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning given to such term in 42 U.S.C. &#167;&#160;1320a-7b-(f).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Final Closing Adjustment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.07(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 7 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Final Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Net Asset Value of Affinity as finally determined in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">FQHC Members</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Charles B. Wang Community Health Center, Inc., Cornerstone Family Health Care, The Institute for Family Health, Morris Heights Health Center, Inc., William F. Ryan Community Health Center, Inc., and Urban Health Plan, Inc.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">FQHC Non-Compete Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Non-Compete Agreements, in substantially the form attached hereto as </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit G</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, to be entered into among Buyer, Affinity and each FQHC Member.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;"> </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">GAAP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means United States generally accepted accounting principles in effect as of the date hereof, consistently applied. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Governmental Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any federal, state, local, municipal or foreign government or political subdivision thereof, or any authority, commission, department, board, official or other instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any Court of competent jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Hazardous Materials</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any waste, substance, chemical, radiation or material regulated, listed, defined or which forms the basis for Liability under Environmental Laws.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Health Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(xvii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">HIPAA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Health Insurance Portability and Accountability Act of 1996, as amended and supplemented by the Health Information Technology for Economic and Clinical Health Act (Pub. L. No. 111-5) and the implementing regulations of each, when each is effective and as each is amended from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Hired Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">HSR Act</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Inactive Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an employee of the Business who is on a leave of absence as a result of (a)&#160;accident, sickness, family, pregnancy, parental or medical leave, (b)&#160;disability or salary continuation under the terms of an Affinity Employee Plan, (c)&#160;workers&#8217; compensation leave, (d)&#160;any leave required by applicable Law, or (e) military service.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Indebtedness</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, as of any date without duplication, all obligations (including any principal, accrued and unpaid interest, premium, penalty, breakage costs, termination fees or other payment) of Affinity (i) for indebtedness for borrowed money, including with respect to deposits or advances of any kind, (ii) evidenced by notes, bonds, debentures or other similar </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 8 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">instruments, (iii) with respect to any interest rate hedging, swap agreements, foreign currency exchange agreements or similar arrangements and related break-up fees, (iv) for any liability for all or any part of the deferred purchase price of property, assets, securities, goods or services (other than trade payables incurred in the ordinary course of business to the extent not included in Net Asset Value), at the maximum value, whether contingent or not, including any &#8220;earn-out&#8221;, purchase price adjustment, release of &#8220;holdback&#8221; or similar payment or any non-compete payments, (v) for any liability under any reimbursement obligation relating to a surety bond, letter of credit, bankers&#8217; acceptance, note purchase facility or similar credit transactions, (vi) under leases required in accordance with GAAP to be recorded as capital leases or leases classified as a capital&#47;finance lease in the Financial Statements and excluding operating leases, (vii) for indebtedness secured by an Encumbrance, except for Permitted Encumbrances, (viii) under conditional sale or other title retention agreements relating to any property purchased, (ix) for all negative balances in bank accounts and all overdrafts, (x) for deferred rent Liabilities recorded in accordance with GAAP, (xi) for any accounts payable or loans of any kind or nature between Affinity, on the one hand, and any officers, directors, employees or agents of Affinity, on the other hand, (xii) escheat Liabilities, (xiii) audit settlement Liabilities, (xiv) bankruptcy reserves, and (xv) any guarantee of the payment or performance of, or any contingent obligation in respect of, any Indebtedness of any other Person. &#8220;Indebtedness&#8221; shall not include any item included in the definition of Net Asset Value.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Indemnifying Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Independent Accountants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a nationally or regionally recognized firm of independent accountants as to which Buyer and Affinity mutually agree.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Ineligible Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Person that (a)&#160;is currently excluded, debarred, suspended, or otherwise ineligible to participate in any Federal Health Care Program or in federal procurement or non-procurement programs or (b)&#160;to the Knowledge of Affinity has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. &#167; 1320a-7(a), but has not yet been excluded, debarred, suspended, or otherwise declared ineligible.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Information Privacy and Security Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Laws concerning the privacy or security of Personal Information, and all regulations promulgated and guidance issued by any Governmental Authority thereunder, including, but not limited to, HIPAA, the Gramm-Leach-Bliley Act, the Fair Credit Reporting Act, the Fair and Accurate Credit Transaction Act, the Telephone Consumer Protection Act, Section 5 of the Federal Trade Commission Act as it applies to the receipt, access, use, disclosure, and security of Personal Information, the CAN-SPAM Act, Children&#8217;s Online Privacy Protection Act, PCI DSS, Part 500 of Title 23 of the New York Codes, Rules and Regulations, Article 27-F of the New York Public Health Law, state data breach notification Laws, state data security Laws, state social security number protection Laws, state consumer protection Laws, any health care Laws pertaining to privacy or data security and any applicable Laws concerning requirements for website and mobile application privacy policies and practices, or any outbound communications (including e-mail marketing, telemarketing and text messaging), tracking and marketing.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 9 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Initial Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 9.01(d)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all intellectual property, intangible property and proprietary rights, title, interests and protections, however arising, pursuant to the Laws of any jurisdiction throughout the world, including&#58; (i) all United States, foreign and international patents, patent applications and statutory invention registrations, utility models, reissues, divisionals, continuations, continuations-in-part, extensions and reexaminations thereof&#59; (ii) all trademarks, service marks, trade dress, logos, trade names and corporate names, uniform resource locator addresses, symbols, slogans, and other indicia of source or origin, including the goodwill of the business symbolized thereby or associated therewith, common law rights, registrations and applications therefor throughout the world&#59; (iii) internet domain names, website content, social media handles, tags, hashtags, social media accounts, or any other online indicia of source&#59; (iv) original works of authorship in any medium of expression, whether or not published, all copyrights and copyrightable works, all registrations and applications for registration of such copyrights, and all issuances, extensions and renewals of such registrations and applications&#59; (v) trade secrets, formulas, designs, devices, technical data, technology, know-how, research and development, advertising and promotional materials, inventions and invention disclosures, methods or processes, and other confidential or proprietary technical, business and other information&#59; (vi) computer software (including source and object code) and computer programs and databases in any form, including firmware, development tools, algorithms, data, data files, records, database management code, utilities, graphical user interfaces, internet web sites, all versions, updates, corrections, enhancements and modifications of any of the foregoing, and all related documentation (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Software</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; (vii) all rights to sue and recover and retain damages, costs and attorneys&#8217; fees for past, present and future infringement and any other rights relating to any of the foregoing&#59; and (viii) all tangible embodiments of any of the foregoing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Interim Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">IP Assignment Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an intellectual property assignment agreement in substantially the form attached hereto as</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Exhibit D</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, duly executed by Buyer and Affinity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">IRS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Internal Revenue Service.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">IT Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all computer systems, including software, hardware, databases, firmware, middleware and platforms, interfaces, systems, networks, information technology equipment, facilities, websites, infrastructure, workstations, switches, data communications lines and associated documentation used or held for use by or on behalf of Affinity in connection with the conduct of the Business.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Key Provider</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Knowledge of Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity&#8217;s Knowledge</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or any other similar knowledge qualification, means the actual knowledge of Michael Murphy, Clara Hansen, Rachel Amalfitano, Lisa Mingione, Scott Breidbart and Jason Robinson after reasonable due inquiry and investigation. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 10 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Law</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any federal, state or local law (statutory or otherwise), ordinance, regulation, rule, code, constitution, treaty, convention, ruling, administrative opinion, subregulatory requirement or other requirement enacted, adopted, promulgated or applied by or on behalf any Governmental Authority, any Order having the effect of law in any jurisdiction, and applicable common law.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Leased Real Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.08(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any debts, liabilities, obligations or commitments of any nature whatsoever, asserted or unasserted, known or unknown, absolute or contingent, accrued or unaccrued, matured or unmatured, monetary or non-monetary, direct or indirect, determined or determinable or any other nature whether due or to become due, and regardless of when asserted or whether it is accrued or required to be accrued or disclosed pursuant to Applicable Accounting Principles.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Licensed Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Intellectual Property licensed to or held for use by Affinity, but excluding the Purchased Intellectual Property.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Losses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means losses, damages, Liabilities, deficiencies, Actions, judgments, interest, awards, penalties, fines, costs or expenses of whatever kind, including reasonable fees of accountants, attorneys and other similar professionals, the cost of enforcing any right to indemnification hereunder, the cost of pursuing any insurance providers, lost profits, multiples of earnings, diminution in value and consequential damages, excluding, any other indirect, special or punitive damages (other than damages awarded as part of a Third Party Claim).  For the avoidance of doubt, consequential damages means Losses that were reasonably foreseeable but were not a direct result of the related breach or alleged breach of this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any event, occurrence, fact, condition, change or effect that (a) has had, or could reasonably be expected to have, individually or in the aggregate, a material adverse effect on (1) the business, results of operations, or financial condition of the Business, or (2) the Purchased Assets and Assumed Liabilities, taken as a whole, or (b) has materially impaired, or could reasonably be expected to materially impair or delay, individually or in the aggregate, the ability of Affinity to perform its obligations under this Agreement or consummate the transactions contemplated hereby&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that, in determining whether there has been a Material Adverse Effect, any event, occurrence, fact, condition, change, effect, development or circumstance to the extent resulting from or attributable or relating to an Excluded Matter shall be disregarded and no Excluded Matter shall be deemed to constitute a Material Adverse Effect. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Material Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (i) the Provider Contracts&#59; (ii) the Payor Contracts&#59; (iii) Contracts related to the provision of management services or functions to Affinity and that have required the approval of DOH under 10 N.Y.C.R.R. &#167; 98-1.11 during the past three (3) years&#59; (iv) Contracts containing a provision or covenant that purports to (A) materially restrict the business activity of Affinity as it relates to the Business as it is currently conducted, (B) materially limit the freedom of Affinity to engage in the Business or compete with any Person in the Business, (C) provide &#8220;most favored nation&#8221; or similar status to any customer or Provider, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 11 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(D) require the purchase of any product or service exclusively from a single party or grant exclusive rights to marketing or distribution or (E) grant to any Person (other than Affinity) an option or a first refusal, first-offer or similar preferential right to purchase or acquire any assets which are material to Affinity or the Business&#59; (v) Contracts for joint venture agreements or similar partnerships entered into within the last three (3) years&#59; (vi) Contracts with any licensed producer or broker relating to the sale of Affinity&#8217;s health plans providing for annual payments by Affinity in excess of Ten Thousand Dollars ($10,000)&#59; (vii) Contracts relating to the settlement of any Actions, other than (A) settlements immaterial in nature or amount to Affinity and the Business, taken as a whole, entered into with former employees or current or former independent contractors in the ordinary course of business, and (B) settlement agreements under which Affinity does not have any continuing obligations or Liabilities equal to or greater than Seventy-Five Thousand Dollars ($75,000) or rights (excluding releases)&#59; (viii) any other Contract with a Governmental Authority&#59; (ix) Contracts with vendors providing for payments by or to Affinity in excess of One Hundred Thousand Dollars ($100,000) during the fiscal year ended December 31, 2019&#59; (x)  any Contracts for the sale or purchase of any assets or business (whether by merger, sale of stock, sale of assets or otherwise) within the last three (3) years with a value in excess of One Million Dollars ($1,000,000) or pursuant to which there are continuing indemnification, &#8220;earn-out&#8221; or other contingent payment Liabilities, including Contracts providing for indemnification to or from any Person with respect to Liabilities relating to any current or former business of Affinity&#59; (xi) Contracts or agreements relating to or evidencing Indebtedness of Affinity or any mortgage, pledge, indenture or security agreement or similar arrangement constituting an Encumbrance that is material to the Purchased Assets, taken as a whole&#59; (xii) Contracts that relate to any off-balance sheet arrangements, loss sharing, or loss guarantee and contingent purchase transactions, special purpose entity transactions or other similar transactions of Affinity, and any hedging, derivatives or similar Contracts or arrangements&#59; (xiii) Contracts that require additional capital expenditures in excess of One Million Dollars ($1,000,000) that are not reflected on the Balance Sheet&#59; and (xiv) all other Contracts involving annual payments of more than One Million Dollars ($1,000,000).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Measurement Time</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means 12&#58;01 a.m., Eastern Time, on the Closing Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Medical Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any measurement period, the aggregate dollar amount of claims incurred by Affinity with respect to covered medical services provided. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Medical Claims Reserve</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to Affinity, the amount accrued or reserved by Affinity for Liabilities for Medical Claims incurred but not reported, and incurred but pending or otherwise unpaid, in each case, calculated as of the Measurement Time in accordance with the Applicable Accounting Principles. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">MHNY</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.17(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Minimum Network Requirements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a sufficient number of Provider Contracts required to have been successfully assigned to Buyer as set forth in the DOH&#8217;s approval for the transactions contemplated hereby, in each case with reimbursement rates that do not exceed Affinity&#8217;s reimbursement rates immediately prior to Closing.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 12 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">MMCOR</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Medicaid Managed Care Operating Report statements required to be filed with DOH.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Montefiore Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any and all proceeds due and payable to Affinity pursuant to or otherwise arising from Affinity&#8217;s rights under various agreements with Montefiore Medical Center, including but not limited to that certain Agreement for Hospital Services by and between Affinity and Montefiore Medical Center dated as of July 16, 2002, as amended from time to time and as extended by those certain letter agreements dated March 26, 2019 and November 8, 2019. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Murphy Executive Employment Contract</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that certain executive employment agreement by and between Affinity and Michael Murphy dated as of January 1, 2019.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an amount equal to Affinity&#8217;s capital and surplus calculated by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">subtracting</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (i) the sum of all Assumed Liabilities from (ii) the sum of all Purchased Assets, in each case as determined as of the Measurement Time on a basis consistent with and in accordance with the Applicable Accounting Principles.  Net Asset Value shall account for the Medical Claims Reserve and the Premiums Receivable Accrual. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Network Failure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Non-Recourse Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#8221;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> means, with respect to a particular Person, any of such Person&#8217;s past, present or future equity holders, controlling Persons, incorporators, directors, officers, employees, agents, attorneys, advisors, representatives, financing sources, Affiliates, members, managers, general or limited partners or assignees or successors (or any past, present or future equity holders, controlling Persons, incorporators, directors, officers, employees, agents, attorneys, advisors, representatives, financing sources, Affiliates, members, managers, general or limited partners or assignees or successors of any of the foregoing).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">NPI</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Order</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any order, writ, judgment, injunction, decree, stipulation, determination or award entered by or with any Governmental Authority (in each such case whether preliminary or final).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; have the meanings set forth in the Preamble.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Payor Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Contracts between Affinity and Payor and any renewal or replacement of the foregoing Contracts.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Payor</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; shall mean the New York State Department of Health.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">PCI DSS</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Payment Card Industry Data Security Standard, issued by the Payment Card Industry Security Standards Council, as may be revised from time to time.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Permits</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all permits, licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 13 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Permitted Encumbrances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) liens for Taxes that are not yet due and payable or that may hereafter be paid without material penalty or that are being contested in good faith by appropriate proceedings and for which adequate reserves have been established if and as may be required by and in accordance with SAP, (b)&#160;statutory or contractual liens of landlords with respect to real property and incurred in the ordinary course of business consistent with past practice and which are not, individually or in the aggregate, material to Affinity and the Business taken as a whole, (c)&#160;liens of carriers, warehousemen, mechanics, materialmen, repairmen and similar liens incurred in the ordinary course of business, (d)&#160;liens incurred in connection with workers&#8217; compensation, unemployment compensation and other types of social security or in connection with obligations for sums which are not yet delinquent or which are being contested in good faith and which are not, individually or in the aggregate, material to Affinity and the Business taken as a whole, (e)&#160;in the case of real property, in addition to items (a), (b), (c)&#160;and (d), zoning, building or other restrictions, variances, use permits, use restrictions, covenants, rights of way, encumbrances, easements and other exceptions to title, none of which, individually or in the aggregate, interfere in any material respect with the present use of or occupancy of the affected parcel by Affinity, (f)&#160;liens securing the Indebtedness that is being repaid prior to or at Closing, (g)&#160;in the case of Business Intellectual Property, third-party license agreements entered into in the ordinary course of business, (h)&#160;liens incurred in connection with capital lease obligations of the Business, (i)&#160;liens that constitute purchase money security interests on any property securing debt incurred for the purpose of financing all or any part of the cost of acquiring such property, (j)&#160;liens with respect to the properties or assets of the Business that do not singly or in the aggregate materially detract from the value of the property or materially detract from or interfere with the use of property in the ordinary course of Affinity&#8217;s operation of the Business, (k)&#160;the replacement, extension or renewal of any of the foregoing, (l)&#160;liens set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule&#160;1.1(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and (m)&#160;liens created by or through Buyer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Person</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means an individual, corporation, partnership, joint venture, limited liability company, unincorporated organization, trust, association or other entity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Personal Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any information that (a)&#160;identifies or relates to a natural person including information that alone or in combination with other information held by Affinity can be used to identify, contact or precisely locate a natural person or can be linked to a natural person&#59; (b)&#160;any information that is governed, regulated or protected by one or more Information Privacy and Security Laws, including Protected Health Information as defined by HIPAA&#59; (c)&#160;any information that Affinity receives from or on behalf of an Enrollee&#59; or (d)&#160;any information that is covered by the PCI DSS.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Pre-Closing Tax Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Tax period ending on or before the Closing Date and the portion of any Straddle Period ending on the Closing Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Premiums Receivable Accrual</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the aggregate dollar amount attributable to the premium capitation receivables for services performed by or on behalf of Affinity with respect to the period of time prior to the Measurement Time, calculated in accordance with the Applicable Accounting Principles. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Prohibitive Order</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 14 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Provider</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any physician, hospital, pharmacy or other health care professional, independent practice association, facility or supplier that has contracted to provide or arrange for the provision of health care services, dental services, prescription drugs or supplies to Enrollees, as well as any vendor required to be part of Affinity&#8217;s network under any Payor Contract.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Provider Contract</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Contract between Affinity and any Provider.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Provider Contract Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Provider Network</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Providers that are contracted directly with Affinity&#8217;s provider network.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Purchased Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Purchased</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Intellectual Property owned or controlled by Affinity or used or held for use in or related to the Business.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Real Property Leases</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.08(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Registered Intellectual Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Purchased Intellectual Property that is the subject of an application, certificate, filing, registration or other document issued by, filed with, or recorded by, any Governmental Authority at any time, and that is owned by or held in the name of Affinity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any emission, spill, seepage, leak, escape, leaching, discharge, injection, pumping, pouring, emptying, dumping, disposal, migration, or release of Hazardous Materials from any source.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Released Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Releasing Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Representative</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, with respect to any Person, any and all directors, officers, employees, partners, members, consultants, financial advisors, counsel, accountants and other agents of such Person.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Required Governmental Approvals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Required Third Party Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 15 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Business</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means operating any health care insurance related business, including (a)&#160;any Medicaid plan, (b)&#160;any health maintenance organization, any preferred provider organization, or (c) any management services or care management administrative services to any of the businesses listed in the foregoing items (a) through (b).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Restricted Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the five (5) year period commencing on the Closing Date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Retained Cash and Investment Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.02(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Retained Cash and Investments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.02(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Risk Corridor Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the Action brought by Affinity under Section 1342 of the Affordable Care Act seeking damages against the United States for its failure to fully pay risk-corridor payments promised by the Affordable Care Act.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Routine Reconciliations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">SAP</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the statutory accounting procedures prescribed or permitted by DOH in consultation with the New York Department of Financial Services.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Software</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in the definition of &#8220;Intellectual Property.&#8221;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Special DOH Indemnity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Losses incurred by the Buyer Indemnitees in connection with (a) any audit by the New York State Medicaid Inspector General or its agents of Affinity&#8217;s compliance with requirements under the Medicaid managed care program, (b) Liabilities due to DOH or any other Governmental Authority in connection with the matters set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.1(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, including Liabilities represented by the line item &#8220;Due to NYSDOH&#8221; on the Balance Sheet, and (c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Liabilities due to CMS or any other Governmental Authority in connection with the matters set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, including Liabilities represented by the line item &#8220;Due to Centers for Medicare and Medicaid Services&#8221; on the Balance Sheet.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Special DOH Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all Liabilities set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.1(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Special HCRA Indemnity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Losses incurred by the Buyer Indemnitees in connection with any audit by DOH or its designee of (i) assessments paid by Affinity pursuant to &#167;2807-j or &#167;2807-t of the New York Public Health Law or (ii) obligations otherwise required by Affinity under the New York Health Care Reform Act. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Statutory Escrow Account</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the escrow account maintained by Affinity in accordance with the requirements of Section 98-1.11 of Part 98, Title 10, New York Codes, Rules and Regulations.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Straddle Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any Tax period beginning before or on and ending after the Closing Date.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 16 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Subsidiary</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; of any Person means any corporation, partnership, joint venture, limited liability company, trust, estate or other Person of which (or in which) more than 50% of (a)&#160;the issued and outstanding capital stock, or other equity interests having ordinary voting power to elect a majority of the board of directors of such corporation or Persons performing similar functions of any other Person (irrespective of whether at the time capital stock, membership or other equity interests of any other class or classes of such corporation or other Person shall or might have voting power upon the occurrence of any contingency), (b)&#160;the interest in the capital or profits of such partnership, joint venture or limited liability company or other Person, or (c)&#160;the beneficial interest in such trust or estate is at the time directly or indirectly owned or controlled by such Person, by such Person and one or more of its other Subsidiaries or by one or more of such Person&#8217;s other Subsidiaries.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Survival Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Tangible Personal Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(viii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Target NAV Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means One Hundred Thirty-Three Million Seven Hundred Seventy Thousand Dollars ($133,770,000).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Tax Return</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any return, declaration, report, claim for refund, information return or statement or other document relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means all federal, state, local, foreign and other income, gross receipts, sales, use, production, ad valorem, transfer, documentary, franchise, registration, profits, license, lease, service, service use, withholding, payroll, employment, unemployment, estimated, excise, escheat, severance, environmental, stamp, occupation, premium, property (real or personal), real property gains, windfall profits, customs, duties or other taxes, fees, assessments or charges of any kind whatsoever, together with any interest, additions or penalties with respect thereto and any interest in respect of such additions or penalties.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Terminating Provider</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.19</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 9.01(d)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Territory</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the counties of Bronx, Kings (Brooklyn), Nassau, New York (Manhattan), Orange, Queens, Richmond (Staten Island), Rockland, Suffolk, and Westchester in the State of New York and any other location in which the Business is conducted on the date hereof and as of the Closing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Third Party Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Transfer Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.18</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Transaction Documents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means this Agreement, the Escrow Agreement, the Bill of Sale, the Assignment and Assumption Agreement, the IP Assignment Agreement, the FQHC </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 17 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Non-Compete Agreements, and the other agreements, instruments and documents required to be delivered at the Closing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Union</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Updated Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Wind-Up Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; has the meaning set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.20</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE II</font></div><div style="text-align:center;margin-bottom:0.12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PURCHASE AND SALE</font></div><div style="text-indent:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Purchase and Sale of Assets</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">General</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to the terms and conditions set forth herein, at the Closing, Affinity shall sell, assign, transfer, convey and deliver to Buyer (or its designee), and Buyer (or its designee) shall purchase from Affinity, free and clear of any Encumbrances other than Permitted Encumbrances, all of Affinity&#8217;s rights, title and interest in, to and under all assets, properties, rights and claims of Affinity (other than the Excluded Assets), whether real or personal, tangible or intangible, vested or unvested, contingent or otherwise, wherever located (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Purchased Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), including&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;the Closing Cash and the bank accounts of Affinity set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(i) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;all right, title and interests in and to the &#8220;AFFINITY&#8221; name and derivations thereof&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;&#160;&#160;&#160;all premiums, accounts or notes receivable of the Business, including premium capitation receivables for services performed by or on behalf of Affinity&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;&#160;&#160;&#160;all prepaid expenses, credits, advance payments, security, deposits, charges, sums and fees of the Business set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(iv) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights, title and interests in and to any of Affinity&#8217;s Business Intellectual Property&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vi)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights, title and interests in and to Business Software (whether proprietary or non-proprietary), Business IT Assets, servers, data storage devices, systems, networks and other computer assets, laptop computers and all technology underlying or enabling Internet sites, URLs, systems or networks, e-mail addresses, telephone numbers and fax numbers&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)&#160;&#160;&#160;&#160;the Murphy Executive Employment Contract, the Provider Contracts, the Payor Contracts and all other Contracts, other than the Excluded Contracts, relating to the Business (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assigned Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 18 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(vii)&#160;&#160;&#160;&#160;all furniture, fixtures, equipment, supplies and other tangible personal property of the Business or Affinity used or held for use in the Business (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Tangible Personal Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ix)&#160;&#160;&#160;&#160;all Permits, but only to the extent such Permits may be transferred under applicable Law&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(x)&#160;&#160;&#160;&#160;the Real Property Leases, including any prepaid rent, security deposits (to the extent not theretofore applied under the Real Property Leases), and options to renew in connection therewith&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xi)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights under warranties, indemnities and all similar rights against third parties to the extent related to any Purchased Assets&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xii)&#160;&#160;&#160;&#160;originals, or where not available, copies, of all books and records and all other data and information in the possession or control of Affinity, including books of account, ledgers and general, financial and accounting records, machinery and equipment maintenance files, customer lists, customer purchasing histories, price lists, distribution lists, supplier lists, production data, quality control records and procedures, customer complaints and inquiry files, personnel records, research and development files, records and data (including all correspondence with any Governmental Authority), sales material and records, strategic plans, and internal financial statements that relate to the Business, the Purchased Assets or the Assumed Liabilities, other than (A) books and records set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(xii) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and (B) Tax Returns and any other Tax books and records not related to the operation of the Business, copies of which, for the avoidance of doubt will be retained by Affinity (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Books and Records</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xiii)&#160;&#160;&#160;&#160;all goodwill, going concern and other similar intangibles relating to the Purchased Assets&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xiv)&#160;&#160;&#160;&#160;(A) any and all occurrence-based third party liability insurance policies of Affinity or its Affiliates and any workers&#8217; compensation insurance policies or comparable workers&#8217; compensation self-insurance programs sponsored by Affinity or its Affiliates and that apply to the locations at which the Business operates, and (B) the insurance policies of Affinity or its Affiliates relating to losses or damages relating to the Business, the Purchased Assets or the Assumed Liabilities prior to the Closing&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xv)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights, title and interests in and to Personal Information&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xvi)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights, title and interests in and to the DSRIP EIP Receivables&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xvii)&#160;&#160;&#160;&#160;all of Affinity&#8217;s rights, title and interests in and to the portion of the Montefiore Claim that is treated as an admitted asset under SAP as of the Measurement Time, calculated in accordance with the Applicable Accounting Principles&#59; and</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 19 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(xviii)&#160;&#160;&#160;&#160;all of Affinity&#8217;s right, title and interest in, to and under any other assets, properties, rights and claims of Affinity (other than the Excluded Assets), whether real or personal, tangible or intangible, vested or unvested, contingent or otherwise, wherever located, which are used or held for use by Affinity in connection with Affinity&#8217;s operation and maintenance of the health plans comprising the Business (such health plans, Affinity&#8217;s &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Health Plans</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), including&#58;</font></div><div style="text-indent:144pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(A)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Rights with Respect to Enrollees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any and all rights of Affinity to provide services to Enrollees in any of Affinity&#8217;s Health Plans and any other individuals who would be default-assigned to Affinity&#8217;s Health Plans from and after the Closing Date if Affinity retained the right to serve Enrollees after the Closing, and the corresponding right to receive revenues (and bonuses) payable by Payors with respect to such Enrollees (and other individuals)&#59; and</font></div><div style="text-indent:144pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(B)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Claims and Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Claims and rights of every kind relating to the Purchased Assets and&#47;or the ownership of the Business arising from the conduct of the Business by Buyer on and after the Effective Time, except to the extent such claims and rights constitute or relate to an Excluded Asset or an Excluded Liability.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Excluded Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The purchase of the Purchased Assets by Buyer and sale of the Purchased Assets by Affinity contemplated by this Agreement shall not include the following assets of Affinity (which assets shall be referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;all communications involving attorney-client confidences between Affinity and counsel&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;all rights and obligations relating to, and any and all proceeds due to Affinity in connection with, the Risk Corridor Claim&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;all books and records of Affinity to the extent not listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01(a)(xii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Affinity&#8217;s rights and claims under this Agreement (including, for the avoidance of any doubt, Affinity&#8217;s right to the Cash Purchase Price)&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Affinity&#8217;s rights and claims under the Contracts on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.02(e) of the Disclosure Schedules </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;the Emblem Claim (to the extent not fully and finally resolved prior to the Closing)&#59;</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;the Statutory Escrow Account and all investment accounts (including accrued interest receivable) of Affinity set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.02(g) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Retained Cash and Investments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;, and the dollar amount of the cash and investments held in such accounts as of the Measurement Time, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Retained Cash and Investment Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; and</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 20 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;Affinity&#8217;s rights and claims to the assets set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.02(h) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Assumed Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms and conditions set forth herein, at the Closing, Buyer shall assume and shall pay, perform and discharge all Liabilities of Affinity (whether arising before or after the Closing), other than Excluded Liabilities (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assumed Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), including the following&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;all trade accounts payable of Affinity to third parties in connection with the Business and all claims under any Provider Contracts or the Health Plans that remain unpaid as of the Closing Date&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;all Liabilities under the Assigned Contracts, including any regulatory liabilities&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;solely to the extent set forth and itemized on the AEP Schedule, any Liabilities of Affinity to or with respect to any present or former employee, officer, or director who provided or provides services to the Business (or with or for the benefit of their respective spouses or dependents)&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;all Liabilities directly relating to Buyer&#8217;s ownership or operation of the Business and the Purchased Assets&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;the DSRIP EIP Liabilities. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Excluded Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Buyer shall not assume and shall not be responsible to pay, perform or otherwise discharge (and Affinity shall retain, pay, perform and otherwise discharge) any of the following Liabilities of Affinity (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Excluded Liabilities</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;any Liabilities of Affinity arising or incurred in connection with the negotiation, preparation, investigation and performance of this Agreement, the other Transaction Documents and the transactions contemplated hereby and thereby, including fees and expenses of counsel, accountants, consultants, advisers and others&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;any Liabilities relating to or arising out of the Excluded Assets&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;except to the extent specifically set forth and itemized on the AEP Schedule, all Liabilities in connection with, relating to or arising from any current or former (i) employee of Affinity or the Business and (ii) employee benefit or compensation plan, program, agreement, policy, practice, agreement or arrangement (including all Affinity Employee Plans), in each case including any related compensation, Tax and other Liabilities, and including any claims or Liabilities in connection with any related disputes, grievances, administrative actions or lawsuits, in each case, relating to or arising at any time prior to and including the Closing, other than as may be required by the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">COBRA</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) with respect to individuals that are &#8220;M&#38;A qualified beneficiaries&#8221; as </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 21 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such term is defined in Treasury Regulation Section&#160;54.4980B&#30;9 with respect to the transactions contemplated by this Agreement&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;all Liabilities relating to any payable to any broker or finder engaged by or on behalf of Affinity in connection with the transactions contemplated by this Agreement or the Transaction Documents&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;any Liability for Taxes (i) attributable to, incurred in connection with or arising out of the operation of the Business or the ownership of the Purchased Assets for any Pre-Closing Tax Period or (ii) of or attributable to Affinity or its Affiliates&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;the Special DOH Payables&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Liabilities due to CMS or any other Governmental Authority in connection with the matters set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 1.1(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, for the avoidance of doubt, that any indemnification for Losses arising from the Special DOH Indemnity shall only be payable pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, subject in all respects to the limitations set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.04 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">hereof. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;The aggregate purchase price for the Purchased Assets and the assumption of the Assumed Liabilities shall be Five Hundred Million Dollars ($500,000,000) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Purchase&#160;Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The portion of the Purchase Price payable to Affinity in cash at the Closing (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cash Purchase Price</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall equal (i)&#160;the Purchase Price, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (ii) the Closing Affinity Employee Payables (which remain outstanding as of the Closing Date), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (iii) the Affinity Transaction Expenses, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (iv)&#160;the amount (if any) by which the Target NAV Amount is greater than Estimated Net Asset Value in terms of absolute value, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">plus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (v)&#160;the amount (if any) by which Estimated Net Asset Value is greater than the Target NAV Amount in terms of absolute value, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (vi)&#160;Closing Date Indebtedness (if any), and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">minus</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (vii) the Escrow Amount.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Cash to Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, Buyer shall deliver, or cause to be delivered, to Affinity an amount equal to the Cash Purchase Price by wire transfer of immediately available funds to an account or accounts designated by Affinity in writing at least three (3) Business Days prior to the Closing Date.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment of Affinity Employee Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At least five (5) Business Days prior to the Closing Date, Affinity shall deliver to Buyer a complete and accurate list, and the estimated value thereof as of the Closing Date, assuming for purposes thereof that the transactions contemplated hereby will be consummated (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">AEP Schedule</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), of (i) Affinity Employee Payables (itemized individually) that will become Purchased Assets and&#47;or Assumed Liabilities, and (ii) Affinity Employee Payables (itemized individually) that Affinity shall pay </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 22 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">immediately prior to Closing, or cause to be paid from the Cash Purchase Price at Closing (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Affinity Employee Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment of Closing Date Indebtedness</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At least five (5) Business Days prior to the Closing Date, Affinity shall deliver to Buyer a complete and accurate list, and the estimated value thereof as of the Closing Date, of Affinity&#8217;s Closing Date Indebtedness (if any) as of the date hereof. At the Closing, Buyer, on behalf of Affinity (as applicable), shall pay the Closing Date Indebtedness (if any) in accordance with debt payoff letters, in form and substance reasonably acceptable to Buyer, to each counterparty or holder of Closing Date Indebtedness in order to fully discharge such Closing Date Indebtedness and terminate all applicable obligations and Liabilities of Affinity related thereto, in each case, by wire transfer of immediately available funds to the account or accounts designated in the debt payoff letters.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment of Affinity Transaction Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. At least five (5) Business Days prior to the Closing Date, Affinity shall deliver to Buyer a complete and accurate list, and the estimated value thereof as of the Closing Date, of the outstanding Affinity Transaction Expenses (if any) as of the date hereof. At the Closing, Buyer, on behalf of Affinity, shall pay the Affinity Transaction Expenses (if any) in order to fully discharge such Affinity Transaction Expenses and terminate all applicable obligations and Liabilities of Affinity related thereto, in each case, by wire transfer of immediately available funds to the account or accounts designated by Affinity.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment to Escrow Agent</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, Buyer shall deliver the Escrow Amount (such amount, including any interest or other amounts earned thereon or added thereto and less any disbursements therefrom in accordance with the Escrow Agreement, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Escrow&#160;Fund</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to the Escrow Agent for deposit into an escrow fund under the Escrow Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Payment of Special DOH Payables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, Affinity shall pay, or cause to be paid, from the Cash Purchase Price, the outstanding Special DOH Payables (if any) to Governmental Authorities in order to fully discharge such Special DOH Payables and terminate all applicable obligations and Liabilities of Affinity related thereto, in each case, by wire transfer of immediately available funds to the account or accounts designated by such Governmental Authorities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.07&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Determination of Net Asset Value Purchase Price Adjustment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;At least five (5) Business Days prior to the Closing Date, Affinity shall deliver to Buyer a written statement (as revised in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Estimated Closing Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) setting forth Affinity&#8217;s good faith estimate of the Net Asset Value of Affinity (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Estimated Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) along with reasonable supporting detail to evidence the calculation thereof.  The Estimated Closing Statement shall be accompanied by a written certification by Affinity&#8217;s chief actuary attesting that the Estimated Net Asset Value (including the Medical Claims Reserve and the Premiums Receivable Accrual included therein) were determined in accordance with the Applicable Accounting Principles.  The Estimated Net Asset Value shall be prepared in accordance with the Applicable Accounting Principles&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Estimated Net Asset Value (1) shall not include any changes in assets </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 23 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or Liabilities of Affinity as a result of purchase accounting adjustments arising from or resulting as a consequence of the transactions contemplated by this Agreement and (2) shall be based solely on facts and circumstances as they are reasonably expected to exist as of the Measurement Time and shall exclude the effect of any event, change, circumstance, development, occurrence, condition, effect or state of facts occurring after the Measurement Time, except as specifically set forth in the Applicable Accounting Principles or otherwise in accordance with this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;In connection with Buyer&#8217;s review of the Estimated Closing Statement, Affinity shall, prior to the Closing, cooperate with Buyer in good faith to resolve any disagreements between the Parties over the amount of any items set forth in the Estimated Closing Statement, and the items set forth in the Estimated Closing Statement shall for all purposes in this Agreement be equal to the amounts initially proposed by Affinity together with any revisions thereto that are mutually agreed by Affinity and Buyer, each acting reasonably, prior to the Closing.  To facilitate Buyer&#8217;s review of the Estimated Closing Statement, and upon Buyer&#8217;s reasonable written request, Affinity will use commercially reasonable efforts to (i) provide Buyer with supporting data reasonably necessary to allow Buyer to verify the amounts set forth in the Estimated Closing Statement, and (ii)&#160;subject to applicable Law and other obligations to which Affinity may be bound, provide to Buyer reasonable access (that shall be during normal business hours and shall not interfere with Affinity&#8217;s normal business operations) to all relevant books and records of Affinity and make appropriate personnel reasonably available to discuss Buyer&#8217;s reasonable inquiries regarding the Estimated Closing Statement.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;As soon as reasonably practicable but in no event later than the ten (10) month anniversary of the Closing Date, Buyer shall prepare and deliver to Affinity a statement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) setting forth Buyer&#8217;s calculation of the Net Asset Value of Affinity (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Updated Net Asset Value</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), along with reasonable supporting detail as part of the Closing Statement to evidence the calculation thereof.  The Updated Net Asset Value shall be prepared in accordance with the Applicable Accounting Principles&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Updated Net Asset Value (1) shall not include any changes in assets or Liabilities of Affinity as a result of purchase accounting adjustments arising from or resulting as a consequence of the transactions contemplated by this Agreement and (2) shall be based solely on facts and circumstances as they existed as of the Measurement Time and shall exclude the effect of any event, change, circumstance, development, occurrence, condition, effect or state of facts occurring after the Measurement Time, except as specifically set forth in the Applicable Accounting Principles. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Affinity shall have thirty (30) days following Buyer&#8217;s delivery of the Closing Statement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Review Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to review the same.  If Affinity objects to any portion of the Closing Statement on or before the expiration of the Review Period, Affinity shall deliver to Buyer a written statement setting forth in reasonable detail and accompanied by reasonable supporting information, its objection to the Closing Statement (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement Objection Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), which shall include Affinity&#8217;s proposed revised amounts and calculations.  During the Review Period, Buyer shall upon reasonable advance notice and during normal business hours&#160;permit Affinity and its Representatives to have reasonable access, subject to their execution of standard hold harmless letters, to the books, records and other documents (including </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 24 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">work papers, schedules, financial statements, memoranda, etc.) and shall reasonably cooperate with Affinity in obtaining work papers from Buyer&#8217;s accountants pertaining to or used in connection with the preparation of the Closing Statement and calculation of the Updated Net Asset Value, and provide Affinity with copies thereof (as reasonably requested by Affinity).  If Affinity does not deliver a Closing Statement Objection Notice to Buyer on or before the expiration of the Review Period, Affinity shall be deemed to have accepted the Closing Statement and the calculations therein in full. Any determination set forth on the Closing Statement which is not specifically objected to in the Closing Statement Objection Notice shall be deemed accepted by Affinity and shall be final and binding upon Affinity upon delivery of the Closing Statement Objection Notice.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;In the event that Affinity delivers a Closing Statement Objection Notice objecting to all or any portion of the Closing Statement within the Review Period, Buyer and Affinity shall promptly meet and in good faith attempt to resolve such objections.  Any such objections set forth in the Closing Statement Objection Notice which cannot be resolved between Buyer and Affinity within thirty (30) days following Buyer&#8217;s receipt of the Closing Statement Objection Notice (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Statement Disputed Items</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be resolved in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(e)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Should Affinity and Buyer not be able to resolve such Closing Statement Disputed Items within the thirty (30) day period described above, either party may submit the matter to the Independent Accountants for review and resolution, with instructions to complete the same as promptly as practicable, but in any event within thirty (30) days of its engagement, and to resolve any objections consistent with the terms of this Agreement, including making the calculations in accordance with the definition of &#8220;Net Asset Value&#8221; as set forth in this Agreement.  The Independent Accountants shall only have authority to make determinations in respect of Closing Statement Disputed Items, and all determinations shall be based solely on the written presentations of Buyer and Affinity and their respective representatives, and not by independent review.  Buyer and Affinity each shall provide the Independent Accountants with their respective determinations of the Closing Statement Disputed Items.  In resolving any Closing Statement Disputed Item, the Independent Accountants&#58; (i)&#160;shall be bound by the principles set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and the terms and provisions of this Agreement, (ii)&#160;shall not assign a value to any item greater than the greatest value for such item claimed by either Party or less than the smallest value for such item claimed by either Party, and (iii)&#160;shall act as an expert and not an arbitrator.  The Parties shall instruct the Independent Accountants to deliver to each of Buyer and Affinity a written statement setting forth its resolution of the dispute within thirty (30) days of the submission of the dispute to such firm, which resolution, absent manifest error, shall be binding and conclusive on the Parties and not subject to appeal or further review.  The Closing Statement shall be modified if necessary to reflect such determination by the Independent Accountants, as well as the resolution by or on behalf of the Parties of any Closing Statement Disputed Item.  All Closing Statement Disputed Items that are resolved between Affinity and Buyer and all Closing Statement Disputed Items that are determined by the Independent Accountants will be final, conclusive and binding on the Parties hereto and may be entered in any Court of competent jurisdiction, and each of the Parties hereto agrees that it shall not have any right to, and shall not, institute any Action of any kind challenging such determination or with respect to the matters that are the subject of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The other Party&#8217;s only defense to such a request for enforcement shall be fraud by or upon the Independent </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 25 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Accountant or manifest error.  Absent such fraud or manifest error, such other party shall reimburse the Party seeking enforcement for all of its expenses related to the enforcement of the Independent Accountant&#8217;s determination.  The fees and costs of the Independent Accountants, if one is required, shall be borne by Buyer, on the one hand, and Affinity, on the other hand, in inverse proportion as they may prevail on the matters resolved by the Independent Accountants, which proportionate allocation will also be determined by the Independent Accountants.  For example, if Affinity claims that the appropriate adjustments are One Thousand Dollars ($1,000) greater than the amount determined by Buyer and if the Independent Accountants ultimately resolve such items by awarding to Affinity Three Hundred Dollars ($300) of the One Thousand Dollars ($1,000) contested, then the fees, costs and expenses of the Independent Accountants will be allocated 30% (i.e., 300 &#247; 1,000) to Buyer and 70% (i.e., 700 &#247; 1,000) to Affinity.  Affinity and Buyer shall enter into an engagement letter with the Independent Accountants, including customary indemnity, confidentiality and other provisions. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Determinations&#59; Adjustments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Final Net Asset Value as finally determined pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is greater than the Estimated Net Asset Value, Buyer shall pay to Affinity the full amount by which the Final Net Asset Value exceeds the Estimated Net Asset Value in accordance with</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 2.07(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Final Net Asset Value as finally determined pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is less than the Estimated Net Asset Value, Affinity shall pay to Buyer the full amount by which Estimated Net Asset Value exceeds the Final Net Asset Value in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Final Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The amount (if any) owed to Affinity, on the one hand, or to Buyer, on the other hand, pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Final Closing Adjustment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#8221;  If Buyer is obligated to pay the Final Closing Adjustment, it shall make the payment in cash by wire transfer of immediately available funds to the Escrow Agent for deposit into the Escrow Fund.  If Affinity is obligated to pay the Final Closing Adjustment, Buyer shall proceed against the Escrow Amount in order to recover such amounts, and Affinity shall, at Buyer&#8217;s request, execute and deliver a joint written direction to the Escrow Agent to authorize such disbursement.  Any payment required under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be made within five (5) Business Days of the final determination of the Final Closing Adjustment. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 2.08&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  To the extent that Affinity&#8217;s rights under any Contract constituting a Purchased Asset, or any other Purchased Asset, may not be assigned to Buyer without the consent of another Person which has not been obtained prior to the Closing, this Agreement shall not constitute an agreement to assign the same if an attempted assignment would constitute a breach thereof or be unlawful, and Affinity and Buyer shall cooperate in good faith and shall use their respective reasonable best efforts to obtain any such required consent(s) as promptly as possible.  If any such consent shall not be obtained or if any attempted assignment would be ineffective or would impair Buyer&#8217;s rights under the Purchased Asset in question so that Buyer would not in effect acquire the benefit of all such rights, Affinity shall cooperate with Buyer in order to obtain for Buyer the benefits thereunder and in any other reasonable arrangement designed to provide such benefits to Buyer.  Notwithstanding any provision in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.08</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to the contrary, (a) Buyer shall not be deemed to have waived its rights under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof unless and until Buyer either provides written waivers thereof or elects to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 26 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">proceed to consummate the transactions contemplated by this Agreement at the Closing, and (b) any Provider Contract requiring consent of the Provider to transfer or assign it shall be addressed in and governed by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.09</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> below.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE III</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CLOSING</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the terms and conditions of this Agreement, the consummation of the sale, assignment, transfer, conveyance and delivery of the Purchased Assets, the assumption of the Assumed Liabilities, and the payment of the Cash Purchase Price (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall take place remotely via the exchange of executed documents and other deliverables on the first Business Day of the month following the month in which all of the conditions to Closing set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are either satisfied or waived (other than conditions which, by their nature, are to be satisfied on the Closing Date), or at such other time, date or place as Affinity and Buyer may mutually agree upon in writing.  The date on which the Closing actually occurs is herein referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Closing Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.  The Closing shall be deemed to have occurred and to be effective as of 12&#58;01 a.m. New York time on the Closing Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Effective Time</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that if the Closing occurs on a day other than the first calendar day of the month, the Effective Time shall be deemed to be 12&#58;01 a.m. New York time on the first calendar day of the month in which the Closing Date occurs.  For example, if the Closing Date is Monday, November 2, 2020, the Effective Time would be 12&#58;01 a.m. on Sunday, November 1, 2020.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 3.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Closing Deliverables</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  At the Closing, Affinity shall deliver to Buyer the documents set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and Buyer shall deliver to Affinity the documents set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS AND WARRANTIES OF AFFINITY </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as set forth in the Disclosure Schedules, Affinity hereby represents and warrants to Buyer that the statements contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are true and correct as of the date hereof and as of the Closing Date, except to the extent that any such representation or warranty refers to a specified date, in which event such representation or warranty shall be true and correct as of such specified date.  The Disclosure Schedules have been arranged in separately numbered sections corresponding to the Sections of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; however, the disclosure of any item in any section of the Disclosure Schedules shall be deemed to incorporate by reference all information disclosed in any other section of the Disclosure Schedules to which the relevance of such item is reasonably apparent on its face.  Capitalized terms used in the Disclosure Schedules and not otherwise defined therein have the meanings given to them in this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Organization and Qualification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity is a New York not-for-profit corporation duly organized, validly existing and in good standing under the Laws of the State of New York and has full corporate power and authority to own, operate or lease the properties and assets now owned, operated or leased by it and to carry on the Business as currently conducted.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.01 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity does not control, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 27 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">directly or indirectly, or have any direct or indirect equity participation or direct or indirect membership interest in any corporation, partnership, limited liability company, trust or other business association.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which it is or will be a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby and thereby.  The execution and delivery by Affinity of this Agreement and any other Transaction Document to which Affinity is or will be a party, the performance by Affinity of its obligations hereunder and thereunder and the consummation by Affinity of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Affinity, and no other proceedings on the part of Affinity are requisite to authorize the execution, delivery and performance thereof by Affinity.  This Agreement has been duly executed and delivered by Affinity, and (assuming due authorization, execution and delivery by Buyer) this Agreement constitutes a legal, valid and binding obligation of Affinity, enforceable against Affinity in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#8217; rights generally and by general equitable principles (regardless of whether enforcement is sought in a proceeding at law or in equity).  When each other Transaction Document to which Affinity is or will be a party has been duly executed and delivered by Affinity (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Affinity, enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#8217; rights generally and by general equitable principles (regardless of whether enforcement is sought in a proceeding at law or in equity).  Each member of Affinity is set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.02 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Conflicts&#59; Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the execution and delivery by Affinity of this Agreement and the other Transaction Documents to which it is or will be a party, and the consummation of the transactions contemplated hereby and thereby, and performance by Affinity of the obligations hereunder and thereunder, do not and will not&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, bylaws, operating agreement or other organizational documents of Affinity&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;conflict with or result in a violation or breach of any provision of any Law or Order applicable to Affinity, the Business or the Purchased Assets&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the termination or acceleration of or create in any party a right of termination, cancellation, acceleration, modification, purchase or sale under, any Material Contract or Permit to which Affinity is a party or by which Affinity or the Purchased Assets are bound or affected&#59; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 28 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;result in the creation or imposition of any Encumbrance on the Purchased Assets&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;require the consent, approval, Permit, Order, declaration or filing with, or notice to, any Governmental Authority by or with respect to Affinity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Affinity has provided Buyer with complete and correct copies of the audited consolidated financial statements consisting of the balance sheet of Affinity as at December 31st in each of the 2019, 2018 and 2017 fiscal years and the related statements of income and cash flow, including the notes thereto, and schedules thereto, accompanied by the reports thereon of Affinity&#8217;s independent auditors for the years then ended (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Audited Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and unaudited consolidated financial statements consisting of the balance sheet of Affinity as at May 31, 2020 and the related statements of income and cash flow for the five-month period then ended (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Interim Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and together with the Audited Financial Statements, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Financial Statements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Financial Statements have been prepared from the books and records of Affinity and have been prepared in accordance with GAAP applied on a consistent basis throughout the period involved, subject, in the case of the Interim Financial Statements, to normal and recurring year-end adjustments (none of which year-end adjustments would, alone or in the aggregate, be material) and the absence of notes.  The Financial Statements fairly and accurately present in all material respects the consolidated financial condition of Affinity as of the respective dates they were prepared and the results of the operations and cash flows of Affinity for the periods indicated.  The balance sheet of Affinity as of May 31, 2020 is referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Balance Sheet</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; and the date thereof as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Balance Sheet Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.  Affinity has also delivered to Buyer copies of Affinity&#8217;s 2018 and 2019 quarterly and annual MMCORs, as filed with DOH, which have been prepared in accordance with SAP consistently applied and fairly present the financial position of Affinity as of such dates and the results of operations for such periods to the extent required by SAP.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Except as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity does not have any Liabilities, except for (i)&#160;Liabilities specifically disclosed, and adequately reflected in or reserved against in the Balance Sheet, (ii)&#160;Liabilities arising from executory obligations under Contracts to which Affinity or any of its assets may be bound that were entered into in the ordinary course of business, other than any such Liabilities resulting from a breach of such Contracts, (iii)&#160;Liabilities which have arisen in the ordinary course of business and consistent with past practice since the Balance Sheet Date, none of which is a material Liability arising from a breach of contract, breach of warranty, tort, infringement, action or a violation of Law, and (iv) Liabilities under this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Affinity maintains, and during the last three (3) years has maintained, systems of internal accounting controls sufficient to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with SAP in all material respects, including but not limited to internal accounting controls sufficient to provide reasonable assurance that&#58; (i)&#160;transactions are executed in accordance with management&#8217;s general or specific authorization&#59; (ii) transactions are recorded as </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 29 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">necessary to permit the preparation of financial statements of Affinity in conformity with SAP and maintain accountability for assets&#59; and (iii) the recorded accountability for assets is maintained at reasonable intervals and appropriate action is taken with respect to any differences.  During the last three (3) years, (A) no written or, to Affinity&#8217;s Knowledge, verbal complaints from any source outside Affinity regarding accounting, internal accounting controls or auditing matters relating to Affinity, and (B) no concerns, charges, or complaints from any employees of Affinity regarding questionable accounting or auditing matters relating to Affinity, have been received by Affinity or members of the management of Affinity.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;The accounts receivable and other receivables reflected on the Audited Financial Statements, and those arising in the ordinary course of business after the date thereof, (i) are calculated in accordance with SAP, (ii) are valid receivables that have arisen from bona fide transactions in the ordinary course of business, (iii) to the Knowledge of Affinity, are not subject to any counterclaims, setoffs, adjustments, defenses, security interests or Encumbrances, other than Permitted Encumbrances, and (iv) have not been factored or sold. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Other than the Indebtedness as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.04(e) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity has no other outstanding Indebtedness.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Absence of Certain Changes, Events and Conditions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.05 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, or otherwise contemplated by this Agreement, during the period since the Balance Sheet Date, Affinity has operated the Business in the ordinary course of business consistent with past practice and there has not been, with respect to the Business or the Purchased Assets, any&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;event, occurrence or development that has had, or could reasonably be expected to have, a Material Adverse Effect&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;incurrence of any Indebtedness or the making of any loans, advances or guarantees, in each case, having an aggregate principal amount outstanding any time greater than Ten Thousand Dollars ($10,000), except in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;imposition of any Encumbrance upon any of the Purchased Assets, except for Permitted Encumbrances&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;material increase in the compensation payable by Affinity (or for which Affinity may have any liability) to any Provider except as set forth in writing in a Provider Contract&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;adoption of any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against it under any similar Law&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 30 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;purchase or other acquisition (by merger, exchange, consolidation, acquisition of stock or assets or otherwise), or sale, lease or disposal, of any property, material asset, corporation, partnership, joint venture, limited liability company or other business organization or division, or assets thereof, in each case, as would be material to Affinity and the Business, taken as a whole, other than in the ordinary course of business consistent with past practice&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;(i) amendment, waiver, modification or consent to the termination of any Material Contract, or amendment, waiver, modification or consent to the termination of Affinity&#8217;s rights thereunder other than in the ordinary course of business consistent with past practice or (ii) entry into any Material Contract in connection with the Business or the Purchased Assets other than in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;receipt of any communications or reports or any notifications from a Payor regarding an adverse change to any material Payor Contract except for changes applicable to all similarly situated plans, and except for renewal or extension negotiations with Payor in the ordinary course of business consistent with its past practice&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;payment, discharge or satisfaction of any material claim or Liability relating to the Business or the Purchased Assets, other than the payment, discharge or satisfaction, in the ordinary course of business consistent with past practice, of Liabilities reflected or reserved against on the Balance Sheet or subsequently incurred in the ordinary course of business consistent with past practice&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;&#160;&#160;&#160;material increase in the compensation or benefits of any employee of Affinity or the Business, or adoption, implementation, termination, modification, or amendment of any Affinity Employee Plan, in each case other than in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;&#160;&#160;&#160;lapse of any existing policy of insurance material to the Business or the Purchased Assets, taken as a whole&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)&#160;&#160;&#160;&#160;acceleration of the collection of or discounting of any accounts receivable and other receivables reflected on the Audited Financial Statements, delay in the payment of Liabilities that would become Assumed Liabilities or deferment of expenses, or other increase in the cash on hand in connection with the Business, except in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)&#160;&#160;&#160;&#160;commencement or settlement of any Action material to the Business, the Purchased Assets or the Assumed Liabilities, except for settlements of Actions or potential Actions in the ordinary course of business consistent with past practice and so long as such settlement will not create any material obligation on behalf of Buyer at Closing&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(n)&#160;&#160;&#160;&#160;conclusion of or agreement to any corrective action plans, consents, decrees, actions or Orders material to the Business or the Purchased Assets, other than in the ordinary course of business consistent with past practice&#59; or</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 31 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(o)&#160;&#160;&#160;&#160;commitment or agreement to do any of the foregoing, or any action or omission that would result in any of the foregoing.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Material Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.06(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> contains a true and complete list and description of all Material Contracts, excluding the Provider Contracts (disclosure of which shall be governed solely by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> below) and Payor Contracts (disclosure of which shall be governed solely by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.06(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> below), that includes the name of the contracting parties, the name of the Material Contract and the date of the Material Contract and all amendments or modifications to it, except for immaterial schedules, exhibits or modifications that do not have, individually or in the aggregate, a material impact on such Material Contract. Affinity has delivered or made available to Buyer accurate and complete copies of all Material Contracts and other Contracts, including all amendments, waivers or changes thereto. Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.06(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, all such Material Contracts are in full force and effect and are the valid and binding obligations of Affinity, enforceable in accordance with their respective terms, except that (i) such enforcement may be subject to applicable bankruptcy, insolvency, reorganization, moratorium or other similar Laws, now or hereafter in effect, affecting creditors&#8217; rights generally, and (ii) the remedy of specific performance and injunctive and other forms of equitable relief may be subject to equitable defenses and to the discretion of the court before which any proceeding therefore may be brought.  Affinity is not in default of or breach under (or is alleged in writing to be in breach of or default under) the observance or the performance of any term or obligation to be performed by it under any Material Contract if such breach would result in a Material Adverse Effect.  To Affinity&#8217;s Knowledge, no event or circumstance has occurred that, with notice or lapse of time or both, would result in a breach of or constitute an event of default under any Material Contract or result in a termination thereof or would cause or permit the acceleration or other changes of any right or obligation or the loss of any benefit thereunder, in each case, that is, individually or in the aggregate, material to Affinity and the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;All of Affinity&#8217;s Contracts with Payor are listed and described on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.06(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and accurate and complete copies of such have been made available to Buyer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.07&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Provider Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> contains a true and complete list of the top forty (40) Providers for Affinity based on aggregate payments made by Affinity to such Providers for the period January 1, 2019 to December 31, 2019 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Key Providers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Affinity has in place a written Provider Contract with each such Provider that is currently in effect. Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity has delivered or made available to Buyer complete copies of all Provider Contracts with the Key Providers, including all amendments, waivers or changes thereto.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, since December 31, 2019 no Provider reflected on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> has </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 32 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">given written notice to Affinity of a termination of its relationship with Affinity, no Provider Contract with a Key Provider has changed in its essential commercial terms, no Key Provider has materially altered the aggregate amount of provider claims it submits to Affinity except in the ordinary course of business, and no Key Provider has otherwise notified Affinity that it intends to terminate its business relationship with Affinity.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;During the current term of each applicable Provider Contract, Affinity has compensated and currently compensates each Provider for services to Enrollees in accordance with the rates and fees set forth in the applicable Provider Contract.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(c)(i) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity has in place a written Provider Contract with each Provider that is currently in effect.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.07(c)(i)(ii) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, there are no renegotiations, attempts to renegotiate or outstanding rights to negotiate any material amount to be paid or payable to or by Affinity under any Provider Contract other than in the ordinary course of business consistent with the past practices of Affinity.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.08&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Title to and Sufficiency of Purchased Assets&#59; Leased Real Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Affinity has good and marketable title to, a valid leasehold interest in, or a valid license to use all of the Purchased Assets (whether tangible or intangible), free and clear of all Encumbrances except for Permitted Encumbrances.  After giving effect to the transactions contemplated by this Agreement and the other Transaction Documents, except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.08(a) of the Disclosure Schedules,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> the Purchased Assets constitute all assets, services, properties, goodwill and rights (including intellectual property rights) that (i) were used in the Business immediately prior to the Closing and (ii) are sufficient to operate the Business following the Closing in the same manner as the Business is operated as of the date hereof and immediately prior to the Closing.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.08(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> sets forth all real property leased, licensed or occupied by Affinity and used in connection with the Business (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Leased Real Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and a list, as of the date of this Agreement, of all leases, licenses and occupancy agreements for each Leased Real Property (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Real Property</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Leases</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). The Real Property Leases constitute valid leasehold interests, are valid and binding on Affinity, and are in full force and effect.  To Affinity&#8217;s Knowledge, there are no contractual or legal restrictions that preclude or restrict the ability of Affinity to use the Leased Real Property for the purposes for which they are currently being used.  Affinity hereby represents and warrants Affinity does not own a fee interest in any real property.  The Leased Real Property is adequate and suitable for the purposes for which it is presently being used and Affinity has adequate rights of ingress and egress into and from each Leased Real Property as is necessary for the operation of the Business as it is currently conducted by Affinity in the ordinary course of business.  Affinity has not subleased, licensed or otherwise granted to any Person the right to use or occupy any portion of the Leased Real Property.    </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 33 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.09&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Intellectual Property&#59; Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Affinity owns (or has the right to use pursuant to an Assigned Contract) all Business Intellectual Property free and clear of any Encumbrances other than Permitted Encumbrances.  As of the date of this Agreement, the Registered Intellectual Property (i) is owned by Affinity, (ii) is subsisting, in full force and effect, and to Affinity&#8217;s Knowledge valid and (iii) has not expired, or, to Affinity&#8217;s Knowledge been cancelled, or abandoned, as applicable.  The Business Intellectual Property constitutes all of the Intellectual Property necessary for the conduct of the Business as currently conducted.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;To the Knowledge of Affinity, the conduct of the Business as currently conducted and as has been conducted for the past three (3) years does not and has not infringe(d), misappropriate(d) or otherwise violate(d) the Intellectual Property rights of any Person, nor does the Purchased Intellectual Property owned by Affinity nor Affinity&#8217;s products or services, infringe, misappropriate or violate any Intellectual Property rights of any Person.  Affinity has not received any written or, to Affinity&#8217;s Knowledge, oral offer of a license or complaint, claim, demand or notice (i)&#160;alleging or implying that it has infringed or misappropriated any Intellectual Property rights of any third party or, with the giving of notice or lapse of time or both, would be infringing or misappropriating any such rights (including any claim that Affinity must license or refrain from using any Intellectual Property rights of any third party),</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;contesting or seeking to deny or restrict or otherwise concerning the validity, use, ownership, registrability or enforceability of any Business Intellectual Property. To Affinity&#8217;s Knowledge, no Person is infringing, misappropriating or otherwise violating or has infringed, misappropriated or otherwise violated any Purchased Intellectual Property, and no such claims have been made by Affinity. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(c) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> sets forth a complete and accurate list of all Registered Intellectual Property, indicating for each such item the registration or application number and the applicable filing jurisdiction, and the date of expiration. Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(c) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, there are no deadlines falling within ninety (90) days of the Closing Date related to (i) registration, maintenance or renewal fees with respect to the Registered Intellectual Property or (ii) the filing of any documents, applications or certificates (including responses to office actions) or payment of fees that are required to maintain any of the Registered Intellectual Property.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(d) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> identifies each item of Licensed Intellectual Property, other than commercially available &#8220;off the shelf&#8221; Software that has not been modified or customized for use by Affinity, and lists all Contracts pertaining to Licensed Intellectual Property.  Affinity has made available to Buyer correct and complete copies of all Contracts pursuant to which Affinity has received the right to use such Licensed Intellectual Property (as amended to date).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(e) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> lists all Contracts pursuant to which Affinity has granted any license or option to any third party with respect to any Business Intellectual Property.  With respect to each Contract listed on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(d) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 4.09(e) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, neither Affinity nor any other party thereto is in material breach or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 34 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">default of, or has repudiated, any provision of the Contract.  All such Contracts shall be deemed &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Assigned Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; for purposes of this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;Affinity has taken commercially reasonable actions consistent at least with industry-standard practice to protect (i) the confidentiality, integrity and security of all trade secrets and confidential information stored or contained in the Business Intellectual Property or transmitted thereby from any unauthorized use, access, destruction or modification, and to Affinity&#8217;s Knowledge no such use, access, destruction or modification has occurred, and (ii) its rights in the Purchased Intellectual Property owned by Affinity.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Affinity has sufficient rights to use all Software, middleware and systems, information technology equipment, and associated documentation used or held for use in connection with the operation of the Business (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Business IT Assets</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The Business IT Assets have not malfunctioned or failed in the past three (3) years, except for malfunctions or failures that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.  Affinity has taken commercially reasonable steps to provide for the backup and recovery of data and information and has taken commercially reasonable steps to implement such plans and procedures.  During the last 12 months, (A) there has not been any failure, breakdown or continued substandard performance, introduction of any malware, viruses, ransomware, bugs or other malicious codes affecting any of the Business IT Assets of Affinity that have caused any disruption or interruption in any of such Business IT Assets, except, in each case, as would not reasonably be expected to be material to Affinity and the Business&#59; (B) there have been no privacy or data security breaches (including ransomware or a cyber-attack) resulting in the unauthorized access, acquisition, exfiltration, manipulation, erasure, use, intrusion, or disclosure of any sensitive data or that triggered any reporting requirement under any breach notification Law or Contract provision, except, in each case, as would not reasonably be expected to be material to Affinity and the Business, and (C) to the Knowledge of Affinity, no service provider (in the course of providing services for or on behalf of Affinity) has suffered any privacy or data security breach that resulted in the unauthorized access, acquisition, exfiltration, manipulation, erasure, use, or disclosure of Affinity&#8217;s sensitive data, except, in each case, as would not reasonably be expected to be material to Affinity and the Business.  Affinity has established, implemented, and maintains cybersecurity policies, programs and procedures that are in compliance with any applicable Law, applicable industry requirements, and Affinity&#8217;s obligations under any Contracts, including reasonable and appropriate administrative, technical and physical safeguards, and disaster recovery, business continuity, and incident response plans, designed to protect the confidentiality, integrity, availability and security of sensitive data in its possession, custody or control against unauthorized access, use, disclosure or other misuse, and to safeguard the Business IT Assets against the risk of business disruption, except, in each case, as would not reasonably be expected to be material to Affinity and the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.09(h) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, each item of Business Intellectual Property will be owned, licensed and available for use by Buyer on similar terms following the consummation of the transactions contemplated hereby as such items were owned, licensed and available for use to Affinity for the operation of the Business as operated prior to the consummation of the transactions contemplated hereby.  </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 35 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.10&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Legal Proceedings&#59; Orders</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.10(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, there are no material Actions pending or, to Affinity&#8217;s Knowledge, threatened against (including by any Governmental Authority) or by Affinity (i)&#160;relating to or affecting the Business, the Purchased Assets or the Assumed Liabilities&#59; or (ii)&#160;that challenge or seek to prevent, enjoin, restrain, prohibit or otherwise delay the execution and delivery by Affinity of this Agreement or the consummation of the transactions contemplated hereby.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.10(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, there are no outstanding Orders or consent decrees or other similar agreements, and no such Order or consent decree or other similar agreement is, to Affinity&#8217;s Knowledge, threatened, and there are no unsatisfied judgments, penalties or awards against, relating to or affecting the Business, the Purchased Assets or the Assumed Liabilities.  Affinity is not subject to any outstanding Order which would reasonably be expected to have a material adverse effect on the ability of Affinity to consummate the transactions contemplated hereby. Other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.10(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Affinity has not received written notice of, and for the past six (6) years Affinity has not received written notice of any Claim pending (or, to Affinity&#8217;s Knowledge, threatened) related to Affinity that would be material to the Business and the Purchased Assets, taken as a whole, or that would reasonably be expected to prevent, impair or hinder Affinity from complying with its obligations hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.11&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Compliance With Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Nothing in this Section shall apply to Affinity&#8217;s compliance with HIPAA or any other Information Privacy and Security Laws, which shall be exclusively addressed in and governed by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> below. Other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.11(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity is, and for the past six (6) years has been, in compliance in all material respects with all Laws and Orders applicable to the conduct of the Business or the ownership and use of the Purchased Assets.  Neither Affinity, nor any of its officers or directors has, within the past six (6) years, received any written notice, Order, complaint, claim, investigation or other written communication from any Governmental Authority or any other Person regarding any actual or alleged material violation of any Law or Order applicable to Affinity.  No Governmental Authority has instituted, implemented, taken or threatened in writing to take, and to the Knowledge of Affinity, no Governmental Authority intends to take, any other action the effect of which, individually or in the aggregate, would be reasonably expected to have a Material Adverse Effect. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;All Permits required for Affinity to conduct the Business or for the ownership and use of the Purchased Assets have been duly obtained by Affinity and are valid and in full force and effect.  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.11(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> sets forth a complete and correct list of all material Permits that are necessary for Affinity to conduct the Business or for the ownership and use of the Purchased Assets, including the names of the Permits and their respective dates of issuance and expiration.  Affinity is and has been in compliance in all material respects with such Permits and no event has occurred or circumstances exist that (with or without the lapse of time or the giving of notice, including as a result of the transactions </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 36 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">contemplated by this Agreement) would reasonably be expected to constitute or result in Affinity&#8217;s material failure, default or violation under any of their respective Permits, or that could reasonably be expected to result in any material loss, expiration, or termination of any such Permit, and there are no Actions pending or, to the Knowledge of Affinity, threatened in writing relating to the suspension, failure to renew, revocation, withdrawal, penalty, payment, fine or modification of any of the Permits.  All such Permits are in full force and effect and have not been revoked.  The execution and delivery of this Agreement and the consummation of the transactions contemplated hereby will not adversely affect, in any material respect, any such Permits or result in the revocation, cancellation, suspension or modification, in any material respect, of any such Permits.  Except as otherwise disclosed in</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> Section 4.11(b) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, all such Permits shall be available for use by Buyer immediately after the Closing, in each case, to the same extent such Permits were available for use by Affinity immediately prior to the Closing.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Neither Affinity, any officer of Affinity nor, to the Knowledge of Affinity, any director, employee or agent of Affinity, in each case acting in their capacity thereof, have (i)&#160;offered, authorized, promised, made or agreed to make gifts of money, other property or similar benefits or contributions (other than incidental gifts or articles of nominal value) to any actual or potential customer, provider, supplier, governmental employee, Governmental Authority or other Person in a position to assist or hinder Affinity in connection with any actual or proposed transaction or to any political party, political party official or candidate for federal, state or local public office in violation of any Law or (ii)&#160;maintained any unrecorded fund or asset of Affinity for any improper purpose or made any intentional false entries on its books and records for any reason. No person while serving as an officer or director of Affinity has ever been debarred, suspended, or otherwise excluded from participating in any state or federally funded health care program.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.12&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">HIPAA and Privacy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Affinity operates, and for the past six (6) years has operated, the Business in compliance with the applicable privacy, security, transaction standards, breach notification, and other provisions and requirements of HIPAA except where any violation or failure to comply would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.  Without limiting the generality of the foregoing, Affinity has executed business associate agreements meeting all requirements set forth in the HIPAA privacy, security and breach notification regulations with all contractors that meet the definition of a business associate under HIPAA.  Affinity has established and implemented such policies, programs, procedures, contracts and systems as are necessary to comply in all respects with Information Privacy and Security Laws, except where any violation or failure to comply with such Information Privacy and Security Laws has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.  Affinity is not subject to a corporate integrity agreement, consent order or similar agreement with any Governmental Authority.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Affinity&#8217;s receipt, collection, monitoring, maintenance, creation, transmission, use, analysis, disclosure, storage, disposal and security of Personal Information </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 37 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">has, for the past six (6) years, complied, and complies, in all material respects, with (i)&#160;any Contracts to which Affinity is party, (ii)&#160;applicable Information Privacy and Security Laws, (iii)&#160;if applicable, PCI DSS, and (iv)&#160;all consents and authorizations that apply to Affinity&#8217;s receipt, access, use and disclosure of Personal Information.  Affinity has all necessary authority, consents and authorizations to receive, access, use and disclose the Personal Information in Affinity&#8217;s possession or under its control in connection with the operation of the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;For the past six (6) years Affinity has, in all material respects, protected the confidentiality, integrity and security of its Personal Information and IT Assets against any unauthorized control, use, access, interruption, modification or corruption in conformance with Information Privacy and Security Laws.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.12(d) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, for the past six (6) years there has been no data security breach or unauthorized access, control, use, modification or destruction of any IT Asset, or unauthorized access, use, acquisition or disclosure of any Personal Information owned, used, stored, received, or controlled by or on behalf of Affinity, including any unauthorized access, use or disclosure of Personal Information that would constitute a breach for which notification to individuals and&#47;or Governmental Authorities is required under any applicable Information Privacy and Security Laws or Contracts to which Affinity is a party. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Affinity is not subject to any Orders, nor are any Orders pending or, to the Knowledge of Affinity, threatened against Affinity or its &#8220;workforce&#8221; (as defined under HIPAA) regarding or relating to Affinity&#8217;s processing of Personal Information. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;The (i) collection, storage, processing, transfer, sharing and destruction of Personal Information in connection with the transactions contemplated by this Agreement and (ii) execution, delivery and performance of this Agreement and the other agreements and instruments contemplated hereby and the consummation of the transactions contemplated hereby and thereby complies with Affinity&#8217;s applicable privacy notices and policies and with all applicable Information Privacy and Security Laws.  Affinity has the right to assign to Buyer, and Buyer shall have the right to possess and use following the Closing, all Personal Information as used or held for use by Affinity in the Business prior to the Closing.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;For the past six (6) years Affinity has performed a security risk assessment no less frequently than annually that meets (i)&#160;the standards set forth at 45 C.F.R. &#167; 164.308(a)(1)(ii)(A), including an assessment as described at 45 C.F.R. &#167; 164.306(d)(3), taking into account factors set forth in 45 C.F.R. &#167; 164.306(a)&#8211;(c)&#59; (ii)&#160;to the extent applicable, the requirements of the PCI DSS&#59; (iii)&#160;any requirements to perform security assessments under any Information Privacy and Security Law&#59; and (iv)&#160;any obligations to perform security assessments set forth in any Contracts to which Affinity is party and has addressed all threats and deficiencies identified therein.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Limitations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding any other provision of this Agreement to the contrary, the representations and warranties set forth above in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall constitute the sole and exclusive representations and warranties made by Affinity with respect to HIPAA </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 38 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and Information Privacy and Security Law matters, and no other representation or warranty contained in any other section of this Agreement shall be deemed to be made with respect to HIPAA and Information Privacy and Security Law matters.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.13&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Employment and Benefits Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;As of the date hereof, Affinity has provided, for each employee of Affinity, the following&#58; (i)&#160;name&#59; (ii)&#160;title or position (including whether full or part time)&#59; (iii) hire date&#59; (iv)&#160;current annual base compensation rate&#59; (v)&#160;commission, bonus or other incentive-based compensation&#59; (vi) employing entity&#59; (vii) current active&#47;leave status and the type of leave (e.g., short-term disability, long-term disability, military)&#59; and (viii) exempt or non-exempt status, to be updated following the date hereof upon reasonable request of Buyer.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Affinity is not a party to, bound by, or negotiating any collective bargaining agreement or other Contract with a union, works council or labor organization (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Union</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and there is not any Union representing or purporting to represent any employee of Affinity, and, to Affinity&#8217;s Knowledge, no Union or group of employees is seeking or has sought to organize employees for the purpose of collective bargaining.  There has never been, nor to Affinity&#8217;s Knowledge, has there been any threat of, any strike, slowdown, work stoppage, lockout, concerted refusal to work overtime or other similar labor disruption or dispute affecting Affinity or any employees of the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Affinity is, and for the past six (6) years has been, in compliance in all material respects with all applicable Laws regarding employment and employment practices (including anti-discrimination), terms and conditions of employment and wages and hours (including classification of employees and independent contractors, and equal pay practices) and other laws in respect of any reduction in force (including notice, information and consultation requirements).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Affinity has not received notice of any pending or, to Affinity&#8217;s Knowledge, threatened (i)&#160;unfair labor practice charge or complaint against Affinity before the National Labor Relations Board or any similar state or local agency relating to an alleged violation or breach of any Laws or (ii)&#160;Action against Affinity concerning employment-related matters, employees of Affinity, or violation of any Laws regarding employment and employment practices or breach of any contractual obligations.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;There are no Actions, including audits, requests for information, investigations, complaints, charges, or claims with respect to any regular or leased employee, consultant, or independent contractor of Affinity pending with or threatened in writing by the Equal Employment Opportunity Commission, the Department of Labor, the Internal Revenue Service, the National Labor Relations Board, or any other Governmental Authority.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(f) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> contains a list of each Affinity Employee Plan.  With respect to each Affinity Employee Plan, Affinity has furnished or made available to Buyer true and complete copies of the governing plan document and amendments thereto and, as applicable, (i) the trust agreement or other governing document for </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 39 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any related funding vehicle, (ii) the current summary plan description and any related summary of material modifications, or (iii) any written notices or other written material correspondence with any Governmental Authority. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Each Affinity Employee Plan and related trust or other funding vehicle has been established, administered, funded and maintained in all material respects in accordance with its terms and in compliance in all material respects with applicable Law. All contributions, benefit payments and premium deposits or payments required to be made by Affinity under the Affinity Employee Plans have been made or paid by the due date thereof, and all contributions, benefit payments and premium deposits or payments that have accrued but have not been made or paid because they are not yet due have been properly accrued in the Financial Statements.  No claims, investigations or other proceedings (other than routine claims for benefits in the ordinary course of business) are pending or, to the Knowledge of Affinity, threatened against or with respect to any Affinity Employee Plan.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;In the last six (6) years, Affinity has not participated in, maintained or been liable for contributions to, nor does Affinity have any Liability, contingent or otherwise, pursuant to Title IV of ERISA or otherwise with respect to a plan that is a &#8220;pension plan&#8221; (within the meaning of Section 3(2) of ERISA) that is or was subject to Section 412 of the Code or Section 302 or Title IV of ERISA or that is or was a &#8220;multiemployer plan&#8221; (within the meaning of Section 3(37) of ERISA).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;No Encumbrance has been imposed on the Purchased Assets pursuant to Section 302, 303 or Title IV of ERISA or Section 412 or 430 of the Code and no fact exists that would reasonably be expected to give rise to any such Encumbrance.  Other than as required by Section 4980B of the Code or other similar applicable Law, no Affinity Employee Plan provides benefits or coverage in the nature of health, life or disability insurance following retirement or other termination of employment (other than death benefits when termination occurs upon death).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;&#160;&#160;&#160;Except as set forth on the AEP Schedule, neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in conjunction with any other event) result in the acceleration of vesting or payment, trigger any payment or funding, or increase the amount or value of any compensation, payment or benefits (including severance and unemployment compensation) to any current or former employee or consultant of Affinity. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;&#160;&#160;&#160;No provision of a benefit, acceleration, or amount to be paid with respect to any current or former employee of, or consultant to, Affinity, would individually or in the aggregate, whether alone or in combination with any other event, (i) result in &#8220;excess parachute payments&#8221; within the meaning of Section 280G(b) of the Code&#59; or (ii) require a &#8220;gross-up&#8221; or other payment to any &#8220;disqualified individual&#8221; within the meaning of Section 280G(c) of the Code.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 40 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)&#160;&#160;&#160;&#160;All employees of the Business are located within the United States. No Affinity Employee Plan (i) was established or is maintained outside of the United States, or (ii) is subject to the Laws of any jurisdiction outside of the United States.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)&#160;&#160;&#160;&#160;No Affinity Employee Plan or other contract, plan, program, agreement or arrangement provides for retiree medical or welfare benefits to any current or former employees of the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(n)&#160;&#160;&#160;&#160;Each Affinity Employee Plan or other contract, plan, program, agreement or arrangement that is a &#8220;nonqualified deferred compensation plan&#8221; (within the meaning of Section 409A of the Code) has (i) been maintained and operated in compliance with Section 409A of the Code and all applicable Treasury Regulations promulgated thereunder so as to avoid any Tax, penalty or interest under Section 409A of the Code, and (ii) been in documentary and operational compliance with Section 409A of the Code and all applicable Internal Revenue Service guidance promulgated thereunder. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.14&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;All Tax Returns required to be filed by Affinity or otherwise in respect of the Business or the Purchased Assets have been timely filed.  Such Tax Returns are true, complete and correct in all material respects.  All Taxes due and owing by Affinity or otherwise in respect of the Business or the Purchased Assets (whether or not shown on any Tax Return) have been or will be timely paid.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;There are no pending or threatened audits, investigations, disputes, notices of deficiency, claims or other Actions for or relating to any Taxes of Affinity or otherwise in respect of the Business or the Purchased Assets. Affinity has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency that has not been resolved. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;There are no Encumbrances for Taxes upon any of the Purchased Assets other than Permitted Encumbrances.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Affinity is not a &#8220;foreign person&#8221; as that term is used in Treasury Regulations Section 1.1445-2.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Affinity is exempt from tax within the meaning of Code section 501(a) and is an organization described in Code section 501(c)(3).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;The IRS has not revoked Affinity&#8217;s status as an organization exempt from tax under Code section 501(c)(3) by ruling letter or otherwise.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Affinity has not participated in any &#8220;reportable transaction&#8221; within the meaning of Treasury Regulation Section 1.6011-4.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 41 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;No claim has been made or threatened in writing by a taxing authority in a jurisdiction where Affinity has not filed a Tax Return asserting that Affinity is or may be subject to Taxes imposed by that jurisdiction.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;Affinity has properly and timely paid to the appropriate taxing authorities all payroll, unemployment and similar Taxes due on or before the Closing Date and has properly withheld and timely paid to the appropriate taxing authorities all other Taxes required to have been withheld and paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party with respect to the Business and the Purchased Assets, and has complied with all information reporting, backup withholding and Tax Return requirements, including maintenance of required records with respect thereto, in connection with any such amounts.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.15&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Brokers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No broker, finder, investment banker or similar intermediary is entitled to any brokerage, finder&#8217;s or other fee or commission or similar compensation in connection with the transactions contemplated by this Agreement or any other Transaction Document based upon arrangements made by or on behalf of Affinity, other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.15 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.16&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Health Care Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compliance with Health Care Laws</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  (i)&#160;The Business operations of Affinity (including its form and rate filing, reserving, marketing, investment, financial, claims, taxation, underwriting, premium collection and refunding, securities compliance and other practices, if applicable) are, and for the past six (6) years have been, operated in compliance in all material respects with all applicable Laws, (ii)&#160;other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(a)(ii) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity is not, and has not, been in the past six (6) years, in material violation of any of the provisions of applicable New York Law with respect to managed care organizations, and (iii)&#160;neither Affinity nor any Person acting on behalf of Affinity has violated or has incurred any Liability under (A)&#160;any federal or state fraud and abuse Laws, including the Stark Law (42 U.S.C. &#167;1395nn), the civil False Claims Act (31 U.S.C. &#167;3729 et seq.), Sections 1320a-7a and 1320a-7b of Title 42 of the United States Code, (B)&#160;Medicare (Title XVIII of the Social Security Act), (C)&#160;Medicaid (Title XIX of the Social Security Act), (D)&#160;any prompt pay Laws, (E)&#160;any quality, safety or accreditation standards, (F)&#160;any applicable licensure Laws or regulations, or (G)&#160;any other applicable health care Law. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Debarment and Suspension</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither Affinity nor any officer, director or current employee of Affinity has ever been debarred, suspended or otherwise excluded from participating in any state or federally funded health care program.  Affinity has not, and, to its Knowledge, its employees have not, engaged in any conduct which could result in debarment or disqualification by any Governmental Authority, and there are no proceedings pending or, to Affinity&#8217;s Knowledge, threatened that could reasonably be expected to result in criminal liability, debarment or disqualification by any Governmental Authority. Affinity is in good standing with, and not excluded or suspended from participation in, or limited in its right to participate in any Federal Health Care Program or any state or local government health care programs.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 42 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Regulatory Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For the past six (6) years Affinity has timely filed (taking into account permitted extensions timely obtained, if any) all material regulatory reports, schedules, statements, documents, filings, submissions, forms, registrations and other documents, together with any amendments required to be made with respect thereto, that each was required to file with any Governmental Authority (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Filings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  All such Regulatory Filings are accurate and complete in all material respects. For the past six (6) years Affinity has timely paid (taking into account permitted extensions timely obtained, if any) all fees and assessments due and payable in connection therewith, including the assessments required under the New York Health Care Reform Act.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Penalties Under Medicaid Programs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity has not been required to pay any civil monetary penalty under Law regarding false, fraudulent or impermissible claims under, or payments to induce a reduction or limitation of health care services to beneficiaries of, any state health care program or Federal Health Care Program.&#160; To the Knowledge of Affinity, Affinity is not currently the subject of any investigation, audit or proceeding that may result in such payment.  Affinity is not a party to any corporate integrity agreement, monitoring agreement, consent decree, settlement order, or similar agreement imposed by any Governmental Authority.  Except as disclosed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(d) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity has not received or otherwise been party to any (i) Orders, letters, communications or other notices from DOH or any other Governmental Authority relating to Affinity&#8217;s failure to meet any of the requirements for continued participation in Federal Health Care Programs or New York State health care programs (including any Orders, letters, communications or notices stating that continued participation may be contingent on Affinity developing, adopting, implementing or taking any sort of corrective or remedial actions), or (ii) corrective action plans developed by Affinity in response to or as a result of the orders, letters, communications and notices specified in clause (i), in each case, material to Affinity and the Business.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Recoupment Proceedings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There are no material recoupments, adjustments or recovery proceedings of any Payor being sought, requested, claimed or threatened against Affinity.  Other than set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(e) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, for the past six (6) years, neither Affinity nor any officers or directors of Affinity has received, or has been the subject of, any audit, inquiry, or investigation that requires, or could reasonably be expected to require, the payment of money by Affinity to any Governmental Authority, or requires or prohibits any activity by Affinity, other than routine reconciliations of eligibility, enrollments and disenrollments, including those conducted by the New York State Medicaid Inspector General, and any associated recoupments (e.g., audits of incarcerated or deceased Enrollees) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Routine Reconciliations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Any and all Routine Reconciliations of which Affinity has Knowledge and for which Affinity has not made repayment in full of the resulting Liability to the applicable Governmental Authority are set forth </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(e) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  There are no claims, Actions, payment reviews, or other proceedings of which Affinity has received written notice, or, to Affinity&#8217;s Knowledge, appeals pending or threatened, before any Governmental Authority with respect to any payments received by Affinity, which could have a Material Adverse Effect, either individually or in the aggregate.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 43 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Marketing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity&#8217;s marketing staff has not violated laws applicable to the marketing or enrollment of Affinity&#8217;s health plans in any material respect.&#160; The compensation payable by Affinity to its marketing staff complies in all material respects with applicable Laws.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Compliance Program</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity has implemented a corporate compliance program which meets all applicable legal requirements in all material respects and staff to oversee the functioning of its corporate compliance program.&#160; As part of its corporate compliance program, Affinity has implemented administrative processes, policies and procedures that are reasonably designed to ensure that Affinity remains in compliance with health care Laws applicable to Affinity&#8217;s Business in all material respects.&#160; Affinity has in place a process to regularly check all applicable Federal Health Care Program or state health care program exclusion and debarment lists to determine whether any of the following are an Ineligible Person&#58; Affinity, its officers, directors, managers, employees, and providers of services and any contracted vendor or agent that provides health care related services to Affinity.&#160; Neither Affinity nor, to the Knowledge of Affinity, any of these individuals or companies is an Ineligible Person who have been excluded or otherwise debarred from any Federal Health Care Program or other governmental health care programs.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;Other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16(h) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity has at all times complied with the requirements of New York State Executive Order 38 and has timely satisfied applicable reporting obligations and waiver requests thereunder.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Duly Licensed Employees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Each employee of Affinity that is required to be licensed in connection with his or her employment holds a valid and unrestricted license to practice his or her profession in New York.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.17&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Related Party Transactions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Other than this Agreement or pursuant to any Affinity Employee Plan listed in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(f) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, no direct or indirect member, director or officer of Affinity, nor any Subsidiary or Affiliate of any such direct or indirect member, director or officer, nor any Affiliate of Affinity, nor any FQHC Member, has any interest in any property or assets owned by Affinity, or has in the past three (3) years engaged in any transaction with or is currently directly or indirectly a party to any Contract with Affinity, including any agreement, arrangement or understanding, written or oral, providing for the employment of, furnishing of services by, rental of real or personal property from or otherwise requiring payment to any such Person.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.18&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Environmental Matters</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Business, and Affinity with respect to the Business and the Purchased Assets, are in compliance, and for the past six (6) years have complied, with applicable Environmental Laws in all material respects.  Except as would not reasonably be expected to result in material Liability, Affinity, with respect to the Business and the Purchased Assets, has not caused a Release, and to the Knowledge of Affinity, there has been no Release at, on, under or from the Leased Real Property.  Affinity has made available to Buyer copies of all material environmental assessments, reports, audits and other material documents in its possession or under its control that relate to the compliance of the operations of the Business and Purchased Assets with Environmental Laws or the environmental condition of any real </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 44 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">property currently or formerly owned, operated or leased with respect to the Business and Purchased Assets. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.19&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Insurance Coverage</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.19 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is a complete list of all material insurance policies and fidelity bonds relating to the Purchased Assets or the Business.  There are no material claims by or on behalf of Affinity pending under any of such policies or bonds as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds or in respect of which such underwriters have reserved their rights.  To Affinity&#8217;s Knowledge, each such policy and bond is a valid and binding agreement, is in full force and effect, and has not been subject to any lapse in coverage.  Since January 1, 2019, neither Affinity or, to the Knowledge of Affinity, any other party thereto is in material default or breach in any respect under the terms of any such policy or bond. Affinity has not received any written notice of cancellation of, material premium increase related to the Business outside the ordinary course of business with respect to, or material alteration of coverage with respect to the Business under, any of such policies or bonds.  Since January 1, 2019, all premiums due on such policies or bonds have either been paid or, if due and payable prior to the Closing, shall be paid prior to the Closing in accordance with the payment terms of each such policy or bond.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 4.20&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Provider Network</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity has made available to Buyer a list of Providers in the Provider Network, including (a) primary care providers identified by name, such Provider&#8217;s distinct National Provider Identifier (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">NPI</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and the number of Enrollees in each such Provider&#8217;s panels&#59; and (b) specialist Providers identified by name and such Provider&#8217;s distinct NPI.  </font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">REPRESENTATIONS AND WARRANTIES OF BUYER </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Except as set forth in the Buyer Disclosure Schedules, Buyer hereby represents and warrants to Affinity that the statements contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are true and correct as of the date hereof and as of the Closing Date, except to the extent that any such representation or warranty refers to a specified date, in which event such representation or warranty shall be true and correct as of such specified date.  The Buyer Disclosure Schedules have been arranged in separately numbered sections corresponding to the Sections of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; however, the disclosure of any item in any section of the Buyer Disclosure Schedules shall be deemed to incorporate by reference all information disclosed in any other section of the Buyer Disclosure Schedules to which the relevance of such item is reasonably apparent on its face.  Capitalized terms used in the Buyer Disclosure Schedules and not otherwise defined therein have the meanings given to them in this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Organization</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Buyer is a corporation duly organized, validly existing and in good standing under the Laws of the State of Delaware.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Authority</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Buyer has full corporate power and authority to enter into this Agreement and the other Transaction Documents to which it is or will be a party, to carry out its obligations hereunder and thereunder and to consummate the transactions contemplated hereby </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 45 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">and thereby.  The execution and delivery by Buyer of this Agreement and any other Transaction Document to which Buyer is or will be a party, the performance by Buyer of its obligations hereunder and thereunder and the consummation by Buyer of the transactions contemplated hereby and thereby have been duly authorized by all requisite corporate action on the part of Buyer.  This Agreement has been duly executed and delivered by Buyer, and (assuming due authorization, execution and delivery by Affinity) this Agreement constitutes a legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#8217; rights generally and by general equitable principles (regardless of whether enforcement is sought in a proceeding at law or in equity).  When each other Transaction Document to which Buyer is or will be a party has been duly executed and delivered by Buyer (assuming due authorization, execution and delivery by each other party thereto), such Transaction Document will constitute a legal and binding obligation of Buyer enforceable against it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors&#8217; rights generally and by general equitable principles (regardless of whether enforcement is sought in a proceeding at law or in equity).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Conflicts&#59; Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">of the Buyer Disclosure Schedules,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> the execution, delivery and performance by Buyer of this Agreement and the other Transaction Documents to which it is or will be a party, and the consummation of the transactions contemplated hereby and thereby, and performance by Buyer of the obligations hereunder and thereunder, do not and will not&#58; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;conflict with or result in a violation or breach of, or default under, any provision of the certificate of incorporation, by-laws or other organizational documents of Buyer&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;conflict with or result in a violation or breach of any provision of any material Law or Order applicable to Buyer&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event that, with or without notice or lapse of time or both, would constitute a default under, result in the termination or acceleration of or create in any party a right of purchase, sale, acceleration, termination, modification or cancellation under, any material Contract or Permit to which Buyer is a party or by which it is bound or affected&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;result in the creation or imposition of any Encumbrance on any of the material properties or assets of Buyer&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;require the consent, Permit, Order, declaration or filing with, or notice to, any Governmental Authority by or with respect to Buyer.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Brokers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  No broker, finder, investment banker or similar intermediary is entitled to any brokerage, finder&#8217;s or other fee or commission or similar compensation in connection with the transactions contemplated by this Agreement or any other Transaction </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 46 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Document based upon arrangements made by or on behalf of Buyer, other than as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.04 of the Buyer Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Legal Proceedings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 5.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">of the Buyer Disclosure Schedules,</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> as of the date hereof, there are no Actions pending or, to Buyer&#8217;s knowledge, threatened against or by Buyer that challenge or seek to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 5.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Financial Capability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Buyer currently has, and will at the Closing have, access to sufficient funds to consummate the transactions contemplated hereby.  Buyer is currently (a)&#160;able to pay its debts as they become due and (b)&#160;has adequate capital to carry on its business.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VI</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">COVENANTS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conduct of Business Prior to the Closing</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except for actions contemplated by this Agreement, and as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01 of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, from the date hereof until the earlier of (A)&#160;termination of this Agreement in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or (B)&#160;the Closing, except as consented to in writing by Buyer, Affinity shall (i) conduct the Business in the ordinary course of business consistent with past practice, (ii) use commercially reasonable efforts to maintain and preserve intact Affinity&#8217;s current business organization, assets, properties and operations and to preserve the rights, goodwill and relationships of its employees, Providers, Enrollees, suppliers, regulators and others having relationships with the Business, and (iii) use commercially reasonable efforts to maintain relationships with sufficient Providers to permit Buyer to meet the Minimum Network Requirements.  Without limiting the foregoing, except as otherwise contemplated by this Agreement or consented to in writing by Buyer, Affinity shall&#58; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;preserve and maintain all Permits required for the conduct of the Business as currently conducted or the ownership and use of the Purchased Assets&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;pay, discharge or satisfy the Liabilities, Taxes and other obligations of the Business and the Purchased Assets which are not in dispute when due in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;not make, change or revoke any material Tax election&#59; not settle or compromise any material claim or assessment in respect of Taxes&#59; not surrender any right to claim a material Tax refund&#59; not amend any material position on a Tax Return&#59; not change any Tax accounting method&#59; not enter into any closing agreement relating to any material Tax&#59; not consent to any extension or waiver of the statute of limitations period applicable to any material Tax claim or assessment&#59; and not file or prepare any material Tax Return on a basis that is inconsistent with past practice&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 47 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;defend and protect the properties and assets included in the Purchased Assets from infringement or usurpation in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;perform in all material respects all of its obligations under all Provider Contracts and the Payor Contracts in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;except as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(f) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, comply in all material respects with all Laws applicable to the conduct of the Business or the ownership and use of the Purchased Assets&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;other than as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(g) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, or as required by any Affinity Employee Plan or applicable Law, not (i)&#160;enter into, adopt, amend or terminate any Affinity Employee Plan (or any other agreement or arrangement which would be an Affinity Employee Plan if it were in effect as of the date hereof)&#59;&#160;(ii) increase the value or amount, or accelerate the receipt of, any compensation or benefits of any of its employees, directors, or officers&#59; or (iii)&#160;increase or alter the Affinity Employee Payables&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;without limitation to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.05(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, not enter into, amend, assign, terminate, fail to renew or waive or release any material rights under any Material Contract, Real Property Lease or labor agreement, collective bargaining agreement or similar labor related agreement, except (i) for such immaterial amendments as may from time to time be required by the Governmental Authority having jurisdiction thereover, except as otherwise set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(h)(i) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or (ii) as set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(h)(ii) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;not take any action intentionally that would render, or that may reasonably be expected to render, any representation or warranty made by it in this Agreement untrue or inaccurate at the Closing&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;&#160;&#160;&#160;not enter into any Contract to support a community initiative or non-Affiliate non-profit corporation or similar entity or charitable endeavor that would create any obligation on Buyer&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;&#160;&#160;&#160;not (i) incur or otherwise acquire, or modify in any material respect the terms of, any Indebtedness for borrowed money or assume, guarantee or endorse or otherwise become responsible for any such Indebtedness of any Person, make any loans, advances or capital contributions to, or investments in, any other Person or issue or sell any debt securities or calls, options, warrants, or other rights to acquire any debt securities of Affinity, enter into any &#8220;keep well&#8221; or Contract to maintain any financial statement condition of another Person or enter into any arrangement (including any capital lease) having the economic effect of the foregoing&#59; or (ii) redeem, repurchase, prepay, defease or cancel any Indebtedness for borrowed money, other than (1) as required in accordance with its terms or expressly required by this Agreement or (2) in the ordinary course of business consistent with past practice&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 48 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)&#160;&#160;&#160;&#160;not sell, transfer, lease, license, mortgage, pledge, encumber, allow to lapse, incur any Encumbrance on (other than a Permitted Encumbrance), or otherwise dispose of, or agree to do any of the foregoing with respect to, any of the Purchased Assets except (i) in the ordinary course of business consistent with past practice, (ii) pursuant to Contracts in force on the date of this Agreement and made available to Buyer prior to the date hereof, or (iii) such dispositions of assets no longer used in the ordinary course of business consistent with past practice of Affinity&#8217;s&#8217; business as conducted as of the date of this Agreement&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)&#160;&#160;&#160;&#160;not make or authorize any payment of, or commitment for, capital expenditures in excess of Two Million Dollars ($2,000,000) in the aggregate, except those budgeted for in a budget made available to Buyer prior to the date hereof&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(n)&#160;&#160;&#160;&#160;not change any material financial accounting methods, practices, policies or elections from those utilized in the preparation of the Audited Financial Statements, other than any such changes as may be required by Applicable Accounting Principles&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(o)&#160;&#160;&#160;&#160;except as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(o) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, not commence or settle any Action relating to the Business, the Purchased Assets or the Assumed Liabilities, except for settlements of Actions or potential Actions in the ordinary course of business consistent with past practice and so long as such settlement will not create any material obligation on behalf of Buyer following the Closing&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(p)&#160;&#160;&#160;&#160;not cancel, amend, compromise, terminate, release or waive any material debts, rights or claims relating to the Business or the Purchased Assets&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(q)&#160;&#160;&#160;&#160;not conclude of or agree to any corrective action plans, consents, decrees, actions or Orders, other than in the ordinary course of business consistent with past practice&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(r)&#160;&#160;&#160;&#160;not adopt any plan of merger, consolidation, reorganization, liquidation or dissolution or filing of a petition in bankruptcy under any provisions of federal or state bankruptcy Law or consent to the filing of any bankruptcy petition against Affinity under any similar Law&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(s)&#160;&#160;&#160;&#160;not purchase or otherwise acquire (by merger, exchange, consolidation, acquisition of stock or assets or otherwise) any property, material asset, corporation, partnership, joint venture, limited liability company or other business organization or division or material assets thereof for which the aggregate consideration paid or payable in the aggregate is in excess of One Million Dollars ($1,000,000)&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(t)&#160;&#160;&#160;&#160;not (i) enter into any transaction with any Affiliate of Affinity, any officers or directors of Affinity (or any of their respective Affiliates), or any FQHC Member (or any of their respective Affiliates) or (ii) amend, assign, terminate, or waive or release any material rights under any existing transactions or agreements with any Affiliate of Affinity, any officers or directors of Affinity (or any of their respective Affiliates) or any FQHC Member (or any of their respective Affiliates), including any Provider Contracts with any FQHC Member (or any of their respective Affiliates)&#59; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 49 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(u)&#160;&#160;&#160;&#160;not allow to lapse any existing policy of insurance relating to the Business or the Purchased Assets&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;&#160;&#160;&#160;not make material loans, advances or capital contributions to, or material investments in, any Provider, except as required by applicable Law&#59; and</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(w)&#160;&#160;&#160;&#160;not enter into a Contract, commitment or arrangement to do any of the foregoing or that would materially impair its ability to consummate the transactions contemplated by this Agreement in accordance with the terms hereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;Access to Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Affinity shall (a)&#160;furnish Buyer and its Representatives with such financial, operating and other data and information as Buyer or any of its Representatives may reasonably request related to (i)&#160;the Business, or (ii)&#160;the Purchased Assets&#59; (b)&#160;use commercially reasonable efforts to provide Buyer (i)&#160;sufficiently in advance of the Closing, copies of such information as is reasonably requested by Buyer and its Representatives in order for Buyer to assume operations on the Closing Date for the transition of the Enrollees, as applicable, and continuity of care, and (ii)&#160;copies of such other information as is necessary for the operation, ownership and management of the Business or which is otherwise reasonably requested by Buyer, and which Affinity is permitted by applicable Law to provide or which is required in writing to be provided to Buyer by DOH (and Affinity shall provide such written consents and authorizations as may be reasonably necessary for Buyer to have access to materials on file with any Governmental Authority), including any information as may be required to permit Buyer to satisfy its obligations to any Governmental Authority following the Closing, including any third party accreditation or review organization (such as the National Committee for Quality Assurance)&#59; and (c)&#160;make available to the officers, employees, accountants, counsel and other Representatives of Buyer upon the reasonable request of Buyer and during normal working hours, officers, accountants, counsel, consultants, investment banker and other Representatives or agents of Affinity for discussion of the Business as Buyer may reasonably request&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Affinity must be given no less than 5 Business Days prior written notice of, and a representative of Affinity must be given a reasonable opportunity to attend, any meeting, or participate in any telephone discussion, involving all or substantially all of Affinity&#8217;s employees, on the one hand, and any such Person, on the other hand.  Any inquiries pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be conducted in such manner as not to interfere unreasonably with the conduct of the Business or any other businesses of Affinity. Nothing in this Agreement or any of the other Transaction Documents to the contrary shall in any manner restrict the ability of Buyer, from and after the date of this Agreement, to discuss the business and affairs of Affinity with any Governmental Authority having jurisdiction over Affinity or the fiscal intermediaries administering Affinity&#8217;s payor programs.  From the date hereof until the earlier of (i)&#160;the Closing Date or (ii)&#160;the date this Agreement is terminated pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity and Buyer shall cooperate to contact such third parties, including customers, prospective customers, specifying agencies, vendors or suppliers of Affinity, as Buyer deems reasonably necessary.  Prior to the Closing Date and after any termination of this Agreement, each Party shall hold and shall cause its Representatives to hold, in confidence, all confidential documents and information concerning the other Party&#8217;s or any of its Subsidiaries furnished to a Party or its Representatives in connection with the transactions contemplated by this Agreement in the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 50 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">manner and for the time period specified in the Confidentiality Agreement, dated September 25, 2019. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Solicitation of Other Bids</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Affinity shall not, and shall not authorize or permit any of its Representatives (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to, directly or indirectly, (i)&#160;knowingly encourage, solicit, initiate, knowingly facilitate, or respond to (other than solely to decline) inquiries regarding an Acquisition Proposal&#59; (ii)&#160;enter into discussions or negotiations with, or provide any information to, any Person concerning a possible Acquisition Proposal&#59; or (iii)&#160;enter into any agreements or other instruments (whether or not binding) regarding an Acquisition Proposal.  Affinity shall immediately cease and or cause to be terminated, and shall cause the other Affinity Parties to immediately cease and cause to be terminated, all existing activities, discussions or negotiations with any Persons conducted heretofore with respect to, or that could reasonably be expected to lead to, an Acquisition Proposal and shall notify each such party that it, or any Representative retained by it, no longer seeks or requires the making of any Acquisition Proposal, and withdraws any consent theretofore given to the making of an Acquisition Proposal and shall promptly instruct (to the extent it has contractual authority to do so and has not already done so prior to the date of this Agreement) or otherwise request, any Person that has executed a confidentiality or non-disclosure agreement within the 48-month period prior to the date of this Agreement in connection with any actual or potential Acquisition Proposal to return or destroy all such information or documents or material incorporating confidential information in the possession of such Person or its Representatives.  None of the Affinity Parties shall, directly or indirectly, and each of the Affinity Parties shall cause their Affiliates and their respective Representatives not to, solicit, initiate or conduct any discussions or negotiations with, or provide any information to or otherwise cooperate in any other way with, or facilitate or encourage any effort to attempt to, or enter into any agreement or understanding with, any Person or group of Persons regarding any Acquisition Proposal. For purposes hereof, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Acquisition Proposal</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means any inquiry, proposal or offer from any Person (other than Buyer or any of its Affiliates) relating to the direct or indirect disposition, whether by sale, merger or otherwise, of all or any portion of the Business or the Purchased Assets or any public announcement of a proposal, plan or intention to do the foregoing or any agreement to engage in the foregoing.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;In addition to the other obligations under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity shall promptly (and in any event within two (2) Business Days after receipt thereof by any Affinity Party) advise Buyer orally and in writing of any Acquisition Proposal or any request for information with respect to any Acquisition Proposal, and the identity of the Person making the same and shall provide Buyer with a copy of all written materials relating to such Acquisition Proposal.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Affinity agrees that the rights and remedies for noncompliance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.03(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall include having such provision specifically enforced by any Court having equity jurisdiction, it being acknowledged and agreed that any such breach or threatened breach shall cause irreparable injury to Buyer and that money damages would not provide an adequate remedy to Buyer.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 51 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notice of Certain Events</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;From the date hereof until the earlier of termination of this Agreement in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or the Closing, Affinity shall promptly notify Buyer in writing of&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;any fact, circumstance, event or action the existence, occurrence or taking of which (A)&#160;has had or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (B)&#160;has resulted in any representation or warranty made by Affinity hereunder not being true and correct (to the extent occurring or arising after the date hereof, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Disclosure Update</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), or (C)&#160;has resulted in, or could reasonably be expected to result in, the failure of any of the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> to be satisfied&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;any written notice or other written communication from any Person alleging that the consent of such Person is or may be required in connection with the transactions contemplated by this Agreement&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;&#160;&#160;&#160;any notice or other communication from any Governmental Authority, other than in the ordinary course of business consistent with past practice and other than that which does not relate to the transactions contemplated by this Agreement or the Transaction Documents&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;&#160;&#160;&#160;any Actions commenced or, to Affinity&#8217;s Knowledge, threatened against, relating to, involving or otherwise affecting the Business, the Purchased Assets or the Assumed Liabilities that, if pending on the date hereof, would have been required to have been disclosed pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.10</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or that relate to the consummation of the transactions contemplated by this Agreement.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;No Disclosure Update shall be deemed to modify, or cure any breach of Affinity&#8217;s representations and warranties in this Agreement or have any effect for the purpose of determining satisfaction of the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (other than </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) or the obligations of Affinity under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Employees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Sixty (60) days prior to the Closing Date, Affinity shall deliver to Buyer an updated version of the file containing the information referenced in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Employee Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), accurate as of such date. Thereafter and until the Closing Date, Affinity shall deliver to Buyer a further updated version of the Employee Information as soon as practicable after change in the information contained therein.  Affinity shall provide Buyer with reasonable access during normal business hours to the employees of the Business not less than forty-five (45) days prior to the Closing Date and with information reasonably requested by Buyer with respect to employment, compensation and benefits of the employees of the Business.  No less than ten (10) days prior to the Closing Date, to be effective as of the Closing but contingent on the Closing, Buyer or an Affiliate of Buyer shall offer employment to all individuals who are employed by Affinity in good standing in the operation of the Business&#59; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 52 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Buyer shall not be required to make offers of employment to or hire (i)&#160;any employee of Affinity who does not satisfy Buyer&#8217;s employment policies regarding employee documentation, drug testing, background screening, and other similar matters or (ii)&#160;any Inactive Employee, except as set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Each such offer of employment shall provide for the payments and benefits required to be provided by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> Each employee of Affinity who accepts Buyer&#8217;s offer of employment and commences employment with Buyer as of immediately following the Closing shall be considered a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Hired Employee.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; Any Inactive Employee who returns to active employment on or prior to the later of (i)&#160;the date that is six (6) months after the Closing Date or (ii)&#160;the latest date on which the Buyer would be required to rehire such Inactive Employee pursuant to applicable Law and who satisfies Buyer&#8217;s employment policies regarding employee documentation, drug testing, background screening, and other similar matters shall be considered a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Hired Employee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; upon such Inactive Employee&#8217;s commencement of employment with Buyer.  From the Closing Date through the date six (6) months following the Closing Date, Buyer shall not terminate any Hired Employee other than (i)&#160;for Cause or (ii)&#160;due to the occurrence of any material adverse change to the Business, and if any Hired Employee is terminated during the one (1) year period following the Closing Date other than for Cause or due to the occurrence of any material adverse change to the Business, Buyer will pay that Hired Employee an amount equal to the base salary that such Hired Employee would have earned during the remainder of the one (1) year period following the Closing Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Severance Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) in lieu of any other severance payments, unless such Hired Employee has a contractual right (whether in such Hired Employee&#8217;s employment agreement with Affinity or in a change in control agreement between such Hired Employee and Affinity) as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that provides for a greater benefit upon termination, in which case Buyer will pay the Hired Employee solely the benefits provided in accordance with such agreement as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For the avoidance of doubt, any termination payments described in the immediately preceding sentence that are made will be considered to be inclusive of any amounts due under the Worker Adjustment and Retraining Notification Act of 1988. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Effective as of the Closing Date, Affinity shall terminate the employment of all of the Hired Employees as of immediately prior to the Closing.  Except as otherwise specified herein, effective as of immediately prior to the Closing, all Hired Employees will cease to be active participants in the Affinity Employee Plans. All Hired Employees shall be eligible to become participants in the corresponding new or existing plans of Buyer and its Affiliates, including group health and other welfare benefit plans in each case subject to the terms thereof. Buyer also understands and agrees that (i) certain Affinity employees have contractual rights that are triggered upon a change in control of Affinity as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; and (ii) Buyer assumes and will perform the obligations pursuant to the contracts under which such rights are granted.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;For a period of one (1) year following the Closing Date, Buyer shall provide or cause to be provided to each Hired Employee who remains employed with Buyer during such period (i)&#160;base salary or base wages and annual or other periodic cash incentive opportunities (excluding any retention or similar bonuses and other special or non-recurring bonuses or cash awards) that are no less favorable in the aggregate than those provided to such </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 53 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Hired Employee by Affinity immediately before the Closing, and (ii)&#160;retirement (excluding pension and retiree medical or welfare benefits), welfare, fringe and other employee benefits which are substantially comparable in the aggregate to those provided to the Hired Employee by Affinity immediately prior to the Closing Date under the Affinity Employee Plans or, in Buyer&#8217;s discretion, which are substantially comparable in the aggregate to those made available to similarly situated employees of Buyer.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Buyer shall assume Affinity&#8217;s Liability for and shall be solely responsible for the payment or satisfaction of (i)&#160;the Affinity Employee Payables payable following the Closing Date, but only to the extent set forth on the AEP Schedule&#59; and (ii)&#160;any and all Liabilities to or with respect to any Hired Employee arising after the Closing Date.  Buyer shall have no Liabilities with respect to any current or former employee of the Business who is not a Hired Employee except for any requirements under COBRA for all individuals who are &#8220;M&#38;A qualified beneficiaries&#8221; as such term is defined in Treasury Regulation Section&#160;54.4980B&#30;9 with respect to the transactions contemplated by this Agreement.  Except as otherwise set forth in the AEP Schedule, Buyer shall have no Liabilities with respect to any Hired Employee relating to the period prior to and including the Closing&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Buyer understands and agrees, as provided in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Buyer is obligated to make a Severance Payment to any Hired Employees who are terminated during the one (1) year period following the Closing Date or who have contractual rights that are triggered upon a change in control of Affinity as set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a) of the Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Buyer shall ensure that (i) all Hired Employees receive credit for prior service with Affinity (or any predecessor entities) for purposes of eligibility, participation, vesting and benefit accrual (but not for benefit accruals under any defined benefit pension plan) under any employee benefit or compensatory plan, program or arrangement of Buyer or any of Buyer&#8217;s Affiliates in which Hired Employees are eligible to participate, except for any employee benefits that are frozen or grandfathered as of the Closing Date, for purposes of qualifying for subsidized early retirement benefits (including retirement treatment under Buyer equity incentive plans) or to the extent it would result in a duplication of benefits, and (ii)&#160; except as otherwise required by Law, all Hired Employees shall receive seven (7) days of paid time off (i.e., personal or sick leave) upon commencement of employment with Buyer, after which the Hired Employees will accrue benefits and paid time off as provided under Buyer&#8217;s policy. Buyer shall make reasonable best efforts to cause (A)&#160;any pre-existing conditions or limitations, eligibility waiting periods or required physical examinations under any group health benefit plans of Buyer or any of Buyer&#8217;s Affiliates to be waived with respect to Hired Employees and their eligible spouses and dependents, to the extent waived or satisfied under a corresponding Affinity Employee Plan in which the applicable Hired Employee participated immediately prior to the Closing&#59; and (B)&#160;subject to Affinity providing adequate data to Buyer, in a format reasonably requested by Buyer in writing, that the Hired Employees and their eligible spouses, dependents and beneficiaries will receive credit for the plan year in which the Closing Date occurs towards applicable deductibles and annual out-of-pocket limits for expenses incurred prior to the Closing Date that were credited for the same purpose to such individual under the corresponding Affinity Employee Plan as of the Closing Date. The aggregate amount of expenses subject to the </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 54 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">immediately-preceding clause (B) shall be added to (and shall increase) the total value of all items listed on the AEP Schedule.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;Pursuant to the &#8220;Standard Procedure&#8221; provided in Section 4 of Revenue Procedure 2004-53, (i) Affinity and Buyer shall report on a predecessor&#47;successor basis as set forth therein, (ii) Affinity will not be relieved from timely filing a Form W-2 with respect to any Hired Employees with respect to the portion of the calendar year in with the Closing occurs during which such employees are employed by Affinity and (iii) Buyer will undertake to file (or cause to be filed) a Form W-2 for each such Hired Employee with respect to the portion of the calendar year in which the Closing occurs during which the Hired Employee is employed by Buyer. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;This </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be binding upon and inure solely to the benefit of each of the Parties. Nothing contained herein shall be deemed to confer upon any Hired Employee or any other Person (or any spouse, dependent, beneficiary of or other Person claiming through such Hired Employee or other Person) any third party beneficiary rights or remedies of any nature whatsoever under or by reason of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as expressly set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, nothing in this Agreement shall be deemed to require Buyer or any of its Affiliates to hire or maintain the employment of any Person for any length of time, or to provide any element or level of compensation or benefits for any length of time. Nothing in this Agreement shall be deemed to create or amend any compensation or employee benefit plan, program, policy, practice, agreement or arrangement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Confidentiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  From and after the Closing, the Affinity shall, and shall use its reasonable best efforts to cause its Affiliates to, hold, and shall use their commercially reasonable efforts to cause their respective Representatives to hold, in confidence any and all information, whether written or oral, concerning the Business and Purchased Assets, except to the extent that (a)&#160;such information relates to Excluded Assets or Excluded Liabilities, except to the extent such information relates to the Business, (b)&#160;such information is generally available to and known by the public through no fault of Affinity or their Representatives, or (c)&#160;is lawfully acquired by Affinity or any of their Affiliates or Representatives from and after the Closing from sources (other than Buyer or its Affiliates or their respective Representatives) which, to the Knowledge of Affinity, are not prohibited from disclosing such information by a legal, contractual or fiduciary obligation.  If Affinity or any of its Representatives are compelled to disclose any information by judicial or administrative process or by other requirements of Law, Affinity shall promptly notify Buyer in writing, if and to the extent Affinity is permitted by applicable Law to do so, and shall disclose only that portion of such information which Affinity is advised by its counsel is legally required to be disclosed, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that Affinity shall use commercially reasonable efforts, at Buyer&#8217;s expense, to obtain an appropriate protective order or other reasonable assurance that confidential treatment will be accorded such information.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.07&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-competition&#59; Non-solicitation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;During the Restricted Period, Affinity shall not, directly or indirectly, either for Affinity&#8217;s own benefit or for the benefit of any other Person, without the prior consent of Buyer, which consent may be withheld in Buyer&#8217;s sole discretion, (i)&#160;engage in, make any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 55 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">regulatory application to engage in, enter into any Contract (including any Provider Contract) in anticipation of engaging in, or assist others in engaging in the Restricted Business in the Territory&#59; (ii)&#160;have an interest in any Person that engages directly or indirectly in the Restricted Business in the Territory in any capacity, including as a partner, shareholder, member, employee, principal, joint venturer, agent, trustee, volunteer, lender or consultant&#59; or (iii)&#160;induce or persuade, or seek or attempt to induce or persuade, any Provider, Enrollee, supplier or licensor of the Business (including any existing or former Provider, Enrollee, supplier or licensor of Affinity and any Person known to Affinity to have become a Provider, Enrollee, supplier or licensor of the Business during the Restricted Period) to terminate or modify its business relationship with the Business in a manner adverse to the Business. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;During the Restricted Period, Affinity shall not, directly or indirectly, solicit for employment, hire or retain the employment of any Hired Employee, or encourage any employee of Buyer or its Affiliates to leave such employment or hire any Person who has left such employment, except pursuant to a general solicitation which is not directed specifically to any Hired Employees or any employees of Buyer or its Affiliates&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that nothing in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.07(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall prevent Affinity from hiring any employee of Buyer whose employment has been terminated by Buyer and such termination was not directly or indirectly attributable to or influenced by actions of Affinity.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Affinity acknowledges that the restrictions contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> are reasonable and necessary to protect the legitimate interests of Buyer and constitute a material inducement to Buyer to enter into this Agreement and consummate the transactions contemplated by this Agreement.  In the event that any covenant contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> should ever be adjudicated to exceed the time, geographic, product or service or other limitations permitted by applicable Law in any jurisdiction, then any Court is expressly empowered to reform such covenant, and such covenant shall be deemed reformed, in such jurisdiction to the maximum time, geographic, product or service or other limitations permitted by applicable Law.  The covenants contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and each provision hereof are severable and distinct covenants and provisions.  The invalidity or unenforceability of any such covenant or provision as written shall not invalidate or render unenforceable the remaining covenants or provisions hereof, and any such invalidity or unenforceability in any jurisdiction shall not invalidate or render unenforceable such covenant or provision in any other jurisdiction.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.08&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governmental Approvals and Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Subject to the terms and conditions set forth in this Agreement, including </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, each Party shall (i)&#160;as promptly as possible, use its reasonable best efforts to obtain, or cause to be obtained, all consents, authorizations, orders and approvals from all Governmental Authorities set forth on </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 6.08(a) </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Required Governmental Approvals</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), (ii)&#160;cooperate fully with the other Party and its Affiliates in promptly seeking to obtain all such Required Governmental Approvals, and (iii)&#160;not willfully take any action for the purpose of delaying, impairing or impeding the receipt of any such Required Governmental Approvals.  If required by the HSR Act and if the appropriate filing pursuant to the HSR Act has not been filed prior to the date hereof, each Party hereto agrees to </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 56 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">make an appropriate filing pursuant to the HSR Act with respect to the transactions contemplated by this Agreement as promptly as practicable after the date hereof, with the exact timing of such filings to be mutually agreed upon by the Parties, and to supply as promptly as practicable to the appropriate Governmental Authority any additional information and documentary material that may be requested pursuant to the HSR Act.  In addition, each Party shall provide or cause to be provided as promptly as practicable any information and documentary material that may be requested by the U.S. Department of Justice or Federal Trade Commission under the HSR Act or by any Governmental Authority with regulatory jurisdiction over enforcement of any Antitrust Laws.  Affinity, on the one hand, and Buyer, on the other hand, shall be responsible for the payment of fifty percent (50%) of any filing fees under the HSR Act and any other Antitrust Laws.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Without limiting the generality of Affinity&#8217;s and Buyer&#8217;s undertakings pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, each Party mutually agrees to use its reasonable best efforts and to take any and all steps necessary to avoid or eliminate each and every impediment under any Antitrust Law that may be asserted by any Governmental Authority or any other party so as to enable the Parties to close the transactions contemplated by this Agreement as promptly as possible, including proposing, negotiating, committing to and effecting, by consent decree, hold separate orders, or otherwise, the sale, divestiture or disposition of any of its assets, properties or businesses or of the assets, properties or businesses to be acquired by it pursuant to this Agreement as are required to be divested in order to avoid the entry of, or to effect the dissolution of, any injunction, temporary restraining order or other order in any suit or proceeding, which would otherwise have the effect of materially delaying or preventing the consummation of the transactions contemplated by this Agreement.  In addition, each Party shall use its reasonable best efforts to defend through litigation on the merits any claim asserted in Court by any party in order to avoid entry of, or to have vacated or terminated, any Order (whether temporary, preliminary or permanent) that would prevent the consummation of the Closing.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Agreement, including this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, nothing in this Agreement shall require Buyer or its Affiliates to take or refrain from taking any action, or to agree to any requirement, restriction, limitation, requirement, or condition (including any conditions that may be required by any Governmental Authority to obtain any Required Governmental Approval) that (i) would reasonably be expected to apply to or affect the businesses, assets or properties of Buyer or its Affiliates or the Business or the Purchased Assets and would, individually or in the aggregate, reasonably be expected to result in Losses to Buyer, its Affiliates, the Business and&#47;or the Purchased Assets, collectively, that exceed One Million Dollars ($1,000,000)&#59; and&#47;or (ii) would reasonably be expected to materially and adversely affect the ability of Buyer and its Affiliates to provide health care coverage under the New York State Medicaid Managed Care, Health and Recovery Plan, Child Health Plus, or Essential Plan programs that make up the Business to the extent such health care coverage is provided by Affinity immediately prior to the Closing (such occurrence, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Regulatory Material Adverse Effect</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 57 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;The Parties agree that, with respect to the Required Governmental Approvals, Buyer and Affinity shall mutually determine in good faith (i)&#160;the scheduling of, and strategic planning for, any meeting with or filing with any Governmental Authority, (ii)&#160;the process for receipt of any Required Governmental Approvals and (iii)&#160;subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.08(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the resolution of any investigation or other inquiry of any Governmental Authority&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">that each Party shall keep the other Party reasonably apprised of the status of the matters relating to the Required Governmental Approvals, and each Party will work cooperatively with the other Party in connection with obtaining all such Required Governmental Approvals.&#160; Without limiting the foregoing, (x) all analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals made by or on behalf of either Party before any Governmental Authority or the staff or regulators of any Governmental Authority, in connection with the transactions contemplated hereunder (but, for the avoidance of doubt, not including any interactions between Affinity or Buyer with Governmental Authorities in the ordinary course of business, any disclosure which is not permitted by Law or any disclosure containing confidential information) shall be disclosed to the other Party in advance of any filing, submission or attendance, it being the intent that the Parties will consult and cooperate with one another, and consider in good faith the views of one another, in connection with any such analyses, appearances, meetings, discussions, presentations, memoranda, briefs, filings, arguments, and proposals and (y) each Party shall give notice to the other Party with respect to any meeting, discussion, appearance or contact with any Governmental Authority or the staff or regulators of any Governmental Authority, with such notice being sufficient to provide the other party with the opportunity to attend and participate in such meeting, discussion, appearance or contact&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity shall not be obligated to consult Buyer or provide notice to Buyer pursuant to the immediately preceding clauses (x) and (y) with respect to matters that that would not create any obligation on Buyer or otherwise impact the operation of the Business by Buyer or any of its Affiliates (including but not limited to discussions with the New York State Office of the Attorney General concerning the use of the proceeds from the sale of the Business under this Agreement by Affinity and the FQHC Members).</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;"> </sup></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Affinity shall give any notices to third parties in connection with the Required Third Party Consents, and shall use its reasonable best efforts to obtain the Required Third Party Consents.&#160; Affinity shall regularly consult with Buyer in connection with the foregoing and shall keep Buyer reasonably apprised of the status of the matters relating to the Required Third Party Consents.&#160; Affinity shall use its reasonable best efforts to obtain, or cause to be obtained, approval from all FQHC Members of the execution and delivery by Affinity of this Agreement, the other Transaction Documents and the performance and consummation by Affinity of the transactions contemplated hereby and thereby.  Buyer shall reasonably cooperate with Affinity in connection with Affinity&#8217;s efforts related thereto.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.09&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">New Material Contracts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Without limitation to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.01(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity shall promptly notify Buyer of any new Material Contract (based on anticipated payments during the twelve (12) months following its execution) proposed to be executed after the date hereof on behalf of Affinity. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 58 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Affinity acknowledges that any Provider Contract that provides that it may be assigned by Affinity without the applicable Provider&#8217;s consent shall be deemed to be assigned to Buyer at and subject to the Closing.  Affinity acknowledges and agrees to promptly supply to Buyer, when reasonably requested, such information and materials (including specific answers or responses) required in connection with receipt of any required consents, authorizations, orders and approvals which relate to the provider network, the Provider Contracts and the continuity of services (such information and materials to be in such form as may reasonably be requested for purposes of filings with the applicable regulatory authorities).  Without limiting the generality of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.08</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, with respect to any Provider Contract requiring consent of the Provider to transfer or assign it&#58; (A)&#160;this Agreement shall not constitute an agreement to assign or transfer any right, benefit or obligation arising thereunder if an assignment or transfer without the consent of the Provider would constitute a breach or violation thereof or adversely affect the rights of Affinity or Buyer thereunder (however, the foregoing shall not excuse or waive any breach of any representation or warranty contained herein) and (B)&#160;before the Closing, Affinity shall use its commercially reasonable efforts to cause such Provider Contract to be assigned with any required consent, and if such consent cannot be obtained, Affinity shall use its commercially reasonable efforts to assist Buyer to obtain its own direct contract on terms acceptable to Buyer.  In addition, Affinity shall, to the extent reasonably requested by Buyer, use its commercially reasonable efforts to facilitate introductions to, and meetings with, Providers. Affinity shall provide reasonable access to all information necessary for Buyer to evaluate the extent to which the provider networks of Buyer and Affinity overlap.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.10&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Closing Conditions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as otherwise expressly set forth herein, each Party hereto shall use commercially reasonable efforts to take such actions as are necessary to expeditiously satisfy the closing conditions relating to the Closing set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof.  </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.11&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Public Announcements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Neither Affinity nor Buyer shall make, nor shall they permit any of their Representatives to make, any public announcements in respect of this Agreement or the transactions contemplated hereby or otherwise communicate with any news media without the prior written consent of the other or in accordance with a communications plan mutually agreed to by the Parties, unless required by applicable Law or any listing agreement with or rules of the New York Stock Exchange or other stock exchange on which securities of Buyer are listed or as may be requested by a Governmental Authority, in which case the issuing party shall use its reasonable best efforts to consult with the other party before issuing any such release or making any such public statement, and the issuing party shall allow the other party reasonable time to comment on such release or public statement in advance of such issuance and shall consider in good faith any reasonable comments of such party. Upon execution of this Agreement and upon the Closing, Affinity and Buyer (or their respective Affiliates) may each issue press releases announcing the transaction, in each case in accordance with a communications plan mutually agreed to by the Parties.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.12&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Reconciliation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If Buyer collects or receives any Excluded Asset from any third party after the Closing, then Buyer shall deliver such Excluded Asset to Affinity as soon as reasonably practicable after receipt thereof.  If Affinity collects or receives any </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 59 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Purchased Asset from any third party after the Closing, then Affinity shall deliver to Buyer such Purchased Asset(s) as soon as reasonably practicable after receipt thereof.  Likewise, Buyer shall forward any claim for an Excluded Liability to Affinity after the Closing and Affinity shall forward any claim for an Assumed Liability to Buyer after the Closing.  Without limitation to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.12</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity shall reasonably cooperate with Buyer in Buyer&#8217;s collection of the receivables that are Purchased Assets.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.13&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Transition Planning</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity shall cooperate with Buyer as may be reasonably requested by Buyer from time to time to develop and implement an integration and transition plan for the Business for purposes of regulatory reporting and any other services mutually agreed to by the Parties, and the Parties shall use their commercially reasonable best efforts to enter into a transition services agreement on terms and conditions to be mutually agreed upon by the Parties.  Without limiting the generality of the foregoing, Buyer and Affinity shall cooperate to develop and implement a mutually agreeable communications plan with respect to the Enrollees and Providers.  Notwithstanding the foregoing, in no event shall Affinity make a general announcement to its non-executive employees regarding the transactions contemplated by this Agreement before any press releases have been issued by Buyer or Affinity in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.11</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.14&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Further Assurances</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Following the Closing, each of the Parties shall, and shall cause its respective Affiliates to, execute and deliver such additional documents, instruments, conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and give effect to the transactions contemplated by this Agreement and the other Transaction Documents.  Without limiting the generality of the preceding sentence, Affinity shall, on and after the Closing Date, transfer (or cause to be transferred) to Buyer such records and data (including electronic data files) that, prior to the Closing, are used by Affinity in providing services related to the operation of the Business, as may be reasonably requested by Buyer (and, in the case of electronic data files, in such format or formats as may be reasonably requested by Buyer).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.15&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Post-Closing Access to Information</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;After the Closing, each Party shall afford the other Party and its counsel, accountants, consultants and other Representatives, during normal business hours, reasonable access to the books, records and other information in such Party&#8217;s possession relating to the Business, and the right to make copies and extracts therefrom at its expense, or shall provide copies of such information to the other Party, in each case to the extent such access is reasonably required by the requesting Party (i)&#160;to comply with reporting, disclosure, filing or other requirements imposed by a Governmental Authority, (ii)&#160;for use in any Tax audits or litigation in which such requesting Party is a party, (iii)&#160;to comply with such requesting Party&#8217;s obligations under this Agreement, or (iv)&#160;with respect to Buyer, relates to the operation, ownership and management of the Business and which Affinity is permitted by applicable Law to provide </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that, Buyer agrees to treat such information as confidential, if applicable.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;In addition, after the Closing Affinity shall provide to Buyer such written certifications, sub-certifications or the like as may be reasonably requested by Buyer to support </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 60 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">any attestation or representation required to be provided by Buyer in connection with any audit, accreditation review or similar proceeding relating to the operation of the Business prior to the Closing.  For a period of six (6) years after the Closing Date, neither Affinity nor Buyer shall, or permit its Affiliates to, destroy or otherwise dispose of any of the books, records or other information described in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.15</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> without first offering in writing to surrender such books, records and other information to the other Party, and the other Party shall have ten (10) days after such offer to agree in writing to take possession thereof.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.16&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-disparagement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  (a) Affinity shall not publicly talk about or otherwise publicly communicate to any third parties (including Providers and Enrollees) in a disparaging or defamatory manner regarding Buyer, or otherwise make or authorize to be made any written or oral statement that may disparage or damage the reputation of Buyer&#59; and (b)&#160;Buyer shall not, and shall cause their respective Affiliates not to, publicly talk about or otherwise publicly communicate to any third parties (including Providers and Enrollees) in a disparaging or defamatory manner regarding Affinity, or otherwise make or authorize to be made any written or oral statement that may disparage or damage the reputation of Affinity&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided, however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that such restriction shall not prohibit (i) truthful statements compelled by legal process, as part of a response to a request for information from any Governmental Authority or as testimony in any legal or regulatory process or proceeding, (ii) any statements in connection with any legal dispute, (iii) filing any necessary documents in accordance with Law or applicable stock exchange requirements or (iv)&#160;factual statements by such Party regarding the business, condition, results or prospects of the Business in connection with any public earnings call or otherwise, so long as such statements are not reasonably foreseen by such Party as likely to defame, disparage, or slander any other Party.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.17&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Post-Closing Buyer Covenants</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;From and after the Closing, Buyer shall use commercially reasonable good faith efforts to&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;promote Enrollee health through (A)&#160;quality, accessible care and services, (B)&#160;partnering with health professionals to assist in providing health care services, (C)&#160;facilitating building linkages and systems for the coordination of care and services among health care, behavioral and social services, as well as educators, to address the spiritual, emotional, and physical needs of Enrollees, and (D)&#160;advocating for a health policy that accords true dignity and respect for all human persons, especially the poor and underserved&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;maintain in all material respects to the extent commercially viable the scope and type of services currently provided to Enrollees by the Business as conducted immediately prior to the Closing&#59;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;&#160;&#160;&#160;subject to the limitations set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.17(a)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, maintain a corporate presence in the State of New York no less significant than the operations of the Business in the State of New York immediately prior to the Closing (including maintaining a regional chief executive officer for the Business that reports directly to Buyer&#8217;s national chief executive officer of community and state programs) and continue to provide a similar or greater </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 61 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">level of employment opportunities to residents of the State of New York as compared to those provided by the Business immediately prior to the Closing&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iv)&#160;&#160;&#160;&#160;promote growth and expansion of the Business through (A)&#160;partnering with health professionals with aligned mission and vision and (B)&#160;leveraging Affinity&#8217;s existing capabilities for scale and efficiency, for accelerating care and process innovation, and for developing predictive health capabilities to foster healthier communities&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(v)&#160;&#160;&#160;&#160;enhance population health capability of the Business by (A)&#160;maintaining existing high standards of quality that endeavor to be cost effective across all populations&#59; (B)&#160;focusing on coordination of care and services among health care, behavioral, and social service needs of Enrollee populations, (C)&#160;developing systems to attain greater standards of clinical excellence and improving Enrollee health status, (D)&#160;focusing on a &#8220;person-centered&#8221; coordination of services and customer service&#59; and (E)&#160;facilitating linkages and systems for coordination of care and services.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;With respect to the covenants contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.17(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, (i) the covenants will survive for a period of eighteen (18) months from Closing, (ii) nothing herein is intended to or shall confer upon any Enrollee or Person (including any Governmental Authority) any legal or equitable enforcement or other right, benefit or remedy of any nature whatsoever under or by reason of this Agreement and (iii) the covenants are subject to any changes in applicable Laws or economic conditions to the extent such changes alter the commercially reasonable expectations of the Parties at the time they entered into this Agreement or the commercial viability of complying with such covenants.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;From and after the Closing until final payment of the Net Asset Value adjustment contemplated by </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(g)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Buyer shall pay or cause to be paid all claims payable and claims payable incurred in the ordinary course of business consistent with industry standard claims procedures.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;For the period commencing on the Closing Date and continuing through the five-year anniversary of the Closing Date, Buyer shall cause the headquarters of the Business to remain located in the Bronx, New York.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;For the period commencing on the one-month anniversary of the Closing Date and continuing through the five-year anniversary of the Closing Date, Buyer shall cause Molina Healthcare of New York, Inc. (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">MHNY</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to appoint to its board of directors a representative designated by the board of directors of Affinity (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Representative</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and approved by Buyer, such approval not to be unreasonably conditioned or withheld.  Notwithstanding anything herein to the contrary, (A) the Affinity Representative shall not be an employee, officer or director of any competitor of Buyer, and (B) Buyer shall have the right to withhold any information, including any written materials, from the Affinity Representative, and to exclude the Affinity Representative from any board meeting or committee meeting or portion thereof if, in the reasonable good faith judgment of either Buyer or the board of directors of MHNY (other than the Affinity Representative), an issue is addressed in such written materials, or is to be discussed, which is not appropriate to be disclosed to or discussed in the presence of </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 62 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">the Affinity Representative in order to avoid a conflict of interest as established by Buyer or MHNY policy on the part of the Affinity Representative or otherwise would require a similarly situated director to recuse himself under New York law.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.18&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Transfer Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All transfer, documentary, sales, use, excise, stamp, registration, value added and other such Taxes and fees (including any penalties and interest) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Transfer Taxes</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) incurred in connection with the sale of the Purchased Assets pursuant to this Agreement and the other Transaction Documents (including any real property transfer Tax and any other similar Tax) shall be borne and paid by Affinity when due.  Affinity shall duly prepare any Tax Return or other document with respect to such Taxes or fees (and Buyer shall cooperate with respect thereto as necessary), and shall give Buyer a copy of each such Tax Return for its review and comment at least fifteen (15) days prior to filing. Following such review and comment period, Affinity shall file all necessary Tax Returns and other documentation with respect to all Transfer Taxes and, if required by applicable Law, Buyer shall join Affinity in the execution of any such Tax Returns and other documentation.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.19&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Minimum Network Requirements</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  In the event that, prior to the Closing, one (1) or more Providers provide notice of the termination (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Terminating Provider</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of any Provider Contract in accordance with its terms (each, a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Provider Contract Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and, individually or in the aggregate, such Provider Contract Terminations would reasonably be expected to result in Buyer&#8217;s failure to satisfy the Minimum Network Requirements (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Network Failure</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), then, prior to the Closing, Affinity shall use its commercially reasonable efforts to assist Buyer in obtaining a direct contract on terms reasonably satisfactory to Buyer with such Terminating Providers that Buyer requests.  If a contract is unattainable with a Terminating Provider, then upon the request of Buyer, Affinity shall use its commercially reasonable efforts to identify and contract with (either directly or through its Affiliates) or assist Buyer to contract with alternate Provider(s) as soon as reasonably practicable as necessary to avoid a Network Failure. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.20&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Sale or Dissolution&#59; Post-Closing Cooperation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Affinity hereby covenants and agrees that (i) for a period of six (6) years from the Closing Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Wind-Up Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Affinity shall not dissolve, liquidate or wind up its affairs and (ii) during the Wind-Up Period, Affinity shall employ or retain one or more other representatives reasonably acceptable to Buyer whom Affinity shall direct and cause to consult with Buyer and its representatives on an as-needed basis regarding the Business in order to facilitate the transition of the Purchased Assets to Buyer following the Closing, including by responding to questions from Buyer and its representatives from time to time and providing reasonable cooperation with Buyer in any pending or future litigation or investigation or other dispute regarding the Business.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 6.21&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Insurance Coverage</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Prior to Closing, Affinity shall tender all actual and potential claims timely and completely to any insurance policies that may provide coverage to such claims in the format prescribed by the relevant insurance policy or policies.&#160;</font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">CONDITIONS TO CLOSING</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 63 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:54pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Obligations of All Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The obligations of each Party to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment, at or prior to the Closing, of each of the following conditions&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;The filings of Buyer and Affinity pursuant to the HSR Act, if any, shall have been made and the applicable waiting period and any extensions thereof shall have expired or been terminated.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;All other Required Governmental Approvals shall have been obtained.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;No Governmental Authority shall have enacted, issued, promulgated, enforced or entered any Order or Law which has, or would have, the effect of (i)&#160;making the transactions contemplated by this Agreement illegal, (ii)&#160;otherwise restraining, enjoining or prohibiting consummation of such transactions or (iii)&#160;causing any of the transactions contemplated to be consummated at the Closing to be rescinded following completion thereof (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Prohibitive Order</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and no Action by a Governmental Authority of applicable jurisdiction shall be pending for the purpose of obtaining a Prohibitive Order&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that, a Party may not assert its right to not consummate the transactions contemplated by this Agreement pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> if such Party shall have initiated or caused such Action or Prohibitive Order.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;The Payor Contracts shall have been assigned to Buyer in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.01</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and all approvals, consents and waivers required in connection with such assignments shall have been received and executed counterparts thereof shall have been delivered to Buyer and Affinity at or prior to the Closing.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;The Parties shall have received a copy of the Escrow Agreement, duly executed by the Escrow Agent.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Obligations of Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The obligations of Buyer to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Buyer&#8217;s written waiver, at or prior to the Closing, of each of the following conditions&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;(1) The representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE&#160;IV </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(other than the Affinity Fundamental Representations and the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Employment and Benefits Matters) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Health Care Matters)), the other Transaction Documents and any certificate or other writing delivered pursuant hereto, disregarding any qualifications or limitations set forth in such representations or warranties as to materiality, Material Adverse Effect, or any other similar qualifier contained in such representations and warranties shall be true and correct in all respects, in each case, as of the date hereof and as of the Closing Date as though made on and as of such date except&#58;  (i)&#160;to the extent that any such representation or warranty refers to a specified date, in which event such representation and warranty shall be true and correct as of such specified date&#59; and (ii)&#160;where the failure of such representations and warranties to be so true and correct, has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect&#59; (2) the Affinity Fundamental Representations shall be true and correct in all but </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">de minimis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> respects, in each case as of the date hereof and as of the Closing Date as </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 64 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">though made on and as of such date except to the extent that any such representation or warranty refers to a specified date, in which event such representation and warranty shall be true and correct as of such specified date&#59; and (3) the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13(h)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Employment and Benefits Matters) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Health Care Matters), disregarding any qualifications or limitations set forth in such representations or warranties as to materiality, Material Adverse Effect, or any other similar qualifier contained in such representations and warranties shall be true and correct in all material respects, in each case, as of the date hereof and as of the Closing Date as though made on and as of such date except to the extent that any such representation or warranty refers to a specified date, in which event such representation and warranty shall be true and correct in all material respects as of such specified date.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Affinity shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;From the date hereof, there shall not have occurred any Material Adverse Effect or Regulatory Material Adverse Effect, nor shall any event(s), occurrence(s), fact(s), condition(s), change(s) or effect(s) have occurred that, individually or in the aggregate, with or without the lapse of time, could reasonably be expected to result in a Material Adverse Effect or a Regulatory Material Adverse Effect.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Affinity shall have delivered to Buyer duly executed counterparts to the Transaction Documents (other than this Agreement).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Affinity shall have delivered to Buyer a duly executed affidavit prepared in accordance with Treasury Regulations Section 1.1445-2(b) certifying Affinity&#8217;s non-foreign status.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;Buyer shall have received a certificate of the Secretary or an Assistant Secretary (or equivalent officer) of Affinity certifying (i)&#160;that attached thereto are true and complete copies of all resolutions adopted by the Board of Directors of Affinity authorizing the execution, delivery and performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the transactions contemplated hereby and thereby, and (ii)&#160;the names and signatures of the officers of Affinity authorized to sign this Agreement, the Transaction Documents and the other documents to be delivered hereunder and thereunder.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Buyer shall have received a certificate, dated as of the Closing Date and signed by a duly authorized officer of Affinity, that each of the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.02(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> have been satisfied.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;Buyer shall have received all Permits that are necessary for it to conduct the Business as conducted by Affinity as of the Closing Date.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 65 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;Buyer shall have received all consents, approvals and authorizations that are set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit E </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Required Third Party Consents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;&#160;&#160;&#160;Affinity shall have delivered to Buyer the Estimated Closing Statement, which in Buyer&#8217;s reasonable judgment complies with this Agreement and is accurate in all material respects.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(k)&#160;&#160;&#160;&#160;Sufficient Provider Contracts shall have been successfully assigned to Buyer to enable Buyer to satisfy the Minimum Network Requirements.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(l)&#160;&#160;&#160;&#160;Buyer shall have received duly executed copies of the FQHC Non-Compete Agreements, which are valid and in full force and effect. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(m)&#160;&#160;&#160;&#160;Affinity shall have received approval for this Agreement, the other Transaction Documents and the transactions contemplated hereby and thereby from the requisite number of FQHC Members pursuant to Section 510(a)-1 of the New York Not-for-Profit Corporation Law and shall have delivered to Buyer a certificate, dated as of the Closing Date and duly executed by the requisite number of FQHC Members (pursuant to Section 510(a)-1 of the New York Not-for-Profit Corporation Law), approving the execution and delivery by Affinity of this Agreement, the other Transaction Documents and the performance and consummation by Affinity of the transactions contemplated hereby and thereby.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 7.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Conditions to Obligations of Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The obligations of Affinity to consummate the transactions contemplated by this Agreement shall be subject to the fulfillment or Affinity&#8217;s written waiver, at or prior to the Closing, of each of the following conditions&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;(1) The representations and warranties of Buyer contained in this Agreement (other than the Buyer Fundamental Representations), the other Transaction Documents and any certificate or other writing delivered pursuant hereto disregarding any qualifications or limitations set forth in such representations or warranties as to materiality, Material Adverse Effect, or any other similar qualifier contained in such representations and warranties shall be true and correct in all respects, in each case, as of the date hereof and as of the Closing Date as though made on and as of such date except&#58;  (i)&#160;to the extent that any such representation or warranty refers to a specified date, in which event such representation and warranty shall be true and correct as of such specified date&#59; and (ii)&#160;where the failure of such representations and warranties to be so true and correct, has not had, and would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and (2) the Buyer Fundamental Representations shall be true and correct in all but </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">de minimis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> respects, in each case as of the date hereof and as of the Closing Date as though made on and as of such date except to the extent that any such representation or warranty refers to a specified date, in which event such representation and warranty shall be true and correct as of such specified date.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Buyer shall have duly performed and complied in all material respects with all agreements, covenants and conditions required by this Agreement and each of the other Transaction Documents to be performed or complied with by it prior to or on the Closing Date.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 66 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;Buyer shall have delivered to Affinity duly executed counterparts to the Transaction Documents (other than this Agreement).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Buyer shall have delivered to Affinity an instrument or instruments of assignment and assumption of the Assumed Liabilities in form and substance reasonably satisfactory to Affinity and its counsel.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;Buyer shall have delivered, or shall have caused to be delivered, to Affinity the Cash Purchase Price in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.06(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;Affinity shall have received a certificate, dated as of the Closing Date and signed by a duly authorized officer of Buyer, that each of the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.03(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> have been satisfied.</font></div><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">INDEMNIFICATION</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Survival</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the limitations and other provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, (a) the representations and warranties contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (other than the Affinity Fundamental Representations and the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Employment and Benefits Matters), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Taxes) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Health Care Matters)) shall survive the Closing and shall remain in full force and effect during the eighteen (18) month period from and following the Closing Date (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Survival Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), (b) the Affinity Fundamental Representations and the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Employment and Benefits Matters), </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Taxes) and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Health Care Matters) shall survive the Closing for six (6) years following the Closing Date, (c) all covenants, agreements and other obligations contained in this Agreement, and the indemnification obligations of the Parties with respect thereto, shall survive the Closing in accordance with their terms, and (d) each of the Special DOH Indemnity and the Special HCRA Indemnity shall survive the Closing through and until the sixth (6</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) anniversary of the Closing.  Notwithstanding the foregoing, any claims asserted in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> prior to the expiration date of the applicable survival period shall not thereafter be barred by the expiration of the relevant representation or warranty and such claims shall survive until finally resolved.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnification by Affinity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the other terms and conditions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Affinity shall indemnify and defend each of Buyer, its Affiliates and its Representatives (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Buyer Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Buyer Indemnitees based upon, arising out of, with respect to or by reason of&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;any inaccuracy in or breach of any of the representations or warranties of Affinity contained in this Agreement (other than the Affinity Fundamental Representations and the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Taxes))&#59;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 67 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;any inaccuracy in or breach of any Affinity Fundamental Representation or the representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.14</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (Taxes)&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Affinity pursuant to this Agreement&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;the Special DOH Indemnity&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;the Special HCRA Indemnity&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;any knowing and intentional common law fraud by Affinity in the making of the representations and warranties set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;any Affinity Transaction Expenses which are outstanding as of the Closing and which are not fully accounted for in the Final Net Asset Value&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;any Closing Date Indebtedness which is outstanding as of the Closing and which is not fully accounted for in the Final Net Asset Value&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;any Liabilities in connection with or relating to any Affinity Employee Payables that exceed the amount itemized in respect thereof on the AEP Schedule and that are not otherwise fully accounted for in the Final Net Asset Value&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(j)&#160;&#160;&#160;&#160;any Excluded Asset or any Excluded Liability.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnification by Buyer</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Subject to the other terms and conditions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, Buyer shall indemnify and defend Affinity, its Affiliates and its Representatives (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Affinity Indemnitees</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) against, and shall hold each of them harmless from and against, and shall pay and reimburse each of them for, any and all Losses incurred or sustained by, or imposed upon, the Affinity Indemnitees based upon, arising out of, with respect to or by reason of&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;any inaccuracy in or breach of any of the representations or warranties of Buyer contained in this Agreement (other than the Buyer Fundamental Representations)&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;any inaccuracy in or breach of any Buyer Fundamental Representation&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;any breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement&#59; </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;any knowing and intentional common law fraud by Buyer in the making of the representations and warranties set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#59; or</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;the Purchased Assets or Assumed Liabilities.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Certain Limitations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties&#8217; indemnification obligations under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be subject to the following limitations&#58;</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 68 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;Neither Affinity nor Buyer shall have any liability for monetary Losses arising under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, until the aggregate amount of Losses related thereto for which the Affinity or Buyer, as applicable, would otherwise be required to provide indemnification, exceeds an amount equal to Five Million Dollars ($5,000,000) (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Basket Amount</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The aggregate Liability of Affinity, on the one hand, and Buyer, on the other hand, for any Losses with respect to matters set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not exceed an amount equal to the Escrow Amount (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Cap</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Cap shall not apply with respect to (i) claims for any knowing and intentional common law fraud or willful breach, or (ii) Losses resulting from, arising out of or relating to breaches of the Affinity Fundamental Representations.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;Neither Affinity nor Buyer shall have any liability for monetary Losses under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> unless and until the aggregate amount of all monetary Losses under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> as applicable, for which Affinity or Buyer, as applicable, would otherwise be required to provide indemnification exceeds on a cumulative basis an amount equal to the Basket Amount, at which point Affinity or Buyer, as applicable, subject to the other provisions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.04</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, shall indemnify the Buyer Indemnitees or the Affinity Indemnitees, as applicable, for the full amount of all such Losses in excess of such Basket Amount, subject in all respects to the Cap.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;From the Closing Date until the sixth (6</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;vertical-align:top;">th</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) anniversary of the Closing Date, the Buyer Indemnitees shall not be entitled to recover any Losses under a claim pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section&#160;8.02(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> unless and until the aggregate amount of all Losses incurred by the Buyer Indemnitees with respect to the Special DOH Indemnity exceed the amounts accrued related to the Special DOH Indemnity in the Closing Statement (as finally determined pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, any and all indemnification payments required to be made by Affinity pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be paid solely from the Escrow Fund to the extent available in accordance with the Escrow Agreement.  Affinity shall not be required to pay any Buyer Indemnitee for any indemnifiable Losses under </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> once the Escrow Fund has been exhausted&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the foregoing limitation shall not apply to (i) any claims for any knowing and intentional common law fraud or willful breach by Affinity, or (ii) any Losses resulting from, arising out of or relating to breaches of the Affinity Fundamental Representations.  The Escrow Agent shall distribute to Affinity, subject to the terms and conditions of the Escrow Agreement, immediately following the Survival Period, the then remaining Escrow Amount in excess of the sum of any amounts with respect to (x)&#160;which Buyer is entitled to, but has not yet received, indemnification, pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(plus the amount of any interest or income earned on such amount), (y)&#160;any unresolved claims for indemnification as of such date (plus the amount of any interest or income earned on such amount) and (z)&#160;any amounts disputed but not yet resolved pursuant to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section&#160;2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Once all indemnification claims are resolved between the Parties in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and all disputes (if any) are resolved between the Parties in accordance with </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 2.07</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as applicable, all remaining amounts in the Escrow Fund, if any, shall be paid to Affinity. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 69 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(e)&#160;&#160;&#160;&#160;The amount of any Losses for which indemnification is provided to an Indemnified Party under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall be net of any amounts actually recovered by such Indemnified Party under policies of insurance (less any costs and expenses of recovery thereof), with respect to such Losses.  If and to the extent any insurance proceeds are actually received by any Indemnified Party after such Indemnified Party has recovered any Losses pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> such Indemnified Party shall promptly pay to the Indemnifying Party an amount equal to such insurance proceeds to which the Indemnifying Party is entitled pursuant to the first sentence of this paragraph.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(f)&#160;&#160;&#160;&#160;No Indemnified Party shall be entitled to be compensated more than once for the same Loss.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(g)&#160;&#160;&#160;&#160;Each Indemnified Party shall use commercially reasonable efforts to mitigate Losses for which indemnification may be claimed by such Indemnified Party under this Agreement to the extent required by applicable Law.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(h)&#160;&#160;&#160;&#160;The right of an Indemnified Party to indemnification or to assert or recover on any claim shall not be affected by any investigation conducted with respect to, or any knowledge acquired (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement or the Closing Date, with respect to the accuracy of, or compliance with, any of the representations, warranties, covenants, or agreements set forth in this Agreement.  The waiver of any condition based on the accuracy of any representation or warranty, or on the performance of or compliance with any covenant or agreement, shall not affect the right to indemnification or other remedy based on such representations, warranties, covenants or agreements.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Indemnification Procedures</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The party making a claim under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Indemnified Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;, and the party against which such claim is asserted under this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is referred to as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Indemnifying Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Third Party Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any Indemnified Party receives notice of the assertion or commencement of any Action made or brought by any Person who is not a party to this Agreement or an Affiliate of a party to this Agreement or a Representative of the foregoing (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Third Party Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) against such Indemnified Party with respect to which the Indemnifying Party is obligated to provide indemnification under this Agreement, the Indemnified Party shall give the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than thirty (30) calendar days after receipt of such notice of such Third Party Claim (a&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Claim&#160;Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  The failure to give a Claim Notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that such failure has a materially prejudicial effect on the defenses or other rights available to the Indemnifying Party with respect to such Third Party Claim or the indemnification obligations are materially increased as a result of such failure.  A Claim Notice shall describe the Third Party Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably determinable, of the Loss that has been or may be sustained by the Indemnified Party.  The Indemnifying Party shall have the right to participate in, or by giving written notice to the Indemnified Party within thirty (30) calendar days from receipt </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 70 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">of the Claim Notice, to assume the defense of any Third Party Claim at the Indemnifying Party&#8217;s expense and by the Indemnifying Party&#8217;s own counsel (which choice of counsel shall be subject to the Indemnified Party&#8217;s prior written consent, not to be unreasonably withheld, conditioned or delayed), and the Indemnified Party shall cooperate in good faith in such defense&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that (i)&#160;the Indemnifying Party shall have acknowledged in writing to the Indemnified Party its obligation to indemnify the Indemnified Party as provided hereunder in respect thereof, (ii)&#160;the Indemnifying Party must conduct the defense of the Third Party Claim actively and diligently in order to preserve its rights in this regard and (iii)&#160;notwithstanding the foregoing, the Indemnifying Party shall not have the right to elect to defend the Indemnified Party against a Third Party Claim (and the Indemnified Party shall have the sole power to direct and control such defense) if the Third Party Claim (A)&#160;could result in any Adverse Claim Consequences or (B)&#160;seeks non-monetary relief, relates to a criminal action or involves claims by a Provider or Governmental Authority.  In the event that the Indemnifying Party assumes the defense of any Third Party Claim, subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, it shall have the right to take such action as it deems necessary to avoid, dispute, defend, appeal or make counterclaims pertaining to any such Third Party Claim in the name and on behalf of the Indemnified Party.  The Indemnified Party shall have the right to participate in the defense of any Third Party Claim with counsel selected by it subject to the Indemnifying Party&#8217;s right to control the defense thereof.  The fees and disbursements of such counsel shall be at the expense of the Indemnified Party, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that (A)&#160;if the Indemnifying Party requests that the Indemnified Party participates in the defense of such Third Party Claim or (B)&#160;if, in the reasonable written opinion of counsel to the Indemnified Party, (x) there are legal defenses available to an Indemnified Party that are different from or additional to those available to the Indemnifying Party or (y) there exists a conflict of interest between the Indemnifying Party and the Indemnified Party that cannot be waived, the Indemnifying Party shall be liable for the reasonable documented fees and expenses of one counsel to the Indemnified Party in each jurisdiction for which the Indemnified Party determines counsel is required.  If the Indemnifying Party elects not to compromise or defend such Third Party Claim or fails to promptly notify the Indemnified Party in writing of its election to defend as provided in this Agreement, the Indemnified Party may, subject to </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.05(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, pay, compromise, defend such Third Party Claim and seek indemnification for any and all Losses based upon, arising from or relating to such Third Party Claim.  Affinity and Buyer shall cooperate with each other in all reasonable respects in connection with the defense of any Third Party Claim, including making available (subject to the provisions of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.05(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) records relating to such Third Party Claim and using commercially reasonably efforts to furnish, without expense to the defending party, management employees of the non-defending party as may be reasonably necessary for the preparation of the defense of such Third Party Claim.  The Indemnified Party and the Indemnifying Party shall use commercially reasonable efforts to avoid production of confidential information (consistent with applicable Law), and to cause all communications among employees, counsel and others representing any party to a Third Party Claim to be made so as to preserve any applicable attorney-client or work-product privileges.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Settlement of Third Party Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnifying Party shall not, without the prior written consent of the Indemnified Party, settle, compromise or offer to settle or compromise any Third Party Claim if the terms of such settlement do not contain a release of the Indemnified Parties or </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 71 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;would result in the imposition of a consent order, injunction or decree that would restrict the future activity or conduct of the Indemnified Party, (ii)&#160;would result in a finding or admission of wrongdoing or violation of Law by the Indemnified Party, (iii)&#160;would result in any monetary Liability of the Indemnified Party that will not be paid or reimbursed by the Indemnifying Party, or (iv)&#160;has an adverse effect on any ongoing business of the Indemnified Party (any of the foregoing, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Adverse Claim Consequences</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;).  If the Indemnifying Party assumes the defense of a Third Party Claim, the Indemnified Party shall not admit any Liability with respect to, settle, compromise or discharge, such Third Party Claim without the Indemnifying Party&#8217;s prior written consent, which consent shall not be unreasonably withheld or delayed.  </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Direct Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Any Action by an Indemnified Party on account of a Loss which does not result from a Third Party Claim (a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Direct Claim</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) shall be asserted by the Indemnified Party giving the Indemnifying Party reasonably prompt written notice thereof, but in any event not later than thirty (30) calendar days after the Indemnified Party becomes aware of such Direct Claim.  The failure to give such prompt written notice shall not, however, relieve the Indemnifying Party of its indemnification obligations, except and only to the extent that such failure has a materially prejudicial effect on the defenses or other rights available to the Indemnifying Party with respect to such Direct Claim.  Such notice by the Indemnified Party shall describe the Direct Claim in reasonable detail, shall include copies of all material written evidence thereof and shall indicate the estimated amount, if reasonably practicable, of the Loss that has been or may be sustained by the Indemnified Party.  The Indemnifying Party shall have thirty (30) calendar days after its receipt of such notice to respond in writing to such Direct Claim.  The Indemnified Party shall reasonably cooperate with the Indemnifying Party and its professional advisors to allow the Indemnified Party to investigate the matter or circumstance alleged to give rise to the Direct Claim, and whether and to what extent any amount is payable in respect of the Direct Claim and the Indemnified Party shall assist the Indemnifying Party&#8217;s investigation by providing reasonable access (including access to the Indemnified Party&#8217;s premises and personnel, documents or records during normal business hours on a mutually convenient basis) as the Indemnifying Party or any of its professional advisors may reasonably request.  If the Indemnifying Party notifies the Indemnified Party that it does not dispute the claim described in such notice, or fails to so respond within such thirty (30) calendar day period that the Indemnifying Party disputes the claim described in such notice, the Losses in the amount specified in the Indemnified Party&#8217;s notice will be conclusively deemed a Liability of the Indemnifying Party and the Indemnified Party shall be entitled to recover the amount of such Losses from the Indemnifying Party in accordance with the terms and conditions of this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If the Indemnifying Party has timely disputed its Liability with respect to such claim, the Indemnifying Party and Indemnified Party will proceed in good faith to negotiate a resolution of such dispute and if no such resolution is reached, to litigate such dispute.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Once a Loss is agreed to by the Indemnifying Party or finally adjudicated to be payable pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, the Indemnifying Party shall satisfy its obligations within ten (10) Business Days of such final, non-appealable adjudication by wire transfer of immediately available funds (or, if the Indemnifying Party is Affinity, in accordance with the Escrow Agreement).</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 72 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.07&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Tax Treatment of Indemnification Payments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All indemnification payments made under this Agreement shall be treated by the Parties as an adjustment to the Purchase Price for Tax purposes, unless otherwise required by Law.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.08&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exclusive Remedy</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except in the case of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(f)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, claims for equitable relief (including the enforcement of any covenant requiring performance following the Closing) or Liabilities or Claims based on any knowing and intentional common law fraud or willful breach, from and after the Closing, the sole and exclusive remedy for all Losses relating to this Agreement or the transactions contemplated hereby shall be the indemnification provisions set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 8.09&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Materiality</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For purposes of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.02(a), Section 8.02(b), Section 8.03(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.03(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, any qualifications as to materiality, Material Adverse Effect, material adverse effect or similar qualification contained in the representations or warranties in this Agreement (other than with respect to the representations and warranties contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 4.05</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, as to which this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 8.09</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not apply), shall be disregarded and have no effect.</font></div><div style="text-indent:18pt;text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TERMINATION</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 9.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may be terminated at any time prior to the Closing only as follows&#58;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;by the mutual written consent of Affinity and Buyer&#59;</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;by Buyer by written notice to Affinity if Buyer is not then in material breach of any provision of this Agreement and&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;an event or condition occurs that has had a Material Adverse Effect on the Business&#59; </font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;Buyer suffers a Regulatory Material Adverse Effect&#59; or</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(iii)&#160;&#160;&#160;&#160;there has been a breach or inaccuracy in any representation or warranty, or failure to perform any covenant or agreement made by Affinity pursuant to this Agreement that would give rise to the failure of any of the conditions specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and such breach, inaccuracy or failure has not been cured by Affinity within thirty (30) calendar days of Affinity&#8217;s receipt of written notice of such breach from Buyer.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;by Affinity by written notice to Buyer if Affinity is not then in material breach of any provision of this Agreement and there has been a breach, inaccuracy in or failure to perform any representation, warranty, covenant or agreement made by Buyer pursuant to this Agreement that would give rise to the failure of any of the conditions specified in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE VII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and such breach, inaccuracy or failure has not been cured by Buyer within thirty (30) calendar days of Buyer&#8217;s receipt of written notice of such breach from Affinity.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 73 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;by Buyer or Affinity, by written notice to the other party, in the event that&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;any Governmental Authority shall have issued a Prohibitive Order restraining or enjoining the transactions contemplated by this Agreement, and such Prohibitive Order shall have become final and non-appealable&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that the right to terminate this Agreement pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 9.01(d)(i)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not be available to any party whose failure to fulfill any obligation under this Agreement shall have been a material cause of, or resulted in, the occurrence of such Prohibitive Order, or who has initiated or taken any action in support of such Prohibitive Order&#59; or</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;the Closing shall not have occurred on or prior to December 31, 2021 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Initial Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> that if prior to the Initial Termination Date, any of the conditions set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> (to the extent that such Order or Law by the Governmental Authority relates to the filing and&#47;or approvals referenced in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">) or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 7.01(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> have not been satisfied (or waived) but all other conditions to the Closing (other than those conditions which by their terms cannot be satisfied until the Closing) have been satisfied or waived by the Initial Termination Date, the Initial Termination Date may be extended by either Affinity or Buyer for up to three (3) months from the Initial Termination Date (the Initial Termination Date, as it may be extended pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 9.01(d)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, is referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Termination Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, further, that the right to terminate this Agreement pursuant to this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 9.01(d)(ii)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall not be available to any party whose failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, the failure of the Closing to occur on or prior to such date.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 9.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Effect of Termination</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;In the event of the termination of this Agreement in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, this Agreement shall forthwith become void (in whole or in part, as applicable) and there shall be no liability on the part of any Party hereto (nor any of its Representatives or Affiliates) except&#58;</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(i)&#160;&#160;&#160;&#160;as set forth in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IX</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 6.06</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE X</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> hereof&#59; and</font></div><div style="text-indent:108pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(ii)&#160;&#160;&#160;&#160;nothing herein shall relieve any Party hereto from Liability or Losses for any fraud, willful breach or intentional misrepresentation or any breach of any representation, warranty, covenant or agreement contained in this Agreement prior to the date of termination.</font></div><div style="text-indent:18pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE X</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">MISCELLANEOUS</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.01&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Expenses</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Except as otherwise expressly provided herein, all Expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid by the Party incurring such Expenses, whether or not the Closing shall have occurred.</font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 74 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.02&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Notices</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  All notices, demands and other communications to be given or delivered under or by reason of the provisions of this Agreement shall be in writing and shall be deemed to have been given (a) when personally delivered, (b) upon transmission by e-mail with confirmation of receipt, (c) one (1) day after deposit with Federal Express or similar overnight courier service, or (d) three (3) days after being mailed by first class mail, return receipt requested.  Notices, demands, and communications to the Parties shall, unless another address is specified in writing, be sent to the addresses indicated below (or at such other address for a Party as shall be specified in a notice given in accordance with this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.02</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">)&#58;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:87.179%;"><tr><td style="width:1.0%;"></td><td style="width:48.900%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:48.900%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">If to Affinity&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Affinity Health Plan, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Address&#58;  1776 Eastchester Road</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Bronx, New York 10461</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Michael Murphy</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">E-Mail&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">mmurphy&#64;affinityplan.org</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">with a copy to (which notice shall not constitute notice)&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Greenberg Traurig LLP</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">54 State Street</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Albany, New York 12207</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Harold Iselin</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">E-Mail&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">iselinh&#64;gtlaw.com</font></div><div><font><br></font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">If to Buyer&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Molina Healthcare, Inc.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">200 Oceangate, Suite 100</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Long Beach, California 90802</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Jeff Barlow, Chief Legal Officer &#38; Burt Park, Deputy General Counsel</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Facsimile&#58;&#160;(916) 646-4572</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Email&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">jeff.barlow&#64;molinahealthcare.com</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">burt.park&#64;molinahealthcare.com</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">with a copy to (which notice shall not constitute notice)&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Milbank LLP</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">55 Hudson Yards</font></div><div style="margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">New York, New York 10001</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Attention&#58; Scott Golenbock</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">E-Mail&#58; </font><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">sgolenbock&#64;milbank.com</font></div></td></tr></table></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.03&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Interpretation</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  For purposes of this Agreement, whenever the context requires, the singular number shall include the plural, and vice versa&#59; the masculine gender shall include the feminine and neuter genders&#59; the feminine gender shall include the masculine and neuter genders&#59; and the neuter gender shall include the masculine and feminine genders.  As used in this Agreement, the words &#8220;include&#8221; and &#8220;including,&#8221; and variations thereof, shall not be </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 75 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">deemed to be terms of limitation, but rather shall be deemed to be followed by the words &#8220;without limitation.&#8221;  Except as otherwise indicated, all references in this Agreement to Articles, Sections and Exhibits are intended to refer to Articles or Sections of this Agreement and Exhibits to this Agreement.  All terms defined in this Agreement shall have the defined meanings when used in any certificates, reports or other documents made or delivered pursuant hereto or thereto, unless the context otherwise requires.  Any reference to $ in this Agreement shall mean the lawful currency of the United States.  All references to statutes or related regulations shall include all amendments of the same and any successor or replacement statutes and regulations, in each case as in effect on the date of this Agreement, and all references to any Person shall be deemed to mean and include the successors and permitted assigns of such Person (or, in the case of a Governmental Authority, Persons succeeding to the relevant functions of such Person).  Any capitalized terms used in the Disclosure Schedules, the Buyer Disclosure Schedules or in any Exhibit hereto, but not otherwise defined therein, shall have the meanings as defined in this Agreement.  All references to statutes and related regulations shall include all amendments of the same and any successor or replacement statutes and regulations.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.04&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Headings</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The headings in this Agreement, the Disclosure Schedules or the Buyer Disclosure Schedules are for reference only and shall not affect in any way the meaning or interpretation of this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.05&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Severability</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The unenforceability or invalidity of any provision of this Agreement shall not affect the enforceability or validity of any other provision.  If any provision of this Agreement or the application of any such provision to any Person or circumstance shall be declared by any court of competent jurisdiction to be invalid, illegal, void or unenforceable in any respect, all other provisions of this Agreement, or the application of such provision to Persons or circumstances other than those as to which it has been held invalid, illegal, void or unenforceable, shall nevertheless remain in full force and effect and will in no way be affected, impaired or invalidated thereby.  Upon such determination that any provision, or the application of any such provision, is invalid, illegal, void or unenforceable, the Parties shall negotiate in good faith to modify this Agreement so as to effect the original intent of the Parties as closely as possible to the fullest extent permitted by applicable Law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the greatest extent possible. </font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.06&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Entire Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement (including the Disclosure Schedules, the Buyer Disclosure Schedules and Exhibits attached hereto), the Transaction Documents, and other documents delivered at the Closing pursuant hereto or thereto, contain the entire understanding of the Parties in respect of their subject matter and supersede all prior agreements and understandings (oral or written) between the Parties with respect to such subject matter. The Disclosure Schedules, the Buyer Disclosure Schedules and Exhibits attached hereto are hereby incorporated in and made a part of this Agreement as if set forth in full herein. In the event of any inconsistency between the statements in the body of this Agreement and those in the other Transaction Documents, the Exhibits, the Disclosure Schedules and the Buyer Disclosure Schedules (other than an exception expressly set forth as such in the Disclosure Schedules or the Buyer Disclosure Schedules), the statements in the body of this Agreement will control. </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 76 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.07&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Disclosure Schedules</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Disclosure Schedules and the Buyer Disclosure Schedules shall be arranged in sections and subsections corresponding to the numbered and lettered sections and subsections contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> and </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, respectively, and any information set forth in a particular section&#160;of the Disclosure Schedules or the Buyer Disclosure Schedules shall qualify or modify (a)&#160;the correspondingly numbered section&#160;in this Agreement and (b)&#160;to the extent the relevance of such information to another section&#160;or subsection of this Agreement is reasonably apparent on the face of such disclosure, such other section&#160;or subsection.  No reference to or disclosure of any item or other matter in the Disclosure Schedules or the Buyer Disclosure Schedules shall&#58; (i) represent a determination that such item or other matter is material (or otherwise establish a standard of materiality) or that such item or matter is required to be referred to or disclosed in the Disclosure Schedules or the Buyer Disclosure Schedules&#59; and (ii) represent a determination that such item or other matter did not arise in the ordinary course of business.  The information contained in the Disclosure Schedules and the Buyer Disclosure Schedules is provided solely for purposes of making disclosures to each Party under this Agreement.  In disclosing such information, each Party does not waive any attorney-client privilege associated with such information or any protection afforded by the work-product doctrine with respect to any of the matters disclosed or discussed in the Disclosure Schedules and the Buyer Disclosure Schedules.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.08&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Successors and Assigns</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The rights and obligations of this Agreement shall bind and inure to the benefit of the Parties and their respective successors and permitted assigns.  Except as expressly provided herein, the rights and obligations of this Agreement may not be assigned (by operation of law or otherwise) by any Party without the prior written consent of the other Party&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">however</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that Buyer may, without the prior written consent of Affinity, assign any of its rights and interests hereunder to any of its Affiliates&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">further</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that no such assignment shall relieve Buyer of any of its obligations or liabilities hereunder.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.09&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Third-Party Beneficiaries</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement is for the sole benefit of the Parties and each of their permitted successors and assigns, and nothing herein expressed or implied shall give or be construed to give any Person, other than the Parties and such permitted successors and assigns, any legal or equitable rights hereunder&#59; </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">provided</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, that the Buyer Indemnitees and the Affinity Indemnitees are intended third party beneficiaries of </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE&#160;VIII</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.10&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment and Modification&#59; Waiver</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement may not be amended, supplemented or otherwise modified except in a written instrument executed by each Party.  No waiver by either Party of any default, misrepresentation or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.  No waiver by either Party of any of the provisions hereof shall be effective unless explicitly set forth in writing and executed by the Party sought to be charged with such waiver.  No failure by either Party to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement shall operate or be construed as a waiver thereof&#59; nor shall any single or partial </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 77 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.11&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Governing Law&#59; Submission to Jurisdiction&#59; Waiver of Jury Trial</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;All matters relating to the interpretation, construction, validity and enforcement of this Agreement shall be governed by and construed in accordance with the domestic Laws of the State of New York without giving effect to any choice or conflict of Law provision or rule (whether of the State of New York or any other jurisdiction) that would cause the application of Laws of any jurisdiction other than the State of New York.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;ANY LEGAL SUIT, ACTION OR PROCEEDING (WHETHER AT LAW, IN EQUITY, IN CONTRACT, IN TORT OR OTHERWISE) ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY MAY ONLY BE INSTITUTED IN THE FEDERAL OR STATE COURTS LOCATED IN THE BOROUGH OF MANHATTAN (AND ANY FEDERAL OR STATE APPELLATE COURT THEREFROM), AND EACH PARTY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF SUCH COURTS IN ANY SUCH SUIT, ACTION OR PROCEEDING.  SERVICE OF PROCESS, SUMMONS, NOTICE OR OTHER DOCUMENT BY MAIL TO SUCH PARTY&#8217;S ADDRESS SET FORTH HEREIN SHALL BE EFFECTIVE SERVICE OF PROCESS FOR ANY SUIT, ACTION OR OTHER PROCEEDING BROUGHT IN ANY SUCH COURT.  Nothing in this Agreement will affect the right of any Party to this Agreement to serve process in any other manner permitted by law.  THE PARTIES IRREVOCABLY AND UNCONDITIONALLY WAIVE ANY OBJECTION TO THE LAYING OF VENUE OF ANY SUIT, ACTION OR ANY PROCEEDING IN SUCH COURTS AND IRREVOCABLY WAIVE AND AGREE NOT TO PLEAD OR CLAIM IN ANY SUCH COURT THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT OR THE OTHER TRANSACTION DOCUMENTS IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES AND, THEREFORE, EACH SUCH PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LEGAL ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.  EACH PARTY TO THIS AGREEMENT CERTIFIES AND ACKNOWLEDGES THAT (i)&#160;NO REPRESENTATIVE OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT SEEK TO ENFORCE THE FOREGOING WAIVER IN THE EVENT OF A LEGAL ACTION, (ii)&#160;SUCH PARTY HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii)&#160;SUCH PARTY MAKES THIS WAIVER VOLUNTARILY, AND (iv)&#160;SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 78 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 10.11(C).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.12&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Specific Performance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Without intending to limit the remedies available to the Parties hereunder, the Parties agree that irreparable damage may occur if any provision of this Agreement are not performed in accordance with the terms hereof, for which damages, even if available, will not be an adequate remedy. Accordingly, the Parties shall be entitled to seek an injunction, specific performance and other equitable relief to prevent or restrain breaches or threatened breaches of this Agreement and to enforce specifically the terms hereof, without, in any such case, the requirement to post any bond or other undertaking, in addition to any other remedy to which they are entitled at law or in equity.  Each Party agrees not to oppose the granting of such injunctive relief on the basis that monetary damages are an adequate remedy.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.13&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Recourse Against Non-Recourse Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding anything to the contrary contained herein, this Agreement may be enforced only against, and any Claim based upon, arising out of or related to this Agreement, any Transaction Documents or the negotiation, execution or performance of this Agreement, any Transaction Documents or the transactions contemplated hereby or thereby, may be brought only against the Persons that are expressly named as parties hereto or thereto and then only with respect to the specific obligations set forth herein or therein with respect to such party. With respect to each named party to this Agreement or any Transaction Document, no Non-Recourse Party of such named party shall have any liability (whether in contract, tort or otherwise) for any one or more of the representations, warranties, covenants, agreements or other obligations or liabilities of such named party or for any Claim based on, arising out of or related to this Agreement, any Transaction Documents or the negotiation, execution or performance of this Agreement, any Transaction Documents or the transactions contemplated hereby or thereby. Without limiting the rights of (a) a Party against another Party in the case of this Agreement, in no event shall such Party or any of its Affiliates seek to enforce this Agreement against, make any Claims for any breach of this Agreement against, or seek to recover any Losses from, any Non-Recourse Party of such other Party and (b) a party to a Transaction Document against another party to such Transaction Document in the case of a Transaction Document, in no event shall such party or any of its Affiliates seek to enforce such Transaction Document against, make any Claims for any breach of such Transaction Document against, or seek to recover any Losses from, any Non-Recourse Party of such other party thereto. In furtherance of the foregoing, each Party, on behalf of itself and each of its Affiliates, hereby (i) waives and releases any and all Claims that may otherwise be available to such Party or any of its Affiliates at Law or in equity, granted by statute or otherwise, to avoid or disregard the entity form of any other Party or otherwise impose liability of any other Party on any Non-Recourse Party of such other Party (whether granted by statute or based on theories of equity, agency, control, instrumentality, alter ego, domination, sham, single business enterprise, piercing the veil, unfairness, undercapitalization or otherwise) and (ii) covenants that neither such Party nor any of such Party&#8217;s Non-Recourse Parties will (and that such Party will cause all other Persons who may seek to claim as, by, through or in relation to such Party or any of such Party&#8217;s Non-Recourse Parties not to) sue, or bring or otherwise pursue any Claim against, any Non-Recourse Party of any other Party on the basis of or in any way relating to this Agreement, any of the Transaction Documents or any transaction </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 79 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">contemplated hereby or thereby (regardless of whether this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section&#160;10.13</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> is enforceable under, or prohibited by, applicable Law or otherwise).</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.14&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Acknowledgements&#59; Disclaimers</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. </font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)&#160;&#160;&#160;&#160;The parties acknowledge and agree that Buyer is an informed and sophisticated Person, and has engaged expert advisors experienced in the evaluation and acquisition of the Purchased Assets and Assumed Liabilities as contemplated hereunder. Buyer has had an opportunity to conduct its own independent investigation and due diligence review of Affinity, the Business and Affinity&#8217;s assets and condition, financial and otherwise. Buyer acknowledges that&#58; (1) in making its decision to enter into this Agreement and to consummate the transactions contemplated hereby, Buyer has relied solely upon its own investigation and the express representations and warranties of Affinity set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement (including the related portions of the Disclosure Schedules)&#59; and (2) neither Affinity nor any other Person has made any representation or warranty as to Affinity, the Business, the assets or this Agreement except as expressly set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> of this Agreement (including related portions of the Disclosure Schedules).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)&#160;&#160;&#160;&#160;NEITHER AFFINITY NOR ITS REPRESENTATIVES, DIRECTORS, OFFICERS, EMPLOYEES OR MEMBERS HAS MADE, AND SHALL NOT BE DEEMED TO HAVE MADE, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY NATURE WHATSOEVER RELATING TO ANY ONE OR MORE OF AFFINITY, THE BUSINESS, THE PURCHASED ASSETS OR THE ASSUMED LIABILITIES OR OTHERWISE IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY, OTHER THAN THOSE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE IV</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)&#160;&#160;&#160;&#160;NEITHER BUYER NOR ITS SUBSIDIARIES, THEIR RESPECTIVE REPRESENTATIVES, DIRECTORS, OFFICERS, EMPLOYEES OR MEMBERS HAS MADE, AND SHALL NOT BE DEEMED TO HAVE MADE, ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, OF ANY NATURE WHATSOEVER RELATING TO ANY ONE OR MORE OF BUYER OR ANY OF ITS SUBSIDIARIES, THEIR RESPECTIVE BUSINESSES OR OTHERWISE IN CONNECTION WITH THE TRANSACTIONS CONTEMPLATED HEREBY, OTHER THAN THOSE REPRESENTATIONS AND WARRANTIES EXPRESSLY SET FORTH IN </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ARTICLE V </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(INCLUDING RELATED PORTIONS OF THE BUYER DISCLOSURE SCHEDULES).</font></div><div style="text-indent:72pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)&#160;&#160;&#160;&#160;With respect to all materials that are described as having been made available or delivered to Buyer, such materials shall be deemed to have been delivered or made available to Buyer if Buyer or any of its representatives or agents have been granted access to a dataroom, electronic dataroom or website in which such materials were available or by transmitting such materials to Buyer or its representatives or agents by any other electronic means. Buyer further agrees that neither Affinity nor any other Person (including the Non-Recourse Parties of Affinity) shall have or be subject to any liability to Buyer or any other Person resulting from the distribution to Buyer, or Buyer&#8217;s use of, any information, documents</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">or materials made available to Buyer or Buyer&#8217;s representatives in certain &#8220;data rooms,&#8221; </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 80 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">management presentations or any other form in expectation of the transactions contemplated by this Agreement.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.15&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Prevailing Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  If any Party seeks to enforce its rights under this Agreement by any judicial action, legal proceeding, case or the like against the other Party, the applicable adjudicating body shall award to the prevailing party or parties (as the case may be), if any, the costs and expenses (including attorneys&#8217; fees and costs of investigation and preparation) reasonably incurred by the prevailing party or parties (as the case may be) in connection with such judicial action, legal proceeding, case or the like, and, if the adjudicating body determines a party or parties to be the prevailing party or parties under circumstances where the prevailing party or parties won on some but not all of the claims and counterclaims, the adjudicating body may award the prevailing party or parties an appropriate percentage of the costs and expenses (including attorneys&#8217; fees and costs of investigation and preparation) reasonably incurred by the prevailing party or parties in connection with such judicial action, legal proceeding, case or the like.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.16&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Release</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  Effective as of the Closing, Buyer, on behalf of itself and its past, present and future Affiliates and each of its and their respective past, present and future equity holders, directors, officers, employees, members, managers, counsel, agents and representatives and each of its and their respective successors and assigns (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Releasing Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), hereby voluntarily, unconditionally and irrevocably and forever releases and discharges (i) Affinity, (ii) each of Affinity&#8217;s Affiliates, (iii) all past, present and future, directors, officers, employees, members, managers, counsel, agents and representatives of Affinity or any of its Affiliates and (iv) all of the successors and&#47;or assigns of any of the foregoing Persons in the immediately preceding clauses (i) through (iii) (all of the foregoing Persons in the immediately preceding clauses (i) through (iv) are collectively referred to herein as the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Released Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) of and from, and hereby voluntarily, unconditionally and irrevocably waive, any and all claims, counterclaims, debts, demands, Losses, costs, fees, expenses, penalties, proceedings, covenants, suits, judgments, damages, Actions and causes of Action, obligations, accounts and Liabilities of any kind or character whatsoever, known or unknown, suspected or unsuspected, in contract, contingent or absolute, matured or unmatured, liquidated or unliquidated, direct or indirect, at Law or in equity (collectively, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) that any of the Releasing Parties ever had, now has or ever may have or claim to have against any of the Released Parties for or by reason of any matter, circumstance, event, action, inaction, omission, error, negligence, breach of contract, tort, violation of Law, cause or thing whatsoever arising prior to the Closing to the extent arising out of or relating to the Business or the Purchased Assets (including with respect to the management or operation of Affinity or the Business) (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Released Claims</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Buyer, on behalf of itself and each of the other Releasing Parties, covenants that none of the Releasing Parties will (and that Buyer will cause all other Persons who may seek to claim as, by, through or in relation to any of the Releasing Parties or any of the matters released by or on behalf of the Releasing Parties in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> not to) sue, or bring or otherwise pursue any Claim against, any of the Released Parties on the basis of or in any way relating to any of the Released Claims (regardless of whether the release of any such Released Claim is enforceable under, or prohibited by, applicable Law or otherwise).&#160; Notwithstanding the foregoing, nothing contained in this </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Section 10.16</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> shall (A) constitute a </font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 81 -</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">release or waiver of any rights of Buyer or (B) release or relieve any obligations of Affinity, in either case of clauses (A) and (B), that are expressly set forth in this Agreement or any Transaction Document. The foregoing release and waiver of Released Claims (X) was made with the advice of counsel and fully, finally and forever settles and releases the Released Claims and (Y) shall be and remain in effect notwithstanding the discovery of any additional Claims or facts relating to any of the Released Claims.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.17&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Counterparts</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  This Agreement and any amendments hereto may be executed and delivered in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement.  This Agreement and any amendments hereto, to the extent signed and delivered by means of a facsimile machine or electronic transmission in portable document format (pdf), shall be treated in all manner and respects as an original thereof and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person.  Minor variations in the form of the signature page, including footers from earlier versions of this Agreement or any such other document, shall be disregarded in determining the party&#8217;s intent or the effectiveness of such signature.  No Party hereto shall raise the use of a facsimile machine or electronic transmission in pdf to deliver a signature or the fact that any signature or document was transmitted or communicated electronically as a defense to the formation of a contract, and each such Party forever waives any such defense.</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Section 10.18&#160;&#160;&#160;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">No Strict Construction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.  The Parties have participated jointly in the negotiation and drafting of this Agreement.  In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.</font></div><div style="text-align:center;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;Signature Page Follows&#93;</font></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">- 82 -</font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:43.181%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.979%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AFFINITY&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">AFFINITY HEALTH PLAN, INC.</font></div><div><font><br></font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Michael G. Murphy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Michael G. Murphy</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> &#91;ASSET PURCHASE AGREEMENT SIGNATURE PAGE&#93;</font></div><div style="margin-bottom:10pt;"><font><br></font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_16"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the date first written above by their respective officers thereunto duly authorized.</font></div><div style="margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.076%;"><tr><td style="width:1.0%;"></td><td style="width:43.181%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.540%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:44.979%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">BUYER&#58;</font></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">MOLINA HEALTHCARE, INC.</font></div><div><font><br></font></div><div><font><br></font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Mark Keim</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Mark Keim</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Executive Vice President of Strategic Planning, Corporate Development and Transformation</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;margin-bottom:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> &#91;ASSET PURCHASE AGREEMENT SIGNATURE PAGE&#93;</font></div></div></div><div id="i3c1195df7064453a9df5c32368f6ff05_19"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:12pt;"><font><br></font></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>moh3q20ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i8a8003e2d0de4ba7a8a36c5695d34338_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.1 </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Joseph M. Zubretsky, certify that&#58;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed the report on Form 10-Q for the period ended September&#160;30, 2020 of Molina Healthcare, Inc.&#59;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:43.621%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.457%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 29, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-9pt;padding-left:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Chief Executive Officer, President and Director</font></div></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>moh3q20ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i08d0fe24ba7549289b6b0734cc6e24c6_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 31.2 </font></div><div style="text-align:center;margin-top:18pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Thomas L. Tran, certify that&#58;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1. I have reviewed the report on Form 10-Q for the period ended September&#160;30, 2020 of Molina Healthcare, Inc.&#59;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="text-indent:24.75pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:43.848%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.002%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.850%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 29, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Thomas L. Tran</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas L. Tran</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer and Treasurer</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>moh3q20ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ia10f8c5798924c78bc23c3a0c67bdca5_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32.1 </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2020 (the &#8220;Report&#8221;), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:right;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:43.621%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.457%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 29, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>moh3q20ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3aabcdc0648e49ea9e6dadc139dc7bbe_1"></div><div style="min-height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">EXHIBIT 32.2 </font></div><div style="text-align:center;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-indent:24.75pt;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2020 (the &#8220;Report&#8221;), I, Thomas L. Tran, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="text-indent:49.5pt;margin-top:5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:43.621%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.457%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:43.622%;"></td><td style="width:0.1%;"></td></tr><tr><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:39pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dated&#58; October 29, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Thomas L. Tran</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Thomas L. Tran</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:4pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>moh-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moh="http://www.molinahealthcare.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molinahealthcare.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.molinahealthcare.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation">
        <link:definition>2101101 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>2402401 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashandCashEquivalentsDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails">
        <link:definition>2406402 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2407403 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails">
        <link:definition>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails">
        <link:definition>2409405 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails">
        <link:definition>2410406 - Disclosure - Significant Accounting Policies - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShare" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare">
        <link:definition>2111103 - Disclosure - Net Income per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShareTables" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables">
        <link:definition>2312302 - Disclosure - Net Income per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomeperShareDetails" roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails">
        <link:definition>2413407 - Disclosure - Net Income per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.molinahealthcare.com/role/BusinessCombinations">
        <link:definition>2114104 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables">
        <link:definition>2315303 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>2416408 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsIntangibleAssetsDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails">
        <link:definition>2417409 - Disclosure - Business Combinations - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements">
        <link:definition>2118105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables">
        <link:definition>2319304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>2420410 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails">
        <link:definition>2421411 - Disclosure - Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsBalanceSheetGroupingDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails">
        <link:definition>2422412 - Disclosure - Fair Value Measurements - Balance Sheet Grouping (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails">
        <link:definition>2423413 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.molinahealthcare.com/role/Investments">
        <link:definition>2124106 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.molinahealthcare.com/role/InvestmentsTables">
        <link:definition>2325305 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails">
        <link:definition>2426414 - Disclosure - Investments - Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails">
        <link:definition>2427415 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails">
        <link:definition>2428416 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails">
        <link:definition>2429417 - Disclosure - Investments - Available-for-Sale Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayable" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable">
        <link:definition>2130107 - Disclosure - Medical Claims and Benefits Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableTables" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables">
        <link:definition>2331306 - Disclosure - Medical Claims and Benefits Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2432418 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails">
        <link:definition>2433419 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails">
        <link:definition>2434420 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.molinahealthcare.com/role/Debt">
        <link:definition>2135108 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.molinahealthcare.com/role/DebtTables">
        <link:definition>2336307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>2437421 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails">
        <link:definition>2438422 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.molinahealthcare.com/role/StockholdersEquity">
        <link:definition>2139109 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables">
        <link:definition>2340308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2441423 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareActivityDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails">
        <link:definition>2442424 - Disclosure - Stockholders' Equity - Share Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueofAwardsGrantedandVestedDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails">
        <link:definition>2443425 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.molinahealthcare.com/role/Segments">
        <link:definition>2144110 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.molinahealthcare.com/role/SegmentsTables">
        <link:definition>2345309 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails">
        <link:definition>2446426 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
        <link:definition>2447427 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies">
        <link:definition>2148111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MagellanCompleteCareMember" abstract="true" name="MagellanCompleteCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" abstract="false" name="BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_MedicalPremiumLiabilityDueToAgency" abstract="false" name="MedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_IncreaseDecreaseInHealthInsuranceFeeLiability" abstract="false" name="IncreaseDecreaseInHealthInsuranceFeeLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CashConvertibleSeniorNotesDue2020Member" abstract="true" name="CashConvertibleSeniorNotesDue2020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" abstract="true" name="CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" abstract="false" name="AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MeasurementInputExpectedRevenueVolatilityMember" abstract="true" name="MeasurementInputExpectedRevenueVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationPremiumTaxRevenue" abstract="false" name="HealthCareOrganizationPremiumTaxRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherMedicareProgram" abstract="false" name="OtherMedicareProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" abstract="false" name="ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" abstract="false" name="MedicalPremiumsLiabilityMedicalCareCostsThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_DetailsofchangeinfairvalueofderivativesAbstract" abstract="true" name="DetailsofchangeinfairvalueofderivativesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_SwinglineSubFacilityMember" abstract="true" name="SwinglineSubFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_IncrementalTermLoanMember" abstract="true" name="IncrementalTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeRevenue" abstract="false" name="HealthCareOrganizationInsurerFeeRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" abstract="false" name="AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MeasurementInputExpectedAssetVolatilityMember" abstract="true" name="MeasurementInputExpectedAssetVolatilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_A4.875SeniorNotesMember" abstract="true" name="A4.875SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_DetailsOfBusinessCombinationsAbstract" abstract="true" name="DetailsOfBusinessCombinationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_CurrentLiabilitiesMember" abstract="true" name="CurrentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" abstract="false" name="QualityIncentivePremiumRevenueRecognizedTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_GovernmentReceivablesMember" abstract="true" name="GovernmentReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" abstract="false" name="FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfBusinessCombinations" abstract="false" name="BusinessCombinationNumberOfBusinessCombinations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_HealthPlanContractTerm" abstract="false" name="HealthPlanContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_InvestmentsAverageMaturityPeriod" abstract="false" name="InvestmentsAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_MaximumAvailableQualityIncentivePremiumCurrentYear" abstract="false" name="MaximumAvailableQualityIncentivePremiumCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesOther" abstract="false" name="AmountsDuetoGovernmentAgenciesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CurrentAssetsMember" abstract="true" name="CurrentAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" abstract="false" name="LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" abstract="false" name="AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayable" abstract="false" name="MedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_CapitationClaimsPayable" abstract="false" name="CapitationClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" abstract="false" name="LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableTextBlock" abstract="false" name="MedicalClaimsAndBenefitsPayableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_InvestmentsMaturityPeriod" abstract="false" name="InvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_SeniorNotesDue2022Member" abstract="true" name="SeniorNotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicareProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidOther" abstract="false" name="AmountsDueToGovernmentAgenciesMedicaidOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PharmacyRebateReceivablesMember" abstract="true" name="PharmacyRebateReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_HealthPlansMember" abstract="true" name="HealthPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_QualityIncentivePremiumRevenueRecognizedAbstract" abstract="true" name="QualityIncentivePremiumRevenueRecognizedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeExpense" abstract="false" name="HealthCareOrganizationInsurerFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" abstract="false" name="IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CashConvertibleSeniorNotesDue2020WarrantsMember" abstract="true" name="CashConvertibleSeniorNotesDue2020WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_QualityIncentivePremiumRevenueRecognized" abstract="false" name="QualityIncentivePremiumRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PercentageOfAdditionalIncrementalRevenueEarned" abstract="false" name="PercentageOfAdditionalIncrementalRevenueEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="moh_ProviderNetworkMember" abstract="true" name="ProviderNetworkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_UnrecognizedCompensationForfeitedRate" abstract="false" name="UnrecognizedCompensationForfeitedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="moh_MaineCommunityHealthOptionsv.UnitedStatesMember" abstract="true" name="MaineCommunityHealthOptionsv.UnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_LetterOfCreditSubFacilityMember" abstract="true" name="LetterOfCreditSubFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_YourCareHealthPlanIncMember" abstract="true" name="YourCareHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ConsolidatedNetLeverage" abstract="false" name="ConsolidatedNetLeverage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" abstract="false" name="AmountsDuetoGovernmentAgenciesRiskAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PassportHealthPlanIncMember" abstract="true" name="PassportHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" abstract="false" name="ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="moh_OtherClaimsPayable" abstract="false" name="OtherClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PremiumTaxExpenses" abstract="false" name="PremiumTaxExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" abstract="true" name="ScheduleOfPremiumRevenueByHealthPlanTypeTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moh_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_OtherSecuritiesMember" abstract="true" name="OtherSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_CashPaidForSettlementOfConversionOption" abstract="false" name="CashPaidForSettlementOfConversionOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_PharmacyClaimsPayable" abstract="false" name="PharmacyClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_WeightedAverageNumberofSharesShareBasedCompensation" abstract="false" name="WeightedAverageNumberofSharesShareBasedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_A4375SeniorNotesMember" abstract="true" name="A4375SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_HealthCareInsuranceFeeLiability" abstract="false" name="HealthCareInsuranceFeeLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthInsurerFeeReimbursementReceivablesMember" abstract="true" name="HealthInsurerFeeReimbursementReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_CallOptionDerivativeAssetMember" abstract="true" name="CallOptionDerivativeAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_MunicipalSecuritiesMember" abstract="true" name="MunicipalSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_ClassOfWarrantOrRightStatedInterestRate" abstract="false" name="ClassOfWarrantOrRightStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="moh_AffinityHealthPlanMember" abstract="true" name="AffinityHealthPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_TradeNameMember" abstract="true" name="TradeNameMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_MeasurementInputMeasurementPeriodMember" abstract="true" name="MeasurementInputMeasurementPeriodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" abstract="false" name="QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" abstract="false" name="MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ComponentsOfMedicalCareCostsAbstract" abstract="true" name="ComponentsOfMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>moh-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_07b0478f-3c8d-4b61-a134-a631e2f28d39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e1ec6cbb-bf91-48b5-823d-0b51a78290d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_07b0478f-3c8d-4b61-a134-a631e2f28d39" xlink:to="loc_us-gaap_Revenues_e1ec6cbb-bf91-48b5-823d-0b51a78290d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cfa0e131-2f59-487d-96f6-d4159abcef7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_07b0478f-3c8d-4b61-a134-a631e2f28d39" xlink:to="loc_us-gaap_CostsAndExpenses_cfa0e131-2f59-487d-96f6-d4159abcef7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_05f284cb-7d4b-487f-b836-026f009cca36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a191832b-eb08-4e70-84fb-5e8e1ed69183" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_05f284cb-7d4b-487f-b836-026f009cca36" xlink:to="loc_us-gaap_OperatingIncomeLoss_a191832b-eb08-4e70-84fb-5e8e1ed69183" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_c7456321-ca6e-4370-afb5-47676c003ad9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_05f284cb-7d4b-487f-b836-026f009cca36" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_c7456321-ca6e-4370-afb5-47676c003ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6f54d92e-d9bf-434c-a2f3-e9f941d49e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_659fc226-1834-4bae-84f2-e54c8f4e7649" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f54d92e-d9bf-434c-a2f3-e9f941d49e9b" xlink:to="loc_us-gaap_InterestExpense_659fc226-1834-4bae-84f2-e54c8f4e7649" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7dd37bee-a897-4da3-8533-41c5d8ba552c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_6f54d92e-d9bf-434c-a2f3-e9f941d49e9b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7dd37bee-a897-4da3-8533-41c5d8ba552c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d355047a-46ff-48ff-b017-721a229608a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_948f85fc-b2c4-4c1b-aef7-2907c4631f8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d355047a-46ff-48ff-b017-721a229608a3" xlink:to="loc_us-gaap_PremiumsEarnedNet_948f85fc-b2c4-4c1b-aef7-2907c4631f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_9bcac790-92f9-4c90-8fa6-c4df19228805" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d355047a-46ff-48ff-b017-721a229608a3" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_9bcac790-92f9-4c90-8fa6-c4df19228805" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_848fc9cf-cba0-4ac6-9e99-99507ea1d14c" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d355047a-46ff-48ff-b017-721a229608a3" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_848fc9cf-cba0-4ac6-9e99-99507ea1d14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_704bfaad-c7ac-42b8-adda-ec387b57a61e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d355047a-46ff-48ff-b017-721a229608a3" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_704bfaad-c7ac-42b8-adda-ec387b57a61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_d3f9ac1c-7d05-4392-aac6-0a3126479ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_d3f9ac1c-7d05-4392-aac6-0a3126479ed3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_41ebbbb6-ac94-4ff2-a179-67fb52406a8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_41ebbbb6-ac94-4ff2-a179-67fb52406a8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_f62f7a09-7559-4a36-991d-5f881d392e73" xlink:href="moh-20200930.xsd#moh_PremiumTaxExpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_moh_PremiumTaxExpenses_f62f7a09-7559-4a36-991d-5f881d392e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_9caaae0e-81f4-44d5-9722-fbc803a6f045" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_9caaae0e-81f4-44d5-9722-fbc803a6f045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_3a9a4a75-c9de-44cd-bca0-13a046f63bb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_us-gaap_DepreciationAndAmortization_3a9a4a75-c9de-44cd-bca0-13a046f63bb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_3e728b18-d0ee-412f-b4b7-1c21029bb19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_84633fb3-a41a-4834-b18d-65d263407bb4" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_3e728b18-d0ee-412f-b4b7-1c21029bb19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a5b4cfa7-c259-4529-bbf8-e488bb16d1e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5fcf0b51-7e54-4c00-a4f4-8b42a6b1b15a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a5b4cfa7-c259-4529-bbf8-e488bb16d1e7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_5fcf0b51-7e54-4c00-a4f4-8b42a6b1b15a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6ec69ec9-36c0-43ab-922f-724f30ba3969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_a5b4cfa7-c259-4529-bbf8-e488bb16d1e7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6ec69ec9-36c0-43ab-922f-724f30ba3969" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1bcf06f3-ad2c-4a26-bd41-ada130c481be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9468e62e-6cf2-433c-94a9-6aec3abf8fea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1bcf06f3-ad2c-4a26-bd41-ada130c481be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_9468e62e-6cf2-433c-94a9-6aec3abf8fea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_263dbe32-0723-40d3-8beb-1c1c1c71d3eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1bcf06f3-ad2c-4a26-bd41-ada130c481be" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_263dbe32-0723-40d3-8beb-1c1c1c71d3eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c911b409-3d29-4e6e-8bfa-8cd027975811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a7696a13-7f47-47c9-88ec-b69e66d0c9a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c911b409-3d29-4e6e-8bfa-8cd027975811" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a7696a13-7f47-47c9-88ec-b69e66d0c9a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b4c8326a-7d3c-4180-8d11-e40d6f0140d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_c911b409-3d29-4e6e-8bfa-8cd027975811" xlink:to="loc_us-gaap_NetIncomeLoss_b4c8326a-7d3c-4180-8d11-e40d6f0140d7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_f9a81ca9-2093-4c5c-91df-517c6fd08553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:to="loc_us-gaap_CommonStockValueOutstanding_f9a81ca9-2093-4c5c-91df-517c6fd08553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_9eb9b7c4-0972-482c-b105-e02702089851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:to="loc_us-gaap_PreferredStockValue_9eb9b7c4-0972-482c-b105-e02702089851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6e83cca-c032-4881-a074-b487e7051233" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c6e83cca-c032-4881-a074-b487e7051233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d7c17d3-30ee-420a-8034-dfeac61014dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7d7c17d3-30ee-420a-8034-dfeac61014dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c668a227-18c8-4f55-950d-9be8e3eddf37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_236d8c23-e02d-4522-9c7d-c873bfdd6892" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c668a227-18c8-4f55-950d-9be8e3eddf37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dae7f227-59db-49d2-aaf1-9bf5d68193a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_540fd5ae-a1b3-4617-8c63-f73942246e1f" xlink:href="moh-20200930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dae7f227-59db-49d2-aaf1-9bf5d68193a8" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_540fd5ae-a1b3-4617-8c63-f73942246e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_408bd1c8-4d18-4757-975d-7a2d134e0cad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dae7f227-59db-49d2-aaf1-9bf5d68193a8" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_408bd1c8-4d18-4757-975d-7a2d134e0cad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dcaa178-d597-4aaf-8c9e-3c70b8c40869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dae7f227-59db-49d2-aaf1-9bf5d68193a8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9dcaa178-d597-4aaf-8c9e-3c70b8c40869" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_71473b49-2b72-4d41-aa8c-871d5a3a8363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dae7f227-59db-49d2-aaf1-9bf5d68193a8" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_71473b49-2b72-4d41-aa8c-871d5a3a8363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4187ecb5-e32d-429c-9929-51884ca49b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e4b6c33-7ab9-42e9-abf1-5c7ef76e95cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4187ecb5-e32d-429c-9929-51884ca49b07" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4e4b6c33-7ab9-42e9-abf1-5c7ef76e95cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_1c4710a5-7c69-4186-b90c-b21bf166dd37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4187ecb5-e32d-429c-9929-51884ca49b07" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_1c4710a5-7c69-4186-b90c-b21bf166dd37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_ace5538f-9cc7-4ad0-9a7a-3b3730922fc4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4187ecb5-e32d-429c-9929-51884ca49b07" xlink:to="loc_us-gaap_ReceivablesNetCurrent_ace5538f-9cc7-4ad0-9a7a-3b3730922fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e52b6924-697b-44db-b4ec-9850df24f8b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_4187ecb5-e32d-429c-9929-51884ca49b07" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e52b6924-697b-44db-b4ec-9850df24f8b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad1d8184-3c75-47b2-b7cc-aa988230fb6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8b4e34e9-6821-4abd-8fe9-efc4ec1c6d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad1d8184-3c75-47b2-b7cc-aa988230fb6b" xlink:to="loc_us-gaap_Liabilities_8b4e34e9-6821-4abd-8fe9-efc4ec1c6d79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a04312ff-a1e5-41bc-8955-3f3e996e1701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_ad1d8184-3c75-47b2-b7cc-aa988230fb6b" xlink:to="loc_us-gaap_StockholdersEquity_a04312ff-a1e5-41bc-8955-3f3e996e1701" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cc8c5025-77e1-441f-9675-c2b3d69a117d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_AssetsCurrent_cc8c5025-77e1-441f-9675-c2b3d69a117d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3f8cbe95-5372-4454-9aa7-3e3e71fd7c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_3f8cbe95-5372-4454-9aa7-3e3e71fd7c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8d552be3-0296-4a31-92bc-64bf17a0c7a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_8d552be3-0296-4a31-92bc-64bf17a0c7a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_0dd5fad7-d90c-4b15-9086-a632562b3593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_0dd5fad7-d90c-4b15-9086-a632562b3593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e75b0dff-b650-4d3a-8c0c-e713263f7979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e75b0dff-b650-4d3a-8c0c-e713263f7979" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_84a96a55-5788-484d-a2de-34c7d02e3a64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_39226ac0-4430-4cea-abbb-1f45d3fcf837" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_84a96a55-5788-484d-a2de-34c7d02e3a64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af9dbe96-68f1-47a0-b4a6-c7994104a255" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_16bf3571-8557-4f44-9bd3-1d82db83a1ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af9dbe96-68f1-47a0-b4a6-c7994104a255" xlink:to="loc_us-gaap_LiabilitiesCurrent_16bf3571-8557-4f44-9bd3-1d82db83a1ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_9cd1bd6b-ae41-4083-8402-72b501c4bb61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af9dbe96-68f1-47a0-b4a6-c7994104a255" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_9cd1bd6b-ae41-4083-8402-72b501c4bb61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e405f1a5-45e6-4502-9fd5-77b310f8ff48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af9dbe96-68f1-47a0-b4a6-c7994104a255" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_e405f1a5-45e6-4502-9fd5-77b310f8ff48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_2cc58103-2c27-4a22-a505-6ca24d0d35e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_af9dbe96-68f1-47a0-b4a6-c7994104a255" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_2cc58103-2c27-4a22-a505-6ca24d0d35e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2c0bcbb7-2bcb-424d-93fb-b499c586c2e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d4514143-3967-4996-9aaa-db81217d8b86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2c0bcbb7-2bcb-424d-93fb-b499c586c2e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d4514143-3967-4996-9aaa-db81217d8b86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a7380e8-0a8b-4872-b9bf-6553d936865d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2c0bcbb7-2bcb-424d-93fb-b499c586c2e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7a7380e8-0a8b-4872-b9bf-6553d936865d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35cbafc7-789b-48b0-8ee2-e5d7530d5d9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2c0bcbb7-2bcb-424d-93fb-b499c586c2e5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_35cbafc7-789b-48b0-8ee2-e5d7530d5d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_61f7bb7f-3d7e-4462-b9ed-bbd8cf6c0571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_61f7bb7f-3d7e-4462-b9ed-bbd8cf6c0571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_28907c7b-5b52-4c22-8383-e202fa384154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_28907c7b-5b52-4c22-8383-e202fa384154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7a35d7ec-33ad-4267-aeae-039b17f0b8df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7a35d7ec-33ad-4267-aeae-039b17f0b8df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93ee0538-a032-4f3f-b5c6-16ea9c7cea5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_93ee0538-a032-4f3f-b5c6-16ea9c7cea5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6efaebf9-9434-4ebd-8efe-b8577c985c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eabdaa3-4990-4c13-86c4-197f5aeb0298" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6efaebf9-9434-4ebd-8efe-b8577c985c7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4b3a0c24-68d2-4642-b699-cb5a1479f506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4b3a0c24-68d2-4642-b699-cb5a1479f506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6afc5b2d-41ba-4127-be90-7f72feba3114" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_6afc5b2d-41ba-4127-be90-7f72feba3114" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7fc77915-db8e-4220-a9f9-8fa8a4569974" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_ShareBasedCompensation_7fc77915-db8e-4220-a9f9-8fa8a4569974" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_21e10517-cb7f-48f3-8193-103fb62115bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_21e10517-cb7f-48f3-8193-103fb62115bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_26e63313-c20c-4de6-babf-d39029deb170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_26e63313-c20c-4de6-babf-d39029deb170" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_f989e1de-e740-4ec5-98f6-bd6383f8e87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_f989e1de-e740-4ec5-98f6-bd6383f8e87b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aff9c39b-5ce2-4639-aaae-fbcb7ee19c31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aff9c39b-5ce2-4639-aaae-fbcb7ee19c31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_33a037b8-9e55-4cea-83c9-3389fdd880fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_33a037b8-9e55-4cea-83c9-3389fdd880fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_9fa819bf-6786-44af-8dc9-c91a66a893e0" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_9fa819bf-6786-44af-8dc9-c91a66a893e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70be9602-2e5c-4525-982b-0f281123a82b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_70be9602-2e5c-4525-982b-0f281123a82b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_87e3a944-4b20-4481-b965-617513363481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_87e3a944-4b20-4481-b965-617513363481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2be83848-3c4b-4a10-b979-3529b1454729" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_2be83848-3c4b-4a10-b979-3529b1454729" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f39e2d6b-b110-4bbd-9c83-c2a1bfa73a2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_90b1504d-1bbe-4dd4-be9a-201a86355ce0" xlink:to="loc_us-gaap_NetIncomeLoss_f39e2d6b-b110-4bbd-9c83-c2a1bfa73a2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_498ca02f-efd0-4eee-9e57-795d2903646b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_498ca02f-efd0-4eee-9e57-795d2903646b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_c8a2b3ae-b030-434b-a55a-a6f382329250" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_c8a2b3ae-b030-434b-a55a-a6f382329250" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_124033ab-8d7b-4429-8af7-137299d98c8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_124033ab-8d7b-4429-8af7-137299d98c8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a8a7ac56-dd7c-4758-8f9a-59ac25dcb943" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a8a7ac56-dd7c-4758-8f9a-59ac25dcb943" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_28bb7498-21f4-4485-b064-d942bebf730d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_28bb7498-21f4-4485-b064-d942bebf730d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e44d5621-83f7-46d2-bc35-d8f6c0fed8fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_e44d5621-83f7-46d2-bc35-d8f6c0fed8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_8270909b-fd1b-4693-8c62-ec57da6d473d" xlink:href="moh-20200930.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_8270909b-fd1b-4693-8c62-ec57da6d473d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2abf436c-5954-4c37-affe-95dadc54df1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_2abf436c-5954-4c37-affe-95dadc54df1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_7a94aea1-2300-4d8b-a4ce-bcd091c879d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_aa33e6cc-9f8a-4cb9-9380-36b60642fc52" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_7a94aea1-2300-4d8b-a4ce-bcd091c879d4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59531d4c-5079-43ef-a0fb-415a9ca56998" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a1ed8ed-0882-4e13-baa4-1e05578cadce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59531d4c-5079-43ef-a0fb-415a9ca56998" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4a1ed8ed-0882-4e13-baa4-1e05578cadce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e154a460-13b2-4843-98de-6ee6e8f7af90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_59531d4c-5079-43ef-a0fb-415a9ca56998" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e154a460-13b2-4843-98de-6ee6e8f7af90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:href="moh-20200930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_fd8d262a-7af8-4bdf-9dd1-be443829b753" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_fd8d262a-7af8-4bdf-9dd1-be443829b753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_5afa2f14-4de3-4989-a4ca-a779ca076932" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_5afa2f14-4de3-4989-a4ca-a779ca076932" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_10ed8eb2-026d-4e38-8f39-c2f872d337d1" xlink:href="moh-20200930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_10ed8eb2-026d-4e38-8f39-c2f872d337d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_93b5507e-47ee-4676-8274-73db04cf981a" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_93b5507e-47ee-4676-8274-73db04cf981a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_31a40315-c6e9-4944-b227-26f92e2c23f2" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_31a40315-c6e9-4944-b227-26f92e2c23f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_c473e03a-aa0f-4f2f-b321-197e6a06a604" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_c473e03a-aa0f-4f2f-b321-197e6a06a604" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_cb3cb27a-6734-4815-99f8-2287d6beee9d" xlink:href="moh-20200930.xsd#moh_OtherMedicareProgram"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_OtherMedicareProgram_cb3cb27a-6734-4815-99f8-2287d6beee9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_1c8292f2-dce0-44ef-a56b-3a8b72a75ba6" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_70686281-020a-4267-9e00-f5151f88b376" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_1c8292f2-dce0-44ef-a56b-3a8b72a75ba6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognized_4a955cf7-42cb-49db-b146-ac16bc3b0a94" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_6122166d-af65-4822-9fb6-78587539a92a" xlink:href="moh-20200930.xsd#moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognized_4a955cf7-42cb-49db-b146-ac16bc3b0a94" xlink:to="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_6122166d-af65-4822-9fb6-78587539a92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_2fe38b86-4b3e-4e8c-9ad0-6ab0b5d459c5" xlink:href="moh-20200930.xsd#moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognized_4a955cf7-42cb-49db-b146-ac16bc3b0a94" xlink:to="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_2fe38b86-4b3e-4e8c-9ad0-6ab0b5d459c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShare"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e04c625-3238-425c-8195-465f5450bdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bb74df1-a8c5-447c-812c-8c5e95950151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e04c625-3238-425c-8195-465f5450bdb8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4bb74df1-a8c5-447c-812c-8c5e95950151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9dd856d4-8fde-4bcc-8041-2b3024f46eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e04c625-3238-425c-8195-465f5450bdb8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_9dd856d4-8fde-4bcc-8041-2b3024f46eaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_93228220-7fe7-4e7e-a336-b4530e921e06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8e04c625-3238-425c-8195-465f5450bdb8" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_93228220-7fe7-4e7e-a336-b4530e921e06" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinations"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurements"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_984a38f0-4052-4bda-8de1-94de4f2431b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aeedaccd-a246-4bb4-80f4-c063b7eeee3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_984a38f0-4052-4bda-8de1-94de4f2431b5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_aeedaccd-a246-4bb4-80f4-c063b7eeee3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_bb2b67ad-6ef9-4473-b544-97880325f1f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_984a38f0-4052-4bda-8de1-94de4f2431b5" xlink:to="loc_us-gaap_DerivativeLiabilities_bb2b67ad-6ef9-4473-b544-97880325f1f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_bfb9c55f-7652-4f20-b6ca-f035cfeee074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b1b2097-5795-4338-b4b2-7d7f18d1a9e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bfb9c55f-7652-4f20-b6ca-f035cfeee074" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2b1b2097-5795-4338-b4b2-7d7f18d1a9e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_66bc6251-90ef-4290-9d5c-b71f615b455d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_bfb9c55f-7652-4f20-b6ca-f035cfeee074" xlink:to="loc_us-gaap_DerivativeAssets_66bc6251-90ef-4290-9d5c-b71f615b455d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsBalanceSheetGroupingDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20200930.xsd#Investments"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ffb90c32-462f-4098-8ba6-6661e49a859b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c38812ed-9e35-4cf2-afaf-1c7015fa07a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ffb90c32-462f-4098-8ba6-6661e49a859b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c38812ed-9e35-4cf2-afaf-1c7015fa07a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_43388846-ba65-4f3f-be7c-27aadde4760f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ffb90c32-462f-4098-8ba6-6661e49a859b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_43388846-ba65-4f3f-be7c-27aadde4760f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8afcb0b-aeec-4278-bf43-0bf09ad257ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ffb90c32-462f-4098-8ba6-6661e49a859b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b8afcb0b-aeec-4278-bf43-0bf09ad257ae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40a029b2-5402-4c85-8a33-27d0884019fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5461e64b-7724-4fa4-9f5f-316234e51747" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40a029b2-5402-4c85-8a33-27d0884019fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_5461e64b-7724-4fa4-9f5f-316234e51747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_40d2466d-dff7-4f64-b224-b13750df7303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40a029b2-5402-4c85-8a33-27d0884019fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_40d2466d-dff7-4f64-b224-b13750df7303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_598e036f-6b06-4a1e-aa7f-d82b789ea847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40a029b2-5402-4c85-8a33-27d0884019fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_598e036f-6b06-4a1e-aa7f-d82b789ea847" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_5911eb00-f805-49b1-aa81-c7dcba5c70b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_40a029b2-5402-4c85-8a33-27d0884019fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_5911eb00-f805-49b1-aa81-c7dcba5c70b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b00da05f-0dfd-4b53-bead-84d5aed8d551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ac782837-78fb-4c92-93b7-ae44fdd03baa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b00da05f-0dfd-4b53-bead-84d5aed8d551" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ac782837-78fb-4c92-93b7-ae44fdd03baa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_baaf604d-de13-4813-993c-eedaf131c2a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b00da05f-0dfd-4b53-bead-84d5aed8d551" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_baaf604d-de13-4813-993c-eedaf131c2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_db470a64-9a02-4475-81b7-5e7b0dcc8db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b00da05f-0dfd-4b53-bead-84d5aed8d551" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_db470a64-9a02-4475-81b7-5e7b0dcc8db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_45102d43-63dd-4b7d-848e-a6c89daf1d2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_b00da05f-0dfd-4b53-bead-84d5aed8d551" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_45102d43-63dd-4b7d-848e-a6c89daf1d2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36da9e62-4ae9-402b-961f-51961c5f7149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_a974b8df-8b76-4fd4-9774-ac3f0406d31c" xlink:href="moh-20200930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36da9e62-4ae9-402b-961f-51961c5f7149" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_a974b8df-8b76-4fd4-9774-ac3f0406d31c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_b589bb3d-cb5c-4328-beaf-e5704ea94536" xlink:href="moh-20200930.xsd#moh_PharmacyClaimsPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36da9e62-4ae9-402b-961f-51961c5f7149" xlink:to="loc_moh_PharmacyClaimsPayable_b589bb3d-cb5c-4328-beaf-e5704ea94536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_4365fc12-3648-44c0-8d41-8c771336d1d8" xlink:href="moh-20200930.xsd#moh_CapitationClaimsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36da9e62-4ae9-402b-961f-51961c5f7149" xlink:to="loc_moh_CapitationClaimsPayable_4365fc12-3648-44c0-8d41-8c771336d1d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_b6cdd559-99cc-4947-b7dd-2c5e254ee437" xlink:href="moh-20200930.xsd#moh_OtherClaimsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36da9e62-4ae9-402b-961f-51961c5f7149" xlink:to="loc_moh_OtherClaimsPayable_b6cdd559-99cc-4947-b7dd-2c5e254ee437" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_62cb3fdb-1051-46aa-81cf-81a846ed404d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_fe5d0bfa-15d5-4eae-8a52-60e7b1b0a978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_62cb3fdb-1051-46aa-81cf-81a846ed404d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_fe5d0bfa-15d5-4eae-8a52-60e7b1b0a978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0f42abdc-3bfe-4566-98e4-76fb86053dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_62cb3fdb-1051-46aa-81cf-81a846ed404d" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0f42abdc-3bfe-4566-98e4-76fb86053dc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f7caf6d7-46c6-4d54-ba13-617a89b40bde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_fc817cf2-3294-4979-b5fe-3cb93ab5db5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f7caf6d7-46c6-4d54-ba13-617a89b40bde" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_fc817cf2-3294-4979-b5fe-3cb93ab5db5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8760ce39-db87-40bf-81fc-85da2272758a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f7caf6d7-46c6-4d54-ba13-617a89b40bde" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_8760ce39-db87-40bf-81fc-85da2272758a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20200930.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_63250321-88ea-43c2-bf56-04dba8cdf1b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_0880e0ca-d74f-4243-b174-0d493882c84b" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_63250321-88ea-43c2-bf56-04dba8cdf1b0" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_0880e0ca-d74f-4243-b174-0d493882c84b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4f90fa8b-c844-4aeb-999b-f6b9fe3d87ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_16cf0573-79ee-41c8-ab9a-9f318e4941bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_4f90fa8b-c844-4aeb-999b-f6b9fe3d87ef" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_16cf0573-79ee-41c8-ab9a-9f318e4941bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_370f4fa1-9dc2-4d57-8c60-fe39494f9e8e" xlink:href="moh-20200930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_4f90fa8b-c844-4aeb-999b-f6b9fe3d87ef" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_370f4fa1-9dc2-4d57-8c60-fe39494f9e8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityShareActivityDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityFairValueofAwardsGrantedandVestedDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20200930.xsd#Segments"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsTables"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_36ac547b-b0fa-417d-8ac9-794555eff64f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_e51c6ea2-5e37-40ec-bc89-2351a0088792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_36ac547b-b0fa-417d-8ac9-794555eff64f" xlink:to="loc_us-gaap_GrossProfit_e51c6ea2-5e37-40ec-bc89-2351a0088792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_95570325-4592-4c44-8785-1352edf19bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_36ac547b-b0fa-417d-8ac9-794555eff64f" xlink:to="loc_us-gaap_Revenues_95570325-4592-4c44-8785-1352edf19bdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_0302e226-28e0-4d90-afa0-3e0eeb657bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_36ac547b-b0fa-417d-8ac9-794555eff64f" xlink:to="loc_us-gaap_CostsAndExpenses_0302e226-28e0-4d90-afa0-3e0eeb657bae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>moh-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended" id="if8a7f95d3dad4f62859b04af5d093887_CoverPage"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended" id="if36608a0ab924adc88fecb6f8956fa84_CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended" id="icbf029eb74c144ecb4fe6416272c9ea1_CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i73399100adae4535bf413304fd0af5d3_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="i867570804974483c921d60c829b02975_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i94a7421a2ca44f209ea8e6289826bd2c_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03f51467-c9cd-4b84-8376-09287f296479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_SharesOutstanding_03f51467-c9cd-4b84-8376-09287f296479" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cf968a3-6ad2-408c-87b6-d4f1b2eb3b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cf968a3-6ad2-408c-87b6-d4f1b2eb3b6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1c89b469-4196-4b9e-976a-cdf4fc56df37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_NetIncomeLoss_1c89b469-4196-4b9e-976a-cdf4fc56df37" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_72e00ac6-f19b-42dd-8f7e-379e9721e016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_72e00ac6-f19b-42dd-8f7e-379e9721e016" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_8ea0cd87-fcd1-48b4-986e-1f2e7745572c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_8ea0cd87-fcd1-48b4-986e-1f2e7745572c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_dec2badd-7aae-475e-bee5-8404546acb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_dec2badd-7aae-475e-bee5-8404546acb0c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef9277db-1eed-4e1e-a997-680eb23c59d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef9277db-1eed-4e1e-a997-680eb23c59d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1cafe077-f4c5-49d9-aa42-9b18e0d0403b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1cafe077-f4c5-49d9-aa42-9b18e0d0403b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cae78c1a-26d6-426f-af87-380debf6af73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cae78c1a-26d6-426f-af87-380debf6af73" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9f05860f-924d-44de-8be6-6bda8a85b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e1ac0a1-42c3-42fd-ba35-18b30f67e11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:to="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_fab6af6e-8981-4cb4-846e-f8305157bdb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:to="loc_us-gaap_EquityComponentDomain_fab6af6e-8981-4cb4-846e-f8305157bdb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:to="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_067a34aa-c01d-4956-956c-a452dadfbfe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_CommonStockMember_067a34aa-c01d-4956-956c-a452dadfbfe7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4b6c109-e4cc-4fec-8666-534884e0b4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4b6c109-e4cc-4fec-8666-534884e0b4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40379ca0-2c82-4687-8eac-0f99f4955229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40379ca0-2c82-4687-8eac-0f99f4955229" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d9d6f27-5352-4e43-8fc4-cebd8857d258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_RetainedEarningsMember_4d9d6f27-5352-4e43-8fc4-cebd8857d258" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5aa2b757-cbdc-4a42-967f-4b740991d0b8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_5aa2b757-cbdc-4a42-967f-4b740991d0b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4cad741b-8de6-42f5-af46-ca8b587e9ded" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4cad741b-8de6-42f5-af46-ca8b587e9ded" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="i30cc4d709e134e7a92a767067a87dbe6_CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:href="moh-20200930.xsd#moh_DetailsofchangeinfairvalueofderivativesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:to="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f1c55a3a-c910-4b62-bd49-018780ef0fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f1c55a3a-c910-4b62-bd49-018780ef0fd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:to="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CallOptionDerivativeAssetMember_342e0ac1-c925-4575-ab72-8a71151a7551" xlink:href="moh-20200930.xsd#moh_CallOptionDerivativeAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:to="loc_moh_CallOptionDerivativeAssetMember_342e0ac1-c925-4575-ab72-8a71151a7551" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f8ac97a6-64c2-4ac8-97cc-e706a552d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f8ac97a6-64c2-4ac8-97cc-e706a552d376" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended" id="i82551ea5df474943afba821414e65cd9_OrganizationandBasisofPresentation"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="i261de674948e4981823ef5aceae9fe5e_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_8b2bfba0-5983-4efd-9007-6a220bc0feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_NumberOfReportableSegments_8b2bfba0-5983-4efd-9007-6a220bc0feb7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ce21d69f-0a57-4a67-9bec-38c090d5223a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ce21d69f-0a57-4a67-9bec-38c090d5223a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_896ad5cc-f782-4592-b1d9-450c11dd821a" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_896ad5cc-f782-4592-b1d9-450c11dd821a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_8f950882-e69e-45c2-95d2-fc443ef5e4ce" xlink:href="moh-20200930.xsd#moh_HealthPlanContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_moh_HealthPlanContractTerm_8f950882-e69e-45c2-95d2-fc443ef5e4ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e55279c-056b-4aeb-b27c-9d6e89603b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e55279c-056b-4aeb-b27c-9d6e89603b07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e9fd3d3b-9224-4bc1-bc23-8788417fef9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:to="loc_srt_RangeMember_e9fd3d3b-9224-4bc1-bc23-8788417fef9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:to="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b723b7df-a1d6-495f-ad6a-1cd0c8f1f095" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:to="loc_srt_MinimumMember_b723b7df-a1d6-495f-ad6a-1cd0c8f1f095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e45de847-ab1d-4fcf-9e75-dc8e99ff4c5b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:to="loc_srt_MaximumMember_e45de847-ab1d-4fcf-9e75-dc8e99ff4c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5d9b7200-b599-4dca-8e0d-e42382764962_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:to="loc_us-gaap_SegmentDomain_5d9b7200-b599-4dca-8e0d-e42382764962_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:to="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_def91492-9fe3-464d-bc58-786ff0cdcade" xlink:href="moh-20200930.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:to="loc_moh_HealthPlansMember_def91492-9fe3-464d-bc58-786ff0cdcade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ed6bffd-616f-44cb-b369-473ce37926a5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4ed6bffd-616f-44cb-b369-473ce37926a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember_7bb40c9c-0928-429f-9558-6d7021c458c0" xlink:href="moh-20200930.xsd#moh_AffinityHealthPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:to="loc_moh_AffinityHealthPlanMember_7bb40c9c-0928-429f-9558-6d7021c458c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_00d6ab4b-3e0b-4912-8627-954dcd38875a" xlink:href="moh-20200930.xsd#moh_MagellanCompleteCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:to="loc_moh_MagellanCompleteCareMember_00d6ab4b-3e0b-4912-8627-954dcd38875a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended" id="i7c9319633f9d4e4a8e9f978f269d15af_SignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended" id="i1395111b28da4d24933cbd86c2f660b4_SignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended" id="i830c7fc51b27412eaa578e205663fe95_SignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended" id="if69a8e3b313c48db9475a8b0be0e6ed3_SignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i79dd0e5f94744d7f9f097ea7638ce032_SignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_643a66d0-389c-463d-a897-07d394a53b50" xlink:href="moh-20200930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_InvestmentsMaturityPeriod_643a66d0-389c-463d-a897-07d394a53b50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_b832061b-68b4-4556-b091-8bbf149db9b9" xlink:href="moh-20200930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_b832061b-68b4-4556-b091-8bbf149db9b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_4bf420c0-e85c-44ba-9981-83fec24a640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_InterestReceivable_4bf420c0-e85c-44ba-9981-83fec24a640d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_43262b32-d0e4-4d29-b3b5-1e65a2fc1888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_43262b32-d0e4-4d29-b3b5-1e65a2fc1888" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6752e185-6d5e-4181-8682-8b08ad02deb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6752e185-6d5e-4181-8682-8b08ad02deb9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_6bcf3701-dc8e-4bd0-b395-14f3726cd3e8" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_6bcf3701-dc8e-4bd0-b395-14f3726cd3e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_be084512-9954-47c6-9ec4-82c32ba4596d" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_be084512-9954-47c6-9ec4-82c32ba4596d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_1e04a19c-0306-4497-8ea8-c81f1aa46381" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_1e04a19c-0306-4497-8ea8-c81f1aa46381" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_da3e4224-74c1-4283-89a5-02716337a049" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_da3e4224-74c1-4283-89a5-02716337a049" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_49c1f7cd-2d5d-4148-904e-e23f56b76c69" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_49c1f7cd-2d5d-4148-904e-e23f56b76c69" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c83b546a-c30b-4ff2-8e90-9c8de3dc9b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c83b546a-c30b-4ff2-8e90-9c8de3dc9b99" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareInsuranceFeeLiability_3d230870-fd45-4012-8668-51d34011401d" xlink:href="moh-20200930.xsd#moh_HealthCareInsuranceFeeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_HealthCareInsuranceFeeLiability_3d230870-fd45-4012-8668-51d34011401d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_b04e982e-240d-43b9-878e-ab10588db270" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInHealthInsuranceFeeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_b04e982e-240d-43b9-878e-ab10588db270" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_dd9605f9-adc8-483a-8add-d72e643d97e4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:to="loc_srt_LitigationCaseTypeDomain_dd9605f9-adc8-483a-8add-d72e643d97e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:to="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_9a226bff-1525-4613-bfae-3b6357e5dccd" xlink:href="moh-20200930.xsd#moh_MaineCommunityHealthOptionsv.UnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:to="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_9a226bff-1525-4613-bfae-3b6357e5dccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a59c7564-8133-4e1f-9909-c4852c35ef6e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:to="loc_srt_ProductsAndServicesDomain_a59c7564-8133-4e1f-9909-c4852c35ef6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:to="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_0709bdc1-6889-40b0-8452-767ae5859322" xlink:href="moh-20200930.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:to="loc_moh_MedicaidMember_0709bdc1-6889-40b0-8452-767ae5859322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c95bd0d-f6a2-4771-aeac-e6f714c42667_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:to="loc_srt_SegmentGeographicalDomain_8c95bd0d-f6a2-4771-aeac-e6f714c42667_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:to="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_02b665f8-9bff-44ae-a004-9fb3886895e0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:to="loc_country_PR_02b665f8-9bff-44ae-a004-9fb3886895e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_c5130b44-8813-4566-ae5e-8ee183f90582_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_c5130b44-8813-4566-ae5e-8ee183f90582_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_c98904fb-84e9-4347-bbeb-489e8f692f15" xlink:href="moh-20200930.xsd#moh_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:to="loc_moh_COVID19Member_c98904fb-84e9-4347-bbeb-489e8f692f15" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended" id="i3338b2bbceb64633925f65a58195e248_SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="extended" id="ia11d417fd5e947bab522e531830709c7_SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_e5a7884e-a1ee-4796-81a8-8378bc5d1363" xlink:href="moh-20200930.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_e5a7884e-a1ee-4796-81a8-8378bc5d1363" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_61b0fdc8-71dd-43db-9dd1-007b3d00788e" xlink:href="moh-20200930.xsd#moh_MaximumAvailableQualityIncentivePremiumCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_61b0fdc8-71dd-43db-9dd1-007b3d00788e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognizedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_5f81a2c6-c408-4155-89c6-fbca8934922d" xlink:href="moh-20200930.xsd#moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_5f81a2c6-c408-4155-89c6-fbca8934922d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_fc9927a8-031b-424a-a96b-8316efb1dd38" xlink:href="moh-20200930.xsd#moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_fc9927a8-031b-424a-a96b-8316efb1dd38" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognized_2ade78d4-c971-48a7-84f9-ba9a20780f07" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_QualityIncentivePremiumRevenueRecognized_2ade78d4-c971-48a7-84f9-ba9a20780f07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_6ecd1838-1905-4847-a219-c010686e4eb9" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_6ecd1838-1905-4847-a219-c010686e4eb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:to="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ab0824e2-2971-4bad-bc20-a2ba3e0f8480_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:to="loc_srt_SegmentGeographicalDomain_ab0824e2-2971-4bad-bc20-a2ba3e0f8480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:to="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_66cd6a8a-bba8-4011-87de-0c84717d0948" xlink:href="moh-20200930.xsd#moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:to="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_66cd6a8a-bba8-4011-87de-0c84717d0948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:to="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5b01423f-0caa-4c1a-bd83-8838d9af762e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:to="loc_srt_RangeMember_5b01423f-0caa-4c1a-bd83-8838d9af762e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:to="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eca1f86-8c00-4e29-bfd1-0242d1fed6b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:to="loc_srt_MinimumMember_7eca1f86-8c00-4e29-bfd1-0242d1fed6b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92abeff7-9d9e-4dcd-8584-c519db602de3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:to="loc_srt_MaximumMember_92abeff7-9d9e-4dcd-8584-c519db602de3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended" id="ie53eba34995e43cc9f21adbca0b33e60_SignificantAccountingPoliciesReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_6b0852cb-cdc3-4e1d-83cb-c9163b00335e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_6b0852cb-cdc3-4e1d-83cb-c9163b00335e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3d34b7e7-04ef-49b7-b424-91d13a11c9e3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:to="loc_us-gaap_ReceivableTypeDomain_3d34b7e7-04ef-49b7-b424-91d13a11c9e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:to="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_b8379771-3428-437b-acd4-74802228e07e" xlink:href="moh-20200930.xsd#moh_GovernmentReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_GovernmentReceivablesMember_b8379771-3428-437b-acd4-74802228e07e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_79302d3d-9144-4917-822a-4c6cf11935ce" xlink:href="moh-20200930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_PharmacyRebateReceivablesMember_79302d3d-9144-4917-822a-4c6cf11935ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_240d2b13-6e54-456d-a5fc-e55c8b5412ba" xlink:href="moh-20200930.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_240d2b13-6e54-456d-a5fc-e55c8b5412ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_6f1e7164-a0f5-497e-b5d3-0a2448d7ebb5" xlink:href="moh-20200930.xsd#moh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_OtherReceivablesMember_6f1e7164-a0f5-497e-b5d3-0a2448d7ebb5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShare"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended" id="id4e026d40cef4162a93af269811382ba_NetIncomeperShare"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended" id="i98610a19cf0f4f5f892bceb7f4e01253_NetIncomeperShareTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended" id="i6369298ed42447bd82e7d6d33f51b6fe_NetIncomeperShareDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinations"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended" id="i11eeb842f02643f1b4c1f5c9e6ee0d4e_BusinessCombinations"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="extended" id="ib4d9e3fdfcc24cec9e54ac03bed298b5_BusinessCombinationsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="ie1920c08063240d7b967c9d4e66adc06_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations_dfc705b0-a6c7-41e3-8054-0abae50770e6" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_moh_BusinessCombinationNumberOfBusinessCombinations_dfc705b0-a6c7-41e3-8054-0abae50770e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_23958cbf-d809-40de-af5a-25e5f821aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_23958cbf-d809-40de-af5a-25e5f821aabd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_fe955a4d-5063-4e5b-bfb4-d84039069a84" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_fe955a4d-5063-4e5b-bfb4-d84039069a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b503df7-36b5-470d-a9c1-a3a2e438236e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_Goodwill_7b503df7-36b5-470d-a9c1-a3a2e438236e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d774dd78-2d52-46ec-8213-88ac5b8543af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d774dd78-2d52-46ec-8213-88ac5b8543af" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0a7232a-644b-413c-a321-ea359f08f225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0a7232a-644b-413c-a321-ea359f08f225" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_YourCareHealthPlanIncMember_db3806f3-fb53-4c83-8fa9-cfed133a006f" xlink:href="moh-20200930.xsd#moh_YourCareHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:to="loc_moh_YourCareHealthPlanIncMember_db3806f3-fb53-4c83-8fa9-cfed133a006f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_a62191be-8d98-4e3f-bf12-0d81c713a968" xlink:href="moh-20200930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:to="loc_moh_PassportHealthPlanIncMember_a62191be-8d98-4e3f-bf12-0d81c713a968" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="extended" id="id0b788d104364c429420470cf4afda8b_BusinessCombinationsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a0cf0ac4-e7d4-43ec-8ac4-f2f382cb963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a0cf0ac4-e7d4-43ec-8ac4-f2f382cb963b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6875b831-8b4c-4b25-9537-cd686cb9aa26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6875b831-8b4c-4b25-9537-cd686cb9aa26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_979544d3-1a01-4a8d-910d-dc6f5226225f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_979544d3-1a01-4a8d-910d-dc6f5226225f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c147476f-ee71-4bbe-b3e5-90a508847510_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c147476f-ee71-4bbe-b3e5-90a508847510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_e5f78594-5754-4dd8-8753-9ff40522e580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_us-gaap_ContractualRightsMember_e5f78594-5754-4dd8-8753-9ff40522e580" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TradeNameMember_59d62c2c-ca9e-4b34-a890-bc4ad70540cb" xlink:href="moh-20200930.xsd#moh_TradeNameMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_moh_TradeNameMember_59d62c2c-ca9e-4b34-a890-bc4ad70540cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember_57f61724-a620-4be7-a28e-5cfd18a1c528" xlink:href="moh-20200930.xsd#moh_ProviderNetworkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_moh_ProviderNetworkMember_57f61724-a620-4be7-a28e-5cfd18a1c528" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:to="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e241311c-4b9a-40b6-9f08-dabc753f0189_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:to="loc_srt_RangeMember_e241311c-4b9a-40b6-9f08-dabc753f0189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:to="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2f2924a-de60-4415-a87b-8d94ede1fa1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:to="loc_srt_MinimumMember_d2f2924a-de60-4415-a87b-8d94ede1fa1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c7321bc-c825-4d8b-8229-8890b45cf7d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:to="loc_srt_MaximumMember_6c7321bc-c825-4d8b-8229-8890b45cf7d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurements"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended" id="i7dfe910b1328494187b7bc022bfb712a_FairValueMeasurements"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended" id="i25a8f56077f1494081959bcffd4950ef_FairValueMeasurementsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i01090b59ca1c46e39a46185b1d534805_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_984cf6ae-0f70-4bfe-83b6-9976d78be1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_984cf6ae-0f70-4bfe-83b6-9976d78be1d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_477f241f-3a5a-4ba7-9aa0-6a8b3e1b2d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_477f241f-3a5a-4ba7-9aa0-6a8b3e1b2d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9f8a543d-d979-4b08-b24f-5fb57c212a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_RepaymentsOfDebt_9f8a543d-d979-4b08-b24f-5fb57c212a0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_941cfd00-d811-4b16-b721-1b9b6e2d8acc" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_941cfd00-d811-4b16-b721-1b9b6e2d8acc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_09025bc1-cb5f-4075-9f73-25d52a6ae55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_09025bc1-cb5f-4075-9f73-25d52a6ae55c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23c3b312-293d-4ae6-9bf6-115b5564f121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23c3b312-293d-4ae6-9bf6-115b5564f121" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b2ec51ae-7ada-4502-8557-6281a342c64a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b2ec51ae-7ada-4502-8557-6281a342c64a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_ab2fc509-813b-4de8-9495-652832814c06" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_ab2fc509-813b-4de8-9495-652832814c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_55e9648f-6137-4727-865a-f131e1591ecd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_55e9648f-6137-4727-865a-f131e1591ecd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1f7beb08-401d-40ad-bb26-cc60aafb8432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:to="loc_us-gaap_ConvertibleDebtMember_1f7beb08-401d-40ad-bb26-cc60aafb8432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26deb99a-c3f8-46ff-9a7f-4c9934475838_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26deb99a-c3f8-46ff-9a7f-4c9934475838_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_5df3f6a9-cdb5-40e9-a245-241c3c8d0854" xlink:href="moh-20200930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:to="loc_moh_PassportHealthPlanIncMember_5df3f6a9-cdb5-40e9-a245-241c3c8d0854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fd2ddad-3025-4139-bb9d-2e632c2855ab_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0fd2ddad-3025-4139-bb9d-2e632c2855ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0a2784ea-9f94-4104-b24d-97b4bef2df1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0a2784ea-9f94-4104-b24d-97b4bef2df1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_673b8996-e2a0-423d-b8c7-ee8e1889475c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:to="loc_srt_RangeMember_673b8996-e2a0-423d-b8c7-ee8e1889475c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:to="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da01071b-6856-4c8f-b754-708a8fa078bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:to="loc_srt_MinimumMember_da01071b-6856-4c8f-b754-708a8fa078bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99d31d89-e757-4ce9-b296-a0d550bb8477" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:to="loc_srt_MaximumMember_99d31d89-e757-4ce9-b296-a0d550bb8477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_62887572-29f6-4661-bc8b-e6958c471491_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_62887572-29f6-4661-bc8b-e6958c471491_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedAssetVolatilityMember_cfcb7b37-7c8e-47c3-86bf-27bfb7307f6f" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedAssetVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputExpectedAssetVolatilityMember_cfcb7b37-7c8e-47c3-86bf-27bfb7307f6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputMeasurementPeriodMember_0f767aac-4f83-4655-b7d7-f2061ec69e1e" xlink:href="moh-20200930.xsd#moh_MeasurementInputMeasurementPeriodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputMeasurementPeriodMember_0f767aac-4f83-4655-b7d7-f2061ec69e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedRevenueVolatilityMember_f42b82e1-6cb7-41db-b545-e606ad3c8321" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputExpectedRevenueVolatilityMember_f42b82e1-6cb7-41db-b545-e606ad3c8321" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="extended" id="i42690f16ad8e4a7c8692012d35150839_FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1a9e23a-8b9a-4adb-8fd9-0406cd467155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1a9e23a-8b9a-4adb-8fd9-0406cd467155" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_35e26913-2f0f-493d-b43f-ce767e93d5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_DerivativeAssets_35e26913-2f0f-493d-b43f-ce767e93d5fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5c7f9b7c-7bdb-445e-997f-5b001a912ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5c7f9b7c-7bdb-445e-997f-5b001a912ca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9e19eb8-e5b5-4064-b1e3-d47a93949de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9e19eb8-e5b5-4064-b1e3-d47a93949de1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6588f67a-f0e3-41ce-afac-5f1937f7b0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_DerivativeLiabilities_6588f67a-f0e3-41ce-afac-5f1937f7b0b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b269092-d1b5-4547-8ac2-42d6bf16b101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b269092-d1b5-4547-8ac2-42d6bf16b101" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a6b650ae-ee95-4f58-b3dc-7caf22b57af7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a6b650ae-ee95-4f58-b3dc-7caf22b57af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8adfeccb-571e-4dc7-ae4a-8d95496215a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8adfeccb-571e-4dc7-ae4a-8d95496215a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a65e845-4333-4e6c-9c55-3e91c01e10fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a65e845-4333-4e6c-9c55-3e91c01e10fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8743b8c4-4b33-4c70-b785-79aa6f1ea1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8743b8c4-4b33-4c70-b785-79aa6f1ea1c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60fc94d6-f29e-46fd-bbe0-2e2c685717da_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_60fc94d6-f29e-46fd-bbe0-2e2c685717da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3f1c78a8-7c0c-44e5-b9a5-800c0606c134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3f1c78a8-7c0c-44e5-b9a5-800c0606c134" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c78e02c4-1c2c-4bf2-a38a-7ae2296920c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c78e02c4-1c2c-4bf2-a38a-7ae2296920c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_d7b195ce-a2ba-4e9b-b40e-b65b2ae6d129" xlink:href="moh-20200930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_moh_MunicipalSecuritiesMember_d7b195ce-a2ba-4e9b-b40e-b65b2ae6d129" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ea6e38b6-0202-43b5-85a2-d6ae11686e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ea6e38b6-0202-43b5-85a2-d6ae11686e75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4e207482-b46c-4b41-889b-786bf47e1304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4e207482-b46c-4b41-889b-786bf47e1304" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_8174b762-8cb3-45f0-a717-56afe9861d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_8174b762-8cb3-45f0-a717-56afe9861d13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c713e2a5-bfa7-4535-898e-756c25f69709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c713e2a5-bfa7-4535-898e-756c25f69709" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_295b1768-15ef-44c4-9c95-4c241b0480b6" xlink:href="moh-20200930.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_moh_OtherSecuritiesMember_295b1768-15ef-44c4-9c95-4c241b0480b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_cc5bf892-6b98-4442-9ab9-14956b52e36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_cc5bf892-6b98-4442-9ab9-14956b52e36a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_37f58dfd-d225-4dde-892f-786c962915ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_37f58dfd-d225-4dde-892f-786c962915ad" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsBalanceSheetGroupingDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="extended" id="i2c5f06de1d7b47e7bc6b993c961cc402_FairValueMeasurementsBalanceSheetGroupingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3846d57a-c33f-4789-a4cb-6369912e3f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3846d57a-c33f-4789-a4cb-6369912e3f5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47dbb889-7410-47e9-9a92-e60c81af77f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47dbb889-7410-47e9-9a92-e60c81af77f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_35fed5a7-cbcc-4cc2-aa35-502a0a81384d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_35fed5a7-cbcc-4cc2-aa35-502a0a81384d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentAssetsMember_cd9b7dc9-03bb-4059-9b19-f2dac3f145fa" xlink:href="moh-20200930.xsd#moh_CurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:to="loc_moh_CurrentAssetsMember_cd9b7dc9-03bb-4059-9b19-f2dac3f145fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentLiabilitiesMember_296719d5-a09c-4b9a-b8ea-8fe02074deae" xlink:href="moh-20200930.xsd#moh_CurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:to="loc_moh_CurrentLiabilitiesMember_296719d5-a09c-4b9a-b8ea-8fe02074deae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fb94e545-88e7-47b2-a516-11ffd79e6189_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fb94e545-88e7-47b2-a516-11ffd79e6189_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CallOptionDerivativeAssetMember_ae485f40-d1a1-4570-b278-4945ccc34d3a" xlink:href="moh-20200930.xsd#moh_CallOptionDerivativeAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:to="loc_moh_CallOptionDerivativeAssetMember_ae485f40-d1a1-4570-b278-4945ccc34d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_6823a5db-26c9-4093-a5dc-5f3b760f0e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_6823a5db-26c9-4093-a5dc-5f3b760f0e28" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended" id="i37ed241ec4f8499f89420b17677c8993_FairValueMeasurementsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_af660e4f-ca43-4a3e-bf23-d0f82c6333a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_af660e4f-ca43-4a3e-bf23-d0f82c6333a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_562e4556-d73b-4a18-8df0-352a75a6bcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:to="loc_us-gaap_DebtInstrumentFairValue_562e4556-d73b-4a18-8df0-352a75a6bcf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_62f34aaf-6434-49a9-bdcd-373c2b38e685_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_62f34aaf-6434-49a9-bdcd-373c2b38e685_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4062ef72-aab8-462f-8a9c-7f2f036269aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4062ef72-aab8-462f-8a9c-7f2f036269aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_36f32100-3986-4891-8cad-4ca3e1a83062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_36f32100-3986-4891-8cad-4ca3e1a83062" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b5060dd1-5416-444a-be22-eb1ebc97874a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b5060dd1-5416-444a-be22-eb1ebc97874a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7c223110-4371-43e6-9c3d-b7c43f1adcd2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7c223110-4371-43e6-9c3d-b7c43f1adcd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ae7f533e-1275-488c-aeb7-03dd3ff1e90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_SeniorNotesMember_ae7f533e-1275-488c-aeb7-03dd3ff1e90c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_589f15cd-f824-42b8-9fc2-ddfbc5d93d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_589f15cd-f824-42b8-9fc2-ddfbc5d93d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9b74e1ef-7256-4df2-b34a-764577890676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_ConvertibleDebtMember_9b74e1ef-7256-4df2-b34a-764577890676" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b1c83b8b-d642-49d4-a4ae-d40c9b029c97_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b1c83b8b-d642-49d4-a4ae-d40c9b029c97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_5567339b-4b5d-43f8-aaa0-0ae53bf92605" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_A4375SeniorNotesMember_5567339b-4b5d-43f8-aaa0-0ae53bf92605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_10bd712b-f813-4864-aef1-f8ab29857cd5" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_SeniorNotesDue2022Member_10bd712b-f813-4864-aef1-f8ab29857cd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_f85d6ad4-869f-42bf-adcc-0123b3f701bd" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_A4.875SeniorNotesMember_f85d6ad4-869f-42bf-adcc-0123b3f701bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_3d34afaa-aed0-44ee-979b-cceecd03728f" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_3d34afaa-aed0-44ee-979b-cceecd03728f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20200930.xsd#Investments"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended" id="if1ce8da111ff4fd980c433e035139457_Investments"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended" id="id79fca504ce442deba754e9888c1f63d_InvestmentsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended" id="icdb4e17fb08747ed96610a8bee330c67_InvestmentsSummaryofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_91543820-4e03-46e5-a646-0115b69c1cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_91543820-4e03-46e5-a646-0115b69c1cef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07351561-cb8e-4f02-9fe9-3e53be2a24eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07351561-cb8e-4f02-9fe9-3e53be2a24eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34661657-4f2f-4747-a119-e9aaee4f0f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34661657-4f2f-4747-a119-e9aaee4f0f70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd07d9d0-e0ec-4568-a981-d5cc4b932f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd07d9d0-e0ec-4568-a981-d5cc4b932f4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d925e9fa-9299-4dbe-b27c-df34b6f9bccd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d925e9fa-9299-4dbe-b27c-df34b6f9bccd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d3fcf00d-8f51-4c54-922f-dcef9c07a1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d3fcf00d-8f51-4c54-922f-dcef9c07a1fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b19d7d1c-27ac-4647-bb70-2aec92d4ed1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b19d7d1c-27ac-4647-bb70-2aec92d4ed1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_fa02f877-0dad-4855-9616-1cda84d452cf" xlink:href="moh-20200930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_moh_MunicipalSecuritiesMember_fa02f877-0dad-4855-9616-1cda84d452cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_36fba725-806f-480a-ad48-25ccef5f3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_36fba725-806f-480a-ad48-25ccef5f3485" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_11e91097-be53-444f-807b-82bf51270a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_11e91097-be53-444f-807b-82bf51270a11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_81e5cf33-7bdd-4745-a767-8a0b6b75ecf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_81e5cf33-7bdd-4745-a767-8a0b6b75ecf0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_db45e25b-f8eb-4d3e-b644-2c98a3c27663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_db45e25b-f8eb-4d3e-b644-2c98a3c27663" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_55cdb094-215e-48b3-96a9-09c7f8c61280" xlink:href="moh-20200930.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_moh_OtherSecuritiesMember_55cdb094-215e-48b3-96a9-09c7f8c61280" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended" id="i789655fc2ecd405681c9e466cfcfe5c1_InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i37672da9df3c45c0978d9bada24e4329_InvestmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended" id="i2e6f7dd8aeb44404a553f2ceabea7103_InvestmentsAvailableforSaleInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e2979c80-ceac-4a5a-9929-39c48daad669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e2979c80-ceac-4a5a-9929-39c48daad669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f1395810-10fd-4ab3-8375-2c94bf25f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f1395810-10fd-4ab3-8375-2c94bf25f8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_f98470f9-114b-4dbd-8abc-87e2f5c3d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_f98470f9-114b-4dbd-8abc-87e2f5c3d151" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fc59c46-dbb5-4f27-b61b-b137c108eeca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7fc59c46-dbb5-4f27-b61b-b137c108eeca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_eea702a4-c4aa-42bc-8593-6e43e6d550a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_eea702a4-c4aa-42bc-8593-6e43e6d550a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_66f499e4-77ea-47d3-b817-a3f658609941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_66f499e4-77ea-47d3-b817-a3f658609941" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended" id="id150608a0c7a414a80f1858c9c00eb03_MedicalClaimsandBenefitsPayable"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended" id="i72a8910f608543e6842ddef8ccbb692e_MedicalClaimsandBenefitsPayableTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="i70297998da364c7ba960049faec7d890_MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended" id="i41e284973ede4883a6e9c31b30763e15_MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended" id="idfeb49f13e3b441484a9a6d650dcd4c5_MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20200930.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended" id="iff0edcf0ec774ed3ad680539bb365626_Debt"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended" id="iad262d098ebe48d88ed4ef6ebb02716d_DebtTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended" id="id727285a31ac42ef863d67012f0d0b12_DebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_bfcb21a0-1727-4387-8347-96e83706dc24" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_bfcb21a0-1727-4387-8347-96e83706dc24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8455595a-0d7b-43ae-a772-ef1056cf16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8455595a-0d7b-43ae-a772-ef1056cf16d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_bd01cdcb-e981-4815-aeb4-5c111ec86a9a" xlink:href="moh-20200930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_bd01cdcb-e981-4815-aeb4-5c111ec86a9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a5510d48-c1c4-4555-b842-e65c7003f0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a5510d48-c1c4-4555-b842-e65c7003f0b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1c736f08-71d1-4e9b-80dd-2a391fa4c446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1c736f08-71d1-4e9b-80dd-2a391fa4c446" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2219e39-cc5e-4d1b-810d-1c0d13363eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2219e39-cc5e-4d1b-810d-1c0d13363eee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_230f6105-485c-48e6-87fd-4f306693975c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_230f6105-485c-48e6-87fd-4f306693975c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3720de2c-25cd-452a-8e0c-69bee983474e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_LineOfCreditMember_3720de2c-25cd-452a-8e0c-69bee983474e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b929bae8-cd3c-46ef-87bd-d5206ba4bd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_ConvertibleDebtMember_b929bae8-cd3c-46ef-87bd-d5206ba4bd8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_057a48c9-d50a-4278-b7d8-23cedde8e9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_SeniorNotesMember_057a48c9-d50a-4278-b7d8-23cedde8e9c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:to="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_05349afc-2e2c-4c04-94aa-3651fdffc9d9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_05349afc-2e2c-4c04-94aa-3651fdffc9d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TermLoanMember_424cd2fa-d524-41db-bdea-60be39fe85cc" xlink:href="moh-20200930.xsd#moh_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_TermLoanMember_424cd2fa-d524-41db-bdea-60be39fe85cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_565dbc4d-efbe-434b-bbe2-0619b3cd8d10" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_565dbc4d-efbe-434b-bbe2-0619b3cd8d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_159e2db3-a5cf-4853-93b5-94674a87e13f" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_A4375SeniorNotesMember_159e2db3-a5cf-4853-93b5-94674a87e13f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_df81e852-55f2-4fe6-ba4d-e312d86676b2" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_SeniorNotesDue2022Member_df81e852-55f2-4fe6-ba4d-e312d86676b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_d474a293-4b1b-4fb7-bf7f-61585492904d" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_A4.875SeniorNotesMember_d474a293-4b1b-4fb7-bf7f-61585492904d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended" id="i2414d4fed8f443a1b28c7b7a9de24f3c_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96f7c9e4-b1a3-4124-a194-6977790804c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96f7c9e4-b1a3-4124-a194-6977790804c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cd45b5a5-07db-422a-96a9-95408065a2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cd45b5a5-07db-422a-96a9-95408065a2ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidatedNetLeverage_14eee692-a513-4aa9-b61c-f3bb313d0b2d" xlink:href="moh-20200930.xsd#moh_ConsolidatedNetLeverage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_moh_ConsolidatedNetLeverage_14eee692-a513-4aa9-b61c-f3bb313d0b2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3c5e2566-db24-4903-875f-99f55a574247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_3c5e2566-db24-4903-875f-99f55a574247" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f3a8da07-a5a0-4710-af95-1cbb675ca1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_LineOfCredit_f3a8da07-a5a0-4710-af95-1cbb675ca1e5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_591b2945-8ba1-410f-acef-8c5a7211b1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_591b2945-8ba1-410f-acef-8c5a7211b1cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e31b9137-4cc2-41a7-b161-2af4b58227b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e31b9137-4cc2-41a7-b161-2af4b58227b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_032c7f7b-9f5c-4d8a-94f6-99b5b47f888b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_032c7f7b-9f5c-4d8a-94f6-99b5b47f888b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_d418aba5-3fc9-44a9-9d76-9440ea600461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_d418aba5-3fc9-44a9-9d76-9440ea600461" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_018ae789-b2a0-4089-a908-36996765302b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_018ae789-b2a0-4089-a908-36996765302b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_1f3c1dba-acb0-4674-ac92-f2db5ce3a0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_RepaymentsOfDebt_1f3c1dba-acb0-4674-ac92-f2db5ce3a0c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_2f62220f-7595-4b16-b234-10b7fa4f54dd" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_2f62220f-7595-4b16-b234-10b7fa4f54dd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_417968e9-4563-4335-8bc1-b35623a73509_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_417968e9-4563-4335-8bc1-b35623a73509_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_595fe3eb-6aaf-4cf3-95ff-5bbde50dae1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_LineOfCreditMember_595fe3eb-6aaf-4cf3-95ff-5bbde50dae1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a230e53e-2929-4cd6-a00b-77fbae50160f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_SeniorNotesMember_a230e53e-2929-4cd6-a00b-77fbae50160f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_20e2f6a1-0173-48f3-a3ba-55652b583b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_ConvertibleDebtMember_20e2f6a1-0173-48f3-a3ba-55652b583b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_cb498682-1a12-44a4-baa8-f4e15b56d71a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:to="loc_us-gaap_CreditFacilityDomain_cb498682-1a12-44a4-baa8-f4e15b56d71a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:to="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a3507e16-d576-478d-bf03-8d460877e29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a3507e16-d576-478d-bf03-8d460877e29e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SwinglineSubFacilityMember_8f77183d-09d3-4c67-8f04-768ff34566b3" xlink:href="moh-20200930.xsd#moh_SwinglineSubFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_moh_SwinglineSubFacilityMember_8f77183d-09d3-4c67-8f04-768ff34566b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LetterOfCreditSubFacilityMember_8b5c3519-2cb8-4a62-8b74-ad03b41ba3ce" xlink:href="moh-20200930.xsd#moh_LetterOfCreditSubFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_moh_LetterOfCreditSubFacilityMember_8b5c3519-2cb8-4a62-8b74-ad03b41ba3ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_59ff2d21-274e-4bae-af94-ccadc5625005_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_59ff2d21-274e-4bae-af94-ccadc5625005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncrementalTermLoanMember_c7e8a122-3638-4961-8fa8-d809771f8774" xlink:href="moh-20200930.xsd#moh_IncrementalTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_IncrementalTermLoanMember_c7e8a122-3638-4961-8fa8-d809771f8774" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_c2520cf8-fb48-4d0f-8896-daca3d3b677d" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_A4375SeniorNotesMember_c2520cf8-fb48-4d0f-8896-daca3d3b677d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_0bef332a-658d-49f8-93cb-a882873567a1" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_SeniorNotesDue2022Member_0bef332a-658d-49f8-93cb-a882873567a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_c19dfd6a-0c02-41db-810b-5cbd23df01d7" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_A4.875SeniorNotesMember_c19dfd6a-0c02-41db-810b-5cbd23df01d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_23db7044-c4f9-410a-9c31-602ca5c5250e" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_23db7044-c4f9-410a-9c31-602ca5c5250e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended" id="i1d75c197419e40ab9c5dfa445ccd8f9f_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="extended" id="i4ef23b5338a34cabbeffa854bb49c7fd_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="i9f73de0fba02470690873e8bd40da91e_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7f0be82d-d314-4b75-aba6-54be0e51c9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7f0be82d-d314-4b75-aba6-54be0e51c9c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_6e41f467-2e20-4537-83ac-d661e88cc8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_6e41f467-2e20-4537-83ac-d661e88cc8fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6ca49de8-8261-45a3-bc3a-3c4f7dff29f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6ca49de8-8261-45a3-bc3a-3c4f7dff29f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f859a906-0028-461e-a49a-672865aab0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f859a906-0028-461e-a49a-672865aab0d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8b8a842-f7fc-4b18-b937-cbd2150b89e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8b8a842-f7fc-4b18-b937-cbd2150b89e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ClassOfWarrantOrRightStatedInterestRate_ba96d95f-2319-4c89-8996-dc5a3b041c97" xlink:href="moh-20200930.xsd#moh_ClassOfWarrantOrRightStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_moh_ClassOfWarrantOrRightStatedInterestRate_ba96d95f-2319-4c89-8996-dc5a3b041c97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63d5b26d-0e7b-4e86-aece-43015321a0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63d5b26d-0e7b-4e86-aece-43015321a0e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_15eaf9d5-86b5-4d85-9be3-11361c220990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_15eaf9d5-86b5-4d85-9be3-11361c220990" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5288941c-2e0f-4c1b-9109-e0995f63d777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5288941c-2e0f-4c1b-9109-e0995f63d777" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3df57f84-efb3-43b4-aa0b-4f44df3047f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ShareBasedCompensation_3df57f84-efb3-43b4-aa0b-4f44df3047f6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_44fbb8bf-7710-44f4-be38-5ec618723d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_44fbb8bf-7710-44f4-be38-5ec618723d56" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42948937-3f4e-48a0-a644-b0152621538e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42948937-3f4e-48a0-a644-b0152621538e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate_2ac8f880-7a3a-457d-9dca-cb8cf5f3b63b" xlink:href="moh-20200930.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_moh_UnrecognizedCompensationForfeitedRate_2ac8f880-7a3a-457d-9dca-cb8cf5f3b63b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a7493b65-9c3d-4ac3-b31d-0181c818016f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a7493b65-9c3d-4ac3-b31d-0181c818016f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24cf32ad-7fa0-4e7d-84bc-710201490d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24cf32ad-7fa0-4e7d-84bc-710201490d3c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:to="loc_us-gaap_EquityComponentDomain_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:to="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b6e33ba6-8be4-45e5-a0c2-efa100825670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:to="loc_us-gaap_CommonStockMember_b6e33ba6-8be4-45e5-a0c2-efa100825670" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0a72f0f4-7554-4cf5-ae9f-1de363f371f9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0a72f0f4-7554-4cf5-ae9f-1de363f371f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_9ce5d629-bae3-4ec0-850a-5f118c03df8d" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_9ce5d629-bae3-4ec0-850a-5f118c03df8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa7120c-cc3a-461d-aea6-e012afd8a956_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ffa7120c-cc3a-461d-aea6-e012afd8a956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1701c386-4e1b-499c-b7f9-bea98c2523e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:to="loc_us-gaap_RestrictedStockMember_1701c386-4e1b-499c-b7f9-bea98c2523e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8a2f371-3fbc-419b-b308-0f766193028c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8a2f371-3fbc-419b-b308-0f766193028c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityShareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="extended" id="i1c194d66bac64eb889aa55b02914cdba_StockholdersEquityShareActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c03ccc70-3a03-43ca-b482-69860dd0ed2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c03ccc70-3a03-43ca-b482-69860dd0ed2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4150f030-ce47-477c-bca5-d49575de40d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4150f030-ce47-477c-bca5-d49575de40d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_912f15a9-ce15-4145-b764-6f1d6986fb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_912f15a9-ce15-4145-b764-6f1d6986fb91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c2ea287-c3ea-426f-98b4-c678058042f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c2ea287-c3ea-426f-98b4-c678058042f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a69b0eb6-0558-4d14-80bd-2f9ebe3c3d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b86b6645-9243-4c1e-850a-e2c53d7e3c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b86b6645-9243-4c1e-850a-e2c53d7e3c2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3deb5c28-8f4c-43a7-9dd1-6f7e4ee7902e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3deb5c28-8f4c-43a7-9dd1-6f7e4ee7902e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_75cfe897-b0fb-40ff-8881-57e6c5e71f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_75cfe897-b0fb-40ff-8881-57e6c5e71f65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5d903bc4-d879-4c5c-9d20-dd013c18cd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5d903bc4-d879-4c5c-9d20-dd013c18cd63" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f488eb52-2100-4594-9dbc-1930084a5d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:to="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ceacf369-ff52-4843-9585-b2047b99c50d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ceacf369-ff52-4843-9585-b2047b99c50d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5078aee4-9db1-427e-987d-d945a7332eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:to="loc_us-gaap_RestrictedStockMember_5078aee4-9db1-427e-987d-d945a7332eb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b24af30-1fc5-4048-b6e0-0ec110f04cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b24af30-1fc5-4048-b6e0-0ec110f04cbf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityFairValueofAwardsGrantedandVestedDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="extended" id="iff269c06fa2a4659821abe114a3537fb_StockholdersEquityFairValueofAwardsGrantedandVestedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_b0b49251-535d-4b68-915e-663dad665320" xlink:href="moh-20200930.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_b0b49251-535d-4b68-915e-663dad665320" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_21dc17cf-6bb6-4267-a8f3-a5c2a82e42ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_21dc17cf-6bb6-4267-a8f3-a5c2a82e42ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:to="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43d5d699-59a8-4b0f-9541-b6ef5af43b0e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43d5d699-59a8-4b0f-9541-b6ef5af43b0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_db93265a-d0f8-4840-971c-224e2419cfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:to="loc_us-gaap_RestrictedStockMember_db93265a-d0f8-4840-971c-224e2419cfe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cca610c2-15d6-40e5-9158-2d42c7167317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cca610c2-15d6-40e5-9158-2d42c7167317" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20200930.xsd#Segments"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended" id="i2e912c3acc6344a9a12c785d56802a52_Segments"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsTables"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended" id="i2822016fd4274d9182184911532a48a5_SegmentsTables"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended" id="if1f59ee3af8f4e8c9af9dd6fc0fb77dc_SegmentsNarrativeDetails"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended" id="i0da021f2375445a9b44584f4ba1f70df_SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2a0f28b1-8f49-46ed-8539-7686000dc41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_GrossProfit_2a0f28b1-8f49-46ed-8539-7686000dc41d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_999f6082-7002-4b9a-b791-b1176fa19d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_Revenues_999f6082-7002-4b9a-b791-b1176fa19d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7f0eae4f-2246-4dd4-bb50-5daf199f5644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_CostsAndExpenses_7f0eae4f-2246-4dd4-bb50-5daf199f5644" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2aa4c1c7-8687-4857-8636-0e0699b79542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_OperatingIncomeLoss_2aa4c1c7-8687-4857-8636-0e0699b79542" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9e3605c0-f12f-4be7-9e44-e6a7dc838f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9e3605c0-f12f-4be7-9e44-e6a7dc838f20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44465b70-d6a4-460c-ac6e-1bfd670c2144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44465b70-d6a4-460c-ac6e-1bfd670c2144" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_13b76276-d7c9-462e-839d-403ff594b32d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:to="loc_us-gaap_SegmentDomain_13b76276-d7c9-462e-839d-403ff594b32d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:to="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_fb17b599-da84-4b18-bfda-f84b21d10acd" xlink:href="moh-20200930.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:to="loc_moh_HealthPlansMember_fb17b599-da84-4b18-bfda-f84b21d10acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3be5dde4-d6e2-41f6-b141-6cab5dfd9a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3be5dde4-d6e2-41f6-b141-6cab5dfd9a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:to="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_db23f932-578e-4214-bf8c-12db383df85d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:to="loc_srt_ConsolidationItemsDomain_db23f932-578e-4214-bf8c-12db383df85d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:to="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6360409a-dbba-4c69-a8fb-d408f0b1f16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:to="loc_us-gaap_OperatingSegmentsMember_6360409a-dbba-4c69-a8fb-d408f0b1f16d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_47e49fa8-b951-4e8a-8079-b81145a17a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_47e49fa8-b951-4e8a-8079-b81145a17a50" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended" id="ia06d57ee0118439e975eb377f2b89dc8_CommitmentsandContingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>moh-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f732fe47-7f8d-4377-9b3b-a1cbfc00d403_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_a794f1d9-900c-41b2-94cb-74f3ee2fd09a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_897610fb-faf0-43b4-a286-0e62c2177550_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable, prior year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_81a2d78a-0c9e-4311-880b-509442a5946a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expense (income), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6186af4b-111a-4404-a56b-3ca9c76af24f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f829ae07-196b-4740-b3d4-5fa41e4b6c26_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_198410c5-01cd-4323-901d-3b14e7791138_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_377af993-0218-4e11-80e9-c45a87cfae8a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_b3eb0fac-7e34-43b9-b8e7-0eb6a9b2e387_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_4feabcce-f134-45b2-a119-4830be5b74a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_99867681-cd3b-4991-95d1-85a90cfeba0f_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherClaimsPayable_ca3d26c4-af12-4efb-9df7-c661e1370e97_terseLabel_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_label_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_documentation_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable" xlink:href="moh-20200930.xsd#moh_OtherClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherClaimsPayable" xlink:to="lab_moh_OtherClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_5452e490-3c29-4bef-9f9c-b4db6fc2465a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_5d074536-3292-45bc-94ed-e7d501046b4c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_406c0bbe-f5b7-4081-9e74-4fabb44af89a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MagellanCompleteCareMember_ab327c34-12ad-48ca-ace8-dfb24f8c1932_terseLabel_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan complete care</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_label_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:label id="lab_moh_MagellanCompleteCareMember_documentation_en-US" xlink:label="lab_moh_MagellanCompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember" xlink:href="moh-20200930.xsd#moh_MagellanCompleteCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MagellanCompleteCareMember" xlink:to="lab_moh_MagellanCompleteCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_3eca9f21-dba2-4a90-9b84-7d7524cb5b88_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_b5d73489-8760-4f27-8d1e-705fe6feacf0_terseLabel_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Warrants</link:label>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_label_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Convertible Senior Notes Due 2020, Warrants [Member]</link:label>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_documentation_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Convertible Senior Notes Due 2020, Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:to="lab_moh_CashConvertibleSeniorNotesDue2020WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_66fdb65f-ec66-4d6f-b48c-9a5eb03a349a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_c2c70baa-b2c9-47bf-9c88-421c1e547809_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_23201ae8-e358-4a29-b19f-89102fb570d1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_0d2d97c3-5837-4779-80e5-1b45340107c9_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_63308475-fb1b-4381-beae-febac902c920_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_c307d5ec-0f5c-4abb-8dcb-42e6117b9882_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_2e0fecd0-363f-4909-a34a-4fe90213471a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d8e976b7-3aaf-4f2a-b0e6-b1180d78e7c4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e84ed49d-d685-4d38-aa7b-e767f9fdade5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_df1e1870-ae5e-4965-a8c4-513073d02a4d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1d6fa334-cf28-4136-b36b-d9a064c6d338_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DetailsOfBusinessCombinationsAbstract_fa8e68f9-1516-44d5-9090-75a4c53ab17e_terseLabel_en-US" xlink:label="lab_moh_DetailsOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of business combinations:</link:label>
    <link:label id="lab_moh_DetailsOfBusinessCombinationsAbstract_label_en-US" xlink:label="lab_moh_DetailsOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Business Combinations [Abstract]</link:label>
    <link:label id="lab_moh_DetailsOfBusinessCombinationsAbstract_documentation_en-US" xlink:label="lab_moh_DetailsOfBusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details Of Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DetailsOfBusinessCombinationsAbstract" xlink:href="moh-20200930.xsd#moh_DetailsOfBusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DetailsOfBusinessCombinationsAbstract" xlink:to="lab_moh_DetailsOfBusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_593692ea-57a3-4353-bb81-17f8d66da241_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareInsuranceFeeLiability_c49afa7b-3669-4281-88b2-2d86ba53cd83_terseLabel_en-US" xlink:label="lab_moh_HealthCareInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIF liabilities</link:label>
    <link:label id="lab_moh_HealthCareInsuranceFeeLiability_label_en-US" xlink:label="lab_moh_HealthCareInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Insurance, Fee, Liability</link:label>
    <link:label id="lab_moh_HealthCareInsuranceFeeLiability_documentation_en-US" xlink:label="lab_moh_HealthCareInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Insurance, Fee, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareInsuranceFeeLiability" xlink:href="moh-20200930.xsd#moh_HealthCareInsuranceFeeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareInsuranceFeeLiability" xlink:to="lab_moh_HealthCareInsuranceFeeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_66e8a476-ddf0-47e9-9c68-ecbe2f6ce3e9_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_3b0a2928-a684-4ca7-b5c5-f0f54ec91c60_totalLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:href="moh-20200930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6efdb3da-eb83-4fea-9e31-585b6c7aaa98_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_5eeae706-d011-4569-9a6d-e7faed08482b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_72de06e7-1ea8-4c71-a933-ec0dc4f65972_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for partial settlement of call option</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_8a6911c1-3aa1-4d97-b54c-264d782d07ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for partial termination of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_eb2a9c27-2969-493b-adad-c68b1677e774_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for partial termination of 1.125% Warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f18c1f6e-4bca-46a0-b745-0b1cc01b591f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_93513871-af22-4a16-a811-94f31d5f5c2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_12bf28a2-52e7-4ed4-85a0-213dee2f7c8d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5d11f112-488d-4c20-ae40-835e5792326c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b73bd2e6-c75f-427e-bf98-e3400cfbc697_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_77a6dd80-1027-4501-9c16-1abd003e3976_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a1a2e7e7-e005-4b68-b8ec-631d08360227_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_80b5c255-5463-4a4b-9ad2-2d631fefd88e_terseLabel_en-US" xlink:label="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maine Community Health Options v. United States</link:label>
    <link:label id="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_label_en-US" xlink:label="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maine Community Health Options v. United States [Member]</link:label>
    <link:label id="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_documentation_en-US" xlink:label="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maine Community Health Options v. United States [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:href="moh-20200930.xsd#moh_MaineCommunityHealthOptionsv.UnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:to="lab_moh_MaineCommunityHealthOptionsv.UnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_4237257f-256a-4a19-8250-887976078933_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_780f71ac-e4d6-468f-8eac-b133e948dd55_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_679a3b98-c6eb-417c-9efe-0ce885ef5967_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_daea5865-1f69-474b-8e18-42c6ce260a13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_91cf5d4d-e1bf-42f3-a19d-6ad355eb750f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_95c00476-f736-4164-b76a-3bf41f9a886a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_d0f855d3-de3d-44ab-bd10-9781167e07c0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognized_1b8fc550-7981-45d6-84d9-950638c4ddb3_totalLabel_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognized_label_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue Recognized</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognized_documentation_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality incentive premium revenue recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognized" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognized" xlink:to="lab_moh_QualityIncentivePremiumRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_2a31188f-9d63-4606-b177-1dae5200c18d_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_c276e603-af27-4d7a-9be3-2808ccc12093_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:to="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7e32f6f8-0cb5-4099-8a45-f18ccbe4a60b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_5e1198bc-095d-4af7-9adb-2dd577d14711_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_758ef8b5-1c90-48d6-93a0-7e172a9cab64_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_9d9d56d1-7b11-41f7-b9cd-992e80c6f698_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_f8c5be51-e004-4b95-a7ed-84ab3b83b1d8_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember_c5c1c53d-49e9-4458-9b87-6ad428cf436f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_1aeaf029-1657-4d80-b2e6-23c9aee52960_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in HIF liabilities</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Health Insurance Fee, Liability</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Health Insurance Fee, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInHealthInsuranceFeeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:to="lab_moh_IncreaseDecreaseInHealthInsuranceFeeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_066c7436-9f32-483e-bf23-d14d68a2d9d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) on debt repayment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c24d7f3c-97cd-4ab9-a05f-c08ef4d0e453_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on debt repayment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2fe5b101-4fe3-404c-aac2-4b0c298cb845_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Asset and Liabilities Measured on Recurring Basis - Disclosure Only</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_90356b8e-64cc-4eb7-b8fe-bdecb0beef2e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_b8d71f3a-0daf-41d2-8ecd-596f9cfc3637_terseLabel_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation forfeiture rate</link:label>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_label_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Forfeited Rate</link:label>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_documentation_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation forfeited rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate" xlink:href="moh-20200930.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_UnrecognizedCompensationForfeitedRate" xlink:to="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_396b9826-6985-46a3-8b09-969f225ac786_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bd51c2c5-670f-4a76-9f9b-7f652e1f6f37_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_161dd208-4f03-4f78-b93f-4f889abfdfc5_terseLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ef35db2a-03f5-4306-aaef-9deb2291be60_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_f40e6a48-4a47-4bbc-9a54-bc02ad7f1518_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_07642f7e-0cfa-4070-9efa-b69e0b392a23_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d913860e-89b2-4801-85aa-ea2763551676_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_19a39332-2b4d-4b68-a1f5-52e0e1da7fd6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_534ff6c0-e448-470a-b809-30a6840e5926_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_41b90590-decb-4458-8e3d-a354ccf5ba44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_0d0d0e89-2bf9-43c1-a145-c7438d9630f6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_4ebef96a-f241-43a1-80e2-73a1e1786867_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_7d0620ef-9083-40c8-ae23-1bc80e013453_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_e559d98e-4a9f-4575-8907-e4373605d0ba_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other operating</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_6ee3f4cb-76db-469e-b0cf-81e7e6d94c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_df66a469-f9ad-4cab-a608-e894526eaf08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_a735c403-93da-4dfa-bebf-8563c6b3ca3d_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares issued:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_cbe6d955-d4f1-433b-8448-5ab865a5eac1_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_2f61ec7d-fc35-4780-a826-5b86566ee294_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MeasurementInputMeasurementPeriodMember_c6a9a8ec-69fe-415a-964f-3ac9bbe715cb_terseLabel_en-US" xlink:label="lab_moh_MeasurementInputMeasurementPeriodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Measurement Period [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputMeasurementPeriodMember_label_en-US" xlink:label="lab_moh_MeasurementInputMeasurementPeriodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Measurement Period [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputMeasurementPeriodMember_documentation_en-US" xlink:label="lab_moh_MeasurementInputMeasurementPeriodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Measurement Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputMeasurementPeriodMember" xlink:href="moh-20200930.xsd#moh_MeasurementInputMeasurementPeriodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MeasurementInputMeasurementPeriodMember" xlink:to="lab_moh_MeasurementInputMeasurementPeriodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_cd8eae04-953d-430e-8ae4-76eb97376c31_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_df3071f2-c805-47cf-8a31-8436c0abe2b8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8c87cead-478b-4961-b589-e9c244f5f739_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_167aada3-36fe-4848-b8ad-774a43257236_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_0b314b2a-470c-457a-9e92-6957326307fc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_a00d98e3-ed69-4c2f-88e5-303209173a57_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_b5eba554-72eb-4e1a-b4b5-f291c2566594_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_29ee74fe-1454-45dc-87f9-fb6742a82024_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6b4a5e7a-5798-4603-99b9-eb2e36dc83cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e6ce2645-0617-46dd-81a8-5058a63a4851_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_1a0f5078-f5f9-4f35-90f1-4d47e43b5f68_terseLabel_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fee reimbursement receivables</link:label>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_label_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee Reimbursement Receivables [Member]</link:label>
    <link:label id="lab_moh_HealthInsurerFeeReimbursementReceivablesMember_documentation_en-US" xlink:label="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Insurer Fee Reimbursement Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:href="moh-20200930.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:to="lab_moh_HealthInsurerFeeReimbursementReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_c5c5d0ac-7594-4ab6-8722-4523f5e0f928_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_2ae230f3-2cee-47e3-b6d6-a1a722c10be7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_17fd9fd9-b443-4e13-86f2-49c77a32b977_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_728cf256-d6ec-4a51-b555-c00be789ada4_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_820743dd-5678-405d-be9c-a3048fc94951_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_1718f03d-af6f-40e3-bc20-c236836adfe4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_072f64a7-38b3-482d-97bd-3677cc085d99_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_e13afed2-cb0d-4a4d-adeb-a9c502ced77d_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_b89e96ec-4772-4d83-a6d1-f0f51d8ab916_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_23cb66bf-9256-431a-b2ff-2c6906b2d2a2_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Premium Revenue By Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Table]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_3bb998e9-1abc-4bfb-ba38-44344ea21629_terseLabel_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Interim Financial Information</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:label id="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation And Interim Financial Information, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:href="moh-20200930.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:to="lab_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_f102705c-ec86-4e0a-9db5-b091c69573f8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncrementalTermLoanMember_1e55239a-b072-4679-a2c7-118320b95a06_terseLabel_en-US" xlink:label="lab_moh_IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Term Loan</link:label>
    <link:label id="lab_moh_IncrementalTermLoanMember_label_en-US" xlink:label="lab_moh_IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Term Loan [Member]</link:label>
    <link:label id="lab_moh_IncrementalTermLoanMember_documentation_en-US" xlink:label="lab_moh_IncrementalTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncrementalTermLoanMember" xlink:href="moh-20200930.xsd#moh_IncrementalTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncrementalTermLoanMember" xlink:to="lab_moh_IncrementalTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_515b1b9c-9718-438d-94ec-7a4380abbc08_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_acce68a9-07fa-4eb2-9480-e148c6d09602_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_858e6a13-6458-466c-8928-09c8d6a8885a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Denominators for the Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8919ee05-26fd-4008-81af-575b510fe31a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_89561e51-7d80-43cb-b66e-0c5af341466c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CallOptionDerivativeAssetMember_0320e345-0be7-49ea-a23a-a64c2aa9a483_terseLabel_en-US" xlink:label="lab_moh_CallOptionDerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call option</link:label>
    <link:label id="lab_moh_CallOptionDerivativeAssetMember_label_en-US" xlink:label="lab_moh_CallOptionDerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option, Derivative Asset [Member]</link:label>
    <link:label id="lab_moh_CallOptionDerivativeAssetMember_documentation_en-US" xlink:label="lab_moh_CallOptionDerivativeAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Call Option, Derivative Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CallOptionDerivativeAssetMember" xlink:href="moh-20200930.xsd#moh_CallOptionDerivativeAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CallOptionDerivativeAssetMember" xlink:to="lab_moh_CallOptionDerivativeAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_c5fe889b-2e4e-43ad-b655-b7779014d6db_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_01bd4e8d-441c-4245-afea-951254d2eaea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_6dd5415c-1040-49c2-88fb-0a69198169d5_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_39476caf-a45d-4781-be17-984baa904e5f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under letter of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_a367c325-ab9c-4f12-a24a-ca930aa30e24_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_b6ec47ab-05ea-4026-9421-a226f325f8fb_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business combinations</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Business Combinations</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:to="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a33a48f6-c353-4304-b643-d9fc7f1b065a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_a812d9b4-1c4c-4006-94f5-61c2ef0defbb_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period claims, favorable development</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_0ce6c3b6-598a-4754-8f04-394e38aee9c9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3345dd2b-8509-429e-af95-ef53e624c49c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_5a2bd8c9-79be-41a9-af05-e6f10b5f0c84_terseLabel_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod" xlink:href="moh-20200930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsAverageMaturityPeriod" xlink:to="lab_moh_InvestmentsAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_100b7cf7-3574-4166-a4d1-ca66a1b9cca9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_413cce99-2c91-492e-8918-19458d00db1f_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_47cad7bd-652b-4a95-b60b-9a4ef2754f78_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_5a43edef-164b-4282-97f2-32d3051da58d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_2ebbf35f-7071-49c8-9600-14d0166b1a43_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivatives, net</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_f64e388d-8b15-46d2-839e-fae9b3cc3ce8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_31bb5417-f63b-4cea-bd21-8c98b4449a03_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_a34a1345-1ce8-488e-96d5-8791a24c5090_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_TermLoanMember_ba550af0-12dc-4813-9e1c-739d12d5f5da_verboseLabel_en-US" xlink:label="lab_moh_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility</link:label>
    <link:label id="lab_moh_TermLoanMember_label_en-US" xlink:label="lab_moh_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:label id="lab_moh_TermLoanMember_documentation_en-US" xlink:label="lab_moh_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TermLoanMember" xlink:href="moh-20200930.xsd#moh_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_TermLoanMember" xlink:to="lab_moh_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_5d4b07f9-5263-4d62-970a-d4d24af76343_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9e4c77c6-0b23-43f4-92f5-e2ce233164db_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_624a6d3d-208f-4f19-a49f-72dbad30a49e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanContractTerm_3b7d7f54-5e06-47a1-a65a-ebabb4219c1d_terseLabel_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_label_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_documentation_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm" xlink:href="moh-20200930.xsd#moh_HealthPlanContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanContractTerm" xlink:to="lab_moh_HealthPlanContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1d0a76f6-9cc5-41e2-9709-eb6698a67546_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3e83f113-76b7-479a-b275-bbabc793165f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock option expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cc842454-8790-4582-8f08-aa6366ea971b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_4c4198df-9128-4b36-a93f-1ebdb0f8a892_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_b6da1372-cecd-45e5-82a7-4ee1a4ab3e36_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GovernmentReceivablesMember_51277003-b275-4786-96eb-542d4c369588_terseLabel_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government receivables</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_label_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_documentation_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember" xlink:href="moh-20200930.xsd#moh_GovernmentReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GovernmentReceivablesMember" xlink:to="lab_moh_GovernmentReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrentAbstract_52481e15-7134-4819-ad5c-c026781623c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt:</link:label>
    <link:label id="lab_us-gaap_DebtCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DebtCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrentAbstract" xlink:to="lab_us-gaap_DebtCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_2a92d4aa-a9a2-400c-9c40-ddfb8c7e3f2d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e2a4b7bd-ef4f-4500-8290-38d06d3be39d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_2c910868-2763-4834-9695-569bd464feaa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_3406cf07-818a-4aac-977c-ba8d33a36709_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_8798f878-7b7c-4bf9-bc60-4603fb16ef7a_terseLabel_en-US" xlink:label="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earned current period</link:label>
    <link:label id="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_label_en-US" xlink:label="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Current Year Quality Incentive Premium Revenue Recognized</link:label>
    <link:label id="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_documentation_en-US" xlink:label="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of current year quality incentive premium revenue recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:href="moh-20200930.xsd#moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:to="lab_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6d5c256e-684e-46d8-bf15-c653634d6ece_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c2804a68-adb7-40b9-8bbc-be2acc54088f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_722c5d7a-255e-4ac1-9dc3-47395321c484_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_a07a280c-05ad-42d3-868e-a920139c23f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansMember_8c7c03a1-dde8-4021-ab4b-ebec1d96b63f_terseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans</link:label>
    <link:label id="lab_moh_HealthPlansMember_label_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans [Member]</link:label>
    <link:label id="lab_moh_HealthPlansMember_documentation_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember" xlink:href="moh-20200930.xsd#moh_HealthPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansMember" xlink:to="lab_moh_HealthPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_bffea3c5-ab06-485a-89ef-d3b2a2e15e34_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_333bc095-b3d5-4bda-a95c-8f79d75cf816_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5497ae15-5562-40fe-a322-a4e4991d5549_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8e765e3c-0028-4707-9966-25e654c30a39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_4d7bccd1-c5f8-460c-9369-5d115b0a4e62_terseLabel_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_label_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Premium Revenue by Health Plan Type [Line Items]</link:label>
    <link:label id="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_documentation_en-US" xlink:label="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of premium revenue by health plan type.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:to="lab_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_08233f34-76a9-420c-beb2-b4ee79e82faf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_0b0a4fed-4a78-4e62-923b-79349f82c134_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_7c6fdd4e-d625-408c-b455-c118186ff5f8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_899d9f2e-c2fd-4d04-a975-a36452eb0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_9ddc6822-f5d0-4a6d-bb90-c53f1d96b535_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_5032b1a9-8c49-4c7e-b857-5d3ac3011740_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5c613afc-3749-49e5-a8ef-8332edb39819_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_2f7303e6-30f0-4790-a18f-d02385e6040d_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_1ec4e67f-a79b-40c2-bd1d-965391ac5643_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_cf25f569-7769-4b6b-9ef3-d81af9d5dad1_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f0297c13-5927-43e6-a4eb-67c00eed1b31_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_794bd5fd-9e9f-4009-a731-5274c72e4ee4_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_6a3741b1-29e5-4dfe-9ee9-99737efd8e9a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract_aba7df90-9a0c-4ce4-8a65-640939828df4_terseLabel_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality incentive premium revenue recognized in current period:</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract_label_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue Recognized [Abstract]</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract_documentation_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue Recognized [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognizedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:to="lab_moh_QualityIncentivePremiumRevenueRecognizedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_YourCareHealthPlanIncMember_04b8ca43-2ab4-4d05-aac8-b10231d1c902_terseLabel_en-US" xlink:label="lab_moh_YourCareHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Your care health plan inc</link:label>
    <link:label id="lab_moh_YourCareHealthPlanIncMember_label_en-US" xlink:label="lab_moh_YourCareHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Your Care Health Plan Inc [Member]</link:label>
    <link:label id="lab_moh_YourCareHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_YourCareHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Your Care Health Plan Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_YourCareHealthPlanIncMember" xlink:href="moh-20200930.xsd#moh_YourCareHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_YourCareHealthPlanIncMember" xlink:to="lab_moh_YourCareHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f485a83f-1d81-4c1d-b5aa-3d8dcd25dbfc_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_8fc6fa03-4760-4781-bf97-d6e91e2154a1_verboseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ebf9dded-5ddd-445a-905d-6ff97dd6fdb0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_6b564d38-7310-438e-b982-cb3911ce295e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1c1c6505-a743-4a54-8630-606b2eb4135f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_28e004ab-1cf4-4d56-ac4f-f32615584f04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_7758d654-a557-4fa7-b53b-f0c115f7c4b6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which entity operates</link:label>
    <link:label id="lab_us-gaap_NumberOfStatesInWhichEntityOperates_label_en-US" xlink:label="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of States in which Entity Operates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:to="lab_us-gaap_NumberOfStatesInWhichEntityOperates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_14b2fc16-70eb-4ca9-b58f-c469880dbec0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_0179dee0-b581-43da-986d-d38fdfa2a26a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c465ed56-bab8-4f3a-9438-96bec70ba189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_42079403-14b4-4919-8132-0483ddbc3539_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SeniorNotesDue2022Member_2d10e151-4177-4d63-8aec-a13375025e2f_terseLabel_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.375% Notes</link:label>
    <link:label id="lab_moh_SeniorNotesDue2022Member_label_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 [Member]</link:label>
    <link:label id="lab_moh_SeniorNotesDue2022Member_documentation_en-US" xlink:label="lab_moh_SeniorNotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SeniorNotesDue2022Member" xlink:to="lab_moh_SeniorNotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_19c22ece-d25e-481c-a13f-345cdea51cff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_ce06d491-8cda-4cb7-9dc9-283567fbdf4e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_8c8fc5da-324a-4330-96c5-6d5fd8a2ee8d_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_be69ba33-d749-49fd-a77b-199c24f948a4_netLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, within one year, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_a032a2b4-2ad6-4bcf-bb05-450bd56d13a7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_fa2c27f9-5333-4f44-a483-9c672a5b735c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_942bd290-5fb5-4321-bde7-02ecdbc70ee0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_aa41ee48-e1f7-4385-93fe-edaf5f39ac1c_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion option derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_db46aa62-91a8-43e1-9bb9-dd69bd55bf0f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_627e29c8-edde-4834-9647-423422e58e01_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Number&#160;of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_1c7bfa27-d989-4b01-8054-ee9cce7b2754_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4375SeniorNotesMember_5ded4ec8-6f4c-4970-9e39-47e5ce188b85_terseLabel_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4375SeniorNotesMember" xlink:to="lab_moh_A4375SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2fe24296-62e0-4cf6-bac7-2e5b23ce58d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_e6447360-9434-4ada-9dbe-281fab5f48a0_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_6693f83d-0def-49af-8c73-fb968d2da9d2_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_030d4776-cc30-4861-94ed-9da619f88c32_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CurrentAssetsMember_494296a6-94da-4c4d-b1b4-ec45c2310304_verboseLabel_en-US" xlink:label="lab_moh_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets: Prepaid expenses and other current assets</link:label>
    <link:label id="lab_moh_CurrentAssetsMember_label_en-US" xlink:label="lab_moh_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:label id="lab_moh_CurrentAssetsMember_documentation_en-US" xlink:label="lab_moh_CurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentAssetsMember" xlink:href="moh-20200930.xsd#moh_CurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CurrentAssetsMember" xlink:to="lab_moh_CurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_18f7519c-4800-4c7a-8660-2fa873a0d10d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5c60991-6bf4-4078-8c4f-fb69d0986c99_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fb2d8e8c-8b19-4101-b7f0-04f9ad8ff473_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_8cac188a-00e0-4e01-9e63-43645777c6a4_terseLabel_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_label_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_documentation_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:href="moh-20200930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:to="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_7f78887d-f115-4cfa-920f-559e9aa89327_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in premiums</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Premiums Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_PR_8938fb13-02fc-4372-8006-66fe82b54f41_terseLabel_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:label id="lab_country_PR_label_en-US" xlink:label="lab_country_PR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PUERTO RICO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_PR" xlink:to="lab_country_PR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1574aa68-de1b-4807-bff6-858652eee044_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020Member_e46fdb1d-16b8-4b7c-9ae4-e3c82644a4b6_terseLabel_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Convertible Notes, net of unamortized discount</link:label>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020Member_8d3adffc-a060-41ba-bf09-b3d0de0394be_netLabel_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020Member" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Convertible notes</link:label>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020Member_label_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Convertible Senior Notes due 2020 [Member]</link:label>
    <link:label id="lab_moh_CashConvertibleSeniorNotesDue2020Member_documentation_en-US" xlink:label="lab_moh_CashConvertibleSeniorNotesDue2020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Convertible Senior Notes due 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CashConvertibleSeniorNotesDue2020Member" xlink:to="lab_moh_CashConvertibleSeniorNotesDue2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_89543eea-b9bb-4542-9dd0-3a22607377af_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_46d6748c-703c-4ae9-8f07-f0e898f7c821_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_09fd8674-0526-428b-8e81-ac546b38ef2c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segment Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ClassOfWarrantOrRightStatedInterestRate_92b7f9e2-563b-4094-b7f3-54ca233ec899_terseLabel_en-US" xlink:label="lab_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated percentage of warrants</link:label>
    <link:label id="lab_moh_ClassOfWarrantOrRightStatedInterestRate_label_en-US" xlink:label="lab_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Stated Interest Rate</link:label>
    <link:label id="lab_moh_ClassOfWarrantOrRightStatedInterestRate_documentation_en-US" xlink:label="lab_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:href="moh-20200930.xsd#moh_ClassOfWarrantOrRightStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:to="lab_moh_ClassOfWarrantOrRightStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ba6b13ff-f642-49a9-9cc8-2d2cc32ae586_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a9811e36-fc6b-4e80-b449-9beabd817074_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b60771ef-ad72-4cab-80b9-ecffb7917d94_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b60ae738-b5cf-4bf5-a86a-e201a2c14cde_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_460b8dee-003c-4890-afff-37831b5a96d8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_18c130a4-981d-4373-a11d-9ded3af94d3e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_ffec53de-d55d-4655-b8ca-8e5a2f1ebd7d_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable [Text Block]</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9048bcd-ff93-42d6-a7ae-8c2424019e74_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_8ad13157-8899-411c-aa76-df7c128e8ba8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_4dca8c46-5401-4c0f-a45f-40965de14ac2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c79aa228-ba42-41e5-8598-791ea12b9a7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_b45ddd64-01dd-4d15-bcd7-7edc4ab89406_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a1f550e2-298e-4751-a1df-a6ebfda658d6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_1bd43098-3ae2-4dcd-9495-111da6168d60_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_c299c01d-3f35-4808-9c1d-ac1907c56995_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_b85491dc-d9c5-4b23-a385-1745d3f5e5ee_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to:</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_ComponentsOfMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:href="moh-20200930.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract" xlink:to="lab_moh_ComponentsOfMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_9a51cef9-7f0d-49b1-ac11-dde3417f8d9b_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_label_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_documentation_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:href="moh-20200930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:to="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_8a25cb6c-d4db-418c-9c45-142e2670134c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ProviderNetworkMember_c832aa6e-8abe-4f8b-a278-0b5b800c934b_terseLabel_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network</link:label>
    <link:label id="lab_moh_ProviderNetworkMember_label_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Network [Member]</link:label>
    <link:label id="lab_moh_ProviderNetworkMember_documentation_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Network</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember" xlink:href="moh-20200930.xsd#moh_ProviderNetworkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ProviderNetworkMember" xlink:to="lab_moh_ProviderNetworkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_783053ae-eacb-4b44-80e6-86ff4cca44a6_terseLabel_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total granted</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_label_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_documentation_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:href="moh-20200930.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_191f3f4a-84ae-46d9-bc37-af41e580a5b5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherReceivablesMember_b2aac837-bdb8-4316-be0a-ab1eadca3a4b_terseLabel_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_label_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_documentation_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember" xlink:href="moh-20200930.xsd#moh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherReceivablesMember" xlink:to="lab_moh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e230eab5-3172-4832-b029-eb0957fe6a09_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_f8f6f12f-20d8-48ab-a9b0-f04f11e57f87_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSEs</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicaidMember_cfd7b30d-22ba-479f-ab3c-9d33bb0776d8_terseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_MedicaidMember_label_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_moh_MedicaidMember_documentation_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember" xlink:href="moh-20200930.xsd#moh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicaidMember" xlink:to="lab_moh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_38c9a970-4987-4202-8047-8992fb856c9a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b6a3b403-5276-4d57-b2d1-f5e3d7fb650d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_5924155e-f387-4aa8-91b0-e396300a21de_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dc88e821-c3d1-4019-b973-3cfe5b31c4c4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_b3c0d045-3e9f-4824-abcf-dffb091c3f80_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f2c352cd-50a4-4a5f-aa1b-6b805606ba7f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5bf085ac-dbb4-449f-bda1-9d0acce5fffa_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4f5fb4da-ec25-44e7-8e88-76f1cfd2ce59_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_06ba91e6-5d6b-4ed7-80ed-532bebebaec3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_fc3acdfa-e02c-4488-b3af-0f69cf328322_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from senior notes offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1b47b428-b96e-49ba-8327-ad2c85bb4fdb_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c174b488-cdae-42de-95b5-1cc86c3408fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_942c374d-6e39-46cd-92f9-0a38fa68d205_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_b712d6d7-323f-45ab-a0f0-37c299eb2d4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_6a322a3e-e1a1-450e-9e1c-7ed0659e3b95_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a1326219-e6fb-47e8-a24a-c3d2a2224d65_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_91abe389-faa7-43ab-a524-bd5f2cc1a8e6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Investments in a Continuous Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CurrentLiabilitiesMember_49747768-cbdb-44a8-97d1-8f8b1143bb36_verboseLabel_en-US" xlink:label="lab_moh_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities: Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_moh_CurrentLiabilitiesMember_label_en-US" xlink:label="lab_moh_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:label id="lab_moh_CurrentLiabilitiesMember_documentation_en-US" xlink:label="lab_moh_CurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentLiabilitiesMember" xlink:href="moh-20200930.xsd#moh_CurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CurrentLiabilitiesMember" xlink:to="lab_moh_CurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MeasurementInputExpectedAssetVolatilityMember_cee46522-807b-4288-8ba3-b65086f8e4b5_terseLabel_en-US" xlink:label="lab_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Asset Volatility [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputExpectedAssetVolatilityMember_label_en-US" xlink:label="lab_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Asset Volatility [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputExpectedAssetVolatilityMember_documentation_en-US" xlink:label="lab_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Asset Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedAssetVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:to="lab_moh_MeasurementInputExpectedAssetVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_118b1671-1f0a-46fb-b16e-83e0945ae72a_verboseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable, current year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract_8d1ee33c-66bd-498e-b78f-9c87a6bf40d4_terseLabel_en-US" xlink:label="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of change in fair value of derivatives, net:</link:label>
    <link:label id="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract_label_en-US" xlink:label="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of change in fair value of derivatives [Abstract]</link:label>
    <link:label id="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract_documentation_en-US" xlink:label="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Details of change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:href="moh-20200930.xsd#moh_DetailsofchangeinfairvalueofderivativesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:to="lab_moh_DetailsofchangeinfairvalueofderivativesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_0b7917d5-8433-4531-a1d3-a2579b39469c_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6b8a4ebc-b46d-4801-86db-def4367b1310_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_54c7d42c-09a5-4ec6-96cf-fb1cbd68c65b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_9bab917e-d32f-4f75-81f5-235e0228592d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_2971199a-6952-4b60-8abe-2d7749fcd86e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Claims</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffinityHealthPlanMember_47c0f1c7-d9c2-4f1f-8cd0-dc5e7c91ec06_terseLabel_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity health plan</link:label>
    <link:label id="lab_moh_AffinityHealthPlanMember_label_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan [Member]</link:label>
    <link:label id="lab_moh_AffinityHealthPlanMember_documentation_en-US" xlink:label="lab_moh_AffinityHealthPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember" xlink:href="moh-20200930.xsd#moh_AffinityHealthPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffinityHealthPlanMember" xlink:to="lab_moh_AffinityHealthPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1b9903be-c68f-4ccc-89c4-907b16ae481d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_7325d5ee-f8f2-47dc-8ca0-3b0400373bd3_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical care costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6a28b6e5-7330-425e-982b-4c35a1193f4d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_790677d2-303c-44c6-b673-92283851e447_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_5f438e33-c660-490c-9fc4-69f8168965b5_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_aac423af-26ac-440e-bba3-3d1e8ebda5e2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_1be67e30-92c5-4330-8173-616c7b7795cc_negatedLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: other operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c8898071-1c11-43b8-849f-a08f6f366afb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6bad5c34-b403-453a-af88-04b9da31c294_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b4373108-d2ae-4bd1-9fa9-c3413dff3ce5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7e1127b0-853b-4ff2-9d1e-59f66c29ecf4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_bad88429-57ec-4e5a-9bbd-8dd5e7a246f6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f3e4b939-1f92-4af2-9676-957c788abe31_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5252c8b0-153e-4fad-922c-97f0131fa3e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_d4a35a53-c915-4361-9cdb-0e357563d861_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract rights - member list</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PassportHealthPlanIncMember_937da5c9-8be0-42ff-bbc8-0f8b48b09d37_terseLabel_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport health plan inc</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_label_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc [Member]</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember" xlink:href="moh-20200930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PassportHealthPlanIncMember" xlink:to="lab_moh_PassportHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_457cb353-704e-41ea-bdce-0316701405e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_74c7f7fe-6114-4a62-a5ee-8b5eea97f975_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_f289b88f-5f67-4f88-a167-5440ecd33ed7_terseLabel_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies</link:label>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Reported to Other Agencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:to="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_f22aafef-3e9c-4049-acbb-ade5a1f5caba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_53ae86b5-97d6-4ddb-a770-309a8b657c84_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_d6007dd6-e66a-42f6-a6f8-9ccb382692f1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e802a933-6f8c-4cfc-a559-3080313c7945_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_636812ed-8f27-4b62-8a51-67fee20acae3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_76b6738c-dfba-463b-b214-a9d6ec43ade5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_057d1f35-29d7-4e64-820e-15fcb4551635_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_e6e15563-f220-4605-b3e6-7b5d1c3f5e44_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_18c2b404-1055-48f0-9171-4231706ba4a1_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_9605bbcd-593f-4512-b981-1daded39e4b9_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption of new accounting standard</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8b8fdefe-989f-45dd-83ba-19570a61f78f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_b61769ef-baf5-47ff-8f86-e94d5d7fdced_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, over one year to five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_dc202b76-618b-4d97-a4e8-fc8030770fe0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6ab4d0e8-c087-43b6-b92b-3c8e475a7b17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_7ff56ae0-f95a-4385-8b5c-ff710a6bc0dd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_c03689fc-bab4-4de6-bd27-d93c309399c9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_7fc6ba4f-c8c2-4786-aace-21463dd6b132_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred issuance cost</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_762050bf-2739-4b1d-b687-a341f5ad5c18_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_bf699af2-5489-40c2-8ee1-1a25e89ea400_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_4a142b1d-d4cf-4891-ad52-3a54cd05f93b_terseLabel_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod" xlink:href="moh-20200930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsMaturityPeriod" xlink:to="lab_moh_InvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_0bd1a0a5-c7f7-4e93-94f8-3fff054b1efa_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock_7bafabf0-925c-4bd8-9d93-2028300e99cd_terseLabel_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue Recognized</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock_label_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue Recognized [Table Text Block]</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock_documentation_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality incentive premium revenue recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:to="lab_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_ff2c9df3-5ce7-405a-b943-891ca6347835_terseLabel_en-US" xlink:label="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum available quality incentive premium - current period</link:label>
    <link:label id="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_label_en-US" xlink:label="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Available Quality Incentive Premium Current Year</link:label>
    <link:label id="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_documentation_en-US" xlink:label="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum available quality incentive premium current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:href="moh-20200930.xsd#moh_MaximumAvailableQualityIncentivePremiumCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:to="lab_moh_MaximumAvailableQualityIncentivePremiumCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_a48e3ba5-9b82-479b-a059-c1b8979fd19d_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_bc7a0aac-741d-42bc-ad78-eca8258a542d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2c3f8314-3baf-481c-8a24-c748698cfdce_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_223ce24d-8321-49c7-be98-1e8aff13327d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities_9e029709-187e-4b16-96e8-a9b9ec913dde_terseLabel_en-US" xlink:label="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration liabilities</link:label>
    <link:label id="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities_label_en-US" xlink:label="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities</link:label>
    <link:label id="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities_documentation_en-US" xlink:label="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:href="moh-20200930.xsd#moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:to="lab_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_cee7c678-c3ce-48ac-b642-5da8ef0476f6_terseLabel_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to:</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_moh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:href="moh-20200930.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_moh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3e4c5bbf-9491-4103-a54b-9905a064e72b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6be319d3-4acf-4d9d-9a5c-c3f15381d9e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6625ca0a-3c28-433a-8c1b-0914b5de15a4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_53ebcefe-f655-4cdb-b079-b61d9de7b005_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_dacd9ed7-de05-482d-a2f6-29a8387e3330_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_39a0762c-bc0f-42c1-817f-83194eb5424b_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees reimbursed</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_85e4ad20-99ae-4649-bc83-1590a0d936db_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_e05d57d1-cd34-48bd-b3ea-2e20b952a8d6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e95061c8-3350-4a52-b83d-80ec7fb1450a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_974c7631-b0c1-4f86-a9e6-f6ac1d145220_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_FairValueOfAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_FairValueOfAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfAssetsAcquired" xlink:to="lab_us-gaap_FairValueOfAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_4cb08ece-bad7-402d-b319-241fcc9fb244_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CapitationClaimsPayable_873a923e-05e4-47b7-af20-0084e314457b_terseLabel_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_label_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_documentation_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable" xlink:href="moh-20200930.xsd#moh_CapitationClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CapitationClaimsPayable" xlink:to="lab_moh_CapitationClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_445ac82e-439a-4c59-9826-43cccd14c7b0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_c106f23f-0183-46d6-8660-a990936b5c97_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c8454bc1-de34-4e20-ac80-6f1bd7dad254_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_a2d608f2-9e63-4a27-b1ef-474abb0020dd_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_9393cde1-5280-458e-944e-dc62fb128abf_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_ccb84336-dd3f-44a7-ab6d-8871fb9e3ebf_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_78e35815-3407-46f7-be14-30bb3bc30b96_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_16fd1a14-3854-4c33-ad25-7c3ed34b44f9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_1f71d272-5245-4559-9171-21ad7500c21c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_987b1191-7d5c-40aa-9f24-5339bc17d3ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8da92f7d-a7b3-4fed-8dc8-031536ed64a5_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_e39828da-32b0-424d-ac99-1c27e9d34fdc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b1ce1e1a-5c6a-4d15-8d32-ca711602eab1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_1df1c57f-198c-41b8-af4f-5c6393b8c433_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_b880c3b0-2fed-419b-a599-01f37ac21d19_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_79b149f4-79fc-4f28-9aea-adc2ef173d7f_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ff6f2697-63f6-41df-9750-21e9b915d77a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_21a86258-9c53-4732-8fa3-dfe877b3a373_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_24e15bbb-834a-49b1-a557-a7606e852bd5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_d72bac85-4696-459b-832b-a7d30d0aa5cf_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt net of unamortized debt discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:href="moh-20200930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:to="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_f9f09922-612c-41f9-bcca-3674cdf167ee_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_a4f522ba-5506-4832-b042-897d28af27a5_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3440143c-b01c-4b61-bb38-a893170cf230_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_4db21a44-e3ba-4e9c-892d-7e22d426ea3e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at September&#160;30, 2020, and 62 million shares at December&#160;31, 2019</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5f6602c5-9ae1-473b-b00b-1a5e81c3ba84_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ConsolidatedNetLeverage_f87b8290-67b2-4050-9ac9-0f59eed74bf0_terseLabel_en-US" xlink:label="lab_moh_ConsolidatedNetLeverage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated net leverage ratio</link:label>
    <link:label id="lab_moh_ConsolidatedNetLeverage_label_en-US" xlink:label="lab_moh_ConsolidatedNetLeverage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Net Leverage</link:label>
    <link:label id="lab_moh_ConsolidatedNetLeverage_documentation_en-US" xlink:label="lab_moh_ConsolidatedNetLeverage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Net Leverage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidatedNetLeverage" xlink:href="moh-20200930.xsd#moh_ConsolidatedNetLeverage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ConsolidatedNetLeverage" xlink:to="lab_moh_ConsolidatedNetLeverage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_45dd0fba-20c3-49da-940c-495d737e6e6c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_f4468e0e-b18f-4bd6-9f0b-09de0e9f91b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_f08063ea-45dd-45f7-ba45-e0f762b362eb_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_1a6b160d-3333-4f83-95d6-5cc1be077fe1_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-risk and other provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable, Adjustments, Change In Provider</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable, Adjustments, Change in Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_e33759ee-1355-4366-911a-feb228d3604a_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_819e83a4-76fb-46ef-bfb9-464dca03dec6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_a4a7c465-a583-4fe0-9468-65cd3c1fe91a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4.875SeniorNotesMember_ce9be6a4-ae4a-4cca-8fdb-55a0784a9cd9_verboseLabel_en-US" xlink:label="lab_moh_A4.875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Notes</link:label>
    <link:label id="lab_moh_A4.875SeniorNotesMember_e26e7b02-760e-4469-93b6-57f3f9dc871e_terseLabel_en-US" xlink:label="lab_moh_A4.875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Notes due 2025</link:label>
    <link:label id="lab_moh_A4.875SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4.875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4.875SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4.875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.875% Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4.875SeniorNotesMember" xlink:to="lab_moh_A4.875SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_51e8fa02-c3d9-41b8-b7bb-aa013a69d7e9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_4f893266-07d5-4fd6-97b4-067dd0e4cf84_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b3be6d7b-68b7-4af6-ab60-7e53d4ca44ef_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8a9240f9-1680-4aad-83a5-55bed3fd346a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_cd20274f-c0fc-40de-842b-9c9e819b8fdc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_7ef23acc-680d-498c-8968-5ac0fd5d4f61_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5badec3-11d1-4c26-992c-35ae14433582_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SwinglineSubFacilityMember_ff226a55-ddce-4a86-b9bb-a8502e7eaa38_terseLabel_en-US" xlink:label="lab_moh_SwinglineSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline sub facility</link:label>
    <link:label id="lab_moh_SwinglineSubFacilityMember_label_en-US" xlink:label="lab_moh_SwinglineSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline Sub Facility [Member]</link:label>
    <link:label id="lab_moh_SwinglineSubFacilityMember_documentation_en-US" xlink:label="lab_moh_SwinglineSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swingline Sub Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SwinglineSubFacilityMember" xlink:href="moh-20200930.xsd#moh_SwinglineSubFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SwinglineSubFacilityMember" xlink:to="lab_moh_SwinglineSubFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_d2448fad-e49c-4a31-b284-92a23679e81f_terseLabel_en-US" xlink:label="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earned prior periods</link:label>
    <link:label id="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_label_en-US" xlink:label="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Of Quality Incentive Premium Revenue Recognized From Prior Year</link:label>
    <link:label id="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_documentation_en-US" xlink:label="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of quality incentive premium revenue recognized from prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:href="moh-20200930.xsd#moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:to="lab_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_a910763f-999b-44ff-b2b0-4faf9f0fd1bb_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e8f8ae47-5b4b-4cf4-850c-887b7af0d60f_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_879dc481-c7fa-40b6-b1c6-1f139cab42e5_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_2fca0432-f514-4460-a59a-1dd377e0a15e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_2d1754a7-0ddf-4e64-b864-6a562caf79d1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_8b692fdf-8336-4f90-8d66-fbce16622f0e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_888ed22c-72e5-4931-9382-6765cc9f7727_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d2b3acfc-69ed-4c8b-93cf-536f7e7e2156_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyClaimsPayable_dae95ce3-0edd-4052-8f5c-9af4fe40bcac_terseLabel_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_label_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_documentation_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable" xlink:href="moh-20200930.xsd#moh_PharmacyClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyClaimsPayable" xlink:to="lab_moh_PharmacyClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9c11fb58-8f3b-4f7d-b5de-936382d13d98_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ddc43792-6d70-4e26-815d-e03e6c7dbb14_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_79c83a7a-8939-421f-9c57-5daa6f1a232e_terseLabel_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Components of Change in Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_label_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_documentation_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:href="moh-20200930.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:to="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_6f2bc169-0187-4b1a-b43a-3ad5e6118f44_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at fair value measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_735e859c-52c4-4e34-9e66-78ac62741949_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_56d93a23-58c6-4632-9015-aee58808cb4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d8a7112d-4829-45b2-8603-724bcfdef10c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_2469ef0f-238d-474f-b13c-9de6cdbaf696_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary judgement</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_974205fd-5478-4d20-8bb1-5b36780046ca_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9c32ac02-68f0-4a20-98ea-24ffd49a877b_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_90eff208-dc0c-4ade-b472-11ccc59c573b_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_69c40544-af54-43c9-b922-3480294ea297_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_a260655f-9ad1-4fef-a2c2-f60a49f0e1c8_negatedTerseLabel_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional incremental revenue earned</link:label>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_label_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Additional Incremental Revenue Earned</link:label>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_documentation_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional incremental revenue earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:href="moh-20200930.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:to="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_cb1b0e09-e248-4716-ad24-305140529e7c_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:to="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_a4f6cbae-5b56-4da5-b43a-d39eb2a16696_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b00882bb-8619-40a2-93b4-4f8f90db8f2d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_576bd344-7323-4c18-bd57-1ee109c997a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_9b13e692-364d-4320-a1a4-e634d1f26bbf_terseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PremiumTaxExpenses_3860edf8-ade0-45a2-824b-ffc6cc0eb4f8_terseLabel_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_label_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Tax Expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_documentation_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An assessment levied by a state government on the net premium income collected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses" xlink:href="moh-20200930.xsd#moh_PremiumTaxExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PremiumTaxExpenses" xlink:to="lab_moh_PremiumTaxExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f8462c0b-d36f-4f39-9576-a663a4f37ba1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Revenue Recognition and Premiums Receivable</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_b664ca29-ae2a-4233-a16b-ad213c099b53_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium deficiency reserve</link:label>
    <link:label id="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_6fa53724-09f4-46e2-8a22-99cfff0ff021_terseLabel_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_label_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_documentation_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:href="moh-20200930.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:to="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f05b4d57-323b-40df-8de4-049c9d0c4493_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_dff1bfea-487e-42ef-ac70-6adb935a93bc_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_e646b951-8b70-4b0d-aaa6-e87fb8072ca1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_97986da9-2730-4ed9-ac4a-a765c4620ac2_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bca5697c-c4e6-4a9c-870d-618a2b786c05_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherSecuritiesMember_8b0ac998-e79b-4565-be8d-dd64b19f6fb1_terseLabel_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_label_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities [Member]</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_documentation_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember" xlink:href="moh-20200930.xsd#moh_OtherSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherSecuritiesMember" xlink:to="lab_moh_OtherSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_7495dbea-22e6-4415-a616-e2ae742bb4c5_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt net of unamortized discount</link:label>
    <link:label id="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)</link:label>
    <link:label id="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:to="lab_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_3375d83a-9a45-4c52-964d-9c2a731e9496_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_7465cae5-c11d-435b-a125-8e337246714f_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4c1018a4-a8f0-49ea-b865-9922cc89c6e5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fb86a3ab-86a5-4053-9d46-d96a5f3a85f7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ab6653c9-91f3-4b65-83a2-80f341bf92dc_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_e127f4f7-0676-45ff-b490-18f85b0bbe6b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_e9732ea7-844f-4bbb-849b-2522e6f9157c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt:</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_f96c2438-a483-4165-85c5-958998175172_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities held to maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4d00d829-091d-425f-83a9-d9de1335aea9_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_109193b4-e094-404f-8419-8cd9a227773f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_367db343-4f81-4601-9e97-ed900d608c8c_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_0706e9c8-a19e-4d05-8657-25c5cc3bfa58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:to="lab_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_53e9b5d1-60b1-4b6f-a3d7-8fc0f7c501fc_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_53b4fd6f-5e5a-48b3-af3f-d9069f1829f0_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_8c4e35ec-429c-4a7b-bda2-583c24e5e921_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ad6d872c-1e65-4be4-be14-463b133ba7b3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_6ad05c5c-a81a-44f3-8092-c183587f82aa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_3653cd8c-ecb8-4e1a-ba17-68dc425746ff_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_a4d43cae-f31b-4c32-bde0-c977f75719eb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_33dd1ad0-88f8-4d1e-b30a-cbf5346aac66_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.125% Convertible Notes, net of unamortized discount</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_e64c9e97-abeb-4139-8274-1bbe568fe40b_netLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_TradeNameMember_cfe455b4-a19c-4078-bf03-782495acc7ec_terseLabel_en-US" xlink:label="lab_moh_TradeNameMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_moh_TradeNameMember_label_en-US" xlink:label="lab_moh_TradeNameMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name [Member]</link:label>
    <link:label id="lab_moh_TradeNameMember_documentation_en-US" xlink:label="lab_moh_TradeNameMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TradeNameMember" xlink:href="moh-20200930.xsd#moh_TradeNameMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_TradeNameMember" xlink:to="lab_moh_TradeNameMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_a1159bc9-72c4-4ab4-af50-af8c1fff37f5_terseLabel_en-US" xlink:label="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Select health plans</link:label>
    <link:label id="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_label_en-US" xlink:label="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]</link:label>
    <link:label id="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_documentation_en-US" xlink:label="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:href="moh-20200930.xsd#moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:to="lab_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MeasurementInputExpectedRevenueVolatilityMember_35fc6e96-056f-4313-87c9-fb2fd37cda70_terseLabel_en-US" xlink:label="lab_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Revenue Volatility [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputExpectedRevenueVolatilityMember_label_en-US" xlink:label="lab_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Revenue Volatility [Member]</link:label>
    <link:label id="lab_moh_MeasurementInputExpectedRevenueVolatilityMember_documentation_en-US" xlink:label="lab_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Revenue Volatility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:to="lab_moh_MeasurementInputExpectedRevenueVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_e738f0cf-eb13-4bb3-a7d7-5b8e6b23ab86_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_579fec65-f7eb-466c-9a4f-46c292a314cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0bd20852-f80d-48c5-bee4-283aad0feca1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate on notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherMedicareProgram_e72de7f6-d508-4a89-9779-d301fa6fdc58_terseLabel_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_label_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_documentation_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram" xlink:href="moh-20200930.xsd#moh_OtherMedicareProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherMedicareProgram" xlink:to="lab_moh_OtherMedicareProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_26d38e1f-7915-4472-8e2d-707695f0f972_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3df0d74b-bddd-4e88-83b7-1640853f1382_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_72757fad-2bcf-4855-8212-c9305e005bf2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1554a893-1a76-48cc-b7b3-5dec94425753_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_aefe9995-f2e5-40ce-8ee7-0c9cb3896a68_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_825426a0-2cc6-4743-ba32-ae73a83869a7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal amount of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_feb21b9a-7cbf-4cba-b0d8-461894235024_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04d67047-ca2a-4684-a08f-379f7177d2b5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_c7c3ec77-51b8-4715-894a-f8572663c6e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock used for share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_aec23a1b-c9a8-49de-8924-3839fe4000d0_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_COVID19Member_53728dcd-db13-4470-92e5-54427ce88aa5_terseLabel_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_label_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_documentation_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member" xlink:href="moh-20200930.xsd#moh_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_COVID19Member" xlink:to="lab_moh_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_9cfd1299-1fa7-4e18-b6ea-7065e3fd0a88_netLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion option</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_e3e3d5fe-a82f-4765-b66c-235979eec480_verboseLabel_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion option derivative liability</link:label>
    <link:label id="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_label_en-US" xlink:label="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Embedded Derivative Financial Instruments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:to="lab_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_5c050b90-1ff0-4c07-ba74-e015b9436843_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c7f36eb6-6a4c-4ea1-92dd-36d9c0cddd29_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d938d7c4-d938-431c-8606-47c89465bc99_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_4a5ce8eb-5c4f-4f12-a552-a6a314d4d8ee_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2b877315-65b9-44ec-aa73-69a184b5579e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_d5c43a43-c30d-4957-bb19-f71abfe17cd8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_9f97276f-15f6-4a08-938f-dcdf5d2902aa_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_1203b5dc-c9ae-4742-ba54-aa6801394876_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: other operating revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_1839cd6f-bb8c-483c-862d-ebf203c0c689_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2be0c787-93a3-454d-9d0b-5d51d3c88c74_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_caad02c1-731b-4a74-bfb9-e54c45f844ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Share Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_848bd157-e3d0-4a45-9316-a4716e93f897_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs, approximately</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Members Eligible For The Health Care Programs</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:to="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2d1c8c82-9bfa-4cd0-9672-99c380a951a8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dc8a980f-9f59-48e1-9fb3-c6f19da5b143_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_33cdb249-ccb1-4376-bf6b-7ad79f59789b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_4cb407b6-e1b0-4a19-9451-4969a24ef837_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_88a1be1b-0ad9-4f87-97c6-850cd75d3e64_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_bc2c3301-dfe1-4fd0-b7d9-46c90df0565a_negatedTerseLabel_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for partial settlement of conversion option</link:label>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_label_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Settlement Of Conversion Option</link:label>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_documentation_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Settlement Of Conversion Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption" xlink:href="moh-20200930.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CashPaidForSettlementOfConversionOption" xlink:to="lab_moh_CashPaidForSettlementOfConversionOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_25d379f4-db75-4450-a26f-c2479d69c1f8_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_61b5289a-7bd0-44ef-a0cb-dbadd348dc1f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_fd1e3931-5215-42bc-89ea-b41db6443d82_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_6f7caff5-7046-494f-ae12-634356fcef60_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_853e9310-96da-4f85-84c0-211a55a916f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_b77f42e0-cb5f-4bf4-86b1-bbb9084d7723_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MunicipalSecuritiesMember_8f170830-eef9-4e02-a165-3c781c19360d_terseLabel_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_label_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Securities [Member]</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_documentation_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember" xlink:href="moh-20200930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MunicipalSecuritiesMember" xlink:to="lab_moh_MunicipalSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_fc8670c8-38a6-462d-bcea-cddda7e94230_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_318d704d-abca-42de-81f4-0f432fe45048_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c9a9debd-9d0b-4c23-bc18-9b7c29602cbc_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_513653da-bdf2-47cd-a06d-e2cc1c801000_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_7e51b60b-f888-4fc3-be31-903ea1acf2bd_terseLabel_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate receivables</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_label_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_documentation_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember" xlink:href="moh-20200930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyRebateReceivablesMember" xlink:to="lab_moh_PharmacyRebateReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_df5169ed-8307-4f07-b640-f56404e375a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b821cc82-0066-40ec-9323-2cd6397afb2c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7c4cc75e-e720-4c85-bf4f-c79d1a549400_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_4554f88d-13ce-4907-8ae6-5213366d1279_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_036aad94-da6f-4e0c-8cc8-14b3c172c7b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8b2654fe-845b-4530-a51c-259b26906cc8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_b0a914a5-d2df-4d7e-9dab-25b944ee23c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_9a19d116-9545-4066-a289-5d6e07ec4db1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_a6ddf9f7-b9ca-4cde-b9b9-d402a34f704e_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_38defdcd-27b8-4679-826e-8ea96181c51b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e7491b6c-24ad-4add-beb6-eda45c5a759d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee1ea0b1-988c-4e9b-90f7-4a31b58a7ed9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_bd1dac35-a73f-4faa-9234-c7cd8a242043_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_382eb754-7e04-409e-8c1a-dfdace8f89eb_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bb732b1a-7b3d-4f2b-9c3d-cb4665113c42_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_302d5b4d-4137-47c9-aada-e3f20f981c34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_465e9f94-719d-4031-8824-fda42bb0ab7e_terseLabel_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality incentive premium revenue recognized as a percentage of total premium revenue</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_label_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue As A Percentage Of Total Revenue</link:label>
    <link:label id="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_documentation_en-US" xlink:label="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Incentive Premium Revenue As A Percentage Of Total Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:to="lab_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_5d03eb3c-071e-4114-b3a1-d25a9b66a71c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LetterOfCreditSubFacilityMember_3b8a6726-7da6-4533-9529-26d98ab01fa7_terseLabel_en-US" xlink:label="lab_moh_LetterOfCreditSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit sub-facility</link:label>
    <link:label id="lab_moh_LetterOfCreditSubFacilityMember_label_en-US" xlink:label="lab_moh_LetterOfCreditSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Sub-Facility [Member]</link:label>
    <link:label id="lab_moh_LetterOfCreditSubFacilityMember_documentation_en-US" xlink:label="lab_moh_LetterOfCreditSubFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter Of Credit Sub-Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LetterOfCreditSubFacilityMember" xlink:href="moh-20200930.xsd#moh_LetterOfCreditSubFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LetterOfCreditSubFacilityMember" xlink:to="lab_moh_LetterOfCreditSubFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d907638d-d572-4c32-bf86-4cb42e5c915b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1d9ba7ff-2189-45ba-a821-d3b25a1b89d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_a01e1c3e-6300-40e8-85bb-901f0bf67671_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_39b738b3-d186-44ca-949d-464e998a8a22_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_8861202d-eba7-4107-bfdd-4942a4c4fdbb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_c1ad0a2e-27f2-43f0-84fc-71a83005a4f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_97188fa8-5a5b-420d-90d4-97b27a4502f6_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_76fd66f5-615f-4b51-81c5-99cbefb5b8f6_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements Adopted and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_62919d79-79a8-4c54-b612-3058125bf081_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ece9820c-c55f-48f0-bd87-048053155ce4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>moh-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:a175e22c-7a95-4ca5-b98c-820e60b7092b,g:1b054d00-3b55-4da4-9ab2-582dbf5e23b1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_3e3f3093-6c0a-42b8-b21b-3bca468cb995" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentType_3e3f3093-6c0a-42b8-b21b-3bca468cb995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2096ac31-4cd0-4ac8-90d3-f0d10003df43" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentQuarterlyReport_2096ac31-4cd0-4ac8-90d3-f0d10003df43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_23f7e505-c286-421d-b9c9-b23b40550cec" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentPeriodEndDate_23f7e505-c286-421d-b9c9-b23b40550cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_19b325ed-3dd7-482f-bc68-56072096311a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentTransitionReport_19b325ed-3dd7-482f-bc68-56072096311a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_accedbd0-ac30-4faf-9c1b-d4cb0bb5c833" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityFileNumber_accedbd0-ac30-4faf-9c1b-d4cb0bb5c833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9f9bad06-945d-4ce7-8b89-bd0bbd6fb72b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityRegistrantName_9f9bad06-945d-4ce7-8b89-bd0bbd6fb72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2891c509-cdf8-4e3e-aee0-c867a872baac" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2891c509-cdf8-4e3e-aee0-c867a872baac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_7d1cd962-8a3c-430b-b7e9-a43e5ad0cccb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityTaxIdentificationNumber_7d1cd962-8a3c-430b-b7e9-a43e5ad0cccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8ca1c0eb-b040-48aa-b553-bfd10925a4d8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityAddressAddressLine1_8ca1c0eb-b040-48aa-b553-bfd10925a4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8cdb71e7-4b68-45ca-9be3-93306f54b7b2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityAddressCityOrTown_8cdb71e7-4b68-45ca-9be3-93306f54b7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_991fc677-9529-4ed2-8af0-1023df9c161b" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityAddressStateOrProvince_991fc677-9529-4ed2-8af0-1023df9c161b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_c04093af-87fb-43a9-908f-4f2ae06b0876" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityAddressPostalZipCode_c04093af-87fb-43a9-908f-4f2ae06b0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_2b3dac39-3906-4790-9964-c115779d1854" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_CityAreaCode_2b3dac39-3906-4790-9964-c115779d1854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a2057394-0ea1-4ed9-91f8-b917a649d054" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_LocalPhoneNumber_a2057394-0ea1-4ed9-91f8-b917a649d054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c6cbf5f8-9c9f-4bf6-8855-b746b3b70d33" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_Security12bTitle_c6cbf5f8-9c9f-4bf6-8855-b746b3b70d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_5fb31f2b-a2bc-4a5b-918d-80d8501f41b3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_TradingSymbol_5fb31f2b-a2bc-4a5b-918d-80d8501f41b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_185b1724-da6a-4ca1-b983-865cd9e15cea" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_SecurityExchangeName_185b1724-da6a-4ca1-b983-865cd9e15cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_5be3b494-dbde-49b0-8966-b048404c452a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityCurrentReportingStatus_5be3b494-dbde-49b0-8966-b048404c452a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_22eda005-f3b1-4c33-988f-6c5c3eb98e8d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityInteractiveDataCurrent_22eda005-f3b1-4c33-988f-6c5c3eb98e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_96ef27b2-2112-4e1b-90f5-591378beb811" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityFilerCategory_96ef27b2-2112-4e1b-90f5-591378beb811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6818f23c-2322-43c2-a068-bb0f6a7ad591" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntitySmallBusiness_6818f23c-2322-43c2-a068-bb0f6a7ad591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8d43c139-845e-4215-9724-a82a91268db5" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityEmergingGrowthCompany_8d43c139-845e-4215-9724-a82a91268db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_050df805-241b-4196-bcac-7919b789b0af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityShellCompany_050df805-241b-4196-bcac-7919b789b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_af0c4000-52e0-4492-b9f9-ebd3a976f338" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_af0c4000-52e0-4492-b9f9-ebd3a976f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_5aa04538-2f8d-4874-bf33-c74dad3b483c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_EntityCentralIndexKey_5aa04538-2f8d-4874-bf33-c74dad3b483c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2ecf6c6f-fb7f-47c3-9fad-03651c140b0f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_CurrentFiscalYearEndDate_2ecf6c6f-fb7f-47c3-9fad-03651c140b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_c2675aae-64cf-4c30-b9e4-80914202f455" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentFiscalYearFocus_c2675aae-64cf-4c30-b9e4-80914202f455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_066f38a5-592d-4007-8bf9-d212cef30423" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_066f38a5-592d-4007-8bf9-d212cef30423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_baf1c66b-5ad1-46b6-9b09-05ac150ef83a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d168154-e32d-409a-87e5-91210152c0b6" xlink:to="loc_dei_AmendmentFlag_baf1c66b-5ad1-46b6-9b09-05ac150ef83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_7902048c-042b-4aab-82a2-8b4fc63edf81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:to="loc_us-gaap_PremiumsEarnedNet_7902048c-042b-4aab-82a2-8b4fc63edf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_2f7831e8-e753-4fb2-a4df-fb503ce1c519" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_2f7831e8-e753-4fb2-a4df-fb503ce1c519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_deb9a5bd-15d9-463e-aabd-1c3f7f11789e" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_deb9a5bd-15d9-463e-aabd-1c3f7f11789e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_4682653f-b381-43a8-bbba-824169c4645b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_4682653f-b381-43a8-bbba-824169c4645b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_85a0d353-80c8-4606-a092-2bb87b9b5264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_162afdc5-5041-4dbb-a8a3-693f144cbf2e" xlink:to="loc_us-gaap_Revenues_85a0d353-80c8-4606-a092-2bb87b9b5264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_17469a79-5d8b-433e-9285-e37e92fe1893" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_17469a79-5d8b-433e-9285-e37e92fe1893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_9c0ff2c7-485f-4e9c-8f37-e3b5f2b0c575" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_9c0ff2c7-485f-4e9c-8f37-e3b5f2b0c575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_32de2e27-94c6-411b-9328-ae8f78c4be2b" xlink:href="moh-20200930.xsd#moh_PremiumTaxExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_moh_PremiumTaxExpenses_32de2e27-94c6-411b-9328-ae8f78c4be2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_22b35715-c07b-46ba-856a-65a94258a7e5" xlink:href="moh-20200930.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_22b35715-c07b-46ba-856a-65a94258a7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_1e10156f-1784-4a64-b1b8-6fe263af7ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_us-gaap_DepreciationAndAmortization_1e10156f-1784-4a64-b1b8-6fe263af7ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_52e6da69-f1b0-49b1-bd26-aa7c6d7794fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_52e6da69-f1b0-49b1-bd26-aa7c6d7794fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3978efea-5ce8-43b4-84ba-066904feab6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_6f4f558d-c458-4bf8-b0e6-e0a66dd0113a" xlink:to="loc_us-gaap_CostsAndExpenses_3978efea-5ce8-43b4-84ba-066904feab6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8b8c5f25-f188-4c2f-a44e-00970e0f918b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_OperatingIncomeLoss_8b8c5f25-f188-4c2f-a44e-00970e0f918b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e64725e6-0cc8-4ea7-9565-7621382f0ab2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e64725e6-0cc8-4ea7-9565-7621382f0ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a52137f9-9f23-476e-ae12-fdd726fb2f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e64725e6-0cc8-4ea7-9565-7621382f0ab2" xlink:to="loc_us-gaap_InterestExpense_a52137f9-9f23-476e-ae12-fdd726fb2f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e69fc703-cf0d-4d03-982e-d8d2a096be01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e64725e6-0cc8-4ea7-9565-7621382f0ab2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e69fc703-cf0d-4d03-982e-d8d2a096be01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_035bd684-921d-48c1-8901-be8814fb1ff2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_e64725e6-0cc8-4ea7-9565-7621382f0ab2" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_035bd684-921d-48c1-8901-be8814fb1ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c3fe221b-b05e-43c0-b7a1-2245480794dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c3fe221b-b05e-43c0-b7a1-2245480794dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70c17af1-c0a9-49b8-83f8-7178ae3e96df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70c17af1-c0a9-49b8-83f8-7178ae3e96df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eb652399-f91f-4b10-b588-52aa916568e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_NetIncomeLoss_eb652399-f91f-4b10-b588-52aa916568e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5ae9af8d-314f-48ee-9dca-d3ac38975021" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a002fd2c-0ed7-459c-a8ab-6bd12ba196a6" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5ae9af8d-314f-48ee-9dca-d3ac38975021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9c1b8799-e7da-4df8-be2f-2c094d5f3e29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5ae9af8d-314f-48ee-9dca-d3ac38975021" xlink:to="loc_us-gaap_EarningsPerShareBasic_9c1b8799-e7da-4df8-be2f-2c094d5f3e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3706fd14-d589-43cd-a10d-42ba1205c10e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_5ae9af8d-314f-48ee-9dca-d3ac38975021" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3706fd14-d589-43cd-a10d-42ba1205c10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cca7b754-49ba-4e23-a979-e5f5418ca133" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2573cdee-1e12-4e71-81c4-95ea10be211b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cca7b754-49ba-4e23-a979-e5f5418ca133" xlink:to="loc_us-gaap_NetIncomeLoss_2573cdee-1e12-4e71-81c4-95ea10be211b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1f5065f4-dada-454f-b7ce-71c81452991a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cca7b754-49ba-4e23-a979-e5f5418ca133" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1f5065f4-dada-454f-b7ce-71c81452991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_48fc1964-98c9-438d-8b9c-eb8d10e34a79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1f5065f4-dada-454f-b7ce-71c81452991a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_48fc1964-98c9-438d-8b9c-eb8d10e34a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_14b86fde-9a47-4eeb-8370-efb7d01f7b8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1f5065f4-dada-454f-b7ce-71c81452991a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_14b86fde-9a47-4eeb-8370-efb7d01f7b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8e2d5d52-1ce4-4497-ac20-f9947f99dad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_1f5065f4-dada-454f-b7ce-71c81452991a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8e2d5d52-1ce4-4497-ac20-f9947f99dad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_dedfc17e-e008-4787-8bc9-38982f841380" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cca7b754-49ba-4e23-a979-e5f5418ca133" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_dedfc17e-e008-4787-8bc9-38982f841380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4b10ad19-1fef-4340-977d-45c6a2f49fab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b10ad19-1fef-4340-977d-45c6a2f49fab" xlink:to="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e94d2c8-c41b-4529-89fc-aec0b7e486df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e94d2c8-c41b-4529-89fc-aec0b7e486df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_bb550791-b517-4c45-ab36-ca2a3df72fba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_bb550791-b517-4c45-ab36-ca2a3df72fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_65f02368-27e6-4d8f-a311-45211a2bdb01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:to="loc_us-gaap_ReceivablesNetCurrent_65f02368-27e6-4d8f-a311-45211a2bdb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9e4f5f5c-cc5c-4cd1-b8ec-f9173a073ebb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9e4f5f5c-cc5c-4cd1-b8ec-f9173a073ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19f4d803-bc91-419e-a1ba-948941abd527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_06705e2b-baab-4764-8d8e-029415b4c05e" xlink:to="loc_us-gaap_AssetsCurrent_19f4d803-bc91-419e-a1ba-948941abd527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a133e43-f41b-41f1-b10c-e6d579f30611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5a133e43-f41b-41f1-b10c-e6d579f30611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2a6ac1ab-0ff3-463a-a4a6-a5f2835ee739" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_2a6ac1ab-0ff3-463a-a4a6-a5f2835ee739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_492706d8-82bb-4fe7-a90c-900a8c8a4782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_492706d8-82bb-4fe7-a90c-900a8c8a4782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_bd1c6211-70be-4ebe-ae50-71c9f02a0869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_bd1c6211-70be-4ebe-ae50-71c9f02a0869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5c61e70b-b7cf-46cd-a572-0f8147a1de4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5c61e70b-b7cf-46cd-a572-0f8147a1de4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_edf3dd27-a48c-4e6b-8c9f-adbeb86ac851" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4f9c9cc4-37d1-4400-8a88-201dacdf152e" xlink:to="loc_us-gaap_Assets_edf3dd27-a48c-4e6b-8c9f-adbeb86ac851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4b10ad19-1fef-4340-977d-45c6a2f49fab" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7f0b63e3-4ebc-4719-92bf-c739a13a4c89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7f0b63e3-4ebc-4719-92bf-c739a13a4c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_7b8e18ab-8b3e-4d76-9414-a3fe94a52cd0" xlink:href="moh-20200930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_7b8e18ab-8b3e-4d76-9414-a3fe94a52cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_61fd8450-3211-4825-a86e-a3c125b7ec71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_61fd8450-3211-4825-a86e-a3c125b7ec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6166859a-a89d-4a75-96b5-bec58d6f3558" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6166859a-a89d-4a75-96b5-bec58d6f3558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fb15254e-1f24-4fef-ae31-7cabc0784f0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8475d007-8765-48c5-bc32-92425a1ca24b" xlink:to="loc_us-gaap_LiabilitiesCurrent_fb15254e-1f24-4fef-ae31-7cabc0784f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_f7687311-c5c6-4ae0-800e-14554aad12d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_f7687311-c5c6-4ae0-800e-14554aad12d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b64d3918-d274-400b-849c-c15cbb927676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_b64d3918-d274-400b-849c-c15cbb927676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_892e8932-085e-460f-a96e-e55d1110a3db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_892e8932-085e-460f-a96e-e55d1110a3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_df1bda7d-1018-41ef-809c-edd29f12a270" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_Liabilities_df1bda7d-1018-41ef-809c-edd29f12a270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_1ce72921-c78f-4a63-9086-25ef4cda8db8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_CommonStockValueOutstanding_1ce72921-c78f-4a63-9086-25ef4cda8db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6afb5fd4-6e80-421a-a5aa-b63735351b7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_PreferredStockValue_6afb5fd4-6e80-421a-a5aa-b63735351b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fb9bece9-17fe-4317-9acc-6e5558e8014e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_fb9bece9-17fe-4317-9acc-6e5558e8014e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ab0ac7b5-327d-4773-9512-815de0b847e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ab0ac7b5-327d-4773-9512-815de0b847e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b06d1068-e89e-4339-abbe-945ab983ef73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b06d1068-e89e-4339-abbe-945ab983ef73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b8eaa701-cbac-4d10-bdfb-17c430650f4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c8c466c6-d671-4c91-92cf-863a1725e6fb" xlink:to="loc_us-gaap_StockholdersEquity_b8eaa701-cbac-4d10-bdfb-17c430650f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d2d631c-fb50-44d6-8564-c90f49abe822" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e3ff3a15-03fa-4dad-816b-5aeb0110218d" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_3d2d631c-fb50-44d6-8564-c90f49abe822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6a26b0df-333f-4795-8ed6-4470cdf01310" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6a26b0df-333f-4795-8ed6-4470cdf01310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_092a7b28-aa55-475d-8e11-fa3deed74560" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_092a7b28-aa55-475d-8e11-fa3deed74560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ba19afc1-8814-46ee-a261-2477724a6e87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ba19afc1-8814-46ee-a261-2477724a6e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6038fbc3-be00-49b4-a382-c38e5d2b8809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6038fbc3-be00-49b4-a382-c38e5d2b8809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_905e9751-62b1-4a3a-98c0-ec61241a7bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_905e9751-62b1-4a3a-98c0-ec61241a7bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9508939c-9944-4f0d-b1b1-c7040c883b0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9508939c-9944-4f0d-b1b1-c7040c883b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_125e4d3f-70a2-4344-836f-8d80de16ffc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_12930a76-8cc4-4664-be52-74838d75cdd7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_125e4d3f-70a2-4344-836f-8d80de16ffc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9e45600-c5ee-4e04-8aa8-768243128620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d9e45600-c5ee-4e04-8aa8-768243128620" xlink:to="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_fab6af6e-8981-4cb4-846e-f8305157bdb6" xlink:to="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_067a34aa-c01d-4956-956c-a452dadfbfe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_CommonStockMember_067a34aa-c01d-4956-956c-a452dadfbfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f4b6c109-e4cc-4fec-8666-534884e0b4ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f4b6c109-e4cc-4fec-8666-534884e0b4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40379ca0-2c82-4687-8eac-0f99f4955229" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40379ca0-2c82-4687-8eac-0f99f4955229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d9d6f27-5352-4e43-8fc4-cebd8857d258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9b299a1f-7475-4400-ba43-91740e8113cd" xlink:to="loc_us-gaap_RetainedEarningsMember_4d9d6f27-5352-4e43-8fc4-cebd8857d258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_5aa2b757-cbdc-4a42-967f-4b740991d0b8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4cad741b-8de6-42f5-af46-ca8b587e9ded" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_b785768d-593b-4617-8063-db8a49d55db4" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4cad741b-8de6-42f5-af46-ca8b587e9ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0c87b5bf-992d-4304-85a2-b2ca7ad9fb4d" xlink:to="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a963995d-d5d2-439d-a204-ae134f4bdaae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_03f51467-c9cd-4b84-8376-09287f296479" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_SharesOutstanding_03f51467-c9cd-4b84-8376-09287f296479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cf968a3-6ad2-408c-87b6-d4f1b2eb3b6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7cf968a3-6ad2-408c-87b6-d4f1b2eb3b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1c89b469-4196-4b9e-976a-cdf4fc56df37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_NetIncomeLoss_1c89b469-4196-4b9e-976a-cdf4fc56df37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_72e00ac6-f19b-42dd-8f7e-379e9721e016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_72e00ac6-f19b-42dd-8f7e-379e9721e016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_8ea0cd87-fcd1-48b4-986e-1f2e7745572c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_8ea0cd87-fcd1-48b4-986e-1f2e7745572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_dec2badd-7aae-475e-bee5-8404546acb0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_dec2badd-7aae-475e-bee5-8404546acb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef9277db-1eed-4e1e-a997-680eb23c59d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ef9277db-1eed-4e1e-a997-680eb23c59d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1cafe077-f4c5-49d9-aa42-9b18e0d0403b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_1cafe077-f4c5-49d9-aa42-9b18e0d0403b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cae78c1a-26d6-426f-af87-380debf6af73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_cae78c1a-26d6-426f-af87-380debf6af73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_9f05860f-924d-44de-8be6-6bda8a85b10b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_SharesOutstanding_9f05860f-924d-44de-8be6-6bda8a85b10b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e1ac0a1-42c3-42fd-ba35-18b30f67e11a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0c14a990-9382-4a3e-acc8-2c17150e7866" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2e1ac0a1-42c3-42fd-ba35-18b30f67e11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="moh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d39ecb9-04b8-4125-af70-949c1249397f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d39ecb9-04b8-4125-af70-949c1249397f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e18e55d-1273-4eac-a125-b940421d2ebc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d39ecb9-04b8-4125-af70-949c1249397f" xlink:to="loc_us-gaap_NetIncomeLoss_8e18e55d-1273-4eac-a125-b940421d2ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d39ecb9-04b8-4125-af70-949c1249397f" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9b62b222-9c22-46a9-b0e6-9b17f8c11d70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9b62b222-9c22-46a9-b0e6-9b17f8c11d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_17c9e4b9-4bdf-4744-a93e-a5500b9e9ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_17c9e4b9-4bdf-4744-a93e-a5500b9e9ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ce114bd-66f5-4d51-9850-6946334f1651" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_ShareBasedCompensation_1ce114bd-66f5-4d51-9850-6946334f1651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d73ec80c-617e-43f5-b882-72e9df69b0ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d73ec80c-617e-43f5-b882-72e9df69b0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4623d754-9170-4bef-bd64-9858b1f34c90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_4623d754-9170-4bef-bd64-9858b1f34c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_091f09d2-298c-4de9-ac15-a89914a83602" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_d38dc715-121b-4100-83e3-3e8bfc6e5f25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_d38dc715-121b-4100-83e3-3e8bfc6e5f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef575785-0501-4910-aeb5-9375e65e8faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef575785-0501-4910-aeb5-9375e65e8faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_bb34de44-0822-4903-9a79-804115e061a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_bb34de44-0822-4903-9a79-804115e061a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_16e6924a-0df9-4ebf-ba45-52788dd40206" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_16e6924a-0df9-4ebf-ba45-52788dd40206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bcad5a5c-21d9-4e2c-a771-04bf6fc07fd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_bcad5a5c-21d9-4e2c-a771-04bf6fc07fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0851d530-88db-43cd-b03e-1d2bb7114ffa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0851d530-88db-43cd-b03e-1d2bb7114ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a0a3a14c-6ae5-4a1c-bf3b-d150e31ae8c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_00760786-2c9c-42a3-8e1a-45109445b687" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a0a3a14c-6ae5-4a1c-bf3b-d150e31ae8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c0b7844e-c9e0-4204-a858-d60b50981f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1d39ecb9-04b8-4125-af70-949c1249397f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c0b7844e-c9e0-4204-a858-d60b50981f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_02d6edee-00ba-4867-a497-23eae990beaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_02d6edee-00ba-4867-a497-23eae990beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fcb49828-679e-4203-8393-ab32f88f57bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_fcb49828-679e-4203-8393-ab32f88f57bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3e226d4d-3852-44e7-986f-f539d212b0cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3e226d4d-3852-44e7-986f-f539d212b0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15e39941-33c8-46fc-ac78-11facf6ae056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_15e39941-33c8-46fc-ac78-11facf6ae056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a89b0e76-448c-459e-8671-0324000f1703" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a89b0e76-448c-459e-8671-0324000f1703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09af0452-29b5-452a-b7bd-c2d4c9fcce97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_717dc8a8-6444-4e54-8919-bcff3e02a154" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09af0452-29b5-452a-b7bd-c2d4c9fcce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_d019ce47-d54d-4bfe-a3db-a72f05692b54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_d019ce47-d54d-4bfe-a3db-a72f05692b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_ea09e34f-58d0-4de0-92f3-90ea284f98d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_ea09e34f-58d0-4de0-92f3-90ea284f98d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88c366ec-5f3d-4ec5-b995-80464ca17b1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_88c366ec-5f3d-4ec5-b995-80464ca17b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_96430d66-40ce-4f1e-b4c9-955f2a155bf9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_96430d66-40ce-4f1e-b4c9-955f2a155bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_5d7f2bf6-dd4e-48fc-a52d-bc0ed0e465c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_5d7f2bf6-dd4e-48fc-a52d-bc0ed0e465c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_f02990f3-6bc4-4a86-8c66-7553b3c42162" xlink:href="moh-20200930.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_f02990f3-6bc4-4a86-8c66-7553b3c42162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_d8ac2e64-d99f-47c2-9523-7f95f213b13c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_d8ac2e64-d99f-47c2-9523-7f95f213b13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_42306fac-b33c-4265-bd80-918d40208195" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_42306fac-b33c-4265-bd80-918d40208195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_78ca2187-1257-4180-a26d-c7ac5fd72934" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_78ca2187-1257-4180-a26d-c7ac5fd72934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87f73643-e210-4c0b-8af7-c34425a38199" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60407096-65f3-45c6-a5c7-5c2999001356" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87f73643-e210-4c0b-8af7-c34425a38199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7f385b8-bb21-4ab2-a129-a5d806ef96b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7f385b8-bb21-4ab2-a129-a5d806ef96b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6cb126e-b45b-4509-b584-4b9717825dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f6cb126e-b45b-4509-b584-4b9717825dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8743cc59-543a-48dc-81bb-2203e072f1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8743cc59-543a-48dc-81bb-2203e072f1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5a09709-24f7-4591-8fcb-da809942f48e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c444fbea-a683-4f5e-87a4-0712d5857989" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5a09709-24f7-4591-8fcb-da809942f48e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e05c76ad-9844-48bd-b795-bad15bcb2f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5a09709-24f7-4591-8fcb-da809942f48e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e05c76ad-9844-48bd-b795-bad15bcb2f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_a5c96872-284d-4187-b327-a36b07fdcf65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e05c76ad-9844-48bd-b795-bad15bcb2f12" xlink:to="loc_us-gaap_StockIssued1_a5c96872-284d-4187-b327-a36b07fdcf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:href="moh-20200930.xsd#moh_DetailsOfBusinessCombinationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_e05c76ad-9844-48bd-b795-bad15bcb2f12" xlink:to="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfAssetsAcquired_30b5b064-80cf-4394-978c-05ab98ec4a8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfAssetsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:to="loc_us-gaap_FairValueOfAssetsAcquired_30b5b064-80cf-4394-978c-05ab98ec4a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities_113f63c6-eac7-4557-b3b9-851c91935883" xlink:href="moh-20200930.xsd#moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:to="loc_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities_113f63c6-eac7-4557-b3b9-851c91935883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_6c482669-996c-4fa9-b969-404cda8fe457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:to="loc_us-gaap_LiabilitiesAssumed1_6c482669-996c-4fa9-b969-404cda8fe457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7ed69939-8cb2-47a6-b354-d7f0a9547786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_DetailsOfBusinessCombinationsAbstract_8ec640a1-6471-4b52-9e67-f87d8baf5e8f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7ed69939-8cb2-47a6-b354-d7f0a9547786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c5a09709-24f7-4591-8fcb-da809942f48e" xlink:to="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1e4c4bb4-99bb-4a3f-9a3c-7361149aebea" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CallOptionDerivativeAssetMember_342e0ac1-c925-4575-ab72-8a71151a7551" xlink:href="moh-20200930.xsd#moh_CallOptionDerivativeAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:to="loc_moh_CallOptionDerivativeAssetMember_342e0ac1-c925-4575-ab72-8a71151a7551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f8ac97a6-64c2-4ac8-97cc-e706a552d376" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9086f10f-1ae1-4cc0-b16e-53569ef0b8bd" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_f8ac97a6-64c2-4ac8-97cc-e706a552d376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_7f63a753-3d58-429f-8798-d4cd1c3c5d4a" xlink:to="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:href="moh-20200930.xsd#moh_DetailsofchangeinfairvalueofderivativesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0be708f9-4e82-4be8-b6bf-465c701c8c9d" xlink:to="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f1c55a3a-c910-4b62-bd49-018780ef0fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_DetailsofchangeinfairvalueofderivativesAbstract_4dc8a2e0-6934-4fe8-8342-6033b58d4d0e" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_f1c55a3a-c910-4b62-bd49-018780ef0fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b80c7fd-d8a6-4b91-82d5-c00f38c22994" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c70ac12b-6d17-4fb6-b127-7f1126b9f9cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3b80c7fd-d8a6-4b91-82d5-c00f38c22994" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_c70ac12b-6d17-4fb6-b127-7f1126b9f9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d179c294-8cfb-427b-949e-b5b5d781b56f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d179c294-8cfb-427b-949e-b5b5d781b56f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e9fd3d3b-9224-4bc1-bc23-8788417fef9e" xlink:to="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b723b7df-a1d6-495f-ad6a-1cd0c8f1f095" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:to="loc_srt_MinimumMember_b723b7df-a1d6-495f-ad6a-1cd0c8f1f095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e45de847-ab1d-4fcf-9e75-dc8e99ff4c5b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5397e883-2255-4a2d-b040-a891e113b0bf" xlink:to="loc_srt_MaximumMember_e45de847-ab1d-4fcf-9e75-dc8e99ff4c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5d9b7200-b599-4dca-8e0d-e42382764962" xlink:to="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_def91492-9fe3-464d-bc58-786ff0cdcade" xlink:href="moh-20200930.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fc370093-61cc-4db6-a64f-49bf1117f500" xlink:to="loc_moh_HealthPlansMember_def91492-9fe3-464d-bc58-786ff0cdcade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4ed6bffd-616f-44cb-b369-473ce37926a5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanMember_7bb40c9c-0928-429f-9558-6d7021c458c0" xlink:href="moh-20200930.xsd#moh_AffinityHealthPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:to="loc_moh_AffinityHealthPlanMember_7bb40c9c-0928-429f-9558-6d7021c458c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MagellanCompleteCareMember_00d6ab4b-3e0b-4912-8627-954dcd38875a" xlink:href="moh-20200930.xsd#moh_MagellanCompleteCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_981346c6-b4dc-4f80-aedf-04de150ab68e" xlink:to="loc_moh_MagellanCompleteCareMember_00d6ab4b-3e0b-4912-8627-954dcd38875a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_12c11be5-1145-4325-a5a9-681a24e1e1a3" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_8b2bfba0-5983-4efd-9007-6a220bc0feb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_NumberOfReportableSegments_8b2bfba0-5983-4efd-9007-6a220bc0feb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ce21d69f-0a57-4a67-9bec-38c090d5223a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStatesInWhichEntityOperates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_NumberOfStatesInWhichEntityOperates_ce21d69f-0a57-4a67-9bec-38c090d5223a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_896ad5cc-f782-4592-b1d9-450c11dd821a" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_896ad5cc-f782-4592-b1d9-450c11dd821a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_8f950882-e69e-45c2-95d2-fc443ef5e4ce" xlink:href="moh-20200930.xsd#moh_HealthPlanContractTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_moh_HealthPlanContractTerm_8f950882-e69e-45c2-95d2-fc443ef5e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e55279c-056b-4aeb-b27c-9d6e89603b07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_414aa314-5391-42f8-8649-cdb704f3ec3f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e55279c-056b-4aeb-b27c-9d6e89603b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bc7570b4-63a5-4874-a227-0add0d085f50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de778551-b7a3-4b65-8576-4bce25dc14be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bc7570b4-63a5-4874-a227-0add0d085f50" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_de778551-b7a3-4b65-8576-4bce25dc14be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_0c61082b-b83a-449b-8f66-c1f073acde67" xlink:href="moh-20200930.xsd#moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock_0c61082b-b83a-449b-8f66-c1f073acde67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_351b05e7-adaa-46ac-8385-fcd7869512e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_UseOfEstimates_351b05e7-adaa-46ac-8385-fcd7869512e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c15ab886-bc42-4c4d-b167-64a4fb156314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_c15ab886-bc42-4c4d-b167-64a4fb156314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_e3d51e8e-24d7-40be-89c1-cc5690dfa419" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_e3d51e8e-24d7-40be-89c1-cc5690dfa419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_02a90894-6021-4511-913b-c95dd8d40a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_02a90894-6021-4511-913b-c95dd8d40a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_59e7ee0f-e4bb-4b72-a6ea-aa5fdd1f03f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_59e7ee0f-e4bb-4b72-a6ea-aa5fdd1f03f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy_0fe3a5e7-1a4e-4846-87ab-f99577b7264b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_ReinsuranceAccountingPolicy_0fe3a5e7-1a4e-4846-87ab-f99577b7264b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_8767cdb1-38d5-4242-ba11-d73685892ff8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_8767cdb1-38d5-4242-ba11-d73685892ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_1a3ae070-52eb-4d16-be61-d351b1738511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_1a3ae070-52eb-4d16-be61-d351b1738511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99bedbe7-be8a-4273-b3e6-7a699a1c55e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_65c097b2-222e-4874-acdd-31c5ab9c58b0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99bedbe7-be8a-4273-b3e6-7a699a1c55e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_00cae29c-4d02-4418-adf5-013a414fd87d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_00cae29c-4d02-4418-adf5-013a414fd87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9130d444-5b21-43cb-a25b-c94d06465af9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_9130d444-5b21-43cb-a25b-c94d06465af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_761e5638-5ae4-4a46-baca-0e4f3592a4ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:to="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_761e5638-5ae4-4a46-baca-0e4f3592a4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock_7080736c-fbfe-45aa-8537-06b647ecfbdd" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:to="loc_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock_7080736c-fbfe-45aa-8537-06b647ecfbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a94642ff-1296-418e-9700-1c78deee5ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4eeb76d3-b6c5-488e-8f21-e7ad4999ba16" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_a94642ff-1296-418e-9700-1c78deee5ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_835af59a-2cfb-47bc-8460-84604c305aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2d6af56d-5f39-41a2-864e-c296c6fac73a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_835af59a-2cfb-47bc-8460-84604c305aab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2d6af56d-5f39-41a2-864e-c296c6fac73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_5276f882-5fd0-4455-a708-429e7bfbc956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_835af59a-2cfb-47bc-8460-84604c305aab" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_5276f882-5fd0-4455-a708-429e7bfbc956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8ea0595-3dcd-436c-b90b-92c13892a349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_835af59a-2cfb-47bc-8460-84604c305aab" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8ea0595-3dcd-436c-b90b-92c13892a349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_22b279d5-1737-445e-99b7-d5f8a37be243" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_22b279d5-1737-445e-99b7-d5f8a37be243" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_dd9605f9-adc8-483a-8add-d72e643d97e4" xlink:to="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_9a226bff-1525-4613-bfae-3b6357e5dccd" xlink:href="moh-20200930.xsd#moh_MaineCommunityHealthOptionsv.UnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_fc427e36-805f-4c02-8396-00180b4e0c4e" xlink:to="loc_moh_MaineCommunityHealthOptionsv.UnitedStatesMember_9a226bff-1525-4613-bfae-3b6357e5dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a59c7564-8133-4e1f-9909-c4852c35ef6e" xlink:to="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_0709bdc1-6889-40b0-8452-767ae5859322" xlink:href="moh-20200930.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_355ea7f5-a146-4666-af57-4b2733849360" xlink:to="loc_moh_MedicaidMember_0709bdc1-6889-40b0-8452-767ae5859322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8c95bd0d-f6a2-4771-aeac-e6f714c42667" xlink:to="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_PR_02b665f8-9bff-44ae-a004-9fb3886895e0" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_PR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1b0c2e52-db31-4dca-af8a-516b5266f7d5" xlink:to="loc_country_PR_02b665f8-9bff-44ae-a004-9fb3886895e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_c5130b44-8813-4566-ae5e-8ee183f90582" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_c98904fb-84e9-4347-bbeb-489e8f692f15" xlink:href="moh-20200930.xsd#moh_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f470ca1c-ee51-4aba-8daf-f61ffcce11e2" xlink:to="loc_moh_COVID19Member_c98904fb-84e9-4347-bbeb-489e8f692f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_277423d2-5668-44bb-921e-2550f59557f4" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_643a66d0-389c-463d-a897-07d394a53b50" xlink:href="moh-20200930.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_InvestmentsMaturityPeriod_643a66d0-389c-463d-a897-07d394a53b50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_b832061b-68b4-4556-b091-8bbf149db9b9" xlink:href="moh-20200930.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_b832061b-68b4-4556-b091-8bbf149db9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_4bf420c0-e85c-44ba-9981-83fec24a640d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_InterestReceivable_4bf420c0-e85c-44ba-9981-83fec24a640d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_43262b32-d0e4-4d29-b3b5-1e65a2fc1888" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_43262b32-d0e4-4d29-b3b5-1e65a2fc1888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_6752e185-6d5e-4181-8682-8b08ad02deb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_6752e185-6d5e-4181-8682-8b08ad02deb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_6bcf3701-dc8e-4bd0-b395-14f3726cd3e8" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_6bcf3701-dc8e-4bd0-b395-14f3726cd3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_be084512-9954-47c6-9ec4-82c32ba4596d" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_be084512-9954-47c6-9ec4-82c32ba4596d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_1e04a19c-0306-4497-8ea8-c81f1aa46381" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_1e04a19c-0306-4497-8ea8-c81f1aa46381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_da3e4224-74c1-4283-89a5-02716337a049" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear_da3e4224-74c1-4283-89a5-02716337a049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_49c1f7cd-2d5d-4148-904e-e23f56b76c69" xlink:href="moh-20200930.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears_49c1f7cd-2d5d-4148-904e-e23f56b76c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c83b546a-c30b-4ff2-8e90-9c8de3dc9b99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts_c83b546a-c30b-4ff2-8e90-9c8de3dc9b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareInsuranceFeeLiability_3d230870-fd45-4012-8668-51d34011401d" xlink:href="moh-20200930.xsd#moh_HealthCareInsuranceFeeLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_HealthCareInsuranceFeeLiability_3d230870-fd45-4012-8668-51d34011401d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_b04e982e-240d-43b9-878e-ab10588db270" xlink:href="moh-20200930.xsd#moh_IncreaseDecreaseInHealthInsuranceFeeLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_5b0602ec-e522-4495-9cad-1a1d80886a80" xlink:to="loc_moh_IncreaseDecreaseInHealthInsuranceFeeLiability_b04e982e-240d-43b9-878e-ab10588db270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd87fd50-2521-4860-aedb-f4c365d8de80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_5df4e609-4d3a-4960-9b31-24b04018e09a" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd87fd50-2521-4860-aedb-f4c365d8de80" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_5df4e609-4d3a-4960-9b31-24b04018e09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_427e4478-f12e-498e-a22b-558f0f4efba7" xlink:href="moh-20200930.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_5df4e609-4d3a-4960-9b31-24b04018e09a" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_427e4478-f12e-498e-a22b-558f0f4efba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_a88126fe-057d-42e5-9aed-ecc78e4d191b" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_5df4e609-4d3a-4960-9b31-24b04018e09a" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_a88126fe-057d-42e5-9aed-ecc78e4d191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_8e146827-d991-4e0f-bb2c-881a76b01315" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd87fd50-2521-4860-aedb-f4c365d8de80" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_8e146827-d991-4e0f-bb2c-881a76b01315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_4a87e9b0-1bc8-4a54-8bc2-571c9273ee9a" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_8e146827-d991-4e0f-bb2c-881a76b01315" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_4a87e9b0-1bc8-4a54-8bc2-571c9273ee9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_42986095-4785-4ca1-b6b5-9ed0cf8f6ac2" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_8e146827-d991-4e0f-bb2c-881a76b01315" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_42986095-4785-4ca1-b6b5-9ed0cf8f6ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_1ec919d6-1fc3-4f70-9fd8-7f739b2a7bf9" xlink:href="moh-20200930.xsd#moh_OtherMedicareProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_8e146827-d991-4e0f-bb2c-881a76b01315" xlink:to="loc_moh_OtherMedicareProgram_1ec919d6-1fc3-4f70-9fd8-7f739b2a7bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_78419aab-0efd-4f7c-b9a1-559cb7561c27" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd87fd50-2521-4860-aedb-f4c365d8de80" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_78419aab-0efd-4f7c-b9a1-559cb7561c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_3238d6a6-b90e-4f9a-bd21-39efe0287bc8" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_78419aab-0efd-4f7c-b9a1-559cb7561c27" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_3238d6a6-b90e-4f9a-bd21-39efe0287bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_a883b1cb-b2df-4a59-8365-2758a4797662" xlink:href="moh-20200930.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_78419aab-0efd-4f7c-b9a1-559cb7561c27" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_a883b1cb-b2df-4a59-8365-2758a4797662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_59a56dbe-765c-4fa5-9b78-7276c4c11770" xlink:href="moh-20200930.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_78419aab-0efd-4f7c-b9a1-559cb7561c27" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_59a56dbe-765c-4fa5-9b78-7276c4c11770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_7ec06708-878d-4c88-8e6b-0b1204cf67dd" xlink:href="moh-20200930.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd87fd50-2521-4860-aedb-f4c365d8de80" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_7ec06708-878d-4c88-8e6b-0b1204cf67dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6c6e1e8b-668d-4e47-bf57-9019a883c48f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6c6e1e8b-668d-4e47-bf57-9019a883c48f" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:to="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ab0824e2-2971-4bad-bc20-a2ba3e0f8480" xlink:to="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_66cd6a8a-bba8-4011-87de-0c84717d0948" xlink:href="moh-20200930.xsd#moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b7c8ce00-2964-42e2-93c0-a6786fdc196e" xlink:to="loc_moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember_66cd6a8a-bba8-4011-87de-0c84717d0948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:to="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5b01423f-0caa-4c1a-bd83-8838d9af762e" xlink:to="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7eca1f86-8c00-4e29-bfd1-0242d1fed6b3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:to="loc_srt_MinimumMember_7eca1f86-8c00-4e29-bfd1-0242d1fed6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_92abeff7-9d9e-4dcd-8584-c519db602de3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5a6704a-066b-403f-813a-ec258dc4b6f4" xlink:to="loc_srt_MaximumMember_92abeff7-9d9e-4dcd-8584-c519db602de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:href="moh-20200930.xsd#moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable_9fffe6db-dd55-4c0c-a84b-1a3762af2d57" xlink:to="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_e5a7884e-a1ee-4796-81a8-8378bc5d1363" xlink:href="moh-20200930.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_e5a7884e-a1ee-4796-81a8-8378bc5d1363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_61b0fdc8-71dd-43db-9dd1-007b3d00788e" xlink:href="moh-20200930.xsd#moh_MaximumAvailableQualityIncentivePremiumCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_MaximumAvailableQualityIncentivePremiumCurrentYear_61b0fdc8-71dd-43db-9dd1-007b3d00788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognizedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_5f81a2c6-c408-4155-89c6-fbca8934922d" xlink:href="moh-20200930.xsd#moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized_5f81a2c6-c408-4155-89c6-fbca8934922d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_fc9927a8-031b-424a-a96b-8316efb1dd38" xlink:href="moh-20200930.xsd#moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear_fc9927a8-031b-424a-a96b-8316efb1dd38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueRecognized_2ade78d4-c971-48a7-84f9-ba9a20780f07" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_QualityIncentivePremiumRevenueRecognizedAbstract_76c2b691-bd06-47ce-a202-16a1b70cb9a5" xlink:to="loc_moh_QualityIncentivePremiumRevenueRecognized_2ade78d4-c971-48a7-84f9-ba9a20780f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_6ecd1838-1905-4847-a219-c010686e4eb9" xlink:href="moh-20200930.xsd#moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems_952611fc-4203-4dba-9772-44614b074cbb" xlink:to="loc_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue_6ecd1838-1905-4847-a219-c010686e4eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b3ea5549-2328-4296-8abd-42fef2c1d3cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b3ea5549-2328-4296-8abd-42fef2c1d3cf" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3d34b7e7-04ef-49b7-b424-91d13a11c9e3" xlink:to="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_b8379771-3428-437b-acd4-74802228e07e" xlink:href="moh-20200930.xsd#moh_GovernmentReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_GovernmentReceivablesMember_b8379771-3428-437b-acd4-74802228e07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_79302d3d-9144-4917-822a-4c6cf11935ce" xlink:href="moh-20200930.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_PharmacyRebateReceivablesMember_79302d3d-9144-4917-822a-4c6cf11935ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_240d2b13-6e54-456d-a5fc-e55c8b5412ba" xlink:href="moh-20200930.xsd#moh_HealthInsurerFeeReimbursementReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_HealthInsurerFeeReimbursementReceivablesMember_240d2b13-6e54-456d-a5fc-e55c8b5412ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_6f1e7164-a0f5-497e-b5d3-0a2448d7ebb5" xlink:href="moh-20200930.xsd#moh_OtherReceivablesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_abc97c25-f141-4b44-8585-f6e0c8d04087" xlink:to="loc_moh_OtherReceivablesMember_6f1e7164-a0f5-497e-b5d3-0a2448d7ebb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_e8c8564f-3329-4a14-83f3-9f6be8c3f870" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_6b0852cb-cdc3-4e1d-83cb-c9163b00335e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_a2a79210-c0fa-4f16-a418-cb287478b10a" xlink:to="loc_us-gaap_ReceivablesNetCurrent_6b0852cb-cdc3-4e1d-83cb-c9163b00335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShare"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3bdeee73-2ea9-4232-b89b-bea23839c0d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_0774acf9-5165-4105-a55f-2adbc6b32f86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3bdeee73-2ea9-4232-b89b-bea23839c0d0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_0774acf9-5165-4105-a55f-2adbc6b32f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_519c3bc3-1a7e-4713-bc6b-ecdf9d4e4cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3cd3a5f1-57e7-48f5-b4f7-95d688793f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_519c3bc3-1a7e-4713-bc6b-ecdf9d4e4cfe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3cd3a5f1-57e7-48f5-b4f7-95d688793f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#NetIncomeperShareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomeperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_478cc4a4-40cb-4878-9845-29524f51650c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_478cc4a4-40cb-4878-9845-29524f51650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aa986ca1-50b0-4095-844d-7695f07207c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_478cc4a4-40cb-4878-9845-29524f51650c" xlink:to="loc_us-gaap_NetIncomeLoss_aa986ca1-50b0-4095-844d-7695f07207c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_367db8ff-dcf0-4848-9011-73ef6a8bfcd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_367db8ff-dcf0-4848-9011-73ef6a8bfcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_30d35ab6-0745-40ce-b046-b1bb7e561c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_367db8ff-dcf0-4848-9011-73ef6a8bfcd9" xlink:to="loc_us-gaap_SharesOutstanding_30d35ab6-0745-40ce-b046-b1bb7e561c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0fdfba5b-4737-4a69-bdc1-e6c384d62cb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0fdfba5b-4737-4a69-bdc1-e6c384d62cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_b7a11799-493d-4bd6-a683-a52f9863230c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0fdfba5b-4737-4a69-bdc1-e6c384d62cb1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_b7a11799-493d-4bd6-a683-a52f9863230c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_6408c036-e758-4332-b6b8-e22c5d5ca346" xlink:href="moh-20200930.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_0fdfba5b-4737-4a69-bdc1-e6c384d62cb1" xlink:to="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_6408c036-e758-4332-b6b8-e22c5d5ca346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9acb1fed-08cb-4774-9737-75023996b9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9acb1fed-08cb-4774-9737-75023996b9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_766e8cd6-0ada-44e1-897a-baeaa4a92a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_766e8cd6-0ada-44e1-897a-baeaa4a92a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_740462e9-c531-413f-87ca-499389df8e7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_766e8cd6-0ada-44e1-897a-baeaa4a92a04" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_740462e9-c531-413f-87ca-499389df8e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fe83ee62-0b16-4040-ae59-0994f0282d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_766e8cd6-0ada-44e1-897a-baeaa4a92a04" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fe83ee62-0b16-4040-ae59-0994f0282d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ad55f1-0871-4281-8b08-0c3f00ddfb0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21ad55f1-0871-4281-8b08-0c3f00ddfb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2c9495e8-3a77-49d3-be6c-ba43698b9b13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_41cc2296-c3f7-4bbf-bb9c-085ad630a006" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2c9495e8-3a77-49d3-be6c-ba43698b9b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_65efeb79-488b-4ea7-817c-746ed0c9f8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2c9495e8-3a77-49d3-be6c-ba43698b9b13" xlink:to="loc_us-gaap_EarningsPerShareBasic_65efeb79-488b-4ea7-817c-746ed0c9f8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6a94be0f-1e20-40e7-aa64-a6a9cdf88896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_2c9495e8-3a77-49d3-be6c-ba43698b9b13" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6a94be0f-1e20-40e7-aa64-a6a9cdf88896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_fe092b6e-3d89-4bf8-8abb-3322f9c136e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10bd590c-b758-4cec-b51a-89bdce07a71d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_fe092b6e-3d89-4bf8-8abb-3322f9c136e2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10bd590c-b758-4cec-b51a-89bdce07a71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9e78b4fc-6b97-48d4-ad14-cb119f2c5099" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_4d39c4f0-5576-4d1a-9530-54b0e5268fd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9e78b4fc-6b97-48d4-ad14-cb119f2c5099" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_4d39c4f0-5576-4d1a-9530-54b0e5268fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_f5a5f01d-0385-479c-8cde-7006f36fb0f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_f5a5f01d-0385-479c-8cde-7006f36fb0f5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4af4e08b-4f42-44b0-a0f0-1b9cffe68a96" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_YourCareHealthPlanIncMember_db3806f3-fb53-4c83-8fa9-cfed133a006f" xlink:href="moh-20200930.xsd#moh_YourCareHealthPlanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:to="loc_moh_YourCareHealthPlanIncMember_db3806f3-fb53-4c83-8fa9-cfed133a006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_a62191be-8d98-4e3f-bf12-0d81c713a968" xlink:href="moh-20200930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5785d3b1-f932-49c3-a247-96123c1cbace" xlink:to="loc_moh_PassportHealthPlanIncMember_a62191be-8d98-4e3f-bf12-0d81c713a968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_3d2096bb-4fa4-4d8e-a442-677c7ab78ea7" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations_dfc705b0-a6c7-41e3-8054-0abae50770e6" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_moh_BusinessCombinationNumberOfBusinessCombinations_dfc705b0-a6c7-41e3-8054-0abae50770e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_23958cbf-d809-40de-af5a-25e5f821aabd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_23958cbf-d809-40de-af5a-25e5f821aabd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_fe955a4d-5063-4e5b-bfb4-d84039069a84" xlink:href="moh-20200930.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_fe955a4d-5063-4e5b-bfb4-d84039069a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7b503df7-36b5-470d-a9c1-a3a2e438236e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_Goodwill_7b503df7-36b5-470d-a9c1-a3a2e438236e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d774dd78-2d52-46ec-8213-88ac5b8543af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d774dd78-2d52-46ec-8213-88ac5b8543af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0a7232a-644b-413c-a321-ea359f08f225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_5db3cc4b-9f65-4ae5-832c-efffca1c925c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a0a7232a-644b-413c-a321-ea359f08f225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#BusinessCombinationsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ca9aa1eb-c36b-4d85-9c73-7231abb874be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ca9aa1eb-c36b-4d85-9c73-7231abb874be" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c147476f-ee71-4bbe-b3e5-90a508847510" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_e5f78594-5754-4dd8-8753-9ff40522e580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_us-gaap_ContractualRightsMember_e5f78594-5754-4dd8-8753-9ff40522e580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TradeNameMember_59d62c2c-ca9e-4b34-a890-bc4ad70540cb" xlink:href="moh-20200930.xsd#moh_TradeNameMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_moh_TradeNameMember_59d62c2c-ca9e-4b34-a890-bc4ad70540cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember_57f61724-a620-4be7-a28e-5cfd18a1c528" xlink:href="moh-20200930.xsd#moh_ProviderNetworkMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2465e043-d41c-4af3-8c19-66c1f716a2be" xlink:to="loc_moh_ProviderNetworkMember_57f61724-a620-4be7-a28e-5cfd18a1c528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:to="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e241311c-4b9a-40b6-9f08-dabc753f0189" xlink:to="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d2f2924a-de60-4415-a87b-8d94ede1fa1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:to="loc_srt_MinimumMember_d2f2924a-de60-4415-a87b-8d94ede1fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6c7321bc-c825-4d8b-8229-8890b45cf7d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6a9d1d74-2650-4821-8624-b7a0e47bb699" xlink:to="loc_srt_MaximumMember_6c7321bc-c825-4d8b-8229-8890b45cf7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1bb9d395-eae8-4cca-b2a6-a8aa4f04c811" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a0cf0ac4-e7d4-43ec-8ac4-f2f382cb963b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_a0cf0ac4-e7d4-43ec-8ac4-f2f382cb963b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6875b831-8b4c-4b25-9537-cd686cb9aa26" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6875b831-8b4c-4b25-9537-cd686cb9aa26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_979544d3-1a01-4a8d-910d-dc6f5226225f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_de9af8d1-7250-447a-a164-1662ca510a73" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_979544d3-1a01-4a8d-910d-dc6f5226225f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_51197c45-99aa-446c-bf36-8782cea7b8f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_9d548bf5-63d2-4479-b7b3-7f24558edaaf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_51197c45-99aa-446c-bf36-8782cea7b8f2" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_9d548bf5-63d2-4479-b7b3-7f24558edaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_06717962-e4f2-4e0e-ada7-7982f1bce31b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4a0b6215-5b0b-4713-a164-4ccf466c9516" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06717962-e4f2-4e0e-ada7-7982f1bce31b" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_4a0b6215-5b0b-4713-a164-4ccf466c9516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_d22873ac-a0f2-4054-adf4-f74a6120ace0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06717962-e4f2-4e0e-ada7-7982f1bce31b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_d22873ac-a0f2-4054-adf4-f74a6120ace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14d197bb-2288-4039-8a03-3f1e8eb5d281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_06717962-e4f2-4e0e-ada7-7982f1bce31b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_14d197bb-2288-4039-8a03-3f1e8eb5d281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_455dc5f1-72a9-46d6-aeaf-c18a67495f96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_455dc5f1-72a9-46d6-aeaf-c18a67495f96" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b2ec51ae-7ada-4502-8557-6281a342c64a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_ab2fc509-813b-4de8-9495-652832814c06" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1250f4e6-1bfc-43bc-b773-6e1f715ba3ef" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_ab2fc509-813b-4de8-9495-652832814c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_55e9648f-6137-4727-865a-f131e1591ecd" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_1f7beb08-401d-40ad-bb26-cc60aafb8432" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_afa85093-15b9-4d46-a5bd-01b46854af8d" xlink:to="loc_us-gaap_ConvertibleDebtMember_1f7beb08-401d-40ad-bb26-cc60aafb8432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26deb99a-c3f8-46ff-9a7f-4c9934475838" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_5df3f6a9-cdb5-40e9-a245-241c3c8d0854" xlink:href="moh-20200930.xsd#moh_PassportHealthPlanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_da01600f-5507-4286-bae7-859d3a699da5" xlink:to="loc_moh_PassportHealthPlanIncMember_5df3f6a9-cdb5-40e9-a245-241c3c8d0854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0fd2ddad-3025-4139-bb9d-2e632c2855ab" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0a2784ea-9f94-4104-b24d-97b4bef2df1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_62a8d07d-e552-4301-a4e8-3fb167ac3389" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0a2784ea-9f94-4104-b24d-97b4bef2df1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_673b8996-e2a0-423d-b8c7-ee8e1889475c" xlink:to="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da01071b-6856-4c8f-b754-708a8fa078bc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:to="loc_srt_MinimumMember_da01071b-6856-4c8f-b754-708a8fa078bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_99d31d89-e757-4ce9-b296-a0d550bb8477" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f7c8859b-58f5-4c34-a09a-f6b21726e790" xlink:to="loc_srt_MaximumMember_99d31d89-e757-4ce9-b296-a0d550bb8477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_62887572-29f6-4661-bc8b-e6958c471491" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedAssetVolatilityMember_cfcb7b37-7c8e-47c3-86bf-27bfb7307f6f" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedAssetVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputExpectedAssetVolatilityMember_cfcb7b37-7c8e-47c3-86bf-27bfb7307f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputMeasurementPeriodMember_0f767aac-4f83-4655-b7d7-f2061ec69e1e" xlink:href="moh-20200930.xsd#moh_MeasurementInputMeasurementPeriodMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputMeasurementPeriodMember_0f767aac-4f83-4655-b7d7-f2061ec69e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MeasurementInputExpectedRevenueVolatilityMember_f42b82e1-6cb7-41db-b545-e606ad3c8321" xlink:href="moh-20200930.xsd#moh_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_3a53822a-578e-4268-96bd-95603b873eb2" xlink:to="loc_moh_MeasurementInputExpectedRevenueVolatilityMember_f42b82e1-6cb7-41db-b545-e606ad3c8321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_22bc3ad4-1849-4e71-b990-c94ae785d864" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_984cf6ae-0f70-4bfe-83b6-9976d78be1d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_984cf6ae-0f70-4bfe-83b6-9976d78be1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_477f241f-3a5a-4ba7-9aa0-6a8b3e1b2d53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_477f241f-3a5a-4ba7-9aa0-6a8b3e1b2d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_9f8a543d-d979-4b08-b24f-5fb57c212a0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_RepaymentsOfDebt_9f8a543d-d979-4b08-b24f-5fb57c212a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_941cfd00-d811-4b16-b721-1b9b6e2d8acc" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_941cfd00-d811-4b16-b721-1b9b6e2d8acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_09025bc1-cb5f-4075-9f73-25d52a6ae55c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_09025bc1-cb5f-4075-9f73-25d52a6ae55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23c3b312-293d-4ae6-9bf6-115b5564f121" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_a0ee5223-6605-407d-97c1-a9e1a163da01" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_23c3b312-293d-4ae6-9bf6-115b5564f121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9bd47be0-2ae5-4c6a-abcc-6f2d59799006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9bd47be0-2ae5-4c6a-abcc-6f2d59799006" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a6b650ae-ee95-4f58-b3dc-7caf22b57af7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8adfeccb-571e-4dc7-ae4a-8d95496215a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8adfeccb-571e-4dc7-ae4a-8d95496215a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_3a65e845-4333-4e6c-9c55-3e91c01e10fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_3a65e845-4333-4e6c-9c55-3e91c01e10fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8743b8c4-4b33-4c70-b785-79aa6f1ea1c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5320c2d7-5869-4a1e-9f8c-c90d3314fade" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8743b8c4-4b33-4c70-b785-79aa6f1ea1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:to="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_60fc94d6-f29e-46fd-bbe0-2e2c685717da" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_3f1c78a8-7c0c-44e5-b9a5-800c0606c134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_3f1c78a8-7c0c-44e5-b9a5-800c0606c134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c78e02c4-1c2c-4bf2-a38a-7ae2296920c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_c78e02c4-1c2c-4bf2-a38a-7ae2296920c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_d7b195ce-a2ba-4e9b-b40e-b65b2ae6d129" xlink:href="moh-20200930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_moh_MunicipalSecuritiesMember_d7b195ce-a2ba-4e9b-b40e-b65b2ae6d129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ea6e38b6-0202-43b5-85a2-d6ae11686e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ea6e38b6-0202-43b5-85a2-d6ae11686e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_4e207482-b46c-4b41-889b-786bf47e1304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_4e207482-b46c-4b41-889b-786bf47e1304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_8174b762-8cb3-45f0-a717-56afe9861d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_8174b762-8cb3-45f0-a717-56afe9861d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c713e2a5-bfa7-4535-898e-756c25f69709" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_c713e2a5-bfa7-4535-898e-756c25f69709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_295b1768-15ef-44c4-9c95-4c241b0480b6" xlink:href="moh-20200930.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_moh_OtherSecuritiesMember_295b1768-15ef-44c4-9c95-4c241b0480b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_cc5bf892-6b98-4442-9ab9-14956b52e36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFinancialInstrumentsAssetsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsAssetsMember_cc5bf892-6b98-4442-9ab9-14956b52e36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_37f58dfd-d225-4dde-892f-786c962915ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dcd432d8-92fc-4e14-b34a-0d1f149cdb3c" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_37f58dfd-d225-4dde-892f-786c962915ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_283663ba-6524-4f0e-9067-79ecdfb23e6f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1a9e23a-8b9a-4adb-8fd9-0406cd467155" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1a9e23a-8b9a-4adb-8fd9-0406cd467155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_35e26913-2f0f-493d-b43f-ce767e93d5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_DerivativeAssets_35e26913-2f0f-493d-b43f-ce767e93d5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5c7f9b7c-7bdb-445e-997f-5b001a912ca6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5c7f9b7c-7bdb-445e-997f-5b001a912ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9e19eb8-e5b5-4064-b1e3-d47a93949de1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a9e19eb8-e5b5-4064-b1e3-d47a93949de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_6588f67a-f0e3-41ce-afac-5f1937f7b0b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_DerivativeLiabilities_6588f67a-f0e3-41ce-afac-5f1937f7b0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b269092-d1b5-4547-8ac2-42d6bf16b101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a20717e7-ad56-4670-929c-0b9bdbd43668" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b269092-d1b5-4547-8ac2-42d6bf16b101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsBalanceSheetGroupingDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bbe06676-4ef7-4406-b205-fa33610b6da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bbe06676-4ef7-4406-b205-fa33610b6da4" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_35fed5a7-cbcc-4cc2-aa35-502a0a81384d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentAssetsMember_cd9b7dc9-03bb-4059-9b19-f2dac3f145fa" xlink:href="moh-20200930.xsd#moh_CurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:to="loc_moh_CurrentAssetsMember_cd9b7dc9-03bb-4059-9b19-f2dac3f145fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CurrentLiabilitiesMember_296719d5-a09c-4b9a-b8ea-8fe02074deae" xlink:href="moh-20200930.xsd#moh_CurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6c7a0cf2-23d6-4cf0-b1c1-f674ad122adc" xlink:to="loc_moh_CurrentLiabilitiesMember_296719d5-a09c-4b9a-b8ea-8fe02074deae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fb94e545-88e7-47b2-a516-11ffd79e6189" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CallOptionDerivativeAssetMember_ae485f40-d1a1-4570-b278-4945ccc34d3a" xlink:href="moh-20200930.xsd#moh_CallOptionDerivativeAssetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:to="loc_moh_CallOptionDerivativeAssetMember_ae485f40-d1a1-4570-b278-4945ccc34d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_6823a5db-26c9-4093-a5dc-5f3b760f0e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFinancialInstrumentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_fe12fbcd-2903-45c3-a64a-1457e967730d" xlink:to="loc_us-gaap_EmbeddedDerivativeFinancialInstrumentsMember_6823a5db-26c9-4093-a5dc-5f3b760f0e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d8b12f-d1e1-46e7-ba81-4b525e87e864" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3846d57a-c33f-4789-a4cb-6369912e3f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3846d57a-c33f-4789-a4cb-6369912e3f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47dbb889-7410-47e9-9a92-e60c81af77f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b22a1346-b51e-430f-b03f-f229a39209ac" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_47dbb889-7410-47e9-9a92-e60c81af77f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6ddf9737-6768-42c9-854f-d8fb29cc1a57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ddf9737-6768-42c9-854f-d8fb29cc1a57" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_62f34aaf-6434-49a9-bdcd-373c2b38e685" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4062ef72-aab8-462f-8a9c-7f2f036269aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_4062ef72-aab8-462f-8a9c-7f2f036269aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_36f32100-3986-4891-8cad-4ca3e1a83062" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_36f32100-3986-4891-8cad-4ca3e1a83062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b5060dd1-5416-444a-be22-eb1ebc97874a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_723026cf-1173-4963-ab1d-c13987401326" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b5060dd1-5416-444a-be22-eb1ebc97874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7c223110-4371-43e6-9c3d-b7c43f1adcd2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_ae7f533e-1275-488c-aeb7-03dd3ff1e90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_SeniorNotesMember_ae7f533e-1275-488c-aeb7-03dd3ff1e90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_589f15cd-f824-42b8-9fc2-ddfbc5d93d40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_589f15cd-f824-42b8-9fc2-ddfbc5d93d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_9b74e1ef-7256-4df2-b34a-764577890676" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_013bf520-6d7e-4ed0-83d7-c5c2ad565466" xlink:to="loc_us-gaap_ConvertibleDebtMember_9b74e1ef-7256-4df2-b34a-764577890676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b1c83b8b-d642-49d4-a4ae-d40c9b029c97" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_5567339b-4b5d-43f8-aaa0-0ae53bf92605" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_A4375SeniorNotesMember_5567339b-4b5d-43f8-aaa0-0ae53bf92605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_10bd712b-f813-4864-aef1-f8ab29857cd5" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_SeniorNotesDue2022Member_10bd712b-f813-4864-aef1-f8ab29857cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_f85d6ad4-869f-42bf-adcc-0123b3f701bd" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_A4.875SeniorNotesMember_f85d6ad4-869f-42bf-adcc-0123b3f701bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_3d34afaa-aed0-44ee-979b-cceecd03728f" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b0fe2af8-ad5f-49cb-8cb3-db0aa8eab91d" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_3d34afaa-aed0-44ee-979b-cceecd03728f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_57f45899-f2e4-43b8-b694-18f86db59b57" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_af660e4f-ca43-4a3e-bf23-d0f82c6333a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_af660e4f-ca43-4a3e-bf23-d0f82c6333a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_562e4556-d73b-4a18-8df0-352a75a6bcf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_bff951b6-4712-4a48-b18b-91b1622dbeda" xlink:to="loc_us-gaap_DebtInstrumentFairValue_562e4556-d73b-4a18-8df0-352a75a6bcf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20200930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75c15f82-75ef-4b18-a99c-45674d3c169c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fb48e995-9cd3-4218-9dd8-d86bb2c65448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75c15f82-75ef-4b18-a99c-45674d3c169c" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_fb48e995-9cd3-4218-9dd8-d86bb2c65448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b7338f8-0f65-491c-8058-e9f8d95364e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d98f9346-4777-471b-a47b-2f16faf0f440" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b7338f8-0f65-491c-8058-e9f8d95364e7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_d98f9346-4777-471b-a47b-2f16faf0f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_acc272c0-9227-4972-8772-1c2803e1dfbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b7338f8-0f65-491c-8058-e9f8d95364e7" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_acc272c0-9227-4972-8772-1c2803e1dfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b51a4401-da4f-4d6d-a80e-db74149b5f36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b7338f8-0f65-491c-8058-e9f8d95364e7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b51a4401-da4f-4d6d-a80e-db74149b5f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsSummaryofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_288e34f8-2fc6-4835-963d-7f49725c8efb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_288e34f8-2fc6-4835-963d-7f49725c8efb" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d925e9fa-9299-4dbe-b27c-df34b6f9bccd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d3fcf00d-8f51-4c54-922f-dcef9c07a1fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d3fcf00d-8f51-4c54-922f-dcef9c07a1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b19d7d1c-27ac-4647-bb70-2aec92d4ed1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b19d7d1c-27ac-4647-bb70-2aec92d4ed1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_fa02f877-0dad-4855-9616-1cda84d452cf" xlink:href="moh-20200930.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_moh_MunicipalSecuritiesMember_fa02f877-0dad-4855-9616-1cda84d452cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_36fba725-806f-480a-ad48-25ccef5f3485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_36fba725-806f-480a-ad48-25ccef5f3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_11e91097-be53-444f-807b-82bf51270a11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_11e91097-be53-444f-807b-82bf51270a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_81e5cf33-7bdd-4745-a767-8a0b6b75ecf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_81e5cf33-7bdd-4745-a767-8a0b6b75ecf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_db45e25b-f8eb-4d3e-b644-2c98a3c27663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_db45e25b-f8eb-4d3e-b644-2c98a3c27663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_55cdb094-215e-48b3-96a9-09c7f8c61280" xlink:href="moh-20200930.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9fefef00-3cc9-4a05-939e-606169d32b55" xlink:to="loc_moh_OtherSecuritiesMember_55cdb094-215e-48b3-96a9-09c7f8c61280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_005e43e9-be57-472c-afe8-691c3f39f6cf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_91543820-4e03-46e5-a646-0115b69c1cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_91543820-4e03-46e5-a646-0115b69c1cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07351561-cb8e-4f02-9fe9-3e53be2a24eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_07351561-cb8e-4f02-9fe9-3e53be2a24eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34661657-4f2f-4747-a119-e9aaee4f0f70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_34661657-4f2f-4747-a119-e9aaee4f0f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd07d9d0-e0ec-4568-a981-d5cc4b932f4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_88646c4c-447b-447f-b9f7-7a88461e6eed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_bd07d9d0-e0ec-4568-a981-d5cc4b932f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9de5d7b-7c0d-40d1-b630-5992bfff7a63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9de5d7b-7c0d-40d1-b630-5992bfff7a63" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e5bceb02-fbe2-44e4-976a-fb0cd0933267" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e5bceb02-fbe2-44e4-976a-fb0cd0933267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_1b2f9dcc-ac6a-4599-a755-240d703016c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_1b2f9dcc-ac6a-4599-a755-240d703016c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e6116c68-b564-44eb-866d-c7f37f8d95a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_e6116c68-b564-44eb-866d-c7f37f8d95a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_20968043-54a2-4e5e-995b-529e67e86625" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_20968043-54a2-4e5e-995b-529e67e86625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d315f2c4-6a9e-4ba1-9aa3-2ca68d8c2f21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_2c9aef61-bbac-4d72-a49b-f9273df0b04c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_d315f2c4-6a9e-4ba1-9aa3-2ca68d8c2f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b9de5d7b-7c0d-40d1-b630-5992bfff7a63" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8fe30ec-f50e-48a1-b9f6-5420de29c5a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_a8fe30ec-f50e-48a1-b9f6-5420de29c5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4f51db4c-41ec-40ab-8e6e-fcc62c1fde5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_4f51db4c-41ec-40ab-8e6e-fcc62c1fde5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4cb23765-56a6-49bf-89ee-0dd9e78d812c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_4cb23765-56a6-49bf-89ee-0dd9e78d812c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_a7066e40-360e-4c83-981c-534786d47035" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_a7066e40-360e-4c83-981c-534786d47035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_1284ae22-1dc8-4b0e-a0fd-17b23872f0ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_a0546125-081a-49c3-b21a-2eb251f53aa6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue_1284ae22-1dc8-4b0e-a0fd-17b23872f0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_a3777d3d-c616-46b4-bd4e-b864af95f8ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_a3777d3d-c616-46b4-bd4e-b864af95f8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_25e983ed-0dbe-478a-bc0c-041547d56af3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_25e983ed-0dbe-478a-bc0c-041547d56af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_fafbb9c3-cae3-4ef2-ad5e-7bc614b67452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:to="loc_us-gaap_HeldToMaturitySecurities_fafbb9c3-cae3-4ef2-ad5e-7bc614b67452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_35f3fe18-a544-4c65-82e4-10c0716ba59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_35f3fe18-a544-4c65-82e4-10c0716ba59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_123c47fe-9499-47f9-932a-fc64506921e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_47e91585-1a9e-4725-8f3b-de5ae7ea23b8" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_123c47fe-9499-47f9-932a-fc64506921e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#InvestmentsAvailableforSaleInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2165ed6-1747-4ba3-92fb-45d9aef355d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c2165ed6-1747-4ba3-92fb-45d9aef355d0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7fc59c46-dbb5-4f27-b61b-b137c108eeca" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_eea702a4-c4aa-42bc-8593-6e43e6d550a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_eea702a4-c4aa-42bc-8593-6e43e6d550a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_66f499e4-77ea-47d3-b817-a3f658609941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4b732193-fb25-411c-a7dc-35f4e5a86cdc" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_66f499e4-77ea-47d3-b817-a3f658609941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_29b1b208-edbe-412c-87b2-74b333ba5435" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e2979c80-ceac-4a5a-9929-39c48daad669" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_e2979c80-ceac-4a5a-9929-39c48daad669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f1395810-10fd-4ab3-8375-2c94bf25f8e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_f1395810-10fd-4ab3-8375-2c94bf25f8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_f98470f9-114b-4dbd-8abc-87e2f5c3d151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_8e719bcb-93b8-4739-b03c-8e0d6161c973" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_f98470f9-114b-4dbd-8abc-87e2f5c3d151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_95114abc-b09d-4003-aeef-c50fdee69d21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_e05430c8-2d49-4f8f-a6c4-b47630627a4c" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_95114abc-b09d-4003-aeef-c50fdee69d21" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableTextBlock_e05430c8-2d49-4f8f-a6c4-b47630627a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c5ac410-8206-478f-8099-8655aa979a31" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_7dcfdeb7-5e42-4cb8-ba3a-190ac9906d6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c5ac410-8206-478f-8099-8655aa979a31" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_7dcfdeb7-5e42-4cb8-ba3a-190ac9906d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_9f663ca4-11e9-41b9-9856-47464dfc3abf" xlink:href="moh-20200930.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_5c5ac410-8206-478f-8099-8655aa979a31" xlink:to="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_9f663ca4-11e9-41b9-9856-47464dfc3abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_c40492bb-088d-42f6-af3e-3d7960196a22" xlink:href="moh-20200930.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_c40492bb-088d-42f6-af3e-3d7960196a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_5de5326c-6d19-4291-b30c-4d36e29b51d1" xlink:href="moh-20200930.xsd#moh_PharmacyClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:to="loc_moh_PharmacyClaimsPayable_5de5326c-6d19-4291-b30c-4d36e29b51d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_94d45649-ad84-4a0b-acfc-67567aa981df" xlink:href="moh-20200930.xsd#moh_CapitationClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:to="loc_moh_CapitationClaimsPayable_94d45649-ad84-4a0b-acfc-67567aa981df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_21ae197c-18ee-4f83-8a89-94fa76e4542d" xlink:href="moh-20200930.xsd#moh_OtherClaimsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:to="loc_moh_OtherClaimsPayable_21ae197c-18ee-4f83-8a89-94fa76e4542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fc27b206-d720-4df8-b83e-6412556e11c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_a3248b6a-6292-4d8e-ad9b-dc6410af1025" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_fc27b206-d720-4df8-b83e-6412556e11c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b42f50a1-082f-4704-b103-a7408bc43a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable_250af9d2-a729-4a20-b586-18984f379010" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b42f50a1-082f-4704-b103-a7408bc43a0b" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayable_250af9d2-a729-4a20-b586-18984f379010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_19b4d623-e637-43dc-9f96-49be2c5c9ddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b42f50a1-082f-4704-b103-a7408bc43a0b" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_19b4d623-e637-43dc-9f96-49be2c5c9ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1a260c2c-e08b-4b8b-950a-57210b2a9e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1a260c2c-e08b-4b8b-950a-57210b2a9e5d" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_721e079c-6520-4339-9175-bde2ef56c7aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_721e079c-6520-4339-9175-bde2ef56c7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfMedicalCareCostsAbstract_0643053d-2417-4571-a930-a24e1c264f83" xlink:href="moh-20200930.xsd#moh_ComponentsOfMedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:to="loc_moh_ComponentsOfMedicalCareCostsAbstract_0643053d-2417-4571-a930-a24e1c264f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_95a16f6a-5908-44ab-85ec-500aca0d8330" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0643053d-2417-4571-a930-a24e1c264f83" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_95a16f6a-5908-44ab-85ec-500aca0d8330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d688350e-a684-4bf9-a1b4-f05253fb7b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0643053d-2417-4571-a930-a24e1c264f83" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_d688350e-a684-4bf9-a1b4-f05253fb7b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a4394065-76f9-4fe1-b96b-6fe4f8ed0786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_ComponentsOfMedicalCareCostsAbstract_0643053d-2417-4571-a930-a24e1c264f83" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_a4394065-76f9-4fe1-b96b-6fe4f8ed0786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_d65afbbd-f833-4a9f-bfe5-8cb9b9040347" xlink:href="moh-20200930.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_d65afbbd-f833-4a9f-bfe5-8cb9b9040347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentsForMedicalCareCostsAbstract_3cfc284c-c9a8-42a0-ba56-c12e49e95412" xlink:href="moh-20200930.xsd#moh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:to="loc_moh_PaymentsForMedicalCareCostsAbstract_3cfc284c-c9a8-42a0-ba56-c12e49e95412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_7350bf4a-79e2-4c5e-b8f2-0c73b7421b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_3cfc284c-c9a8-42a0-ba56-c12e49e95412" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_7350bf4a-79e2-4c5e-b8f2-0c73b7421b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_d71c1d7d-2355-4335-b03f-a8eda1fb3329" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_3cfc284c-c9a8-42a0-ba56-c12e49e95412" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_d71c1d7d-2355-4335-b03f-a8eda1fb3329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f9b61916-42d0-4143-aeff-f4c7192ce3d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_PaymentsForMedicalCareCostsAbstract_3cfc284c-c9a8-42a0-ba56-c12e49e95412" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f9b61916-42d0-4143-aeff-f4c7192ce3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_869372f6-05fd-4715-82fe-55440b21b58d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_9eff74e0-c97f-44d2-aeb9-df56aa294d4f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_869372f6-05fd-4715-82fe-55440b21b58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20200930.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4ed45cbc-a188-402c-a066-92d6a7040dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_9406479c-13cd-4b9d-9809-1a8937fa5ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4ed45cbc-a188-402c-a066-92d6a7040dbd" xlink:to="loc_us-gaap_LongTermDebtTextBlock_9406479c-13cd-4b9d-9809-1a8937fa5ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d3d8793-65ce-4a4e-ae9f-19ddedd8eae5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5bc8285a-7482-45c0-8238-d6725b5d8c40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d3d8793-65ce-4a4e-ae9f-19ddedd8eae5" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_5bc8285a-7482-45c0-8238-d6725b5d8c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1a452527-8643-4253-8466-17f65d3b0d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1a452527-8643-4253-8466-17f65d3b0d1d" xlink:to="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_230f6105-485c-48e6-87fd-4f306693975c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3720de2c-25cd-452a-8e0c-69bee983474e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_LineOfCreditMember_3720de2c-25cd-452a-8e0c-69bee983474e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_b929bae8-cd3c-46ef-87bd-d5206ba4bd8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_ConvertibleDebtMember_b929bae8-cd3c-46ef-87bd-d5206ba4bd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_057a48c9-d50a-4278-b7d8-23cedde8e9c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1fb49d07-fab4-44be-a46b-2f1f7905711b" xlink:to="loc_us-gaap_SeniorNotesMember_057a48c9-d50a-4278-b7d8-23cedde8e9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:to="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_05349afc-2e2c-4c04-94aa-3651fdffc9d9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TermLoanMember_424cd2fa-d524-41db-bdea-60be39fe85cc" xlink:href="moh-20200930.xsd#moh_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_TermLoanMember_424cd2fa-d524-41db-bdea-60be39fe85cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_565dbc4d-efbe-434b-bbe2-0619b3cd8d10" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_565dbc4d-efbe-434b-bbe2-0619b3cd8d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_159e2db3-a5cf-4853-93b5-94674a87e13f" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_A4375SeniorNotesMember_159e2db3-a5cf-4853-93b5-94674a87e13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_df81e852-55f2-4fe6-ba4d-e312d86676b2" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_SeniorNotesDue2022Member_df81e852-55f2-4fe6-ba4d-e312d86676b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_d474a293-4b1b-4fb7-bf7f-61585492904d" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8b84bbc3-26fb-4774-a15b-bf31c0308c7b" xlink:to="loc_moh_A4.875SeniorNotesMember_d474a293-4b1b-4fb7-bf7f-61585492904d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_06e4f658-9dda-4021-81a4-06df89649c00" xlink:to="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_bfcb21a0-1727-4387-8347-96e83706dc24" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_bfcb21a0-1727-4387-8347-96e83706dc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8455595a-0d7b-43ae-a772-ef1056cf16d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtCurrentAbstract_0c589532-c6f8-4765-8572-44bfff6ee93b" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8455595a-0d7b-43ae-a772-ef1056cf16d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_bd01cdcb-e981-4815-aeb4-5c111ec86a9a" xlink:href="moh-20200930.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_bd01cdcb-e981-4815-aeb4-5c111ec86a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a5510d48-c1c4-4555-b842-e65c7003f0b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_a5510d48-c1c4-4555-b842-e65c7003f0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1c736f08-71d1-4e9b-80dd-2a391fa4c446" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_e5e877a0-4c1b-4fcd-881f-0dc37e52ad67" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1c736f08-71d1-4e9b-80dd-2a391fa4c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2219e39-cc5e-4d1b-810d-1c0d13363eee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_b3a3e13f-c9a3-49eb-a407-74ed50efcdf6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_e2219e39-cc5e-4d1b-810d-1c0d13363eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_55d83580-2358-4d76-9638-764fba7a8d06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_55d83580-2358-4d76-9638-764fba7a8d06" xlink:to="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_417968e9-4563-4335-8bc1-b35623a73509" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_595fe3eb-6aaf-4cf3-95ff-5bbde50dae1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_LineOfCreditMember_595fe3eb-6aaf-4cf3-95ff-5bbde50dae1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_a230e53e-2929-4cd6-a00b-77fbae50160f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_SeniorNotesMember_a230e53e-2929-4cd6-a00b-77fbae50160f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_20e2f6a1-0173-48f3-a3ba-55652b583b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b191e073-54c6-4c35-91eb-ceb794e49084" xlink:to="loc_us-gaap_ConvertibleDebtMember_20e2f6a1-0173-48f3-a3ba-55652b583b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_cb498682-1a12-44a4-baa8-f4e15b56d71a" xlink:to="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_a3507e16-d576-478d-bf03-8d460877e29e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_a3507e16-d576-478d-bf03-8d460877e29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SwinglineSubFacilityMember_8f77183d-09d3-4c67-8f04-768ff34566b3" xlink:href="moh-20200930.xsd#moh_SwinglineSubFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_moh_SwinglineSubFacilityMember_8f77183d-09d3-4c67-8f04-768ff34566b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LetterOfCreditSubFacilityMember_8b5c3519-2cb8-4a62-8b74-ad03b41ba3ce" xlink:href="moh-20200930.xsd#moh_LetterOfCreditSubFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_216dd9c7-2ab9-44b5-96ab-4a50fa90321e" xlink:to="loc_moh_LetterOfCreditSubFacilityMember_8b5c3519-2cb8-4a62-8b74-ad03b41ba3ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_59ff2d21-274e-4bae-af94-ccadc5625005" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncrementalTermLoanMember_c7e8a122-3638-4961-8fa8-d809771f8774" xlink:href="moh-20200930.xsd#moh_IncrementalTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_IncrementalTermLoanMember_c7e8a122-3638-4961-8fa8-d809771f8774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_c2520cf8-fb48-4d0f-8896-daca3d3b677d" xlink:href="moh-20200930.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_A4375SeniorNotesMember_c2520cf8-fb48-4d0f-8896-daca3d3b677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SeniorNotesDue2022Member_0bef332a-658d-49f8-93cb-a882873567a1" xlink:href="moh-20200930.xsd#moh_SeniorNotesDue2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_SeniorNotesDue2022Member_0bef332a-658d-49f8-93cb-a882873567a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4.875SeniorNotesMember_c19dfd6a-0c02-41db-810b-5cbd23df01d7" xlink:href="moh-20200930.xsd#moh_A4.875SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_A4.875SeniorNotesMember_c19dfd6a-0c02-41db-810b-5cbd23df01d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020Member_23db7044-c4f9-410a-9c31-602ca5c5250e" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_219b3818-e431-4409-9c70-e94140bf335f" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020Member_23db7044-c4f9-410a-9c31-602ca5c5250e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af2f2c32-96d9-4032-89a9-e9aba1e27624" xlink:to="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96f7c9e4-b1a3-4124-a194-6977790804c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_96f7c9e4-b1a3-4124-a194-6977790804c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_cd45b5a5-07db-422a-96a9-95408065a2ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_cd45b5a5-07db-422a-96a9-95408065a2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ConsolidatedNetLeverage_14eee692-a513-4aa9-b61c-f3bb313d0b2d" xlink:href="moh-20200930.xsd#moh_ConsolidatedNetLeverage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_moh_ConsolidatedNetLeverage_14eee692-a513-4aa9-b61c-f3bb313d0b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3c5e2566-db24-4903-875f-99f55a574247" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentTerm_3c5e2566-db24-4903-875f-99f55a574247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_f3a8da07-a5a0-4710-af95-1cbb675ca1e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_LineOfCredit_f3a8da07-a5a0-4710-af95-1cbb675ca1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_591b2945-8ba1-410f-acef-8c5a7211b1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_591b2945-8ba1-410f-acef-8c5a7211b1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e31b9137-4cc2-41a7-b161-2af4b58227b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e31b9137-4cc2-41a7-b161-2af4b58227b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_032c7f7b-9f5c-4d8a-94f6-99b5b47f888b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_032c7f7b-9f5c-4d8a-94f6-99b5b47f888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_d418aba5-3fc9-44a9-9d76-9440ea600461" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_d418aba5-3fc9-44a9-9d76-9440ea600461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_018ae789-b2a0-4089-a908-36996765302b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_018ae789-b2a0-4089-a908-36996765302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_1f3c1dba-acb0-4674-ac92-f2db5ce3a0c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_us-gaap_RepaymentsOfDebt_1f3c1dba-acb0-4674-ac92-f2db5ce3a0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_2f62220f-7595-4b16-b234-10b7fa4f54dd" xlink:href="moh-20200930.xsd#moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_af090575-2b07-49e0-a625-2c3acaee4b1d" xlink:to="loc_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount_2f62220f-7595-4b16-b234-10b7fa4f54dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_40b7fabc-0255-45e5-a229-ba7bed9949c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3eada5e2-ec53-433a-9bdc-f4ba17f158a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_40b7fabc-0255-45e5-a229-ba7bed9949c2" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3eada5e2-ec53-433a-9bdc-f4ba17f158a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_64769636-96c9-4716-901a-4473b479cbd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d060d144-22d1-4dcb-bf1c-7261c9179505" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_64769636-96c9-4716-901a-4473b479cbd3" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d060d144-22d1-4dcb-bf1c-7261c9179505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ea4b3a09-da4a-44f6-af6d-0f71f16045c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ea4b3a09-da4a-44f6-af6d-0f71f16045c5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_deef05b6-1bd2-46cd-8e6f-02764f2f0cd7" xlink:to="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b6e33ba6-8be4-45e5-a0c2-efa100825670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7d06f739-8f18-4479-adee-ad7d51437082" xlink:to="loc_us-gaap_CommonStockMember_b6e33ba6-8be4-45e5-a0c2-efa100825670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_0a72f0f4-7554-4cf5-ae9f-1de363f371f9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_9ce5d629-bae3-4ec0-850a-5f118c03df8d" xlink:href="moh-20200930.xsd#moh_CashConvertibleSeniorNotesDue2020WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8a6af3c0-90ce-4009-807a-f73536c2628a" xlink:to="loc_moh_CashConvertibleSeniorNotesDue2020WarrantsMember_9ce5d629-bae3-4ec0-850a-5f118c03df8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ffa7120c-cc3a-461d-aea6-e012afd8a956" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_1701c386-4e1b-499c-b7f9-bea98c2523e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:to="loc_us-gaap_RestrictedStockMember_1701c386-4e1b-499c-b7f9-bea98c2523e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_b8a2f371-3fbc-419b-b308-0f766193028c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_216088eb-d51f-44ff-9d47-f994692b5edb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_b8a2f371-3fbc-419b-b308-0f766193028c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9a1b797c-b103-4ef7-af27-59f6e0789833" xlink:to="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7f0be82d-d314-4b75-aba6-54be0e51c9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_7f0be82d-d314-4b75-aba6-54be0e51c9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_6e41f467-2e20-4537-83ac-d661e88cc8fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_6e41f467-2e20-4537-83ac-d661e88cc8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_6ca49de8-8261-45a3-bc3a-3c4f7dff29f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_6ca49de8-8261-45a3-bc3a-3c4f7dff29f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f859a906-0028-461e-a49a-672865aab0d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_f859a906-0028-461e-a49a-672865aab0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8b8a842-f7fc-4b18-b937-cbd2150b89e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_f8b8a842-f7fc-4b18-b937-cbd2150b89e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ClassOfWarrantOrRightStatedInterestRate_ba96d95f-2319-4c89-8996-dc5a3b041c97" xlink:href="moh-20200930.xsd#moh_ClassOfWarrantOrRightStatedInterestRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_moh_ClassOfWarrantOrRightStatedInterestRate_ba96d95f-2319-4c89-8996-dc5a3b041c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63d5b26d-0e7b-4e86-aece-43015321a0e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_63d5b26d-0e7b-4e86-aece-43015321a0e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_15eaf9d5-86b5-4d85-9be3-11361c220990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_15eaf9d5-86b5-4d85-9be3-11361c220990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5288941c-2e0f-4c1b-9109-e0995f63d777" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5288941c-2e0f-4c1b-9109-e0995f63d777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3df57f84-efb3-43b4-aa0b-4f44df3047f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ShareBasedCompensation_3df57f84-efb3-43b4-aa0b-4f44df3047f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_44fbb8bf-7710-44f4-be38-5ec618723d56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_44fbb8bf-7710-44f4-be38-5ec618723d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42948937-3f4e-48a0-a644-b0152621538e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_42948937-3f4e-48a0-a644-b0152621538e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate_2ac8f880-7a3a-457d-9dca-cb8cf5f3b63b" xlink:href="moh-20200930.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_moh_UnrecognizedCompensationForfeitedRate_2ac8f880-7a3a-457d-9dca-cb8cf5f3b63b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a7493b65-9c3d-4ac3-b31d-0181c818016f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_a7493b65-9c3d-4ac3-b31d-0181c818016f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24cf32ad-7fa0-4e7d-84bc-710201490d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d0cf6746-b1b7-41cf-80de-68aa5dd37134" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_24cf32ad-7fa0-4e7d-84bc-710201490d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_357a4372-6589-4fee-b798-4afeaf40ebc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_357a4372-6589-4fee-b798-4afeaf40ebc3" xlink:to="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:to="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ceacf369-ff52-4843-9585-b2047b99c50d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5078aee4-9db1-427e-987d-d945a7332eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:to="loc_us-gaap_RestrictedStockMember_5078aee4-9db1-427e-987d-d945a7332eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1b24af30-1fc5-4048-b6e0-0ec110f04cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3995cc71-d3c7-4de2-b13a-21f039a15def" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1b24af30-1fc5-4048-b6e0-0ec110f04cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable_025806a8-eefd-4b5e-a204-30599ecdfdcf" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c03ccc70-3a03-43ca-b482-69860dd0ed2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c03ccc70-3a03-43ca-b482-69860dd0ed2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4150f030-ce47-477c-bca5-d49575de40d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4150f030-ce47-477c-bca5-d49575de40d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_912f15a9-ce15-4145-b764-6f1d6986fb91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_912f15a9-ce15-4145-b764-6f1d6986fb91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c2ea287-c3ea-426f-98b4-c678058042f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1c2ea287-c3ea-426f-98b4-c678058042f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a69b0eb6-0558-4d14-80bd-2f9ebe3c3d51" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_89c4c7c1-04fa-4d63-8dc9-004baa9a3c4d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a69b0eb6-0558-4d14-80bd-2f9ebe3c3d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_c2c89853-60e8-4368-a308-89e605481868" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b86b6645-9243-4c1e-850a-e2c53d7e3c2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b86b6645-9243-4c1e-850a-e2c53d7e3c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3deb5c28-8f4c-43a7-9dd1-6f7e4ee7902e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3deb5c28-8f4c-43a7-9dd1-6f7e4ee7902e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_75cfe897-b0fb-40ff-8881-57e6c5e71f65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_75cfe897-b0fb-40ff-8881-57e6c5e71f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5d903bc4-d879-4c5c-9d20-dd013c18cd63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_5d903bc4-d879-4c5c-9d20-dd013c18cd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f488eb52-2100-4594-9dbc-1930084a5d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b0e0d80a-758f-421f-9b89-00008e74bff3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f488eb52-2100-4594-9dbc-1930084a5d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#StockholdersEquityFairValueofAwardsGrantedandVestedDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b4439339-a1d9-4278-b3f4-b11c152c6525" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b4439339-a1d9-4278-b3f4-b11c152c6525" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:to="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43d5d699-59a8-4b0f-9541-b6ef5af43b0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_db93265a-d0f8-4840-971c-224e2419cfe2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:to="loc_us-gaap_RestrictedStockMember_db93265a-d0f8-4840-971c-224e2419cfe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cca610c2-15d6-40e5-9158-2d42c7167317" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1116cc30-4f2d-455f-9b45-5e26ac8a935e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cca610c2-15d6-40e5-9158-2d42c7167317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e43ad1-5ca2-4037-a2b5-73959363dc80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_b0b49251-535d-4b68-915e-663dad665320" xlink:href="moh-20200930.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_b0b49251-535d-4b68-915e-663dad665320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_21dc17cf-6bb6-4267-a8f3-a5c2a82e42ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d5270040-980d-4c3d-b015-9832f47eb102" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_21dc17cf-6bb6-4267-a8f3-a5c2a82e42ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20200930.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_599be687-c765-45c8-b52c-32c65b600ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3643e0d2-a9a4-462d-b478-7dd57a5c06fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_599be687-c765-45c8-b52c-32c65b600ec7" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3643e0d2-a9a4-462d-b478-7dd57a5c06fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_eacbcb33-f4b5-46ee-944b-04238407b37e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f85244f7-c255-4d2f-9d4c-961b09730372" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_eacbcb33-f4b5-46ee-944b-04238407b37e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f85244f7-c255-4d2f-9d4c-961b09730372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cb052da6-08c9-42d6-a6f1-6c7d73f3e001" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_6ed1eb28-c6c5-4d13-81d4-336238d74898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cb052da6-08c9-42d6-a6f1-6c7d73f3e001" xlink:to="loc_us-gaap_NumberOfReportableSegments_6ed1eb28-c6c5-4d13-81d4-336238d74898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20200930.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1e39f63b-5b06-4dfe-bfd0-dbcffe8ddf2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1e39f63b-5b06-4dfe-bfd0-dbcffe8ddf2e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_13b76276-d7c9-462e-839d-403ff594b32d" xlink:to="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_fb17b599-da84-4b18-bfda-f84b21d10acd" xlink:href="moh-20200930.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:to="loc_moh_HealthPlansMember_fb17b599-da84-4b18-bfda-f84b21d10acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_3be5dde4-d6e2-41f6-b141-6cab5dfd9a37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_7711a879-9556-4f67-901b-c773d3e945fa" xlink:to="loc_us-gaap_AllOtherSegmentsMember_3be5dde4-d6e2-41f6-b141-6cab5dfd9a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:to="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_db23f932-578e-4214-bf8c-12db383df85d" xlink:to="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_6360409a-dbba-4c69-a8fb-d408f0b1f16d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:to="loc_us-gaap_OperatingSegmentsMember_6360409a-dbba-4c69-a8fb-d408f0b1f16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_47e49fa8-b951-4e8a-8079-b81145a17a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b0c1dbc0-1850-403a-9635-81fba4f60173" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_47e49fa8-b951-4e8a-8079-b81145a17a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0c89d331-dc4c-4e16-873e-7a3e7c636de4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_2a0f28b1-8f49-46ed-8539-7686000dc41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_GrossProfit_2a0f28b1-8f49-46ed-8539-7686000dc41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_999f6082-7002-4b9a-b791-b1176fa19d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_Revenues_999f6082-7002-4b9a-b791-b1176fa19d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7f0eae4f-2246-4dd4-bb50-5daf199f5644" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_CostsAndExpenses_7f0eae4f-2246-4dd4-bb50-5daf199f5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2aa4c1c7-8687-4857-8636-0e0699b79542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_OperatingIncomeLoss_2aa4c1c7-8687-4857-8636-0e0699b79542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9e3605c0-f12f-4be7-9e44-e6a7dc838f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9e3605c0-f12f-4be7-9e44-e6a7dc838f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44465b70-d6a4-460c-ac6e-1bfd670c2144" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_7818b27d-4492-47cc-b6ed-ec5013726e97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_44465b70-d6a4-460c-ac6e-1bfd670c2144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_125c05db-1a4c-43e8-9c72-b37c03ec8b3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_11f7e6dc-9cd1-4948-b14e-0b83681fa707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_125c05db-1a4c-43e8-9c72-b37c03ec8b3a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_11f7e6dc-9cd1-4948-b14e-0b83681fa707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>moh-20200930_g1.jpg
<TEXT>
begin 644 moh-20200930_g1.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$&17AI9@  34T *@    @ ! $[  (
M   4   (2H=I  0    !   (7IR=  $    H   0UNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-H96EL82!(
M861E<G-B97)G97(   60 P "    %   $*R0!  "    %   $,"2D0 "
M S<R  "2D@ "     S<R  #J'  '   (#   "*      '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ_\  $0@
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M7HK!0MJV?,2S[$<UXQ5OG_F?2MM=07D"S6DT<\3?=>-@P/XBI:^?/#WB2_\
M#E\)[&0F,G][ Q^20>X]??M7NVD:K;ZUI4%_9G,4RYP>JGH0?<&N*O0=)WZ'
MNX#,88Q-6M)=/\B[1117.>H%%%% !1110 4444 %%%% !1110 4444 %%%%
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M??".%F\17LX^ZEKL/'=G4C_T$USXE)TG<]+*Y2CC(6_K0]<HHHKQ#[\****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$\5U;QSVTJ30RJ'CD1@RNI&001U%? M>P_!;XM'PU<Q>'?$4W_$GF?%O._\
MRZ.3W/\ <)//H>>F:!V/IVBD4AE!4@@C(([TM BIJU\=,T6]OUB,YM;>281
MXW[5)VYP<9QCI7E/A3X_P^*O%6G:);^')87O9=AE:[#!!@DG&SGI[5ZCK_\
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MQ.!6O9?"G6II@+R:VMHL_,VXNWX ?XBO2_#WARQ\-Z?]FL$)9N99G^](??\
MH*TK8F"BU%W9S8#*JTZJG55HKOU-:BBBO(/M KY^\7V:6'B_4K>( ()RR@=
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M4444 >D?!_\ X^]5_P!R/^;5ZE7EOP?_ ./O5?\ <C_FU>I5XN*_C,^[R?\
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M^UM7CN'MA*L3?9T#,I;.#@D<<8_&L+P?\7?#GC?7#I6BQWPN!"TQ,\*JNU2
M>0QYY%9WQ_B\SX1WC9QY=Q WU^<#^M>5_LU?\E)U#_L$R?\ HZ&@9]/UYWXD
M^-?ACPIXCN]$U:#41=VA4.8X496W(K@@[_1AUQ7HE8-WX'\+ZAJ<VHZAX?TZ
M\NYB#)-<VZREB %&=P/8"@1PW_#1O@K_ )Y:K_X#+_\ %T?\-&^"O^>6J_\
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MOUZI7-/\.?!CR!_^$7TI&!!!BM$3!'<;0,5TM @HHHH **** "BBB@ HHHH
M*^??%O\ R..J_P#7T_\ .OH*OGWQ;_R..J_]?3_SKOP7QL^=S[^##U_0QZ**
M*]0^0"BBB@#TCX/_ /'WJO\ N1_S:N9\>_\ (]:G_OK_ .@+73?!_P#X^]5_
MW(_YM7,^/?\ D>M3_P!]?_0%KCA_O,O3_(]RM_R*J7^)_J<[11178>&%%%%
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M^1WT/_L(V_\ Z,6@$>W/XU^. C8_\(I".#RMF21]!OKUOP3>:QJ'@S3[KQ-
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M:>)O^?./_O\ I_C7M]%..+J122L9U,EPU2;FV[MWW7^1XA_PK3Q-_P ^<?\
MW_3_ !H_X5IXF_Y\X_\ O^G^->WT57UVIY$?V%A>[^]?Y'B'_"M/$W_/G'_W
M_3_&C_A6OB;_ )\X_P#O^G^->WT4?7:GD']A87N_O7^1PGPZ\,:IX>N+]]4@
M6(3*@3;(&S@G/3ZUW=%%<M2;J2YF>KA\/##4E2ALCY3U#X%>/KR^N[S^S[7,
MT[N$^UIDY.<]<=_6OJM22H)&TD<@]J6BH.@XGXM^'=5\5?#VYTG0H$GNIIHC
MM>0)\JL&)R3CM7GWP?\ A;XI\%^/3J.MVD*VCV<D7F17"MAB5(&.O\->[T4
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MM(J *N23DD5Y!X6^%'Q5\)7[ZCX>:SL+N6$PNS312'86!(PP8=54Y'-?3-%
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M]P))"/T-=K\-/"FL^&M)OIO%5^NH:UJ5SY]Q.KE\*% 5,D#I@].!G XKM**
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>moh-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moh="http://www.molinahealthcare.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20200930.xsd" xlink:type="simple"/>
    <context id="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f8089a429f642bbacfc310486fd7f75_I20201023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-10-23</instant>
        </period>
    </context>
    <context id="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i96d66342f0554395ae8b108843d586cb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifccb71ed99474db29c92a1c32422fdb8_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3cd81903ac784f3c95b719f7294b0fd8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4249323997a74c5394dec06850d9f0ff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i5a9d47f2dd374531b3635ad709e30b61_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57bc664f05b14a159d4a8313d75faeee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if84d8cff947c4de9b53a8f49e428deeb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i49f2fd8b17184789ae8cfea2f06254dd_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic740cdd3e1084065ac35011ddfb13474_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id9475aa9426a4b6f8e55461a9f80ca69_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ief76444e7aed463c9fd6220ebe36686c_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id344fdf6e2c44551837ef61def1551e5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic13075558c9348ac82d3505a66e25fd8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8d34ec6b04954e97a9776fc5aedb9282_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i31f3031a4db94a98813421cfe891840e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9ecabd9c5a444209a8aff852fbc4b21c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i97892307215d43df8f22c0fbb18dcb61_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i0058815da1e149d0ad521442a393bdb0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5d0f3207cc784b74b39646cac08d8410_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ia5169226800d4ed096165ba76faed776_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ife5003122e804b988dea74c354c83d41_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i509d18c4ec7246019d82673921cdfeb0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i857bc8d2434e40239068a4279a5cd1f0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7ee588c43d0c4cb79042f4cb63afaa3e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic5afc4b5afff4b129fe93aba117db965_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iab11086ddd47417bb18ccbb3186696ce_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8c897de179cf4b5485a5907b73918b51_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9c3a00daa4bd49bb8c6a462ee00a7935_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8e25cb2bdbeb4161b0c79bc643ab2e01_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibf672f433e474e1390b199db5bd6d157_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if2e39a6516be42729bf559f4b31b0042_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic225d023312e446db67441be17efc548_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1b143b9b73dc4003a812274a03246027_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i7cc23cfa3d184d399207901dadbc36b8_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icfd68fed97114006a3e5e802d1c89c42_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i907d5beeecf040dd9ceadd4dd8ece877_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i772d4e400b1f469faf8028c4422dbcb3_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ide746b337aa049e7b40293ed6f01a425_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7722c16ae6c94fc29e287a669c377710_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i7e79de45409e408d8a51666f4d41bb77_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0b51ea44331043d0bc2c91aad3925ba5_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0ec3a4bd50d040a2aded930121774fb7_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ib17d434488324479a0237837e1d52044_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i81fbd2b196d1417d8d35142ae0959b35_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ic1742427719e433ba0aeb9e8493e3bb8_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="icf4919d73e0b4df7a87e1da456ef828e_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i3b37edd89d46497ab1c4734ff26bcd16_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i8def59bebfc44b69808ea12af90bd829_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="ie988e47ff15147608fa252205cc655bd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4e2fcc6a71f44a2d81e67581370faa03_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i1867d439641b408886f363900a45fc2e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="idfd328f3fb2a48b38a19eaf541451af9_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i85567348a9a24e39aafcb86cb42628ce_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8ee959cf00f54dcaaf758268793bb7d3_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i032e64312b634c9192f40d8aad600f2b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i795403e420354184bcfbf7b34e4879dd_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icfb9c978b5184509bd25b72a644093ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i446692be62344c64a03638faefd95842_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie7e315d8927941868fea6f62af5f9ae4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4b9468a421a64284ad5b14f3032873c3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i391a70c55331438f93619826459906eb_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idd699a73b5be49539d4149d71a08fadd_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MagellanCompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i0b8da8ee91eb4ef58dbbb2775da3afce_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="if6e8716ea12c44aaaacb9d6db8985ade_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie6a3fd1845154357ac826603e0ae69b7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0147887cf13f4458be0b3970d80acbc0_D20200618-20200618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">moh:MaineCommunityHealthOptionsv.UnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-18</startDate>
            <endDate>2020-06-18</endDate>
        </period>
    </context>
    <context id="i1e4e51fc373341cb966c120414402a2c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf82ebc1b18c49939d196d8bf9931c3e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">moh:CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if72eeeb9a99b4477ab11023ecac0d4ae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0c9cc48effd74e3db60699619b9bc2e7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i71a512cf78114e5cbc32223760854d4b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2833620245ff437a9d61acd7e7dbfa4d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33f1b142cbf04ffc961177d0573c2b33_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id396aa5e78ce44cca988d14d35592f10_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:HealthInsurerFeeReimbursementReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic1cccaa6b1874d0b97e1e7d43c952948_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if6158f7ac8714b678e788253d6cc7e0e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2dcf40f147894f828c6c0e0d48d7b212_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">moh:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:PR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if9a2b45e286440acaf152463d403a03c_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="id749608c745740b08f21cdaad564831d_D20200701-20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:YourCareHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-01</endDate>
        </period>
    </context>
    <context id="i87dd32a9ad2d4055800c9652ac634681_I20200701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:YourCareHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-01</instant>
        </period>
    </context>
    <context id="i4beec814285e499c89a31cc2a5afc464_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i433cfe399a704a47bba65a8c3a8b4e14_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i70c7a62c77174856b9b975dfcec870fa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8354adbb632c45a49e8c71116d0bd934_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie5b787b7098243d881eb301f892af3a4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icb06886bec8d4d3a8d4d744db0da88ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:TradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic6d40c8167db46f2a37e7382c7546b67_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:TradeNameMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if0f13a84316c4f71b4b314485e38873d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if845f286887c45ceb4f63de315dc91f9_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i421938697dd9476f9e8ed3a9387bbc72_I20200901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-01</instant>
        </period>
    </context>
    <context id="i044a1952a952424d842a4e7856f32813_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputMeasurementPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i16ad5df3e0954d1db28ec31f056ff595_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputExpectedAssetVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i79740d5150ff4f4db489bbeb8788d206_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">moh:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4e6dcbb92a8c4409987fd92c2d6dd158_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i058f38bcf796477da567b0db7952dc1e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9e90c966b6be4707a4a4282651786edc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6748d59d26dd4b4e9a668279c29380d7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibfdb1a74a3b545d0aee5dd04c31c43db_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5933b867152b47d29c8a2374b54fa5a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if75cd98fb83f46158ac380589d92af6e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib7ec79780ff9483fafe419776c6fff72_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e9ab90b62c74c95810d0a07c314ddd4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie806826c7c874d3cbee4baa4d5c22d75_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8f05ad2ae9724998ae461d78e2462361_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie647fc62813f495f8d1417451ba88a73_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i57fc15dc5d8d48bea4aaa778a0932e03_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0a101af7d174776bc9ad4386eed46b9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibcf557a6480b4644969946f54ab51f8e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic2741d275f3f4c36bced0a05c8aefec9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie22b9a72648d4042884d35282e080c18_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8bef829bfb5741c39a8a5d311beab675_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2a868439a3ab4ddba3f5532d5ceda157_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i78ca2500088d432999b9943027a2975b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if6ad5bafcd3a45f386f7d9e4c0f9f4a0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifa0f2cbbc505437587d85744ac0979eb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i79dc47d8b0274fb7814a8ba0de483d90_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6363a2d3e25d4dd98cfe015a124dada4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7caaaa444e8946e8a72451037d62eb94_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3048d9541ec340368f67b9914fdd4373_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib9c2e228625445018b01f1a9744f8c80_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85a0edf748fe453aa44bb4508f73e5f4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i52d9bab2071e4d2bbff6fa531b293a7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if241099a610c4f3785fd872f815a3259_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8832b45f6ca43d392a187f977e3dbf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i690ef92af3884583b912258ff28d709f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i668462f9d37f4932b5b594b4f0fcb1e9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59cc966e3845472abbcb53a46a0573e8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibcef928989144ada890aa6c205760cfe_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i234c36ce5254435e9cd31cb07a130065_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i73f8fb252fba435384882b7d0bd11132_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4993dfb9cae343e7a0595de8c3b268ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id693148d77924496941bc5d2a267a6d8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icc37b2026d5149db9253f8ee18a2d9b2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id0c9899abdda479e99525c731ad8ded7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i522376b3702049e087e884d659c89675_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iece312dcb67946698766f966c89eafa2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id50eed5aa516417bbac56da2beaea590_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i68b250a3de064792b082df53482bf14c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3c760dd71e144ec18a78b0cb8844490b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia96df6f9f64a43558623ace7f058a832_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idcc73a3dc4644046892c7265608f9887_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifa4f9337eb184ec2bdfe4334c287f7b5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0202efdf49a94c0fa927080c97980d08_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb61a08e25544eebb8b370e51386f60b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1d6efdc95e7240149d457a1f9ae63e55_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ec964ecd3644f5a8e9d165b2153cfe2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2526f7970b8c4c11bfd963e67d99f188_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1e4e03da2559470b9e01c0f4e7f534db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic12f63d329ee4926b7f91daa16eca22b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ae382dc57714c32a69f64a22d44f4c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3796bb08765846f69522f7b72d8e436a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4ad60777eaf94a25b4eb9085704435f9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i721461de0d57453f954cd5a2ea7e6120_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf4f5c72cbac46beb3ae4a136d11034d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11b1b5fd2c3d451da9d56d574c319476_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeFinancialInstrumentsAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3586192295fd40e39cdd133fd5eda38f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3035128b95994c0192502f66cc8725c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9eafdb5b66a49c39b778405016244ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d552ba27235403b8fea92d279192c84_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28a5c4abcb034316be3389b51a439633_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2f50b9933fcc48f99b974e53b1d2003b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">moh:CallOptionDerivativeAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie0209dd5a4ba48f1b5ae0d8164855055_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7cc3a3bcad764ec5b23c25c4598cbcf6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">moh:CurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:EmbeddedDerivativeFinancialInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icfe4a0d7268840d4a04e16db85cbe422_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i957912dee94240ee9072f0022698ffe5_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="if265cab40d764aa8a6f7a638b651c059_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i58388cfb135745d5a3d2212619472938_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa0145a0902d4f00a6773060e4727efb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1ded383a09c049409bb8aa4e1578f251_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7126a354069c4673ae6ccf8c5fe6c977_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if95b0e5cb5ad441cbe5353c0775eada6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if151f099c6024c06a2e13a64537444dc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib2aeeae1e1894e5ba53a5d2f756ecd8d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idf1097073c7c4951a8a0493f53a52d9f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i920b911bb1d54c89b67a30da5c6a439a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i45acf5d8b86b488a9df5b605c415166a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4d429d24c23a4067aa9eefd0f1237fb1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1a584d33b6bd4620a88cdb8f036b2df2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i607fd186209b46f88148885246fba93d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifd06b3418b6d4f8889dd763f2cfe3ecb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia2d1a36636ff4190a026b7df75b9f3d5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iff0aba0320264b41967f2e901f1c1b66_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i338d7f40d6294accbb73f4a509d10ae4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaf2d1b248d0349fc8ac32939e896036e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ide774a0690994809ae6d22cf1b4a5ec5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f28d6910080420eadec07f4dd9557ee_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="icb5372aaf360432383af74ac21bc50e1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9afc1ea189844c5eb735f3f4d963e7ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92d5297b47514ec9a062d743f1f8ebfa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1ccea875e1a344df9d2d0328fcf08ab5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if4004e550b88493b9d96d33568d57593_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic451188dc3fe4b559f5d53786e36984b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if9cd3c1e16c54817acea356e158e1192_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6353bdf90f6442659a69205e4bac7e7b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie3bb5a95ca0d417782d4613370c18f6c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:CashConvertibleSeniorNotesDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i4ec3ae376fbe4ad4a14e9b7642cf575e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i91235a939abc46cc8cfe1379d6385693_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i57960c7b966c4efba497e4524f1b3ddc_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id0fd66717c68402a9c361f8c9ddd1136_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:SeniorNotesDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i30bd18227ccc47deafa6692e187cac66_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4.875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d5fccb82c934bd1a15e322807ce290d_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i27fd4a76e49d4598ab2278e6e645278d_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i2c6273b5316944e4a596a67c24741345_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">moh:SwinglineSubFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i145a7ab1554b4757b2e887181fd98cc8_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">moh:LetterOfCreditSubFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iea4eec6ff70b47cb9fc4f0eee52a397e_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:IncrementalTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:IncrementalTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ie5e5997156224aac9afd99b367288856_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0212554bfd054535bec808876e3e5018_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id69307e89f364334ae9a43b18c71f4fe_I20200602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-02</instant>
        </period>
    </context>
    <context id="i1b80a28bab8c433a9545d7749e346c8a_D20200602-20200602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-02</startDate>
            <endDate>2020-06-02</endDate>
        </period>
    </context>
    <context id="ic2c093122fce40f5b352eff79a18d1c2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2538a5ed9cd54fd5ada2143661d2e391_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i550d7fb1a5cf4341ba55c9010cbc88be_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">moh:CashConvertibleSeniorNotesDue2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ic4024fea4fe14739828013441b0f2c9a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0123ff206dc2499598383ffd43d68eb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iffdf9fbfeb9745b5b757815afe72494f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8fe4a961d1eb4aa8b35c53d34bea3f7c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5eb569255aff4cb1a507ded6878088ab_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5fa4dac681a24334be8e8b77ddebd9c6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1eb474cbb156487da5ef2d111573f379_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id606f46ed6204025ae6c824bbc5386c5_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ideda1271d72d4f0f8c9490daadf92cba_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6768058042744166a9675351d4ec6518_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i09b03eb47e834f2ea94525c02f9c659c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib455ca5f2b5947a895ea50f53562ffd9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51b83677a3114d00b5fb75fa5b867b67_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1601849c348540f59d2211b5d20125f8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i23f1814b002a47d38a368f6700e92992_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>moh:segment</measure>
    </unit>
    <unit id="state">
        <measure>moh:state</measure>
    </unit>
    <unit id="member">
        <measure>moh:member</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="business_combination">
        <measure>moh:business_combination</measure>
    </unit>
    <unit id="security">
        <measure>moh:Security</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF8zLTEtMS0xLTA_c6f9def2-59b4-4056-8152-17e7e852f0f5">0001179929</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF80LTEtMS0xLTA_d16db0bf-a0ee-45c8-a404-153888cd9ed3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF81LTEtMS0xLTA_19023719-c46c-4aff-be84-99e5fabde668">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF82LTEtMS0xLTA_12efe96a-4206-4294-9b51-541450964955">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80L2ZyYWc6MWY5YTU5ZWQzN2M4NDNkZmI1MjU5NzdhOGZkMWMwNTkvdGFibGU6NTc0NWE1NWU1YzQ0NDFiOWIwNGJiMjFmNDJlODVjODAvdGFibGVyYW5nZTo1NzQ1YTU1ZTVjNDQ0MWI5YjA0YmIyMWY0MmU4NWM4MF83LTEtMS0xLTA_58da4ecd-0d7c-4691-84b7-0885532b166c">false</dei:AmendmentFlag>
    <moh:HealthPlanContractTerm
      contextRef="ie7e315d8927941868fea6f62af5f9ae4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAxOA_433cf4cd-b6db-4c94-b366-da8b885a7b9b">P3Y</moh:HealthPlanContractTerm>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIwNQ_b867bab6-89db-4d51-870f-e673f35a08fa"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_36c7aba9-b228-4098-809b-4b0742eb5288"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_6f9e707f-eddf-4292-bc86-3bc4e82d34e9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_897dcfc8-9208-498d-a87d-164137209947"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTI1L2ZyYWc6ZTg1NjU3Mjg1NDk3NDQzODg2OTM2MWE2ZTFhYTE5ZDUvdGV4dHJlZ2lvbjplODU2NTcyODU0OTc0NDM4ODY5MzYxYTZlMWFhMTlkNV8xMzc0Mzg5NTM0NzIxMQ_e217e431-349f-4209-9c6c-c5fa100385e7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTE2L2ZyYWc6NDE4MzA4MzM2MDY4NDFiNjg2MTU4OWYxZTVhZjM4ZDUvdGV4dHJlZ2lvbjo0MTgzMDgzMzYwNjg0MWI2ODYxNTg5ZjFlNWFmMzhkNV8xMzc0Mzg5NTM0NzIwNg_46376686-0cdf-492b-b931-076d93d0ff3f"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <dei:DocumentType
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM5_f86f02a1-3a6a-4393-9def-f116ca176d4e">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MDdmMGI2ZDAxZGRmNDY4NDliZGE3MTgxMzk4YjNlNmMvdGFibGVyYW5nZTowN2YwYjZkMDFkZGY0Njg0OWJkYTcxODEzOThiM2U2Y18wLTAtMS0xLTA_33a83564-72f7-456c-8911-9b96b6bcd738">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18xNDA_5471bae4-3173-4e3c-a656-a0d798db6685">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6YTY2Y2FkYjQ2YzFkNDVjMWE4YzdjOTUwN2NlZTFmOTUvdGFibGVyYW5nZTphNjZjYWRiNDZjMWQ0NWMxYThjN2M5NTA3Y2VlMWY5NV8wLTAtMS0xLTA_910cd5ef-8e39-4547-9ba9-ee862ba321c9">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTMy_e3115353-f9c9-4608-b054-6135ce8a3ed6">001-31719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTMz_3f31babd-d07a-4fdd-a518-c84d44f26560">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8wLTAtMS0xLTA_27b7b602-9490-48ee-b3f2-b7af75a4c2e9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8wLTMtMS0xLTA_87b0f515-d717-46cc-b9f2-43b8b48903ec">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF8zLTAtMS0xLTA_1c2659ae-ba9d-4aa9-a4a5-e45c44cb93b2">200 Oceangate, Suite 100</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTAtMS0xLTA_3e0a408e-a8e6-4a68-89a9-3664f764ca12">Long Beach,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTEtMS0xLTA_07170472-ff9d-43d3-a2ef-071319194a68">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6ZWRhMmFmNzZjY2NjNDUwYjhhYWI5ZjRlOTM5Yjc1YzQvdGFibGVyYW5nZTplZGEyYWY3NmNjY2M0NTBiOGFhYjlmNGU5MzliNzVjNF80LTMtMS0xLTA_ffda9a94-e325-4c7b-87d6-017ee2fa548e">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQy_5bf3333a-7ae5-48be-a41a-6ce1da3b2f49">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM0_495c599b-21b8-4983-ae26-1f5151171dc5">435-3666</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTAtMS0xLTA_e617eabf-3896-4fe2-860e-f32f5ce8c38a">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTEtMS0xLTA_46995e0f-0c97-4675-a33b-dfe164006073">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGFibGU6MTgxNjA3MDI5NzU3NGE3OTllYjliYWI0MjdmNGU1MzQvdGFibGVyYW5nZToxODE2MDcwMjk3NTc0YTc5OWViOWJhYjQyN2Y0ZTUzNF8xLTItMS0xLTA_b43dad89-f739-45de-9518-cea9d4090a76">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM1_6bfb9400-f31b-42fe-8ff7-702f11f33fd4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM2_65003c4f-c1de-4f10-b4a7-a7806ac5ae39">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM3_c1a44f8f-e90f-40ee-adf0-4049b733afc2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQw_c39e97f6-350e-4fc3-8af6-60e9296cf44b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTM4_33701d84-0c3d-457f-bef7-ccb4c1375123">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yMTQx_384ca72a-6f3e-44ca-95ec-6c648052f227">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i3f8089a429f642bbacfc310486fd7f75_I20201023"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xL2ZyYWc6YjVkYjhkZGJmYWUyNDY0MGE0ZmQ3ZDg0MDY0N2QyOTcvdGV4dHJlZ2lvbjpiNWRiOGRkYmZhZTI0NjQwYTRmZDdkODQwNjQ3ZDI5N18yNzQ4Nzc5MDcxNjA3_4e7562f4-be74-4dc2-abb6-cce70de2aa12"
      unitRef="shares">59300000</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:PremiumsEarnedNet
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS0xLTEtMS0w_8cdb70b7-117a-40c2-8d4d-ee01fcb3bc77"
      unitRef="usd">4768000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS0zLTEtMS0w_e0bb33ec-8f65-4515-96d9-2d3c8e7936a9"
      unitRef="usd">4084000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS01LTEtMS0w_33f02825-16a7-41e6-a0b6-f9c3d5f9771c"
      unitRef="usd">13444000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNS03LTEtMS0w_741a8b5e-940a-4004-8745-c1e6ab5956be"
      unitRef="usd">12085000000</us-gaap:PremiumsEarnedNet>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi0xLTEtMS0w_837db78b-77e8-4b1b-8d37-55d124427df6"
      unitRef="usd">170000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi0zLTEtMS0w_f75894e2-24f1-42de-be5c-6cfb0d94e69b"
      unitRef="usd">119000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi01LTEtMS0w_dcb649b8-3335-4843-a169-788e67f16d25"
      unitRef="usd">477000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNi03LTEtMS0w_bd051657-ab48-432d-ba3b-41b950f11d48"
      unitRef="usd">367000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy0xLTEtMS0w_36763518-b711-4dc7-ae74-00a5df9f90d1"
      unitRef="usd">69000000</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy0zLTEtMS0w_4c66d939-b8fb-4cdd-b06a-5c94c4caf12f"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy01LTEtMS0w_8e151dad-a7b1-4f9e-9e02-423bee7993bb"
      unitRef="usd">206000000</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfNy03LTEtMS0w_056c9b0f-ded2-430b-8094-b6a51205fb35"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeRevenue>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC0xLTEtMS0w_bac5718d-a043-4976-8f23-f2f63005a456"
      unitRef="usd">14000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC0zLTEtMS0w_c1b1cbb9-18be-4181-bc71-23ca093e3b9a"
      unitRef="usd">40000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC01LTEtMS0w_411954f2-11d6-4628-a348-1253ac746966"
      unitRef="usd">61000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOC03LTEtMS0w_7adff3e6-4ebd-447f-b0e7-03515cb37c15"
      unitRef="usd">103000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS0xLTEtMS0w_7adcf18d-572d-406c-bbe2-d1f4249c22da"
      unitRef="usd">5021000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS0zLTEtMS0w_5d4c28f8-de78-4463-9a5d-7fcadfb1e704"
      unitRef="usd">4243000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS01LTEtMS0w_7f66fa77-0df6-45e3-8697-b0289fb0f3c2"
      unitRef="usd">14188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfOS03LTEtMS0w_0dbae95a-a9b5-41f7-881f-82d6699fcd5b"
      unitRef="usd">12555000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtMS0xLTEtMA_19376960-4ebb-4a8e-aa04-bb0b8db53c0a"
      unitRef="usd">4098000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtMy0xLTEtMA_0ff8fccf-54d1-4aed-a264-04c39d7515cd"
      unitRef="usd">3523000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtNS0xLTEtMA_4bf7459b-2ca3-4d6b-9a73-254c7593cab8"
      unitRef="usd">11412000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTEtNy0xLTEtMA_8df70ff1-aa93-46bf-88bb-e2ed0bed3dc0"
      unitRef="usd">10360000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItMS0xLTEtMA_10a4ac5e-44b0-4c88-aba8-d012dbeff732"
      unitRef="usd">368000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItMy0xLTEtMA_ba1a95b3-f731-465f-8bd6-d78cf1ed97d5"
      unitRef="usd">323000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItNS0xLTEtMA_a0b6bca2-b005-4906-b1ac-0f0b4ad9e466"
      unitRef="usd">1030000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTItNy0xLTEtMA_bc66bf44-7376-4567-a71e-94f9db6b3bb1"
      unitRef="usd">953000000</us-gaap:GeneralAndAdministrativeExpense>
    <moh:PremiumTaxExpenses
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtMS0xLTEtMA_9de58684-46d2-473a-a844-8a815e9de1be"
      unitRef="usd">170000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtMy0xLTEtMA_7fabb6b4-3750-4f46-a384-b9f43ea26842"
      unitRef="usd">119000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtNS0xLTEtMA_f70e1790-bbfc-4060-b211-77f36a089e0f"
      unitRef="usd">477000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTMtNy0xLTEtMA_4641532e-079e-4dda-b069-51447fc1c1dc"
      unitRef="usd">367000000</moh:PremiumTaxExpenses>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtMS0xLTEtMA_81c78450-954d-417f-a032-d6b17b2cf4af"
      unitRef="usd">70000000</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtMy0xLTEtMA_2d1273e5-f098-4d2f-9f6c-66a8cdf24293"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtNS0xLTEtMA_ade345eb-d7cd-4722-8afd-119bdc87be8a"
      unitRef="usd">209000000</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTQtNy0xLTEtMA_12a9427a-c572-4c26-a7f4-59f0d380b52a"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtMS0xLTEtMA_bee13d33-41e6-487e-b5f5-8056cfa527c5"
      unitRef="usd">23000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtMy0xLTEtMA_90f90d83-5d02-427e-9d20-800fbe96c4af"
      unitRef="usd">21000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtNS0xLTEtMA_c477147d-5925-4376-b51b-79a142af5925"
      unitRef="usd">64000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTUtNy0xLTEtMA_dabb09f4-9312-48a3-91df-1ca7eb86a427"
      unitRef="usd">68000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtMS0xLTEtMA_ba2e3bc4-4a30-4795-8162-a2d9812702fc"
      unitRef="usd">3000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtMy0xLTEtMA_8b765ef7-665f-4825-8e22-e7dff5dfcf6c"
      unitRef="usd">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtNS0xLTEtMA_e1de166a-ee5f-4356-8103-b9a27bcb5453"
      unitRef="usd">9000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTYtNy0xLTEtMA_ca3824c6-df65-4c12-bc0a-fdbbff73f912"
      unitRef="usd">5000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctMS0xLTEtMA_ddd912bb-0f60-4763-85c4-d67c17fbd10d"
      unitRef="usd">4732000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctMy0xLTEtMA_cdae399b-4ffb-445d-bcbe-8b6a732306eb"
      unitRef="usd">3986000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctNS0xLTEtMA_dccfe74a-cd13-4fa9-8517-6c2a0e4d9b69"
      unitRef="usd">13201000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTctNy0xLTEtMA_4ac778e7-78a6-41ce-9b00-280efaa83063"
      unitRef="usd">11753000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtMS0xLTEtMA_65994dd7-4e8a-40a1-a5b7-2d727a5e003d"
      unitRef="usd">289000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtMy0xLTEtMA_9605590e-8b2b-4761-a444-2753385a61c4"
      unitRef="usd">257000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtNS0xLTEtMA_1a2612c6-2b53-4bf7-a351-1039d3afa868"
      unitRef="usd">987000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMTgtNy0xLTEtMA_5da0d947-3be1-4227-a81d-c1dcf2a08e26"
      unitRef="usd">802000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtMS0xLTEtMA_24ac8e79-e0b2-49a5-8774-09e6d1bf4555"
      unitRef="usd">27000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtMy0xLTEtMA_8bfe7852-f996-4360-a4e1-63dd1b871bc3"
      unitRef="usd">22000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtNS0xLTEtMA_9243f93d-74e9-4e39-a667-18e077442ce6"
      unitRef="usd">72000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjAtNy0xLTEtMA_b35179ac-8ba1-417c-85f0-99bbc1176780"
      unitRef="usd">67000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtMS0xLTEtMA_585a9894-6fab-4e97-9c01-0b15491c4c5d"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtMy0xLTEtMA_ce1f58e8-1787-4a15-bff1-7ec26539804a"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtNS0xLTEtMA_0755bc40-8386-4530-8425-26533228aff7"
      unitRef="usd">-5000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjEtNy0xLTEtMA_d2727c57-3e88-4edf-baf1-e206a0a11d3c"
      unitRef="usd">15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItMS0xLTEtMA_176f4a97-9dea-4992-8052-c001fcea1491"
      unitRef="usd">-27000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItMy0xLTEtMA_bb91fc51-1fbd-45ba-9844-0fb1e3e7701a"
      unitRef="usd">-24000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItNS0xLTEtMA_ae11dba0-0d52-4912-ab2b-6d22ae2df4c8"
      unitRef="usd">-77000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjItNy0xLTEtMA_2c922025-037c-4030-8cfb-afae7b7f066b"
      unitRef="usd">-52000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtMS0xLTEtMA_d1aa7e6c-eca0-41aa-a936-7a19f2d161d4"
      unitRef="usd">262000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtMy0xLTEtMA_dc843b4d-afcb-4f0d-a7b9-6deba5e53684"
      unitRef="usd">233000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtNS0xLTEtMA_bf161825-e2e3-4071-a1e1-2f98133e5d4f"
      unitRef="usd">910000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjMtNy0xLTEtMA_a509d06c-604c-43ec-955d-70e76ea47c0f"
      unitRef="usd">750000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtMS0xLTEtMA_7e55eed8-8c60-4739-8a88-9452ab310982"
      unitRef="usd">77000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtMy0xLTEtMA_93e05cc4-e7ce-4218-b6c3-c18478519052"
      unitRef="usd">58000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtNS0xLTEtMA_3fa4def2-9957-417a-a2d0-40e82f6a123d"
      unitRef="usd">271000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjQtNy0xLTEtMA_f54a9ded-e300-4eda-b85a-a092f442ce2c"
      unitRef="usd">181000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i96d66342f0554395ae8b108843d586cb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtMS0xLTEtMA_9cad71aa-9b2d-410c-972d-b0217785efa9"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtMy0xLTEtMA_085dd245-b702-4804-9c60-8db84d170fce"
      unitRef="usd">175000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtNS0xLTEtMA_bd300e1c-8ebe-4e9c-a586-01d27b34ef13"
      unitRef="usd">639000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjUtNy0xLTEtMA_f215bb9c-8ae5-4cda-bd5e-fbc673eeacb1"
      unitRef="usd">569000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctMS0xLTEtMA_91e1e96e-4301-4d53-b1e6-3ab5c2a6b13d"
      unitRef="usdPerShare">3.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctMy0xLTEtMA_18fb0887-7239-46af-b7ad-0594acfff017"
      unitRef="usdPerShare">2.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctNS0xLTEtMA_6c3385d8-22dd-4c85-95dd-749909976b4e"
      unitRef="usdPerShare">10.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjctNy0xLTEtMA_af437401-1948-46c7-87d4-b220b0bb61d1"
      unitRef="usdPerShare">9.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtMS0xLTEtMA_d8ecfcbd-a929-4710-9252-1a9bdd072968"
      unitRef="usdPerShare">3.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtMy0xLTEtMA_52aa9f1b-31ff-4ab3-8647-a8a30abcd5d6"
      unitRef="usdPerShare">2.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtNS0xLTEtMA_a240d5cc-08ea-4d1b-ac83-de115693a2f3"
      unitRef="usdPerShare">10.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOjg3MjFjNjllNDMzODQ5MWM5OTNiOGFkODY2NDI2M2I0L3RhYmxlcmFuZ2U6ODcyMWM2OWU0MzM4NDkxYzk5M2I4YWQ4NjY0MjYzYjRfMjgtNy0xLTEtMA_11d71459-30a7-4f8c-96be-626db681df87"
      unitRef="usdPerShare">8.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC0xLTEtMS0w_8f669590-1dd9-40bf-a2b5-ed5d6787f24f"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC0zLTEtMS0w_e98cdfc0-c710-4eaf-9a7b-0c9f535261b1"
      unitRef="usd">175000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC01LTEtMS0w_b1853129-6bbe-4867-aa51-d4aaacd80ff6"
      unitRef="usd">639000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNC03LTEtMS0w_00031fb3-62f6-461e-ad57-356c8f31b538"
      unitRef="usd">569000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi0xLTEtMS0w_37c6852f-fd06-416c-a4ca-d7d82f168634"
      unitRef="usd">6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi0zLTEtMS0w_868844c9-8f56-482a-9d85-37b174209a6f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi01LTEtMS0w_66e0f18e-d481-42d4-8e15-7209bd86c870"
      unitRef="usd">43000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNi03LTEtMS0w_75145f76-af68-4c4c-a6ed-88d764b1db40"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy0xLTEtMS0w_13debc00-4414-4499-890a-b400ba1262a3"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy0zLTEtMS0w_27b2782c-9a87-4f6c-be86-e76b4a33249d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy01LTEtMS0w_94c30633-ff56-43a8-b865-7474bd311d78"
      unitRef="usd">10000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfNy03LTEtMS0w_8d42d66c-2271-440e-9250-f54724efee15"
      unitRef="usd">4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC0xLTEtMS0w_f0231f38-a923-4468-95f7-f4b71025ab7c"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC0zLTEtMS0w_5bb80fee-1706-4501-9b67-9ca15eee8573"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC01LTEtMS0w_03dcff2a-2eaa-4ff2-8ac1-2de1032c1966"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOC03LTEtMS0w_9d915d5a-3111-4014-9436-f8a28102747f"
      unitRef="usd">13000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS0xLTEtMS0w_a1512577-6818-4740-9c3d-6afb6b123418"
      unitRef="usd">190000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS0zLTEtMS0w_851936bb-968d-4029-b3f0-8783dba0b95d"
      unitRef="usd">175000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS01LTEtMS0w_bc655fe7-ffbc-4145-9f80-165da6d7c0b1"
      unitRef="usd">672000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMy9mcmFnOjdkZmYzM2VmNmM3NzRmZTFhNjYwOTYwY2JmNjcxM2JmL3RhYmxlOmFlN2QzMDU0NGZlZjQyNzliYjRiZGU3YmVjZmVmNWZjL3RhYmxlcmFuZ2U6YWU3ZDMwNTQ0ZmVmNDI3OWJiNGJkZTdiZWNmZWY1ZmNfOS03LTEtMS0w_005c7262-6357-4a12-8d48-7c98604c8186"
      unitRef="usd">582000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNi0xLTEtMS0w_bb32e3ee-44b5-42f4-a013-eef4b6489266"
      unitRef="usd">3196000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNi0zLTEtMS0w_eaf5e8a7-dbb6-4132-b0e8-149c9ccc9ac9"
      unitRef="usd">2452000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNy0xLTEtMS0w_1054930e-cde8-4dee-82a1-8adc0f2aa767"
      unitRef="usd">1769000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfNy0zLTEtMS0w_6d6adf40-aff3-4c9f-aa39-a94e87cc57e6"
      unitRef="usd">1946000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOC0xLTEtMS0w_bf133e3f-b877-4d54-8e21-233f5789cb3b"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOC0zLTEtMS0w_8af6ac66-9b37-4e0b-a50f-51bc9c717ab3"
      unitRef="usd">1406000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOS0xLTEtMS0w_a1fd37cb-05c5-46be-8156-59e0899ab9ae"
      unitRef="usd">213000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfOS0zLTEtMS0w_0e06929e-faae-4c3e-82ea-f0492c1c88eb"
      unitRef="usd">163000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTAtMS0xLTEtMA_e9d9a600-4a89-4c06-80cc-45a7e40a21e5"
      unitRef="usd">6953000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTAtMy0xLTEtMA_02d52de9-16a1-418d-a0e5-391ea9b80213"
      unitRef="usd">5967000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTEtMS0xLTEtMA_e03a7332-0d3c-4e6b-a2f0-4f2a48c7338f"
      unitRef="usd">395000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTEtMy0xLTEtMA_451b4fd0-dca8-46e8-a5ae-e28428859a29"
      unitRef="usd">385000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTItMS0xLTEtMA_8193b118-4483-4cc6-95e8-dc2fc3ea219b"
      unitRef="usd">265000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTItMy0xLTEtMA_20fab758-042d-4394-aca5-e528d097ed46"
      unitRef="usd">172000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTMtMS0xLTEtMA_e9dcf01b-c1a5-446a-b48d-156927f869c4"
      unitRef="usd">93000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTMtMy0xLTEtMA_bcfd59e6-bb91-40d3-a4a8-db067e07fa18"
      unitRef="usd">79000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTQtMS0xLTEtMA_38a6cc30-80c7-4435-aa73-c4593d54fecb"
      unitRef="usd">74000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTQtMy0xLTEtMA_79c257a7-43c8-4674-a687-6d361ca6ce84"
      unitRef="usd">79000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTUtMS0xLTEtMA_3e8f5cef-c4f6-496e-97d0-78710004f908"
      unitRef="usd">101000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTUtMy0xLTEtMA_4e661475-ab2b-4210-b0c7-a76d0d302ddf"
      unitRef="usd">105000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTYtMS0xLTEtMA_70d3f96a-cf29-4b30-b3eb-59bf333fa319"
      unitRef="usd">7881000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMTYtMy0xLTEtMA_c746cc13-9212-4dfe-976a-554aeaa69802"
      unitRef="usd">6787000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjAtMS0xLTEtMA_96bb2760-3aeb-4233-821e-908cdf40a3a1"
      unitRef="usd">2289000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjAtMy0xLTEtMA_412087fc-da36-43e5-87f1-debaf268e387"
      unitRef="usd">1854000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjEtMS0xLTEtMA_49366502-1511-4deb-9fee-e7797bf7d973"
      unitRef="usd">640000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjEtMy0xLTEtMA_43b14014-c2fb-473a-8c7f-0a40cb8bfed9"
      unitRef="usd">664000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjItMS0xLTEtMA_77093f8e-df39-45af-b0cb-18e17c11619f"
      unitRef="usd">566000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjItMy0xLTEtMA_75be610a-cb1e-471f-84b4-1ea91f3c1a8e"
      unitRef="usd">502000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjMtMS0xLTEtMA_7722f575-4feb-4f0e-8f79-659ba1699cb9"
      unitRef="usd">61000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjMtMy0xLTEtMA_b15d9d66-fa73-44d8-add2-5c7fe8c4e96d"
      unitRef="usd">249000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjQtMS0xLTEtMA_83d9b2fe-23de-4f05-a140-ed38838ef66f"
      unitRef="usd">3556000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjQtMy0xLTEtMA_8c717ff0-1c8e-4beb-92a1-dfc7387e8dd7"
      unitRef="usd">3269000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjUtMS0xLTEtMA_7afc2f5b-4262-4025-8478-5c77a42c6460"
      unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjUtMy0xLTEtMA_18b0a595-4a20-49cc-908f-58d75ea5e771"
      unitRef="usd">1237000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjYtMS0xLTEtMA_93b6b771-2527-47ad-9855-8f10939376b6"
      unitRef="usd">226000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjYtMy0xLTEtMA_5e12f16e-47b6-4aeb-a157-238d0ce95bdf"
      unitRef="usd">231000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjctMS0xLTEtMA_238a934d-5cad-4c61-a54a-7f03ae1b694d"
      unitRef="usd">85000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjctMy0xLTEtMA_ad5d6cd9-4c29-4890-badc-60acbeb6564f"
      unitRef="usd">90000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjgtMS0xLTEtMA_e7f0fe82-d289-49d7-9a2d-0a7d12c4ebe6"
      unitRef="usd">5680000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMjgtMy0xLTEtMA_57b935fd-cdef-4c74-885c-16002add9360"
      unitRef="usd">4827000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzE5_d5c265df-3cc8-47b6-8901-47255cba1221"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzE5_dc877d60-ddf6-4a26-8f2a-18583ac3737c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzMz_60b33212-4342-491b-adb6-2627a08d1bd8"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzMz_eab024fa-f5bc-42c1-8cb9-705e315e5830"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4XzY4_ba4302d1-94e9-4032-8087-557c367b93dd"
      unitRef="shares">59000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMC0xLTEtMC90ZXh0cmVnaW9uOmVmMmNiNDBlN2YzZDQ2OGFiMmQ2NGE1NWU3MTBlNjE4Xzg5_5ae5ae99-96d9-47e7-815b-d0c9c4bc7cdc"
      unitRef="shares">62000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMS0xLTEtMA_0443cf66-1eda-4618-ac7a-b710c28b8434"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzAtMy0xLTEtMA_00001f6b-58da-40c0-a1bc-a38e4056de45"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzIy_97f5b429-6f2b-42d1-8c17-41e6c860237c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzIy_c1ea64e1-e3d9-4422-b58e-b2dbc9ad772c"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzM2_0dbdb35c-c024-44aa-b772-db841adf0f9b"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzM2_511d4a10-30ef-486d-992d-a4b60d933785"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_0c587742-209e-47f9-89eb-431ac045c732"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_1c8ffd73-79d3-4b24-ae5e-33509230487d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_21cd6ca3-64e2-4c7a-87fc-401a3080d8bb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOmU1NDlmZTNjMTMwMDRhMjNiODBjYjM4YTY2ZTQyZDFlXzU4_b9a9196d-71b5-401e-a9cd-173af6313ef6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMS0xLTEtMA_9dfd96cf-26b4-4280-a45a-9d4cab8029b8"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzEtMy0xLTEtMA_7690d9b8-d4f2-4317-b50b-e4c03af30a0d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzItMS0xLTEtMA_35443e21-982a-49e4-a57b-a2717b7e0396"
      unitRef="usd">181000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzItMy0xLTEtMA_7ffe920b-9465-4e44-ac6d-ed825e34b5f3"
      unitRef="usd">175000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzMtMS0xLTEtMA_9e34d778-43f1-4ca7-b676-446a11e837ad"
      unitRef="usd">37000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzMtMy0xLTEtMA_b81c2052-ac37-48b6-940d-22bc04fd5c80"
      unitRef="usd">4000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzQtMS0xLTEtMA_89d090f6-22be-4826-83f1-bbaf4ee39b1b"
      unitRef="usd">1983000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzQtMy0xLTEtMA_d209ba10-d61d-413e-833f-9712207516fe"
      unitRef="usd">1781000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzUtMS0xLTEtMA_b14f3f25-434c-473d-9b38-1232d9804769"
      unitRef="usd">2201000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzUtMy0xLTEtMA_14802871-7e45-4f2b-a8bd-1c761dd33a22"
      unitRef="usd">1960000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzYtMS0xLTEtMA_eba49ab5-6ccb-48b1-b8c6-ec6cf1832939"
      unitRef="usd">7881000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xOS9mcmFnOmFkNTRlMjQyZGM5NzQyNGFiNDVmMjI5ZmViMTc0ODlkL3RhYmxlOjgzZTFlYjAzN2QyODQzNjU5ODNlZDQyMDlkODhhYzQyL3RhYmxlcmFuZ2U6ODNlMWViMDM3ZDI4NDM2NTk4M2VkNDIwOWQ4OGFjNDJfMzYtMy0xLTEtMA_14144a2c-3ca0-42a4-8467-687a24f96083"
      unitRef="usd">6787000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0xLTEtMS0w_169db7ff-9160-47cc-8f0b-dbbe538f6bcd"
      unitRef="shares">62000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0zLTEtMS0w_d543b3ba-63a7-4575-8755-2f347396e423"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a9d47f2dd374531b3635ad709e30b61_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS01LTEtMS0w_68233338-5a2b-4327-87c6-0e6ad55b255a"
      unitRef="usd">175000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i57bc664f05b14a159d4a8313d75faeee_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS03LTEtMS0w_667259f8-e02e-4353-9f92-ccdec300c701"
      unitRef="usd">4000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if84d8cff947c4de9b53a8f49e428deeb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS05LTEtMS0w_46643207-e288-4a5a-b471-5612e495c040"
      unitRef="usd">1781000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNS0xMS0xLTEtMA_6c6fa333-a9bc-4176-b18b-a3f9d09520f8"
      unitRef="usd">1960000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNi05LTEtMS0w_7f897128-721f-4d85-b0c1-338884bd22dc"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNi0xMS0xLTEtMA_3a98f37b-981f-42be-9499-462c37cf7536"
      unitRef="usd">178000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy0xLTEtMS0w_6c58972d-9862-42d3-bf79-9dcd0c552f10"
      unitRef="shares">3000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy01LTEtMS0w_7edf75e4-5890-4fbb-9fbf-70e66637cd4f"
      unitRef="usd">9000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idf49f5e0e96b48aebd29d46eee339245_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy05LTEtMS0w_d98f7da1-c27e-4b84-bd4d-9b6b0e385fdf"
      unitRef="usd">437000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfNy0xMS0xLTEtMA_1e97c72d-51ab-41c7-8ea2-1445329f45aa"
      unitRef="usd">446000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOC01LTEtMS0w_ae4ea174-57ac-4a74-b8a7-bed05744f13a"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOC0xMS0xLTEtMA_3f66ee2a-3be0-47d1-9465-cd09f6a786c2"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i49f2fd8b17184789ae8cfea2f06254dd_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOS03LTEtMS0w_70e1dedb-4209-4105-b165-74886ad9a313"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfOS0xMS0xLTEtMA_e99f7fef-8196-43f5-a3ca-1001a7bbab86"
      unitRef="usd">-19000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6a96e299507d4cdba865bbd1f5a8f172_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTAtNS0xLTEtMA_02adf040-8fe0-4572-b248-a75f3bd7bfa2"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iabf526601a194124b21ff81d2e1ae411_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTAtMTEtMS0xLTA_2b001464-1009-4a33-ac76-7ec81c8722d1"
      unitRef="usd">4000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="ic740cdd3e1084065ac35011ddfb13474_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMS0xLTEtMA_2f31519d-8927-4544-9af7-d459d9d712b5"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic740cdd3e1084065ac35011ddfb13474_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMy0xLTEtMA_43e41927-95ca-4a47-9489-93c6b086a11e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9475aa9426a4b6f8e55461a9f80ca69_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtNS0xLTEtMA_9c2e77ae-d5f5-467f-9698-7f61d66f385e"
      unitRef="usd">140000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief76444e7aed463c9fd6220ebe36686c_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtNy0xLTEtMA_4f2e6a29-bc0b-4c05-9c12-cc0ab237d616"
      unitRef="usd">-15000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id344fdf6e2c44551837ef61def1551e5_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtOS0xLTEtMA_ae640a19-3035-4d81-b230-7bd85b57e53e"
      unitRef="usd">1522000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic13075558c9348ac82d3505a66e25fd8_I20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTEtMTEtMS0xLTA_6fd58e21-7990-49f8-bad3-715dd38c60c0"
      unitRef="usd">1647000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i8d34ec6b04954e97a9776fc5aedb9282_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTItOS0xLTEtMA_8b2fedf3-4574-4101-99b4-e18d5fa4d161"
      unitRef="usd">276000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTItMTEtMS0xLTA_afe67e64-48ac-4319-8645-828f93a300d9"
      unitRef="usd">276000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i31f3031a4db94a98813421cfe891840e_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTMtNy0xLTEtMA_c4305f7e-cd6d-49da-8ae2-0f2b8dac0308"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTMtMTEtMS0xLTA_c3236b49-2dfb-46e1-b9d8-5e41e2f4949b"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ecabd9c5a444209a8aff852fbc4b21c_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTQtNS0xLTEtMA_4410f915-b0fd-47af-95b9-e692edf2a0f4"
      unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTQtMTEtMS0xLTA_983aca7b-a8b5-4be7-a0fb-ce2c28e58afd"
      unitRef="usd">26000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i97892307215d43df8f22c0fbb18dcb61_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMS0xLTEtMA_4feb3703-62af-4461-8267-649c6ec74b63"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97892307215d43df8f22c0fbb18dcb61_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMy0xLTEtMA_2196821c-be43-40bf-8d0b-ff6728d79f76"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0058815da1e149d0ad521442a393bdb0_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtNS0xLTEtMA_0177d926-5a01-4807-bf9a-9bf86cddf896"
      unitRef="usd">166000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d0f3207cc784b74b39646cac08d8410_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtNy0xLTEtMA_02be6992-5421-4b19-9d64-4f26acfae435"
      unitRef="usd">32000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia5169226800d4ed096165ba76faed776_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtOS0xLTEtMA_b4830db9-f136-4551-81eb-e65c1bcf2fd4"
      unitRef="usd">1798000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ife5003122e804b988dea74c354c83d41_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTUtMTEtMS0xLTA_8fda3ed1-5b9d-4ce4-977f-e1165eb6f2d3"
      unitRef="usd">1996000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i96d66342f0554395ae8b108843d586cb_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTYtOS0xLTEtNzU_9cad71aa-9b2d-410c-972d-b0217785efa9"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTYtMTEtMS0xLTI2Ng_4a1e8eb8-5e8e-4e9c-9917-257c5343c3f4"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTctNy0xLTEtODE_f0231f38-a923-4468-95f7-f4b71025ab7c"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTctMTEtMS0xLTI3Mw_c4e29c36-e03b-4537-8bbc-b5b17b0f4815"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i509d18c4ec7246019d82673921cdfeb0_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTgtNS0xLTEtMjgz_dc3d282c-89d0-46fe-a324-4acf26ab70c9"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTgtMTEtMS0xLTI3OQ_36378d99-ac54-4dfe-b07d-26b7763a467e"
      unitRef="usd">15000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMS0xLTEtODA1_ea7c53ab-0fbe-4baf-a084-82b0da893f3f"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMy0xLTEtODA2_a75f9a16-444c-4b1a-94af-0fb9a5831b75"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i857bc8d2434e40239068a4279a5cd1f0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktNS0xLTEtODA4_7c5dd012-3fe7-4021-a990-ea09f8491706"
      unitRef="usd">181000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ee588c43d0c4cb79042f4cb63afaa3e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktNy0xLTEtODEw_c808aac0-7f8f-4f64-ad6b-97e270275eb6"
      unitRef="usd">37000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic5afc4b5afff4b129fe93aba117db965_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktOS0xLTEtODEz_4e4bc459-297f-41c9-9f05-271fffba7e9e"
      unitRef="usd">1983000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOmM0MzY1MTljM2QwMjQxMzJiM2MxZTNkYzRiM2E3YjA0L3RhYmxlcmFuZ2U6YzQzNjUxOWMzZDAyNDEzMmIzYzFlM2RjNGIzYTdiMDRfMTktMTEtMS0xLTgxNA_be2e44d3-daa4-4d29-bf41-7b0de47e23af"
      unitRef="usd">2201000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="iab11086ddd47417bb18ccbb3186696ce_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0xLTEtMS0w_2d5a6bce-a79b-441a-b124-9ab1d10dd811"
      unitRef="shares">62000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iab11086ddd47417bb18ccbb3186696ce_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0zLTEtMS0w_a42e8abe-9fe9-4813-b219-e03e76b690d5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8c897de179cf4b5485a5907b73918b51_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS01LTEtMS0w_1373454c-ae2a-4d0c-8a38-f891f01d2655"
      unitRef="usd">643000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9c3a00daa4bd49bb8c6a462ee00a7935_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS03LTEtMS0w_01d0b346-55d8-433e-8886-b9c529995739"
      unitRef="usd">-8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8e25cb2bdbeb4161b0c79bc643ab2e01_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS05LTEtMS0w_8234f798-45f6-43f6-9ecc-600f97ce7f08"
      unitRef="usd">1012000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNS0xMS0xLTEtMA_8c04208c-f64a-4abf-93e2-63697cb79ffb"
      unitRef="usd">1647000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="if2e39a6516be42729bf559f4b31b0042_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNi05LTEtMS0w_677b1816-a261-4aa0-9d2a-ea3171243703"
      unitRef="usd">198000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNi0xMS0xLTEtMA_f8872c0c-8195-45c6-a794-95a01b36ee40"
      unitRef="usd">198000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1b143b9b73dc4003a812274a03246027_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNy05LTEtMS0w_611889e0-d5a4-43fc-b6ba-4328dac3a890"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cc23cfa3d184d399207901dadbc36b8_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfNy0xMS0xLTEtMA_c95fd7bd-6a60-4949-92b9-fcbbf4d31a80"
      unitRef="usd">85000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOC01LTEtMS0w_9e9a543d-1df8-4262-a81a-fdbafdc916f4"
      unitRef="usd">-103000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOC0xMS0xLTEtMA_0927d5d3-b394-443c-b1ea-73072bad0b2f"
      unitRef="usd">-103000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfd68fed97114006a3e5e802d1c89c42_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOS03LTEtMS0w_a73a84ed-ac9e-41ab-b6e2-5694727b775a"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfOS0xMS0xLTEtMA_cda91a7a-d9ee-4370-bae4-6681ecd815ab"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i907d5beeecf040dd9ceadd4dd8ece877_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtMS0xLTEtMA_64e2ee6d-b3cc-4c69-b353-75c5a5e66cc8"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8a72f96a673e4cc5bbd41d82e60c5e0c_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtNS0xLTEtMA_28a5dd2c-6105-432e-b010-6e493bd57e5e"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic225d023312e446db67441be17efc548_D20190101-20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTAtMTEtMS0xLTA_6f58fbad-b276-4221-a62e-b65f9d4507b9"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i772d4e400b1f469faf8028c4422dbcb3_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMS0xLTEtMA_0d873964-ac83-4539-b04d-c39ea9127546"
      unitRef="shares">63000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i772d4e400b1f469faf8028c4422dbcb3_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMy0xLTEtMA_e2416c1d-7c60-447c-8b30-6a9da3ac0619"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide746b337aa049e7b40293ed6f01a425_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtNS0xLTEtMA_c201c0ce-67a1-4f4d-8cf8-d5f1343e3e4e"
      unitRef="usd">543000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7722c16ae6c94fc29e287a669c377710_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtNy0xLTEtMA_ac65d333-7d27-46b5-a76a-b15abc11914e"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e79de45409e408d8a51666f4d41bb77_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtOS0xLTEtMA_1c2da2e9-7365-46d9-a5fc-917c3791d9aa"
      unitRef="usd">1295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0b51ea44331043d0bc2c91aad3925ba5_I20190331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTEtMTEtMS0xLTA_8a813144-87af-4da9-b018-af49dad5455f"
      unitRef="usd">1835000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0ec3a4bd50d040a2aded930121774fb7_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTItOS0xLTEtMA_c45734f7-f5ee-403a-bf81-034661090535"
      unitRef="usd">196000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTItMTEtMS0xLTA_91e81f06-6488-492d-a40c-5fed7fdce644"
      unitRef="usd">196000000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTMtNS0xLTEtMA_b80b0f01-3636-4849-8445-68bd28576962"
      unitRef="usd">-321000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTMtMTEtMS0xLTA_7d2a1076-4b41-426b-b679-cc4bb1856b50"
      unitRef="usd">-321000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib17d434488324479a0237837e1d52044_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTQtNy0xLTEtMA_847751d5-30ed-4fb4-b6ff-b2d4a3347b8a"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTQtMTEtMS0xLTA_54ed18ca-856e-4d03-b753-f90690890669"
      unitRef="usd">8000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i524a66a7b24e410aa48a08076da99e01_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTUtNS0xLTEtMA_a3d74bb0-762b-4bb8-9ed7-356e298042c6"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i771af627cd9f4575813bc9e7c90a74f1_D20190401-20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTUtMTEtMS0xLTA_e7facc23-9c79-4df7-b888-1d80c38bac24"
      unitRef="usd">18000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i81fbd2b196d1417d8d35142ae0959b35_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMS0xLTEtMA_ddf45be6-5e53-48dd-81dc-5478a51ad445"
      unitRef="shares">63000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81fbd2b196d1417d8d35142ae0959b35_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMy0xLTEtMA_b6190576-e196-42c1-8d3e-26df49f6ace1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1742427719e433ba0aeb9e8493e3bb8_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtNS0xLTEtMA_7f44017c-067c-40ba-ba18-b3a63d9a48de"
      unitRef="usd">240000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf4919d73e0b4df7a87e1da456ef828e_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtNy0xLTEtMA_3b6f7e10-795e-4a93-bd95-c8915b3f7476"
      unitRef="usd">5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3b37edd89d46497ab1c4734ff26bcd16_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtOS0xLTEtMA_c63f0b3d-8c31-456c-b080-cebed000bd80"
      unitRef="usd">1491000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8def59bebfc44b69808ea12af90bd829_I20190630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTYtMTEtMS0xLTA_d59f9721-3926-4cc8-8e01-8a7c9f29fbd1"
      unitRef="usd">1736000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie988e47ff15147608fa252205cc655bd_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTctOS0xLTEtODE3_7a5ef181-b62d-479b-8095-29803c44310d"
      unitRef="usd">175000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTctMTEtMS0xLTgxOQ_959a89a9-bed8-4cdb-8249-fe95433ec075"
      unitRef="usd">175000000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTgtNS0xLTEtODIy_8370ab09-17be-4f12-8df4-1f4cf13fe675"
      unitRef="usd">-90000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTgtMTEtMS0xLTgyMQ_f02d4294-7f4c-4e1a-b5d4-d4d24afe58c3"
      unitRef="usd">-90000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9cdf147ba0ee4c1f85c93d2154cb6a09_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTktNS0xLTEtODI1_04cc691f-1692-4300-8730-eae64060af3c"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMTktMTEtMS0xLTgyNw_2f9efabd-9292-422f-9e53-6e8541954469"
      unitRef="usd">10000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i4e2fcc6a71f44a2d81e67581370faa03_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMS0xLTEtODM4_9ad6b412-a85f-4652-9f33-b1d7464e9791"
      unitRef="shares">63000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e2fcc6a71f44a2d81e67581370faa03_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMy0xLTEtODM2_60938893-46f3-4909-8b81-d42727d61c12"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1867d439641b408886f363900a45fc2e_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtNS0xLTEtODQw_d2ead299-d91d-4120-be35-408f0f770cfe"
      unitRef="usd">160000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfd328f3fb2a48b38a19eaf541451af9_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtNy0xLTEtODM0_342d85d9-06bd-48b3-ba1a-9e6a8e76c501"
      unitRef="usd">5000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85567348a9a24e39aafcb86cb42628ce_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtOS0xLTEtODMy_e3672fc2-86de-4850-a542-b233812eee89"
      unitRef="usd">1666000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yMi9mcmFnOjI3NWZlYmQxNjQxMjRhNDdiNzkyMzJmOTZiOWI4NTU1L3RhYmxlOjQ4NWVkY2ZmYmU3MDQyYWE4OTY1ZmI4NjgxOGU1YmYyL3RhYmxlcmFuZ2U6NDg1ZWRjZmZiZTcwNDJhYTg5NjVmYjg2ODE4ZTViZjJfMjAtMTEtMS0xLTgyOQ_8926ce27-ff43-4df7-914b-ff66a029a7df"
      unitRef="usd">1831000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNS0xLTEtMS0w_8a668315-05cc-4738-b5f2-443f4797e602"
      unitRef="usd">639000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNS0zLTEtMS0w_25610389-0569-403e-a5c3-b00d0d0dd613"
      unitRef="usd">569000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNy0xLTEtMS0w_7644c966-69e5-4f9e-afcd-720966fcd183"
      unitRef="usd">64000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNy0zLTEtMS0w_500844b4-3ae9-47a6-b6b6-1da6a8ad4b39"
      unitRef="usd">68000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOC0xLTEtMS0w_4da44f08-2d8b-4aa2-bd8b-a879e4ca829a"
      unitRef="usd">3000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOC0zLTEtMS0w_48c52421-7517-4488-a42d-790c6f7d8710"
      unitRef="usd">-7000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOS0xLTEtMS0w_9142da1c-cf08-4948-a9c3-a7df6c2ee7e8"
      unitRef="usd">43000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfOS0zLTEtMS0w_746f6d8d-ae88-456f-bffa-c090ea8ca99c"
      unitRef="usd">29000000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTEtMS0xLTEtMA_48873374-199c-4b2f-85b3-54c230707794"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTEtMy0xLTEtMA_8d9606c7-b94f-4d78-a63f-ee2333d4a5ac"
      unitRef="usd">15000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTQtMS0xLTEtMA_14b06685-7993-4769-900d-9774574a679d"
      unitRef="usd">2000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTQtMy0xLTEtMA_a5ca25d7-6b7d-4f40-95dc-258bfe6e202c"
      unitRef="usd">0</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTYtMS0xLTEtMA_42b29abd-21e2-4b60-83e7-35b9e113ac26"
      unitRef="usd">369000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTYtMy0xLTEtMA_05bc5c57-e3f1-4db2-8da4-5cee9e087b2a"
      unitRef="usd">-50000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTctMS0xLTEtMA_83637689-e191-4302-94c5-9c4f1899138d"
      unitRef="usd">98000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTctMy0xLTEtMA_45ca4d49-951e-472e-a67e-df8ee2ab70a1"
      unitRef="usd">6000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTgtMS0xLTEtMA_fac6f4f9-de9e-4440-95bc-40b7ff75d0bf"
      unitRef="usd">431000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTgtMy0xLTEtMA_1a9a932d-9a76-4227-963b-9c8733c9098b"
      unitRef="usd">14000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTktMS0xLTEtMA_cd992b35-5304-4ea8-8807-eee556fade15"
      unitRef="usd">-24000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMTktMy0xLTEtMA_68269258-992b-4712-a780-c2cf517c0c23"
      unitRef="usd">-355000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjAtMS0xLTEtMA_761f9191-773a-40c5-9837-1ce7694d05b9"
      unitRef="usd">55000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjAtMy0xLTEtMA_2c907e21-776c-4b21-9c70-00204c60266f"
      unitRef="usd">37000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjEtMS0xLTEtMA_b50927e4-b353-4e47-be68-9354c4df21cf"
      unitRef="usd">-188000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjEtMy0xLTEtMA_9a191cc1-bd34-44b9-9d3d-6a783a37d469"
      unitRef="usd">-4000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjItMS0xLTEtMA_5e12e717-7a27-4fd5-98c4-1a91be3d838e"
      unitRef="usd">34000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjItMy0xLTEtMA_9b309ec8-b747-4122-b149-870ea8bb3c2c"
      unitRef="usd">4000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjMtMS0xLTEtMA_21ee678f-7376-4e33-93b6-7020777f616e"
      unitRef="usd">591000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjMtMy0xLTEtMA_9519ab58-85a3-4b4f-b63a-0738f8f00b89"
      unitRef="usd">398000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjUtMS0xLTEtMA_982561fa-5781-4693-a8fe-5e872c2098ab"
      unitRef="usd">670000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjUtMy0xLTEtMA_41da54a8-52f7-41b8-8f2f-f865184c4f7c"
      unitRef="usd">1938000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjYtMS0xLTEtMA_0673aafc-c1d4-4b93-8984-213c79d8b131"
      unitRef="usd">891000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjYtMy0xLTEtMA_4f597f65-cc2c-4137-8284-b54f2a3ecc20"
      unitRef="usd">1890000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMS0xLTEtNzkx_6530fbc1-2d75-4937-b9fc-e5865e6d8d76"
      unitRef="usd">62000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMy0xLTEtNzkx_c157287f-0c66-4896-a159-41ce956b95d6"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMS0xLTEtMA_84ee3479-8d89-4171-b8a3-249949d13c81"
      unitRef="usd">64000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjctMy0xLTEtMA_0ac06817-ed3a-4dd6-b25b-6f12cf5b3bab"
      unitRef="usd">30000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjgtMS0xLTEtMA_9eb322e1-3fc4-498a-966a-d4b0520cbd96"
      unitRef="usd">-3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjgtMy0xLTEtMA_41daf00e-e403-48d8-bcba-d299bcab6e8b"
      unitRef="usd">2000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjktMS0xLTEtMA_cec5fcda-8334-4043-8584-cec620fd935e"
      unitRef="usd">98000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMjktMy0xLTEtMA_0d670c24-fefd-44cd-a6e7-3075210827f4"
      unitRef="usd">-80000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzEtMS0xLTEtMA_c7efca1b-9b6d-4821-8b75-ef44124a989e"
      unitRef="usd">789000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzEtMy0xLTEtMA_dab31b3c-8a9d-453c-9b5b-61edc1a3e054"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzItMS0xLTEtMA_7b21545c-09a9-435c-9ab2-c8f4e4a7cd84"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzItMy0xLTEtMA_b9d45f5f-7754-499f-b287-9b87cea0439c"
      unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzMtMS0xLTEtMA_1e8bfd09-89c4-489a-911a-024ea10eed3c"
      unitRef="usd">453000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzMtMy0xLTEtMA_7fb2708c-caf4-4ff2-8607-154eb2720ff9"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzQtMS0xLTEtMA_4fb14572-5749-4a63-acc4-986f0a13cda8"
      unitRef="usd">380000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzQtMy0xLTEtMA_91c9789f-8aeb-44c2-b842-4853b3a83629"
      unitRef="usd">220000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzUtMS0xLTEtMA_4223f80e-84b3-432b-847b-a1a322721cfd"
      unitRef="usd">30000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzUtMy0xLTEtMA_bda37bfa-e253-4756-8816-186c94526899"
      unitRef="usd">514000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzYtMS0xLTEtMA_edd12318-50f8-4e16-aa9d-3cec63cc7da5"
      unitRef="usd">27000000</moh:CashPaidForSettlementOfConversionOption>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzYtMy0xLTEtMA_41bc608c-0e2c-4e24-a3a5-fbb0a286ba2f"
      unitRef="usd">578000000</moh:CashPaidForSettlementOfConversionOption>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzctMS0xLTEtMA_234afb9d-a6da-484c-b200-711c03eea040"
      unitRef="usd">27000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzctMy0xLTEtMA_b8444246-c50d-4d0a-a260-60ef42296b99"
      unitRef="usd">578000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzgtMS0xLTEtMA_64154494-cbb5-42ec-8ae3-5268e5697549"
      unitRef="usd">12000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzgtMy0xLTEtMA_2b9cc095-f446-4f13-bab8-4c9c9939cd1d"
      unitRef="usd">240000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzktMS0xLTEtMA_93c262b4-682e-48bf-ac4e-2c23b6be91a2"
      unitRef="usd">-5000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfMzktMy0xLTEtMA_2b766f69-6e8e-43e6-86f9-09a3de206fa0"
      unitRef="usd">24000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDAtMS0xLTEtMA_bd5ab820-a86a-4c07-beee-047831b71a1c"
      unitRef="usd">69000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDAtMy0xLTEtMA_51630e57-18e4-444b-a96c-a055c473a317"
      unitRef="usd">-510000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDEtMS0xLTEtMA_ddf1dfd1-bf4d-4510-95af-f79d741e0152"
      unitRef="usd">758000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDEtMy0xLTEtMA_c16a18f2-9e51-4cbd-b04b-eebb7f189ec8"
      unitRef="usd">-192000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDItMS0xLTEtMA_9e901491-7d72-4a2c-a1cd-f0f9224f7a21"
      unitRef="usd">2508000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDItMy0xLTEtMA_2566f88a-e60c-462d-93e8-e2a68702a5a4"
      unitRef="usd">2926000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDMtMS0xLTEtMA_8fc2f907-90aa-4f89-af66-7a49f52ce4f0"
      unitRef="usd">3266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOjNlNmQ2OTcxMjU4YTQ1Yjg4ZDc0YWM0NDUwMmVkZDMwL3RhYmxlcmFuZ2U6M2U2ZDY5NzEyNThhNDViODhkNzRhYzQ0NTAyZWRkMzBfNDMtMy0xLTEtMA_2afd326c-8a5a-4813-a5f6-0019daa0b448"
      unitRef="usd">2734000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfNy0xLTEtMS0w_131ab9ec-d164-4552-9c76-4f36419dd972"
      unitRef="usd">8000000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfNy0zLTEtMS0w_c171bb27-ccfa-41b9-be01-0034b8cc5aad"
      unitRef="usd">7000000</us-gaap:StockIssued1>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMS0xLTEtODQ4_b0e693ed-7351-4c64-9717-726db5d1ca7e"
      unitRef="usd">106000000</us-gaap:FairValueOfAssetsAcquired>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMy0xLTEtODQ5_8af3745f-aab0-4ede-a8a7-ae788624d568"
      unitRef="usd">0</us-gaap:FairValueOfAssetsAcquired>
    <moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMS0xLTEtODUy_38644bb6-9698-4441-a3e0-5bf074070ccc"
      unitRef="usd">40000000</moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities>
    <moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMy0xLTEtODUz_c4ee26aa-52f7-4b4a-a52c-cf2fd493bcf0"
      unitRef="usd">0</moh:FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMS0xLTEtODU1_37f8733c-9926-4c51-8bc9-1c62b2bf8a05"
      unitRef="usd">4000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMy0xLTEtODU3_b63ced24-17a0-46be-bc99-4670375177d4"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTMtMS0xLTEtODU5_f6e63668-6a6b-451b-82b3-74f11e4208ce"
      unitRef="usd">62000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTMtMy0xLTEtODYx_ae145d24-d984-4b59-b6ae-40ddb7b6b5cc"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i032e64312b634c9192f40d8aad600f2b_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMS0xLTEtMA_9cb54d79-b17c-4964-9844-45f2d4a6dae3"
      unitRef="usd">-2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i795403e420354184bcfbf7b34e4879dd_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTAtMy0xLTEtMA_32c78a0e-e06a-4edc-838e-899c0c875804"
      unitRef="usd">124000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="icfb9c978b5184509bd25b72a644093ea_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMS0xLTEtMA_b375ce09-5d13-4387-9c6e-a263fe0c91f7"
      unitRef="usd">2000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i446692be62344c64a03638faefd95842_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTEtMy0xLTEtMA_759ba360-c7c1-4a82-97e0-f0816635d69d"
      unitRef="usd">-124000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMS0xLTEtMA_e5cabf1f-6a38-456a-bede-df7db0b07c1f"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8yNS9mcmFnOjA5YjI4OGZlMThmNjQxM2JhNWYyYTQ5MWVhODFiNDBkL3RhYmxlOmE0YjY3YTAwMzJhMjQzMDZhYjk4MzE2OTU0NTVkYmI5L3RhYmxlcmFuZ2U6YTRiNjdhMDAzMmEyNDMwNmFiOTgzMTY5NTQ1NWRiYjlfMTItMy0xLTEtMA_b93f8a17-d635-48db-8c0b-93e37269fd0f"
      unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ5MQ_1b452f25-da79-4c22-8a54-01aac5931b71">Organization and Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#x201c;Marketplace&#x201d;). We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2020, the Health Plans segment consisted of health plans operating in 15 states and the Commonwealth of Puerto Rico, and served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. The health plans are generally operated by our respective wholly owned subsidiaries in those states and licensed as health maintenance organizations (&#x201c;HMO&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state Medicaid contracts typically have terms of&#160;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAxOA_433cf4cd-b6db-4c94-b366-da8b885a7b9b"&gt;three&lt;/span&gt;&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#x201c;RFPs&#x201d;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments - Health Plans Segment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close as early as the second quarter of 2021.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, we completed the acquisition of certain assets of YourCare Health Plan, Inc. See Note 4, &#x201c;Business Combinations,&#x201d; for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, we completed the acquisition of certain assets of Passport Health Plan, Inc. See Note 4, &#x201c;Business Combinations,&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, our Kentucky health plan had been selected as an awardee pursuant to the statewide Medicaid managed care RFP issued by the Kentucky Cabinet for Health and Family Services, Department for Medicaid Services. On October 23, 2020, pursuant to a protest filing appeal with regard to the RFP awards, a court ordered the addition of a sixth health plan to the Kentucky Medicaid program for 2021. That ruling did not rescind the Medicaid contract award to our Kentucky health plan for 2021, nor did it have any impact on the earlier novation of the Passport Medicaid contract to us. The new Medicaid contract is currently expected to begin on January 1, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Magellan Complete Care (&#x201c;MCC&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, we entered into a definitive agreement to acquire the MCC line of business of Magellan Health, Inc. The purchase price for the transaction is approximately $820&#160;million, net of certain tax benefits, which we intend to fund with cash on hand. The transaction is subject to federal and state regulatory approvals, and other customary closing conditions, and is expected to close around the end of 2020. In connection with this transaction, Magellan Health, Inc. has agreed to provide certain transition services following the closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Texas Health and Human Services Commission (&#x201c;HHSC&#x201d;) notified our Texas health plan that HHSC had upheld our protest and had canceled all previously awarded contracts associated with the re&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;procurement awards announced in October 2019 for the ABD program (known in Texas as &#x201c;STAR+PLUS&#x201d;). In addition, HHSC canceled the pending re-procurement associated with the TANF and CHIP programs (known in Texas as &#x201c;STAR/CHIP&#x201d;). HHSC further indicated that it was deliberating next steps with respect to both re&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;procurements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Puerto Rico&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We will exit Puerto Rico&#x2019;s Medicaid program when our current contract expires on October 31, 2020. We are working closely with the regulatory authorities and the provider community to ensure that our members in Puerto Rico have reliable continuity of care. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Illinois&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In March 2020, we terminated our agreement to acquire all of the capital stock of NextLevel Health Partners, Inc. due to the seller&#x2019;s stated unwillingness to close pursuant to the terms of the acquisition agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results for the entire year ending December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2019, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of medical claims and benefits payable of our Health Plans segment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Settlements under risk- or savings-sharing programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Purchase price allocations relating to business combinations, including the determination of contingent consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The assessment of long-lived and intangible assets, and goodwill for impairment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for potential absorption of claims unpaid by insolvent providers;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for the outcome of litigation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of valuation allowances for deferred tax assets;&#160;and&lt;/span&gt;&lt;/div&gt;&#x2022;The determination of unrecognized tax benefits.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMjI4_19d32be4-18c1-4af1-bd74-d2c81d9ee769"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfStatesInWhichEntityOperates
      contextRef="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNDc2_8180130d-953e-44f0-a340-a434be0f2a69"
      unitRef="state">15</us-gaap:NumberOfStatesInWhichEntityOperates>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i1862c14ec2e84f2f90f95c57f1d2245e_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNTcz_9e34ac7e-2af9-4bf7-8960-60b2f23c80d5"
      unitRef="member">4000000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <moh:HealthPlanContractTerm
      contextRef="i4b9468a421a64284ad5b14f3032873c3_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAyNA_91e39ff4-f0d9-4c32-b3cb-25665b649721">P5Y</moh:HealthPlanContractTerm>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i391a70c55331438f93619826459906eb_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTA5OTUxMTY0MTQ3Nw_532f2334-c463-4a00-8edb-1aba3ac79bdf"
      unitRef="usd">380000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="idd699a73b5be49539d4149d71a08fadd_D20200401-20200430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTA5OTUxMTY0MTUwMg_2c27da22-3310-437c-a70d-caaa1abb4fdf"
      unitRef="usd">820000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ2OA_c1198164-64e8-450e-b063-2d06b2b914ad">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results for the entire year ending December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2019, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;</moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfNjQ4Ng_f3b3adaa-e0ef-49ac-840d-444aeb447e88">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of medical claims and benefits payable of our Health Plans segment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Settlements under risk- or savings-sharing programs;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Purchase price allocations relating to business combinations, including the determination of contingent consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The assessment of long-lived and intangible assets, and goodwill for impairment;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for potential absorption of claims unpaid by insolvent providers;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of reserves for the outcome of litigation;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The determination of valuation allowances for deferred tax assets;&#160;and&lt;/span&gt;&lt;/div&gt;&#x2022;The determination of unrecognized tax benefits.</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxODc_cd1ff90e-9c7c-4403-ab46-76a1931a23cd">Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#x201c;AFS&#x201d;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#x2019; equity as other comprehensive income (loss), net of applicable income taxes. Held-to-maturity (&#x201c;HTM&#x201d;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses, and unrealized losses arising from credit-related factors with respect to AFS and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy requires that all our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, our AFS securities are classified as current assets without regard to the securities&#x2019; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 5, &#x201c;Fair Value Measurements,&#x201d; and Note 6, &#x201c;Investments.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable relating to our AFS and HTM securities is presented within &#x201c;Prepaid expenses and other current assets&#x201d; in the accompanying consolidated balance sheets, and amounted to $9 million and $12 million at September 30, 2020, and December 31, 2019, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of interest income. No accrued interest was written off during the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Premiums Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our Health Plans segment contracts related to our Medicaid, Medicare and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are recognized as &#x201c;Amounts due government agencies&#x201d; in the accompanying consolidated balance sheets, and included the following categories by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Medical Cost Corridors. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit Sharing. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#x2019; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#x2019; health status, risk scores and Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Affordable Care Act (&#x201c;ACA&#x201d;) established a minimum annual medical loss ratio (&#x201c;Minimum MLR&#x201d;) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Corridor Settlement. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the United States Supreme Court held that &#xa7;1342 of the Affordable Care Act obligated the federal government to pay participating insurers the full Marketplace risk corridor amounts calculated by that statute, and that impacted insurers may sue the federal government in the U.S. Court of Federal Claims to recover damages for breach of that obligation. In June 2020, the Claims Court granted us judgment in the amount of $128.1&#160;million for our 2014, 2015, and 2016 Marketplace risk corridor claims, which we received in October 2020. Since we accounted for the judgment as a gain contingency at September 30, 2020, it will be recognized in our fourth quarter 2020 financial results. The judgment does not create additional Minimum MLR rebates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September&#160;30, 2020, Marketplace risk adjustment payables amounted &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to $265 million and related receivables amounted to $59 million, for a net payable of $206 million. This net payable consisted of $230&#160;million in payables relating to 2020, and $24 million in receivables relating primarily to 2019. As of December&#160;31, 2019, Marketplace risk adjustment payables amounted to $368 million and related receivables amounted to $63 million, for a net payable of $305 million, which related primarily to 2019 and prior periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quality Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, &#x201c;Organization and Basis of Presentation&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#x201d; recognition of quality incentive premium revenue is subject to the use of estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Maximum available quality incentive premium - current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Quality incentive premium revenue recognized in current period:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earned current period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earned prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Quality incentive premium revenue recognized as a percentage of total premium revenue &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health insurer fee reimbursement receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bear underwriting and reserving risks associated with our health plan subsidiaries. Until the second quarter of 2020, we limited our risk of catastrophic losses solely by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#x201c;third-party reinsurer&#x201d;). Beginning in the second quarter of 2020, we now retain certain of these risks through our wholly-owned, captive insurance subsidiary (the &#x201c;captive&#x201d;). We continue to reduce our exposure to significant catastrophic losses by insuring levels of coverage, with the third-party reinsurer, for losses in excess of what we retain with the captive. Because we remain liable to our policyholders in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#x2019;s financial condition, including its ability to maintain high credit ratings. We report reinsurance premiums as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Intercompany transactions with our captive are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Deficiency Reserves on Loss Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the profitability of our medical care policies to identify groups of contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. In the third quarter of 2020, we recognized a premium deficiency reserve of $10&#160;million for our Medicaid contract in Puerto Rico. As described in Note 1, &#x201c;Organization and Basis of Presentation,&#x201d; we will exit Puerto Rico&#x2019;s Medicaid program when our current contract expires on October 31, 2020. No premium deficiency reserve was recorded as of December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Health Insurer Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the ACA, the federal government imposes an annual fee, or excise tax, on health insurers for each calendar year (the &#x201c;HIF&#x201d;). Public Law No. 115-120 provided for a HIF moratorium in 2019; therefore, there was no HIF incurred or reimbursed in that year. The HIF was reinstated in 2020, but the Further Consolidated Appropriations Act, 2020, repealed the HIF effective for years after 2020. The HIF is allocated to health insurers based on each health insurer's share of net premiums for all U.S. health insurers in the year preceding the assessment. Our HIF liability for 2020 is $277&#160;million, of which $271&#160;million was accrued as of January 1, 2020 and an additional $6&#160;million was accrued in the second quarter, with a corresponding deferred expense asset amortized to expense through December 31, 2020, on a straight-line basis. We settled the 2020 HIF liability in September 2020. The HIF is not deductible for income tax purposes. Due to the reinstatement of the HIF in 2020, our effective tax rate is higher in 2020 compared with 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We have obtained a contractual commitment or are receiving payments from all states in which we operate Medicaid programs to reimburse us for the HIF, and such HIF revenue is being recognized ratably throughout the year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, nondeductible expenses such as the HIF, certain compensation, and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was subsequently modified by several ASUs issued in 2018 and 2019. We adopted Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we recognized the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020, which was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In March 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by a change in the reference rate from the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued, if certain conditions are met. ASU 2020-04 is effective immediately and expires after December 31, 2022. We are evaluating the effect of reference rate reform and this guidance on our contracts and other transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMjA_5bb931ca-e53d-45b6-9c4d-1a0cd3b3f3e7">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNzY_2f1748a2-d7e2-4498-b006-4b6fba7255eb">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxOTU_0bccd8eb-b41c-45cf-99fb-130db27fe591">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNC0xLTEtMS0w_bb32e3ee-44b5-42f4-a013-eef4b6489266"
      unitRef="usd">3196000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNC0zLTEtMS0w_fddbf0ab-be3d-4b10-884e-56bc0027b86e"
      unitRef="usd">2679000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNS0xLTEtMS0w_eeb8a577-0898-42bc-ab29-a41966d46f75"
      unitRef="usd">70000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNS0zLTEtMS0w_f319ed37-ea82-490d-ae44-3290c659a6d3"
      unitRef="usd">55000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNi0xLTEtMS0w_8fc2f907-90aa-4f89-af66-7a49f52ce4f0"
      unitRef="usd">3266000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjRlNzI2Y2NmNTI1MjRlYTY5NzAzNjYyZGU0NmIwMDkwL3RhYmxlcmFuZ2U6NGU3MjZjY2Y1MjUyNGVhNjk3MDM2NjJkZTQ2YjAwOTBfNi0zLTEtMS0w_2afd326c-8a5a-4813-a5f6-0019daa0b448"
      unitRef="usd">2734000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM3NDM4OTUzNjkzODI_1ec4af3b-a91c-45de-870b-f42bea181b52">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#x201c;AFS&#x201d;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#x2019; equity as other comprehensive income (loss), net of applicable income taxes. Held-to-maturity (&#x201c;HTM&#x201d;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses, and unrealized losses arising from credit-related factors with respect to AFS and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy requires that all our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, our AFS securities are classified as current assets without regard to the securities&#x2019; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 5, &#x201c;Fair Value Measurements,&#x201d; and Note 6, &#x201c;Investments.&#x201d;&lt;/span&gt;&lt;/div&gt;We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of interest income. No accrued interest was written off during the nine months ended September 30, 2020.</us-gaap:InvestmentPolicyTextBlock>
    <moh:InvestmentsMaturityPeriod
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTY0Mg_320ef10a-2146-4bd5-9c70-04c6454ad76a">P10Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTY1OQ_97cde43d-0e71-4240-8f63-eba4d55f0c89">P10Y</moh:InvestmentsAverageMaturityPeriod>
    <us-gaap:InterestReceivable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjQ1MA_0453853f-924f-492f-84cf-a53b2d9de4ab"
      unitRef="usd">9000000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjQ1Nw_1f30aa12-6c38-4b33-bfc5-337915257c75"
      unitRef="usd">12000000</us-gaap:InterestReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM3NDM4OTUzNjkzODM_ca3f0e87-8221-4481-9e68-9e81ce0c3cca">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Premiums Receivable &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our Health Plans segment contracts related to our Medicaid, Medicare and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are recognized as &#x201c;Amounts due government agencies&#x201d; in the accompanying consolidated balance sheets, and included the following categories by program:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Medical Cost Corridors. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit Sharing. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Retroactive Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#x2019; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#x2019; health status, risk scores and Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Affordable Care Act (&#x201c;ACA&#x201d;) established a minimum annual medical loss ratio (&#x201c;Minimum MLR&#x201d;) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income. &lt;/span&gt;&lt;/div&gt;Risk Adjustment. Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quality Incentives&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, &#x201c;Organization and Basis of Presentation&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;,&#x201d; recognition of quality incentive premium revenue is subject to the use of estimates.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReservesReportedToOtherAgenciesTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMjE_5141ef21-0420-4ca8-98f0-59eca36ae2ed">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.282%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.283%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReservesReportedToOtherAgenciesTextBlock>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNC0xLTEtMS0w_72082654-efbe-47d7-bc14-ce3d478b025f"
      unitRef="usd">136000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNC0zLTEtMS0w_58d79e5e-2c0a-41a9-b18f-925df4801ff3"
      unitRef="usd">92000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNS0xLTEtMS0w_3b749b87-6d0f-4dc8-82f7-edb71cbca9aa"
      unitRef="usd">83000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNS0zLTEtMS0w_9d563176-31c9-49e2-98f0-2cd432ca745d"
      unitRef="usd">95000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNy0xLTEtMS0w_dfb8e52b-c019-4705-b172-8c1ddb01d85c"
      unitRef="usd">38000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfNy0zLTEtMS0w_37b27f71-4d5a-48d4-93dd-4c7668824e2c"
      unitRef="usd">14000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOC0xLTEtMS0w_557bc3f9-097b-4512-9d7f-d58bb741b41d"
      unitRef="usd">35000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOC0zLTEtMS0w_9c119dd5-e3cc-4d5d-938c-fc343528b119"
      unitRef="usd">36000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:OtherMedicareProgram
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOS0xLTEtMS0w_049ffa98-aa5a-43fa-afd8-c4a5fcc987ac"
      unitRef="usd">30000000</moh:OtherMedicareProgram>
    <moh:OtherMedicareProgram
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfOS0zLTEtMS0w_073d3409-3e10-43e5-8a72-46d9744687b1"
      unitRef="usd">21000000</moh:OtherMedicareProgram>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTEtMS0xLTEtMA_77397080-8b95-4201-af36-e1287f15643e"
      unitRef="usd">265000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTEtMy0xLTEtMA_4db7f196-92ca-416d-a1c5-4b8133d440be"
      unitRef="usd">368000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTItMS0xLTEtMA_ad8ac93b-1320-48ab-8773-e46c46027130"
      unitRef="usd">33000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTItMy0xLTEtMA_878b35b3-3d8a-43c6-976e-fb3bd24bd437"
      unitRef="usd">15000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTQtMS0xLTEtMA_7dec078c-0cee-47e2-bbad-8c9d681a085c"
      unitRef="usd">20000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTQtMy0xLTEtMA_ccd7af5c-b2d0-4b3d-8adf-7878c23ddc0a"
      unitRef="usd">23000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTUtMS0xLTEtMA_81f82b1a-2ec3-4020-b676-be902fbd974c"
      unitRef="usd">640000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOmMxZmU4YTIxOWRiMTRjYzRhN2E0NmI1ZTAzODVkNjRmL3RhYmxlcmFuZ2U6YzFmZThhMjE5ZGIxNGNjNGE3YTQ2YjVlMDM4NWQ2NGZfMTUtMy0xLTEtMA_b6b4a520-5765-4208-af1b-a7c3e826bce9"
      unitRef="usd">664000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i0b8da8ee91eb4ef58dbbb2775da3afce_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDg4MA_49e66510-b6c0-4d65-bddd-a135327aa7c7"
      unitRef="usd">-75000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="if6e8716ea12c44aaaacb9d6db8985ade_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDkwOA_28fe8791-31c9-4349-9a3b-c30f688e1739"
      unitRef="usd">-88000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="ie6a3fd1845154357ac826603e0ae69b7_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMjE5OTAyMzI4NDg5NA_68ef9cc9-53d7-4bd4-821d-5419f1bf0e05"
      unitRef="usd">-163000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i0147887cf13f4458be0b3970d80acbc0_D20200618-20200618"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfODA3NQ_32054a92-e106-44b0-8a9d-2730d37303b2"
      unitRef="usd">128100000</us-gaap:LossContingencyDamagesAwardedValue>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTExOA_8cbff3d6-fec6-4382-b977-e94f59143cca"
      unitRef="usd">265000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE1Nw_001b08e4-237f-4dd1-92d3-734281bc0629"
      unitRef="usd">59000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE4Mg_7335860e-121c-481d-8e80-7437288c6f12"
      unitRef="usd">206000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTE5NQ_835d3e8d-acf8-4d2a-94ce-994aba411a77"
      unitRef="usd">230000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTIxOA_18e8917e-5de0-4857-8ca3-a27df08ba578"
      unitRef="usd">24000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTMwNw_ba4b147c-ced5-4a72-bbb1-9edc3550a1be"
      unitRef="usd">368000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTM0Ng_885a09f6-ace8-4b87-b84e-d40a99099d75"
      unitRef="usd">63000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTM3MQ_5d863b44-5c60-42c8-be9b-d328eda9114b"
      unitRef="usd">305000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:PercentageOfAdditionalIncrementalRevenueEarned
      contextRef="i1e4e51fc373341cb966c120414402a2c_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTkxOA_8b7f9b51-848f-4e5e-a8fd-1666e7d874e8"
      unitRef="number">-0.01</moh:PercentageOfAdditionalIncrementalRevenueEarned>
    <moh:PercentageOfAdditionalIncrementalRevenueEarned
      contextRef="idf82ebc1b18c49939d196d8bf9931c3e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfOTkyNA_4e084d92-c72c-4508-9f48-b90f5583f59c"
      unitRef="number">-0.04</moh:PercentageOfAdditionalIncrementalRevenueEarned>
    <moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTQ_bbe083f8-0eae-42f9-97e5-a8585ea04ee8">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Maximum available quality incentive premium - current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Quality incentive premium revenue recognized in current period:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earned current period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Earned prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Quality incentive premium revenue recognized as a percentage of total premium revenue &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock>
    <moh:MaximumAvailableQualityIncentivePremiumCurrentYear
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC0xLTEtMS0w_009db8d7-be02-4e88-accf-6384ed6bab87"
      unitRef="usd">69000000</moh:MaximumAvailableQualityIncentivePremiumCurrentYear>
    <moh:MaximumAvailableQualityIncentivePremiumCurrentYear
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC0zLTEtMS0w_5ad75196-1fab-4d49-996f-0c41dcde838c"
      unitRef="usd">47000000</moh:MaximumAvailableQualityIncentivePremiumCurrentYear>
    <moh:MaximumAvailableQualityIncentivePremiumCurrentYear
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC01LTEtMS0w_d43887c4-b233-4b69-8f3e-5a3eabb0602b"
      unitRef="usd">195000000</moh:MaximumAvailableQualityIncentivePremiumCurrentYear>
    <moh:MaximumAvailableQualityIncentivePremiumCurrentYear
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNC03LTEtMS0w_7e866ab6-2701-438f-b5e2-12c72c0237ee"
      unitRef="usd">138000000</moh:MaximumAvailableQualityIncentivePremiumCurrentYear>
    <moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy0xLTEtMS0w_c5927c94-6bd8-44e4-9fd8-61de494fe743"
      unitRef="usd">63000000</moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized>
    <moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy0zLTEtMS0w_d4924a52-d54a-441e-a1f9-6632d24db3cb"
      unitRef="usd">46000000</moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized>
    <moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy01LTEtMS0w_d1e8b630-68c9-41b6-abf6-7c3d7e871995"
      unitRef="usd">180000000</moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized>
    <moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfNy03LTEtMS0w_c1de9f10-41b3-4267-9a69-3db79b625b9e"
      unitRef="usd">109000000</moh:AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized>
    <moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC0xLTEtMS0w_4e416721-fa4c-469a-aecb-282ffaa0c385"
      unitRef="usd">19000000</moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear>
    <moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC0zLTEtMS0w_9eb8d2a9-900e-456d-8728-6ac2b19b52ee"
      unitRef="usd">5000000</moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear>
    <moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC01LTEtMS0w_b7047fd1-2d5d-4cc5-a498-cbf4cac31f6b"
      unitRef="usd">23000000</moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear>
    <moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOC03LTEtMS0w_7097f723-ea5d-4c60-af74-faf040b100b9"
      unitRef="usd">35000000</moh:AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear>
    <moh:QualityIncentivePremiumRevenueRecognized
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS0xLTEtMS0w_0127212f-710c-4970-9f4c-0d575a8bae43"
      unitRef="usd">82000000</moh:QualityIncentivePremiumRevenueRecognized>
    <moh:QualityIncentivePremiumRevenueRecognized
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS0zLTEtMS0w_a4831de5-acbb-45d3-b679-cd086000f095"
      unitRef="usd">51000000</moh:QualityIncentivePremiumRevenueRecognized>
    <moh:QualityIncentivePremiumRevenueRecognized
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS01LTEtMS0w_7935b84e-d57f-445a-9afe-ed9454c3c826"
      unitRef="usd">203000000</moh:QualityIncentivePremiumRevenueRecognized>
    <moh:QualityIncentivePremiumRevenueRecognized
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfOS03LTEtMS0w_85ff3eae-d04b-4b27-9c04-8b044586a991"
      unitRef="usd">144000000</moh:QualityIncentivePremiumRevenueRecognized>
    <moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtMS0xLTEtMA_bafbe86d-7bf3-4d81-9c76-b6931922a109"
      unitRef="number">0.017</moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue>
    <moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtMy0xLTEtMA_e85550ff-b825-4074-b0a5-10e593230478"
      unitRef="number">0.012</moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue>
    <moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtNS0xLTEtMA_0e9ea1de-9064-4f51-a1a2-2e455c82aa14"
      unitRef="number">0.015</moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue>
    <moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjljZDUzN2JjZGEyZDRkMjU5MWRlYTExYzljNjg0ZDNkL3RhYmxlcmFuZ2U6OWNkNTM3YmNkYTJkNGQyNTkxZGVhMTFjOWM2ODRkM2RfMTEtNy0xLTEtMA_e51008d2-4955-4453-b513-2bf1edb40501"
      unitRef="number">0.012</moh:QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNjA_20850db4-dd36-44bc-ad92-f1cc0e11f626">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMzA_e90f4f78-f5bb-49d6-bf9c-c774c4be88cc">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health insurer fee reimbursement receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if72eeeb9a99b4477ab11023ecac0d4ae_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfMy0xLTEtMS0w_679d5bf2-c2cf-4081-af98-b87ee7ccfe0b"
      unitRef="usd">1180000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i0c9cc48effd74e3db60699619b9bc2e7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfMy0zLTEtMS0w_ff87db9f-7c18-4804-89a4-fdb397c06e98"
      unitRef="usd">1056000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i71a512cf78114e5cbc32223760854d4b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNC0xLTEtMS0w_e79d4707-bc4f-4751-b34e-baec87d1a0bf"
      unitRef="usd">175000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i2833620245ff437a9d61acd7e7dbfa4d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNC0zLTEtMS0w_ac13ad63-8cb1-467b-8aab-05d64247e2b5"
      unitRef="usd">150000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i33f1b142cbf04ffc961177d0573c2b33_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNS0xLTEtMS0w_8c295187-01e8-429f-9239-01365321391e"
      unitRef="usd">180000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="id396aa5e78ce44cca988d14d35592f10_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNS0zLTEtMS0w_0cebd5c0-86f7-4ed8-a141-b6fded3e1ba1"
      unitRef="usd">5000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ic1cccaa6b1874d0b97e1e7d43c952948_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNi0xLTEtMS0w_b1e7467f-7925-4424-9390-706acacffe1d"
      unitRef="usd">240000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="if6158f7ac8714b678e788253d6cc7e0e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNi0zLTEtMS0w_7fca9206-5b1e-4ef1-a2be-254253cd0bfb"
      unitRef="usd">195000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNy0xLTEtMS0w_88984336-d1e3-4c0f-a468-25e60e04ae5b"
      unitRef="usd">1775000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RhYmxlOjg5NzUwMDUyOTljODQxNTM4MTNkYWY3NDVjODA0ZDM3L3RhYmxlcmFuZ2U6ODk3NTAwNTI5OWM4NDE1MzgxM2RhZjc0NWM4MDRkMzdfNy0zLTEtMS0w_9e4ba18a-da8d-4de2-beec-9f87e7292c61"
      unitRef="usd">1406000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReinsuranceAccountingPolicy
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcxNjQ_32399f19-7dbd-43eb-8ed8-3a761babd8b8">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bear underwriting and reserving risks associated with our health plan subsidiaries. Until the second quarter of 2020, we limited our risk of catastrophic losses solely by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#x201c;third-party reinsurer&#x201d;). Beginning in the second quarter of 2020, we now retain certain of these risks through our wholly-owned, captive insurance subsidiary (the &#x201c;captive&#x201d;). We continue to reduce our exposure to significant catastrophic losses by insuring levels of coverage, with the third-party reinsurer, for losses in excess of what we retain with the captive. Because we remain liable to our policyholders in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#x2019;s financial condition, including its ability to maintain high credit ratings. We report reinsurance premiums as &lt;/span&gt;&lt;/div&gt;a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Intercompany transactions with our captive are eliminated in consolidation.</us-gaap:ReinsuranceAccountingPolicy>
    <us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts
      contextRef="i2dcf40f147894f828c6c0e0d48d7b212_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTA0NDUzNjA0ODYwNDE_7fda1dae-d9fc-4c2c-8c79-47113b71d628"
      unitRef="usd">10000000</us-gaap:PremiumsReceivableAllowanceForDoubtfulAccounts>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTc_05b39a82-a3cc-4f0a-9169-5457e7416305">Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate.</us-gaap:ConcentrationRiskCreditRisk>
    <moh:InvestmentsMaturityPeriod
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTI1MTY_fcfa0a56-12f0-4899-a40b-aca7ee76f38b">P10Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsMaturityPeriod
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTI1MzM_fcfa0a56-12f0-4899-a40b-aca7ee76f38b">P10Y</moh:InvestmentsMaturityPeriod>
    <moh:HealthCareInsuranceFeeLiability
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM1NDY_a878f554-98a1-45c0-ac87-d5e3985d7d06"
      unitRef="usd">277000000</moh:HealthCareInsuranceFeeLiability>
    <moh:HealthCareInsuranceFeeLiability
      contextRef="if9a2b45e286440acaf152463d403a03c_I20200101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM1NjA_969547e3-6e66-4d5c-83e3-62b294590862"
      unitRef="usd">271000000</moh:HealthCareInsuranceFeeLiability>
    <moh:IncreaseDecreaseInHealthInsuranceFeeLiability
      contextRef="i8dd596c0bfc54a5f8111652f7d7cf1ed_D20200401-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTM2MTY_1efc0fec-ff02-4dd6-94fe-027508a02758"
      unitRef="usd">6000000</moh:IncreaseDecreaseInHealthInsuranceFeeLiability>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMTU_d7294ed2-097e-49ab-ac1d-30f1e2ca6177">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, nondeductible expenses such as the HIF, certain compensation, and other general and administrative expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80MC9mcmFnOmY2NzljY2U3ZDMyODRlMTliYzU5OTM1YWE1OWFhOGEzL3RleHRyZWdpb246ZjY3OWNjZTdkMzI4NGUxOWJjNTk5MzVhYTU5YWE4YTNfMTcyMzY_862fee82-b21b-41c3-bb31-2fcf5fbbaa56">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Losses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was subsequently modified by several ASUs issued in 2018 and 2019. We adopted Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we recognized the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020, which was immaterial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In March 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by a change in the reference rate from the London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) or another reference rate expected to be discontinued, if certain conditions are met. ASU 2020-04 is effective immediately and expires after December 31, 2022. We are evaluating the effect of reference rate reform and this guidance on our contracts and other transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RleHRyZWdpb246MmFiZmMwMDE1MmZlNGIwNjk1ZjIwZTIxNWY4Y2UwMWFfNDE4_3a42bf51-d6d9-429c-8acf-725bb9f2ac89">Net Income per Share &lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 9, &#x201c;Stockholders' Equity.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RleHRyZWdpb246MmFiZmMwMDE1MmZlNGIwNjk1ZjIwZTIxNWY4Y2UwMWFfNDI2_3a5c9bf0-7412-4b7a-b567-64d4886939e6">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.981%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 9, &#x201c;Stockholders' Equity.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS0xLTEtMS0w_fcad0154-3eb8-4518-83d1-e8e470f6a06a"
      unitRef="usd">185000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS0zLTEtMS0w_412e764f-8e70-4863-92d1-1ef47e482432"
      unitRef="usd">175000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS01LTEtMS0w_b1853129-6bbe-4867-aa51-d4aaacd80ff6"
      unitRef="usd">639000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNS03LTEtMS0w_00031fb3-62f6-461e-ad57-356c8f31b538"
      unitRef="usd">569000000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ife5003122e804b988dea74c354c83d41_I20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy0xLTEtMS0w_2aa22d6b-a0cd-48d6-8291-ac69e695a488"
      unitRef="shares">58700000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i8def59bebfc44b69808ea12af90bd829_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy0zLTEtMS0w_782385f6-a73f-4f11-b1e9-f3e8a7a7b6b7"
      unitRef="shares">62200000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy01LTEtMS0w_2a36149a-b093-4f36-abd2-7a81f4a89afb"
      unitRef="shares">61900000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfNy03LTEtMS0w_29813d87-2475-47d3-8836-a4756f8b3c95"
      unitRef="shares">62100000</us-gaap:SharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS0xLTEtMS0w_a83357f1-010f-4d4c-8f78-c3e16195188a"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS0zLTEtMS0w_eb362188-9889-4293-87a7-2890e58cb7e5"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS01LTEtMS0w_64926d70-17b4-4bf1-9461-2423c2fce4a7"
      unitRef="shares">2800000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfOS03LTEtMS0w_3de77080-0985-464b-aae0-b7096b936cc2"
      unitRef="shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMS0xLTEtMTA3OQ_921323c3-24cb-4699-aec7-95b6ecfbc570"
      unitRef="shares">0</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMy0xLTEtMTA3OQ_7210e80f-04c3-4153-96ca-53a0ebf57579"
      unitRef="shares">0</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNS0xLTEtMTA3OQ_60bc29ec-75d8-4d51-ab68-b8bb0029ee49"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNy0xLTEtMTA3OQ_886b5e5e-3481-4aa8-b908-fafda4fc2f96"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMS0xLTEtMA_a4384528-076c-4b8e-a7e6-bb52e175e3ae"
      unitRef="shares">58700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtMy0xLTEtMA_83412398-6d5c-451f-af64-08f74c105be0"
      unitRef="shares">62200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNS0xLTEtMA_6e6fbb91-a035-4720-aea9-bd8b6a388606"
      unitRef="shares">59200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTAtNy0xLTEtMA_5b6ecef5-9815-447a-910f-8edc3653b9ca"
      unitRef="shares">62200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItMS0xLTEtMA_cfebecfd-5e9a-47c6-a66d-d6dee35e1329"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItMy0xLTEtMA_11bfba31-ed64-425f-b445-e8fd12545d0f"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItNS0xLTEtMA_2c1ce694-04e3-4634-af7d-d523f6d80cef"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTItNy0xLTEtMA_b8cd18bf-253e-4d03-8575-7344058b4936"
      unitRef="shares">1800000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtMS0xLTEtMA_f051b07a-95e7-42c2-ad6e-e7e89e090eb4"
      unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtMy0xLTEtMA_42e44925-789b-437b-b802-cdc46873e3e8"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtNS0xLTEtMA_c2fea5b7-766a-40d3-a97c-8db4d85d1b59"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTMtNy0xLTEtMA_e27e2419-89f5-49bf-8d7f-3c6cf9ba865f"
      unitRef="shares">600000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtMS0xLTEtMA_0adfe496-a48e-4702-b303-08bc2514cec3"
      unitRef="shares">59600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtMy0xLTEtMA_895b7286-cb38-4145-ab4e-40748b2e4dee"
      unitRef="shares">63600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtNS0xLTEtMA_f9beded8-f05e-4f23-9322-5a918206e333"
      unitRef="shares">60000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTQtNy0xLTEtMA_83fb3976-2880-4cec-a8af-7704c7cc21c4"
      unitRef="shares">64600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtMS0xLTEtMA_91e1e96e-4301-4d53-b1e6-3ab5c2a6b13d"
      unitRef="usdPerShare">3.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtMy0xLTEtMA_18fb0887-7239-46af-b7ad-0594acfff017"
      unitRef="usdPerShare">2.81</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtNS0xLTEtMA_6c3385d8-22dd-4c85-95dd-749909976b4e"
      unitRef="usdPerShare">10.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTYtNy0xLTEtMA_af437401-1948-46c7-87d4-b220b0bb61d1"
      unitRef="usdPerShare">9.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctMS0xLTEtMA_d8ecfcbd-a929-4710-9252-1a9bdd072968"
      unitRef="usdPerShare">3.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctMy0xLTEtMA_52aa9f1b-31ff-4ab3-8647-a8a30abcd5d6"
      unitRef="usdPerShare">2.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctNS0xLTEtMA_a240d5cc-08ea-4d1b-ac83-de115693a2f3"
      unitRef="usdPerShare">10.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80Ni9mcmFnOjJhYmZjMDAxNTJmZTRiMDY5NWYyMGUyMTVmOGNlMDFhL3RhYmxlOmNkMDE2Zjc5YzM2YTRkNTI4YzU1ZTVlYmQwMGQyZjcxL3RhYmxlcmFuZ2U6Y2QwMTZmNzljMzZhNGQ1MjhjNTVlNWViZDAwZDJmNzFfMTctNy0xLTEtMA_11d71459-30a7-4f8c-96be-626db681df87"
      unitRef="usdPerShare">8.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV81NDk3NTU4MTQ1NTA3_e612911e-8781-48e4-9c3c-cc3e9ee5faf2">Business Combinations&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the third quarter of 2020, we closed on two business combinations in the Health Plans segment, consistent with our strategy to grow in our existing markets and expand into new markets. For both transactions, we applied the acquisition method of accounting, where the total purchase price was allocated, or preliminarily allocated, to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition dates. We expect to complete the final determination of the purchase price allocations as soon as practicable, but no later than one year following the closing date in accordance with Accounting Standards Codification Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The table below illustrates the intangible assets acquired, by major class, for the two acquisitions. Acquisition-related costs were insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2020, we closed on the acquisition of certain assets of YourCare Health Plan, Inc., a Medicaid health plan, for a cash purchase price of $42&#160;million. In connection with this transaction, we added approximately 47,000 Medicaid members in New York. We recorded goodwill of $31&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from expected synergies to be achieved, including the use of our existing infrastructure to support the added membership. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 1, 2020, we closed on the acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan. Effective on that same date, the Kentucky Medicaid agency approved the novation of Passport&#x2019;s Medicaid contract to Molina Healthcare of Kentucky, Inc. As a result, we added approximately 325,000 Medicaid members in Kentucky. As of September 30, 2020, the purchase price allocation was preliminary due to the proximity of the acquisition date to September 30, 2020, and the time and level of effort required to develop fair value measurements for the assets acquired and liabilities assumed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated total purchase price of $60&#160;million includes our initial cash payment of $20 million in September 2020, plus estimated contingent consideration which consists primarily of an amount due to the seller for members we enroll in the open enrollment period for the 2021 plan year, over a minimum threshold, which resulted in an initial contingent consideration liability of $40&#160;million. We expect to settle this liability in the first quarter of 2021. Contingent consideration liabilities are remeasured to fair value at each quarter until the contingencies are resolved with fair value adjustments, if any, recorded to operations. See further information in Note 5, &#x201c;Fair Value Measurements.&#x201d; We recorded goodwill of $27&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from the assembled workforce, and the future growth associated with the member contract rights that are incremental to the contract rights identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the intangible assets identified in the transactions described above. The weighted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average amortization period for the identified intangible assets, in the aggregate, is 10.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible asset by type:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights - member list&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider network&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <moh:BusinessCombinationNumberOfBusinessCombinations
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV85ODk1NjA0NjY1OTgy_be672752-ca0d-4f1e-b7a9-bb60db5bff91"
      unitRef="business_combination">2</moh:BusinessCombinationNumberOfBusinessCombinations>
    <moh:BusinessCombinationNumberOfBusinessCombinations
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMzc0Mzg5NTM2MzE4OA_a90d2f7c-5558-4b33-bf1d-7d27802d703a"
      unitRef="business_combination">2</moh:BusinessCombinationNumberOfBusinessCombinations>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id749608c745740b08f21cdaad564831d_D20200701-20200701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjI0_c9460686-a09d-4fca-ae5b-b927ebddbbbd"
      unitRef="usd">42000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i87dd32a9ad2d4055800c9652ac634681_I20200701"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjM3_8accfd48-c265-4fbf-a87c-e821ca9a9db7"
      unitRef="member">47000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <us-gaap:Goodwill
      contextRef="i87dd32a9ad2d4055800c9652ac634681_I20200701"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMzc0Mzg5NTM1NjMzNg_9e240bab-1925-4c5d-baec-f461b8f1cf8c"
      unitRef="usd">31000000</us-gaap:Goodwill>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i4beec814285e499c89a31cc2a5afc464_I20200901"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xNjQ5MjY3NDU1NzU5_b7c5b6a1-b268-4acf-906b-62690422b978"
      unitRef="member">325000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMTk5MDIzMjY5OTI2_b5b1c7db-7a92-4827-9e15-23adbfa21b81"
      unitRef="usd">60000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i05f6beea3bd3459a8c30a2e6d9551531_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjM0MjUw_23c57e85-1e91-4e17-b98c-4c230f2ee322"
      unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i433cfe399a704a47bba65a8c3a8b4e14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMTk5MDIzMjY5OTM0_a4c51c9d-9660-4446-8064-b06e669faa24"
      unitRef="usd">40000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:Goodwill
      contextRef="i433cfe399a704a47bba65a8c3a8b4e14_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8yMDM0MDk2NTEyODE3OQ_af243e71-ed60-4923-a8fa-1c740256419f"
      unitRef="usd">27000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV81NDk3NTU4MTQ1NTIw_7535e482-a22a-4dee-bfe6-8a4073e7bba0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the intangible assets identified in the transactions described above. The weighted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;average amortization period for the identified intangible assets, in the aggregate, is 10.7 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.266%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intangible asset by type:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights - member list&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade name &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider network&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGV4dHJlZ2lvbjoyMjdiZDkxMDcxN2U0YTA3ODdiNzhkNjFmNjI3OWRjMV8xMDk5NTExNjQzNzg2_ccc27431-ca4a-411f-9985-300c67f438f4">P10Y8M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="i70c7a62c77174856b9b975dfcec870fa_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTEtMS0xLTI2Mzc_94fd8be2-19d9-4114-ba1b-90070865a6ab"
      unitRef="usd">24000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8354adbb632c45a49e8c71116d0bd934_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTMtMS0xLTYxNTE_252f8931-3d04-48db-a6a5-e7921532e4f3">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie5b787b7098243d881eb301f892af3a4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV80LTMtMS0xLTI2Mzc_75cb98bd-89b3-4b91-b0a1-07f105c0b54a">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="icb06886bec8d4d3a8d4d744db0da88ee_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTEtMS0xLTQ5NTI_94c44849-fba0-423b-8570-8ed205ddaf8e"
      unitRef="usd">15000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic6d40c8167db46f2a37e7382c7546b67_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTMtMS0xLTQ5NTI_e7971d49-0b59-4abf-bc94-055845925e94">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="if0f13a84316c4f71b4b314485e38873d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTEtMS0xLTI2Mzc_df75e707-f84f-4213-9104-65099e951076"
      unitRef="usd">8000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="if845f286887c45ceb4f63de315dc91f9_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV81LTMtMS0xLTI2Mzc_5c214de4-331d-4bd2-ab6b-6353e90cbbc6">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMTAwL2ZyYWc6MjI3YmQ5MTA3MTdlNGEwNzg3Yjc4ZDYxZjYyNzlkYzEvdGFibGU6MjcxMWJlNWFjMDk2NDIxNjg1MGM4NmRiMTBmNzliMWUvdGFibGVyYW5nZToyNzExYmU1YWMwOTY0MjE2ODUwYzg2ZGIxMGY3OWIxZV82LTEtMS0xLTIwMTk_45ec589b-69ba-4090-a6af-39205e58a992"
      unitRef="usd">47000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQyNQ_9fbec62e-ee3a-47b3-a15f-7d08d81922b2">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions that we use to a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2019 Annual Report on Form 10-K, Note 4, &#x201c;Fair Value Measurements.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $40 million, in connection with the Kentucky acquisition described in Note 4, &#x201c;Business Combinations.&#x201d; Such liabilities are reported in &#x201c;Accounts payable, accrued liabilities and other&#x201d; in the accompanying consolidated balance sheets. The fair value of the contingent consideration was estimated using a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;simulation-based option pricing model through the end of the measurement period of approximately 5 months, and included certain non-observable inputs. The key assumptions included a U.S. Treasury based risk-free rate of return, expected asset volatility of 35%, expected revenue volatility of 9%, forecasted membership enrollment, and other estimated revenue, asset and payment correlations and discount rates. The model produced an estimated range of undiscounted amounts Molina could pay under the contingent consideration arrangement of $25&#160;million to $75&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSEs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Call option derivative asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Conversion option derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values and the presentation of our derivative financial instruments in the accompanying consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Call option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets: Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Conversion option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities: Accounts payable, accrued liabilities and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information regarding our derivative financial instruments, see Note 11, &#x201c;Debt,&#x201d; and Note 12, &#x201c;Derivatives,&#x201d; in our 2019 Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the first quarter of 2020, we received $27 million for the settlement of the call option derivative asset, and we paid $39 million to settle the outstanding $12 million principal amount of the 1.125% Convertible Notes, and settle the related conversion option. For more information, refer to Notes 8, &#x201c;Debt,&#x201d; and 9, &#x201c;Stockholders' Equity.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &#x2013; Disclosure Only &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.125% Convertible Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;For more information on financing activities, refer to Note 8, &#x201c;Debt.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i421938697dd9476f9e8ed3a9387bbc72_I20200901"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTA5OTUxMTYzMTA5Nw_bb42fb65-066b-4a79-866f-7922032d49cd"
      unitRef="usd">40000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i044a1952a952424d842a4e7856f32813_I20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYxNg_2ef5ba68-8797-4c57-8762-e399f14901ae"
      unitRef="number">5</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i16ad5df3e0954d1db28ec31f056ff595_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYwNQ_3341eb7e-3068-4c19-b61a-b8a4fbec6401"
      unitRef="number">0.35</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i79740d5150ff4f4db489bbeb8788d206_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfOTg5NTYwNDY2MDYxMA_300e4030-c52c-420a-b29f-cef26c9311e8"
      unitRef="number">0.09</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4e6dcbb92a8c4409987fd92c2d6dd158_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTY0OTI2NzQ1MjI1OQ_ee72cb93-87d0-47c2-acde-e18fd5da8b89"
      unitRef="usd">25000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i058f38bcf796477da567b0db7952dc1e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTY0OTI2NzQ1MjI3Mg_7eee120f-3646-4d50-8c2d-6b04e8a8067b"
      unitRef="usd">75000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQ0Mw_233f1f0e-7425-4d2a-bdf2-842e761e2dc6">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2020, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.209%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2019, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.326%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.355%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Directly or Indirectly Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSEs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Call option derivative asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Conversion option derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC0xLTEtMS0w_baeea074-19c8-4d52-b3da-405bc9a48021"
      unitRef="usd">1041000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6748d59d26dd4b4e9a668279c29380d7_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC0zLTEtMS0w_9e2e60eb-b0b9-4886-8c31-c4efed76715e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibfdb1a74a3b545d0aee5dd04c31c43db_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC01LTEtMS0w_417b4c40-623c-4071-a4b2-59fe6ec755bb"
      unitRef="usd">1041000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5933b867152b47d29c8a2374b54fa5a6_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNC03LTEtMS0w_580e873f-1727-4bf0-aeb6-b8b57a23f496"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS0xLTEtMS0w_e4d25192-d881-4089-af20-e92be7f3fae6"
      unitRef="usd">417000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib7ec79780ff9483fafe419776c6fff72_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS0zLTEtMS0w_5a058346-6c3d-4f33-a221-13f55c33a6be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e9ab90b62c74c95810d0a07c314ddd4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS01LTEtMS0w_1a7553c4-ef2e-4414-b473-c00b9877a398"
      unitRef="usd">417000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie806826c7c874d3cbee4baa4d5c22d75_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNS03LTEtMS0w_985b4de7-b99d-4c17-a301-4b949e639a87"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi0xLTEtMS0w_1084a760-9959-4d88-a01f-d94fb1667543"
      unitRef="usd">168000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie647fc62813f495f8d1417451ba88a73_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi0zLTEtMS0w_e9782069-2ced-4d7f-b325-59518350b01c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57fc15dc5d8d48bea4aaa778a0932e03_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi01LTEtMS0w_4f043452-bc47-4ef0-9c48-0d5cdfdaf500"
      unitRef="usd">168000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia0a101af7d174776bc9ad4386eed46b9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNi03LTEtMS0w_822541a5-187a-4df5-8196-8ae0c3f5b437"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy0xLTEtMS0w_3f1e282a-99b6-432f-ac07-f2eba1c9f9be"
      unitRef="usd">136000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic2741d275f3f4c36bced0a05c8aefec9_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy0zLTEtMS0w_7ce21307-f9d8-4f29-aa4d-ea4e9b579ce4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie22b9a72648d4042884d35282e080c18_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy01LTEtMS0w_2bff5847-ec8f-4259-bd96-134745c1b5fe"
      unitRef="usd">136000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8bef829bfb5741c39a8a5d311beab675_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfNy03LTEtMS0w_2c522cba-1ff1-45cf-b153-ea3c38d538f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC0xLTEtMS0w_6800d2a5-15f8-4c29-88e8-ad751883c62d"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2a868439a3ab4ddba3f5532d5ceda157_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC0zLTEtMS0w_bfb3b818-1b83-4873-b540-c8b97cfb4675"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i78ca2500088d432999b9943027a2975b_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC01LTEtMS0w_3333eff9-cdc3-4b64-a366-20ed4371a91e"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6ad5bafcd3a45f386f7d9e4c0f9f4a0_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOC03LTEtMS0w_94eaa9c4-c037-4416-b264-11b148201e83"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS0xLTEtMS0w_b0f9bd9a-a208-4c34-9c0c-93f6274f4c7b"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i79dc47d8b0274fb7814a8ba0de483d90_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS0zLTEtMS0w_c77508a0-4853-498d-999c-aadd68b2e597"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6363a2d3e25d4dd98cfe015a124dada4_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS01LTEtMS0w_10a57105-e9b6-4b11-ba23-b120dcfba96e"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7caaaa444e8946e8a72451037d62eb94_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfOS03LTEtMS0w_b6118822-265b-43d5-89ca-5bc69020092d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItMS0xLTEtMA_ebd9eb3f-908b-4909-97da-efc66694773b"
      unitRef="usd">1769000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItMy0xLTEtMA_e478bc8b-48fa-4f49-99d6-a6a82256b25d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItNS0xLTEtMA_1a3db20e-6e82-46b2-9ee1-3e0185d03843"
      unitRef="usd">1769000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTItNy0xLTEtMA_aa4458d9-7586-442a-a35c-ab1262f87ed5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtMS0xLTEtMTM1NQ_05e9afa4-5f4e-4db6-a972-90f2d30e5499"
      unitRef="usd">40000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtMy0xLTEtMTM1Nw_33674685-37df-421a-99bd-14aecf64409c"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtNS0xLTEtMTM2Mg_803c89e8-7ab1-461d-a508-13473b370f8a"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTQtNy0xLTEtMTM2MA_694e3d83-d3a5-43a4-81a9-8869724c8125"
      unitRef="usd">40000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtMS0xLTEtMTMzNg_80ffd9d3-57ff-46f9-98fc-102dd5574f33"
      unitRef="usd">40000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3048d9541ec340368f67b9914fdd4373_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtMy0xLTEtMTMzNw_e8fdd9bc-7627-457c-99ca-5c5111f18ab2"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3080bd3f3a8642f9bd388c5be3a364ca_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtNS0xLTEtMTM0MA_ae6fb122-3862-4523-a8c8-6caf96086018"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib9c2e228625445018b01f1a9744f8c80_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjA2MDRmYWMyZjYzYTRiYmRiN2YyMTkzOTVhMTVhM2E4L3RhYmxlcmFuZ2U6MDYwNGZhYzJmNjNhNGJiZGI3ZjIxOTM5NWExNWEzYThfMTUtNy0xLTEtMTM0MQ_ae42af0b-799d-423e-a748-3ed5c512de9d"
      unitRef="usd">40000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC0xLTEtMS0w_032e84e3-528a-4c96-bbd9-aa4dd3ec00d0"
      unitRef="usd">1178000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i85a0edf748fe453aa44bb4508f73e5f4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC0zLTEtMS0w_b4ee8885-cbe1-42fb-b521-edd8a597a995"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i52d9bab2071e4d2bbff6fa531b293a7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC01LTEtMS0w_b39259b6-c5cb-4a3e-9c65-7825658d544e"
      unitRef="usd">1178000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if241099a610c4f3785fd872f815a3259_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNC03LTEtMS0w_914e6837-7d90-4868-a6d9-47b36e2798c5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS0xLTEtMS0w_97a92cf8-aa52-42b9-a4d4-eff1f4005254"
      unitRef="usd">420000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8832b45f6ca43d392a187f977e3dbf4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS0zLTEtMS0w_2a4f7e3c-0e79-4315-a3b9-f5614fa8326a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i690ef92af3884583b912258ff28d709f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS01LTEtMS0w_aacfd77f-490b-43eb-a70e-d5c718076abf"
      unitRef="usd">420000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i668462f9d37f4932b5b594b4f0fcb1e9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNS03LTEtMS0w_c6607c26-2ab4-4005-91e3-bda3d61c6eaa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi0xLTEtMS0w_f2d07007-29e8-4b9f-85ad-c073ec1ad744"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcef928989144ada890aa6c205760cfe_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi0zLTEtMS0w_9cdcd374-b53a-43f9-a279-91bcca2086ac"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i234c36ce5254435e9cd31cb07a130065_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi01LTEtMS0w_b68b5418-63f5-44c9-955d-3e49375116dd"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i73f8fb252fba435384882b7d0bd11132_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNi03LTEtMS0w_998635f2-0598-4825-9b18-d49ef90c9343"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy0xLTEtMS0w_d2803aba-f9b4-4509-bd68-4cc7160e427f"
      unitRef="usd">127000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id693148d77924496941bc5d2a267a6d8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy0zLTEtMS0w_c264d17b-e53e-473b-8f93-ccca913d3a5b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc37b2026d5149db9253f8ee18a2d9b2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy01LTEtMS0w_11d1aace-e573-44c0-851e-794f66e5ffbf"
      unitRef="usd">127000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0c9899abdda479e99525c731ad8ded7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfNy03LTEtMS0w_d93bdfec-ffc4-4698-9917-16fa7d3b54e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i522376b3702049e087e884d659c89675_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC0xLTEtMS0w_f8215fb4-575e-48e4-9a1b-2f4e3df54cd2"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iece312dcb67946698766f966c89eafa2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC0zLTEtMS0w_3531bc6c-0b89-4e9c-b0d6-4f98f6d503ff"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id50eed5aa516417bbac56da2beaea590_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC01LTEtMS0w_09b9d4d5-6eec-443e-9743-6bdeeb23e75e"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68b250a3de064792b082df53482bf14c_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOC03LTEtMS0w_7ac805ac-c4ba-4233-a76b-1ad8565e77f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS0xLTEtMS0w_b25a14bb-eabc-4035-95ba-06aca7850cc0"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia96df6f9f64a43558623ace7f058a832_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS0zLTEtMS0w_5a5091bd-4065-4356-872c-75eb4e14648a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idcc73a3dc4644046892c7265608f9887_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS01LTEtMS0w_17a7dd96-bb79-491d-8b4e-9a2ed328308a"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa4f9337eb184ec2bdfe4334c287f7b5_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfOS03LTEtMS0w_b8782039-49f0-406c-8fa9-acc97952a855"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtMS0xLTEtMA_1b72bce8-d08d-4120-9d43-d93c830ad47d"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb61a08e25544eebb8b370e51386f60b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtMy0xLTEtMA_2c63b5d9-f8de-4d46-9d68-cb5cf72f094b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d6efdc95e7240149d457a1f9ae63e55_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtNS0xLTEtMA_249973d0-51c5-489b-91f2-67273d8cde4d"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ec964ecd3644f5a8e9d165b2153cfe2_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTAtNy0xLTEtMA_255bba13-d374-4bb6-8be5-963722541209"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtMS0xLTEtMA_83f44fed-c6a2-402c-9f6a-a016158e6626"
      unitRef="usd">7000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2526f7970b8c4c11bfd963e67d99f188_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtMy0xLTEtMA_c2a13b76-9c46-410e-bea3-3d0f6b66c363"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1e4e03da2559470b9e01c0f4e7f534db_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtNS0xLTEtMA_65869e34-efe5-4c3d-80ad-ed4bcdaeccb3"
      unitRef="usd">7000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic12f63d329ee4926b7f91daa16eca22b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTEtNy0xLTEtMA_1e2b5a62-4d6f-4df6-a28a-7ec92c194eed"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItMS0xLTEtMA_475d59ec-dbbc-4e9b-b659-b39f22023c03"
      unitRef="usd">1946000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItMy0xLTEtMA_cc78a935-ae14-41b1-a287-b3acfb1994ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItNS0xLTEtMA_195e6bfa-f0bb-4421-9e91-ddf2aa54bbc9"
      unitRef="usd">1946000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTItNy0xLTEtMA_b2349657-7f05-4277-a82a-c86fa049e88c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DerivativeAssets
      contextRef="i4ad60777eaf94a25b4eb9085704435f9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtMS0xLTEtMA_7f5cd9f3-4785-49af-be06-5c007b95426e"
      unitRef="usd">29000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i721461de0d57453f954cd5a2ea7e6120_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtMy0xLTEtMA_d1554624-0c31-495a-abc3-18d872cff720"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="iaf4f5c72cbac46beb3ae4a136d11034d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtNS0xLTEtMA_a3ac1fd2-b5b0-49b9-a237-9df4a09ab034"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i11b1b5fd2c3d451da9d56d574c319476_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTMtNy0xLTEtMA_0d914e44-d830-4bff-8fa4-339c0e8a0b3c"
      unitRef="usd">29000000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtMS0xLTEtMA_d60866b9-972d-4b19-8c08-2e7bf1a7b8e0"
      unitRef="usd">1975000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtMy0xLTEtMA_d1cd2f48-c067-4ac4-b6cb-c1041da2cdc3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtNS0xLTEtMA_b8d98585-6a69-4c09-b33e-10108c644eac"
      unitRef="usd">1946000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTQtNy0xLTEtMA_0feac716-b7fe-4fd6-ac7f-388382ee469b"
      unitRef="usd">29000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilities
      contextRef="i3586192295fd40e39cdd133fd5eda38f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtMS0xLTEtMA_5818e081-e22a-4676-bafb-49eb5b310384"
      unitRef="usd">29000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i3035128b95994c0192502f66cc8725c3_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtMy0xLTEtMA_2993dcc2-2764-4d3d-81ba-f9d1bbcaffd0"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="id9eafdb5b66a49c39b778405016244ea_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtNS0xLTEtMA_9fa1b723-892e-4f97-98cb-3f22c379873c"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i9d552ba27235403b8fea92d279192c84_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTYtNy0xLTEtMA_eb172798-8c1d-4e31-ae97-89eaed5167f0"
      unitRef="usd">29000000</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctMS0xLTEtMA_d9b72057-66df-407a-8e71-c2d0eeefa4e7"
      unitRef="usd">29000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7ae382dc57714c32a69f64a22d44f4c9_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctMy0xLTEtMA_63027d59-2974-4cc5-8ad8-3e25d15b66c8"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ib9a4a50cf6104828a98dde3cf7ec3f9a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctNS0xLTEtMA_a2b5ca6b-2e41-4d09-8bb1-47cb4f09992c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3796bb08765846f69522f7b72d8e436a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjFkZmU2YTczNDQ0ODRmMDE4YjFlN2MyOTgzYWRkYzVmL3RhYmxlcmFuZ2U6MWRmZTZhNzM0NDQ4NGYwMThiMWU3YzI5ODNhZGRjNWZfMTctNy0xLTEtMA_2216713a-4db2-48a5-bf2d-dccead337df4"
      unitRef="usd">29000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMjQyOA_2320d949-166f-41e5-8513-54effa7194ad">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair values and the presentation of our derivative financial instruments in the accompanying consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.022%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative asset:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Call option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets: Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative liability:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Conversion option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities: Accounts payable, accrued liabilities and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i28a5c4abcb034316be3389b51a439633_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNC0zLTEtMS0w_cacf9824-dc6b-48b2-881e-7d4a40e74a9f"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i2f50b9933fcc48f99b974e53b1d2003b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNC01LTEtMS0w_8b01f637-6c97-4894-92e5-e09622e64d4e"
      unitRef="usd">29000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ie0209dd5a4ba48f1b5ae0d8164855055_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNi0zLTEtMS0w_ace862ff-1b85-4517-84f0-07cd4d8d3909"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i7cc3a3bcad764ec5b23c25c4598cbcf6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOjYxMTkxNDNkM2E0NTRjMTliMDA1OWRjZmY2ZmYxYzhlL3RhYmxlcmFuZ2U6NjExOTE0M2QzYTQ1NGMxOWIwMDU5ZGNmZjZmZjFjOGVfNi01LTEtMS0w_dc9198f2-a2a6-4ec9-ac6c-33c077a4914f"
      unitRef="usd">29000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="icfe4a0d7268840d4a04e16db85cbe422_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTgwOA_8aa0e75d-00a5-4727-bd9f-b59bf3b53329"
      unitRef="usd">27000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i957912dee94240ee9072f0022698ffe5_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg3OQ_9da7f8ae-ebf5-4f0f-95bd-b59ac94fc349"
      unitRef="usd">39000000</us-gaap:RepaymentsOfDebt>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg4NQ_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4"
      unitRef="usd">12000000</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTg5MA_04a18703-99ee-45b3-9a21-09a2eff622ac"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RleHRyZWdpb246MDA1MmUzMjUxOWQ5NDkyZGFiZmJhOTA1MTY3NjgyYjBfMTM3NDM4OTUzNTA1NjE_69cc7b09-6f2e-4190-8cde-36a267304f8d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.125% Convertible Notes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;For more information on financing activities, refer to Note 8, &#x201c;Debt.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0wLTEtMS0wL3RleHRyZWdpb246YWViOWY2YTNiNzBhNDJjZjk4ODUwMGM1Mjc2OTQ1MjVfNA_c747b537-b0de-448c-8595-8a4c52e1c47c"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i58388cfb135745d5a3d2212619472938_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0xLTEtMS0w_0d15ad2f-e10d-4141-a3d0-83a311639b3c"
      unitRef="usd">789000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iaa0145a0902d4f00a6773060e4727efb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC0zLTEtMS0w_d8f1052a-da7c-44c0-848d-ad60dd2e3c1d"
      unitRef="usd">816000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1ded383a09c049409bb8aa4e1578f251_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC01LTEtMS0w_4a34fa32-0995-4182-8c65-19141b016dbe"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7126a354069c4673ae6ccf8c5fe6c977_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNC03LTEtMS0w_2f617ec9-10e3-4bd0-9513-522935ba451a"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if95b0e5cb5ad441cbe5353c0775eada6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0wLTEtMS0wL3RleHRyZWdpb246NDUxYjkxZWUzNmYzNDk1ZWI5ZTkyNzQ5ODY3Y2YyOTlfNA_0c727ed5-099f-4dd7-a977-10d3562c6a99"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if151f099c6024c06a2e13a64537444dc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0xLTEtMS0w_7e0e5ea3-89ab-4a65-8d7e-a01045a61875"
      unitRef="usd">697000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib2aeeae1e1894e5ba53a5d2f756ecd8d_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS0zLTEtMS0w_4ae5a519-0e85-4020-9d98-8396fb08cee6"
      unitRef="usd">731000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="idf1097073c7c4951a8a0493f53a52d9f_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS01LTEtMS0w_674427c9-07fa-4f2e-bd64-41b251c43904"
      unitRef="usd">696000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i920b911bb1d54c89b67a30da5c6a439a_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNS03LTEtMS0w_3634e980-b80b-4620-a279-d39bf863c2dd"
      unitRef="usd">745000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45acf5d8b86b488a9df5b605c415166a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0wLTEtMS0wL3RleHRyZWdpb246YzQxZTk5Zjg3M2U1NGYzMzgwOWExZmZhMzZhY2UxODNfNA_471ac8cb-0794-42e7-833b-8b0aa6ca9727"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i4d429d24c23a4067aa9eefd0f1237fb1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0xLTEtMS0w_3f7448b4-d88f-4327-98c2-2d20afa560f8"
      unitRef="usd">327000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1a584d33b6bd4620a88cdb8f036b2df2_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi0zLTEtMS0w_683bc919-3d0f-449b-abaf-84b876c36f8f"
      unitRef="usd">337000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i607fd186209b46f88148885246fba93d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi01LTEtMS0w_67d63fbc-67e1-4ff4-90e6-6f5b4e54e1c0"
      unitRef="usd">327000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ifd06b3418b6d4f8889dd763f2cfe3ecb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNi03LTEtMS0w_373aad98-7501-4de6-854c-97cd5504eb1f"
      unitRef="usd">340000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia2d1a36636ff4190a026b7df75b9f3d5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy0xLTEtMS0w_a24500f5-3497-41dd-a5a5-f7c8e90e4873"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iff0aba0320264b41967f2e901f1c1b66_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy0zLTEtMS0w_c8359ac8-9968-498d-99ac-0bdf08d2ec51"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i338d7f40d6294accbb73f4a509d10ae4_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy01LTEtMS0w_e3a10abb-defd-4211-ac32-2a8d52b74663"
      unitRef="usd">220000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="iaf2d1b248d0349fc8ac32939e896036e_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfNy03LTEtMS0w_a7e704c2-5472-41b8-95e0-39a9a140691e"
      unitRef="usd">220000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ide774a0690994809ae6d22cf1b4a5ec5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0wLTEtMS0wL3RleHRyZWdpb246MzEwN2UwNjU3ZmY5NGZmNmI1OWJmZWQ2Yjg0MWU2NTBfNA_eacf1e00-2415-46df-a0d9-e4dd6bcaf79e"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6f28d6910080420eadec07f4dd9557ee_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0xLTEtMS0w_7d6886fc-05dc-4387-a99d-55cca8b6e3fb"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="icb5372aaf360432383af74ac21bc50e1_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC0zLTEtMS0w_f5ad836d-6846-49ed-994f-2a9cf8af5b8f"
      unitRef="usd">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9afc1ea189844c5eb735f3f4d963e7ba_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC01LTEtMS0w_cd2b7e99-4463-439c-93d9-a001ac372802"
      unitRef="usd">12000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i92d5297b47514ec9a062d743f1f8ebfa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOC03LTEtMS0w_32697718-2cce-4fc5-84b1-c47dc6d01d4e"
      unitRef="usd">42000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1ccea875e1a344df9d2d0328fcf08ab5_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS0xLTEtMS0w_56e7e64d-673a-491b-a4c1-65dd5653574c"
      unitRef="usd">1813000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if4004e550b88493b9d96d33568d57593_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS0zLTEtMS0w_60f3dd6f-b729-456e-9d68-53aa55db4bbe"
      unitRef="usd">1884000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic451188dc3fe4b559f5d53786e36984b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS01LTEtMS0w_5ebddce4-81ef-4c51-ab43-c50858feac48"
      unitRef="usd">1255000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="if9cd3c1e16c54817acea356e158e1192_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV80OS9mcmFnOjAwNTJlMzI1MTlkOTQ5MmRhYmZiYTkwNTE2NzY4MmIwL3RhYmxlOmY1MjgyOTU1ZjZkYzQ4YjdhNWNlZGQ4YWFkYjlkYTdlL3RhYmxlcmFuZ2U6ZjUyODI5NTVmNmRjNDhiN2E1Y2VkZDhhYWRiOWRhN2VfOS03LTEtMS0w_fedf4c8a-435b-4895-9a6d-83261bf94164"
      unitRef="usd">1347000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg4NA_a5fb335a-ed0b-4cc5-92f8-1f96e8e7e61b">Investments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSEs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our available-for-sale investments as of September&#160;30, 2020 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment gains amounted to $11&#160;million for the three and nine months ended September 30, 2019. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2020, and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that unrealized losses at September&#160;30, 2020, and December&#160;31, 2019, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of our available-for-sale investments were in a continuous loss position for 12 months or more as of September&#160;30, 2020, or December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event &lt;/span&gt;&lt;/div&gt;of insolvency of capitated providers. Therefore, such investments are reported as &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $93 million at September&#160;30, 2020, of which $91&#160;million will mature in one year or less, and $2&#160;million will mature in after one through five years.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg4OA_17aa09d1-89e0-4231-b8b5-ec12025fb7e4">The following tables summarize our investments as of the dates indicated:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSEs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS0xLTEtMS0w_352c599f-2e1c-4a2b-b978-da8cdf2f0719"
      unitRef="usd">1007000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS0zLTEtMS0w_259fe14e-93df-421f-a770-9026be0142ba"
      unitRef="usd">35000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS01LTEtMS0w_77f6cb46-c334-423e-ac89-06ff9a239a85"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNS03LTEtMS0w_d0e8460a-bd3c-45cc-ac56-2d376d099e94"
      unitRef="usd">1041000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi0xLTEtMS0w_a037af47-afd9-4345-8069-3ff26c930c61"
      unitRef="usd">408000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi0zLTEtMS0w_7642d7ee-f504-405d-baf4-7765918bc7da"
      unitRef="usd">10000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi01LTEtMS0w_5d4fc1a6-2f74-4adb-9234-d5c273dc2ffa"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNi03LTEtMS0w_bf9c4f07-9a36-4aa5-a0e1-c6b20458a3d3"
      unitRef="usd">417000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy0xLTEtMS0w_9c825256-fd6d-4998-8efc-6dd48017003c"
      unitRef="usd">166000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy0zLTEtMS0w_5554c384-5c01-45b6-8167-e58a38f67f71"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy01LTEtMS0w_dafc4f4d-8915-4894-9154-927298bfaa92"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8f05ad2ae9724998ae461d78e2462361_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfNy03LTEtMS0w_80081971-9c34-4c34-a7da-491b65491ebc"
      unitRef="usd">168000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC0xLTEtMS0w_b563dacd-db99-471a-a35b-0c33cd33723f"
      unitRef="usd">133000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC0zLTEtMS0w_0b27ab08-848a-4bdb-87cf-4d817a17a61b"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC01LTEtMS0w_61dd44a9-519a-4532-9db4-2484bd9b507e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcf557a6480b4644969946f54ab51f8e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOC03LTEtMS0w_b74952d3-90ac-4f3c-bb5e-d9bfa65067b2"
      unitRef="usd">136000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS0xLTEtMS0w_2b5d967e-39be-49f6-91ff-187d04c9bfce"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS0zLTEtMS0w_28cae912-de02-41f0-a970-84c1cead368d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS01LTEtMS0w_72be7a45-c8ae-4aad-813e-41c20a6c4566"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibae5ff39e4304ad9a6e47e2789c2db02_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfOS03LTEtMS0w_6226a618-7e7f-475d-abd7-1884a2be8e7f"
      unitRef="usd">5000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtMS0xLTEtMA_694d9017-0726-4af2-8774-a5946adad16a"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtMy0xLTEtMA_febfa04a-e33e-47ae-aa27-8fa5ca275587"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtNS0xLTEtMA_69b1457f-037b-4cf2-9d26-a744fc696587"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifa0f2cbbc505437587d85744ac0979eb_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTAtNy0xLTEtMA_18a77e0e-ba85-4af4-a264-7b33608af292"
      unitRef="usd">2000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtMS0xLTEtMA_328d4c56-b4e4-4775-93a0-e5e59d8a87c4"
      unitRef="usd">1721000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtMy0xLTEtMA_cb467455-76ca-4c55-bea6-42bf5ab4e2a3"
      unitRef="usd">50000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtNS0xLTEtMA_b639150c-1d46-4f08-abd0-76d56493094d"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmVhZDkzYmQ3ZTRjMDRlNDI5YTI4ZmEwNDkyZjY3Mzk5L3RhYmxlcmFuZ2U6ZWFkOTNiZDdlNGMwNGU0MjlhMjhmYTA0OTJmNjczOTlfMTMtNy0xLTEtMA_19f0e381-fe73-496d-9c2d-ba6fa6a50856"
      unitRef="usd">1769000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS0xLTEtMS0w_7ce41c96-e195-4fc2-a43c-5e277acfde4f"
      unitRef="usd">1174000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS0zLTEtMS0w_657abf31-029a-416c-b8e0-b55c0805209e"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS01LTEtMS0w_bce75dc7-a1eb-4bec-8a6c-25b3f1cbc9ab"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNS03LTEtMS0w_0d3825ff-dd1b-4d00-be4e-424478168e26"
      unitRef="usd">1178000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi0xLTEtMS0w_84416a17-722a-4278-9bd9-ebca456ea5a8"
      unitRef="usd">420000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi0zLTEtMS0w_888629b2-db27-4ce2-9a39-6bdbde0056ed"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi01LTEtMS0w_e7933a6b-b5d2-4f12-bcbb-db5c39a30594"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNi03LTEtMS0w_7773f571-b11a-433b-a1fe-434943fc234e"
      unitRef="usd">420000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy0xLTEtMS0w_8b176ad9-dfa3-499e-a8c3-d417f3921ae6"
      unitRef="usd">78000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy0zLTEtMS0w_8b56b4ff-4fb9-4bbb-9181-2bb4b45c5aa6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy01LTEtMS0w_9f51022f-b25c-4ac1-b4d7-8e0599f5c7e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59cc966e3845472abbcb53a46a0573e8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfNy03LTEtMS0w_96470513-af11-449d-86e6-9488e4ede52a"
      unitRef="usd">78000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC0xLTEtMS0w_5ab51ef8-dbb0-4c2c-9212-b5757b251a1c"
      unitRef="usd">126000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC0zLTEtMS0w_3fefd858-c455-4bcf-b484-311467ebe9c7"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC01LTEtMS0w_2ca1cb0e-8b93-499c-ac1e-70a01755532c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4993dfb9cae343e7a0595de8c3b268ca_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOC03LTEtMS0w_d1bf556a-abc0-49ae-a41c-47f2afe48598"
      unitRef="usd">127000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i522376b3702049e087e884d659c89675_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS0xLTEtMS0w_7faa11ee-d141-43eb-9048-dda90c60f024"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i522376b3702049e087e884d659c89675_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS0zLTEtMS0w_49a2ada5-7d5e-4232-8a3f-e9c2c479704a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i522376b3702049e087e884d659c89675_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS01LTEtMS0w_f4b3bc4d-26a0-4f92-a662-47d773934c1e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i522376b3702049e087e884d659c89675_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfOS03LTEtMS0w_30f64671-6919-4603-8be1-8ab433a93e35"
      unitRef="usd">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtMS0xLTEtMA_920f8bb0-abd7-41d7-bfd0-43190426b38b"
      unitRef="usd">86000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtMy0xLTEtMA_e3d25d12-bf42-417d-a30b-49a60bc8c8e4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtNS0xLTEtMA_32c3449f-15b2-48ff-9c6b-719fb6c4791f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c760dd71e144ec18a78b0cb8844490b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTAtNy0xLTEtMA_c625e28e-97d7-4efe-a92d-b276f2f7dfab"
      unitRef="usd">86000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtMS0xLTEtMA_54fe31fb-fbef-4591-99ab-aa36575fa9dc"
      unitRef="usd">49000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtMy0xLTEtMA_b54c1c78-9eb3-4af0-8322-2287ddeb05da"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtNS0xLTEtMA_77e37215-9335-4bee-a64a-415c3bf4c052"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0202efdf49a94c0fa927080c97980d08_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTEtNy0xLTEtMA_805d21e4-ab91-4e64-b56f-ea942f7cbf58"
      unitRef="usd">49000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItMS0xLTEtMA_59d6b472-979c-413c-963d-68b246da01be"
      unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItMy0xLTEtMA_d399c53f-9bbc-4382-b926-15b7b815265f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItNS0xLTEtMA_f7eb4589-d0f7-4188-a97e-f38d4c7680ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i06790a8bb4e54fdfbe5adb8586ea4112_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTItNy0xLTEtMA_8d8e9fe6-df1d-4ada-b0c9-ad5fc3741aae"
      unitRef="usd">7000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtMS0xLTEtMA_cf4fdd93-1da3-449c-a4a3-719b2f3da766"
      unitRef="usd">1941000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtMy0xLTEtMA_c55f8049-30b5-430f-9601-cb13ea08ebc4"
      unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtNS0xLTEtMA_f7bd2659-3427-4d57-ace1-b93d6701061c"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmM3ZDVkOGY4ZWZkYzQzMTJhNTc1Yjg4ZjI5ZjUxNjQ0L3RhYmxlcmFuZ2U6YzdkNWQ4ZjhlZmRjNDMxMmE1NzViODhmMjlmNTE2NDRfMTMtNy0xLTEtMA_af977459-5de6-4ca7-ac1a-de2e3398eda1"
      unitRef="usd">1946000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg5NQ_f4c2758e-17ce-477d-a6ef-2c6947a08d46">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our available-for-sale investments as of September&#160;30, 2020 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfMy0xLTEtMS0w_de46e8c9-1414-4d0b-87e5-950e31b0f63a"
      unitRef="usd">193000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfMy0zLTEtMS0w_48418e19-0e54-4248-b736-f969addc31c7"
      unitRef="usd">195000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNC0xLTEtMS0w_b253b96d-b1e0-4c53-95d3-6afad30f7424"
      unitRef="usd">943000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNC0zLTEtMS0w_a202c5ad-12ee-40b4-a966-683f2e927d5d"
      unitRef="usd">975000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNS0xLTEtMS0w_98dab157-e26a-42c5-96cc-b77b2d3dbced"
      unitRef="usd">160000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNS0zLTEtMS0w_89700813-e232-4ee5-926a-bc82ef2b72b8"
      unitRef="usd">165000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNi0xLTEtMS0w_d9c53d54-656d-4264-91c4-873f5ce735fb"
      unitRef="usd">425000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNi0zLTEtMS0w_32169eec-df25-4e6e-975d-d996aa2d6a64"
      unitRef="usd">434000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNy0xLTEtMS0w_e94bfe68-0d56-4e92-a7d9-2ae05c84be01"
      unitRef="usd">1721000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOmFjMmMyMjFmNTE2NzQ5ZTZiMzE2MzEyM2Q4ZjcyMDBhL3RhYmxlcmFuZ2U6YWMyYzIyMWY1MTY3NDllNmIzMTYzMTIzZDhmNzIwMGFfNy0zLTEtMS0w_69b99780-e12f-4617-b514-1fc2f3e210fb"
      unitRef="usd">1769000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfNTIw_6c69e755-a129-45f2-93a3-d730fd58f28c"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMTA5OTUxMTYzMDkzMQ_bc25626e-f940-43ca-9d3f-43ae625a5809"
      unitRef="usd">11000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMTA5OTUxMTYzMDkzMQ_dbc4b057-b367-4d9d-8769-428861fc7a86"
      unitRef="usd">11000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjg5Ng_ab1adedb-e34f-4bcd-803e-3ceebcfb575b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months as of September&#160;30, 2020 and December&#160;31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2020 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Number&#160;of&lt;br/&gt;Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0xLTEtMS0w_054783cd-b24d-42ad-86d3-d5fba22a4849"
      unitRef="usd">35000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0zLTEtMS0w_3d4aecf5-c7ba-46ad-af39-654240c5e364"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i9e90c966b6be4707a4a4282651786edc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC01LTEtMS0w_ff90dca4-9829-4ca2-98af-edf82038b39c"
      unitRef="security">18</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC03LTEtMS0w_485ecd92-dab4-47a0-8e9a-6d7f43ad33eb"
      unitRef="usd">222000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC05LTEtMS0w_1cc5a5d0-830a-47d5-8b7d-d7224ee507af"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="icf95aad9cb9e48a787c5e792b4e1c8cb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNC0xMS0xLTEtMA_daaa0432-76c1-41ed-a834-de591a341bee"
      unitRef="security">167</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0xLTEtMS0w_fc948932-4663-41c0-8a46-385b2d84daef"
      unitRef="usd">104000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0zLTEtMS0w_67339be9-9139-4b74-abcf-9576e306e1fa"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="if75cd98fb83f46158ac380589d92af6e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS01LTEtMS0w_f9b58b2e-f940-409a-baf4-8b177bab4da4"
      unitRef="security">7</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS03LTEtMS0w_0e8a6193-813d-4614-bada-7c32dfa9acbd"
      unitRef="usd">143000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS05LTEtMS0w_19dc5906-4c7a-4cf7-a94f-fc361950ddfa"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ib8970aba64ea4b83ad1a40a38d637ef6_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfNS0xMS0xLTEtMA_64ad6cd1-8703-46c1-b050-ec4548250de2"
      unitRef="security">72</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0xLTEtMS0w_12071966-9537-45c3-9221-e5e111f6a965"
      unitRef="usd">139000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0zLTEtMS0w_66e09fa6-a14f-4f0e-a782-55cd2c212215"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS01LTEtMS0w_1c1e29a5-2f98-4bb4-83a7-a182db9fc9d2"
      unitRef="security">25</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS03LTEtMS0w_0a8e68b2-fea5-4ff4-b8b8-c58423b330dd"
      unitRef="usd">365000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS05LTEtMS0w_5975f1a4-7359-4593-a922-e69fd409ee3c"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RhYmxlOjIzNGFkMGI1MzU0NjQ1NTc4ZDRhMjZlODQxMDRjOGRjL3RhYmxlcmFuZ2U6MjM0YWQwYjUzNTQ2NDU1NzhkNGEyNmU4NDEwNGM4ZGNfOS0xMS0xLTEtMA_f4cc5306-229d-4555-ba0c-fc74f51a86dc"
      unitRef="security">239</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjc1OQ_51bde8be-cd08-4a72-934a-85655361fbbf"
      unitRef="usd">93000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjc3OA_ecb30356-6ff6-46bf-9aff-44be8402d1da"
      unitRef="usd">91000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81Mi9mcmFnOjQ0NWUxZTE1Y2YzNTQ5NTU5NTkzMzIyNzY4ZmJmYWQ1L3RleHRyZWdpb246NDQ1ZTFlMTVjZjM1NDk1NTk1OTMzMjI3NjhmYmZhZDVfMjgxOA_d795c084-df07-4ebc-9091-67f9f82509d3"
      unitRef="usd">2000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <moh:MedicalClaimsAndBenefitsPayableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkxOA_7140d991-85e0-460f-b43e-00b4b4880d54">Medical Claims and Benefits Payable &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other&#x201d; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $168 million and $132 million as of September&#160;30, 2020, and December&#160;31, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of medical claims and benefits payable recorded at December 31, 2019, and 2018 developed favorably by approximately $66 million and $253 million as of September&#160;30, 2020, and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the nine months ended September 30, 2020, medical care costs related to the prior year reflect the release of additional reserves for moderately adverse conditions included in our prior year estimates, partially offset by higher than expected costs for settling certain claims with certain providers. The differences between our original estimates for such claims in 2019, and the ultimate costs in 2020, were not discernible until additional information was provided to us in 2020 and the effect became clearer over time as claim payments were processed. The release of &lt;/span&gt;&lt;/div&gt;additional reserves for moderately adverse conditions included in our prior year estimates was substantially offset by the replenishment of the reserve recorded in medical care costs related to the current year.</moh:MedicalClaimsAndBenefitsPayableTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkyMA_ffbedd22-e69c-4e62-a601-dca12952b5fc">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfMy0xLTEtMS0w_3b120643-e002-4a6e-a2b1-bfc8b9383479"
      unitRef="usd">1615000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfMy0zLTEtMS0w_88801cda-45c5-4510-bb2b-7ace2208d102"
      unitRef="usd">1406000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:PharmacyClaimsPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNC0xLTEtMS0w_255911bf-056a-4b43-9f77-c6e5dc4a39e6"
      unitRef="usd">148000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNC0zLTEtMS0w_2019ac2b-6add-4372-a2eb-5091b3e39773"
      unitRef="usd">126000000</moh:PharmacyClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNS0xLTEtMS0w_b0caa7a8-5eeb-4aeb-af9f-295c1436d803"
      unitRef="usd">73000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNS0zLTEtMS0w_b3d0e416-b6e1-4095-9fc9-fa0d8c6a1e16"
      unitRef="usd">55000000</moh:CapitationClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNi0xLTEtMS0w_2363e804-8c07-4920-b6de-60d1d4681fae"
      unitRef="usd">453000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNi0zLTEtMS0w_259e9e30-ea80-48c1-abcb-6a1fe32cc79c"
      unitRef="usd">267000000</moh:OtherClaimsPayable>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNy0xLTEtMS0w_747b6ae2-6ef1-4234-ba40-baba50436157"
      unitRef="usd">2289000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOmFlNTcwYmVlZTM0MjRkZGFhNzc4MWQ5NzY1ZGI5ZmYwL3RhYmxlcmFuZ2U6YWU1NzBiZWVlMzQyNGRkYWE3NzgxZDk3NjVkYjlmZjBfNy0zLTEtMS0w_412ff660-7796-4768-bd00-2352fe7b46f2"
      unitRef="usd">1854000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfNDQ1_048c939e-e8cd-4c63-9d7c-7eb38271ef7a"
      unitRef="usd">168000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfNDUy_15c7cf89-6e2f-4555-9fbf-dd51a5d74b58"
      unitRef="usd">132000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTkyMw_56b48202-b160-40de-a2c4-0de6ce2d432e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNC0xLTEtMS0w_515a5da9-893c-429b-9542-9da12ddac920"
      unitRef="usd">1854000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ibf672f433e474e1390b199db5bd6d157_I20181231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNC0zLTEtMS0w_02cd81ca-ea74-456d-a821-74ea240014d1"
      unitRef="usd">1961000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNi0xLTEtMS0w_8282575f-4aab-44b6-9be7-3c368cab675f"
      unitRef="usd">11478000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNi0zLTEtMS0w_0add1bbc-f2c9-4f39-b29c-4856074d0a3f"
      unitRef="usd">10613000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNy0xLTEtMS0w_f73a4418-62a5-4406-bdf7-a59ea7ba4df6"
      unitRef="usd">-66000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfNy0zLTEtMS0w_fb25c2b0-f380-4f9a-ad91-4120dcd31973"
      unitRef="usd">-253000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOC0xLTEtMS0w_6650e1b5-629a-4989-8290-32ff1935b330"
      unitRef="usd">11412000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOC0zLTEtMS0w_6f587bfb-1729-47c1-8f1b-a89d051968e4"
      unitRef="usd">10360000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOS0xLTEtMS0w_5d869c65-7966-4f91-bb5e-93e7395273fa"
      unitRef="usd">50000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfOS0zLTEtMS0w_fa896077-5494-4961-87bf-da78ce7e1c86"
      unitRef="usd">131000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTEtMS0xLTEtMA_b3f377a2-192d-4853-b34f-d1ebceebc080"
      unitRef="usd">9500000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTEtMy0xLTEtMA_2641e272-c5a0-420d-8f7f-ac33618e5f4e"
      unitRef="usd">8996000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTItMS0xLTEtMA_ce1786a4-ff4a-452b-abfd-e2054c54d17a"
      unitRef="usd">1527000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTItMy0xLTEtMA_74090dd2-e0c8-4135-affa-e61a4f40f2c7"
      unitRef="usd">1481000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTMtMS0xLTEtMA_2c8ee551-cf1a-4860-b4f4-c1284a2bc964"
      unitRef="usd">11027000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTMtMy0xLTEtMA_66670e2b-2c09-40e2-ab25-832e0bf6338e"
      unitRef="usd">10477000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTQtMS0xLTEtMA_315677e4-41c8-41ce-98e9-2d77443bdf36"
      unitRef="usd">2289000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8ee959cf00f54dcaaf758268793bb7d3_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RhYmxlOjY3ZWU3MTM1Y2ViYjRjMTA5MTUyMWMxZmE0ZmM1ZjE0L3RhYmxlcmFuZ2U6NjdlZTcxMzVjZWJiNGMxMDkxNTIxYzFmYTRmYzVmMTRfMTQtMy0xLTEtMA_4c4bdd64-a1dc-4880-8f63-fb4cdd57d2f5"
      unitRef="usd">1975000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTExMw_f73a4418-62a5-4406-bdf7-a59ea7ba4df6"
      unitRef="usd">-66000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81NS9mcmFnOmIwOTE0MWNlYzVlMDQ3MzRiMTFlMzE5MmRkODQ4NzhkL3RleHRyZWdpb246YjA5MTQxY2VjNWUwNDczNGIxMWUzMTkyZGQ4NDg3OGRfMTEyMA_fb25c2b0-f380-4f9a-ad91-4120dcd31973"
      unitRef="usd">-253000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDI4MA_cc0f7a84-9d8b-49fa-923c-a3bc81ce7076">Debt &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current portion of long-term debt: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.125% Convertible Notes, net of unamortized discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current portion of long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Reported in &#x201c;Accounts payable, accrued liabilities and other.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, we entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) that replaced our prior credit agreement. The terms of the Credit Agreement are substantially similar to the terms of the prior agreement. Among various provisions, significant changes incorporated to the Credit Agreement included:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;An increase of the revolving credit facility (the &#x201c;Credit Facility&#x201d;) from $500 million to $1.0 billion;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;An increase of incremental term loans available to finance certain acquisitions from $150&#160;million to $500&#160;million, plus an unlimited amount as long as our consolidated net leverage ratio is not greater than 3:1;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The ability to engage in acquisitions where the consummation of such acquisitions is not conditioned on the availability of, or on obtaining, third-party financing;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Termination of the term loan facility under the prior credit agreement, which was repaid as described below; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;LIBOR succession provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2020, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September&#160;30, 2020, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the nine months ended September 30, 2020, we recognized losses on debt repayment of $5 million in connection with repayment of our term loan facility and other financing transactions. In the third quarter and nine months ended September 30, 2019, we recognized a loss on debt repayment of $2 million and a gain on debt repayment of $15 million, respectively, in connection with convertible senior notes repayment transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;High-Yield Senior Notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.375% Notes due 2028.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2020, we completed the private offering of $800 million aggregate principal amount of senior notes (the &#x201c;4.375% Notes&#x201d;) due June 15, 2028, unless earlier redeemed. The 4.375% Notes contain optional early redemption provisions, with redemption prices in excess of par. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15 of each year, commencing December&#160;15, 2020. A portion of the net proceeds from the 4.375% Notes offering was used to repay $600&#160;million principal amount outstanding under the term loan facility of our prior credit agreement, and the balance is intended to be used for general corporate purposes. Deferred issuance costs amounted to $11&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;5.375% Notes due 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $700 million aggregate principal amount of senior notes (the &#x201c;5.375% Notes&#x201d;) outstanding as of September&#160;30, 2020, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.875% Notes due 2025. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We had $330 million aggregate principal amount of senior notes (the &#x201c;4.875% Notes&#x201d;) outstanding as of September&#160;30, 2020, which are due June 15, 2025, unless earlier redeemed. Interest, at a rate of 4.875% per annum, is payable semiannually in arrears on June 15 and December 15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.125% Cash Convertible Senior Notes due 2020  &lt;/span&gt;&lt;/div&gt;For a description of the 1.125% cash convertible senior notes due January 15, 2020 (the &#x201c;1.125% Convertible Notes&#x201d;), see Note 11, &#x201c;Debt,&#x201d; in our 2019 Annual Report on Form 10-K. In January 2020, we paid $39 million to settle the outstanding $12 million principal amount of the 1.125% Convertible Notes, and settle the related conversion option.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDI4Ng_3e97f4fd-a9f5-4e9a-8b86-90372984d443">The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Current portion of long-term debt: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.125% Convertible Notes, net of unamortized discount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current portion of long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.375% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.875% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Reported in &#x201c;Accounts payable, accrued liabilities and other.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNC0xLTEtMS0w_7031cbed-cfac-4879-bdae-69caaa160e56"
      unitRef="usd">0</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="i6353bdf90f6442659a69205e4bac7e7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNC0zLTEtMS0w_2567b300-b78d-4cba-abb1-c4397aedb02a"
      unitRef="usd">6000000</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ide774a0690994809ae6d22cf1b4a5ec5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0wLTEtMS0wL3RleHRyZWdpb246NzVlYjQ1NTRiOWQ2NDVmN2FiZDRhMWZiZDQ4MGZlMGNfNQ_eacf1e00-2415-46df-a0d9-e4dd6bcaf79e"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0xLTEtMS0w_8c5ec021-b980-410e-9e3f-da734ea3634a"
      unitRef="usd">0</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNS0zLTEtMS0w_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4"
      unitRef="usd">12000000</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNi0xLTEtMS0w_8177af22-48e4-4760-8f64-57f4f5db3f64"
      unitRef="usd">0</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfNi0zLTEtMS0w_35bb5202-9b15-432f-a195-6bf0a890d49a"
      unitRef="usd">18000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0wLTEtMS0wL3RleHRyZWdpb246Nzk2Zjk2NzFlMzg5NDdmMzhiNDVjNDQyNjRmNzA5ZmFfNA_c747b537-b0de-448c-8595-8a4c52e1c47c"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i4ec3ae376fbe4ad4a14e9b7642cf575e_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0xLTEtMS0w_bddaac18-b492-499b-9ac0-a04a0b748a41"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i91235a939abc46cc8cfe1379d6385693_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOC0zLTEtMS0w_6940d01b-a286-44bd-a064-93a911834458"
      unitRef="usd">0</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if95b0e5cb5ad441cbe5353c0775eada6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0wLTEtMS0wL3RleHRyZWdpb246OTEwMjM0NDIyM2VjNDE5YWIzODJjYmYyN2FhZDUzMTVfNA_0c727ed5-099f-4dd7-a977-10d3562c6a99"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0xLTEtMS0w_b7613901-d821-4c44-9e32-f6468ccaef8e"
      unitRef="usd">700000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="id0fd66717c68402a9c361f8c9ddd1136_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfOS0zLTEtMS0w_7a437c33-0ecc-4954-9ca3-40af5ddca677"
      unitRef="usd">700000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i45acf5d8b86b488a9df5b605c415166a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMC0xLTEtMC90ZXh0cmVnaW9uOjJkOTgzNjRkMzU2MzQ3N2VhYWJkNmZhMzExOWE5YWM0XzQ_471ac8cb-0794-42e7-833b-8b0aa6ca9727"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMS0xLTEtMA_1545d7b3-685f-4833-9e25-1c13babd745e"
      unitRef="usd">330000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i30bd18227ccc47deafa6692e187cac66_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTAtMy0xLTEtMA_bea1dd2a-942e-4f0a-b9d2-c65268ed98c0"
      unitRef="usd">330000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="ibbdfa73eb72e44a38da18c9bbd3ada87_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTEtMS0xLTEtMA_1ef8c03a-dcfb-4fb9-88ce-67984f980328"
      unitRef="usd">0</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i6353bdf90f6442659a69205e4bac7e7b_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTEtMy0xLTEtMA_ebbe2152-5e86-45c5-ac7f-576f05f6e449"
      unitRef="usd">214000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTItMS0xLTEtMA_514d63d8-d996-46a7-be40-2e2da8b62e3d"
      unitRef="usd">17000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTItMy0xLTEtMA_17169c13-0be3-4da9-989a-3d6be22f2806"
      unitRef="usd">7000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTMtMS0xLTEtMA_0230ad62-4079-4e82-af02-f74121dd26cf"
      unitRef="usd">1813000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i3cd81903ac784f3c95b719f7294b0fd8_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RhYmxlOjMyNGVkNDYzN2U5ZTQyODQ4ZTI2ZGY1OGZhNTM4ZThjL3RhYmxlcmFuZ2U6MzI0ZWQ0NjM3ZTllNDI4NDhlMjZkZjU4ZmE1MzhlOGNfMTMtMy0xLTEtMA_34c64f6e-7f64-49f2-81af-8d60f848665e"
      unitRef="usd">1237000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i3d5fccb82c934bd1a15e322807ce290d_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzE0_08172bc8-735b-4165-9e94-3773c874bcec"
      unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i27fd4a76e49d4598ab2278e6e645278d_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzIw_d52d4054-d8ed-4e84-87ec-7d73848c2baf"
      unitRef="usd">1000000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i2c6273b5316944e4a596a67c24741345_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzI2_697ca9fa-da65-437f-a6b9-36427885308e"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i145a7ab1554b4757b2e887181fd98cc8_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNzU4_abb80125-70c3-4ece-be6d-7316211ef517"
      unitRef="usd">100000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="iea4eec6ff70b47cb9fc4f0eee52a397e_I20200531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfODc3_1c87cded-a534-4f82-a212-11835439df64"
      unitRef="usd">150000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfODgz_a3334ebc-2b8a-4347-9130-5df65c8a3508"
      unitRef="usd">500000000</us-gaap:DebtInstrumentFaceAmount>
    <moh:ConsolidatedNetLeverage
      contextRef="ic76b3f4a71a24dd0b5f5e432282942bd_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfOTc5_a00149f6-2853-4ea6-9abf-6aec6321fab4"
      unitRef="number">3</moh:ConsolidatedNetLeverage>
    <us-gaap:DebtInstrumentTerm
      contextRef="ie5e5997156224aac9afd99b367288856_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMTMyNw_e2cce557-83d1-4622-b1a5-71f42f58ab54">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="i0212554bfd054535bec808876e3e5018_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMTk2MA_d760e043-ccae-424c-9fec-1482bfe05c43"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA0MA_60fbe4d2-b373-4384-8ffa-7b5f910da67b"
      unitRef="usd">-5000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA2Nw_ce1f58e8-1787-4a15-bff1-7ec26539804a"
      unitRef="usd">-2000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjA3MQ_d2727c57-3e88-4edf-baf1-e206a0a11d3c"
      unitRef="usd">15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjcwMg_ccd9970d-1c3e-45ce-b202-84fa4509f388"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjc3NQ_39aa4def-ee62-4c54-983b-42c92f2ca30d"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjgyNw_ccd9970d-1c3e-45ce-b202-84fa4509f388"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMjg4Ng_1d80a134-5cc6-4764-a984-82b45d0bf141"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzAwNQ_ccd9970d-1c3e-45ce-b202-84fa4509f388"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzE0Nw_ccd9970d-1c3e-45ce-b202-84fa4509f388"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="i1b80a28bab8c433a9545d7749e346c8a_D20200602-20200602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzE4Mw_f807c93d-2123-42a5-9f6f-c72d39b3ff7d"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="id69307e89f364334ae9a43b18c71f4fe_I20200602"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM0Nw_d671aa96-17d4-451d-b8dd-3cf3a55016ca"
      unitRef="usd">11000000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM1MQ_465328e4-5b9a-4059-b40f-9043d2387266"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzM3Nw_a16428a5-d6a4-461e-afaa-d44e075e9deb"
      unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzQyOQ_465328e4-5b9a-4059-b40f-9043d2387266"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i57960c7b966c4efba497e4524f1b3ddc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzU0Mw_465328e4-5b9a-4059-b40f-9043d2387266"
      unitRef="number">0.05375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzYyMA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzY0Ng_76e48bbc-c653-4d0d-be7f-d5da18c34823"
      unitRef="usd">330000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzY5OA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9ea5b5d5df2448a0b803a44bbfc97cea_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzgwOA_b9806fa8-4c1a-4713-b3ac-b9dc7e6017da"
      unitRef="number">0.04875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzg4Ng_b9bcbbf9-4ff7-4ddb-8c45-9a8df1c77eeb"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfMzk1NQ_890043d2-0167-45e9-b0fb-6ce97f0a8259"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie3bb5a95ca0d417782d4613370c18f6c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDAxNQ_7acb01dd-65ee-4838-9b05-88c59d6d3d73"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="i957912dee94240ee9072f0022698ffe5_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDEyNQ_9da7f8ae-ebf5-4f0f-95bd-b59ac94fc349"
      unitRef="usd">39000000</us-gaap:RepaymentsOfDebt>
    <moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount
      contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDE1NA_7d15d8e7-b235-425d-ab2c-f81ad2e4c9e4"
      unitRef="usd">12000000</moh:LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if265cab40d764aa8a6f7a638b651c059_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV81OC9mcmFnOmFiMzM1MDI2Yzk2ODQyYzFiN2ViMTRkNTlmYTM2YjU3L3RleHRyZWdpb246YWIzMzUwMjZjOTY4NDJjMWI3ZWIxNGQ1OWZhMzZiNTdfNDE4MQ_04a18703-99ee-45b3-9a21-09a2eff622ac"
      unitRef="number">0.01125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjMxOA_9001c2ca-81a7-4b99-a81b-56d3038c5f9c">Stockholders' Equity &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program will be funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase will be determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. No shares were purchased under this program through October&#160;29, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with existing cash on hand and was completed in March 2020. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 3.4 million shares of our common stock for $446 million in the first quarter of 2020 (average cost of $132.45 per share). In the first quarter of 2020, we also paid $7 million to settle shares purchased in late December 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;1.125% Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of the 1.125% Warrants, refer to our 2019 Annual Report on Form 10-K, Note 12, &#x201c;Derivatives,&#x201d; and Note 14, &#x201c;Stockholders&#x2019; Equity.&#x201d; Approximately 310,000 of the 1.125% Warrants were outstanding at December 31, 2019. In the first quarter of 2020, we entered into privately negotiated termination agreements under which we paid $30 million to the counterparties for the termination of the remaining 1.125% Warrants outstanding, which resulted in a reduction of additional paid-in-capital for the same amount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our employee stock plans, approximately 192,000 shares of common stock vested or were purchased, net of shares used to settle employees&#x2019; income tax obligations, during the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation is recorded to &#x201c;General and administrative expenses&#x201d; in the accompanying consolidated statements of income. Total share-based compensation expense amounted to $15 million and $10 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;million, respectively, in the third quarter of 2020 and 2019. Total share-based compensation expense amounted to $43 million and $29 million, respectively, in the nine months ended September 30, 2020 and 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, there was approximately $76 million of total unrecognized compensation expense related to unvested restricted stock awards (&#x201c;RSAs&#x201d;), and performance stock units (&#x201c;PSUs&#x201d;), which we expect to recognize over remaining weighted-average periods of 2.4 years and 1.5 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 11.5% for non-executive employees as of September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, unrecognized stock option expense was insignificant. No stock options were granted or exercised in the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for RSAs and PSUs is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate fair values of RSAs and PSUs granted and vested are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjE5OTAyMzI1ODU4Mw_0b5032ce-57d5-4290-8d8e-302a2aa9cd36"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i4249323997a74c5394dec06850d9f0ff_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTE2_e98241c1-5aea-412d-89ee-24ff9b94e6ed"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMzI5_6cd9daed-dc00-4edf-9e1b-cd2acb76ea22"
      unitRef="shares">3400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMzYz_4c838b8a-9c14-4669-9d39-76359ec80067"
      unitRef="usd">446000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNDEy_602d7fd0-f8b4-4bfd-b7f8-a81459447efa"
      unitRef="usdPerShare">132.45</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iea47c210f1144e4480cf2edf4264a395_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNDcw_687f0bdc-2558-4422-9209-20d05b831126"
      unitRef="usd">7000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <moh:ClassOfWarrantOrRightStatedInterestRate
      contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNTIz_73ace182-2ee8-4bc5-9a21-cf93031573d5"
      unitRef="number">0.01125</moh:ClassOfWarrantOrRightStatedInterestRate>
    <moh:ClassOfWarrantOrRightStatedInterestRate
      contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNTYw_083c737d-7ce1-4a15-b42e-45ab316d1abf"
      unitRef="number">0.01125</moh:ClassOfWarrantOrRightStatedInterestRate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i2538a5ed9cd54fd5ada2143661d2e391_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNjk0_b320e907-20d1-444a-9892-3345addd8081"
      unitRef="shares">310000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <moh:ClassOfWarrantOrRightStatedInterestRate
      contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfNzA0_55a66ba7-4fbf-4272-8a1f-f862db0c96b6"
      unitRef="number">0.01125</moh:ClassOfWarrantOrRightStatedInterestRate>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i550d7fb1a5cf4341ba55c9010cbc88be_D20200101-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfODY1_db266e50-4711-4ae7-b489-8f76d55f0de4"
      unitRef="usd">30000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <moh:ClassOfWarrantOrRightStatedInterestRate
      contextRef="ic2c093122fce40f5b352eff79a18d1c2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfOTI3_f8a7c1fd-41e6-4436-9253-5546e9cc7e47"
      unitRef="number">0.01125</moh:ClassOfWarrantOrRightStatedInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic4024fea4fe14739828013441b0f2c9a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTExOA_226aaa2b-d59c-4161-8815-88c3e6461913"
      unitRef="shares">192000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTQzMw_8bf8ad18-f4c0-4f69-b09d-fdd8dd486529"
      unitRef="usd">15000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTQ0MA_d0d63899-28f3-4875-a413-3ac4e3c9ca91"
      unitRef="usd">10000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTUyNw_c1533faa-7e4b-4bf4-a811-0f850b901aa7"
      unitRef="usd">43000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTUzNA_301169d3-7747-413a-a808-379dd2566565"
      unitRef="usd">29000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ifccb71ed99474db29c92a1c32422fdb8_I20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTYwNQ_d4340e9f-3cab-4974-8101-f4ace1652386"
      unitRef="usd">76000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTgxNQ_a2de122e-de29-496d-9dfd-de5d1afd1df0">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTgyMg_6db1b6f4-2b72-4b2d-a959-5cedbbcfa2fd">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <moh:UnrecognizedCompensationForfeitedRate
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMTkxNg_4f977ec3-bfbe-43a2-ab3d-85eb31690bac"
      unitRef="number">0.115</moh:UnrecognizedCompensationForfeitedRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjEwOQ_52daa097-21dc-49ae-8ebc-3997b3cd9fbe"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RleHRyZWdpb246OGFlMTI2MjM3MjNjNDhmYjg3ZjQ5OGJlZGRhNTI1NTZfMjMyNw_27558e42-b22e-42a1-aefa-13e13bbd5a1d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Activity for RSAs and PSUs is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;447,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;334,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;187,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,368)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;589,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;116.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;474,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate fair values of RSAs and PSUs granted and vested are presented in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i0123ff206dc2499598383ffd43d68eb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS0xLTEtMS0w_842b06c2-06c8-4011-9099-a03bfc8b42c4"
      unitRef="shares">447680</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i0123ff206dc2499598383ffd43d68eb2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS0zLTEtMS0w_61eeb79c-3cee-445d-8ddb-cab0c3e1b975"
      unitRef="usdPerShare">102.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS01LTEtMS0w_97630785-d714-4494-a3b7-a6a8d8824cd2"
      unitRef="shares">324078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if90aba0bcaea40bf87ae8eaa3bc12cdb_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMS03LTEtMS0w_500aff70-e8fa-4293-a971-dccc08124352"
      unitRef="usdPerShare">101.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi0xLTEtMS0w_ae53301a-08f2-4ca5-babc-db163b9b7140"
      unitRef="shares">334233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi0zLTEtMS0w_ef36b0b8-dfdc-47fa-afc1-35bfe50bd618"
      unitRef="usdPerShare">125.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi01LTEtMS0w_d5e31ba1-fca0-4f1c-bd9d-ff3932af042d"
      unitRef="shares">187028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMi03LTEtMS0w_06c93e3b-2718-41ad-a40c-baa6daee4417"
      unitRef="usdPerShare">123.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy0xLTEtMS0w_86016cc7-27d2-49dc-a152-3138387b1d55"
      unitRef="shares">166115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy0zLTEtMS0w_d9b5af12-241e-4add-9ea3-8d57fa8469ab"
      unitRef="usdPerShare">96.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy01LTEtMS0w_ae6a66ab-8c12-4676-853c-a3f7d0e4297c"
      unitRef="shares">7368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfMy03LTEtMS0w_e8af9535-11c7-4d3f-8ac8-1651dcb37b5c"
      unitRef="usdPerShare">68.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC0xLTEtMS0w_54de6309-d980-4b29-9475-1956c468f166"
      unitRef="shares">26439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC0zLTEtMS0w_b32c351f-9384-455c-a0fd-37c035856640"
      unitRef="usdPerShare">114.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC01LTEtMS0w_2a557ce8-b35b-4ff4-b169-522bfed849ac"
      unitRef="shares">29271</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNC03LTEtMS0w_7420182b-5f30-4861-a667-025d0d90d2a1"
      unitRef="usdPerShare">98.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS0xLTEtMS0w_8aa88ed9-8360-4bb2-b69c-7086c007bd52"
      unitRef="shares">589359</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ife7fb7307e4a4afaaaeabbbf8eff09ef_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS0zLTEtMS0w_bc6d3386-05c6-4251-9228-dce78278a947"
      unitRef="usdPerShare">116.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iffdf9fbfeb9745b5b757815afe72494f_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS01LTEtMS0w_16be8206-3786-44a3-8e6f-b70754bd65e5"
      unitRef="shares">474467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iffdf9fbfeb9745b5b757815afe72494f_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOjI5YmZhOGYwM2E1ZjQ4MDc5Zjg4NTcyMDFlZjQ5Nzc0L3RhYmxlcmFuZ2U6MjliZmE4ZjAzYTVmNDgwNzlmODg1NzIwMWVmNDk3NzRfNS03LTEtMS0w_add4343b-5d5b-432f-81a6-f25a9b4f72c8"
      unitRef="usdPerShare">110.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNS0xLTEtMS0w_a682e38b-7e3f-4150-a306-9391b4ee1ea0"
      unitRef="usd">42000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNS0zLTEtMS0w_d284b493-4bf9-43a6-89e0-2d918f28c443"
      unitRef="usd">32000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNi0xLTEtMS0w_35e12861-bde1-49a9-bf89-bfe6a83f3a2a"
      unitRef="usd">23000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNi0zLTEtMS0w_e2a16b4b-17b8-480a-ae9d-f8e8a040028f"
      unitRef="usd">19000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNy0xLTEtMS0w_b8294038-b7ad-46bb-81ef-1c2954120b3d"
      unitRef="usd">65000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfNy0zLTEtMS0w_342d826f-67ad-4a3e-8fa0-b0bc554fd900"
      unitRef="usd">51000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7e77ce870c2348c5b6918697b10dc088_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfOS0xLTEtMS0w_e8dbf883-0f58-432e-a758-7d581b7abfc3"
      unitRef="usd">21000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i99d81e7c09ce4d5a924d3e0e84f8198b_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfOS0zLTEtMS0w_d27c165d-30ef-4cf7-b7b6-750347eb84ba"
      unitRef="usd">18000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i7d5b2546cb874604bc8a43ab560860e4_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTAtMS0xLTEtMA_56392fab-c813-4b25-a931-b61c338c596c"
      unitRef="usd">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ic7d42211602e4a3594b2b37dcc924ce5_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTAtMy0xLTEtMA_257261b5-cb36-498c-af78-f81df62ea361"
      unitRef="usd">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTEtMS0xLTEtMA_1d3db5ee-aad1-4010-8f49-ebc509e2c8f2"
      unitRef="usd">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82MS9mcmFnOjhhZTEyNjIzNzIzYzQ4ZmI4N2Y0OThiZWRkYTUyNTU2L3RhYmxlOmMwMjNiMWVhNzk0MjRjNGVhZWYyYThmZjdlMWQwZThhL3RhYmxlcmFuZ2U6YzAyM2IxZWE3OTQyNGM0ZWFlZjJhOGZmN2UxZDBlOGFfMTEtMy0xLTEtMA_db801a87-e204-459c-a596-056b475c3c50"
      unitRef="usd">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTM0MQ_09dc35d0-bb81-45aa-9b2c-82e739a1a797">Segments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. Margin for our Health Plans segment is referred to as &#x201c;Medical Margin.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin to consolidated income before income taxes: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, and investment income and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTU_708f643f-924b-48f7-88ee-9763716e97f4"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RleHRyZWdpb246OWQ1YzZjODg0MWM4NGVkZWE0MDljZTI3M2NhYTRjNDhfMTMzMw_24a021d8-3e0c-42ee-8b79-d8ec0055694d">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin to consolidated income before income taxes: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.321%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Health Plans&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(463)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, and investment income and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="i8fe4a961d1eb4aa8b35c53d34bea3f7c_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS0xLTEtMS0w_b478eeea-d0e4-48e5-8f71-6779870ef6cb"
      unitRef="usd">5020000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5eb569255aff4cb1a507ded6878088ab_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS0zLTEtMS0w_9ddeb060-d055-4558-bb8d-8235035b2806"
      unitRef="usd">4239000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5fa4dac681a24334be8e8b77ddebd9c6_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS01LTEtMS0w_f5f0e113-5191-402f-8cef-fb504d9af342"
      unitRef="usd">14181000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1eb474cbb156487da5ef2d111573f379_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNS03LTEtMS0w_3f2c4b14-d6af-49de-9850-cbdcb7ba4fe7"
      unitRef="usd">12546000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id606f46ed6204025ae6c824bbc5386c5_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi0xLTEtMS0w_cb6277fd-920e-434c-ac64-6af91c9bed47"
      unitRef="usd">1000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ideda1271d72d4f0f8c9490daadf92cba_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi0zLTEtMS0w_188cf359-1d83-4674-97da-6da7208a29d3"
      unitRef="usd">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6768058042744166a9675351d4ec6518_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi01LTEtMS0w_aa409d4c-5866-419b-9134-6d95aaf7cfde"
      unitRef="usd">7000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i09b03eb47e834f2ea94525c02f9c659c_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNi03LTEtMS0w_3838d98e-4815-4274-ac44-72022924f7f9"
      unitRef="usd">9000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy0xLTEtMS0w_11caff84-7d15-4f84-b98c-46f81eaa3c4f"
      unitRef="usd">5021000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy0zLTEtMS0w_c913185f-b3f0-4f77-b677-adb41bbc7abe"
      unitRef="usd">4243000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy01LTEtMS0w_a3bc39b8-21f5-48f4-98a1-a89899813cda"
      unitRef="usd">14188000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmUwZjYwMzJiZDdmMjQwZjU5Yjk1NmQ5OTg0MDEyMjFjL3RhYmxlcmFuZ2U6ZTBmNjAzMmJkN2YyNDBmNTliOTU2ZDk5ODQwMTIyMWNfNy03LTEtMS0w_fb75d497-3626-441a-80b3-7fd42abb25cc"
      unitRef="usd">12555000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="ib455ca5f2b5947a895ea50f53562ffd9_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS0xLTEtMS0w_d1ef46f0-5a81-48fc-b91b-766a4a1e5a86"
      unitRef="usd">670000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i51b83677a3114d00b5fb75fa5b867b67_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS0zLTEtMS0w_f63d6afb-7cee-4655-9a0a-0aeb887487e5"
      unitRef="usd">561000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1601849c348540f59d2211b5d20125f8_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS01LTEtMS0w_98bfe614-8dfc-4f02-a514-d3258e010925"
      unitRef="usd">2032000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i23f1814b002a47d38a368f6700e92992_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfNS03LTEtMS0w_b980bb0b-80f2-4cb7-85dc-7b65ad446f3d"
      unitRef="usd">1725000000</us-gaap:GrossProfit>
    <us-gaap:Revenues
      contextRef="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC0xLTEtMS0w_f5c93aae-c220-4017-aee0-65a1f64228f3"
      unitRef="usd">253000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC0zLTEtMS0w_fc9b0ed0-f209-44ea-9f2a-ae9db71ebc61"
      unitRef="usd">159000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC01LTEtMS0w_ec71ec29-5db0-4a34-a2c1-3e9448841b07"
      unitRef="usd">744000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfOC03LTEtMS0w_e3b46d04-2396-4749-89dc-ac9dfeb2038d"
      unitRef="usd">470000000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtMS0xLTEtMA_cb73bf30-f475-4d69-9b68-5df1a31e954d"
      unitRef="usd">634000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iae58b8616b7a43819652b9f9b98c5291_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtMy0xLTEtMA_7fd500b5-6f6c-4248-85b5-45e0691fe852"
      unitRef="usd">463000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2cf64c978def4d82b77230b72ef60133_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtNS0xLTEtMA_25634bca-ab93-4f13-9c45-3bd49d064107"
      unitRef="usd">1789000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ic1a60280e0284ff7b683e27b0d5eeaa4_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTAtNy0xLTEtMA_eafa4bbd-08a4-429e-9c4a-ae2d75ed5b28"
      unitRef="usd">1393000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtMS0xLTEtMA_0eaa0e07-31ed-4069-85bb-dfcadcf02b2d"
      unitRef="usd">289000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtMy0xLTEtMA_c072d300-c669-487c-b1e5-f524f2ae7f72"
      unitRef="usd">257000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtNS0xLTEtMA_d9fc9cca-a1da-4b74-bf65-9cd5e08e2eed"
      unitRef="usd">987000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTEtNy0xLTEtMA_b2ffdefd-d94a-4fe1-bbb7-fa2624b484ec"
      unitRef="usd">802000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItMS0xLTEtMA_dac13334-ec73-431d-b84c-16251fb54c86"
      unitRef="usd">-27000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItMy0xLTEtMA_971c999f-c8df-4a5d-8c07-cb5259d56967"
      unitRef="usd">-24000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItNS0xLTEtMA_f8d74149-6dbe-4eeb-b270-37ebb25b14ce"
      unitRef="usd">-77000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTItNy0xLTEtMA_84f9771b-d230-45af-bf05-d498771b1e1e"
      unitRef="usd">-52000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtMS0xLTEtMA_079c7c70-06c1-4847-8ced-08701957e3ef"
      unitRef="usd">262000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtMy0xLTEtMA_73737a76-40fb-4827-b3b2-a9ac82bdb6a0"
      unitRef="usd">233000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtNS0xLTEtMA_1bea3983-90c1-4c3d-ba92-2b172f7a510f"
      unitRef="usd">910000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ie4888b75a1ab46cb8d72a8224b66d363_D20190101-20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82NC9mcmFnOjlkNWM2Yzg4NDFjODRlZGVhNDA5Y2UyNzNjYWE0YzQ4L3RhYmxlOmRlOWIwNmMzZDg4MzQ5YWJiNTI3NTZlMDY3NjNiNGIzL3RhYmxlcmFuZ2U6ZGU5YjA2YzNkODgzNDlhYmI1Mjc1NmUwNjc2M2I0YjNfMTMtNy0xLTEtMA_84714c93-baa0-4839-9e1b-0ef4e915a428"
      unitRef="usd">750000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV82Ny9mcmFnOmNiZDBiNjI3MzEzMDQzOTk4ZmNkN2JjZDFmZTFkZTg4L3RleHRyZWdpb246Y2JkMGI2MjczMTMwNDM5OThmY2Q3YmNkMWZlMWRlODhfMTI2Ng_b15d645c-5785-46b2-b861-0656b9606062">Commitments and Contingencies &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Penalties associated with violations of these laws and regulations include significant fines, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business we are involved in legal actions, some of which seek monetary damages which are not covered by insurance. We have accrued liabilities for certain matters for which we deem the loss to be both probable and reasonably estimable, but the outcome of legal actions is inherently uncertain and our estimates of such losses could be understated, and could also subsequently change as a result of further developments of these matters. For certain pending matters, accruals have not been established because we believe we are not liable or because such matters have not progressed sufficiently through discovery or factual development to enable us to reasonably estimate a range of possible loss. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i83cc1ad1070a4f1380588ee073f6f0dc_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8xMjcvZnJhZzpmOTBjYThmYjBlNGU0NjlmODQ5Y2RmNTBiNzgxZjA3ZC90ZXh0cmVnaW9uOmY5MGNhOGZiMGU0ZTQ2OWY4NDljZGY1MGI3ODFmMDdkXzIxOTkwMjMyNTcxMDY_0b5032ce-57d5-4290-8d8e-302a2aa9cd36"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936376552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 23, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate, Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937201752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="nump">$ 4,768<span></span>
</td>
<td class="nump">$ 4,084<span></span>
</td>
<td class="nump">$ 13,444<span></span>
</td>
<td class="nump">$ 12,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationPremiumTaxRevenue', window );">Premium tax revenue</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeRevenue', window );">Health insurer fees reimbursed</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Investment income and other revenue</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5,021<span></span>
</td>
<td class="nump">4,243<span></span>
</td>
<td class="nump">14,188<span></span>
</td>
<td class="nump">12,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Medical care costs</a></td>
<td class="nump">4,098<span></span>
</td>
<td class="nump">3,523<span></span>
</td>
<td class="nump">11,412<span></span>
</td>
<td class="nump">10,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">1,030<span></span>
</td>
<td class="nump">953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PremiumTaxExpenses', window );">Premium tax expenses</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeExpense', window );">Health insurer fees</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">4,732<span></span>
</td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">13,201<span></span>
</td>
<td class="nump">11,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expenses, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationPremiumTaxRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Premium Tax Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationPremiumTaxRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PremiumTaxExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An assessment levied by a state government on the net premium income collected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PremiumTaxExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937482504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 190<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">$ 582<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635016495208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,196<span></span>
</td>
<td class="nump">$ 2,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,775<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">163<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,953<span></span>
</td>
<td class="nump">5,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">395<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets, net</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">101<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,881<span></span>
</td>
<td class="nump">6,787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable</a></td>
<td class="nump">2,289<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">640<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">3,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">226<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">5,680<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at September&#160;30, 2020, and 62 million shares at December&#160;31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="nump">1,960<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 7,881<span></span>
</td>
<td class="nump">$ 6,787<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634933720120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">59,000,000<span></span>
</td>
<td class="nump">62,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936561400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Adoption of new accounting standard</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th">
<div>Retained Earnings </div>
<div>Adoption of new accounting standard</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">62,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 643<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 1,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">62,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">1,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">543<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">62,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 1,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 1,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">61,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(446)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (446)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">61,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Mar. 31, 2020</a></td>
<td class="nump">1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="nump">1,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">58,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 1,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">166<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 2,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634932629816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on debt repayment</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(369)<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(98)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Medical claims and benefits payable</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(188)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(670)<span></span>
</td>
<td class="num">(1,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">891<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">98<span></span>
</td>
<td class="num">(80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from senior notes offering, net of issuance costs</a></td>
<td class="nump">789<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of term loan facility</a></td>
<td class="num">(600)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(453)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings under term loan facility</a></td>
<td class="nump">380<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of warrants</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(514)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CashPaidForSettlementOfConversionOption', window );">Cash paid for partial settlement of conversion option</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of principal amount of convertible senior notes</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">69<span></span>
</td>
<td class="num">(510)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="nump">758<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">2,508<span></span>
</td>
<td class="nump">2,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">3,266<span></span>
</td>
<td class="nump">2,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Common stock used for share-based compensation</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_DetailsOfBusinessCombinationsAbstract', window );"><strong>Details of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of assets acquired</a></td>
<td class="num">(106)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities', window );">Fair value of contingent consideration liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_DetailsofchangeinfairvalueofderivativesAbstract', window );"><strong>Details of change in fair value of derivatives, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember', window );">Call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_DetailsofchangeinfairvalueofderivativesAbstract', window );"><strong>Details of change in fair value of derivatives, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_DetailsofchangeinfairvalueofderivativesAbstract', window );"><strong>Details of change in fair value of derivatives, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivatives, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">$ (124)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CashPaidForSettlementOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Settlement Of Conversion Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CashPaidForSettlementOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DetailsOfBusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Details Of Business Combinations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DetailsOfBusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DetailsofchangeinfairvalueofderivativesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Details of change in fair value of derivatives</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DetailsofchangeinfairvalueofderivativesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931936232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, the Health Plans segment consisted of health plans operating in 15 states and the Commonwealth of Puerto Rico, and served approximately 4.0 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies. The health plans are generally operated by our respective wholly owned subsidiaries in those states and licensed as health maintenance organizations (&#8220;HMO&#8221;). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of&#160;<span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVhNDQ5MDhhMzI4MDQ0ZGZiMmVmNjc1NWRjZDliMDVlL3NlYzo1YTQ0OTA4YTMyODA0NGRmYjJlZjY3NTVkY2Q5YjA1ZV8zNC9mcmFnOmRjYWI1ZjhmOTBlMDQ0Nzg5OGFmZGFiMmU4NTk1ZTZhL3RleHRyZWdpb246ZGNhYjVmOGY5MGUwNDQ3ODk4YWZkYWIyZTg1OTVlNmFfMTAxOA_433cf4cd-b6db-4c94-b366-da8b885a7b9b">three</span>&#160;to&#160;five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFPs&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled; and regions or service areas. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments - Health Plans Segment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we entered into a definitive agreement to acquire substantially all of the assets of Affinity Health Plan, Inc. The net purchase price for the transaction is approximately $380&#160;million, subject to various adjustments at closing, which we intend to fund with cash on hand. We currently expect the transaction to close as early as the second quarter of 2021.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we completed the acquisition of certain assets of YourCare Health Plan, Inc. See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, we completed the acquisition of certain assets of Passport Health Plan, Inc. See Note 4, &#8220;Business Combinations,&#8221; for further information.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, our Kentucky health plan had been selected as an awardee pursuant to the statewide Medicaid managed care RFP issued by the Kentucky Cabinet for Health and Family Services, Department for Medicaid Services. On October 23, 2020, pursuant to a protest filing appeal with regard to the RFP awards, a court ordered the addition of a sixth health plan to the Kentucky Medicaid program for 2021. That ruling did not rescind the Medicaid contract award to our Kentucky health plan for 2021, nor did it have any impact on the earlier novation of the Passport Medicaid contract to us. The new Medicaid contract is currently expected to begin on January 1, 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Magellan Complete Care (&#8220;MCC&#8221;). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into a definitive agreement to acquire the MCC line of business of Magellan Health, Inc. The purchase price for the transaction is approximately $820&#160;million, net of certain tax benefits, which we intend to fund with cash on hand. The transaction is subject to federal and state regulatory approvals, and other customary closing conditions, and is expected to close around the end of 2020. In connection with this transaction, Magellan Health, Inc. has agreed to provide certain transition services following the closing.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Texas Health and Human Services Commission (&#8220;HHSC&#8221;) notified our Texas health plan that HHSC had upheld our protest and had canceled all previously awarded contracts associated with the re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurement awards announced in October 2019 for the ABD program (known in Texas as &#8220;STAR+PLUS&#8221;). In addition, HHSC canceled the pending re-procurement associated with the TANF and CHIP programs (known in Texas as &#8220;STAR/CHIP&#8221;). HHSC further indicated that it was deliberating next steps with respect to both re</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procurements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We will exit Puerto Rico&#8217;s Medicaid program when our current contract expires on October 31, 2020. We are working closely with the regulatory authorities and the provider community to ensure that our members in Puerto Rico have reliable continuity of care. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illinois</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In March 2020, we terminated our agreement to acquire all of the capital stock of NextLevel Health Partners, Inc. due to the seller&#8217;s stated unwillingness to close pursuant to the terms of the acquisition agreement. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results for the entire year ending December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2019, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable of our Health Plans segment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div>&#8226;The determination of unrecognized tax benefits.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930192120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income (loss), net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses, and unrealized losses arising from credit-related factors with respect to AFS and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable relating to our AFS and HTM securities is presented within &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets, and amounted to $9 million and $12 million at September 30, 2020, and December 31, 2019, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of interest income. No accrued interest was written off during the nine months ended September 30, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Premiums Receivable </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our Health Plans segment contracts related to our Medicaid, Medicare and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are recognized as &#8220;Amounts due government agencies&#8221; in the accompanying consolidated balance sheets, and included the following categories by program:</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a minimum annual medical loss ratio (&#8220;Minimum MLR&#8221;) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Corridor Settlement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the United States Supreme Court held that &#167;1342 of the Affordable Care Act obligated the federal government to pay participating insurers the full Marketplace risk corridor amounts calculated by that statute, and that impacted insurers may sue the federal government in the U.S. Court of Federal Claims to recover damages for breach of that obligation. In June 2020, the Claims Court granted us judgment in the amount of $128.1&#160;million for our 2014, 2015, and 2016 Marketplace risk corridor claims, which we received in October 2020. Since we accounted for the judgment as a gain contingency at September 30, 2020, it will be recognized in our fourth quarter 2020 financial results. The judgment does not create additional Minimum MLR rebates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of September&#160;30, 2020, Marketplace risk adjustment payables amounted </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to $265 million and related receivables amounted to $59 million, for a net payable of $206 million. This net payable consisted of $230&#160;million in payables relating to 2020, and $24 million in receivables relating primarily to 2019. As of December&#160;31, 2019, Marketplace risk adjustment payables amounted to $368 million and related receivables amounted to $63 million, for a net payable of $305 million, which related primarily to 2019 and prior periods. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, &#8220;Organization and Basis of Presentation&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; recognition of quality incentive premium revenue is subject to the use of estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maximum available quality incentive premium - current period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized in current period:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned current period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized as a percentage of total premium revenue </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. Until the second quarter of 2020, we limited our risk of catastrophic losses solely by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;). Beginning in the second quarter of 2020, we now retain certain of these risks through our wholly-owned, captive insurance subsidiary (the &#8220;captive&#8221;). We continue to reduce our exposure to significant catastrophic losses by insuring levels of coverage, with the third-party reinsurer, for losses in excess of what we retain with the captive. Because we remain liable to our policyholders in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. We report reinsurance premiums as </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Intercompany transactions with our captive are eliminated in consolidation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves on Loss Contracts</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the profitability of our medical care policies to identify groups of contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. In the third quarter of 2020, we recognized a premium deficiency reserve of $10&#160;million for our Medicaid contract in Puerto Rico. As described in Note 1, &#8220;Organization and Basis of Presentation,&#8221; we will exit Puerto Rico&#8217;s Medicaid program when our current contract expires on October 31, 2020. No premium deficiency reserve was recorded as of December 31, 2019.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health Insurer Fee</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the ACA, the federal government imposes an annual fee, or excise tax, on health insurers for each calendar year (the &#8220;HIF&#8221;). Public Law No. 115-120 provided for a HIF moratorium in 2019; therefore, there was no HIF incurred or reimbursed in that year. The HIF was reinstated in 2020, but the Further Consolidated Appropriations Act, 2020, repealed the HIF effective for years after 2020. The HIF is allocated to health insurers based on each health insurer's share of net premiums for all U.S. health insurers in the year preceding the assessment. Our HIF liability for 2020 is $277&#160;million, of which $271&#160;million was accrued as of January 1, 2020 and an additional $6&#160;million was accrued in the second quarter, with a corresponding deferred expense asset amortized to expense through December 31, 2020, on a straight-line basis. We settled the 2020 HIF liability in September 2020. The HIF is not deductible for income tax purposes. Due to the reinstatement of the HIF in 2020, our effective tax rate is higher in 2020 compared with 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medicaid program, we must secure additional reimbursement from our state partners for this added cost. We have obtained a contractual commitment or are receiving payments from all states in which we operate Medicaid programs to reimburse us for the HIF, and such HIF revenue is being recognized ratably throughout the year. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, nondeductible expenses such as the HIF, certain compensation, and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was subsequently modified by several ASUs issued in 2018 and 2019. We adopted Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we recognized the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020, which was immaterial. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by a change in the reference rate from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued, if certain conditions are met. ASU 2020-04 is effective immediately and expires after December 31, 2022. We are evaluating the effect of reference rate reform and this guidance on our contracts and other transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931919544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income per Share</a></td>
<td class="text">Net Income per Share <div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.65&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 9, &#8220;Stockholders' Equity.&#8221; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936141960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2020, we closed on two business combinations in the Health Plans segment, consistent with our strategy to grow in our existing markets and expand into new markets. For both transactions, we applied the acquisition method of accounting, where the total purchase price was allocated, or preliminarily allocated, to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition dates. We expect to complete the final determination of the purchase price allocations as soon as practicable, but no later than one year following the closing date in accordance with Accounting Standards Codification Topic 805, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The table below illustrates the intangible assets acquired, by major class, for the two acquisitions. Acquisition-related costs were insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2020, we closed on the acquisition of certain assets of YourCare Health Plan, Inc., a Medicaid health plan, for a cash purchase price of $42&#160;million. In connection with this transaction, we added approximately 47,000 Medicaid members in New York. We recorded goodwill of $31&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from expected synergies to be achieved, including the use of our existing infrastructure to support the added membership. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2020, we closed on the acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan. Effective on that same date, the Kentucky Medicaid agency approved the novation of Passport&#8217;s Medicaid contract to Molina Healthcare of Kentucky, Inc. As a result, we added approximately 325,000 Medicaid members in Kentucky. As of September 30, 2020, the purchase price allocation was preliminary due to the proximity of the acquisition date to September 30, 2020, and the time and level of effort required to develop fair value measurements for the assets acquired and liabilities assumed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated total purchase price of $60&#160;million includes our initial cash payment of $20 million in September 2020, plus estimated contingent consideration which consists primarily of an amount due to the seller for members we enroll in the open enrollment period for the 2021 plan year, over a minimum threshold, which resulted in an initial contingent consideration liability of $40&#160;million. We expect to settle this liability in the first quarter of 2021. Contingent consideration liabilities are remeasured to fair value at each quarter until the contingencies are resolved with fair value adjustments, if any, recorded to operations. See further information in Note 5, &#8220;Fair Value Measurements.&#8221; We recorded goodwill of $27&#160;million for this transaction, which is deductible for income tax purposes. The goodwill recorded relates to future economic benefits arising from the assembled workforce, and the future growth associated with the member contract rights that are incremental to the contract rights identified.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the intangible assets identified in the transactions described above. The weighted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average amortization period for the identified intangible assets, in the aggregate, is 10.7 years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible asset by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931839896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to the three-tier fair value hierarchy. For a description of the methods and assumptions that we use to a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, refer to our 2019 Annual Report on Form 10-K, Note 4, &#8220;Fair Value Measurements.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, our Level 3 financial instruments recorded at fair value on a recurring basis included contingent consideration liabilities of $40 million, in connection with the Kentucky acquisition described in Note 4, &#8220;Business Combinations.&#8221; Such liabilities are reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets. The fair value of the contingent consideration was estimated using a </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">simulation-based option pricing model through the end of the measurement period of approximately 5 months, and included certain non-observable inputs. The key assumptions included a U.S. Treasury based risk-free rate of return, expected asset volatility of 35%, expected revenue volatility of 9%, forecasted membership enrollment, and other estimated revenue, asset and payment correlations and discount rates. The model produced an estimated range of undiscounted amounts Molina could pay under the contingent consideration arrangement of $25&#160;million to $75&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option derivative asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the nine months ended September 30, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivatives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the accompanying consolidated balance sheets:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets: Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities: Accounts payable, accrued liabilities and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our derivative financial instruments, see Note 11, &#8220;Debt,&#8221; and Note 12, &#8220;Derivatives,&#8221; in our 2019 Annual Report on Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, we received $27 million for the settlement of the call option derivative asset, and we paid $39 million to settle the outstanding $12 million principal amount of the 1.125% Convertible Notes, and settle the related conversion option. For more information, refer to Notes 8, &#8220;Debt,&#8221; and 9, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% Convertible Notes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For more information on financing activities, refer to Note 8, &#8220;Debt.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634932327000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all our investments classified as current assets to be available-for-sale. The following tables summarize our investments as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of September&#160;30, 2020 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains were insignificant for the three months ended September 30, 2020, and amounted to $6 million for the nine months ended September 30, 2020. Gross realized investment gains amounted to $11&#160;million for the three and nine months ended September 30, 2019. Gross realized investment losses were insignificant for the three and nine months ended September 30, 2020, and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at September&#160;30, 2020, and December&#160;31, 2019, primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our available-for-sale investments were in a continuous loss position for 12 months or more as of September&#160;30, 2020, or December&#160;31, 2019. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, and U.S. Treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event </span></div>of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value. Such investments amounted to $93 million at September&#160;30, 2020, of which $91&#160;million will mature in one year or less, and $2&#160;million will mature in after one through five years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930045768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text">Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable includes amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $168 million and $132 million as of September&#160;30, 2020, and December&#160;31, 2019, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2019, and 2018 developed favorably by approximately $66 million and $253 million as of September&#160;30, 2020, and 2019, respectively.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2020, medical care costs related to the prior year reflect the release of additional reserves for moderately adverse conditions included in our prior year estimates, partially offset by higher than expected costs for settling certain claims with certain providers. The differences between our original estimates for such claims in 2019, and the ultimate costs in 2020, were not discernible until additional information was provided to us in 2020 and the effect became clearer over time as claim payments were processed. The release of </span></div>additional reserves for moderately adverse conditions included in our prior year estimates was substantially offset by the replenishment of the reserve recorded in medical care costs related to the current year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical claims and benefits payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931681416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current portion of long-term debt: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% Convertible Notes, net of unamortized discount</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current portion of long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Reported in &#8220;Accounts payable, accrued liabilities and other.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we entered into a credit agreement (the &#8220;Credit Agreement&#8221;) that replaced our prior credit agreement. The terms of the Credit Agreement are substantially similar to the terms of the prior agreement. Among various provisions, significant changes incorporated to the Credit Agreement included:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of the revolving credit facility (the &#8220;Credit Facility&#8221;) from $500 million to $1.0 billion;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An increase of incremental term loans available to finance certain acquisitions from $150&#160;million to $500&#160;million, plus an unlimited amount as long as our consolidated net leverage ratio is not greater than 3:1;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability to engage in acquisitions where the consummation of such acquisitions is not conditioned on the availability of, or on obtaining, third-party financing;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Termination of the term loan facility under the prior credit agreement, which was repaid as described below; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LIBOR succession provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of September&#160;30, 2020, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of September&#160;30, 2020, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the nine months ended September 30, 2020, we recognized losses on debt repayment of $5 million in connection with repayment of our term loan facility and other financing transactions. In the third quarter and nine months ended September 30, 2019, we recognized a loss on debt repayment of $2 million and a gain on debt repayment of $15 million, respectively, in connection with convertible senior notes repayment transactions. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">High-Yield Senior Notes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our high-yield senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the high-yield senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2020, we completed the private offering of $800 million aggregate principal amount of senior notes (the &#8220;4.375% Notes&#8221;) due June 15, 2028, unless earlier redeemed. The 4.375% Notes contain optional early redemption provisions, with redemption prices in excess of par. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15 of each year, commencing December&#160;15, 2020. A portion of the net proceeds from the 4.375% Notes offering was used to repay $600&#160;million principal amount outstanding under the term loan facility of our prior credit agreement, and the balance is intended to be used for general corporate purposes. Deferred issuance costs amounted to $11&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">5.375% Notes due 2022.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $700 million aggregate principal amount of senior notes (the &#8220;5.375% Notes&#8221;) outstanding as of September&#160;30, 2020, which are due November&#160;15,&#160;2022, unless earlier redeemed. Interest, at a rate of 5.375% per annum, is payable semiannually in arrears on May 15 and November 15. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.875% Notes due 2025. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had $330 million aggregate principal amount of senior notes (the &#8220;4.875% Notes&#8221;) outstanding as of September&#160;30, 2020, which are due June 15, 2025, unless earlier redeemed. Interest, at a rate of 4.875% per annum, is payable semiannually in arrears on June 15 and December 15. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.125% Cash Convertible Senior Notes due 2020  </span></div>For a description of the 1.125% cash convertible senior notes due January 15, 2020 (the &#8220;1.125% Convertible Notes&#8221;), see Note 11, &#8220;Debt,&#8221; in our 2019 Annual Report on Form 10-K. In January 2020, we paid $39 million to settle the outstanding $12 million principal amount of the 1.125% Convertible Notes, and settle the related conversion option.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930306968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program will be funded with cash on hand and extends through December 31, 2021. The exact timing and amount of any repurchase will be determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. No shares were purchased under this program through October&#160;29, 2020. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, our board of directors authorized the purchase of up to $500 million, in the aggregate, of our common stock. This program was funded with existing cash on hand and was completed in March 2020. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 3.4 million shares of our common stock for $446 million in the first quarter of 2020 (average cost of $132.45 per share). In the first quarter of 2020, we also paid $7 million to settle shares purchased in late December 2019.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1.125% Warrants</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the 1.125% Warrants, refer to our 2019 Annual Report on Form 10-K, Note 12, &#8220;Derivatives,&#8221; and Note 14, &#8220;Stockholders&#8217; Equity.&#8221; Approximately 310,000 of the 1.125% Warrants were outstanding at December 31, 2019. In the first quarter of 2020, we entered into privately negotiated termination agreements under which we paid $30 million to the counterparties for the termination of the remaining 1.125% Warrants outstanding, which resulted in a reduction of additional paid-in-capital for the same amount. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our employee stock plans, approximately 192,000 shares of common stock vested or were purchased, net of shares used to settle employees&#8217; income tax obligations, during the nine months ended September 30, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation is recorded to &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income. Total share-based compensation expense amounted to $15 million and $10 </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, respectively, in the third quarter of 2020 and 2019. Total share-based compensation expense amounted to $43 million and $29 million, respectively, in the nine months ended September 30, 2020 and 2019. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, there was approximately $76 million of total unrecognized compensation expense related to unvested restricted stock awards (&#8220;RSAs&#8221;), and performance stock units (&#8220;PSUs&#8221;), which we expect to recognize over remaining weighted-average periods of 2.4 years and 1.5 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 11.5% for non-executive employees as of September&#160;30, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, unrecognized stock option expense was insignificant. No stock options were granted or exercised in the nine months ended September 30, 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for RSAs and PSUs is summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:40.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair values of RSAs and PSUs granted and vested are presented in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930019464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two reportable segments: the Health Plans segment and the Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Health Plans segment are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management. Margin for our Health Plans segment is referred to as &#8220;Medical Margin.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin to consolidated income before income taxes: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, and investment income and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931780952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic, and as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Penalties associated with violations of these laws and regulations include significant fines, exclusion from participating in publicly funded programs, and the repayment of previously collected revenues.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business we are involved in legal actions, some of which seek monetary damages which are not covered by insurance. We have accrued liabilities for certain matters for which we deem the loss to be both probable and reasonably estimable, but the outcome of legal actions is inherently uncertain and our estimates of such losses could be understated, and could also subsequently change as a result of further developments of these matters. For certain pending matters, accruals have not been established because we believe we are not liable or because such matters have not progressed sufficiently through discovery or factual development to enable us to reasonably estimate a range of possible loss. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634929018472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock', window );">Consolidation and Interim Financial Information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Interim Financial Information</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the nine months ended September 30, 2020, are not necessarily indicative of the results for the entire year ending December&#160;31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in our December&#160;31, 2019, audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our audited consolidated financial statements for the fiscal year ended December&#160;31, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Principal areas requiring the use of estimates include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of medical claims and benefits payable of our Health Plans segment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment contractual provisions that may limit revenue recognition based upon the costs incurred or the profits realized under a specific contract;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Health Plans segment quality incentives that allow us to recognize incremental revenue if certain quality standards are met;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Settlements under risk- or savings-sharing programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Purchase price allocations relating to business combinations, including the determination of contingent consideration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assessment of long-lived and intangible assets, and goodwill for impairment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for potential absorption of claims unpaid by insolvent providers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of reserves for the outcome of litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The determination of valuation allowances for deferred tax assets;&#160;and</span></div>&#8226;The determination of unrecognized tax benefits.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income (loss), net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses, and unrealized losses arising from credit-related factors with respect to AFS and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all our investments have final maturities of less than 10 years, or less than 10 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221;</span></div>We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of interest income. No accrued interest was written off during the nine months ended September 30, 2020.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Premium Revenue Recognition and Premiums Receivable</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Premiums Receivable </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our Health Plans segment contracts related to our Medicaid, Medicare and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. The state Medicaid programs and the federal Medicare program periodically adjust premiums. Additionally, many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are recognized as &#8220;Amounts due government agencies&#8221; in the accompanying consolidated balance sheets, and included the following categories by program:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retroactive Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, and is based on our best estimate of the ultimate premium we expect to realize for the period being adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various states have implemented temporary premium refunds and related actions in response to the reduced demand for medical services stemming from COVID-19, which are resulting in a reduction of our medical margin. In some cases, these premium actions are retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. In the second quarter of 2020, we recognized approximately $75&#160;million for certain of these retroactive premium actions that we believe to be probable, and where the ultimate premium amount is reasonably estimable. In most of those states, the refund period extended into the third quarter of 2020, and one additional state, Michigan, enacted a premium refund mechanism in the third quarter of 2020. Consequently, we recognized an additional $88&#160;million related to these retroactive premium actions in the third quarter of 2020, resulting in $163&#160;million recognized in the nine months ended September 30, 2020. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could increase the level of existing premium refunds, and it is also possible that other states could implement some form of retroactive premium refund during the fourth quarter of 2020. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a minimum annual medical loss ratio (&#8220;Minimum MLR&#8221;) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income. </span></div>Risk Adjustment. Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. As described in Note 1, &#8220;Organization and Basis of Presentation&#8211;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span>,&#8221; recognition of quality incentive premium revenue is subject to the use of estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of amounts due from government agencies, which may be subject to potential retroactive adjustments. Because substantially all our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReinsuranceAccountingPolicy', window );">Reinsurance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. Until the second quarter of 2020, we limited our risk of catastrophic losses solely by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;). Beginning in the second quarter of 2020, we now retain certain of these risks through our wholly-owned, captive insurance subsidiary (the &#8220;captive&#8221;). We continue to reduce our exposure to significant catastrophic losses by insuring levels of coverage, with the third-party reinsurer, for losses in excess of what we retain with the captive. Because we remain liable to our policyholders in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. We report reinsurance premiums as </span></div>a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. Intercompany transactions with our captive are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 10 years, or less than 10 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, and U.S. Treasury securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state or commonwealth in which our health plan subsidiaries operate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S.&#160;federal statutory rate primarily because of foreign and state taxes, nondeductible expenses such as the HIF, certain compensation, and other general and administrative expenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate may be subject to fluctuations during the year as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including projected pretax earnings, the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Adopted and Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Losses.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was subsequently modified by several ASUs issued in 2018 and 2019. We adopted Topic 326 effective January 1, 2020, using the modified retrospective approach. Under this method we recognized the cumulative effect of adopting the standard as an adjustment to the opening balance of retained earnings on January 1, 2020, which was immaterial. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which provides optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by a change in the reference rate from the London Interbank Offered Rate (&#8220;LIBOR&#8221;) or another reference rate expected to be discontinued, if certain conditions are met. ASU 2020-04 is effective immediately and expires after December 31, 2022. We are evaluating the effect of reference rate reform and this guidance on our contracts and other transactions. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidation And Interim Financial Information, Policy [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27758-158548<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6811-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6816-158387<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27830-158548<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634934773528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text">The following table reconciles cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,266&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,734&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock', window );">Amounts Due to Government Agencies</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.400%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.283%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">640&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">664&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock', window );">Quality Incentive Premium Revenue Recognized</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maximum available quality incentive premium - current period</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized in current period:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned current period</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earned prior periods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quality incentive premium revenue recognized as a percentage of total premium revenue </span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fee reimbursement receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quality incentive premium revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserves reported to other federal agencies or authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReservesReportedToOtherAgenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634934004488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of Denominators for the Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of net income per share:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.10&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.75&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.65&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. All warrants outstanding as of December 31, 2019, were settled in the first quarter of 2020. For more information refer to Note 9, &#8220;Stockholders' Equity.&#8221; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931736552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Summary of Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the intangible assets identified in the transactions described above. The weighted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">average amortization period for the identified intangible assets, in the aggregate, is 10.7 years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intangible asset by type:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade name </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 11.25pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931706552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Fair Value of Assets Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at September&#160;30, 2020, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.209%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2019, were as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Directly or Indirectly Observable Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option derivative asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option derivative liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair values and the presentation of our derivative financial instruments in the accompanying consolidated balance sheets:</span></div><div style="margin-bottom:6pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative asset:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Call option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets: Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative liability:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion option</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities: Accounts payable, accrued liabilities and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Asset and Liabilities Measured on Recurring Basis - Disclosure Only</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% Convertible Notes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For more information on financing activities, refer to Note 8, &#8220;Debt.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634932369160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Available-for-Sale Investments</a></td>
<td class="text">The following tables summarize our investments as of the dates indicated:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSEs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,946&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our available-for-sale investments as of September&#160;30, 2020 are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Available-for-Sale Investments in a Continuous Loss Position</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months as of September&#160;30, 2020 and December&#160;31, 2019:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2020 </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Number&#160;of<br/>Positions</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931919544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Medical Claims and Benefits Payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock', window );">Components of Components of Change in Medical Claims and Benefits Payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amounts by which our original estimates of medical claims and benefits payable at the beginning of the year were more than the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,360&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,027&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,477&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634931736552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text">The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,<br/>2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Current portion of long-term debt: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.125% Convertible Notes, net of unamortized discount</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current portion of long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.375% Notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.875% Notes due 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred debt issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Reported in &#8220;Accounts payable, accrued liabilities and other.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930268696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Restricted Share Activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Activity for RSAs and PSUs is summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:40.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">447,680&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125.99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">187,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96.19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,368)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,439)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,359&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">474,467&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate fair values of RSAs and PSUs granted and vested are presented in the following table:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930049992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Operating Segment Information</a></td>
<td class="text">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.<div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,243&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,188&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,555&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin to consolidated income before income taxes: </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health Plans</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(463)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">987&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">910&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, and investment income and other revenue.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, and other costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635016646712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> member in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>state </div>
<div>member</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>state </div>
<div>segment </div>
<div>member</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember', window );">Affinity health plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember', window );">Magellan complete care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStatesInWhichEntityOperates', window );">Number of states in which entity operates | state</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Contract Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStatesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of states the entity operates in as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStatesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MagellanCompleteCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634933499080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,196<span></span>
</td>
<td class="nump">$ 2,452<span></span>
</td>
<td class="nump">$ 2,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</a></td>
<td class="nump">$ 3,266<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
<td class="nump">$ 2,734<span></span>
</td>
<td class="nump">$ 2,926<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635044302376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 18, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsMaturityPeriod', window );">Maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_InvestmentsAverageMaturityPeriod', window );">Average maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable', window );">Risk adjustment payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable', window );">Risk adjustment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable', window );">Risk adjustment, net payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 305,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear', window );">Risk adjustment, net payable, current year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears', window );">Risk adjustment, net payable, prior year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_HealthCareInsuranceFeeLiability', window );">HIF liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_IncreaseDecreaseInHealthInsuranceFeeLiability', window );">Increase in HIF liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member', window );">COVID-19 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPremiumsReceivable', window );">Reduction in premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">163,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=moh_MedicaidMember', window );">Medicaid | PUERTO RICO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts', window );">Premium deficiency reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=moh_MaineCommunityHealthOptionsv.UnitedStatesMember', window );">Maine Community Health Options v. United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Summary judgement</a></td>
<td class="nump">$ 128,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareInsuranceFeeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Health Care Insurance, Fee, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareInsuranceFeeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInHealthInsuranceFeeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Health Insurance Fee, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInHealthInsuranceFeeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of premium revenue by health plan type.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPremiumsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change in the premium receivable balance on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPremiumsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=SL6953423-111524<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_PR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_PR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=moh_MaineCommunityHealthOptionsv.UnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=moh_MaineCommunityHealthOptionsv.UnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936401544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract', window );"><strong>Medicaid program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther', window );">Other</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract', window );"><strong>Medicare program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing', window );">Risk adjustment and Part D risk sharing</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherMedicareProgram', window );">Other</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract', window );"><strong>Marketplace program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment', window );">Risk adjustment</a></td>
<td class="nump">265<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold', window );">Minimum MLR</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesOther', window );">Other</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">$ 640<span></span>
</td>
<td class="nump">$ 664<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Premiums Liability, Medical Care Costs Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherMedicareProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Medicare Program</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherMedicareProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937559448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MaximumAvailableQualityIncentivePremiumCurrentYear', window );">Maximum available quality incentive premium - current period</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_QualityIncentivePremiumRevenueRecognizedAbstract', window );"><strong>Quality incentive premium revenue recognized in current period:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized', window );">Earned current period</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear', window );">Earned prior periods</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_QualityIncentivePremiumRevenueRecognized', window );">Total</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue', window );">Quality incentive premium revenue recognized as a percentage of total premium revenue</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember', window );">Select health plans | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PercentageOfAdditionalIncrementalRevenueEarned', window );">Percentage of additional incremental revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember', window );">Select health plans | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems', window );"><strong>Schedule of Premium Revenue by Health Plan Type [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PercentageOfAdditionalIncrementalRevenueEarned', window );">Percentage of additional incremental revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current year quality incentive premium revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of quality incentive premium revenue recognized from prior year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MaximumAvailableQualityIncentivePremiumCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum available quality incentive premium current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MaximumAvailableQualityIncentivePremiumCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PercentageOfAdditionalIncrementalRevenueEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional incremental revenue earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PercentageOfAdditionalIncrementalRevenueEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quality Incentive Premium Revenue As A Percentage Of Total Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_QualityIncentivePremiumRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quality incentive premium revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_QualityIncentivePremiumRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_QualityIncentivePremiumRevenueRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Quality Incentive Premium Revenue Recognized [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_QualityIncentivePremiumRevenueRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of premium revenue by health plan type.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937618472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember', window );">Government receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">1,180<span></span>
</td>
<td class="nump">1,056<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember', window );">Pharmacy rebate receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember', window );">Health insurer fee reimbursement receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_HealthInsurerFeeReimbursementReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936844712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 185<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 639<span></span>
</td>
<td class="nump">$ 569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted-average number of shares issued:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Stock purchases (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_WeightedAverageNumberofSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net income per share (in shares)</a></td>
<td class="nump">58.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.2<span></span>
</td>
<td class="nump">62.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Warrants (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net income per share (in shares)</a></td>
<td class="nump">59.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="nump">64.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.80<span></span>
</td>
<td class="nump">$ 9.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="nump">$ 8.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_WeightedAverageNumberofSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_WeightedAverageNumberofSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936450664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details)<br> member in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($) </div>
<div>member</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>business_combination</div>
</th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>member</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfBusinessCombinations', window );">Number of business combinations | business_combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_YourCareHealthPlanIncMember', window );">Your care health plan inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Purchase price of the assets</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport health plan inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Purchase price of the assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number Of Business Combinations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_YourCareHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_YourCareHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634933189688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Intangible assets amortization period</a></td>
<td class="text">10 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contract rights - member list</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contract rights - member list | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contract rights - member list | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_TradeNameMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworkMember', window );">Provider network</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_TradeNameMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_TradeNameMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937093240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedAssetVolatilityMember', window );">Measurement Input, Expected Asset Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputMeasurementPeriodMember', window );">Measurement Input, Measurement Period [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedRevenueVolatilityMember', window );">Measurement Input, Expected Revenue Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport health plan inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport health plan inc | Fair value, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member', window );">1.125% Convertible Notes, net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member', window );">1.125% Convertible Notes, net of unamortized discount | 1.125% Convertible Notes, net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount', window );">Debt net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedAssetVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedAssetVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputMeasurementPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputMeasurementPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=moh_MeasurementInputExpectedRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634925086424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">GSEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember', window );">Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember', window );">Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | GSEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">(Level 1) | Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | GSEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">(Level 2) | Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | GSEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities, available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Call option derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">(Level 3) | Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Conversion option derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeFinancialInstrumentsAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930073016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Balance Sheet Grouping (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=moh_CurrentAssetsMember', window );">Current assets: Prepaid expenses and other current assets | Call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=moh_CurrentLiabilitiesMember', window );">Current liabilities: Accounts payable, accrued liabilities and other | Conversion option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=moh_CurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=moh_CurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=moh_CallOptionDerivativeAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=moh_CurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=moh_CurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_EmbeddedDerivativeFinancialInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634934151656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember', window );">4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member', window );">5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember', window );">4.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member', window );">1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Senior notes | 4.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Convertible debt | 1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Senior notes | 4.875% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Convertible debt | 1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634933479560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,721<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">166<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">GSEs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635041522952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities of Available-for-Sale Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue', window );">Estimated Fair Value</a></td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930795064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized investment gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized investment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Debt securities held to maturity</a></td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Held-to-maturity, within one year, amortized cost</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Held-to-maturity, over one year to five years, amortized cost</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634936253784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale Investments (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Security</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | Security</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | Security</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Estimated Fair Value</a></td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">Total Number&#160;of Positions | Security</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635010004440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount', window );">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</a></td>
<td class="nump">$ 1,615<span></span>
</td>
<td class="nump">$ 1,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PharmacyClaimsPayable', window );">Pharmacy payable</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_CapitationClaimsPayable', window );">Capitation payable</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_OtherClaimsPayable', window );">Other</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="nump">$ 1,961<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CapitationClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capitation Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CapitationClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PharmacyClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PharmacyClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634934485032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayable', window );">Non-risk provider payables</a></td>
<td class="nump">$ 168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior period claims, favorable development</a></td>
<td class="num">$ (66)<span></span>
</td>
<td class="num">$ (253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937469192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Insurance Claims</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">$ 1,854<span></span>
</td>
<td class="nump">$ 1,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ComponentsOfMedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">11,478<span></span>
</td>
<td class="nump">10,613<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">11,412<span></span>
</td>
<td class="nump">10,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">8,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,481<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">11,027<span></span>
</td>
<td class="nump">10,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">$ 2,289<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Components of medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable, Adjustments, Change in Provider</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for medical care costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634933971688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred debt issuance costs</a></td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member', window );">1.125% Convertible Notes, net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember', window );">4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member', window );">5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember', window );">4.875% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility | Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount', window );">Debt net of unamortized discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Debt net of unamortized debt discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">1.125% Convertible Notes, net of unamortized discount | 1.125% Convertible Notes, net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrentAbstract', window );"><strong>Current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount', window );">Debt net of unamortized discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Debt net of unamortized debt discount</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Debt net of unamortized debt discount</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.875% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current portion of long-term debt:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Debt net of unamortized debt discount</a></td>
<td class="nump">$ 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634928931080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 02, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt repayment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000,000)<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense (income), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="num">(15,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of principal amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember', window );">4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member', window );">5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember', window );">4.875% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member', window );">1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility | Incremental Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ConsolidatedNetLeverage', window );">Consolidated net leverage ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility | Credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000.0<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility | Swingline sub facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term loan facility | Letter of credit sub-facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred issuance cost</a></td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 5.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior notes | 4.875% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 330,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 4.375% Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of principal amount outstanding</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | 1.125% Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount', window );">Debt net of unamortized discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ConsolidatedNetLeverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Net Leverage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ConsolidatedNetLeverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_SeniorNotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4.875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_CashConvertibleSeniorNotesDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_IncrementalTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_IncrementalTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=moh_SwinglineSubFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=moh_SwinglineSubFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=moh_LetterOfCreditSubFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=moh_LetterOfCreditSubFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634932932024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 453,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of 1.125% Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">514,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000,000<span></span>
</td>
<td class="nump">$ 29,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_UnrecognizedCompensationForfeitedRate', window );">Unrecognized compensation forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=moh_CashConvertibleSeniorNotesDue2020WarrantsMember', window );">1.125% Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ClassOfWarrantOrRightStatedInterestRate', window );">Stated percentage of warrants</a></td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">310,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of 1.125% Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount</a></td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 446,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Shares repurchased (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Number of common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ClassOfWarrantOrRightStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ClassOfWarrantOrRightStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_UnrecognizedCompensationForfeitedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation forfeited rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_UnrecognizedCompensationForfeitedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=moh_CashConvertibleSeniorNotesDue2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=moh_CashConvertibleSeniorNotesDue2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937423208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares) | shares</a></td>
<td class="nump">447,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">334,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(166,115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(26,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares) | shares</a></td>
<td class="nump">589,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 102.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">125.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">96.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">114.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 116.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares) | shares</a></td>
<td class="nump">324,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">187,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(7,368)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(29,271)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares) | shares</a></td>
<td class="nump">474,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 101.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">123.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">68.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">98.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 110.67<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139635020557240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Total granted</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total vested</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Total granted</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total vested</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Total granted</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total vested</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634930245912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139634937090808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">$ 5,021<span></span>
</td>
<td class="nump">$ 4,243<span></span>
</td>
<td class="nump">$ 14,188<span></span>
</td>
<td class="nump">$ 12,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">(4,732)<span></span>
</td>
<td class="num">(3,986)<span></span>
</td>
<td class="num">(13,201)<span></span>
</td>
<td class="num">(11,753)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">289<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="nump">987<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: other operating expenses</a></td>
<td class="num">(634)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
<td class="num">(1,789)<span></span>
</td>
<td class="num">(1,393)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">5,020<span></span>
</td>
<td class="nump">4,239<span></span>
</td>
<td class="nump">14,181<span></span>
</td>
<td class="nump">12,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans | Operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Margin</a></td>
<td class="nump">670<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: other operating revenues</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>69
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M11WER75D1$:#P9+4&Q9J=BS]PM8:%A07V@86ZHX,$WF!#@M%40C*$12%-AL
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MWJ(]D&+;/)A_%E**O/FZX7'"RUJ@?E\+(3\.Z@ZZMT?3?P!02P,$%     @
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MD/>10 2 _Q]@S$X#4:#H3$=_ 5!+ P04    "  "3%U16#/%,\X%   '%P
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M31S!Z*4$^K7DIF2U2CV0UP2LV);PJFP*](I4&75L>%,>XDDPI&L!Q2ZVO8A
MOXK<9-F>;AM.5:&SC-<J2P\6LY=#*WN+>,3#4XX-%+BJ7J\PT"\Q74GA9$NJ
MVKX93'6(C;PP,6CB*B>]A$"_AAPK]$$\K31-60BCR BC!85B!U/4JP?RJ\<7
M5JW>2\)+U1<MK,*&3$6 B7',L:%0Z*@OJ%<.Y%>.C[3"549 050;=RJ0R%0&
MA(9QM(%"Z.!YT&V\1C^*+IBGF)I*D0P/"Q9,&CAX]F*"7B,FI]B96A'%R; J
M65"3!+E6O%<4Y%>4N639KS4K<L+%NS<)@M/+YA0IGWW"@GIA07YAN65ER2H@
M]#!GX&UP'@10E4 .5#=7JR((HT#UX$T7#,1:G4]5#:SEFG%]:+T$K)9"'0ES
M6JTN0)0:4 E4(RQ)N2#\W1L8!Y<O+?'^ !PCBX7J?0\-K$UPNS*F<!G+XH,<
MQZP7-G2R26JKK2-LEXJQ.VKJS,Q>OE(AM,0TLM*'TCI74_6,N?H@QW/M91&=
MD,4\I_KR2:6);@S?T^JE:[&2-,4-&F<O&VCJ.!>B7@&17P&5?M=E76!]\&\;
M5E9N.%GK^[<M:<_:5M*6KFDZY&QB'"<.U*LB\JOB(Y%8?5+--N:56G5[\;$T
M26EBR(VME4H<93SLU3#TJ^&^/ IG";)>]9C*AY#1&UA0,(T=NS7L]3'TZZ-1
MSYO,^I\3@,8]E*6!L* L#<3XX)927Q%_Q7Q%*Z'T>ZG,@O.I"@#?W[KN7R3;
M-!>7"R8E*YO'-<&*N :HWY>,R9<7?1?:W7U?_P=02P,$%     @  DQ=45LS
MC\G% @  _ @  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RE5EUOVC 4
M_2M6M(=6ZL@'A(\*(E&@ZJ2N1:7;'J8]F.1"K#IV9CO0[=?/=F@$Y;OC@=C.
M/>>><W,3N[ODXD6F  J]9I3)GI,JE5^[KHQ3R+"L\1R8OC/C(L-*3\7<E;D
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MCREPTQ(.[\0<EBFB L.+[$C-+#I'1-P<7BQ.8"$0TW!F_O<G$-, 9.X]K)M
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M_DV9;>NOJGS*RC+;U"_74:@6?250_[_+LO+KF^K;+X>O>)W]'U!+ P04
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M]N;;QULR_P8_]Q^_?)N3ASLRNYG_3NX^/_PY)WWRQ_R6O/GM+?F-B(K<BZ*
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M:%:(?R"<:KG4SU!6HEJXG--W:G!,*/;I89F)AIDI7*%1EU^ZQ2TBTJ<>5):
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MNIP=O.8.(93634*8CTKLCP LV0%/?R*FF<;>%.J[%$* ?>1@^/9\>'N&^'/
MX6(/;EN&CP+*-R;J;<),_ 2@OD,SF8F?C?B^ 4R6TP>3ZEX@$9.,7)#LJZ0K
M5MXA-UY+=R?#IDC=;#854EQ2#J$J%V7:K>,N&R)%)GUY/\!@^.1PA4Z@-23.
MN 0@1TW;XV)84 [\.*M24N4Y8[:NG;U5:&8$HPY?3!>+Q:!"1=6:7*P(@P>
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MF[HP[%(97@QE^$[O1OR"IE01!Y+6A$(Y'^X-:\L9NN*_R(RA=UR,6]1$4(W
MA(0G5+F>-7=FG?IXQSL;F'BK.>-CPQ@SR?]$]XV 1*7D2"&#^W(,@8A 4@PU
M^YI@3N,@@M&4+H@M:GZRR!IT?:X<J\6K;UC";U'"Y0CSL[B]?+6_R:Q>_ ^;
M3)>E%83E\=8)B1D-]:!EP\,QW(NC-E,Q6]K^3"W"AS+J^/+H4]F6<2#)DH\
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M/B$&>YHD1K!V^?Q*GJT\W-WQB51 "K5?9Q["*VO*+ZUN$J+$>=)E"#C VE0
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M?CB;"5\NA.4ENB%?PM HN-+E1\Q15"IOP'KC7-R_L(/I5G[Y%U!+ P04
M"  "3%U1:0\RZE$7  !Z1@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6S-7&EO'$=S_BL#QGXA <M3AVE= $5+D5Z(,4-*-H(@'WIG>G?;FLO3,US2
MOSY/5?4UN\.E[#A!ODCD[G1U=9U/5=?PU;KIOMJ5UGUV6Y6U?;VWZOOVQ>&A
MS5>Z4O:@:76-;Q9-5ZD>OW;+0]MV6A6\J"H/3XZ.GA]6RM1[;U[Q9Y?=FU?-
MT)>FUI==9H>J4MW=6UTVZ]=[QWO^@RNS7/7TP>&;5ZU:ZFO=?VDO._QV&*@4
MIM*U-4V==7KQ>N_L^,7;XR>T@)_XQ>BU37[.Z"CSIOE*OWPL7N\=$4>ZU'E/
M)!3^N]'GNBR)$OCXW1'="WO2PO1G3_T]'QZ'F2NKSYOR5U/TJ]=[IWM9H1=J
M*/NK9OU!NP,](WIY4UK^-UO+L\^Q8S[8OJG<8OQ>F5K^5[=.$,F"TZ-[%IRX
M!2?,MVS$7/ZD>O7F5=>LLXZ>!C7Z@8_*J\&<J4DKUWV';PW6]6^NS;(V"Y.K
MNL_.\KP9ZM[4R^RR*4UNM,T>^9\>OSKLL1^M.LP=[;="^^0>VC]F%TW=KVSV
MKBYT,5Y_"#X#LR>>V;<G.PE>Z_8@>W(TRTZ.3HYVT'L2#O^$Z3VYA][4@?_S
M;&[[#L;R7SLV>!HV>,H;/+UG@_.FMB!<*+' NL@^UKWN3)6]-[6J<Z-*?"*^
MA2>F1/RW;I!]7NDL#VMTD2W"8[;'!_"WWF:FSLNAT%F/IY7(R&;- NK$_BK[
MH%79KW+5Z1F(YP<SWMC@&3O,K2F,ZB#) WS'%)K6U+0W"%2JAJO3)EA3EIDJ
M?H.)RZ;$EBET!Z9JG6MK$20R<)ZI;*%,ER'H6#PHYP M(HV/X'TV4]9_0J=B
M=F@E?6"</%K\VQ36D\$N*W6CL[G6M3]O\1('R%?;7-F>R-<DQ1)[YD/7D<TD
MSQUD9SB.39R)]\V;JE7U'>)&"2G#NH@S6%=M%0<EFS"A2P/_)J4<;*O)'Q1L
M("!W2A;[,]:PBJP27]/D:QD\!<J<ZRZX"P3>X<FF#](UY1VX+, N!<9-D7K:
M.)W!PCNM.J)-Y_X)!(3VL= 6AH=:#84A;D>L>P5,6EH\/O32*E+^@ /(ULHB
M5[2L[WZE^FRPN@N*WB:+[900U 9/=!EEJ0S'X,]@QSAUUC=9,\"FICB=Y-#+
M86%LCF^\'/#XAAB.?SS@"-J1C,J[69;KKD=:S JL+!L[0+)RCG4SE 7[2@]+
MP7Y01#&T)6E"G"Y= A:)#$N2>=_:=_8GCA,%WE2F]\9F_YKV[(I/,M<B:O"'
MM;\-M23<-;3PORCL'>'Y60C/SW9&SR^6S?Z=[0WBH[93\??/46!'$%,.@>I;
MXBT]1%':]'<BMR\'UP?94M?P=3(/LMZ6UJN8LEH$H=RT)67I?_S+Z<G)T<M_
M/3N[Y!^/7SZ&3GX?#%E0C+ID_I7Z"@\)#%-$BH[F+%0M%D!-+AZT3<<[5R$/
MX'G=R]+2J+DI3<\!/XI!E;9YB$JG;W0].!;T+7"FQ2_%P+$U+N*C<O F_^H'
M#L$2HW(VO\)@GRY;=$U%RVQRNH/L4H2$10@N2!,B%+_#(.J+TG"9X$7&4GS^
MDO59:/@ QV:?QC1%S3++2V4JX7\.52TH!;;J3LU+)DNV+[DRNT3\A[_H)6GA
M9: ^]2T[/ $0.FG;-3?&1L54ZBZC/-%[Z5$Z:I!UF#6"IPB@;2.)-V^L)'/D
M*\V1L&?K;)A1B*,T?X2 JS+;ZIRR5V#@ 3Y_!X-DK]B DL2-#V\P6+CAP+'6
M<?<'Q>N\8QMD_0GO9A&"I"=&(;%0'1(UI:M*)TR@0NA+YS'"<V?LUWTZEU4W
M4*G=MRO5B6LTRTY5-BZ^'+I\!?&0U^2:><Q=%NUTJ=C*P.]\L/!P2Z95S9W&
M[<R9A;>:+7L@@>%+ISQ&,?S=RY$9D==8RZ+#FK*IE_LEI%8(>H)@ZJ4ARQ'O
M$E"U;)IB;0 M*#(:@ G3C2UHTCX)XG2D#UK5-KWF+).IN6VZ-C MQCO4( K[
M)3TB3-T0>VQU.(3],_LPU!MZ"(Z-GV+"<D(*6T1N5#DX^$J&(SB)"**VTFRX
MO;IU0GE)0MD1^)^'P/]\-VQ6=L7RY1_>(22 "S*LJ0SP%TF%+W+Z0<<O4DR9
M^X>02KM^GT0SRU:H)$OR<ZPARX"$'1H5_X)CS!NX(R5= G&@=P,W8N.!'379
MU[I9UVFH#=L(%$(8Z1%FX6X,ICH=T"/$7I+YNPC":!K/M,Y[!.@M&E(4>P.'
M.G)R!%E*1+31;.O$8LNPEA[.QTC@7MF$1$%9T-2A!&$<35N.LJG#U1G7OTX\
M2&7DR;2P;RC:.,!H%0Q3\+T33"P%'MPH2=9>G O(P(I ONED<;<Y]4)8C;[P
M( 9<"K^*M!+-NZ3^,*-CB>P"23\$7_EAIX%_C%Q,><<W+\Y^1CI,C9D$T/KT
M##->Z9(%4>@YM$A5%L.*6;9>&=(:'E]VS= **H6&UPT>8Z2%7(=_E@W5G5(S
M1I@DIA>0Q-"U#>+PBTS=*%.2_>YCP;Z%ED:;LK> H_V^V0_N$A\ %ME>[V'8
MV?OK@,+B$CX!^4I'&H>E<EE+X4\JUJ$.*7F)E.CP54-98T:I$NJ>C6E 6+9O
M\J^KIJ1H37L>__"2K0[,4E',=1#92J=7U$J[89NC$/V(*#^>H1KD0*1:KC\D
MA/ #B+ITS ^;,O"'_/#YXEL."6>#Y/]@^&_[H,P6.>;6@:XHA]FF(.ADI#81
M"$4GED>H92-"#D@#,/'J?CENT _D +*P#6-(X!34*_L,"PBQ PDUJ#L9EL.'
M6\:T308E,S7(8?/\J5M/ @82NHC9U_J2#A(Z<&FLMV$M 37K$8B':OO(TK#R
MA1$L0WAI13AY[&J  -#M72P(/$QCA)JZ)*<'*E%*GR*(%<KF7#NO5)T='W%9
M!E'Z7#'Z&&X%A2PULM="LRLBG T LY3(4_=)(\-&=M@,$JB4?W-"YW(47V;L
M](3_>#%#I$+G!/%)_,ZK#'6<NJ]:'K>"03F-H9RD4,6EUX@F3GM#[0<##V"J
MX'O(]8:D@O(^UMX$9_P(&<6&,0!G60L5D3L@01(6!P%70I%1 31AER5 K\];
MD8)WZ;0F")Y8,+]SG2NJ8[#PCNL#5XZ; "&DI_0K)WD#6]Y2.ZEIP^HCUCS(
MWC>;,83Z$X.5NL2EUXU@YD^=!YO?V'2&4^KLWP!.LV<SG_S>$Y%?F,@%%#5(
MQ6!G/OT195[R/"Q)[.C /;8CZ9V&I'>Z,V]=8F<#(''E*I6KI,HB)MSWEK[0
M2/&(FU/)\6_?Q'\62RCK#)!#%86O^ZK.8$.NXM&%;X9=<#EKBIG[J1,57K#K
MM*7*=2BH#NYGP 5AS26-5*(X!RIW1"7NW/"/!#-#"KF\N(PY1+P/NL0Y#> +
M1T]5W#"<<4;FF[@Y.6GL7;5CGF(2DH3@P[!L+G4TLR0/4@1%85FX>I4.@,SO
M6]P9E3@H&5WN:+U.<H!@[<)58).>]V6+1'8&CD'"08[2"":WT50LEE'R[@EW
M5&HS4/N'.\UA<X"/HF [H6]GU."Y\RX6M>P:AY,]!$>00OBHFT#U(O<'9A2L
M"FWSSLP]9#W(Z+H!2002HVW7B9 W=4#+01?6@:Q0ARX#X^_(T$'V*?:/"+1U
M@Y;6?9 S%>6T#V+>O60V]8V]/1)S4+\ 1TLRFII= 0FJSEUX_0NPVEUX^"S?
MCVJB!(FBJ';J?$&B"Q'\,G+^F31R 8V<!8U\8HU<18U<LD:B$5TZ$[DPM:D@
M\HM/5^*PKBUU3FCBO.DZ4P"XP%@R1K\Q#&_J*F0-)^2D+U.Y/7S-Y($7$ CU
M,0BM+QB<A)X8YSSJ/!UD7UA9@91_@MC+'7N)%F<L2/&\K.7018QYEU3!Y*-Q
M$"IVC 6&MAG)]&VNR2PBL^J63T6UKR6,>>"%?"T=)(%0T9<8_/F#L$^/_(M6
M)KTGKUPQ5D&\["R+H8XM4)_LA9H1U8R.[R.[WT+-&R[? R," W$@1 MJPL&N
M&9-8 O"H0+EZDK#$?IZ4NLP$(_^"=$QWGGP-)!*3>PJQC((04,]-:E7F@V^6
MK?R!?'%"N+OO&KEG#WGB++TDN[XG&NX(=AZ5(<B2@0;ZR# FW#':T6F=)TT8
MNCN\;$>_!=T$F"U'9Q$%SBF,@=<Y9V !J\K"$N?@5GK'^,(%!1MS'W$P)V#I
M^\L^C0VE^]WS!P:H 2X8UQ4GH:GFN)WK>.=(V>47F%LS6&\_#-V!VJ1#2E%)
M5W![ND2-4B!U>;@M$,#?0YJ::QN*[]XP!?D6$$WE+U2];_F<B,UU587*Z?SG
M7S[^M$\74K%DEUX]/6)$A61,22SR) '4EZ;>LMY^E. ]MT(X&@,X1IHIC: ,
MA@C83:X]J1O 6:CDDIA.-M?8JB:>?&^(9>C!=G+[Y.C0W9Z[S;;4["JH7]W!
M8HB ;+,>9Z!8WV+;[WYXAD!:EG1LQMK.?V5W.S[+YEF]*R(%&RUGG>M@CF)U
M:Y3Y>MJTG*,;.VFT?*S*59\H1:R7Q2QQ<&^!^K:7RSAIOU"#;66Z"5D02TT]
M"ME,%0 39F&6JIX!=2E&3VK#/&$0.0I*8ROOK9.;[,(BU%%/]_[N]#2(/X&^
M#XM^%P.SL65_=_S\2;+))O3\EAMZZ$(B38/*B2(-:WXKZ0S<)7.E+M$N817<
MY=2W"..2@D8.[^<SB#A?S(UWD";1F+Z/(^*+=#,I_?YM63FM)==V"[@U4MB6
MPGX:=!3[4+N#2;=M9+KN%F'C?H^^ZN2R/-0YR36FY>!"&N$.+4QH*>7]@A,X
MO&Y!;&FZ5X"\FM95H1*I9"?ICC.<1W& F"P7F"Z4WW./"V&RH7F#V!C2X "4
M-HP#TO<P[HJZ&#%-"O1(Z@&'=38Z(:DN@CGPK8G[.:2A!%61D@?K0V_8PU=#
MCR#%2NINOA%RA1NW62P0FW[,;828S@9?W(78&9^--4[(-0%SA)U]8I8@1_T6
M;P6E;V1(HVZ<#$?=]#3=TLT'2KFECNEEQ-Y(#K,M;L^)9"<-D<#C/U35OHR@
MY=KG/E_%GE_$;F]+<)&^/4C1N92"9PN0+1A#G!/=,R@R=(S/SP*-M 16$8#7
M-3=_7+JDQF7&)A9H)!L&6I#"Z;/O1^<19B;H=-H)U8Z@NO.MB##Y0F@,K ZR
M]ZZ.[?22$2*%3T';\# E]Z(HLP?RU0WJL:J.Y#Y*7DXK' 0O*CPJW<\\,F4#
MX9XF!_26JX4YQP.7H'QY'6L_MN!8MGI;+L+*.'\TJJ^L!(8 "6F_;72Y%2?&
M%T>^;;AM&^=G&WI/-R<M'GT??"!IS/P]DN)@D'9[N%_L;A6$P?1K:;M&4?B6
M!?;MU5>>IP/1T4TX(92:FXA#J!Y&0OA_H)1_=R,('^,\PUD_ZJVDQ=DL3F#0
MQ;V'P&/@=_P]L?3T>TY)+I$G1))"-O1)FIK&\N+C\#L>WZ3N@XO-838"!14W
M0NY[)#;FD)/K,$ 60ADW#2XN8YU[D)VE71\\S]W6X]!M_;D#>#-_Q''3MU2&
MT?$ND_%,CK;'+[/=\U6CQNR/H3'[X\Z>:6R%3MY&?O/B+/W97\BW'?CDN<@F
M-A:H=<2JG>@?>?C@7"Q)SW'J(DW4HXG1MZYQ/QX$]-<R7>SYIKT7W]D/5TJ^
M))V@XAJ"W-AO7+,S'H(&0@9 ?G_AR9-Z?@(CN1+P=V2&T%0RX;KK;OGX*(Z?
M'SV@$A =.MIS<L!\YVIZ9>&%;1&37N^U;AAE+R5)865.0X0</]9TU' CS#4L
M?J-H1CG.-H!S?O)@T]TW)IN_0,[E0^6@[[BP-BED\N1 KRSLH879>,$B+C':
MH=L;PRTE8HN&0%SKQ<B013P5M[\I$S.KR@V,[/,EP(PF.1<+4QHWOQD7R2SR
M(V+;N3-7-OLM>+_S&^C.@P>R4%\GFP>+WYHTKSED;9>W+.)^U37#4D2[1G(!
MQ\VZ)HYSU3H<ZYD-XA[SZQZ,'/ZJW?"5U!;)99V^;7F ECY.Y[*G-"##3U+!
M<#4E4QY.RC,1<Z@$-^4U8V?Q7E)SM]$RA;4KW9U< AEWC!@"^!G2/L]3EMHG
MY5$B]DK0/*-U+SODJ$/MJ5"FY['$V 'FFM%=AZ^#_#AL^ O">XD['&V3^H<L
MPA5 <4R.MI3&_IW,G(IABU6[N-)Q(]&ZW$\,CHP\%CXVVQ5JDC==CA]Z5X(2
MNQ^>AR3.A1$JP":#S_^ 7GS] B?JNR&9WPJI 0+W&4.F)?,MBEY4%#XFL]2]
M\T:S\65K3"?;TUC)@YNC VX^>/,"86NXB0$)CQD7[M9CH?E^F ODKE_ D!OW
M!,WP2WD,0Q%@5S3Y4/E1K'#)OAR '_F:7MB:(%1QIW<NX88;OH;Z?03"P!IB
M/UR3PE992A2+YXHM,RZ!?!4?^V#IPW*!8$-DDR"Q+:Q)%<4']@&3"[TYX"1Q
MX?]FZF)ZNLP-K=#O=)>0S&1QT__^D3Z>4O_<,>8<3T>-G&/3DC=':<([1@GH
M013S"=1/.+""U1U!F430@5<_B+!5\OE16O\[RU:K?.5N9V6\ ;%O+0D_W OL
M @'.AO5.&'028]/) W-R/'/UF6:N)D/1MR]WKR"X2R@9'$XFNB9GBG"V6'.Y
M3H,TO[B[KF[Y%L:CW5A62&O.AME[,0BO >ZR()W<9>X2RSM%4.B"V-/(S@)A
M61O,Y0QXHD[03W@]0 8XI8W_X>/[^)8-P1L\HB03<0>:NWV.68ECXZLN3U0J
MW.WS3L#Z14E>Y?L;L>?);ZJ K5JO(>WXOAW51G-Y?<<5:^FW?!,?7Y)(7\,8
MK%3JH=?&#]ROF9AZH?K?9#"A)=QQRX4E)5KILE;FUC5PTN\\MKAQETKTW6\X
MGD6E&'KAX;+,F?YL>G9;\=1=/S6_[6\5XIR+ QM42W<V#NN.'EDPA?"&1=+"
M#UUD?L+'<!><DAYP^BX@GSPE7*HU/S0^K^0'P4=\_^E?#=CH54R<<O/%&&G<
MA.LX<1K-LIKK?DTO8\E+3QXRQ'%5ON4,C506@R^XN5Z;W(_>K6RPF,,LSW>&
M=,NYCLF!E O)N>JZ.PJ..\>%C^-+M<=/'JRR-]XF[IJZ(5U)]#TK&GF72::Y
MLO\ B^ZSR=CW-VWGT-DGAKY\\?7/H=9TN_=<[#)BMH38=7@AY6U#(WJ^V_K^
M[/IM:+,:>"YVF%SVI>4I^M#IO?X2EM'6^\=/9J.7=2-:W!^SG#WZW+0H6IZ<
M/'_\(IV/2Z"G>Q+&/4W2A_"UDI=U_04:D'\ADP1SRN,W'#+!JO5'DVO04]:9
MW(?^2NT,D6S@*PE-_U2(5;#V8__Z:9Q>#7MQ:X11 #='"+4A*_NY$10@UDVT
M;ESO<0TU5-QHOHG7- MA* S).A5,M@GEQ61=BY.5?LA,*C5L$0(C1+EUE"A#
M4_EKJ8/L04/<L'4L<'$@NR(+N2*P6K%A7J@.&\AF;)DPMF!DUU_XF_VCI[-I
M$MY03I^>PE#>JYSBPNB]Z7<L,0XCTQ1&!G05PI$_NGM!B$"0NV.E7%J84#$0
M8&[C2\HT7<Y#5=_\1J-40]*5G &$%=QBE5>U0'5E6IMF^=$[U9)2Q9:52P,^
MP77AN)SA W#YA"B/0_/;\W-5?\U^YB!=B%2\\W[Z^/;GY'(%!ZL;]ZKQB*P,
M<TB.FLNXK.M2R+1,!"VN=DY:NHE^N2T</ JV!A%+8]F],LG3W&I!O9C-E[)/
MQ$-IOM%E:><6T5LVF.Y$]9)L:*R31H?9+^J-R<)IN:,<<K)@/QCI=>0'SI"A
MG6#;C\:M@W>5[ECA'^E10%J%JN%]T^7ZL3C$&1Z@?@X'-[Y6XB!(;T%Q9+D<
MYB4\P/FB"@4+K;U.YK/QT;M;9R'GJ $,%ZU!W]?OSH.V"U/PM0I=$A,\I:IU
M_'*M&^'QPXGID6$'LDZ-_TA U:IXP>RNW^2NFFJWAU\=GLS8A\F? R%!\A\]
MX=OTNI>_#!(^S?P?5CF3/R<2'Y>_RG+!4SDHQ?0"2X\.?GBVAQ*._]")_-(W
M+?]QD7G3]TW%/Z)B0OBF!_#]HFEZ_PMM$/[<S)O_!E!+ P04    "  "3%U1
M="A#A"D%   V$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6SM6&US
MVS8,_BLXK]NU=UZL%[^F2>Z2IEM[MVRNTVT?=OM 2[#-12(=DK*;_?H!E"S;
MB:VFUX_K%TH4@0<@@ <F?;;6YLXN$!U\RC-ESUL+YY:GG8Y-%I@+>Z*7J&AE
MIDTN'$W-O&.7!D7JE?*L$P5!OY,+J5H79_[;V%R<Z<)E4N'8@"WR7)B'*\ST
M^KP5MC8?)G*^</RA<W&V%'.\1??[<FQHUJE14IFCLE(K,#@[;UV&IU=#EO<"
M?TA<VYUWX)U,M;[CR?OTO!6P0YAAXAA!T&.%;S#+&(C<N*\P6[5)5MQ]WZ#_
MY/=.>YD*BV]T]J=,W>*\-6Q!BC-19&ZBU^^PVD^/\1*=63_"NI3M]EJ0%-;I
MO%(F#W*IRJ?X5,5A1V$8'%&(*H7(^UT:\EY>"R<NSHQ>@V%I0N,7OU6O3<Y)
MQ4FY=896)>FYBULY5W(F$Z$<7":)+I23:@YCG<E$HH67'\4T0_OJK./(&NMT
MD@KYJD2.CB"/X$8KM[#P5J68[NMWR,O:U6CCZE74"'B+RQ.(@S9$010TX,7U
MUF./%Q_!.[3=ORZGUADJE;\;#'1K UUOH'O,86)06F0(>@9OA%V 4&GY\O:^
MD"N1H7+V4& ;89FFIW8I$CQO$0\MFA6V+CXN$&8Z(X[Q?APGC3B3:)5(2A\D
M9+7M1\"M[;;WB#"<D8G#M!3@;X\E26BI#8NLI5M(!8[L"0I@OA3J@4V2*4M1
M3 4+344F5(+@Z]*2L'!,>W#:*SKM1,91X8D5.0U%0H9SSH<%ORO%.)\U9!T]
M<N\AP7FO9Q0#>P(<D&?M;&MMRBT*A$&RFV1%6CKPPW?#* I>3[984JUHXJWZ
MQ?#UYQW=C\@)4#&3XU,T=473$([@Y7M%-,\RZECVU;9JGGC] N)V..K3,VKW
M!R.8/&>K@P!Z/?CHH__5%?$D2\]*C'<\ZI>.#^(N-/"L5_.LU\BSG;U_$<T:
M4;_1[!O-_A\TZ]<TZS?2[+*JF^N"2PM^UBLTBFW#Y1P5_WP>(EDCYF&2[2?M
M&I-J$K8?Y>T&4SJYR)2"I.=&Y*=P(Y7,B0$WOTQ\.&EA)HD4"V&X5EY &'-,
M1A'\1K$T,(QAU*MPJ"!KG(FT=R#2?XJR #W66!@'UV!X:0,8#R'L?LYJW .R
M6AJ,J0!#N!'F#MTRHXT?MQGU66^XAQ['$/8J**[EN"JS#:=3RLU\FQA1)8:V
MW.\&//8;2V%0E\*@L10^%"*3[@'>$]<4'ZMA;#"7Y.0$5ZC(B0DU13I9_OOX
MY%<613/ZH29[7] )E0ZJ:#T)[BL'9.W LG+ 5 Z8V@'",EYIB4;J=(=2[:H#
M>3/<5ZHHHC!J2[@G:E6.)<%6:]P'#>+>B?=1[_F5-MFTONU-Q[K4C?CDZT"L
MA,PV03D2A1_I[F ,ET#I(:=^1$-WP!R@DF<F#.'#EX21PK$/>@IORT ]M16S
M+69:..2R"X/11G8O;N0*]+B*XTV_? '#B(9>R)TKH&KO=K_,2V%!,#R+4OG[
MGS^/_%@G/!G ]S1&?NQMWAO8,:S9,7SVN9]X@-3+^0YUB B-0%_9'7<:M-EZ
MP=EH5UEI![T^C*E+Y2)Y(*$I_9CLR8:#'O6; -ZAR-R"$F +0[9FR&(RGQ;&
MXA,##%[W*.HZ7&Z;Y(;MP< 77[L;] ]VHL[.739',_<W=CI9,3/+:VW]M?Y3
MX+*\"V_%RW\4J,O.R67(<$:JP<F #GRFO*67$Z>7_F8\U8[NV?YU@2)%PP*T
M/M/:;29LH/ZKY.(_4$L#!!0    (  ),75'JN H[%P0  #D)   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;(U6Z6[C-A!^E8%:M#:0Z/*QMF,;R%4T
M0#<(UFGSHR@*6AI;1"A2(:EU\O8=4HKB+&RC!DP.I3F^N3B:[Y1^-@6BA==2
M2+,("FNK6129K,"2F5!5*.G-1NF263KJ;60JC2SW0J6(TC@>1R7C,EC._;,'
MO9RKV@HN\4&#J<N2Z;<K%&JW")+@_<$WOBVL>Q MYQ7;X@KMG]6#IE/4:<EY
MB=)P)4'C9A%<)K.KH>/W#']QW)D]&IPG:Z6>W>$N7P2Q X0",^LT,-J^XS4*
MX101C)=69]"9=(+[]+OVW[SOY,N:&;Q6XHGGME@$DP!RW+!:V&]J]SNV_HR<
MODP)XU?8M;QQ %EMK"I;84)0<MGL[+6-P_\12%N!U.-N#'F4-\RRY5RK'6C'
M3=H<X5WUT@2.2Y>4E=7TEI.<7=Y3WN]DIDJ$"C6L"J81>H]L+=#TYY$E$XXQ
MREIU5XVZ](BZ*7Q5TA8&;F6.^6?YB*!U^-)W?%?I284KK$(8Q&>0QFE\0M^@
M\W?@]0V.Z+ME6G*Y-?#0>?OWY=I83>7QSPG]PT[_T.L?'L/;%#>H#=R@5)0Q
M9I4V0.T#MD"X5F556^8KDGBNF.$9,)G##1>UQ1SV$M+[0QG3_T!Z*!VGT3R2
MQ8T2U'GD,UB753!H/1Q;>$ 9$UDM.D"2S/./>C#.[@P>"XWX*;5 B;%8KHG'
M9>>>#)]Z[[)'2S+=HWIWDBI:"+)LS@!?,Y(X:+\/]W6)V@5RYN/3,OP,R63D
MUB]N'0^FM([&T_W SYK(&:#[R%B*LXL#L][S-6ZY=,7@_'8/R"!7.8PFX1<8
MIV$*XR2<.BJ!)]_=F)^S[P1DBR!K[QM)FL8 -Z;&G.Q9E3U#5>NLH,O"P"\_
M3=(DO>CV7AI.^MW)<Y^[:R4'\HFN6M.DXD>QF$"X_YYOOJ;6OH .16W/C]'4
M.>.HV\V&KD,'.W?U1A<BU4-6:VXYFAGTDCX\,:V9M&;/]*2C$Z*/8HXI6G$X
M]@)N_Q%KWI;X8;13DA@/W!*',8R'1-T?8CQOFZ:7]BG?@S 9TD9!35PED.F8
M]FF8C(Y)OS=:)Q][>5]#)#]V^\2I^??DS\?*]5<72.QBRX2 2EF4EA/Y]L%"
M8$H*5%<R7?<1GMKX'B6-EJ:KJ>D2,;Z62K2%RD.X)*V[]^1\JF?37#=9VV_)
MF6^P,]BA]OUN!>GGTBO?<&TLO-1,VZ9^74.&0",.2D7L7#:3OAVZQ&,5W),S
M0 I=&:3QA:^ 0HD<M?D5;E]J;M]"_RZY\'%=*:I_"@U-))_YO4O&-$!4;0B]
M"0]=N='>.*.^W_JA3;%2M;3-9.N>=M\%E\TX_&!O/BJ^,DU-;D#@AD1CRG(
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M//X^H'_RMI,M*V9PH<3?/+/Y-!@%D.&:;87]HG:_8VV/)Y@J8?P3=M7=83^
M=&NL*FIA8E!P6;W9M]H/1P*C\ V!N!:(/>]*D6=YPRR;3;3:@7:W"<U]>%.]
M-)'CT@7EWFHZY21G9W>8\90)6 C&"P-,9C!'B6MN#2S9GJT$0NO!O4Q[TK6D
MT<EUTQI]7J'';Z"/X4Y)FQOX36:8G<IWB6E#-S[0G<=G >^QO(1>V($XC,,S
M>+W&_)['Z[V!]Z?-4<,?G*VXX):C@1MN4J',5B/\<[TR5E/>_'M&4[_1U/>:
M^C_OZ-?\>Q;45>R5*5F*TX!*TJ!^PF#VD".LE:!RXW(#UH>PU.J)9V0>V4M)
M:QD7!M0:U%9#43-+GYFM#LS*.@68O^V%F248+IV,Q>P**"06BQ6YT<7E!M-Z
M$76@=2LI9X6@\C-M^(1X05WDPM'D*1[T<9ENM492NK4@E26=/(/6K[^,XCC\
M>#O_O/2?T<<V?("H,X@2_^Z' UCFC HSW3<TH_X(HG@ "U9RRWS9'XZ&/4@2
MJ.+=3WH0#X;PH"S9_0'B3CP:>]11TH<SP4Z:8"=G@[U01:DD2NO=]F*5,[E!
M,AM^,B7.JGY/2M"IX^2BFIY0]#L-S1_-$8JMERQ1<Y4=Y<@E./VL4%N'7^NE
M@#N!.LRG+FJT,>VH&=K5*!P46'4%2\+7L$>F39T:=%S#>@8'5:L]['*>YMX$
MI?F&2T)%8WGAL_A8U;GDKU!72/+2.;!VD6, .R2.A:*')8]5ZE.[)4CQW%4Z
M_L^1 >4CE]6?U.5FJ]24_;QD0NPKU[%]X8P@!16A-A7K$_TY2Q(V=-=I40:/
ML2L&:ZZ-=6Y0VGO\,Z7%2?-]4:>N?](C&K\HTKOO^Z-SY(D5$\RQ.M2.>X\'
M$;PKG@M7_V2U]V=$I3VD*@ZITGO'H8;68-"&5ISTVG7AO@+KI*/82?<&X5&I
M224O-#>/WB#EFT#=$O7!+ -)"%$O<J57>.8N/]]#?=Q)PA!&G?%X<$(\ZB3Q
MT+6L450S]RV.N(9N/R2#AS_F>*22.O'Z<^<:#Y-7.U?W:#8H4&_\!&3(%*J0
M:DQH=ILAZ[J:+9ZO5Q/:'=,4=P,"UR0:7@ZI$^EJZJD65I5^TE@I2W.+_\QI
M4$3M+M#Y6BE[6#@%S>@Y^Q]02P,$%     @  DQ=40PL:R,Z P  W 8  !D
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M?&M /R)W [IGE)W5K&*AQ%8?%X;<.#IPZB\6#X1OJ!HZ#]8*:%[WU.KAR4>
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MV@7@]ZE"QXJ):S7*UK+W#U!+ P04    "  "3%U1"?TB-LD$  !W%   &0
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M'^)M6GW.7W[E^R/RZOF6>5HV_Y*7?:PS(\MM6>7K_6"1P3K)=O_'W_8K(0T
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M>;>4.P^Y>6C+GI54P$.#]B:A I[.GW>::4/:V:*%>WH+ES4[G[UY:,>>E93
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M?;A[4>6;YO&!]WE5Y>OFQR<>BYSJ /'^0RXV!OL7]1,)CX^@O/X;4$L#!!0
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M;Z$,YGA)Y3-;?X4FGT#'2QD5YA>M&ZQCH70I)"L:LG)0D+)^XK=F'S8(KG^
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M5+F)"H,@SK*<L)""D&>RLR5+:T$CU1LX>09'A\RD&XYQ'>78&N7'WB*-.TH
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M,XO$&_@*?F#&<)Y5X.R*"!S%_+-\^K"\ F>_?9Y80LZ<XRV_G&56S():9G'
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M,\6Z57FW(^A.KX3OJ9#K:KVY)5@N?=4%\OR:4O&THP88OHW,_@502P,$%
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MUA$Y8>%X:/G"0WPQ$7AI2B^" 4_T_RB)K>B>T/[.4/\C"L9K*,<-R=H.VX6
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M!VBY$Y+EM;$:09X6U3]]J2?BR$#YL1N0VH"8!OX9 Z\V\"Z-X-<&_J41@MI
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M[3&#!P4IW=;^-NT$C+'[X^RD*-CN"Z.9X. F_^:&44#:.I1+19]--WM48@.
MPF@#2M-XB/Q6I%C!5K?':9N.:YZ=H.9_N\X9"%"$#46;LW_,J_QNQ?.K_R6Y
M_E<Y%/RJQN::.W:1BU,0N3P%D2=P)N?71ZG1:Z[&P?V[=_MV*+*OG!#?V_<2
MZYNB=469IJ+Q<IHD(%Y<PH9>D[5Y[.[QF_P$4E(QO>J"(>[M'Y#0BE]W60]V
M(9JLWOYNI^<OZX;]BSKZ U!+ P04    "  "3%U1EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    (  ),75&-$'19B 0
M *8D   /    >&PO=V]R:V)O;VLN>&ULQ9I-<^(X$$#_BHK+SAZR@#^23&J8
M*@)D0E4"U)C*=4O8 E2Q)5:2R2:_?F5[F&DVIG<O'4Y@R1'/BMRO6_:7%VV>
M5UH_L[^+7-E!9^O<[J;;M>E6%-S^H7="^9ZU-@5W_M!LNG9G!,_L5@A7Y-V@
MU[OL%ERJSM<OA[$6I@L/M!.IDUKYQJKA28H7^ZN_.F1[:>5*YM*]#CKU]UQT
M6"&5+.2;R :=7H?9K7ZYUT:^:>5XGJ1&Y_F@TV\ZGH1Q,GW7G%202[ZR=8OC
MJ^_<@PPZEST_X%H:Z^HSZO&Y9]P+?W)S5#I])W,GS)@[\<WH<B?5IAK&7T47
M7$8]#X?/9A)OS/^91KU>RU2,=5H60KEF'HW(*T!EMW)G.TSQ0@PZ([T7ABWX
M1E07Y7]EFC47Z#P9F"YS(WV'F68U(R'/?);,'Z;CX7(R9LG2?SQ.9LN$S>_8
M=#:: \@ @0S.!CF:/RX 9(A AA\(>3M\&,Y&$Y;<3R;+! !&"&!T-D#V:<$!
M9(Q QF?[5R?+^0A 7B*0E^=;C\/D'D!>(9!7M)!SL^%*OM4=C*N,W7(K+=-K
MMC#"PO!SC4!>TT(F<J.D/Y<KQX9IJDOE?&1F"YW+5 H+(#\CD)]I(6=^W*E*
M=2'8S@?O9,O-4?3N8>&[1\MV6UJIA+5LI(N55,T)$ YU"[%<[K@T[(GGI6"/
M@MO2B.H/CO PJ_2)M3)5>V'=.R3,(7UBB3R*K,I\V"CGLK#-;2N46$MG?=+P
M"C$QD_2)53(6*P=9,&'TB8V1.)T^;W6>"6-_8Y._2I]W0C;,$WUB421B\VYY
M84KH$SO!!XE"-BN^7ELC7<=;H?X5;/N8$OKG=,*? <3$I- GM@*.&<+,&1-$
M0"R(-GFQ3[XRRH7]'4)BH@B(1=%JL59*M HA]L4)G1TX(2;FD(#8(4!KK5.(
MB2,@%@?JMZ-[.\"<$A [I?);Z]QA,@FH9=(BNE9(S# !L6$.QFL%PZP2$%L%
M+8>.5QYFE>"L5HG@5@=FE9#8*CAF##$QKX3$7L$Q+R$F)I:06"PXYA7$1#>X
MB,6"8UY#3,PQ(;%CVC.>L7!<YD?Q*,04$Q(KICWEN6 S;HP_@)B8=$)BZ9S"
MG"K'U>8($]-.2*R=4ZG9C_F$F)B$0F()G<:L>R F)J&06$*G,6]YSA7<SL8D
M%!%+Z#3F@U:;"XB)22@BEA#,QR]84A8%-Z]5XM%T0$Q,0M''[89YS&IGP/#4
ME3Y9?^2N-! 3DU#T@=7-SVBY_QG@(2;ZK(580L>8P[U'J_+A"S_81<*/,#$+
M1<06PNLQN(D181:*B"V$8\*L.,(L%!%;",>$67&$62@BME!=W?I(Y(?*REQ4
MH:@.F$MA"C:&CS8BS$(1L85^8+Z[Q8]RN!@34$Q=!;55Y+^((28FH)BZ"FK'
M;!+C80HQ,0'%U%50.^;!\A 3$U!,704==CC^<VEB_HF)_0,HOXM4JU3FLMG[
M\'?[-VCS&'W:7_NG>W@O)O.Q3(ELYG_"^G8?Z]*%8=5'\S OBJLM^769YR/?
M-E</FF>'UVP.KPA]_0=02P,$%     @  DQ=4;P!UL'@ 0  ["   !H   !X
M;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:.T[#0!2%X:U$7@"3^YCP4$)%
M0XO8@!4F#Y'$EF<0R>Z)0A&.14&#YE36V/+UW_B397O^DG9MV7:'O-GV>7+<
M[PYYT6Q*Z1]"R,M-VK?YINO3X7QDU0W[MIR7PSKT[?*]7:>@T^DL##]G-(_S
MGS,GKZ<^_65BMUIME^FI6W[LTZ'\,CA\=L-[WJ14FLEK.ZQ3633AN+ONSN&R
MD9OSY&;R_+9HAN<W:4+M((4@K1]D$&3U@QR"O'Y0A*!8/V@&0;/Z0;<0=%L_
MZ Z"[NH'W4/0??T@F:*,4X*D$=8$6@MR+01>"X(M!&(+DBT$9@NB+01J"[(M
M!&X+PBT$<@O2+01V"^(M!'HKZJT$>BOJK01ZZ^AAFT!O1;V50&]%O95 ;T6]
ME4!O1;V50&]%O95 ;T6]E4!O1;V50&]#O8U ;T.]C4!O0[V-0&\;O2PAT-M0
M;R/0VU!O(]#;4&\CT-M0;R/0VU!O(]#;4&\CT-M1;R?0VU%O)]#;46\GT-M1
M;R?0VT<ONPGT=M3;"?1VU-L)]';4VPGT=M3;"?1VU-L)](ZH=R30.Z+>D4#O
MB'I' KTCZAT)](ZH=R30.XX^5OZGWKF<=BE?>[[7>/W_I+J<STW7RU^6WSM'
M-]0%YP _-SQ^ 5!+ P04    "  "3%U1%-1QY- !  "M(   $P   %M#;VYT
M96YT7U1Y<&5S72YX;6S-VLENPC 4!=!?0=E6Q'@('01LVFY;%OT!-WE 1!);
MMJ'P]W7"(+6BJ(A*O1LB8OO=%ULZFV3TMK7D>YNZ:OPX681@'QCS^8)J[5-C
MJ8DC,^-J'>)?-V=6YTL])R8&@R'+31.H"?W0UD@FHR>:Z545>L^;>-N7IADG
MCBJ?]!YW$]NL<:*MK<I<ASC.UDWQ+:6_3TCCRFZ.7Y36W\0)"3N9T([\'+!?
M][HFY\J">E/MPHNNXRRVJ9@/VXI\>K[$B1[-;%;F5)A\5<<EJ;>.=.$71*&N
MTEW1F_/)(>XP[7[YU?E=F7.!<>;4&>OCB3FZ/.YP).WJOHV%R(7R_",>$V/I
MJY^/VM,NJ/AE=MS>#^.6W7EXUEVNW^.O9WRL?V$? J0/"=*' NDC ^EC"-+'
M+4@?=R!]W(/TP0<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5H\@J4&05*+(*
M%%D%BJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDBJT215:+(*E%DE2BR
M2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(FN&(FN&(FN&(FN&
M(FN&(FOVG[*^&[/\ZQ?H[36M==D<\EGWE<+D$U!+ 0(4 Q0    (  ),75$'
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @  DQ=45(-B,KN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @  DQ=49E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  "3%U1B5B603D%  !B%0  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @  DQ=432#^ ;'!0  21H
M !@              ("!? T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+
M 0(4 Q0    (  ),75'P/8P!/@,  *4*   8              " @7D3  !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  "3%U16#/%,\X%
M   '%P  &               @('M%@  >&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL4$L! A0#%     @  DQ=45LSC\G% @  _ @  !@              ("!
M\1P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  ),75%2
M$C[;G@@  .XU   8              " @>P?  !X;"]W;W)K<VAE971S+W-H
M965T-BYX;6Q02P$"% ,4    "  "3%U13YH>GD\(  #T)0  &
M    @(' *   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M DQ=41V<SD-B#   I2   !@              ("!13$  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    (  ),75&(59)R5AL  ,10   8
M          " @=T]  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  "3%U1(2<='^T#  #]"   &0              @(%I60  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (  ),75'K/1)(- <  .H1
M   9              " @8U=  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @  DQ=4>.W*J"Y"    AD  !D              ("!^&0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  "3%U1+@(T
M?^(&   8$@  &0              @('H;0  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    (  ),75&19SU)X@4  (4.   9
M  " @0%U  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M DQ=4?6G@&/\"   +!@  !D              ("!&GL  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  "3%U1<TN.UI,'  !6$@  &0
M            @(%-A   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    (  ),75&PZE-6#@4  !8,   9              " @1>,  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @  DQ=42"'F:\W!0
MH0L  !D              ("!7)$  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  "3%U1:0\RZE$7  !Z1@  &0              @('*
ME@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  ),75%T
M*$.$*04  #81   9              " @5*N  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @  DQ=4>JX"CL7!   .0D  !D
M     ("!LK,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  ),75$,+&LC.@,  -P&   9              "
M@3?*  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @  DQ=
M4?1+;8!  P  N 8  !D              ("!J,T  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    "  "3%U1U*2[I+,#  "R"   &0
M        @($?T0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   (  ),75&P^C1LX0,  .D.   9              " @0G5  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @  DQ=42+_E)>K @  EP<
M !D              ("!(=D  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    "  "3%U1F.C^-5\$  "6$0  &0              @($#W
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (  ),75&UXB*5
M#0,  "0*   9              " @9G@  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @  DQ=4>$*WO_F P  P X  !D
M ("!W>,  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  "
M3%U1G]?<CN0"  !F"@  &0              @('ZYP  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (  ),75$)_2(VR00  '<4   9
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M970S.2YX;6Q02P$"% ,4    "  "3%U1901SS9X"  #[!@  &0
M    @($1!@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M  ),75&F&$<H6@4  %4D   9              " @>8( 0!X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @  DQ=4:D5K'!H!0  H!\  !D
M             ("!=PX! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    "  "3%U1HI"1?MX"  "#"0  &0              @($6% $ >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  ),75&DC[%4" ,
M +4)   9              " @2L7 0!X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @  DQ=41WZ41,? P  <0L  !D              ("!
M:AH! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  "3%U1
M5( &I-T"  !2"   &0              @(' '0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    (  ),75&.;$'1FP(  %<&   9
M      " @=0@ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @  DQ=4868QM=S P  =0L  !D              ("!IB,! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    "  "3%U1@\D[77\$  "L&
M&0              @(%0)P$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    (  ),75$5+O3Z, 8  + C   9              " @08L 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @  DQ=4;TR3@ -
M!0  5!8  !D              ("!;3(! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    "  "3%U1%6^,A_(#   G$0  &0
M@(&Q-P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  ),
M75%4P(PR_@(  /X)   9              " @=H[ 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @  DQ=481<6C(" @  3P0  !D
M         ("!#S\! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M    "  "3%U1'T!(G5 $  !/$@  &0              @(%(00$ >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (  ),75&,P81)10(  %X+
M   -              "  <]% 0!X;"]S='EL97,N>&UL4$L! A0#%     @
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H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     _ #\ ,!$  /91 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>264</ContextCount>
  <ElementCount>355</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Net Income per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShare</Role>
      <ShortName>Net Income per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2118105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2130107 - Disclosure - Medical Claims and Benefits Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</Role>
      <ShortName>Medical Claims and Benefits Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135108 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2139109 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Net Income per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShareTables</Role>
      <ShortName>Net Income per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomeperShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/BusinessCombinations</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2319304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Investments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - Medical Claims and Benefits Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables</Role>
      <ShortName>Medical Claims and Benefits Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Debt</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2345309 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Segments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails</Role>
      <ShortName>Significant Accounting Policies - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails</Role>
      <ShortName>Significant Accounting Policies - Amounts Due To Government Agencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails</Role>
      <ShortName>Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Significant Accounting Policies - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Net Income per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomeperShareDetails</Role>
      <ShortName>Net Income per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomeperShareTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417409 - Disclosure - Business Combinations - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails</Role>
      <ShortName>Business Combinations - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2420410 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2421411 - Disclosure - Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Fair Value Measurements - Balance Sheet Grouping (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails</Role>
      <ShortName>Fair Value Measurements - Balance Sheet Grouping (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Investments - Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Contractual Maturities of Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Investments - Available-for-Sale Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails</Role>
      <ShortName>Investments - Available-for-Sale Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2432418 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437421 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438422 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2441423 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2442424 - Disclosure - Stockholders' Equity - Share Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails</Role>
      <ShortName>Stockholders' Equity - Share Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2443425 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails</Role>
      <ShortName>Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2446426 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="moh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2447427 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails</Role>
      <ShortName>Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="moh-20200930.htm">moh-20200930.htm</File>
    <File>exhibit21affinity-apa.htm</File>
    <File>moh-20200930.xsd</File>
    <File>moh-20200930_cal.xml</File>
    <File>moh-20200930_def.xml</File>
    <File>moh-20200930_lab.xml</File>
    <File>moh-20200930_pre.xml</File>
    <File>moh3q20ex311.htm</File>
    <File>moh3q20ex312.htm</File>
    <File>moh3q20ex321.htm</File>
    <File>moh3q20ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moh-20200930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>75
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moh-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 264,
   "dts": {
    "calculationLink": {
     "local": [
      "moh-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moh-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "moh-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 482,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 6,
    "http://www.molinahealthcare.com/20200930": 1,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 12
   },
   "keyCustom": 51,
   "keyStandard": 304,
   "memberCustom": 32,
   "memberStandard": 32,
   "nsprefix": "moh",
   "nsuri": "http://www.molinahealthcare.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.molinahealthcare.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Net Income per Share",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShare",
     "shortName": "Net Income per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Business Combinations",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118105 - Disclosure - Fair Value Measurements",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Investments",
     "role": "http://www.molinahealthcare.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130107 - Disclosure - Medical Claims and Benefits Payable",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable",
     "shortName": "Medical Claims and Benefits Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135108 - Disclosure - Debt",
     "role": "http://www.molinahealthcare.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139109 - Disclosure - Stockholders' Equity",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - Segments",
     "role": "http://www.molinahealthcare.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Net Income per Share (Tables)",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShareTables",
     "shortName": "Net Income per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Business Combinations (Tables)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Investments (Tables)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - Medical Claims and Benefits Payable (Tables)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables",
     "shortName": "Medical Claims and Benefits Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Debt (Tables)",
     "role": "http://www.molinahealthcare.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2345309 - Disclosure - Segments (Tables)",
     "role": "http://www.molinahealthcare.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Organization and Basis of Presentation (Details)",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i391a70c55331438f93619826459906eb_D20200901-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails",
     "shortName": "Significant Accounting Policies - Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i8ee959cf00f54dcaaf758268793bb7d3_I20190930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:InvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:InvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReservesReportedToOtherAgenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails",
     "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ReservesReportedToOtherAgenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MaximumAvailableQualityIncentivePremiumCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails",
     "shortName": "Significant Accounting Policies - Quality Incentive Premium Revenue Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:QualityIncentivePremiumRevenueRecognizedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MaximumAvailableQualityIncentivePremiumCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Significant Accounting Policies - Receivables (Details)",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails",
     "shortName": "Significant Accounting Policies - Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "if72eeeb9a99b4477ab11023ecac0d4ae_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Net Income per Share (Details)",
     "role": "http://www.molinahealthcare.com/role/NetIncomeperShareDetails",
     "shortName": "Net Income per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:BusinessCombinationNumberOfBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "business_combination",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Business Combinations - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:BusinessCombinationNumberOfBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "business_combination",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417409 - Disclosure - Business Combinations - Intangible Assets (Details)",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
     "shortName": "Business Combinations - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420410 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i16ad5df3e0954d1db28ec31f056ff595_I20200930",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421411 - Disclosure - Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Fair Value of Financial Instruments on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i28a5c4abcb034316be3389b51a439633_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Fair Value Measurements - Balance Sheet Grouping (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails",
     "shortName": "Fair Value Measurements - Balance Sheet Grouping (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i28a5c4abcb034316be3389b51a439633_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ia533dfe1902b48fbb0bcb8ba4cfb46b0_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i1ccea875e1a344df9d2d0328fcf08ab5_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Investments - Summary of Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails",
     "shortName": "Investments - Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Contractual Maturities of Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Investments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i55535562ca144329a62ab6dc2d21ad48_D20190701-20190930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Investments - Available-for-Sale Investments (Details)",
     "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
     "shortName": "Investments - Available-for-Sale Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432418 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Medical Claims and Benefits Payable - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails",
     "shortName": "Medical Claims and Benefits Payable - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i3cd81903ac784f3c95b719f7294b0fd8_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
     "shortName": "Medical Claims and Benefits Payable - Components of Change in Medical Claims and Benefits Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437421 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ifccb71ed99474db29c92a1c32422fdb8_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438422 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ie5e5997156224aac9afd99b367288856_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "iabf526601a194124b21ff81d2e1ae411_D20200101-20200331",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchasedDuringPeriodValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441423 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i0123ff206dc2499598383ffd43d68eb2_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442424 - Disclosure - Stockholders' Equity - Share Activity (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails",
     "shortName": "Stockholders' Equity - Share Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i0123ff206dc2499598383ffd43d68eb2_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443425 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
     "shortName": "Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446426 - Disclosure - Segments - Narrative (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i5ef20d2fbc4b43959e9902d9459c3ba7_D20200701-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447427 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
     "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ia6bfe7a86bb74920a147b73772e2e69f_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "ibf672f433e474e1390b199db5bd6d157_I20181231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "if2e39a6516be42729bf559f4b31b0042_D20190101-20190331",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Basis of Presentation",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Significant Accounting Policies",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20200930.htm",
      "contextRef": "i6e43d57897d04ef1a4029e7136dad5de_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 66,
   "tag": {
    "country_PR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PUERTO RICO",
        "terseLabel": "PUERTO RICO"
       }
      }
     },
     "localname": "PR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "moh_A4.875SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "4.875% Senior Notes [Member]",
        "label": "4.875% Senior Notes [Member]",
        "terseLabel": "4.875% Notes due 2025",
        "verboseLabel": "4.875% Notes"
       }
      }
     },
     "localname": "A4.875SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_A4375SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "4.375% Senior Notes",
        "label": "4.375% Senior Notes [Member]",
        "terseLabel": "4.375% Notes"
       }
      }
     },
     "localname": "A4375SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffinityHealthPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affinity Health Plan",
        "label": "Affinity Health Plan [Member]",
        "terseLabel": "Affinity health plan"
       }
      }
     },
     "localname": "AffinityHealthPlanMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "terseLabel": "Risk adjustment, net payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net (Payable) Receivable, Prior Years",
        "terseLabel": "Risk adjustment, net payable, prior year"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayableReceivablePriorYears",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "terseLabel": "Risk adjustment payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "terseLabel": "Risk adjustment receivable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable (Payable), Current Year",
        "verboseLabel": "Risk adjustment, net payable, current year"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivablePayableCurrentYear",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails": {
       "order": 1.0,
       "parentTag": "moh_QualityIncentivePremiumRevenueRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current year quality incentive premium revenue recognized.",
        "label": "Amount Of Current Year Quality Incentive Premium Revenue Recognized",
        "terseLabel": "Earned current period"
       }
      }
     },
     "localname": "AmountOfCurrentYearQualityIncentivePremiumRevenueRecognized",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails": {
       "order": 2.0,
       "parentTag": "moh_QualityIncentivePremiumRevenueRecognized",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of quality incentive premium revenue recognized from prior year.",
        "label": "Amount Of Quality Incentive Premium Revenue Recognized From Prior Year",
        "terseLabel": "Earned prior periods"
       }
      }
     },
     "localname": "AmountOfQualityIncentivePremiumRevenueRecognizedFromPriorYear",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 4.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "terseLabel": "Minimum MLR"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "terseLabel": "Marketplace program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 8.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid, Other",
        "label": "Amounts Due To Government Agencies, Medicaid, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidOther",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "terseLabel": "Medicaid program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 6.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due To Government Agencies Medicare Program",
        "label": "Amounts Due To Government Agencies Medicare Program [Abstract]",
        "terseLabel": "Medicare program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 1.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "terseLabel": "Risk adjustment and Part D risk sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 5.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Other",
        "label": "Amounts Due to Government Agencies, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesOther",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 2.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment",
        "label": "Amounts Due to Government Agencies, Risk Adjustment",
        "terseLabel": "Risk adjustment"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationNumberOfBusinessCombinations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Number Of Business Combinations",
        "label": "Business Combination, Number Of Business Combinations",
        "terseLabel": "Number of business combinations"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfBusinessCombinations",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of members eligible for the health care programs.",
        "label": "Business Combination, Number Of Members Eligible For The Health Care Programs",
        "terseLabel": "Number of members eligible for the health care programs, approximately"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19 [Member]"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]",
        "label": "California, Illinois, New Mexico, Ohio, South Carolina, Texas, Washington, and Wisconsin [Member]",
        "terseLabel": "Select health plans"
       }
      }
     },
     "localname": "CaliforniaIllinoisNewMexicoOhioSouthCarolinaTexasWashingtonandWisconsinMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CallOptionDerivativeAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Call Option, Derivative Asset [Member]",
        "label": "Call Option, Derivative Asset [Member]",
        "terseLabel": "Call option"
       }
      }
     },
     "localname": "CallOptionDerivativeAssetMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CapitationClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Capitation Claims Payable",
        "label": "Capitation Claims Payable",
        "terseLabel": "Capitation payable"
       }
      }
     },
     "localname": "CapitationClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CashConvertibleSeniorNotesDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Convertible Senior Notes due 2020 [Member]",
        "label": "Cash Convertible Senior Notes due 2020 [Member]",
        "netLabel": "1.125% Convertible notes",
        "terseLabel": "1.125% Convertible Notes, net of unamortized discount"
       }
      }
     },
     "localname": "CashConvertibleSeniorNotesDue2020Member",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CashConvertibleSeniorNotesDue2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Convertible Senior Notes Due 2020, Warrants [Member]",
        "label": "Cash Convertible Senior Notes Due 2020, Warrants [Member]",
        "terseLabel": "1.125% Warrants"
       }
      }
     },
     "localname": "CashConvertibleSeniorNotesDue2020WarrantsMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CashPaidForSettlementOfConversionOption": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash Paid For Settlement Of Conversion Option",
        "label": "Cash Paid For Settlement Of Conversion Option",
        "negatedTerseLabel": "Cash paid for partial settlement of conversion option"
       }
      }
     },
     "localname": "CashPaidForSettlementOfConversionOption",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ClassOfWarrantOrRightStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Stated Interest Rate",
        "label": "Class Of Warrant Or Right, Stated Interest Rate",
        "terseLabel": "Stated percentage of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightStatedInterestRate",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "terseLabel": "Components of Components of Change in Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ComponentsOfMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of medical care costs.",
        "label": "Components Of Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to:"
       }
      }
     },
     "localname": "ComponentsOfMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ConsolidatedNetLeverage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidated Net Leverage",
        "label": "Consolidated Net Leverage",
        "terseLabel": "Consolidated net leverage ratio"
       }
      }
     },
     "localname": "ConsolidatedNetLeverage",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "moh_ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "label": "Consolidation And Interim Financial Information, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Interim Financial Information"
       }
      }
     },
     "localname": "ConsolidationAndInterimFinancialInformationPolicyPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_CurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current Assets [Member]",
        "label": "Current Assets [Member]",
        "verboseLabel": "Current assets: Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "CurrentAssetsMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current Liabilities [Member]",
        "label": "Current Liabilities [Member]",
        "verboseLabel": "Current liabilities: Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "CurrentLiabilitiesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_DetailsOfBusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details Of Business Combinations",
        "label": "Details Of Business Combinations [Abstract]",
        "terseLabel": "Details of business combinations:"
       }
      }
     },
     "localname": "DetailsOfBusinessCombinationsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_DetailsofchangeinfairvalueofderivativesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details of change in fair value of derivatives",
        "label": "Details of change in fair value of derivatives [Abstract]",
        "terseLabel": "Details of change in fair value of derivatives, net:"
       }
      }
     },
     "localname": "DetailsofchangeinfairvalueofderivativesAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities",
        "label": "Fair Value Of Contingent Consideration Liabilities Assumed In Noncash Investing Or Financing Activities",
        "terseLabel": "Fair value of contingent consideration liabilities"
       }
      }
     },
     "localname": "FairValueOfContingentConsiderationLiabilitiesAssumedInNoncashInvestingOrFinancingActivities",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_GovernmentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Government Receivables [Member]",
        "label": "Government Receivables [Member]",
        "terseLabel": "Government receivables"
       }
      }
     },
     "localname": "GovernmentReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthCareInsuranceFeeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Care Insurance, Fee, Liability",
        "label": "Health Care Insurance, Fee, Liability",
        "terseLabel": "HIF liabilities"
       }
      }
     },
     "localname": "HealthCareInsuranceFeeLiability",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Expense",
        "label": "Health Care Organization, Insurer Fee Expense",
        "terseLabel": "Health insurer fees"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeExpense",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Revenue",
        "label": "Health Care Organization, Insurer Fee Revenue",
        "terseLabel": "Health insurer fees reimbursed"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeRevenue",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationPremiumTaxRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Care Organization, Premium Tax Revenue",
        "label": "Health Care Organization, Premium Tax Revenue",
        "terseLabel": "Premium tax revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationPremiumTaxRevenue",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthInsurerFeeReimbursementReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Insurer Fee Reimbursement Receivables [Member]",
        "label": "Health Insurer Fee Reimbursement Receivables [Member]",
        "terseLabel": "Health insurer fee reimbursement receivables"
       }
      }
     },
     "localname": "HealthInsurerFeeReimbursementReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthPlanContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Plan, Contract Term",
        "label": "Health Plan, Contract Term",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "HealthPlanContractTerm",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health plans.",
        "label": "Health Plans [Member]",
        "terseLabel": "Health Plans"
       }
      }
     },
     "localname": "HealthPlansMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_IncreaseDecreaseInHealthInsuranceFeeLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Health Insurance Fee, Liability",
        "label": "Increase (Decrease) In Health Insurance Fee, Liability",
        "terseLabel": "Increase in HIF liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthInsuranceFeeLiability",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency",
        "label": "Increase (Decrease) In Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_IncrementalTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental Term Loan",
        "label": "Incremental Term Loan [Member]",
        "terseLabel": "Incremental Term Loan"
       }
      }
     },
     "localname": "IncrementalTermLoanMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_InvestmentsAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments, Average Maturity Period",
        "label": "Investments, Average Maturity Period",
        "terseLabel": "Average maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsAverageMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_InvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments, Maturity Period",
        "label": "Investments, Maturity Period",
        "terseLabel": "Maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_LetterOfCreditSubFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Letter Of Credit Sub-Facility",
        "label": "Letter Of Credit Sub-Facility [Member]",
        "terseLabel": "Letter of credit sub-facility"
       }
      }
     },
     "localname": "LetterOfCreditSubFacilityMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "terseLabel": "Fee-for-service claims incurred but not paid (\u201cIBNP\u201d)"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)",
        "label": "Long-Term Debt, Current Maturities, Net Of Unamortized Premium (Discount)",
        "terseLabel": "Debt net of unamortized discount"
       }
      }
     },
     "localname": "LongTermDebtCurrentMaturitiesNetOfUnamortizedPremiumDiscount",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "terseLabel": "Debt net of unamortized debt discount"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MagellanCompleteCareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Magellan Complete Care [Member]",
        "label": "Magellan Complete Care [Member]",
        "terseLabel": "Magellan complete care"
       }
      }
     },
     "localname": "MagellanCompleteCareMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MaineCommunityHealthOptionsv.UnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maine Community Health Options v. United States [Member]",
        "label": "Maine Community Health Options v. United States [Member]",
        "terseLabel": "Maine Community Health Options v. United States"
       }
      }
     },
     "localname": "MaineCommunityHealthOptionsv.UnitedStatesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MaximumAvailableQualityIncentivePremiumCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum available quality incentive premium current year.",
        "label": "Maximum Available Quality Incentive Premium Current Year",
        "terseLabel": "Maximum available quality incentive premium - current period"
       }
      }
     },
     "localname": "MaximumAvailableQualityIncentivePremiumCurrentYear",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MeasurementInputExpectedAssetVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Expected Asset Volatility",
        "label": "Measurement Input, Expected Asset Volatility [Member]",
        "terseLabel": "Measurement Input, Expected Asset Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedAssetVolatilityMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MeasurementInputExpectedRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Expected Revenue Volatility",
        "label": "Measurement Input, Expected Revenue Volatility [Member]",
        "terseLabel": "Measurement Input, Expected Revenue Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedRevenueVolatilityMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MeasurementInputMeasurementPeriodMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Measurement Period",
        "label": "Measurement Input, Measurement Period [Member]",
        "terseLabel": "Measurement Input, Measurement Period [Member]"
       }
      }
     },
     "localname": "MeasurementInputMeasurementPeriodMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicaid",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable",
        "label": "Medical Claims And Benefits Payable",
        "terseLabel": "Non-risk provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider",
        "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider",
        "terseLabel": "Change in non-risk and other provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical claims and benefits payable.",
        "label": "Medical Claims And Benefits Payable [Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_MedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Premium Liability Due to Agency",
        "label": "Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies",
        "totalLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "MedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 3.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Premiums Liability, Medical Care Costs Threshold",
        "label": "Medical Premiums Liability, Medical Care Costs Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Municipal securities.",
        "label": "Municipal Securities [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Claims Payable",
        "label": "Other Claims Payable",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherMedicareProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 7.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Medicare Program",
        "label": "Other Medicare Program",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMedicareProgram",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Securities",
        "label": "Other Securities [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PassportHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Passport Health Plan Inc",
        "label": "Passport Health Plan Inc [Member]",
        "terseLabel": "Passport health plan inc"
       }
      }
     },
     "localname": "PassportHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for medical care costs.",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_PercentageOfAdditionalIncrementalRevenueEarned": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of additional incremental revenue earned.",
        "label": "Percentage Of Additional Incremental Revenue Earned",
        "negatedTerseLabel": "Percentage of additional incremental revenue earned"
       }
      }
     },
     "localname": "PercentageOfAdditionalIncrementalRevenueEarned",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_PharmacyClaimsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmacy Claims Payable",
        "label": "Pharmacy Claims Payable",
        "terseLabel": "Pharmacy payable"
       }
      }
     },
     "localname": "PharmacyClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PharmacyRebateReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pharmacy Rebate Receivables [Member]",
        "label": "Pharmacy Rebate Receivables [Member]",
        "terseLabel": "Pharmacy rebate receivables"
       }
      }
     },
     "localname": "PharmacyRebateReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PremiumTaxExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An assessment levied by a state government on the net premium income collected.",
        "label": "Premium Tax Expenses",
        "terseLabel": "Premium tax expenses"
       }
      }
     },
     "localname": "PremiumTaxExpenses",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ProviderNetworkMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Provider Network",
        "label": "Provider Network [Member]",
        "terseLabel": "Provider network"
       }
      }
     },
     "localname": "ProviderNetworkMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quality Incentive Premium Revenue As A Percentage Of Total Revenue",
        "label": "Quality Incentive Premium Revenue As A Percentage Of Total Revenue",
        "terseLabel": "Quality incentive premium revenue recognized as a percentage of total premium revenue"
       }
      }
     },
     "localname": "QualityIncentivePremiumRevenueAsAPercentageOfTotalRevenue",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_QualityIncentivePremiumRevenueRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quality incentive premium revenue recognized.",
        "label": "Quality Incentive Premium Revenue Recognized",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "QualityIncentivePremiumRevenueRecognized",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_QualityIncentivePremiumRevenueRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quality Incentive Premium Revenue Recognized [Abstract]",
        "label": "Quality Incentive Premium Revenue Recognized [Abstract]",
        "terseLabel": "Quality incentive premium revenue recognized in current period:"
       }
      }
     },
     "localname": "QualityIncentivePremiumRevenueRecognizedAbstract",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_QualityIncentivePremiumRevenueRecognizedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quality incentive premium revenue recognized.",
        "label": "Quality Incentive Premium Revenue Recognized [Table Text Block]",
        "terseLabel": "Quality Incentive Premium Revenue Recognized"
       }
      }
     },
     "localname": "QualityIncentivePremiumRevenueRecognizedTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Line Items]",
        "terseLabel": "Schedule of Premium Revenue by Health Plan Type [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeLineItems",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_ScheduleOfPremiumRevenueByHealthPlanTypeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of premium revenue by health plan type.",
        "label": "Schedule of Premium Revenue by Health Plan Type [Table]",
        "terseLabel": "Schedule Of Premium Revenue By Health Plan Type [Table]"
       }
      }
     },
     "localname": "ScheduleOfPremiumRevenueByHealthPlanTypeTable",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_SeniorNotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Due 2022 [Member]",
        "label": "Senior Notes Due 2022 [Member]",
        "terseLabel": "5.375% Notes"
       }
      }
     },
     "localname": "SeniorNotesDue2022Member",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value",
        "terseLabel": "Total granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_SwinglineSubFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Swingline Sub Facility",
        "label": "Swingline Sub Facility [Member]",
        "terseLabel": "Swingline sub facility"
       }
      }
     },
     "localname": "SwinglineSubFacilityMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_TermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan [Member]",
        "label": "Term Loan [Member]",
        "verboseLabel": "Term loan facility"
       }
      }
     },
     "localname": "TermLoanMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_TradeNameMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trade Name",
        "label": "Trade Name [Member]",
        "terseLabel": "Trade name"
       }
      }
     },
     "localname": "TradeNameMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_UnrecognizedCompensationForfeitedRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized compensation forfeited rate.",
        "label": "Unrecognized Compensation Forfeited Rate",
        "terseLabel": "Unrecognized compensation forfeiture rate"
       }
      }
     },
     "localname": "UnrecognizedCompensationForfeitedRate",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_WeightedAverageNumberofSharesShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Share Based Compensation",
        "label": "Weighted Average Number of Shares, Share Based Compensation",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesShareBasedCompensation",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moh_YourCareHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Your Care Health Plan Inc",
        "label": "Your Care Health Plan Inc [Member]",
        "terseLabel": "Your care health plan inc"
       }
      }
     },
     "localname": "YourCareHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20200930",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r152",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r152",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r172",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r107",
      "r112",
      "r214",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adoption of new accounting standard"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r107",
      "r112",
      "r214",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r107",
      "r112",
      "r214",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r295",
      "r297",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r476",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r295",
      "r297",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r476",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r178",
      "r278",
      "r280",
      "r424",
      "r475",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r178",
      "r278",
      "r280",
      "r424",
      "r475",
      "r477"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r285",
      "r295",
      "r297",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r476",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r285",
      "r295",
      "r297",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r423",
      "r476",
      "r479"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r179",
      "r180",
      "r278",
      "r281",
      "r478",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r278",
      "r281",
      "r478",
      "r492",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesQualityIncentivePremiumRevenueRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r47",
      "r49",
      "r50",
      "r459",
      "r484",
      "r485"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r50",
      "r51",
      "r104",
      "r105",
      "r106",
      "r350",
      "r480",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r312",
      "r313",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Termination of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllOtherSegmentsMember": {
     "auth_ref": [
      "r147",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.",
        "label": "Other Segments [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "AllOtherSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r206",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r97",
      "r160",
      "r167",
      "r174",
      "r213",
      "r347",
      "r351",
      "r377",
      "r430",
      "r457"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r38",
      "r97",
      "r213",
      "r347",
      "r351",
      "r377"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r196"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r193",
      "r222"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r197",
      "r200",
      "r447"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r197",
      "r199",
      "r446"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r201"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r197",
      "r201",
      "r448"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r197",
      "r198",
      "r445"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), without single maturity date and not allocated over maturity grouping.",
        "label": "Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value",
        "totalLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithoutSingleMaturityDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesofAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r191",
      "r194",
      "r222",
      "r434"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Debt securities, available-for-sale",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r300",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r355",
      "r360"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r294",
      "r296",
      "r329",
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r335",
      "r336",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r334",
      "r337",
      "r340"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r331",
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r23",
      "r87"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r7",
      "r88",
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r81",
      "r87",
      "r92"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r81",
      "r378"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Schedule of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r450"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r266",
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r202",
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities",
        "verboseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r12",
      "r257"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "terseLabel": "Common stock, $0.001 par value, 150 million shares authorized; outstanding: 59 million shares at September\u00a030, 2020, and 62 million shares at December\u00a031, 2019"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r62",
      "r437",
      "r465"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r141",
      "r452"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r268",
      "r269",
      "r279"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "verboseLabel": "Contract rights - member list"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "netLabel": "Convertible debt",
        "terseLabel": "1.125% Convertible Notes, net of unamortized discount"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r286",
      "r293",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r66",
      "r424"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Medical care costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedLabel": "Less: other operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt, Current [Abstract]",
        "terseLabel": "Current portion of long-term debt:"
       }
      }
     },
     "localname": "DebtCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r431",
      "r432",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r387",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Percentage of contractual interest rate on notes"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r32",
      "r99",
      "r258",
      "r261",
      "r262",
      "r263",
      "r386",
      "r387",
      "r389",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r208",
      "r225",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r208",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "Total Number\u00a0of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized investment gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Gross realized investment losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Available-for-Sale Investments in a Continuous Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]",
        "terseLabel": "Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r24",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Deferred issuance cost"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r24",
      "r388"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Deferred debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r318",
      "r319"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r85",
      "r237"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r85",
      "r155"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r41",
      "r42",
      "r374"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Call option derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r40",
      "r43",
      "r358",
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r40",
      "r43",
      "r358",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender).",
        "label": "Derivative Financial Instruments, Assets [Member]",
        "terseLabel": "Call option derivative asset"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Change in fair value of derivatives, net"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r356",
      "r359",
      "r361",
      "r362"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r41",
      "r42",
      "r374"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "verboseLabel": "Conversion option derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r63",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r118",
      "r121",
      "r127",
      "r128",
      "r129",
      "r133",
      "r134",
      "r438",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r63",
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r121",
      "r127",
      "r128",
      "r129",
      "r133",
      "r134",
      "r438",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r135"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeFinancialInstrumentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument embedded in host contract.",
        "label": "Embedded Derivative Financial Instruments [Member]",
        "netLabel": "Conversion option",
        "verboseLabel": "Conversion option derivative liability"
       }
      }
     },
     "localname": "EmbeddedDerivativeFinancialInstrumentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock option expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109",
      "r115",
      "r117",
      "r136",
      "r214",
      "r257",
      "r264",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r363",
      "r364",
      "r365",
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Fair Value of Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r363",
      "r375",
      "r376"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsBalanceSheetGroupingDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r363",
      "r375"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r364",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r363",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r363",
      "r364",
      "r367",
      "r368",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r292",
      "r293",
      "r364",
      "r395"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "(Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r292",
      "r293",
      "r364",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "(Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r364",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "(Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r395",
      "r396",
      "r397"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r369",
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value, recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "negatedLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r390"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r215",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r226",
      "r227",
      "r228",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r235",
      "r236",
      "r425",
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r232",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Intangible assets amortization period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r85",
      "r251",
      "r252"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss (gain) on debt repayment",
        "terseLabel": "Gain (loss) on debt repayment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r229",
      "r230",
      "r429"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r65",
      "r97",
      "r160",
      "r166",
      "r170",
      "r173",
      "r176",
      "r213",
      "r377"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "terseLabel": "Margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r191",
      "r203",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "terseLabel": "Debt securities held to maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r205",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Held-to-maturity, over one year to five years, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r204",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "netLabel": "Held-to-maturity, within one year, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r101",
      "r160",
      "r166",
      "r170",
      "r173",
      "r176"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r98",
      "r116",
      "r117",
      "r158",
      "r320",
      "r327",
      "r328",
      "r468"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r93",
      "r316",
      "r317",
      "r321",
      "r322",
      "r323",
      "r324",
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) in health care insurance liability balances during the period.",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "terseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPremiumsReceivable": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in the premium receivable balance on the balance sheet.",
        "label": "Increase (Decrease) in Premiums Receivable",
        "negatedTerseLabel": "Reduction in premiums"
       }
      }
     },
     "localname": "IncreaseDecreaseInPremiumsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r129"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "terseLabel": "Warrants (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r122",
      "r123",
      "r125",
      "r129"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Investment income and other revenue"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r154",
      "r385",
      "r388",
      "r440"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r212",
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r427",
      "r449",
      "r491"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r27",
      "r97",
      "r168",
      "r213",
      "r348",
      "r351",
      "r352",
      "r377"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r97",
      "r213",
      "r377",
      "r433",
      "r461"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r97",
      "r213",
      "r348",
      "r351",
      "r352",
      "r377"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r363"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r470",
      "r473"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical claims and benefits payable, ending balance",
        "periodStartLabel": "Medical claims and benefits payable, beginning balance",
        "terseLabel": "Medical claims and benefits payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r472"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "terseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Insurance Claims"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r10",
      "r432",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Amount outstanding under letter of credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Term loan facility"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-term Debt and Lease Obligation, Current",
        "totalLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "terseLabel": "Non-current portion of long-term debt:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r32",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r245",
      "r246",
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "verboseLabel": "Summary judgement"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r28"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other operating"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r81",
      "r83",
      "r86"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r52",
      "r55",
      "r61",
      "r86",
      "r97",
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r116",
      "r117",
      "r126",
      "r160",
      "r166",
      "r170",
      "r173",
      "r176",
      "r213",
      "r377",
      "r436",
      "r464"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements Adopted and Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other expenses, net",
        "negatedTotalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other expenses, net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStatesInWhichEntityOperates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of states the entity operates in as of the balance sheet date.",
        "label": "Number of States in which Entity Operates",
        "terseLabel": "Number of states in which entity operates"
       }
      }
     },
     "localname": "NumberOfStatesInWhichEntityOperates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r166",
      "r170",
      "r173",
      "r176"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r354"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r53",
      "r56",
      "r345",
      "r346",
      "r349"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net",
        "totalLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r44",
      "r47",
      "r210"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized investment income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r45",
      "r48"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Less: effect of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Liabilities Disclosure [Abstract]",
        "terseLabel": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r82",
      "r472"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r72",
      "r75",
      "r102"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Common stock purchases",
        "verboseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedTerseLabel": "Cash paid for partial termination of warrants",
        "verboseLabel": "Cash paid for partial termination of 1.125% Warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r73",
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Purchase price of the assets"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Net cash paid in business combinations",
        "terseLabel": "Net cash paid in business combinations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r192"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and capitalized software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at fair value measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r435",
      "r463",
      "r469",
      "r486"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsReceivableAllowanceForDoubtfulAccounts": {
     "auth_ref": [
      "r184",
      "r186",
      "r216",
      "r217",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the estimated valuation allowance to reduce gross premiums receivable to net realizable value.",
        "label": "Premium Receivable, Allowance for Credit Loss",
        "terseLabel": "Premium deficiency reserve"
       }
      }
     },
     "localname": "PremiumsReceivableAllowanceForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r21",
      "r22"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Cash received for partial settlement of call option"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-term Debt",
        "terseLabel": "Proceeds from senior notes offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r76",
      "r100"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from borrowings under term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r77",
      "r80",
      "r102"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r39",
      "r238",
      "r391"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r13",
      "r20",
      "r462",
      "r490"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r93",
      "r185",
      "r188",
      "r189",
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceAccountingPolicy": {
     "auth_ref": [
      "r93",
      "r453",
      "r454",
      "r487",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.",
        "label": "Reinsurance Accounting Policy [Policy Text Block]",
        "terseLabel": "Reinsurance"
       }
      }
     },
     "localname": "ReinsuranceAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Repayment of principal amount of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r79",
      "r100"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Repayments of Lines of Credit",
        "negatedTerseLabel": "Repayment of term loan facility",
        "terseLabel": "Repayment of principal amount outstanding"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReservesReportedToOtherAgenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.",
        "label": "Reserves Reported to Other Agencies [Table Text Block]",
        "terseLabel": "Amounts Due to Government Agencies"
       }
      }
     },
     "localname": "ReservesReportedToOtherAgenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r87",
      "r92",
      "r428",
      "r458"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "verboseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "PSUs",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r264",
      "r315",
      "r460",
      "r483",
      "r485"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109",
      "r115",
      "r117",
      "r214",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r480",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Premium Revenue Recognition and Premiums Receivable"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r60",
      "r97",
      "r151",
      "r152",
      "r165",
      "r171",
      "r172",
      "r178",
      "r179",
      "r182",
      "r213",
      "r377",
      "r441"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue",
        "verboseLabel": "Add: other operating revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Credit facility",
        "verboseLabel": "Term loan facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of Receivables"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Summary of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Available-for-Sale Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r32",
      "r99",
      "r258",
      "r261",
      "r262",
      "r263",
      "r386",
      "r387",
      "r389",
      "r451"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable": {
     "auth_ref": [
      "r283",
      "r284",
      "r300",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule, table or text reflecting equity-based arrangements (such as stock or unit options and stock or unit awards) with individual employees, which are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain equity-based awards at future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares or units issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]",
        "terseLabel": "Schedule of Deferred Compensation Arrangement with Individual, Share-based Payments [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualShareBasedPaymentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Summary of Denominators for the Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Asset and Liabilities Measured on Recurring Basis - Disclosure Only"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Restricted Share Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r7",
      "r92",
      "r428",
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r160",
      "r163",
      "r169",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r160",
      "r163",
      "r169",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Operating Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r300",
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r34",
      "r95",
      "r137",
      "r138",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r147",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r160",
      "r164",
      "r170",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r181",
      "r182",
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtNarrativeDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant\u00a0Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r298",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityShareActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)",
        "terseLabel": "Shares outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r147",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r165",
      "r166",
      "r167",
      "r168",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r182",
      "r231",
      "r239",
      "r240",
      "r241",
      "r475"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r35",
      "r104",
      "r105",
      "r106",
      "r109",
      "r115",
      "r117",
      "r136",
      "r214",
      "r257",
      "r264",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r136",
      "r424"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "negatedTerseLabel": "Common stock used for share-based compensation"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r257",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Number of common stock issued (in shares)",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r11",
      "r12",
      "r264",
      "r299",
      "r308"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r11",
      "r12",
      "r257",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Common stock purchases (in shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r11",
      "r12",
      "r257",
      "r264"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Common stock purchases",
        "terseLabel": "Shares repurchased, value"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r12",
      "r17",
      "r18",
      "r97",
      "r187",
      "r213",
      "r377"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r97",
      "r104",
      "r105",
      "r106",
      "r109",
      "r115",
      "r213",
      "r214",
      "r264",
      "r312",
      "r313",
      "r314",
      "r325",
      "r326",
      "r343",
      "r344",
      "r353",
      "r377",
      "r379",
      "r380",
      "r384",
      "r481",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r264",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior years",
        "verboseLabel": "Prior period claims, favorable development"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsofChangeinMedicalClaimsandBenefitsPayableDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Shares repurchased (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r286",
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "verboseLabel": "GSEs"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFairValueofFinancialInstrumentsonRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsSummaryofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r120",
      "r129"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Denominator for diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedTerseLabel": "Stock purchases (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r118",
      "r129"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]",
        "terseLabel": "Weighted-average number of shares issued:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomeperShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922890-210455"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409961&loc=d3e20517-108367"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6811-158387"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99397103&loc=d3e6816-158387"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r504": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r505": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r506": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r507": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r508": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001179929-20-000139-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001179929-20-000139-xbrl.zip
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M4!4W2F5AP3]\.#T_O?Y%?#PY.KO^*"[.CLX'XO3\>/L!<VQO /3JKDQ[!1<
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MTW&(9:U#_@.2SB/)?SBI6HO\PRQ:C?2X?U[7:=L+T0\@&X\D^N'H:FUPF2H
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M,G%5 <U]3'^6>A;@SH(FZ!PYFYH@).6M@: _8K/2#$8HSN0-"_]5.4PU^ )
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M6QG!HS8D$@SN5[$S]S<%1T:SL:>\Y\F>>VLG3(U^V)Q^/Q"2>0J=,^('QU7
MVV6"$9-ZD8&GI;<HR$YAOF>UQ S%A@<NK4&_#YXUQ@\CTDYM2P<U9QE-1$4U
ML:&^1FI:R2,H&^3BA8L4&A 8F<'+ANA85@/<W'YFJNS\\\\#<8WZ[,-GC(3
M H$JR,'R:^O\M"S MR8#, .%QZI%^ETM=W))L?'&]H<7X<(9>(058V-B^@IT
M6$E%"*U7#9RZBY2>LN;)RQ'BW*DLFN,X;B8:UA&W*WP;QN/J\M:XK5_]!3A
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M&)80>/P8Q8+J.&"UP0GJ553@Z>S8A]L[^QO#GN_8(:5P-=5VVU1[3/21!V8
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MT*TK-X@5VM9G7'1C]'>/==!3&D_,C9KU8_,=. V$ C>CW$$3.;@MT*0CZN<
MFCC6KCZ"MPDL?F!U8]5(48]E4#0(;9&@BD/5N3F@[7/ V]:@TALBGV"M\'(5
MA; OT]+BCD9RMTQ?K59]J,/<Z&.1FP2;.;M*$K!+<>^AN9+">-@L)[1=8R$)
M;K>6DGY!&TCW?G>5:109NUWN79EK[EX!Q%$27AQ1;PR>.SWU9F*P?,7G-?D1
M+SR;!DTKE+O22=KM"80'-221)C+I%)PBO]T@***.]!2'ZHRCL4)8D.E$1][2
MH85Q)HIF^V$![,=,P=0)0&L=54$K_0 L^>F79T\.P( Q<< TGB+?HW( W70!
MLH"2B:H#\PE!_M"\)81P$U$O&45]W;?,:&MJHB\8%%"*N5LY6H JJJN+X4&W
M+P"5@XH(C,:!UTE<Q%4["""7.@<;Q,G-3.4,/(H% =@!$!Y!LLHCYJM RE":
M$LW-/(9EX0P\7^=\[6J9Q;7\JO+-0:MU??-Q6$*6T0.'"O3H:!F<$%Q#RH25
M,NF2LIB W?.[*W*;6L1+=1\R-3:%+W]K8Z^#W&/.N'3=>!;L>-]FI&6T5R_V
M2= ,$%;HL:P'6*VMOPA&O&P>I--<]2%6L(-? \:+3/)!!3G!UZ3DZ^:M::]T
M)?"EPWD <>B3-ON@8G2W6[ZI0[CJQH3^6.ARK#'C&KB51!Q-'92#9>68.V]W
M7^SMR*V#X=;&:#/LQ'WB78U!!I^5=Q3C,H2TO+\R+6_<\T.U4 MQ5RW$0:B%
M")KY 9JYQWF436#JUB307*_+"W-R7_"PPL=3J!Z1/!P;DWE/!G>GIGZ/S,M.
MC3<<GCX-A<!>?E4\T:L RI-)C7C)C:HZ->0@X$] P/_Y\5A\4NE0]:O9C,,=
MF4B+9_?OML7/$L3[V*1I25N\CXN0B3Y R)QMA'VR&9U:9TI\H.$UXR<#<4T]
MY8$/"\1#Q*.7UE4#\<E8JW/XB$/*E[_D9RP7EZGXL"TNYS+[UI@P;O>3'<JL
MB;S*/P8YZID<G9MLBZ#%"M5G !4RGY=-);\+1V4![0.-[$Y-_6Y<%?%CIP:[
M^FSZ(1 J=+S:T/#;W9CC0V4K'$ST:+%^/#KJ82NK=HID(Y<QBM24@,_K=,&I
MU> 231-.#7#9"$NSHBB%(M=YP0V=*0M1Q>&@K5?\;&;*>@31(SXV+N;=F,M#
MLXA'?&B(2+# I .1F @_H7F*23%),S=X7,V;DD -'EG#U;C[ \/JG!-='9N[
M!$7IR8.,GZ8ZS^D,/:Z:D0[$T$@;PPVP35%8H4* U1FV?6,Z4XZ-RQJXQSBJ
M]V-JZY8['B>PI3%X_;]7&9/\H@PLFW%S49OGZ7X">/EOI<QU^]+Z]XTE:50$
M#8RYQ(,&0C"#W-JXF0FQ.+#ZL92]Y$PJSC' A.-J@L>FM 7G9)!I!F_^M02/
M)&9$^. Q]$BQ?/20QU7V7@\=<&3*&YFC,JDPF6N 9Y #Z8"D6QG+E8AB3X:<
M_J5D;@9(XV0[]"G8%1F"&.;DC=<HS=SUY!;:>,C(ZY4$U &/7K'^DPDJ[VWO
M[&[(S8VO,ZU#:+F#\^VW>)]>'/4"J/9V],MIIM,L+ZG-D+@ \?9[#T96CEPJ
M;-TT@!'87[]J(K#3I7D);I]*6RTLJ^=3-BG)XK6*)AG,>#RGK>Z$2_,B>L0Q
M#)J,7G<?OF[CHAQNB[-M<6ZVQ>[N[M;^9@6;JU/W1JIN:YJB(XH)#;!TP&7?
MP]:JJCZ*E$2:5S_X:=P"*@URV"<YI!I$WTB@&W-X9AOMJ^V=_7!ZV\GY]ENT
MKRYQ,^C&X!^\R4I;;%U%P"I;ER;6F1%'L&,5%EA)G*98V,"'3HW^)JW=-<11
M^\2JIYED&Z./&U'56$+Y=CPNV.^K&;%F$2TFK!,2B:(:Q)&0PQSK*1>A#6 G
M<+7B4:1C;LVEHR]<%<D3H9*D,>9>X9_2<H0#8R@$J)#P.P9B8^@>%>O<&Z/4
M32S!.FZL\M%9R0:F;Q3;P"&0C?+,JM$0YQ]L1.[!-\9B%9=K.\N!1]\YRP\B
M;M2^\^2;T =M\ 6*96ZHS;K:'!9GIJ-@4_9+FF,U!(<&>;8;,WA00:7,/58"
MG=9AKJ\I"Q&7Q*E<^4?%=,/$U>FU2R7A1G<**+DNTI;.VRNS*<*=U.UC08Y3
M76)G6I6!\P;B3"GVB+\0F1Q3*C@!F26*"C"KHXJIG.,.N-E*7M[0F^0AZL82
MT!=#8ZVY@7&D)E.M5H*+]:.QHLH'!I:(9XS'T6HZBX7J0B$L OQ&4IP9KM0T
M69QCN'8( RMM<[2YAI63=O6N'*HT[JK2..QPE4;?=6U]N)@[^(6E-=5>:H7E
M,_QX3/TP\QLY980;]P1_1NH $^98N\P "?55M T[B9#6XJ_\/6H)7Y;+ZUA.
M2>X'#"DT<F=]27780=\DB3\$Q,/4*MG @TU,?;=WT$M\<(C #,JBPI$$F3MH
M(#P-Q-B8V,$^T>[;QC\JK(R5;U:?U[77#C/!6% K;&"4EIM_#KTAU#X710P?
MUD-\]T)5!J)@%*ZQZ5>=EJF8X=>#"MJ"+9BQ._V%IRWVPW:[J)(VVP(5[O3\
M8)$>LBHR)%P)W[+4W3TQ28PLZW>)QM(Y%>QICX?'[NS5_X3KMG39V.#BIMTZ
M'2*E^%'5IM)J[RH%=DZ%^U#%8DMPK."FLUZ@O,:C<ZZG]Y88IZ;P@1LJYWK*
M(QG5EJ";!S^D500^8/01'B:1I %9M:08!C-[7/Z95?B3HF!A)*=H-_@GF.I9
M40*,IT>:+Y/^PK__[>7!6T8/4'RI9ZMEQ08.C< O.2-OX%_\$IK#L@V1>-W9
MGYDX:7:,AZ<!X>B6"]QZ"Y3$QA7NH15I*A@4S#J0B:IW//!6$R0&LCI!!-32
MWUI9,A=8&JM5HDWVZV8EW)D:,]K)$&QWVI"!*KCD/O4HKTO\9\K&%K0_CM0]
MHE($Z"HT@2SKM5JQI/@,7?-O]38G_;2@1F8M X&$$?L:PW!5<8,H6=X^&0CC
ME$2FJ*?PH,)%H*0/X&!L0 RC*@S^Z3TJ-D;&K#I'2Q[G^@23=?*5S),\FBC9
MFBS_A)AP)7([Z)F" ^&W+@*)1>+:<EI$**"H!I6#4=CX.F-4N7$I@2.*VMUK
M:(,V%$25H=%46+6<ZZS::O!:O+!I07O2\AP9V&+;*Z?FA5Y!,6)00[GR]@4R
MT]*VMU'2%O1O\+EZYG.E&2O4"[ !>I6$]F1"^8?;._N=&F^(XS\=T2; S"#;
M0;:#;#\IV9XJ6I(J;:1G5=3N^$-DKKE[,F=(M;'_A#[&.(-'QV*DN:>V;DR[
M 1R'KB"X1)SC235+G$_CHYMI691<>8&^5&#T7C&Z O)K]!G9A>G&-!Z:SNQP
M!2FCOSJIT[D+]F$=CX>BIC"X1*\;LY]SXO9X4(4'"+9:UT0!ME_ '\77W0'D
MYE  7=4&AA PII%6P;!LJ_G5E&\B/[HZ%G31N/_)S$VBXG$;!J5"N :G=:8C
M*IE (.W(ZI2 8,!A1Q1(IL4(Q#*GL('S+&6*=9-PQR(\FW#(;$ ]AG;$%Z&S
M.E<%O_ A%(Q5E$@.27E2!K70*[50)SE>6#V3$:=07G$T>DYY^]V8VH-41<(5
M!R@\D;)D^%*(R$VQ[JA M4RL54"F&N2H03N;.9H@QVF9C.E\ '\?EYHC=CK/
M2Q_1G(OE=6E<DD5QRT:DG*40)3 !R68\T(&@_-P!#?I'4!SIUAGF?6Z]2W2B
M**65?_L@M17''#Z^5(3UC*A]K9]=2FQ)YR;NVNLZU%Q??:T2-9U@:/"8NAU@
MN,N:0C4N\\;XO@^Z>0UY38<2QU5A&>4%@6:!=W%E977X .:(TM."3F8IJ:)$
MA.E8YU%B<FJ(0(FYWUP>?-;QT?G6U<71)Q[<\40G,6P#+@B?B\\9<DK%V(N3
MN3@^%>^OK@;DU(G]G1U\V36%C?=>^ DB@_YB[!>86XPQR$OJ1X%#O*SY8B".
M<._ &P^V/MRZ]:(<@CSZ783R+*C(#P^X)9TS@;T%'*!'[H";F+=U4=X42/]+
M;B@@7_V6E5A(CDSJY]F\.O*+>NMW9-D)#RYR?31RC*$6DK',<7.L):<]'A\_
M7NSBT9 \=V[!L7<,9=^H8:X+SFA.S5 C-/*T.MVOWH7UA)%VU)YB:S=-!P N
MFHN-'% !43DC5DG>S@506ZG4ODL*R5H!/%Y]Y)QLV(1 ;>2YQ -%V!2QB=P7
M_VMU;< W_&,GYZ\[?'(>;)%NV2(:84M@&ZI3;MZ#XNK&;)Y9M.TU5I_%FQNA
M]JR3\^VYH,,NG "CE2#M%^[LO1M3>:B3H9M3J9-Z-,;3.+!0Y1:P$6/ N%&4
M66OQR9AAB ;GH$IO\M:.-]'@"M>?1TBK<S)BIJ7-2YD5WJ3FMFE\3-V$'( ?
M@7IC2I_$ZVZ,3>*&ZU$UIZ.YM&!6ZCPJ;AQ!S<=<G@5&2"BUAO]HVFX\>K0W
M2\)LP(X3F<NF&>N\L-Y>+@O.@DG!JDX(DX$\*$H_8. (:IS03))>_ A2O84Q
MFP'G,^75ZZU27Z7?0G(/A%'WR*/94A856G>4>T5I5L)]Y 0K\"30.TG,V%3?
M93)UYFAD+'A;:%;3=S"A3!/2%MQE2H2'0/R.@G(XZ4EX33Y/AP:GE<-3.=<5
MTS4<Q$:,H!L$0\$/(&@*#8JIF59%77&,B6\TYIJPGU&E=_'S*=);<-\(LI5S
M\A.J/A<8)6(,$,P2ES<5)[:6B W[YLK2S2/J%'2;JYH]_YA;8.>+0>9@WW,4
M\E8_M;>@O'IV7S!K7E+R"*%S%'*,/"_S"?_5NLHGP-1. !'/L*-WBX:-9H!,
M2N[(]H6EA?SR?**G/MR'[R@I0*Z^3G'1R-'TZ6Z<XP;"!\Y</L%0&/)19*9S
M)J#C"_>1/"%ZEV\#<R=Q1RYF[R^IX$CJY]<1"105EPQUB_4S=0.24]U^]VNK
MMH2.O\&KL\HE4:;@W%(R<0Y:@/Z8L?M58#$LU3F@)^@^4W'L0'S)S,T6Z*L!
M9>U("R.@IC>@OQ(SY10_:A55D"KSNBXU3K5X% H"LW.JH^Y=PYJD#A7 52FL
MC4N6Q'BK$[1:K(#91E3&X?!LFAJXFLB@%J&F0%;!!D\FX&W,+RPQ]R\WH^(&
MG>6&N^D$EYXQQ+Z,<'FL-AUCN!NK4# 1!B@XI(0\QX+XSJ:\XXG-#>%?-F@(
M>I_4B$S&&%B:I+@\M!;DFX^T@[G!?#+W$[[$]?FD)^# O!;FG%/NLP54*G.:
M/8QU)&G!*WD&"18HPHZEL>.7T^;3F#<->*.M]BV539!+ZU1!4/95B*/.J_(=
M4X%5#6UO=>"-$W%]RR06C W8[A,NB<92G%Y;0E>.B;HQ^GL9/YN5,+B-U"D_
M:@NCG!**S,R='8(ZP2T@EBEP'C&(-W$D&-O 5?,J9Y;**ZBEGG2U&;EOW#0J
M*9T11-)JEZM=)RYRWR4>Q6)FYR)SM9J"5J: M]44;)^Q3GV:X[('!$>C1^*%
MCH;5Z=+<Y6[,Z)E%%0)0>F?GVV]!O\#$:5@ VAEZC.XLL^4A!73B_/2J0H8'
MX3UWBA:KL(0]WO/[3HUV)=YS7%+""3:AY+/?VSE308WT28U<7G5CX ]%ZSCE
M^%PB+K'G,ICA5Z%L_R]?Q =SWS57_W1+5=\[%%Y'1N8YV-AY,XKA@R48U[.Q
MBV?XT,>@$>1(=1PGBN(J%!H";XZP1@>M@$3UADP5+L36B-8T E(",P]<V,D5
M7NI&*)+OLQ+KCZ."<D_H<86/-^<WNH!MU,50%A,-D"S.EZU#K.U@19DS;.I$
M)3'YMO"%X+ L_.J:(C?3_I8T%D8!QS+',JHJBSVR29#O'LGW_RA*04+<!MN-
M&3P_[_,@>)^=G&^_!7M9 G<WIG(_"8?=J-<+X&E>)7Y6*]*-^=Q[%>IXMH>&
M^%+QUF\ED&-4(2#5QK_D4,&7)A=^TM%$JD1\*NUT,A^(8WB6%!_A%@7W7F)L
M(!%'*5@?0.7,#,29SB7<E6'5$)A!A/PGWEFEXR$FQZ*1\]\22R\NS5!G^ >E
MZ0FK\%LZ[(Q+C-!CJN>\.K$#?<15]G?@ 8;\R;OR)W=W0@)EV(?NI0;/Y$TW
M!O[G6M\PJ GA*,H;L5$G$S4KCZCM2LQ -<V.+@-J\C)PY]N8\DX-([EB *2#
MV]_X7 *ZFL^<8Y -ERF!^)!3^(2_Y^6PT8*FD<E> \TTOU0(I$FI(;&9TA_-
MBA'4\-QFZI8/N+IJA-/S/V.3&NQ XY. 7&LKT/5()9<]T$S^&C2S/5 _UQD_
MP;KLDU0CEA)6F_0T6?(IN8^'&\/@/G9POOT6\!K]JAL3>.CVC1!8F"G;1/%J
M@K,:RQWGBE9FC8,HNYG((C>8W\Q8B-9ME&7F/W%68<9?TI\#X6U^?K9']:K1
M7OD!_&& 686$-T??N@\#0F*E/$!7K^T_>P0TKO#FOS']CJ%@^3'^DP=AJQVW
M:EJ<-(I.$:;,(C(?$(&\I('+C!I+BRFO1!'J^=&<OW^ +JC91SVO"@60T?X:
MO[C$2 :<K!+$CVH+X*CNDWE1]<D,NJ)7NB+"HO]8/)$:BJ73 $WB9@GLN^3P
MI(8?Q,KI&G\2K8P+C^"X_-&!V?O$[ :SN;LQ]H<P=6(X"[U*>FWA6R+F8Z15
M%M&G(Y\L_6L9CZLV[AZ?7-Y(RN!F>'+-9Z59G4<+,J&^(N2_<IL(N)F8><LX
MX?7Y:R-*QR#FHR;LSZ#.Q6WDOU<@N]:,N!2"TO+Y-#(GSU/AH6ODT7XI!1=%
M5GLL1%?/W4 ]:-Y-FY2_65?=O*;NB(QJ;W*"3AEI'"2XT05W=J9.651;3O5"
ML ^7'LF3((I=PCV0Y;?2I?Y7:U&IBT%CTZZW><0!]:4")1:DSI2_MP7"[+^C
M%6(070_]+,7U1%L' XF15YUN;@OQP7"#!SDS#C,"KHU-.2P&R\?JN(FE@&%>
M;H"2]6)2M8#*E:*%15U(OV.1BO0V3-W8@K$7:FAK:G6+)_=JW/@&KP-[HTJA
M"WU<^J0Q?;-:<80U-K!;GE"4J!N3>:A;@:E,(!LF<DCNBG(X6%H8\QF;V1*R
M.^I!CH=Y9"@*.TPDXQ6!IDOBIMP,%>G-B-%6J+'S@)0 :)[20ZAY)*7Q&$UU
M[*(KZRZYTA'8A^$RL;&[V:K&&SC9(W7EH+%)TV,?[RHAO9K+8FH'MV+9VURP
M:CA#B%,,<X3SB-N[2R&_D",!8[V9&(R$,N(4T<./'N:GTZG45MV//K?N8Q<H
MD?/[4(T^^O8WC5071!5AG&9![2X:'J-OA]/41,[5@SGC<+A73@,PG<L*TRDK
M.*Y^Y&J/;G#_2E%>(0]N&XR[,?IO9<)V8Y0/I;$KK.[&X+]%8M1L*&Y5[(&:
MQ[@H =7FUIAQ4JS8"08/U*P#I^#:Y8<HB=I&9<H]Q1?:2K#:H^)%;$V*1D91
M6 WVB8^6M*NTQ(D#G,-!4P(A :B##HIUSE$2A[:5F3NN12U!VJHZ]%&KZ1#,
MFD[*Z;?,FF.X%G&@>N@4(LH";>7.O:GGT@ FH ODW"S[%7ZNOJP,>2=YM%GD
MSHIH5/E6_6/0YB@SMU-B4-!OPMR56!9D S5BBQ."Y(+'$M*D>/_YH]N4=W?$
M^?8OV\?;E_!_'E/R]>'6[O;NKHA+6T'MR1RM,=B\Q<:+33$'ARUOE./74\%]
MV^&,R>9$<+<'/4513!P@N(N(;T?#WSC:;!HEZ"Q;'15M- 1J:;AH=# D'9.O
M@J2K&@7RKRT\49=Y2RU!WK7>2G!]7'(#LXQ-NFC=J&R,G<2<152]A,/AU*6&
M\GL;N*8+E\(KCS>]0^Q3M%)TBD?@1>(Z9:X^_59K'#HUSWT9; 1ZRZ2,8> 9
M<! R<OY@1LYNAS-R^KY/;;S?]%J(U8COF^1.C4 8.!&^:H[%$9V<X #8XI "
ML240>X<B,'#I&#O%U!<V:M9K+$ ^0&%#Q2F@C9--=ZN3(R>FS4"0%WA$>0 W
MS]^** P6FY6I49EC:@M]W$+07MMJ866Q-Y +_%01M'K6\*2(J4$@B^S],4 W
M%DE4_FA3I[M D]<B-<A'K70QFOZKT3"S&;<*7-$<#2F8*0))R07))V'](DAX
MC36<K%;UL]:N5:F[*L#/R\DD&5KS1;6-0WPZ=W6J-6N5Y.D0*\'C8V!6T&ID
M=-)Q7$;5DZX)6//0 '4L-IGB8[=K,):O)P:6"/;!]R:!.<-6_1^[.P/@\Q;4
MP<+>VQQ@W<C(,6D5U&WP"6Y9]96PSZ35VA%$#BT"#CW%L.R2/;JY+=SV\F^M
M#=6!PLM;+9S<MD;F /_<1(*/W!2-S>_13,ZU8WK7G%:3B]A<8%:MIA(;Q6C3
M9&[4/9DH#KQP9MSLDZ4P^]4=!XTQC<N3]8I\F?G6!Q3K)2MYL$\K25X'"_U&
M?6#DFLWEC876FXVPL%]SQ[@K$K2\5?/U%JO#T&(D9ILYFUS)1\/+>?-SIL1'
MH"(NZU(>929M&ETCG6/>'$J@(+AN\5Y%BD!A7^P.Q-[.[FLW6A@L3;2M$FIY
ML[<TK],]**C>DMGP[N<0L9/L&(T*+ZY@<$1?ZH_UW74*W[=TB"<[Q_1OT>:3
M3A+"B*Q)@@2IUKMY",YLR%XRZLT&URV<5@Q6="VL\_T:7<1\R[%6"*X^=JF)
MV^: Q0,2YFO>N^I=9K$)9KMO7!OGY+9@5XO44IV\]BUU1IW=EK;&PZ@J=YG%
M+Q9[HC6W&P+/ N,<[=T!:&1,0Z?0H-M<FGC;LAG06]*$LY&T26=#S>Y_[ GH
MO+7O+0N0WE:1U=Q;DZ?GL3=00\:,MER;/Y%/E"I:'4+I4"K'L(.E,R3*584O
MZFYT[NRI8A$O1NWNCOZ<B;P:C"/##>@U-".:MYKWMG]M]N'S8#A56U30O7I&
MMGMK/V\O>V->-7F6T<=9(''5:M'WE:331_B6F@T_3$+IT=*=5X$5E'"XV744
M?.=6X I7H(':0\T!J<]B2T/CRV<FF3'+M#=_=(D-F9/ 3-\:5D@0Z%-<"'9O
MWV$#W]6-63PD*K2[1QB<.[M";J?; W$"VR"8&#2;JKOF,6@89&P$0P[\V2O^
MC E1CW( ^A>S'"SMPYTVA&X*KS'QH'WB!T9^0GLZ>S+8))GF7W>J;KICBZ\@
MZ#BX)G6TJT*8_D LA.[[*P+BDGOY=F,N?TH4:MN+VRT1K[?2=&FF;68?+;BU
M^'F!0K60N*XPEMJZ*->JN?4SV5X<NJI;,I795&K*_A*4TA-)[*\";XA*/C.0
MN<\U6-P_EW6AQNN^F4(<1+)/(OGQ_)=NC/R9%1"]VMX]V%"A@*B#\^VW0,/F
MDI8I]H]'^"+89.M^2]V8T<,ZF>;EB%.D"]_1"IN W3HW;U7"4#R9<E_RDOJ*
MC4IJ5$JPB7R) ^?+VPH$-<O[SQ^K4X7JU-O'0[^59-;>:;V=H-,A!LQI:[5\
MUHSQCMC0GHYA$A7?/M)8=I]."?J^P..M*9C;%#%V+F%H2O4'CW#W.GR$&Y1K
MIY3KI^//E]T8^D.T*'L5&O/D,!LHYMZUGSD-&8PH;A;)@ L^\M^J*\0F C%K
M,U"/P1[H$\OB)C72&/,FI[(;LWAH^K_O D%M/52<4RDM@4+*N70MFRO'NGG6
MU_*&7<\D/ER[O=_RD3 ?5<_@6E/FS=,P8O\&.2M?G?:YYE'?[1ZNO.%'W$6S
MD<:.=L5'D_/YR96/;@UYPD,PX="(:9W]KQP HE)6#OU_(QCQ[BL\Y=W9&]#)
M5\IGP#3W OU['!7^RYB5G+ ;<XRBF. QE!]NHBB[MD$*?M4G:NFR]XK/DNDY
MYV;&)\R'_&4(!O1*5Q! F#@A$&O,H3BA?!'B5&]I=V-F#\-$;HB>JN:FZKG5
MI]!W2EX+1JTM;C(K,3'&I56$#;)'3 ^.,N<)B']A:DDW)O' -@$NXEPE1MW:
MV_P1/37D _Y-RKP9!0:V[\:\'UJTDY=#TDJPZW9C G</MTK\S[FS')HT2RKW
M>).NB@ :%]].;6G%&T ;-:!)[HCM(V2C&,I<4Q0#_J%B'9>2&?_QT+]8D"97
MDN/JRZLPRO*#H"JW\0*&JDOZ(5)ZYE]H@;N#0=%)\5RM6RD(^4'JI.Q59[,G
M==#PNE/C#:<,3T"P3;8%RIGSP G;HAOSN'O43K8[-=15EL*JI!NJPM!HN%F7
M&SSPO0FIQRM_5QE^[?:)5/E'2;@8WP._9F(21E>A='^3)+2ATR,X>=EU-C8V
M]TAH]*?!0QFZL2HI@&&,51M AMJ[ZISNL,H-@O-0!Q[VH.J4BO@W\-1$<_/0
ME.((^ ?%+/$O>#PBPU*:K8NL^)(4U]H8CW=<CBL?_&#"_8;+20ZD6-7',B2Z
M]DKW7IQV8^#/S)!ZN;VWTZGQ!D.J_\),4-[=&/I#SV2,I<+Q&ZN+&K$.=\I?
M';@ %IY$5BF$<M?3"I.]@DNMRF,1-JTJ6N1"N*HZ='F9'39:Y[@'&3V<;.'J
MSV!SQ3TQ<VBNN+DF88?KDU!TSZ'XAE!@X*KW%.\9Y#0E>34,BR6I7!=6R728
MA#J9?K%B"_*F&Y-X:/_+.B]QZ5$BS]'7:5IPYF[8F0/7,)%1A1_0\M+JAP9^
M[AL_=V/H]^-B/K)!7B;^P\?_@D'\*^K'\UYAH,$SZ$>"W0C\V"=^/#X5[Z]Z
MVMOZPF$L'*/'<)K%P$)@Y;_'?KQ7'E, ^#2+X7=P1?*\] E-J^Z]=5L.>A8<
M&)U0VE0J"0#5JIG.EV5/!=;O$^NCW]E7DV+*@Q]XO"2,&R,.QD33W[Y4 ?]D
M+_EWCS$,]H-K9D8?,16*X4;P/DQTQ%-^AA'VT! N%](,,6G* 0,OY 37OY%0
M+/73]5T=14)5PIU5"2]"54)0:P]0:W@&U$#'Z:&60Z3V1(-NHSRA:_G5%TIY
M8)@Y./B+B=^44037X$:--5C<B7:(>'^:2Q9,6=000=P\8U[=AH\>*O2NJ)HK
M+P@V38R-@<U>8A 24T)1MTXM'L?Y#'0*.. X1L;CFLD8\^\*Y:N]\T8=&CP8
M1JOS"3Y^Y%.N*^/"*=;A?%7VU=71Q0"1VQ%B=>=MJPNF!VK#U#^F'K6!S&)8
MPSB_=8!LL77@U#?7:561?QOF[5:R& &[3BD#+^)UJ>$(8<7N@PB_%+5P$>5N
M"<C=1N2H44TZDM9J.AZ]@?<C2!HZTGA^BOC5.LKKE]'WX&Q+;5-\;F/KX\<]
M@"@PE+@UE.:]0+#,G1\1P3 =2B$B(IW/,_9KEKO(>)DUDI*;/S4ZL13S*3<]
MR0UA1E506DS<Q?<U8?1&=!B<YNTU8JE2"79K=@?C]>]WB\:_=[V5([)[9.3@
MZ%H,3?F0'IJ*VL\4*B7-0N+3X!H"D(KAF]]-1B!9PU(G+0"%"DF8S:;*4!I0
MZZG*',,/[2L]5#&:7LZ.&@%+SA&8L=;/\$GFKIZB7EXL!IU6R,R%+G#JF<D4
MM_0!6M^'QM0T"*%$?2_8BNA>$U0YG3X?HF1JXN2CJ)S"$*L\ 4DHZ9QB$*FD
MW75K8]3B?69'AT#80HGS:&W,4B1[<5W#2L#POI(5GCI>OM@5?RQMZ(7P&]K&
M6PSUZNSD9MU*"QCS7I(]N;=D^Q1K0I%LPU<N-O/8T*VG<H%"#51?H<1A$\)Y
M+>&^%51.Z;N,?\MJO*(ZTKL>I4^W];AR,) ZU81PTWQFC*W"C;XA$R/-TH$]
MGK#5 K;Q:VOPB_N+0R#'B[7RR2BJN$6%5@DT0?0NY>4FQG:L&("3G7"XBK$@
MW8,K8L!35MU$+_"B48F 8_WJ :L9XU9>?=7*9<DB?W%TXEY+55QWP)56'M>\
M"OXN3\V!YR0+ N8/.4Q/TB<B,'I*Q%S$2>QN[X(R[M2X5S;9H"TB;5$_(KA9
M?TA=3&"\XPF#"81(4+]<IMQDW1C[ VM]ZMT?+0W.223KL0'//6CC>0^J)$'?
MEG=.YB4H'#0ZZ]Q&0JL:@ZW\NWMF84MJ/9B3M>D3-IRI0BBE@>U[Q_:PVYQB
ML\:4%K0;,WEH\I&N)U"U>7,6(S*<'CGCH]'<0S*P.@4!7(,-7[!]ZVDR(9/;
MN53IT&<KL4_EVD36]U!3VB:V6P2".B3+@L*E;DQS3BZ6W+( +.](YXCDDA@,
MQMX>('KW_""@R1=^U.)%#JMW6+DU2V@#5O>8PK,8K07#PE7]T1A,P;8][F@\
M9<+';3 (%GC-9,1.6G5<<B9O6O#6%]63^$RP]02J2QM141J\Y^/IQ=&1&W=T
MU[@K<EJJ _.%<:B!D"H3F8S8;A(G&69L*P?LC-T:XF\0Q$-+^L,A/A4+VJQ/
MVLRJ+0^'>RV_8K*^-KWHD7=;G^'X&4!5>!Q'DO^A&AG7_:2)_%L%3!"XQ;D?
M^)@K<';B.%&.%HUG!>S@?G/ZJH+8;DSHH>?XJ_"!6\T!JV@"3=X%6(C;;44&
M%]6L<(&YAVCEH;7VB94PP_06%ACTO_%XOPI,+2N?;B&H!IC49R& 9J*'W &\
M=RG[3Z8"YV![9Q<LQDX-^<%%."'MX<ZTAY<A[2'HY/OJ9 *![<;H'VKP3R?S
M7$=:9@,Q<0!P _A2@I\:S>L@F^MK%^$!*SCK(Y7GU'1GT&K65I_ UX$Z:N/L
M&JWCN2_:(\KZ_JYYE3? 807?5[3N!%2?'C7[R3;'XZTN+.FBM*_Z"SQ5C*SF
M#HBQ+<=Y8Q 4C?$>>TYIEC<*46*8,MPH;3'=S)]1W3J"R1S&"./V4<NL5@5!
M<'1Z*-,]AIMK-M);7OU!/.HF&KBSS]PIKNM*UFY,Z9EY! '<J)OS?1IB[N#+
MNC&+A]8+^%DT<F@;)A\#V"0N%G;+J)IZ$CCK*O!OG_C7YX]=6+#&NS&'9[8O
M[6WO[/<DSRF(=@]%V^._=F,6ST^X^Y+$&(2[C\+=C>%_ Z"R&X-\*(V7U@UT
M8RH/-?"73D68FXQ3NSR,Y4+74?B%LM*,Y:RU$7^!.KA*EXO]P;?/9@]JI$<L
M?JF:_'"&Y2C!3OAK "-W#C>&P4[HX'Q[+N"(YT#9JT]E.\,3D<JU6;ZQ^<1=
M[H@Q_!5SMSCY5W*J%1]Z-M M$%@YH1JJ)@)&?;8:FZBDG*X*)V;0Z'3G,"\P
ML\O]=@<<)0;8X->"DL,X-Y-'R]LQ)Z/1?NN*RS*9MBK*@@#V2P Q^0\+\#\0
MAX7]]:_97W=?]3X=+(AWE\7[DZ^;/XI![X.;=$*U\-V8US,3]U=H3@=Q[^)\
M>R[N!-G0C<$_U&I6J::,P('(ISI)X!^E,#=V@#@47P9"Y9&<\J=H0K9PK'.P
ML^V88$)^50ZI?5JF4_IY:@A)@KJ9%'.^P_\&MTY-CLF'J1[[LF..&BD'T/%1
M_BYMC)USO>IT17LX6.YN$H2C?\(1NU9]W9C$,]OX=G? T.W4@,.V]X0DNY?8
M_T&T@V@'T;Y3M*G>-,AVD.T@VT]*MIO-([LQAP<XK4LZFN+93Z.1*57(),DW
M6VQZN*M&?TS$4"R3@J$W'=(A-KVO.F]B'7ZN$-F?2_)E&WR3NW8NM%(-TM$K
MZ7!%@^US.H^-WXU)_<%]$ 0&8:WBONV#%+<-Z9)=G._3D/5K!/WE+N18F8>;
M8Y#TOPB?8V]#]US2 S[':JIMB=W]@,\1]/,]]3.#XH,>\WG$W9C(0\[8', W
MXJ5G\Q;ZA09?@Y#\JZ3I&C:^AL6L8$GQ]D\JUA'!WB>(^]$"[72/3B4"E&?T
MW#84+P.^JY$B:/>J0+-]$2)?1IL.\C\#&:3\M@H>C0!%K6K^)F.00I<<-ZLQ
M/;QGYO#(_=3@AT3[3A#M[I15IX4*%AOF%PRJ?@IL7Z$TB261CS?V-\5<2>MQ
M_2*3 KM' 0SS*; I-YX3QS+G'C2GV0Q8E]39$>%(=F-B?S[>W:EYK%@.T2B+
MW-L8]\/Z#^";3T3@>V52!E'ODJ,?)+V#DC[3\/#^69]/YM :)/M@(PZ2W<'Y
M]ENR=?Y%'!MK-6)[4C)I-R;R4._RB.5D2"&.HE5:SPBD5?K'BY=[/GP"ER!
M/(+!'V/\!1Z"B=I?J&6?3.48ABS'8.3D!5W_4T;=FJX*ZEV#)?JZR+'I9E):
MPL4?E=C;;BKGP@)A@5:.L%/N<4\ 7BEUK'?]39:,(,A/G^3'E 5\BPT@3(:P
MOMQ;LAN3>69[)-4=JK!'=G"^O9;QJZ.+;@S\H7MBW8]<UJU.J%%Z#/M5[M'
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M<1U#E1$\$"Y3F/'&\!F2Y+M*D-;X;'Z&&Z/4:0L8&N9;CXYBV5^Q3D+%3E4
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M!2%'UG(E:"6>"C1:,;:\[XVCS27,W-O,21^K_JK[?Y#)S93?;8H:,#1?@,;
M7VZO'JJNQAY I5@@$ZX7Q>)Y$VNVJGT(81/2)7)F-+<!PSX=IAP6P/>H^[ =
MV)+681N]=ES>562\9#)V8QH/\%>>WQ'LUV^=P8Z-B9%G!_ 7];4QP,ZV";OI
MS:LZG2F_%7E<:D ]1VJO/DC";81P=KT55/6MV1H2Y6I[==YH*P.F;&GYB-6
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MCP<<\32P'/BE$7-B451U-?X@Y.F%"SNG+GUX_%-JF>-Y'V5.K7 <124^#+\
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M1?_!Q4K8^:;VL658>]]S-00D ,O^&GP6CJ]]=">Y)X1T'L7G[R@=,\*0P9+
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M6>9ZD[%OYP!;O$O?##>4P#VTU0,F=TI;ZW-)@;AL5.-^A63;\$S_4TP@"(I
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M)8 6=G3"77&<'+-WQ=!HF#=$N-#:V 8V VD';; KY=:+XMCA)VQB>QS/,C
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M/MT*9RT;N$6HCM#6WENV#X78S.JR43HXX89;%)O4F?!,F8#''!M VA;A7+4
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MX %=H&#.%)&F+*',D2,-U!469@#F_N)+>WMWP N'LX0$>:Q<*PD%6F;<*J6
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M#IL-&A)G#U\J^5:2R,J <P;?S[9R*1$VUC;>*9D"(_&B ):CF];P),_?PES
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MM0SU/G'RL,3)BWWBY+LMKR7LGA@$U"QA1?5V;,+"02A9AI&)%L,U1<$5C3F
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MHB8Y;5@1 B-:!D*^B6^[B,HJ3TUR0-V:!@.I=060@XQN@.FWT4I_J[\MK<%
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M/EREK:)PYTH=N@MF48JHGD:2'W=+(07+7#3VBD/".[B8W?5W9UD7DZM]+-,
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M@!N(>X6.YA9*HSTE)U)=YUE08INF:Z?!W<YM;S<Y*QI?.7Z657C+2L.B-F@
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MLK<PPLO/;S^>P,NOSNFED_\]/OU\>?+KQ/OG9UC$=R>R.^_A@_!]&2F,$,=
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M-6Z#. DLX@V%X+ 270ZP XUX#A[$>1XM@YR^' 8+D#64ZJ-D$5::;^*Z0;P
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MJ@>2LS:!R9F3-S:Z;.TFE!!,A:"5\G$&B^/77E2_)%O37[K?A9@)3E]V-H;
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MUY2I!6& 1V%4)D(0)"EQ*K&A"L39<@IU4.):$()%D)4DA'=H!.ER! ;"VK*
MB;!$"2P+?(Y'T^N91ZBSK!!KS%8XG[TB Q.D0XLJ2LZ)37J]3!TL9>4:1<"D
M<I8N@62 T:%.8)(PU@41/:M#8ON[F9W4+\\(9?GBS;R6CGN#B_O-/3P"K;9
M&BS10XP>)3$Z*:(BJH!<+:L5)IT%K+&L&!M0*$+1$D60PCGGB>Y+)@P*9U0=
M:A7N IZY(BCS(BNYE#Y[S"'*LA&XM#J;2$X@L.PR(%O*RNP)RMS("K(L@O=!
M,072*&NB)6()&)@S+BV"77F]O=,?E5^?C19UJQV+,RX&(%B(L!G(WE@.:#VR
MF,#*Z.J@SK6B"767%RVU1!%E$BH2K70VY,2X0BX@8L1E5<)27CZW+Z'L/P4
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M$B(;;T2T":2^)VC5Q1("1LV,,0FS(P.H*!CRCEEE6)E?DNM@";\7O*Y1;WS
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M-M3OUH^\0OX*\*WVX/VUQV*GLWE<FG)U[J@-=RD6D]PO+2OFG2.^&0+87+;
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MGR9+3%!@@U?2",0L-0,I2L5I)AL31-F8G:4:I.9KZ8>6TOISH\Z8 T_(K;,
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ME1O6!+1)UF6I04K Y!"DYS88GB%?N'C-1#VE84%'B,:&G8E)$'YO&0KKT=M
M$H".K$(T!ER2H(/%<\-.$E#56Q2F7$5P]^+PI2^Y+A#?\2773_T%7Q)$($?!
MA<@A <O*2R42A0L.N8T\U&#%JJ<=' PV\UOL]TE_-OM;[?V#'RD%.;^P+F,
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MFS)2B1?FU=1 ,^<)S*)NMP1S@IJI,D+$H&TI'Y%%(6VRWI@8DX\NU*EP8)[
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M0I4:X]18(W5CBI./%Z[I^.-8ANGHC@<1S\X2]E/W)B5_.6K/^CB!5TL5_^G
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MH7/QO1C'3F]P4@8L5GWO9-AH8O]]&C:VVH/W2XM70[A!+$W>E$T>+$W>'.E
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MVC!*Q_Z!RZZ=E8Y#AF,.SI7,_H$+"H(V/M$8<N F,TIG#\TK2EN&TD6&YA7
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M@!Z4]E0G%R@)1:Q<\Z;T4FO7H15 ^X)ESBO:9T'[A ,2,')K'8B4\@\A0W9
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M"&M9:8S P&>7+OF8 S1+&]S)KF6E*X#PN47O%>&-(7PBV>]L1G(I%4\NY&#
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MS;K8,/KP9?BX&\)17.0$_VZGU\G7.BKZ\?\<!6+?O>[A:>@.8_CG-(OP\NJ
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MLZ1AL.'GPGQ?5SX'!P8&;SN_')IN_]<.0((/=MP9AA-SAO&LSG/P9-PO7[G
M2OH=%F"$:Q%&^_W7WS$B..F.CG 1]N,K6)06*:^!E+,C=/#W#MA(2G(N!:$
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M?>HK9OLM-=4><^F*AV .^?[!Q^^[!Y^RW8,_^=[IYYRC-<8%<:+@1)@L(RH
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M296@XP:CTOA"]YROSXK +=.J@J#U8/@U[30=#,R@M3$=0+NHJUO4_\)JHMJ
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M]1)<5%GS+C!EN4-].0Y<_IH+ .XM#4;9(@>Y-+[ WIQ,>9EGT:JHV,9VYV(
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M4:]RM['-U1IIDI;K/0ZNUTKMBJ5VQO^XQ"9_>,C,IZ(X7A#-O2?"R:)0BHG
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MR6-0\?]:17!P0--LGPO'E)Q,UQE3F0QRU3$-I^[?)>;WN=#2U!Q.U, @[)T
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MW9:+B@'42@H/,]0F3M-<F^7^/8FM-,.>QJ8:=@=#W$NC9[R9WB+9H8 ^FLI
M<A^PKF@NB7*&$\.D![IN32X5;*;SQZ<[C6W4I#C3G70RA#4< L<N]Q2F89?&
M^"NXNF&+T^2^U=>UQ:_)H&Y^DK\EW7>\#W=/@3X!<%DJI",N^)P([(UBK04.
M%;SC>9X9>E%-[3LCW6N[95K2C;LFVSO\K%1N,AT+4(5!8?UU2:P2@7B1&:TS
MK;W,-[:7Y'.ND'2O[39I23=N$[[[Y^?<JX);(4CN"E!RS"FLG&2)YTP%;S2E
MPF(CM(LM^CIB6./+.>56I=IT!]-33(N9*,NC6)=%9A:C6$;#'@LT.!F$#<Q8
M73 I0@RY$R:JA_62/<*\L9<["SEAS<@I9GAE_S,-5#4(RFJRJ%)&9;,;58JZ
MX%'N,*R"O3\E154,!9X[-E]#OXQT)6/05QG">**HG\)*D^DYWN:TKT'"UL/F
M+"^O9_'GQ&"-)HQDP&B[WQHE%U>25;8\JGN9;"]@@=;!*LZ88843N7*Z0$]3
M'C)ILBC01WF?Y1E@WYO^69U#VPS2;D[WQ-#T#Z<'3N>/65ZH<$$Q6JSS.J=S
M:1 AI]%QR;F@#B:J<# .087(8#[<):=M6..PS4S3OIMF8>['G6DJ13IC@WO6
M]*JJ):\-UI>8ZE3"GIU2_9K<Y%9&;7-*E%"1P'H$8E3TA!9%$:0'319 '9W/
MX_D?1(OK+;>/B@7KJ*7*"0W*T5-=>&4C_$P=#^URW^URG^WM?!8A4\)K1IQD
MCH@\4T1' 41*9S'/%8^Y=AO;Y_T$_Y-.S%3GC!JPT*A_DDYX]U,* B!!HVX+
M,*G$D3$CH3ID4&9#@(K=ZGR8 "&[\)+#.FL$4ZOZTSRK:4Y^JFZS^VY6]2.Y
M)WP8N6'7EGE9>X-QZ-#-3I4#OC\\-/V*<*>O_Q-K+>#KO2MSN],G*4F&_G8G
M?.::_.KC*!DSK^MS3%,==DY[/71"T^6J;+-*NZ_92EV&X+^5IN[6FOH\$1DU
MS\"DLV#EO$S/=RW+&SG'W6=5]N:QJ0B"^UPJ+7T&NIH:T$ Z2,H+;WSNEV/3
M#(4JIC$E&I5U5V'/^VF>8 K&'\!3_]D;N*_/#()V#]S9[L&?GZT%$.)1D2R8
M '9<U$3+D(/>R54>#,P_J!Q85V=.,"UF.%GGK(&#=)JQUQN<)F*>7 ^PFV$7
MQ&XH\[\OW]R-1-(+CSMMXO=[$U_S_SIMO +=N>(OS5-2YRW:VV20EB\X37)*
M13)A@GOF9!1>U#_\5O=VZ?;3A*4O+9;#A'O.\GNVLC+'IRH*7]V_^G@K?;10
MVK/\3+ MSNB%'V=;%W_VL]M2M@4&_(UN^_//<G[Q0]O!KN%@\^QJ [JDI<$#
M=M-65ZJFO+R,[O1-]%7>Q*4SE/?Y+N?,_K+YPM$PA,YN>8S_]?EC_%?H$GYI
M.YA'-2%[>,;PBO/QQ#=RHPC]-2H\K^.B(@U=U6M>I5_]HY\NJE<A^$]I1MH-
M=)L-5"'EPE$!7M+D>]E<5[A/^\A;/_**&O'BSG'T,7&%7[ "71DM'?UZ'69P
MU8YA5Z8,#<.TN@7!ZU-[D'2/+E"9_O@%T:LR^:_8G[PJV&R^F6ZOMO<O,/!)
MQY49CY7QO1!_ND'/M2?1H&;9>SWN%C-YB"SS+%HGK. ZUT'KC'DM<NVX-?*R
M0H7SO6;*';93;[ +O(M/*)FV[#WSI0?/_OACC_W[R]^_OS[[^]7[K[M?/N:[
M?[WO?3IX_?T3W&_ORV'V]ZN]KXN]9_;_VONZ=[#+/QWO??UT\.^O>[__>;9W
M\/7[W[__YVCWX,V7_;]VV3[>C[V/>R^KOC,?,DSXU]XJ+XD-&2,B*$6,<Y$4
M7(G@"VNLDAO;Q?F$_T??VK1%G<>/.GG.\[Q@SE A.-.F8,86WC'/J/%"(>I0
M7:$._-"BSH.BSH\IZN3&RYSJ@M!H+!$>2Z;J(I+,">J=#XHK#,/*%G5:U%D[
MU+E1K+1%G8="'3I%'2\X%E$2Q#+.B;"%)BKR0'+#@[$V*S)F-[:IOJAH>@L[
M#RVESQEV@E!*69D;:JPH'))V9A1CL(\+SPM>D1W:DIVU@!T^A1T95%$ +R4,
MB2A@4"0V#XQ0ADEH&>,R!( =?E&!^ =L4;_@W*7L)][=:W<UOLX]&F[+)=U*
M5_&$=I2/?I2MA[94*G]>)^$*J_[-^6A?+'?2KH*%M/=8PWM<6VH6A+RI9HJR
M;M7:\<8R^_VB8,05FV8_.8Z\[+T>-T=>:1AB)V68[L<&";YJGG-+EJ]#EL\:
M\0B7:R:=%J2P7A$A@B ZPD\%]4%H$8,4?.E9Z&MRY9^ V%V9Z)>0HQ9^'C_\
MK#(>T<+/O<'/CX:+4#-A<D9\+@S #PW$T*A)47!81.$M=W9C6YRO:]7"3PL_
M#PT_*PU,M/!S;_#3B%#0H&S!,U(H;"5);4&,C061CGN)K4"UQM9^ZJ*B:"W^
M/+2X/F?\66F$HL6?>\.?6:C"@96E(\T0>C@1K) $2*PFW%NI;<%RJS%4D=TZ
M'6R%^+,BK^]C\%_-G6.]\.P"N]Z[+P73QP<^=^+ZN2KBO!D.CJ?5.%OXN0;\
M[#>34440M)",P@X2CHA"&V*"LX0I%J,QF>,*Z<\33$9][L)[%XZ35GCO07AG
MKA,L?N*9T41G62 B+SQ1DBE2&,<LU39GF.;P!'.KGKGLWHG7H97=>Y#=F=_!
MRDS(Z&&%8,6(<"XG1FA%G,6Z18[36%@LQMX*[Q,3WCLQV5OAO0?A;>079EI&
MR3@))@EOD1$3I8 -%3.16=@35F]L\W72O*O,.:%TBZVET7XP&)O>=3TB5RX3
M\)1\H%=_Z<>-MBOU4;3>T+L U@_-L[&42499)))FC@@M,RP6ZD@&=#<WRIJ
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MF?7/,9-$L*S !,LZ(=OZ@*]K"R ]@_&']??KU>X@VB&L\)D'G5&VY[5' 1D
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MI%-@H=-UV@KDXQ/(GVQ WPKDL@62S&E()@DW%CEL& @D ]%T@2)E)_GVR8%
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MW3=YHQ<F:]9RB&MQB,UY/Z!/T46? A+16+ 7O$06>%_N!!HC$Y$PNKP0@38
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MY!W3B!,N$/!-D'ZLN'8T\A!C[D+;RGPK\_>1&]3*_))D?LZO /9&##%HE+
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MJQP)P;!U/H@@LS]/W9C^MAC68MA]O^X*>@I;#/LY#)OS%5K*<1#>(ZRC13P
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M%[>_+]C6P;Z*,0+]3XA)+A$/ B,-8HNDPSQJJS$LV+,7Z@?[XD[K-DZ/I>K
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M";'TQ6A/OL\:WS:*E)B)G&%N@[$R<A6ITL;3X/ E\:PMP-PZP.S,EQ>0&N-
MLW=/I%Q\'2B\UE$C&Y0@6C,O:5C4&*#URC]L":562\V!#S#K> C.YDAE1H,
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M14JNU;"/4D8#&&?:&.M"L%R9:(R@PBM&;- A!M5JV%64W)GE'0QS(46/4O+
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M@ZX_V.NV0&+U_]_:A_\=@FFT.O[H"ZEG]TS$R69>K;+S:O5H<QKL**6A\J?
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MG%26X6 %V *P['?NC%@@.1-(3EPK3#(>C<;(:0R*JP0I::DR*##CDI;,TQ!
M2O++AMKKJ1 YSVX5,"Y\$D$[+1W7VIJ0A)-8> ZFHARU'"UNE9=$6_.&@*^3
MS[]VMP[$[OY/5J??2./3SDG]Y.?1YO:'7[OM79BSW;T=^NW7YGHCNU6X(M9K
M[T!\&A":-"I09IE#VF%KI;=&494#OO1] [[N))SN>KJQ>,*)!TY-H-SG1H48
M)),U\*@!)Y!'*CE23+AGA<O$J\(2*(S:<12T3H@SJI#1GB(:*+;)"HF37EEC
M5U1R6?A#QE<.26*%Y@'(3;J0E1*KM0].)\RDHR'1 LEGA>3$JR(U<[DR'&+
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MY6!-"8.9B!E 4G('<)4J45AVDH@G3EX3_5? ^JQ@G6I/J%FN?JN1,5(C;G2
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MP!-[7 C!09/C2/C<%EPXB321"L6L*.@D55)D96V>"CT7^+XL?._2N:08Z2\
MZHF1'FP"$X 'I$WN*J8-1_ "?E!%C7;)6D-+GY,"[6*JOP1.)Z:ZQE@3HP@R
M/@?NY!]6A5%9;RG@9W25]OSHTZP%/C5_7E.]*G5TP[GY_:WUY74).I^$4%:"
MH>>XY-Q(8[A,@ELG<@.78JW/ =^<:U;HA&3!^H""R]V6%+'(YN*%V.?Z*HPI
MRA+P#9M5ZX#BOG]E6"W6^E, >&*M8T>5=5@CS7/A41<<TLHGQ$,N&@O_SZ7G
MU@I\"WR+M3[GH)Y8ZV"<!<ZM08(8 +5@%)G@.*)< \*-$UC%F5GK!=I+ ^UB
MK3\'3J<.UA4W@@:&#+8>\<0\<DY$!!!-5@HLE<MM2MFCS[H6^&#]^>HVY &D
MJHAE5=LRQ,-NOWE]?;#7Z0IT-HJ4F(F<86Z#L3)R%:G2QM/@,"TF^CR0S'19
M ^I$,%)%Q(R+B)LDD2$I(:)S&5\/5.-!&5C"=.*"U <B]2DU_&*V/P+44T4"
MM+?1$(I"Q!1QDC"R1F&PXCWQT08F=2CG<07:Q7A?$&A/Y=Y3%Y7E GEM8XZV
M#4@3!J^(I]A*SX64!=H%VL5X?PF<3HQW2:FTDFBDHDJ(*Q&0=4&!7JUS[;#<
MMR7-EUZ]W ?MWU:_KM:V0!CUA[WC6J<[*(?L5^?=6)RH=\X++#A3 LQ +13G
MUF.C3'3%@I\#IJEOO<LL,[+BW_V0A@>#B4)8T9R!DRC22G%DA>'2!AN(M#.(
MJ2VN_*7!:K'AYQ;6QV>P3M'!"G.+(LL*O@)]WUJJD$Y6>'@A8,'+.5T!=['B
M%P7<C6F9[0@78!I@IG)3QY0/X4%Z6UCBY*61!=P%W,6.?S&D3L0PT5:IB'-U
M,RVR=@V*-94<*<>8Q!JT[9S<,D_:]2V6_&FC0AALO!G6Y9/G/UDF]F4F]EY^
MK]P):_[B1[:Z ]NZKUMOW-YFW .5P0.&[C#W(LV#_./:YC=+6X=V)O.QX)J#
M]TZ1&(SAB@='C3?4$L\HIS0%ITM/D7E7+NK3KCM&=>"Y=*WCD8.-KP0RS&(4
M110F:*N5KRK9*CJK2K:SP-"<E^$NM%EH<V:T69RB<T"8$VLL]QU07 BDI+<(
MJ%,@%ZU$G+HD++ HM6QE33RZGF=AR\*6A2U?B"V+E_DQ;#GE97:2&2*P1R1P
MX,B$=8Y"P4">04@.ZV=XF%VUI4*6A2P+63Z#15[<_+.BRBDWOTDX,DU0BHHA
M;F1 .:@2.2N3E59@+61EB4NS!'19.5Q_'^0]M58]3M[2S<[05L]S&A)WZ??P
MZ]/':MO>SV:G&I^L*'3T\*[W^]KYP+JI[XPAQNFJ$@##*H,.KONV%T$+:/X=
M_SAJAL'>*02GOCB>(SSYBG4P(\/!]5^Y.!^S80^";Z,/.NJ( [^SM7^!/C/8
M\[87W]0V.GZU]C4>#F+;Q5Z-X3>US LU@'2[1C#Z7/N_6JZ1?"XF<>KGWEEO
M^L.JU0[H2@?(ID'LO;6M(WO<7_G]_/K XER8[XM3=>V,I#3C&1GM3F"WW/HZ
M+Q^@(?;RIV D]H5'4-OK92+_KZ:PG!NL+:,:<QZ2HS%))43PP3@LX@^ULK:5
M(9,30-]G&= 9]/_YNUV[:M4N8&?$QPE3ID(N4RL(CT3ID$04E(:4L+0>CT0+
M?">&=UDP2*=Y#!A+0B,/!#N.$R<B&*\-=3JN7 7),5@ E7]< NF5HY)"&V4=
M95A'[JRU23%!<XD>:SV1%+Y7,<4$C14UP7*U[&$_OCU]\<?IT4ZS4TU_]:6+
M/ 1C&6]$8U:U8'DOCD]^QI<?;]/5:IM>(-/1>US AJ;7OHU7R;7OW7190E8E
M4P^Z[,WO"58&NUB#Y7<;T"WGEB^8U:[OI.9>K;A,@G/(71[% PW&WG,^C+KR
M8=:C'\M6DF4K,>>>:[Q4%U01PBM:7,[E@R?I=8\NQ5E=IUA>H5O.XS*?'4#6
M\@GD30]_GP>^-D#-+,W$54ZVVL3+]N13MYS[[T-_ #;Z /;?1]OLU;[;UC#>
MA6GH<C/-A2>Y:5,LR4;(9WK7=SB=(8B69+ZR5_^&EK"W[*&K4<7N *I93>T=
MKE-N^>A;%I5ZCB#[VT:G!M=J-;N=_C^N$G)/7>@+-LYSNOW?=WN'V4$4:R&Z
MP0V-K._SF,MTWK-$YS8^&6%M,-Z9R+556GD1E:&.1^*UKW(PB"&4D1))>;_S
MFSK;7?]^L/D)WMO>/=@Y^7Q2W_KW7F/+DYW]GWQW?T/L[G_[U8!K7SR_V3D)
M!XWMS_"9O=9N^\M^8[W^J][^0!HGWYN;ZWOM^GZKW=CZ0!OK7U)CNHR9\I$3
M;R2*Q C$DZ?(<N:1B%0IZU.(/%<:?T,4GZ.2"\]T:%W(:(G)J,0GOC@-30JO
M2:&L2XP@3'-I92(]<CIBY(3P6&-!L5G.:HJ%@@H%E:"_EZ.@28$XYZ,2P2MD
M272(N^B1ML!#5#B6B'?>6#>#ANF%@@H%S1$%E5"Z%R:@2>4[')BF(B44 @$"
M"AC4G\@CXI1SI8G4D<J1*?8*V\P]LS^KWNT-?E;A8M=VF"L%.:K"FMHH;)V5
M/%KN-+.!6(XMTT$R%9.<D?)3/#Z/HIGFE,='<S"O+%%(40JF%E4:&1<,BLY;
M+F2TPNJ5-4X?G0E6BN>\3JP67\E3 'CB*]%:2VH<1<%1A;B/%!G+#)(NN! Q
M!@R'&1@J!;X%OL7/,"OX3OP,8)<Q9J5#3@2*>"(4.>\<H%EX!D#&PO "WP+?
M4KKN>1$Z,<254BP)19 C!#1DQARR)($ASKCA+'G*>)PW#?E9PTJ>MP)]'4#E
MFX>V-9L^[\O;Y$(8[XV4D6DNN*+6@5P1S')IL5 LZF*+SP/3'$_;XHXH:<'X
M#LGFW%D3D=6>H<")2LQ08J-<69LK?U_I1_.R4"T5Z.<4U5,&NA/2\91 N7<&
M<0?*O2&:(.H<=UQX86UI-56@_:S0+L;[(Z ],=Y-$@13FI"CPB-N/1@)/"BD
M(YCM\*97D1=H%V@7$_XE<#HQX8WD"@O"D$V$(,Y-0%I&B0S7.O(8HJ!VSA3K
M9SU(?UX+_EV_'P<W'*67/G(3C@$CD 70&[V-C+.H@%J,"!&L0D>E]K88\7/
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M)3MN9ME2HN/G#^M FXG!H<@XB$[G@5$QBXB!;>Q\<D()-\<E.E(W@R]#?UP
M(_[LQ9\9_+!#\[:^I4I'M8TKXG(Q9@,(:&)<6:8[[%?[N@;P: Y.I43. A[Q
M":&GG'U+J8]K.6T>"WX(21Y2\(/R5<7Y[&MHX%7)GZ;@1QEL&6P9;!ZLN-N
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M9T;9&!RF=F5M"2N;W,>FN. W0/GS;XF8T@&;G0#[]2TRL_)\/Q*BG6%V'EQ
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MNX/1R(\0(.,F/[0*SZ+L@'@L$Z/)P(EV,B]4[E+A ]4B9<KGE&=..^G\A;;
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M\S3W0@L=M-9>&V-" >N1*A^N&%2Z!J9/NP/Z%D WUVA&ZZ+P3I&"9Q@;,8R
M>VQ)#GK/IFEN'.[MDX7:Y')5N=_'L@/ZL6YR?HS[F&^$=NT^YD> =8VXC\T<
MYT5&4FDS(IBD1#%6$&=]7K"\T"H.C*;9"G;V/.SD]E.TAX(+*H"S;U0NI)$F
MEWE!I0;D8$*)UAYZS!@Q"P31S.#XPXSPO,"A\E@$Y[- 3)[F4AB722\W7HA<
M;(HL;^VAUAY:@Q>ZB3UT([1K[:%'@'6S(!>PM>""&R(=!KTY"Z2@.B.!2:V,
M"#FSN-.9IELK@[H51KGJ>U6BP,L9!K?M2-W 8KABX@83'(JP",9+M+;^98>N
MS9M$>OT6!T4T!E.4^/@BMLT^-[7B/B=L'!S[1!\=#?T1CM(*V,'[&^)*'%(T
M/W&C'A2#'U0!20"WY 2L21^_J(;&A$&W.SC%28+QK6\^E>-\0_2[F],!!LY-
MYG3DZ5:AQ.H'-+ ;SWWXV30)?C</>[U9);>=)J$>4N_\/1R>M#N(PY->GQ^>
MM$R/_)L!WT_-Z75<M2N3&4N^YI-8KH4A _=E']QJU>_TED\*9/ZVTZ]G$(_^
MO@RD/-QT:-7C[]EU4.+&8<)?>8T5%>Y']R+;RN4Z$O&B44NWKL!9CU>[?H3E
MHO=Z8!&6U18;DZPY6_>.V\3,*@?/1U.RAQQ-Z>V>[G[9Z^Q^A&?\\37=_?+^
MR][;?Q]__OCI[-/!<>_S%]?=_?CN]//!\?%B-.73C^VS7;;S_?/'UWS_X-W9
MWMO=]/-'C+[\ZWC_[>?>'OOP_?.K?W;WW[Z9SZ3KK&">%X;DG@<BJ$R)YFE&
M%%?4".^IU^G&"[%.]4(KJB%L4>O!HY92KJ ^MZFR7CBI%1..^]07(A14%091
MBZH*M>"'%K4>-&HU.C^P0ABA.!$F*)Q+GI%"^90P!VHKL,(*P7$"PAJAUHK,
M^K4V#J\<M?A$=J>OMD2[A:B'!%'-3MU<>LJP MLX3W'6NR(F%/B'SW3! ]=,
M;[Q@MV[2_;!+=AZAQ-O<"<8H$)%YH;E4PC##<V<MF"?6R]8H>502WVC!S33-
MC#"$YJ8@HD@UT1Y[[A:^T"GP%2O"QHNUZD6URH@5+=;1)#D8C'6W3H$N:_<]
MK6%12[_TP\;IS ON9%ZHW*7"!ZI%RI3/*<^<=M+YUC)[1#C=;"5J"J9$R@MB
M<NV(R(PA!?6!4,N4%)2EAKN-%]FMAT(M*T]K'@]KP? 1@Z$715&87&JJ3716
M7<YTP9@P6>9XQENC]5&!X<QHY8*Y@F6!9!$,-?>D"#HE)C562A&<2M.-%_+6
M@XCO"PP?;?:\;!IXJ^3YRFHK[S2U?H.G;!/O;0KK@2K>E27>[[MM:72L6P5\
M$P6\WTS ^\*94!2<I$$6N)W!$YW#3[F3!04/Q03+-UZP52G@!^1PM.BU]NBU
ML@1\BUX/";V:B?C<TDPZPE,?B+ A)R8W&<EERD7N32&,QCES:X1>;2+^2:;E
M5I:(;Z'JP4#5[L$VPE1I;&T?RHPK%K0AMJ!8.L0DT8I38C)J.0?C6V46P&J-
M\G-M1GZM,O*MZ#\LT3^;BCZ3.<NHD<0:GA&A"DMTR L"9JH+&?.:9Q2\K#42
M_:>2FO]VX0#,:\:1JRW(%\0)GW*V:A6K\K 1?V6Y_1;Q'Q#BOVX:>]1Q9Z3W
M1&M'B0!:DR((1;RQ,E6>V2(P0/Q5E8BO3O36/"K7(F^+O/=12- B[\-"WIFM
M[4R14EWDQ+,4!Y4HL+7!M2:IS(S(I>4 P-@ X=$@[P6M@JI7VP/.&W9L^3O*
M2:<_B?Q[=3^=C2O;#)4,*;40*BTT9T4JA N&^9#E4CKKE$FE/\S$Q@UZ]UP,
M*P7#?Y=H8B2NU<2(IEO)/^96:@5FW )\^",4_O?^9  4[!^]ZHQL=S":#/T!
MW.:?W8']^HLE?.]E+>'=KWL?=]FG'T=B[]6;+_NOWG<_O\5[;\M/#"3[Q]Z7
M3Q]?IRCY(*U=__O[L\\?W8EA(MO_^(Y^^O$9SCE*=S_N"I#RKR"YZ>ZK[I?/
M!SM\E^T=?SH Z7]U#-*ZF^Z^.TR5LURZE!A3@'TDM2;*,$L*YG.N +YSE9?8
M#CSKW39V"O72.RW3+!64"LE]4?""<0!Y+D2P&H[W )LGL/R N7[C1;7XH^2\
M/#1Y>D$V2G+\_%[SSV:$43GPAM#,B=R!1Q_@]6S.0ZJ#2%$8SHO!E4R_K"Z]
M9N>NCSZQD^$0UJ5[EASK;SZYO.5KN7ZK=6X6F[_">UAL 'L*,#GR_44!*ENS
M[H=2@A#C:JJN30O#^Y>@#X=Y6H1,\$ 4F#9$%"$G10'>ALHSGM/,JSP RXU/
M!^>T7#*<KF12$7CT+#9@^]WK[O@X^;,+W%5_%;NVX9?1>JD_W4KV)\.++A0[
MNP&WC#I@V\#9IQVXX/'@-#EM<EU/]_61CY<UDQ%PZ*AL%_>MXT_CIR >7SU<
M[12O//SF :9_T@SN5TC2;KQUTAG%9]8G)\/!"5QU[!.OAWT ^U'2\QJQ'OD]
M&5R\9)N)0=,Q <'#A<*C['''AV1PXH<:=484GA%*9D]_!2+,%G+H<<E&\/=H
MTL5+Z='(XW\)G!ME+([]P+757= U\&SQ8+B)]:/U7%7L+/C5 Y/X,4#U*)G@
MXHP'U:O%I6Z\'+8;Q"6[F'?+-H.]SJ2'2^4!K#?AN@XMJ:1\Q;@VNR_?;^$?
M2)ZR*V%%TA[8>V.\17V2+?E[A)P._^&38$<GY&8X:N%>6PF\R]##H\)M\7I@
M//IA]PQ)6MY],P&^:-P)^0;GM9Q=(8]A#"PP?9[R4>"AG'<3B]T4PW#0.__6
M%9/VX/BDTXM,"!>KV1.>?<JR)4^53U$*:BGQ%;?7G'SAPW7P]."!/2N2)?\-
MMAM+G^]6SUM>9"M^2I^O(_O=M3UHCX%07;\?%BW#G7ZI%$'.P:4LOWS"-N*/
MW=-#)G3*J"L(]ZDE@H%^ ]]>$5=XFZ929DJX13LL+W@J,F6*8*@0.M/>V: R
MGMG49('*11OQX'SGT60& C%%4 D1"L14_^U@&S=2\WU]Q"EP? >4WU&_$X#?
MX1L4%X!>! IP\D>SKJ=;5]ND5SIL%<,*5I9_G Q&'3SFV=!WX>!OOFI/6@5/
M&B=6;E<Z.T4;\$<GX\M/671%[U?#@J_<UQ76(/9NPL+;K0OF6"5O0'@2FI)W
MR?]-,*HZMYB-/X^G+0Y/ -J(&7K]E410?::[I_ILM/';/!0!#BVL]^)27;HB
M(:QX1<K  )@#@V'DBF>E1H&CX$GT+WZ"Y'B(*/D?/P\-Y"!V4=! [[Q$@ 59
M^\=O>E$$+G?.KN%L77C>3\%A/?L, ZMMI26[+=MH&'B6LYMU_?U)[UZA[J;1
M\.4W;1]V#1]6IM=[H"?57?4 H/#:/9R?PH*T/:W;GM;WL%P+/:U;!FH9J&V*
MWM[RSEN_,_J0E/$3[/U^T SD/-X.\.TU[FYC/J5;;"TW6S4C\>T._4>WQ[4(
M7FB544>]$5H7ADLKN>/"8-@KMU72(;^BEOC:HU;?EP Y2ZW_ZO*S&R8>JO*S
M#Z=PS=/='__J?'[E>KM?WL'O'^#:7^E>[YW</SA*=U^]/MO]\N;+8OG9YX-_
MPO-O_]CM_>OK'OMTMO<*?C_H=O8//K#/K[[*_5?O3G</=LYV/^[-][,W(B^\
M]YJXU LB"B])$7)*LCQ719[ZD%FS\4)NIBNK/WM M;LMVJP]VDAO9*:8E#H$
M80W5,LV==UF1%VE1Z'I'?7Y%_6R+-G>,-K/M[\HY;](L!;21D@@I"RRG<Z1@
M7*9<&E:DV<8+L<GXK;N^MFC3HLWJT29HX;3-"JJ9X&C2%+XP>8YL[93-KK%/
MJD6;.T:;V93W($/J*>5$4H5;FG#RL?6!!"-3X90.7+"-%U1LTJ)M%]3"S?K!
M#7I0.5@UALI,%+G3T@?F**4RYX'GZAJ;@UJXN6.XF0U:YX%98:@@+M.!".4\
M485,B37.FMQH$7P.<,,VI<C6"&Y6V=]G;6-.L1J\[? SARXN2[,@,G"66 K*
M46J?V8()8ZSD16;E-0(U+83<'D*:0W"LR5B>!T<42ST17%@"UJ8@ "B*6F6\
M$WG;<><1BJ)WFK*<NIPY$=)06"54ZK1V03%K]#6B&*THKD(49Z$*6A0V<*D(
M=04G(LL%46"!D<SIG*6%9LKQC1>B%<5')HI9GA6I+%+!<B%HEFF5Y9)+ZH2W
MF:3+-QAN1?%FHCCSX[46J7*@"V61941098BB'+2B4U+KD-O@_,:+O!7%1R:*
MJ3(I1Q?8%UP$YK42DDF;LJ! %)5=NC=&*XHW$\6&CUOPPJD";-."2H(8"0:J
M$ 14(F.*B9 'M?'BL8YL8V)-^]>^'/1CU9ANA[:U<XKFTZ.!I8X%8X417$GE
ME4J94]AEAAN=M\48OQI=FY/6*+4ZA +@U"&ZXD\&6V^*+!34:\VM"&4QQH.9
M+]0.6VM![-8@)L$!DQFSF@K!F=(9TR9SECE&M1-%6^/QZT%L%CBQX)O10@9B
M>$@!Q/*<F S^T,X(:HS-M?&QQD/<>I9W"V(MB#T4$%M!B]T6Q.X8Q!HA)VXL
M5Z8@C :)[:H$486F1!>J4*J@W#I=E8ZL:E9+BV(MBJT]BJV@76V+8G>,8K-H
M70!*.:%RPC.6$2&H)D5J.,F#$V!"&R:M+2M2Y(.9WKW\%M>E$6Z9:]SAC-CV
M*1_+4U[0\'@]FL==U$QLZ 'Q;:?K1W7+P?$@MLBL \Q)IV\'/9^8V"FP_FVL
MO_O1LR4Z-+:-A]:Q/4[[L&WCH;;Q4-MXZ*$U0FG[QK2-AUH&:AL//:4N0&WC
MH;;QT*IC@67#\[;CT%.Y1MMQJ-TF^]"3$D9(:;4,S$@E<ETHZ;5,@^0R8R$X
MM?1&MK?#P6CTYW 0.N-'DGQXW]W_N'.ZU]O]\?G5D=C] =?]^*_.WL$.W.=S
M=_<5W._+7F?O[<Z/<\F'MYBDV(;[[7W=?W7T8^]5%[[?H;OX3KT/I_!N;)?M
MI)^^+'06<M0'D8642(T#LXI@B5'4D#S+M-#4P\?9QHLL;_L*M9BR?I@BJ2EX
MEN>:4RI<FAJ)R;2@I2FRW&3YTCOR6DRY,:;,:LM"QG%S/8 (F#1$9%(2I5--
M4NU-4>2BR+W<>"&SMIU'BRGKARG @;00RG)12 'VB7*,46JD P1A,EQG:^&U
MBR=:N+DQW,RJP%1A@L^H((4#ZT6$E!$ML<$'9[+P0"C% &[89LI7-1:]!9P6
M<%8'.(P'6E!ATI1ID3M>:)X5 4SNU"NF%%MEM58+.#<&G%G!EE%%:DQJ2)$&
M1H0U.2FDLP0L3JF= '>*NXT7=#-GJZK7NH<MEG4)!SRLOQJCVB/GCVP7]M<L
M[,K#]U<-W5N]AMAV[EDRB/./9S-YJUD"HVF%U@H>1VX5\AI/=,' 1TPY$;Y%
M\?3%1=,C7TX(_!O]^WPY6=L7(:IUG8%9FNLB,R87BJ6:BMSD/,^99SY3X:DW
M[KH?Q;W_LA'L#-(JKK4GEK&4B)3F1'N?$E#;-&2"L2)P\!3DK;>\M4U*UDT8
MO2Q,D=',Y%KP@JI,,J."PHW;DBGZU%MWW9LP-J*$5IG4NY0$EBHBA-=$!:9!
M(I4S.?7&9A2L:+E.;4I:85R)PVL!;*W*"^>#< 4SH!-Y:G(<Z)M2SI]Z\ZY[
M$\99#,U;D#C+%)'.@&;47!#-+"7<*R&*0E"3YALO<M%VTGMLPFBISE)6I![^
M$"'D)BNX9[E)G?1>:_'4VW?=FS#.XDN>&Y&Y5!#&548$> ^D4 Z;S"H7O&$I
M+]S&"W'[G/S]-?!:O^#"0SER1:5?:QH$^<./1N>C(/[[B>^/'E84A-TF"G+=
M9,V:J)>__<HPR,O!:#S:[KO7%9.T>F8)/;-[L(TZI@R);!]:H(0)''PPD4LB
M7*:( @, K,! -:=>20&:)N/GS;Z_/^"<Z9,7R54'0UJ1O*U(GDU%,@].8B$;
MR4)FB6"B((4T.(;-IYFBP1>2@?&7G8]1MB+Y<$5R!2&1:]< M-)Z2VG=FRE0
M)D$Y&JN)-HH3$2@GR@I)N'%"N303%.,F=#,OSH<Q6WE]N/*Z@JA)*Z_W)J\S
M[>IUT,(81])""]"NRJ.\8M*!N5QZA\--45ZY6A/]^C3F?DT]_[)-S6U&@-VN
ML=V:0-']]@Z?AYLI,78B+?X8C%K$60YQ7C==[!34 :B)G( [[8@ &Q[M>4-<
ML-K9D#+#P,5F%]@'-POFKDV#RA6F79Z<3-^^E78KTRN7Z9D58=.<.9ZFQ&8@
MSJ+(+3'42Q(D$X%IGX><81W1JH8=M3+]\&5Z!9VE6YE>M4PW/'FG@E46/7GJ
M-!$F%\2$3()[ "Y=6GCF/>AI5;0RW<KT"OLLMS*]<IF>Z6F#C25\< 3<(9#I
MX"DQQN3 +"P#(HE">+OQHDAOO2_POF3ZOHL![B\"$"L ZKS_9M+WXQL% 1Y8
MR/%^_?P1O"3\M @Z>X/^8!YWJDAC"SU+0<].T^UWVE+.N2#>YIP(3ATQA;"$
M9DS28*2PV%>%W=J::%,#ZR:GM_?=6SF]:SF=F0@JIU8I%8@M7"!"2T<*<.^)
M-9))Y62FLASD]-9USZV<KIF<KL ?;^7TCN6TX9X'\*T$%8IDSG@BO#?$L#PE
M//<X(<5087&Z>*M/'YN<KL#';N7TKN5TID\+$52>4T,<XRD14@=B0BJ)$ZK
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M6/"&P+9@B@^;_CRPL"LC3=.XP]?^X+24R$F__'G8&7T=59]44H.(LI4<' _
MOK_RH%J<2E]QYA#U.@@IX\%F&0R DZ.<#&"1&R)08>K(5^[DN#/NPL<5T=[C
M66_*LVKBQ3, :*9J8#,B^W:_CXOQ_IR:^)]I\.O, [U]C%:\\K:R?"E:OE1M
M3AW6=U.54UYK-*]SZHM5FFE477!7#T&$RZNQM+S:OR;@4M6F]6:U3L@$J$S
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M%YY]G2X'N6;>0^,#TC;IDUR7\^%3R<WA2M ]#629C9:"HWOKKUFNLIS$7I"
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MY#+/L? 5_(]H=V5GIGE6YW*]L 3-Q%D$[#1 C.MKK(S$G*@L8;A29F:2$!X
ME)?=_-5/)UE#)E2MFRB\@T5SNP'9B%X09.\-<[^KW_K,SF1QIRYAF?"2>WI
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M8;3E!4XD[%BXUMO>X,B"%_I>&,#'5C(1\!\O<JW_I':4B,@*QQ8VW;#N)B(
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MZ%(S7Q>32PK_?YU!L&$&P6&KSB"H,PB>ES3O1%F.62X[<M[!OG!NM]0<N)H
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M'RF?:.7$[+IR -!$\R"$]-[9'+RG%@_ TI4EAM\X/#(7G0")'<CR+YMG0I(
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M%S$6;"@J9I<?!]7@H15.Y7N&A^_M81Z^1/&*SG7A+^D1V7/*HTE1P)VE[F/
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M;N7+X4N&!6T\FR<VMX(^MZX-46QB; ;J<!X!<1U!-<)3.=4JNW<2.25S.13
MJA./6+.[*A5$V+)1A$HRMNP[[ <J69,>M9+5K6._'4\V.9/A">R))44Z**Z^
M+T#LSD/E1:-:@>IU:76Z2L>=I1&V6=&M.+/6,%B3C*H',NH "5^RZ1L)BL2$
ME(;)Y<<+AA:&M2C1&K.&7#)O:7U%_/2&V/L.:YH-'.7")3"6;3N1J:D.IW#;
MP2XC'=^C@1UX"QU/1M/THP^@T7R]6KV![2EH5:S4Y6 <W1=991^$M[EY(+JQ
MV_Q+Y01W$_I]!7U;IO#2/!AS&]@X@PKQ&!TEH'=R;7 RQ#ZAJ7:$R08K9"C,
M>;/Q*A]TZ6E@JA1"DQYI](^P]S-RMV!4$B6R? NSCE"^[@;%B=H <]_G]@%:
M%\?K[043H6>PR*8BNG\ 4<<M=46;B'5(3@KI-2@*MJ)9BDN1$81R&@5HEE)_
M!U75P'X/2M73@SI*-R$G3I<8NDW+6M(+MPYL/!#8Z"X.;*QC(_7?U.&0UQ(.
M>1F;]NOGR]._GEU=GUZ>?K"NCC_Q0,W3?WP]N_X7>CZ_8O5.-FX3OY2^EJ=V
MM#S3V-"SJZNOIY?6Q=?+D]^/KQ8<KS)JZO(.:ZI%/G73,'K' \-V!8^?)5-#
MF?L"Q,.XI*?60Q[/+.-4M5$'Q6."DW)YQ"VV0(5K$X_O.5I/H]=$UCE()J]@
M TZC*(^MOX)=_>Y!%V<&:2X4T9(#A?@!0-RW9[%XI_[ : C(LOMW7D 0I(>*
M^@>L*=G?<-@\I,8(OR01_,=5RTOFV"3F^'/BSG]W>-CL'K87?MUJ+OYNV;+M
M=G,X&&RT[/+O>MU>O=F=VNQP\=?FLC\3Y3+UPBW V_27-]TWF7Y F</O6E:;
M;I%:;\E/.[/O^./WAJJ%><=S6CQQQ87:F4.]@Y^&0PX?$F:DQ5QCNVQF9I]3
M9&P+><M6MXESQHBO5G-[2LRX#,DGM,]ZS4'1E"S;PF)3LKW4EORQ_5-!]7J8
MU!]W*Q@Y"^_%BZ'LF$=',,(NT,4H_R27"0A\HC<-G-<"ECE^P'^'8_[_\A)B
MV$K3/"9H7-CHK1K++W"@JW\O[P)^=*RZJQB?<2-,4+WX7^RDBE\,X#O!G8^S
M;.4\9ZD6^_N BJ2D%,K8K>8VM1#A< >Z8/\%JO5OPLIH^:N.3VGZ5*3YE(V*
MGINM=\K8^@-:S\AVOMU0 _T#>2K'$6(\?K_I+7H&Q,Y9>818'IYN'? 4]6Y[
M(1/I/'Q8:20AF.&L%N4-6&K?)B1:5@D\R+VV?8" 35G@%WF-^/&GQV\)"JN?
M?@F??I#TBKS^>;%8#:I^^VS(6P-I+W;:=G_8;'?VFVI?'1^2_<WW&ZLU+]HW
M7E1MLEU;C1O3_U1?C9,].5&1DW]NJ,J5''C_N&0Y5I^5$19>N3(C7!4?U2##
MU7E=V;EJ^GHV^JKO?G5Q4]_]^NX_C;:R*TZG+'\)%18SF^DQ[J?]YEOEN*VR
M\;9W?*OL7#5]5<+E4]_]^N[7=__-K[U6J]'B_VR/QI[(RT+O/N+LX<I1#@7[
M'^-AV0LG]?K!LG5/7]MFM6U61=ML"WZ9O> 8CT+<KG"-1Z\A):AZ6$*PRWGI
M+[]' ^ZP!\L-4TR-+P+^R:&PHVOL,+2([GZF(H8'2R3,JX5]^KWQ_]_>M?<D
MKL31KS(A-[FZD=H'(+A[32I%K$N+0G6%?S9#J;38!])6P4]_9Z8/8!<69 &+
MUL28R-#';^9WYGG.&>^4G_)S_L^&Y,"Q^/>VY,"7(B5YOZGSQ3NZYVP$3BB:
MQ6\L3 @]GC[45A#.?M$F%!Z$]A&MYQ<:$1'8=C7/0\D1<7H6<GDP17JH$854
M<J& [0UZ0T@<4";2&(LHDUC& E2>?"S +T8"_.2@XD*5SEDI5E":*-/CQ]<=
M$]W3_3>\Z%_KVB2N^;'):'ZB/=7&0G-YS#9S,,49M82N,=0"O1#H>[I#M-<"
MF;OP8"HNY ]P-?[SS1B=VHY],0S\Y%"S,;P&IE_Z;C=#J,XHXN0?1I%3509V
M&?J$AKD'ABO2^6)1T^@3[J'P0'?5GR)^%KK$T1FB*6-!T_TO(\H7&1 T('2-
MD7=J^U;7\<("&6!#2\-WR_8@')R2=M30H@<-#\OR\6OPQ("!05B.QBOH>X5,
M0-WM<G?CCN \U]C&<XN3_&Z_\MRNEOKU_ITN"S=Y2=!UZ57,2<(-W:ZV#<FZ
ML^2^RL@_&OVV8!J2<&?6.-ELO3I,2[FAZPJ?:RG2N"[PM%QM6*W^E=GNMSA9
MN7MLL3?Y5I]GVG?%D=17G]OVE=Y^'5AUY;S?4G14]MR4J[>TW#>M.KIWBVU8
MLG)NR*^]4;O/<^URB6[?Z[1JW=GP1\FO6ZV\5)7U.GXN]+VV<L/6?[1RLF#V
MV]46(U5%KBY<6)+0?;Q_%4=UY?%%ZDMC65%'DM#Z27?R-,>J6C9_TLUG<VR)
MSA:[12W+T2QD(2RI7:Y ED&^'<]6]MF,/?Q1;)K4ZV&) RSK&ZDR3F$49NUC
M/_90!H*(5W<TXF(:"9 0.1947B<L?O2+FA""1GQ0&G6[/?U7-9U 1 ++N!.=
M!B-0_K8C%S8";O88"ZY$[3>Z:^P118B1$YG)4/_1B47!8[&8@(M/X#>24#)F
MI6 ":950<><H=,F-I<Y#>?C85'A&+^;9,7T+JR%/M)G"MPG0>$H.V80O% +1
MF-^)1?8&\;GQ"+RG AW%+E28"*J.+4520:DTP-K2 +F-2 ,@U-NB-$!4%,5&
MS:(@XPP^#7U9%P<YU0W8J&[ O.!_3928@"@+E7N@U$'E_E(\%Y7FCL<KF;,E
MQ*)Y5L;;8)6CS*'H('O>2BL_H0HGZQ*1_TQ27HU-_)9GS3,45UR/^[S[A^4*
M%%/,;9)1_0Z+R\65EO0J(]WH&%[(?'2HA;LB.^4A[NSU%<,S=T=V3<8[2QJ:
MHY#IUX6!I=!F7G_9]M\;%G&7O3FZ2&9S:D*KK6!/NOZ9+E(+LN#K%N_]VW
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M\>)@,#XUYR4?C+^_&8[+;23OP$_A4^'H4?X5W8P"^B#/T-&XN;_VR+'S;&/
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M[G64R'T?2K07\30T6^NTD1T86LY:4$XXJ%AN$"CK/ ^$9FX9X\+C'_LQ7NO
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M)Z%MN(W]36M2(X$UB>AOK[+&.^G!,\(%+9V&+0:+,F+L&!-U+%KC4J/[SAY
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ML]3@FQR\VP%S'[S:Y]#$?8EYOWIY?=O%Q:G#@P+Y9/&]<ED:Y[9<=6$R8%0
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M\EQY.;AV>:MC'&[E@SXV6DUW8&W4-[VO"P:6'\%/X1]_^7]02P,$%     @
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MI@L$,HGS  1_"J-"\(H8-SW]<,RWSR()LI]?SBHB7G]V5;SC*S^L*>"U1U=
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MV9GYCR+KCR;-]3INJ90F64]?^9,F:^&-$D0D97$G=9E8XRQ),B86151)-HJ
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M;Y1KU!WDH:;+ V.\@_(BH_5_=H7OX_"_%WIY"Y/A.+&!1_51'R4!D]#V%^7
MK'R;>1:6Q^"T""UDLR?>8^2?-F+:JN'3AP8;W/-N>.?OZL2^2J4B:![ZVZG<
MB+,D8"Y/T$KWF>ET?G5_WM.!MD8%*QBQ0<;2^%@1IX0A,6FK2P%;SYOZ^)7G
M<\+$?0H,:. ,;I?;;U/(\\O7PPP#9YR2,@G"/"UMNVQ)=*")I*BSXEQSKII<
M$74!=\*4JZZ;!K?+][-V'Q/+CU]^]?]W/'EQB4;S]9D<"\$EX10!#V@BQ^A)
MX%X3;[V7F:)3Q%C;T_@]4/>7RM\3S_K3X5,Y<G] I/<G>-UZDDDCC<X$8%&T
M$QVZ( !7:>H5M58:%&[/MN,JQN,?S3<G3G<S\B %]KK#3N^ OO%7-T<17>"V
M/++?$>]Q#O";Z;\[SZHI[PEPCDNM@$I!DF1HA/HLB(W,$:TCRX9IST.3 _\G
MP;5'CO^?*M5VT5D#BI6[UM*%9>XOWPT_7LQN$B=!96.5DT29DOV:DB7HX91R
M+%G211_.3IT =J;2%CS]NP=-]3BNKX3*=PL?)CY!F=Y-25J7T +ED41?*BD&
M(7&#=Y2$*'TR5$D:NW0L77GL::KU4/E5O@=\.QE_+D$4;V#V^WCRKQM )FMF
M.,+0^"+* *6;C06B8D[,>A85[W1!M.GAIZO6PV79HNKV8M,"+IE@93;!>2)I
MT*0$])'D0\1%(U-F78<5^VG75#^>R[*_L!O66>\"XT3KK.^D@2TENO<17\,Z
MZ]J[Q)*1A.MR^&,Y(U;CJA*,IR!-"-K5?8./7F>]AA)WD5K3.NN)9^Y*O\D$
MNIS=,84+B@DE;D!" I8]ZY(C^"W56=])]EOKK.\BN*9UUG4T@K. 1IKEJL26
MAE+_R1&+EEJ0N)N;5.T%?")UUO?6X-Z"ZS=&YF<_G/S#7\YQOKX4?EKDDNX1
M#;/Y.17C7CH 78EP,2F#8S0PP:UTDN$K8T*DG(<<#.-^\"CFBB+=N]S&0T]K
M+=X.!3>X\C8K38W)#(5,+7/*A9ASDDY1R)N%7*OBQL:'5RBYT>VYK<6_4]$-
MRBBN)<J5%!2I03@O-;,JL*2$M%1M5D3EJANW8_SH+_THPOL+@-DOD_'\TW#T
M<5EJU%_>=HY[X3\MPLI>WY7KI@"*<X&.9NDA2TTBSI2,4@?,,RV2ITUN2@\%
M?HQ<0V=ES-H#H=D4KSH#L:)8B,[H9&P EOH*JGEZN8:],K%&XN$NVFQ1X6,R
MC@!I6IK%(\+/,)F5 X*?(,P&$A=W=$0R$5[YTL_1$.<])=K;(( %CDM,"Z(]
M@.F9$:J6=IK4VOZTK$!RGA=X7+9>29%(<L8A'G17 Y>9J!R4B1P-+]JDBM(J
MD&=&D8/T4+D^Z^OQZ.,'F%P5',O^*[_ZV7RR" Y\ [/S_-O(7T>_0EHV?ORI
M].&<CQ"W9#$G2DFRK%PN,HW.%KI=++B@@2?K8WS$?#L4PS.A3J^J:E#_HV!^
M-9K.)O,BDU>C&4Q@.GN',EH(*KV%2<1?^(\P0-N8JX#RB$'E(AY%7#:"<)44
M][CMJC:EW;I#?":<:ZR[IU$&Y)Z']6KT:3X;<!%%$*QTQ,8%67I NRYD31A3
M096N+HPW<6LJ8']FO.Q;VPUJB-S)[\LF"5Y?\7$>HO!)$F8E6@<ECB<X1TET
MB+=D"5K=I6?M 8[V=G!]11X?E6C5M?14@HZ_7MD7UUB!0U0,?5OC$[HHBG)B
ME3)$<\N\D#QJV:37XSJ48]W'U]?V@_OISE)OX!A^C>A>;$D77"TC?[<!.TZ(
M[Z&*>Y '!TJ]3U8PKFB6N%6RD".1(D3T)4SI+E("CE3P IHD7_7+AD>"</LB
MPR["KAQM]\)/+^X=8;V'T7 \6;0D^VD.14<W904"SU%15]I:!R(36.*D4T0K
M;@7.74;:I>ITQ^'ZMW+KZ&;<5K -#IK+@<-L>>!PVUU.*7!:VDPT$X9(PPVQ
M6GF2F6# E&,0FY2/W@3F9$V$@R7?(*]R%=--G9(.J%J:")MA'<= .%QMC_#@
M )DW,!"VH//96URT!,$5$(F?I"9>A82Z"U);)4M6Z+?.A$>,@[Z(L(NHVV3<
MW+_?6NY:N/<%*'<8DK*$7WPB(7!-8M34^QRL%+Q1OLTZFOZMA1JJ6D^J.5#.
M#0N0K!:AXSH!;G2>E$;71.J<B?,F$QF=$U(:985MH?XG5B2TN8U00_X-*[UO
MKVS6!>"?%4#WT^?.11WW4<91*H"6 UI-:29*4=P]N=4DX#N"'K9+PFOGDF]:
MKOW;J #:EBR[Z*!VYM\#90U5RB+K4J@RE=X6%%PIE:@(ERR*TFD5M]<.YP_?
M6('(G931L4#D+I)L8%+<VS/OW=3]/(%_SV$4ORP83G/B*:&M(VB)SV?"D9("
M1SAHP2.W2ODVA?,>QW:RID9MO32X^M\4,GT+</G&=('8M([)XQB/5+NDMGZW
M\:>R<EK4*>D 57./2Z%)I7\Z)U*@IKT$2T0.3!L?A>B4GOSM\.>Q>B1/@#Z[
MZ*0GVDS?09Q/)K@"+W=7ZKFQ$CQQV4F4 94ES+,$(@09(/.469.[]2[@CA@[
M5$NK'5ASD$HJYVO>I0YK(X)U3A/@GJ(E)Q()-AH"8(%9Z]!L[Q+Q^&V4.VAF
MK.POTXJ!76LYJ1U@G&A5@YTTL"TA?@_Q-:QJD$VTZ%X%HFS&32R6RC<4G>VL
M V>&:S"N2R6IIZ'%3E4-:BAQ%ZFUK6J 'C,U+!!ME2[]+3()I1J5H=;;[*FQ
MH=HZ^T2J&NPD^^U5#7807-.J!LXEP9)U!(PR" 30BN3(3D^34C0$*TV77GG?
M4E6#O36XM^ :F,>K<=>W=Z*:6XN(2OQU1F9IC1M]M(& +IVPI6'2-8FVWP;H
MY*RBJAI89X9NP8Q;X_]Q9"V/:[9#.\XI31T5=N#% ?+O:>U8(A1>"<NY)\I8
M0.M$6^)T0.]-:8IVBQ$0FD0:],V,1\Y?^B;&+F*O? VTBNKE'Y\@SB MJN/]
M8WSI9\L\G\6N%W,,)@A#< ]%H"8*8G7(A)M25T90DSNUAMMIT/X/4FII:MR'
MF"O7=ET%>N_[ZSX]-^<\V6CC?20R6X%O@E)HP29#,J>:0=0.V&.%9G88[B0Y
M4$.T/:T&[^ SC.:P1M0L>; <&-%(6")9"B0HJ7 ]I-HG$:U8S>W<:3W8,NQ)
MLJ&FJ+<&*_=71NWVA^-\FTUX%_(_7716NCXX_M%/AP>T(JPY>NNB5C6$LE+Z
M"@GG:&9( 0O2XWZA':>,)Z&8HE:XS:?V>P*I=*6S;)_U5=NL);IT?C<T?N#-
M>#3Y"LGKN_Q33@TSI9IR*D<HVE#BN(N$!A=22%+HU2:FE>]^:LSB4%/^[#/J
MI;BR/X\G[WU)?(G+\A4EK/7NNT%@W@$7GMA%,56/JX?-R1$JJ8X)I<=4DV"O
MK@"/>%O6.QM7'8,F2FP03/03&BF?%P7SKD4V$ IP]6&"\$PSD27A/TB1200T
M8 "_5;E)2Y%5(,^9/ <II<'APC6*6_F4<CF7XR*.@8HFNV B,3@I(J6"4M\M
M$Q4H16(S'GV3DGU;$3UGVM114X.DN'W*!Y:2$PZ"): 6099:DL"@]&\PW@DG
M78*G4F'F.7.NM6J;5-FZ65WO"6V@E;497722*4*1+ +Q&?UUE9D3)IM 0Q.^
M;43SG!EUN'H:!,[>@[)I?:6A>&R.D\0*HY4TI<LU)Y(G'="1"ZQ-E=^'83UG
M%E546,N*5@?(:7G;:5$*(OA2[4 2B6\'<50;8AS$E ,7L'IX_W0\YN/4QCHZ
M-8^C_*=23>O>'?[M/_\^1!MA$B^^O(;/<+FXE/,Z:$4]$ "'+VA6E@21T("-
M/G,>E/&Y2PS+(0DL#\ [>@!$O]39GNA22X5]!9NOX[U)/.\ MN^LEZUHCY[_
M4DWM7:+1J^KLZ$13@M/(DR'*:D>D9_CB91M)=#0)P63VJ4W+WN,3K'N"S-/@
MURZJ:LFKQ57B="$!MKPXM#YEB#$091"53!$M$9"^=-!2TFG.E&][4;*.Z6GD
MQE32YC;>'*B*EMG ]Z#Q)33AM0(K\2T1 IUFT)&XJ!01X%BD#!AM<Y;_ *;G
MQI)]5-'36B)N"&RD"#;*TJ08H47T98*Q"DU![W5F4-K9]L42\3Q9LH\J&IS3
M;P@;N(Z0I#DZF33)O/2RUKG44 )*./"H+:Y[)K5)R=R,YYE[7Q64U( ['R9^
M-,TP*6)Y#Y//PXA3/M\8B5("K::;?W435-UA+BV]L9J3.9*S5H,EXR>FX@8;
M8]4YI9BDX,D2QTNE6V 271,T!6EBI9ED3$$T:<KR].GZF.OWU-FZBV:;E)"<
M?!I/_ R^#AZZL2TSB\9ZBRXP17 2% G.*V(IC513'9EHTOKB053]FW#'4_A:
M(<I:VFK@+[X87UVAR8.3_G4\F7WT'^%''_\%:0TG@@3*T19ED9=^[9D3+ZPG
MQ@/GKD2DQB9-$KL"?-8$:Z##VED'\Q'*YY._7 .53&!.E0M\CA:P!!=(D&@!
M!ZT"]Z 3XRN%@3;G%VP;X!D2HY[ &W@&"V]I"T'!:Q V:(+:+:5K JZ#RG.2
MM ?&M-5@VH0P;\?T#.E36U,-@K9>E,K.>8@?@T4_T$_CZ?"FQ+,$3HVT'%FM
MRRHG&;$626Y*?ITTP 1M8_]LQ_2,251+4PVBN'Y[_V&R.*;YLF@CLL9QRXP,
M1G-B8Q!$JDR)1Q^#*.TS.*M98DU,GD=P/6,RU=18@SBNW][_,OX,DU&9[OM/
MX]%T/('TLO3^_#093E=S/6Z-,B: H\4?LC>(6>!*ZBP0HW3D*FMG:)/"B/N
M?=;4:ZS;BG5"BOUW/KN R1H@[E1@1EO"%&3T-M$7<+'<FT<N6:#2TM"EZ]3&
MAS]#<M01]+KF3;V@]DTSOKZPN.%H5"%;QXD.SB)2R8GSP1&<L])!<1"Z4?/*
MKA"?(;$:ZW&=<?90QKU$$"E!>ACQS:&7R<JFG$CBI; M_AVNBSP7PR\ZS1U3
MODFWHUU /F/6-=/E.N]<WT4+-E4*JUR9X*$A6I<?Z#R]E1H#/**QK!.P9 )Z
M7B9$7$:<0 VR&"7EFR,B'AJM5ESXGKVK ^>>":E)4"4.2]!, A699,Z=%XY3
MYYM<OAT*O.+.?X.DN-U?91 /A)4Z*5,ZGJ!(I+&.>!D#T4([QW"KR*KUGK\5
MW!&#??K@V@,[?!U]-:T*L!'C72JG-"D$B^B,9!1Q@D,;!$T2T#1:YK,QN7'6
MY,, _^36X7IK&8[X4"%/? -L8&A8) :,2 V&!&_Q7VC;*K &[A7R;)0"M!5<
M[UEKQV!3=2T]E1RT^[-Y73Y]TQA,J Q)>4-BB&A#Q\B)]T(11;FG."M<EINX
M*=L '3W2L9KF5\L&U-! @X5I$ZZ;FG =D#5MR+@5VI$Z,59180=>'"#_?AFB
MH_$T9DZX2*4 ?*8DL,A(UD;ZQ' E3DT\D+Z9\5C7Q9Z)L8O8*P>YO)A/)B56
M\:MCN>2"2=$1*D(@DBHTK0)SN.,F'T5F4N455VOCB?N&1Q^AOV(EJ8_KB:QR
M:=PEG*\"^9?G^=HPEU3I(U"NJITGP8(G-@,ME]@)?)=:N-N>?TJZ/$QX#=;H
M.X_G[O3RW7#ZK\4JE(.34(JL6@NEP7S 54@Q31C+.1D'FK7I2_<0J).U\ZII
MHD%<VAVV4K%JXN/]"L!=L+6T]AX"=QQ[KYXJMW*DDAZ:KBB;, *^'2$FPATM
M02A1$*^E)[AO&<"5T C:Q&OLGR./6'Y'HL@.XJ]M__G+R_/%D<O* >YR'_0@
MK<J2XM+I<<%4)9^3&TND0Y@Q"IE$)UOPX6'ZMR7JZ6/<1I@-SL1WNB/5E@NO
M4B!<HUDK49M(]E3*U8E@-,T4>)/Z#$_[OKLZ;9KK9NMZT=_]]>LQ&F(PN2KQ
M9I7OK3<]NO5]]:/36;FG%@82EPRBS%8ZEZV3G)9(*V.B=4YLOJ?>-,JQ[Z=S
M=HH%]*\,XT1Z:=')LH$X%ICF/"&#V_8U/MK]=)C=O82O2@ E3&?O<+C%F.DM
MNBOX"_\1!CYK34%F$KW$)< +("%S01+-ED<MA/!-BKYUA_@MWB?NP+MUNZN)
M[IK<6-]'>BNT@=(<I%*:)"-"J=1AB4V9$J&X-\KK$'.3YF=;\#QK_NRGE6-=
M/RN3I<(=AF3$6A*><-[:E;:2V>H4E NJ=07*$[A^/H \U;7T5*Z?[TWLGLVR
M* ^S;$B8A?0^$RT%SLEY1T)"PU@8$7D0%K1M6Y!I,ZXG?4BY$P^V$^U@?318
MK=Z.)PLQWZV?&RI:W_@V':"V/+;< >O1BY@>KNMQOXIJN1/> 2P+]]G5>'X7
M66ZXH.@K9\*80=/.:728 TLD,N&LD90)WJ3)2Q=PQZY46IU$U35RY!5)4K3U
MLBE7_;@F2Q0-L=Y%8C+/5&BNG6_B]AYI)=K1**^FY .6HETTU*(@C9],ON ^
M_@X^(6A(UT+8#E?H+#BCZ"PXBW:E=8S8Z!.1$7U.YJW Z;0@U(XX3Y!4+375
M8)5Z.9T-K] S.<\=7H*@J*8I,:(DTR69SI, G!,(#$)T!F739)G:!>0)4JJ9
MCAK$"Y0SY=GR3+G<6RRV>A,Y%ZS$T O#\ MHXF)ISV>B%)EYW/:;K$:;P)RL
M@W:PY'M@P\W+T %52P=L,ZSC^%J'J^T1'AP@\P;[S19TN/Z%K%!9.AD@$A(E
M5B1#HHJ\= ]24C?QGOIDPB/^4E]$V$74#0CP'D;#\611J.8V9,%D)000QHU"
M"\A&XB$80D5*(F<&CC:)"%]#TK_I4$-%XYKR;>"ZO(//X\O/N,6]F$ :HB4<
M%]EU2W"XVV6FT.W/MA3YYKCCN1PY22F'J)(32=(6RG\0U4D0H9[<F]3J'7TN
M)=#0Z"E37H)RP4A@D(GAI6%<RORZ.H/14AEC2_7W)KO 1C0G08+#Y=PDIOC^
MA>=BGPLL6K1V TE:<G2/DB1>>C2L)8TN4.[0<VE_ WW2_L&!4F]0KO)K1&_\
MU0WCN^!J&U>^&=BQ8LH/4]R#/#A0ZDVBR+?AHQFXS[:T$\V(+X;K@H8I4.\M
M^.!8HPCR/MGP:/1X3V380=B5X\7/T-=1ZV:L4MH(X4))J4FX]A5LWJ/"/"C<
M(!W7=.7"?V.8^.:G'R/,MX;DQU7%5CEM\!Z8G^: FKCI\\5H2(;Q@,8G$^B1
M:&0L9(;?^L"=52:F+JK<]OP34&85T55_+_]B-S$L6Y6TQU7':I>+*Y%QMC'B
M2LI%$-E0%E*G%W/CXT] F34$5]$,OTXCF5[<\PW6Z$9O;J<2^@79>R09NAU2
M A!G<#&)$2 F*@RWN8-N.PYW KIN(=BMIG>3_(I7"'XZ6R0([)%"<?^O*V9)
M; 6UD@B1602;/"OY<C(G9VF40@ 5B@F'SNU@"[Z#1;7PSPX4V/(9;<2V">"*
M\))Q.7I%900I>8+@C9+@K+6192W2X$&L!XOP_?SJRD^^C/.]G^V?R]/QP6V$
MW7DJ*QJ(*4A@)@=JC320G-:,>AL A*!1?T7?A\8X\(@^7D":7\)Y/ON,CRN:
M_GD\>>_+<G93T/GU;?2R11M$1UFZ-)E0OF027#;$>&NE9J !FKAE.Z$\N#W+
MRA!?US4_NRJ11/\-Z<5X>AWA-G!,26$1N(22J*=!E40]C?-@*F@7<9W*+:2R
M*]#^M]QV[%KKU-)2:0UN2A[!&^/\:GY9,HI^F8RGT]]&$UR$R@1^0;'_"'D\
M@0_^CP$UN-DIS4@,%DK;5$Y<!D=$\??0IN$2PA&8UPW],Z9C _4V.)W;=Q*O
M\;N[20B)&YM6!O'S4KE5&H(VFR/@O ? 2:'S\Y0X^A7Z/SE:4[T-[I>V"^GK
MZ0Q"HB8Y]+^  HI+:73WG&4DJ1AE<(+G-I4LNP)\3DRKHJ1&EU3WWH 5U-?7
M<I0JD (7X0"%](9'XC-8HAV+(@N7=6QB['7 UE<29'_$J:V0)Y/PN*6]<W)<
M@<N>..X<D2E J>@22<I"!IU=B+')(K4%S['NQZNK?36EJ(+X&]A;=;N?=)A+
MRWOUI]^"_=',R!HL:=J#?0\5/W7:HG^#_RLI,K'4(O)4$2<<$$W1RG1)\*":
MI'H_?;H^EH+YU-FZBV:;1"$^U(,^B1P16R(V*T9D5!+E52I\1L@N4N-9;K+Q
M/HCJ&^^_M9/"UV(9:VFK18)FUV[S@;ED$HN$&X_VKT;?. 1#"?<0'4\24ILH
MIJX GS7!&NBP<A#&]@;VV5.>K3&$II(^:A7.7)?2H3%Y*Y-4?-4)W7A5OW6
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MF@80+@.Z.2LG/QOO)+]^ZK&/??>5]+B*F"I'/G7M':^T2B'*1""7G'\A$6(
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M6<G4Y?3HVRN%4O.(J3<-;*!.Y0BPZ\A'GWG&27/B=,(=#$T;8AUN8^!P7V/
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MZ.ZC1XP9ACB[A??+?;396DJ,%YY(91)Q*7H2@XU991&T6+GOV'BFT&FP;YE
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M:')^S?H;8?RFW_2;?M-O^DW_=Y/L11E%%1D9%1D% 1DY%059%7G%_WB-A$4
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M^^K48 F>E],V/<8_+\O:>R4SXU/3O<Z&0Z '[ ,X2?OL]>8T10M?<\4H._E
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M+G%G!1?:(Y;=5B<6ZX0Q@\T-=,/"#9A=)6;U%AN3F)UT(UE&KZ!>_OIO_N6
MZ2E/G8]8Q@3?-VLCZ]XN/E%"5T]HU&/4(L>&CT1 \S,QV61H#'7,1-N*WXBO
MX\;/TI:BU5!.)XHP=9H/J'V2,Y-SA4\BWY"P>')# M;L<3F"R[G@QJC[US[/
MTX*B$]B//PM*VW3[,MHQZ"8T U35@C#4Y_[S;/7V#6'8QEJ7GM#LP>PMU?2P
ML]!<&'C66M=LB@+;OC0)PAM5TK?#6%,V3L%Z,69:GJ=A=SZ&A#O&ME3L?IU:
M+)@6)E"9[:'>XJUG$X3;]D<^3QQ,\$],7!9K9GO#/LE)6=H+$O#1P+[[SHSS
MG)L!S5A/.S,;\*8[%Q(>OMDO%)IU2AK=92,;_O5+\E+#>6@@X30B.KCAQ=.&
M@/!N@ _6<OB<J8@3[S;_[OBH;KB!#'?F>K7'A;*:9UT;2QH#7?G"E\B\P^4B
M-/O;"-^R):89<^<L"Y8@ YNR(;RT;&&J-]4GZK>K)%EG1Z/4E.?IW9UTKD]:
M%CM-O?*X+D4C4$2M3''Z5& YS;^_<A1OK",=OP4_%!$!Z]YM]JV*G8.XIQHR
MPSZ^A.<G814SCW#C.^,'F+/K1YQ#MW6"H]M_E1[^) R<H+%G>R!(<+?J_5\K
M9'>(0)*I-!8RM.*<%[NA=I&$X0"4WI\?0RG]E?\ ,\3<_;%DN_7QD'!C&19"
M6NY( >&("*S26VWZV:B3)EPW)E4Z^"[EAX"*-_A+1[Q5Z(/8;-0.G4C>^^5?
MK^35!4GAC0]=0__4Q4_47ZNK_"MK989]>1 $.7ZN 7^E]M9V0OC+LPYL'?>'
M72%FR<%"TBX??9<[%1&;*N1$78B*JH#6$0$.VRLWU;I_<&B\?!9[_*X:8=6,
M]8R3)P*4JY+%:S]4+27BN+:9Y<BG+PEYF_.SX-!S,]SKS?K]=NACW><#:1GL
MIJ963L+>>WSOTMO1AT+<Z2<!D:3S3TF0\,8,2\J\>S<((7TC%8'>$@2/A&L@
ML^T\/86^OF^2ES -SF3 9FR_.<FO8^NBC;QCI#NMV)ETJ!Y<WD^;DWRAP\SH
M=6+5N09.3)V,%0ZM^VA>(4W4,T=7EXOAK0X%R]3]<-T!.*8_FXX(9%N@""!I
MDB8VD7,(EKNXLN:TFN\O4LZ7C)!JX\U<VR6? @'6:<.PU&NVT=FG7FIZTJTV
M@I#);0H$[<_R]5+M.H/Y'P=*[,O+8TH3.=/I:E^4-FYV"F-S=&J6U *Q'%=Q
M(6Y.BA5\0VW8<<'887;D$I?D$T=.+A#*V]H:EHZM;9'%Y<^?WY[P3&O6N>W*
MI27VGH>Q?5#JVDI#OR;X-@YN58Z5CGY?D25?^KDN1B^BD:'AG7?2,Q^FJA)N
M#!$8+VLA9?B^/:934QH.9?#RR4?PI5>8QA"J%0*US9PFIXTTU@,Y6T)_;&F6
M.+?YN)@U- LDF];#2,OKC6C[6 ?&!C9G*XTRIN:UPZ0H)&7DFM[5FH0',00M
MW@ELQ]7U/@Y,R P*9%8:70$=C:82OMEN&_DS'5.0T$Y^;H[3X-Y*F!!N= Y!
M!TW<NC*<,Z0SG7MK^=+MU,IS50);NW:C[*NID8&S</HU[LR)Q-RY$Y7MG_<9
M4JPFW[^)(;L:"!JCH_":P?0W_-D+NGAYST?HE;1B(A!.@N"MHXEXWT$)><33
M,HL?=Q1'%.='+C!/:I?F"/%FBI#7(^?,(F%R[_"B_1[^TDPN@6:L5P@..W?;
M!B!;G#XM3CF@$I JB@Z7UMM*X/D\LMNQDCBR6!5O)6*F:I5[B>+ ^'NU+2O>
M%8-^C-</S',M=:5:&WVPPT#7$7BNZLN4ZL5-ZX;T-^:K&<'F+HJE$Q97S5_+
M,(AYW&\'50J1*IH1;A? ?2F:!6[<8MTZ?I/#5*2F,$]OR(8+&+483';X7,-@
M?_<Y5>/]:H'3JDXEED.>>8/RM<7'X=_8WTO+/>:Z_^YU9LBLF20F5B%N3CIZ
MV#?2O19I]-5PYT.<[4JS139\9<#V!.@3C!@,TX#JWAE^OSLIHG"UJBY;%1JI
M&7XF@$XV$"/K-E@\;QM]F[;A L[=?/;4S>FJ_6?@'[;NMQ1U_/T]'=W.?UO$
M3GXYG99\UTHLAZ]3C<S&KH30UW!J8-GY8=CXNYI,CL\Q$D%$(*BC=XA<O#-,
M$7^Y!JL;^T'>371</D'1F#G!/$+MG5?/]RIET&3VWAJ:JN&,RP1U=(G"]/T!
MU:S[^PHO&=YQ6N1RW<K9?7@O930S5%-4]UAOM;\#/<'//^R^X)&H* .)$#P<
MS8->;K=@2GRX7(4Y&;R^[Y,'?1V?WV)YJ4.C2BT^4=SIUN#[/4M1B3U5<X_-
M-YS0MYI=<) 5$7BD1OD6Q\AWC>_LHK/GA[J]N\HR4GWD3D7 2LHZ[IFNL55O
M(BSD-0YT[1$1L+C^],Z\YX5+):EW.[\(S;U@8 @^8!\TZP:#83K2,; 0*>0#
M?DMU*KYD-HIWM;);]C\ZKQPA@H&CRTT$H5)LX)--_Q+QKV=&SWY^GT-MQ%G$
M0"; B[ 819&=9, ,4X?5Y+Q.9((>TAY)D%*4YJ6C4?0M*DALG8$C*8DR]I:X
M)DWINWET"!VK4-E5/XI\I,LE6!^T0^C_3F\BI%6L#&Z23!'>"9[$?4\0_E+B
M)]#90HUA;3-<%6]&.Z$/Q9GAHZ]G.F[)C3PD LYHBJF.8EG7M'N9'-GC>ORD
M1"]S(CXH/WVSVWPP%SWPT[ZF/"M05]X@U8X08A89-A#&-_@PMW\O1%S/_</;
M-#TGYWSZY7AR>OLB3K7C8SKTL<R,57?^^KZL'(]E4&Z:0#"5UUPI$8!) L&5
M\3!;N]D$&M>)<B79R:!N^M"7["^O.U$\TN4U.T4$3G'-H@Z7WA&!65D2OO/W
MW ^/Z<0D;T:TI_O2@^%(\$A=Y#YL0'[:K?U@9*(-Z08G_^&CTNI/UY7[N!3P
M:HR?S0[]!@37@<N5(C]X"#ZB43!+,Z.)V_?C$IIE0ML460WBE3'V'6 "2Z@H
M)[-6;#\K12"/9JO??RC/*S-GB$#' FDIHX-$0.6(KB$4ZXE/5$&=A$)V/N Y
MVGJS>M&13+9][7FQXD,:FK\>VD60'(4](#U3#=YQ_6O%M%;Z\RE1XR_%\Q*\
MKGL0C_"IQ,?^ESYK8MZBEN%-UJ&+\))COU>0[SN,*J.5;42@7$710N&9_<_2
MC^VK.M#LO"]J+@$]VH5#O,DW 7X[5(WXB[W>=+6P,!DPS122E\&Y=K 'M)$5
M> J]1O"L3T0FZ!\KP#OUAR ;K,*$Q"?U]@LS^.13UPFU6J2L?Z?NU?Y#?]NG
M9KF)]"Y&E <:#W6/N$&Y>Y0PGOSK_E2U=E*O.-.V55],T'3T_ "1Y_.OL!^D
MPF3FF [Y=B''-),DV[?FL&SV+M@FDBM",+':E]1*7@J%4AWMH2F^NW%'1\H?
MHU@U1XY>Q[3-7T!TBP4R:]A,W:\LS-%579AA%7ZLQE2T3H%0Y(QM9,)>FQ%C
M^OHH- (E@;/$_%! /#KJ7J/CWFF)R% 66LNEW7Y!!"8U+:=8;N-]ASS4C!<,
MJ.<(*0+?MU]74A>:A7% ?KY=UO@J[M%-VK_Q$N_O57S&Y1=.-C.X\7JUND[>
MUFP$'>1':/8RXMSGE3!F+:_HN^O[6LIXW%H]%//Y2I((G<WP1K<-C.] @RSN
MU6S6Y2\:8L>*1:$G>0>E)X76&^++:?:U BD]6KWJK:&B&'@K!),*4_J8X:+T
M_2[BD]713\V+AL,!R")YD,BOR$R&%,%'G2&[KJ//P_Y29E%F.%PC3&!(2X!5
M'@@A8-VZ( ]0AZ(JT2>/'(A ?U\?'U/!:EXL!2SW6!O>:8XDU)\E7*V?F1W%
M)YV "%5H0D(P!C'!2KA& @I[/YBV%7X2 2KT(F(5O$>*OUVW/KDJ5/*O#=!Y
M;^C7;WI'HF[KP8>")*>GG=(E5)$"/"\M7/?R'"NV'B;^%DE?Z,Y[1:.+:>RC
M,603_[T^J(3/H %2']5?EV!?L6W98WK,J.A^6)LRJ"X^',9*FE48<W 2S+3L
MED/:"8N6)("\_D=9HVX'GX(L%D)]"4T724&AW= SY&&0G>[OIWRQ:9OIBSXA
M%8MHOJDA O6%[+)$$P%M]OWW2>]+Y7T8BA^]5]?*X<($(#DF]XK-/3B3O+UB
M-T)^WJ,]<=LZ3V8B%@YP @&H)[#KN=:XZZV!-09]#AE=/H6+]L$K(@MC\>"V
MAJ\8^%/).LLYU5,/OCV/BXE((B,"9@)SSTX8G:G<^W4N: F1RZH@KE$XX% M
MS#C+IN#$"M]'G[TX3"%M)^SP,P)A"HL0JCIFM<NS8!;7FI\.R):W>A0]L@&/
M?!:F.O2/<HH@SJ<>A)K=ZL/3O_Z\_NIPX&ZJ9;5[4M%^Y_VP\)$G61C/UAJ/
MK%-9Z2WKQWIGK8LHSKQGH<XY6268,&"0M&X<&F0XA$N07PEOAO_DY4"P;?IY
M(5O?>(* V41I33=WW4,N3JH[U *1WQO4<26SUH9?;,Y%55C?6/M6)&BXWZ;]
M9DJ1DS>E5\P7.8\*Q7'-HW#Z&CR3ECW'*/G\?7V?(!'JGY.$P\:CHARN7&PZ
M09\*302L2,GOZAO8.*:L=81 @WU8,[P4?_"QU7FU&^ R^)HC(YS30P6?0.43
M%+K.XE11,EQ=5]"9'9 2*+AQDM[:MKU2Y4X^308),M_(IC6[='AS,&FKG2I\
MU6;4?Y.4/Q(ERDM45*UEZ:%3DZW>2A[TI0*P;^&70.$:;QO"<:&SEM( U-&O
M6_E4RP#DE:]/=Z3X I\J0 407H]V'K5E%<,4<)%"M&<3#ZY7G]:ZR*M7?[MT
MM9F+?Y'[:.M+F'@YMN#QIL(K<'J/=9E.Y@M'<!!3W^X>!?\N6?<?.TOK'SNK
MUY9!P9#=14.X"MEX%+S&'7GWDSYK>QU-9:YD/&*>#L)]1+^P$8ND\1Q.I.\E
M1_$9OF#:IJIKWW<2)P*T(^]H>8A V4UJ6% 1\H>FG\IU3RZ84XKQI\3CYOO?
MAW^R/$CF.=UZZ^-4&'8SX^#:O[TR_.,?-73FP0 T\A:6[V2ZY+T[PV!9/M=S
M!]9V+I1U7L6;.R99\][S&#^L]^VB4%7^LT2 ;K!E9F<%?$($#+'Y!/:"I^B5
M'L@Q ;E@,Z/C%QI0D+0"M[,+0=?#D^;!F!(U R*@X4TZ?^X2 6[(G 7N%0&V
M0 30/P@*F[NW]R:RM4ZBHGX2]@BZM)CUIJ."Z _2,R81]UG%*"8%'LYF[AZ-
M",>IT:-<&T3KZS]5Z#YZ0,GY-1\BPD>[C[J3]\G\:5'UGI/)IR[97%Y5C\Z9
MWNT=M<M_7I,N7MR0%=Z;"3\X@;35-\2.KE>H)=IN2$@''J"V_\=#-6J-.R ?
M/];/?$=W8)EP=QHN$ 'D)2*P=01/"$ RUDF_@P;/G^SIG3DKFV/PB:J'MM>P
M)-#/Q)!=N;7UU=QVI@;_NV*JG^@/[<]Q98TU^\7SKR8GQ4V@%^[=CN^2VX[H
M0[J2BF*4R[SGX0Z"0 0*<*.5_3<OU23IBW,-=7H-7UB>K V<_L]&A/[9B*:_
M; X>,[?9VK)=A$;_60O$7U<=$LI&&OOL'^YI@JE@VHKFUN,.A@7,'W=%*';P
M7!)6UZB8[M?Q&7I5)/4@N JF=G$H5>0AXOD>4X2-1EU#;1VAM^+K8.WC8PN'
MQ15U[YF1AF*C:X^N#N@*[+_)RUF]A(P+XQN&F6+V5_3[<O1_OLT0K%BDW2ZF
M$A9:J @Z(&7MJ 91C"WB9G[)A/9GA).0C8,9W=A]DXA$=+/-E@YP&9H@&?^#
M<VJ3AY)K30^5)K\5 6>1E,ZMK2RO^)P]H9,F'%(XR5 @L)#T!502:JD#0 UZ
M7F)/\L%8A<J4["0>!\@1@#+!2'#O(2,V[F/MU2:::#7Z+'0"[)=E;%]X'P2,
MZI">&0W7X,-E2,>9$62P6>4R\D5"SRBR'$0%LW*A&T5)AV:?^G6 ($3;3/0H
M0;EO]Z O5]^?1[2'?9&&X::&AV$-:MT<204[M0 APSWZR?=@ +Q1O*J5E%]]
M9WO)QF1!>=6<EW%AH/YM+# 7=A'J9(KU#+>]WE<R$E)0G;!?'ALNMIB2K!-$
M'=7 1K)3ZO&:!K^;*GVUW<5:^7Z]@#,4\1?MADT6?6UO]&OR,_LA$K==F4_*
MC$Y;'L8Z*FY/MJ?V7FI*'/ZY>UL3#,&;X@SF9SCP5^J'_>+,;;[-/[4/\F#W
MK0 $&/,S1]_!+O;M29_"*PV49WDHQ.Z/71/2\6H$B7_:O@0191\AP4;8 59W
M3CA>S1(K:#Q<7GP]\%/2.6;5*;&TR=./9$:WJ-9MM6]K\J*;W4D@MQG-N)LE
M;A:C$^3&\[Z0]R)7@&!2N[:XD]6C^?7FFH3ZY"?5&2,FCUG#K7)!>ZVV>>$:
M=AC4%VD>%WZIOKWKW?3P<X.W'@4]LC[K>.69S*5>-<:VANR\7R82Q(L/-)RU
M%/JD7#HL8/WQ^[F?743 >U30AY!?Z05[I8N!M**?!,>7S+W(;R@/^)K4+*LF
M>_QBK!@4,02$/&A(R0M7,\?E+WB@/ 0^8;(27PEZC4J1IQZ0Z].<G I GU(3
M?8]STV]XU6JV7NAFD=J+]%:IAHG<8I?5_!$Y&)')*%Y.FL"I&<Y4=SL(VP3G
M@GX:$'$WZ9;\]'1$NX#?2D]3_=F*NJRZVW@A:=SZ B1"6LUW3AQ:#DTVN-8S
MJT]7%C7UV&Y4.&*,"#2Z)>$@&"+01@!A??6+QB^?I(=2I_O95U^5^;C$P]4I
ML.@]GA"2Q4;6 3/IJY!FA2D-E8>>H<S>7FUAL=",I!=35E;SL]@!/YZA@]V=
MW8JY,Y%=ZD0^?I)])4BPZL[$72CG6A!H!Q5*6@AJP:R9!\4S/K[&3:%W5%^T
M_?)N4]#';.^4-I-MC8*)4@UFJ'![ QD6I%MT5_M(@72V>/W.6I#3BBFUL5>X
MM-U^AIR4X/Z(3[<_XO,:*3[G?_RT#RTYET-7+;28L<U$#Q/!%<^)'PS!U$8"
M.'R:[ )<\IYM2-!RWFM^5]2QW/"2M SA8\&%NHQXB/O0XS3"?2Z#NL_8)=\.
M3E!%2,6_%9G?[3\V:N+X?P-02P,$%     @  DQ=4:.Z:YV*Y@  %H4) !0
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M^!Z/9X;AYI.U'"68E,6&H?.2U0:V,HSE!I^>'SPC_ZG(RW*A<$2H##(8$DV
M*$,!9+% ,%$4A1*QE$?I)%>NQV6<&U]^K?10@KR1%]R\VEUKSZB.?*WJ9ZSF
M?X-Z]([4_$9K.X.KTM-#,8M;T1XQ_S$N0$_C[.VNTZ*K8>N'MK@+J7M[*YO_
M?EAO[@S:_;Y>PO1OB@>]R5W6IP257L<6(<$H#'BBOP=NO'*B&)(@%#!F(9)9
M1L(PQBY+Q# QYK8*;&3>':_31F:PV@E=FWVYV?FXK0D#1\J.]L?'?V1FWR@
MOMNH\+VAYNV(M&K4X+>*@(XF_EC[/"1]$O- 22;EWO/0>DFO9[8VC$$W+3V]
MSXNK%5W>U59_\\/V_'1SPA9G&56$Q#"(0@R1-&>9@220HX3BC"LJL9,CB$OG
M<V/+GZ58<KH"O!:WGIE,KJ5:[@C4C2&=1H+%D@6*<IC)&)FK9 (9EAD,)$LI
M89&,<;:HMLZVKS<21]R*?8Y$[5,\(M9(2<HXEU"%!NN$19"&(8$(QP&3"<L0
M#1?W+X(>7@WQEX*\Z@RXT+^Y6:[7YO":T94)G!EQH+3 :9;B$'(1ZYT_(2$D
MB= <E5 2<"49#50[4!L/_U<>IL,Q#9,/DER+:4;(SIP;"_.1C;BMV$#E!;C:
M =[^N),=M,+[L]N&0.;36G/J?U(;;0@R+RVS06VX.Y[5%TI-LZW%M^ T%E'*
M$:0JC+3%I1@D0F60IVDHPSC3UE=FZS*VW_S<;*IK^WWE$;SZ">9\%":Y\VWY
MXK.+%7D$#WL/I?-PF<BWR D?)R^@X^KW^.\<>&DRSYOC G=]9GJ>&GKB]B@;
MOBL_K-]*5FDF_)D6O\G*--X$-7R5_*&H-Z>&)F51T>7Z6T&-C7%9EK(Z>'.:
MH"22B 0PYI&VK9E4D"C"(4."I8I'*$V<]I9C"3HWSNSHZ7HB-])(VI[9O?[X
MC'ZJMU71G.89)6M[<*?F)J)MIRCXKK88&UU!JRQHM/U^_!OVL4?%[PGA2+).
M?(8X+N+[IXPC]S<P0.V1+E=& FUB?Z4KN1/!R/@SK=I_O:?+XM_IZD%>LK(J
M**\6B0@RE,0IC",2F>,9#@F2 LI,)$$8H)0A[A2=-E22N:T,[\IJ>5?G=3&B
M@EI6Q\"TP8-BMP9, O7()%^S^D[P"[!5"JJ\@"4U!RR[ = _Z[E#5[4'.VA5
M? *_;C3S&<QV+KI>(]D&"S-M&-NYF.W%L)W=X$#/*KT5:^[D'\KE6I;E5WG3
M.'69H%$4I#Q@3'^B"<L@"G (B<P01(HRAA!5V"VBM[>WN?'B1K9!L;K]N-K1
MGC>T1J8V6Z#<?8-L /#JY=/;X;3^.C:Z[WG>6+WD?N+X,[V1*SWFQI]G):LZ
ML.9G><=DL: LCC(>(QA&5$"$.87Z*\%0*!8AA7E(XLCVY/%X-W/CAHVD@+>B
M JYEM3^"ZP'T]-&D'YA&)H4M0ALIFRB_7QM!+=GT!%3VIY9^()OH]'(H=$X'
MF:<1Z3G0['EYLH/-TPIT#S@MGI[8-?UD8I=_U_MO*39ND'^5)J.F%)>/LM"Z
MU#Z2;S7;;PW"12PY)2H*H6!4;W I"2!A&,%,9$F$.$L8=O)6G(UF<R/_1OS:
M[UWD^J,J2G OB\8'?C;IQER_'DN3="[RSFBEFRYA6?OA=9SQ-SB!%JC&7Q\8
MJ&Q.<V:4V&S@^,_"Q]^[<O\8D0%CC>ETN=.&"NB^@[JBY>U5OM8M5TMFCG?6
MR[RH$Q:]?9#F>_PK+>JPA]:T98G(8H0)Q%D:0*2B#&(12I@%B9*IDI0KZQQ
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M&[?^VF-$8[NB,T9VMI-]OTIF-EM$CF5ELWY_*%VMY;6Z*J185AMK0H4RQ%D
MJ4RDWA:F":28(YB$<9#%(H@H$F[$]+*+N5'0-UG<@55.UT!17J?"<Z6:/1!M
M2>4<:$:G#[WKR15HQ!O!2^*X]G[I8:^7B8G@F);[4_[HDQ-'^1E)/E3RKER$
M(E4TCA'D*L(0A;'>5<0I@X+0($4\%;%;,8'S19H;>9P=2 5^K6=:K9QKOH;S
M!]CR#FS281M[YS3-B$T7IK8'\BSBRW92_6,$ANVAZ"VB:[]E]U"LM[*BRU5Y
MK39),K0,;+FN12BW>QE%L4RQ(C!,PA0B)!)( A+ +*&()S%E829M ["L>IP;
M&[="&[N%M6*;;!=;N?]L'QEDAW@_?XZ"X^C'Z@V$UPIL) 9=D6TVD /!M ^N
M\@[J1"%5I\#U$SGEA$Y/O)1=.Y-%23FIU8V-<GO1G9R'%^_>E>Q>)"1.220I
M3#(:0Q0G,60,AS#,%!9I*FB$K+R/?0DT-VHW<@*Z*S-0;"6UIR$O W6:\J>&
M?^058:=.D]-'*W0!6I7 ,YU J]0%J$=KIY?^Q6L-E_VB,O6P3;3F3#5\3DN4
M3ZQ[5C OW4RVP/D$I;O^>6W7?7G\BZ2KZM9T_6%=/A0F+/"]E-NZ(PN."%7F
M[BM.4P)1I!<]C%D$(X%31I.8"QS;KGPG^IK;HO:7#^^[!2CMJ?$4IJ<7*8](
MC;S^-)(VY+65]0)H:2^VA2(MC^QMH+-?,#Q".-%:<!Z43@QO"4X/>9]J83)>
MME2E2[FVKPQ(:]H4/6LI?-OBVP?Y+;\TQ>R?%FDJ,459"H50 429))#P%$/)
MF8Q4RF4LK>*@[;J;&Z=>WC5U9<6#!#?YHRS6]7Z!&F&=.-8"Z9@%-"(1AC3%
M"").,\@2GD 5J 1)3D*>!C:E*D= >H+BE%,B?7I!\XO?R&O:IG3AQ@[?U=<S
MWL;?<M!([!5"A\RS7J&<*@-M+Z3524C=,M%:(]27D?9T(]-EIK56Z%F&6ONW
MW%8Z(9>+JR9G2%-3PGC.OEL+XYN]2*42+!842H9C$Z] (9%Q"!.<L)1GE%)B
M=2O=U\G<5K56SF<5-K2HM;.Z'4OT0MI/K[Z &IE4!V%D/>UM0-C=O):;J]=2
M\A_TXOBC?ETC$1+S S0_="Y;>YN>A )LE-M,?*MGQXUN^NNRNLT?JB9R8Q.X
M\3PW<"(EE5F@C> @#"%*4FT$T]243E)4B@ C'#&7*N+^1)N;&3==+26+8>LG
MHM<=C-%O7BVJ+>V"F'YO=#L2OC1&(F7_J+]&N)*%=+.,5[)'=6C DD,/Y^=D
MZB2K-%(LLDC(()49#"7%>BN=A9"2.(:2!X(CE28D<XI+[^EK=K:=2;3:W&=J
M$C8%UN^IEE:;,*6LJE7CD98KP'>A[,,S+;W$W8YP/:$Y,H,^SY[435UK!!TG
M1](1-,;*AO2RNU?+>W1$[[X,1\=>&4@FC8M=J4EMET#C6FWRW"XP34D8\M"$
M16H#4!!S-H<XC%(D,AR)(*-\0 ;:$]U:S8;I\\_6%'-/E\_I19/;7>L'8_CE
M=Z=LY;;C(%E$"8\R&!%SO4=B!JF@ O(4LS#-,IEE:*&_"Y9/.00M(77[?67T
M!Z6,MQT$2Y;W!^S83-]*6@.ZD]7@>!) =[JW@\4KY9_H<EK:M]-_C_HM7QM&
M_]?WLM!S9WWS8<WS._DQ+\N%"C$/52HA8IQ"E-( L@PE,& AYT'($A(JESW_
M@3[FMGG?B@B6M8QNM'$(1#NJ.!.:D>EAATHC'OC."'@\A9PS)?2H[Y,&#G4S
MZ=3OT?/E=.][U/WP_]VZ,F&N0NC/HOR<EWHF_3_+^ZM<R 6)DS#&9G^H(E,S
M+DPAQ6$("5)Q*!*5\,@JRJ&_F[EM$AM)02OJ!6B$!5I:8,2UOP/H0?;T+8 ?
MO$:>_4.A<KH*.(W$&9<!/8U/=AUP6L'NA8#%TV=GU&@O'19AQ%2$:0232&;0
MY-& .-%K?13&0LI(91P+EV5^OXNYK?+?3!^@+:+@[C'8@Z7=:G\>0B-/]XYP
M%Z 5;Y3<%B]4'RF+Q::7U\I7\4++GLP4+Y\<>B@LS=;XW1\FIM)DP*X+WC7)
M$C=?:2+"4(6A7NTQ%A#QR*2G0 '$<2*3C$1QE'*WP^&3?<YM_6]%!K*1N<GI
MDM<%-S>\4.<T=4["?QI]VR-BKYB.?E3<P-F*6Z/9E"]M)!Z!21P \GMZ?+K;
MB4^1K7'8/TVV?W5NI;$_Y76A#&E1UYAE,1.13"'/$@51E$G(%#&%25 0<,5X
M2K+%?9,DNJ)%94=Z<U#-A0%>*C@>&;R1-\OUVAP7O*&KNL;8O.MD.WQ*6493
M(7  PR#2MG*B^8%PO6,.*1,::1F3+&T_I7=KVX(.,U#,_4/:J#?FOE/\E_R&
M[-;_.8@Z(P-CN@KK6WC^*Y56=Q_S662]\:G7/T;>G!%&<KI:Z@-D&UJ&@U4[
MMZN7#EE?)%TM_U.*^OZ%AC22F<R@#(($(I9BR+#D,(U#$> X#:(H<RO08=OU
MW+:\/Q5:*%"T$G8*S8&5_H/KX9?#$-@M>., ._*R9.5DNI$=&.%]%@5Q!<QO
MN1#KWB<N).**RGZ)$><6!L2=TN5:FK)H#VO-J4U\:\NBCS_\HG\GS5:MDFV!
M\04.6,*C)($)2F.(*&*04&&B^C61*:D$QM:YR!S[GAN/U>*#K?R@C<)N-0"/
M/X!&!] HX1#TYS@F_;PV,M(C$YLCR*<3VIZ-MD.\Y7BH3Q5\Z1M]MVC,8?CU
MA68ZMCA=G.8P59\%;0YLPJN;;E-@LTYLOD!1G$5)IF"4I-0X=!"(HR2 &&<D
M2X,,DSAV*SEZNE.K.32#DJ->W$"[8&<X4%E(.91(I!"E6$$L]3]9&,>2("Q$
MDGAQQW4%>UJ/W&G MKPY\PK@V!=GQSUO6U!KB4?WOCV S@0.N-U>Y^"#>P %
M2S?<0V\.#-JMK]^V65S3C-"8$0QY*AE$8<8AD4K"@$N,$ZD2DF9N!/.\@_F1
MR>77K^^^?74,F7T.FAU1# =B9%)H!!NEMLQAG;T&CC[O8=K@SX/:[05P'GYJ
MX'3EW*3M,66&\]72).K9)6"FDB8X36"H3*A.IO?L6(88HHBG7$9I0$.K3'RG
MNYK;%GTG*=B(ZISHV@)@RVGN!;:QI_PPQ-SG_TDPO'+!\=ZFY8636N]QQ.DW
M!GK$&!/A0UD^/*].7M^*'+Z969"0JT0@ 67(C/^*BJ'>U F84A$GB619$BBG
MLC'.(LR-7[JWO+PCIZ,W@/M0V#'.N "/S$2U@"5HQ+_85/L]>*^^NS+<%/C5
M5K&2R^JA\'DK/AA-KW?8[E),>^,\&*6]^^'A+0T-3/IZ*U<KTR)=/RU(PH/
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M&0([R\$SL".S1K< I38C-*9YT20^$<U.PN0';_*-^[,D'"#R:538=#NI?>&
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MUW^3M"BW=^B+,,TH%32&<6J.83#"D&%-&%F&*(JC)(MBIZ0HWB2;&ZN\?9"
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MFPJ[<8P2(2(&<1(0B"(B(54D@5(EL4PCQ!%QBCNQZ'-N:T)'3K 5=% %8QO
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M6,EK]?)*>W>=;3R.UB:W1KWKK]/S[K(5FT(E 4XQC#(3W8_U5H^D)(%)2IA
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M0YQB"2G19EU,>!0KIQ)+9\@R-W+:R%7[J-5^::6C8]HY V-'8!/!/3*Q=;0
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MRRS;*QT./3<3K)7.-9AU!]7YD^=P $;FEU:P 0?-5R"XANL. 6/26-R>+\2
MV-K7ZIX-G-T],'%4[&M!#T->#SXQS.;Z*C>U*\WX/G>A7G?%^^+AH5A5UIZ)
MFM4$\(ZN<[X+F8PQ)Y1D 40$9Q!I^" .4 8Q(9%B.$GUKUW.C0/EF!N+?=5O
M1FF^AHZ9K4.7P<[\F@#<D1G2N.1?>.GW0:O&*U\K KJ:7(%*EU%B5"_$TZ<Q
M-E242>VQ"_%Z;9)=.MQ AUI][[F^*YKRH+=E\2C+S?.M_J9NKE?59>BC^<B"
MI31F*(AA$F4I1"+)((M$"%4B8Y$IEB:!<.N*83^YU4L[;2<,/= /NJX[Q3TV
M<E\!V4I<Y9!Q^IAOZ+**.%\7:O-GGROHTO6Q=+3YQ7PB9ULCM&'%1FQPN\.\
MDORJ GPGO$>'FS-@7IUN]K-/ZWAS1N7 ^>8^@AO%K<O-XKTYVBYS45GUGS;R
M8?VA>*#Y:I&0"(5)(J&*C:5'*88D9 &4,4GC(*!1:-<%O&^2N9EQ+^0$E:#@
M]UI4R[-9+Z3]_.,+J)&99A!&UIQB T(/>^C'.\RA__::-7K'GX0?;#1LF<#J
MLV[OO)#YXI?5)M\\W]&_VA+HO!I<'V(J7P+'6.(HA#S6MHMIY@49R6(8<R43
M%H<<<63SXI^=:6YO?RVLB?\!+\4%M;QV#' >X'X:\ K;R%PP&#%K/K!&8T\*
MZY85UI+_[;YX^C]Z# U)2,P/T/S0X8/SXT]""M9JMLQ@_\# 0I+%ZOY.E@_&
MS;UO?LEB'H@ )3"61$&$(P0IXPH*I5A 0AXK'+AX?X[.,C=:,,(Y%G<\"I[=
MZ>-B2$9^Y8U\4,/^4-]\675;=:^JV >"UTJ)1R>:MOIAGZX'%0U[/^RMX97I
M'YVO[C6K&.O#Y,15_[RKLK!0$8^3B N8!!3IPT&B(*4A@RG#09(&*7-L1S)
MAKG1Q%Y>P+L"@^6^E<S%7:O.+HP=R8P,]\@4=+S;5 ?_%QI<[8NYC-HWRA;
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M-Q]2S8T>*UG!=B<L6.J_RPO#+8>MEZ7=-_4JC'XJ[0VZ7-=!EWNU0+UB>\6
MT>P*L$HWH)4;+[;R(JS'#*\<)MB;1EA>A.6Y(,O+!G>_"-JU^M7;0U'5&=9[
M@HEPR$65LE>LVMY%1ISU>OM@<H*_:N3T+E('.^EG;LI=DX%]I\P%D4%$LH#
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MI4R9C$,B8HBH26D51$!"$ZY-)!4F,0X%D4X52YQFG]O;:^%6O:!3J-O"N%X
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MD#EH=CMD#/<0C=L?M'R@_+GNUM&TZ%@(*DG"90P#:;HL!DD$L4HX)%0A)5'
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M(#&-8IA@GD*4QA$D09A *F6"<8 Y0TX92[VSS8V';K__YEBAL!],@6D6AI&
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M>23()XICV\-\H\!>=-"1?==DY)=Q87;(:QX-[JD2GMV_W9[Z@PR#KB]-VFW
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M^<A$W,)L7AS0B@[^S,UM32,\^+T6WV]QLLN0\YMR[23!Q#G80] Y3,H>-,K
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MHB8-C"#QL(1ADLK$3Q(>4*-"+*.D+VU*>"_RXEEO^RC/50T&H%K)NE9?,RT
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M\#E.RACWF"LVVY^*M;JCTLD==?_T)H/C0;>S*O+;S:;,Z':CS^:_%)\4%KJ
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M%% V"NNBG,5C7J?BDPH0\+*S3/LS=3#0X3WF)2C'C^9EXIMMC"9FPFYX=D:
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MXJ+LYOA/*1S[ZB:E6.QD>>KF\^\8R/RGFURED4Y61!8,A-4,BS*:V]@<P*5
MO$["5"JZZD1="X Z" 4//:#>5=( SGYS\[^G5<1P&S%?CUOS7DJB+04O*8;(
M04APGBL(CCD>LV;95\FV/T/3L+F0_C'5E_@;0-+'%!(N"F2EQ*773&#82QA7
M:+EU4B"BR> XI65A4.J8C[[.'9"MU P;K?6/GL-%W@!N/LS3%S>^OL>+!G:5
M\;@GK)%-(F.,&B $_$L$] F\2:$4-&KNB.;)5PDG.M V[,7&_C'5MSH:0-A]
MXJG-N"8(!Q_0M@IJ$SCJ'5AA4#K.1WD[1Z2:TSWLE8G^4;._B!O(.7Z8E]M-
MR^\?)FZZ:D.!WMV75=7L-*[#V?0NN47Z.#Z_P CW;[@L"KLG&2%Z$L+5Y=6D
MW$]ZKC&*+*FU)#CD];"YC"N&D@!)1:EMYD1M&_W:AP&KS5H+'EDO86-C*&C
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M"T$8R0*7*:O>K,TV H9)(!QODSI8Z&V IIPU;#A8;%88ES(YG24X*A0B7RG
MN!9=0?0+.3?"<M7E>OPNR'E,Q7"6YW#%/D;)@5(>>J]*$8/6<;SN1JN)]3%0
M4,;8<G&OI#@D ZVT2])(RQGKLA7=>^K@^CY41;->Y#6P4;B9T?&75'K3?;E
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MW$HSW$3K,IKXWLS8S5O;[P5UV-:WGWA;P,0&RD[BTB'" 5$8ZPJ"#!C*':3
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M' 6L$BRW89'2T9N<(89,2I5B&9E+*6B>LG+&YQ"K#)7MA_QA4Z=53.  >FW
M(CYB;\1)Y-)Y!42O)I^&!)X(!9YZKU-IPOJP>+ZGB.(A)<-:QB'@\#"R.$@W
M#8"KJPSO[RTDQ^R=Q&U%<US$3EGP,5!(*G CHF+!TR$MX^Z^8+5CZT$-X?Y:
M:QV:=[R?3U?^OU-8?IY]3%^NYN'"+=+9_+2,\YU,5FH>>>THU=:"L#RBJ*,"
MIPP')UE&UX8S7B=XZ8V#'\/.'H"V7?!=3?5MM$O8ROMLP_MUTBI%E,*7-%VL
MN52"F$"X@J1E*8(K"7SE#23&@HPR."X>A$E;JSOV>/6P7N;QD'D,S;1N<Q\*
M=&0=2BJGB'M6"3&U%F"+2+4DC%NKO'552OEWHG+8XJ3AM_^=M-0 !%?>^OAK
M^I3"U7R\O'LU1RN53$ 33EQT($2B8*QVX%UR3CC+'.G2_W!GO#U-4B=PR1\*
M7#W)OP$DW>FAM/$95@OD9+F<C_W5<I-&<Y/)V9>BL5)T\[N;S]UTN1AI@4$;
M2Q:"Y!0$+5WG="A#B2TW-F:3=)5[A0?0/*R3V!=L9L/H\$>!ZZV;\<%]7XW0
M*<R>K_[?8I23X2DI5N:@*$#VR\05:8%8*S)AAD4I!T/MLZ0/ZT<."=[^--H
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MO'O8F:T>\NY1UH;A.TC_'3"UOS(&;L;U7[.K^2F*\K;S^MMIV+24BIZ;L@5
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ME9C$?".T[>Q)4Z3@C %)S8!RGH-+(8-*02(/3A+[+<"X)YV=I+.M -E2:QV
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MCM/:6"E]K$5UF8Y3Y24$TG1 37;:"\.>O!%NK,3>_.D]@>!0K<T&%>'(('A
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M_OX+A=]/> TI"2M2G;$MB%=O!3A+O_ D')/(<XFE\6'?F^AQ4YT3H?AD6NT
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M6977+_AUMIC<=CYRCIXS;VN^)^O(D$),V0A.1 HCA&6!-QF>^P)-XVXB[@:
M0VFMBU;GOSY^FJ^&UWU?5:P_.U&.HTY%RKJ9GDRZ51J"-76O+8LF6HT4VK:
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M.7HIC Z067%U9 (#;^M\;Z%0*.Y3^9\5OB<#R4[-_?MHK#_8/6D-3RD8SI(
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MJ]3V>JYMIV;_>BB@'-)81(ON^[X2-'KO:8A267,E0M>LQ?\XJ S:V\NYL^@
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MG&U?K=O=ZFN!&[IB<L(4FD.XU!+STZ@HF^+ATTQMO\20M\<0N_Q*KAR(3$(
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M#(X-T)+,,GJ#-!<)%0KEC!0E#:J7,&%ED9%-P'*-C!8*KU06QR3;3H+1VY:
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MH%2HW$![%\F X> U=_'>%9PD67)9UT@QP\MD@?(YJ3#UVHW N"?3H221;4>
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M+3(P,C P.3,P+GAS9%!+ 0(4 Q0    (  ),75'V@CYDF"4   :! 0 4
M          "  2O( P!M;V@M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M  ),75% $5CY)5<  *.Z P 4              "  ?7M P!M;V@M,C R,# Y
M,S!?9&5F+GAM;%!+ 0(4 Q0    (  ),75%BR"0:3S<  #=7   3
M      "  4Q%! !M;V@M,C R,# Y,S!?9S$N:G!G4$L! A0#%     @  DQ=
M4:.Z:YV*Y@  %H4) !0              ( !S'P$ &UO:"TR,#(P,#DS,%]L
M86(N>&UL4$L! A0#%     @  DQ=44&(#,FBC   .%D& !0
M ( !B&,% &UO:"TR,#(P,#DS,%]P<F4N>&UL4$L! A0#%     @  DQ=46_Q
M( BA"   KRT  !               ( !7/ % &UO:#-Q,C!E>#,Q,2YH=&U0
M2P$"% ,4    "  "3%U1'3-3,X((  #.+   $               @ $K^04
M;6]H,W$R,&5X,S$R+FAT;5!+ 0(4 Q0    (  ),75'N84TK] 0  )@7   0
M              "  =L!!@!M;V@S<3(P97@S,C$N:'1M4$L! A0#%     @
M DQ=47)>Z6+N!   21L  !               ( !_08& &UO:#-Q,C!E>#,R
;,BYH=&U02P4&      P #  $ P  &0P&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
